

AM

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number
WO 01/23604 A2(51) International Patent Classification⁷: C12Q 1/68,
C07K 14/00, C12N 15/63, 05/10

1035 de Ploermel, Sillery, Quebec G1S 3S1 (CA). PI-CARD, François, J. [CA/CA]; 1245 de la Sapinière, Cap-Rouge, Quebec G1Y 1A1 (CA). ROY, Paul, H. [CA/CA]; 28 Charles Garnier, Loretteville, Quebec G2A 2X8 (CA).

(21) International Application Number: PCT/CA00/01150

(74) Agents: DUBUC, Jean, H. et al.; Goudreau Gage Dubuc, The Stock Exchange Tower, 800 Place Victoria, Suite 3400, P.O. Box 242, Montreal, Quebec H4Z 1E9 (CA).

(22) International Filing Date:
28 September 2000 (28.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2,283,458 28 September 1999 (28.09.1999) CA
2,307,010 19-May 2000 (19.05.2000) CA

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GI, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (for all designated States except US): INFECTIO DIAGNOSTIC (I.D.I.) INC. [CA/CA]; 2050 René-Lévesque Blvd., West, 4th Floor, Sainte-Foy, Quebec G1V 2K8 (CA).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


(72) Inventors; and

(75) Inventors/Applicants (for US only): BERGERON, Michel, G. [CA/CA]; 1145 des Érables, Quebec, Quebec G2K 1T8 (CA). BOISSINOT, Maurice [CA/CA]; 109 Jean Bruchési, St-Augustin-de-Desmaures, Quebec G3A 2N2 (CA). HULETSKY, Ann [CA/CA]; 1231 des Pins Avenue, Sillery, Quebec G1S 4J3 (CA). MÉNARD, Christian [CA/CA]; 1174 du Pont, St-Lambert-de-Lévis, Quebec G0S 2W0 (CA). OUELLETTE, Marc [CA/CA];

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A2

(54) Title: HIGHLY CONSERVED GENES AND THEIR USE TO GENERATE SPECIES-SPECIFIC, GENUS-SPECIFIC, FAMILY-SPECIFIC, GROUP-SPECIFIC AND UNIVERSAL NUCLEIC ACID PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY ALGAL, ARCHAEAL, BACTERIAL, FUNGAL AND PARASITICAL MICROORGANISMS FROM CLINICAL SPECIMENS FOR DIAGNOSIS

(57) Abstract: Four highly conserved genes, encoding translation elongation factor Tu, translation elongation factor G, the catalytic subunit of proton-translocating ATPase and the RecA recombinase, are used to generate a sequence repertory or bank and species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes and amplification primers to rapidly detect and identify algal, archaeal, bacterial, fungal and parasitical microorganisms from specimens for diagnosis. The detection of associated antimicrobial agents resistance and toxin genes are also under the scope of the present invention.

WO 01/23604 A2

TITLE OF THE INVENTION

HIGHLY CONSERVED GENES AND THEIR USE TO GENERATE SPECIES-SPECIFIC, GENUS-SPECIFIC, FAMILY-SPECIFIC, GROUP-SPECIFIC AND UNIVERSAL NUCLEIC ACID PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY ALGAL, ARCHAEAL, BACTERIAL, FUNGAL AND PARASITICAL MICROORGANISMS FROM CLINICAL SPECIMENS FOR DIAGNOSIS

BACKGROUND OF THE INVENTION*Classical methods for the identification of microorganisms*

Microorganisms are classically identified by their ability to utilize different substrates as a source of carbon and nitrogen through the use of biochemical tests such as the API20ET™ system (bioMérieux). For susceptibility testing, clinical microbiology laboratories use methods including disk diffusion, agar dilution and broth microdilution. Although identifications based on biochemical tests and antibacterial susceptibility tests are cost-effective, generally two days are required to obtain preliminary results due to the necessity of two successive overnight incubations to identify the bacteria from clinical specimens as well as to determine their susceptibility to antimicrobial agents. There are some commercially available automated systems (i.e. the MicroScan™ system from Dade Behring and the Vitek™ system from bioMérieux) which use sophisticated and expensive apparatus for faster microbial identification and susceptibility testing (Stager and Davis, 1992, Clin. Microbiol. Rev. 5:302-327). These systems require shorter incubation periods, thereby allowing most bacterial identifications and susceptibility testing to be performed in less than 6 hours. Nevertheless, these

faster systems always require the primary isolation of the bacteria or fungi as a pure culture, a process which takes at least 18 hours for a pure culture or 2 days for a mixed culture. So, the shortest time from sample reception to identification of the pathogen is around 24 hours. Moreover, fungi other than yeasts are often difficult or very slow to grow from clinical specimens. Identification must rely on labor-intensive techniques such as direct microscopic examination of the specimens and by direct and/or indirect immunological assays. Cultivation of most parasites is impractical in the clinical laboratory. Hence, microscopic examination of the specimen, a few immunological tests and clinical symptoms are often the only methods used for an identification that frequently remains presumptive.

The fastest bacterial identification system, the autoSCAN-Walk-Away™ system (Dade Behring) identifies both gram-negative and gram-positive bacterial species from standardized inoculum in as little as 2 hours and gives susceptibility patterns to most antibiotics in 5 to 6 hours. However, this system has a particularly high percentage (i.e. 3.3 to 40.5%) of non-conclusive identifications with bacterial species other than *Enterobacteriaceae* (Croizé J., 1995, Lett. Infectiol. 10:109-113; York *et al.*, 1992, J. Clin. Microbiol. 30:2903-2910). For *Enterobacteriaceae*, the percentage of non-conclusive identifications was 2.7 to 11.4%. The list of microorganisms identified by commercial systems based on classical identification methods is given in Table 15.

A wide variety of bacteria and fungi are routinely isolated and identified from clinical specimens in microbiology laboratories. Tables 1 and 2 give the incidence for the most commonly isolated bacterial and fungal pathogens from various types of clinical specimens. These pathogens are the main organisms associated with nosocomial and community-acquired human infections and are therefore considered the most clinically important.

Clinical specimens tested in clinical microbiology laboratories

Most clinical specimens received in clinical microbiology laboratories are urine and blood samples. At the microbiology laboratory of the Centre Hospitalier de l'Université Laval (CHUL), urine and blood account for approximately 55% and 30% of the specimens received, respectively (Table 3). The remaining 15% of clinical specimens comprise various biological fluids including sputum, pus, cerebrospinal fluid, synovial fluid, and others (Table 3). Infections of the urinary tract, the respiratory tract and the bloodstream are usually of bacterial etiology and require antimicrobial therapy. In fact, all clinical samples received in the clinical microbiology laboratory are tested routinely for the identification of bacteria and antibiotic susceptibility.

Conventional pathogen identification from clinical specimens

Urine specimens

The search for pathogens in urine specimens is so preponderant in the routine microbiology laboratory that a myriad of tests have been developed. However, the gold standard remains the classical semi-quantitative plate culture method in which 1 µL of urine is streaked on agar plates and incubated for 18-24 hours. Colonies are then counted to determine the total number of colony forming units (CFU) per liter of urine. A bacterial urinary tract infection (UTI) is normally associated with a bacterial count of 10^7 CFU/L or more in urine. However, infections with less than 10^7 CFU/L in urine are possible, particularly in patients with a high incidence of diseases or those catheterized (Stark and Maki, 1984, N. Engl. J. Med. 311:560-564). Importantly, approximately 80% of urine specimens tested in clinical microbiology laboratories are considered negative (i.e. bacterial count of less than 10^7 CFU/L; Table 3). Urine specimens found positive by culture are further characterized using standard biochemical tests to identify the bacterial pathogen and are also tested for susceptibility to antibiotics. The biochemical and susceptibility testing normally require 18-24 hours of incubation.

Accurate and rapid urine screening methods for bacterial pathogens would allow a faster identification of negative specimens and a more efficient treatment and care management of patients. Several rapid identification methods (Uriscreen™, UTIscreen™, Flash Track™ DNA probes and others) have been compared to slower standard biochemical methods, which are based on culture of the bacterial pathogens. Although much faster, these rapid tests showed low sensitivities and poor specificities as well as a high number of false negative and false positive results (Koenig *et al.*, 1992, *J. Clin. Microbiol.* **30**:342-345; Pezzlo *et al.*, 1992, *J. Clin. Microbiol.* **30**:640-684).

Blood specimens

The blood specimens received in the microbiology laboratory are always submitted for culture. Blood culture systems may be manual, semi-automated or completely automated. The BACTEC™ system (from Becton Dickinson) and the BacTAlert™ system (from Organon Teknika Corporation) are the two most widely used automated blood culture systems. These systems incubate blood culture bottles under optimal conditions for growth of most bacteria. Bacterial growth is monitored continuously to detect early positives by using highly sensitive bacterial growth detectors. Once growth is detected, a Gram stain is performed directly from the blood culture and then used to inoculate nutrient agar plates. Subsequently, bacterial identification and susceptibility testing are carried out from isolated bacterial colonies with automated systems as described previously. Blood culture bottles are normally reported as negative if no growth is detected after an incubation of 6 to 7 days. Normally, the vast majority of blood cultures are reported negative. For example, the percentage of negative blood cultures at the microbiology laboratory of the CHUL for the period February 1994-January 1995 was 93.1% (Table 3).

Other clinical samples

Upon receipt by the clinical microbiology laboratory, all body fluids other than blood and urine that are from normally sterile sites (i.e. cerebrospinal, synovial, pleural, pericardial and others) are processed for direct microscopic examination and subsequent culture. Again, most clinical samples are negative for culture (Table 3). In all these normally sterile sites, tests for the universal detection of algae, archaea, bacteria, fungi and parasites would be very useful.

Regarding clinical specimens which are not from sterile sites such as sputum or stool specimens, the laboratory diagnosis by culture is more problematic because of the contamination by the normal flora. The bacterial or fungal pathogens potentially associated with the infection are grown and separated from the colonizing microbes using selective methods and then identified as described previously. Of course, the DNA-based universal detection of bacteria would not be useful for the diagnosis of bacterial infections at these non-sterile sites. On the other hand, DNA-based assays for species or genus or family or group detection and identification as well as for the detection of antimicrobial agents resistance genes from these specimens would be very useful and would offer several advantages over classical identification and susceptibility testing methods.

DNA-based assays with any specimen

There is an obvious need for rapid and accurate diagnostic tests for the detection and identification of algae, archaea, bacteria, fungi and parasites directly from clinical specimens. DNA-based technologies are rapid and accurate and offer a great potential to improve the diagnosis of infectious diseases (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.; Bergeron and Ouellette, 1995, Infection 23:69-72; Bergeron and Ouellette, 1998, J Clin Microbiol. 36:2169-72). The DNA probes and amplification primers which are objects of the present invention are applicable for the detection and identification of algae, archaea, bacteria, fungi, and parasites directly from any clinical specimen such as blood,

urine, sputum, cerebrospinal fluid, pus, genital and gastro-intestinal tracts, skin or any other type of specimens (Table 3). These assays are also applicable to detection from microbial cultures (e.g. blood cultures, bacterial or fungal colonies on nutrient agar, or liquid cell cultures in nutrient broth). The DNA-based tests proposed in this invention are superior in terms of both rapidity and accuracy to standard biochemical methods currently used for routine diagnosis from any clinical specimens in microbiology laboratories. Since these tests can be performed in one hour or less, they provide the clinician with new diagnostic tools which should contribute to a better management of patients with infectious diseases. Specimens from sources other than humans (e.g. other primates, birds, plants, mammals, farm animals, livestock, food products, environment such as water or soil, and others) may also be tested with these assays.

A high percentage of culture-negative specimens

Among all the clinical specimens received for routine diagnosis, approximately 80% of urine specimens and even more (around 95%) for other types of normally sterile clinical specimens are negative for the presence of bacterial pathogens (Table 3). It would also be desirable, in addition to identify bacteria at the species or genus or family or group level in a given specimen, to screen out the high proportion of negative clinical specimens with a DNA-based test detecting the presence of any bacterium (i.e. universal bacterial detection). As disclosed in the present invention, such a screening test may be based on DNA amplification by PCR of a highly conserved genetic target found in all bacteria. Specimens negative for bacteria would not be amplified by this assay. On the other hand, those that are positive for any bacterium would give a positive amplification signal. Similarly, highly conserved genes of fungi and parasites could serve not only to identify particular species or genus or family or group but also to detect the presence of any fungi or parasite in the specimen.

Towards the development of rapid DNA-based diagnostic tests

A rapid diagnostic test should have a significant impact on the management of infections. DNA probe and DNA amplification technologies offer several advantages over conventional methods for the identification of pathogens and antimicrobial agents resistance genes from clinical samples (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.; Ehrlich and Greenberg, 1994, PCR-based Diagnostics in Infectious Disease, Blackwell Scientific Publications, Boston, MA). There is no need for culture of the pathogens, hence the organisms can be detected directly from clinical samples, thereby reducing the time associated with the isolation and identification of pathogens. Furthermore, DNA-based assays are more accurate for microbial identification than currently used phenotypic identification systems which are based on biochemical tests and/or microscopic examination. Commercially available DNA-based technologies are currently used in clinical microbiology laboratories, mainly for the detection and identification of fastidious bacterial pathogens such as *Mycobacterium tuberculosis*, *Chlamydia trachomatis*, *Neisseria gonorrhoeae* as well as for the detection of a variety of viruses (Tang Y. and Persing D. H., Molecular detection and identification of microorganisms, In: P. Murray *et al.*, 1999, Manual of Clinical Microbiology, ASM press, 7th edition, Washington D.C.). There are also other commercially available DNA-based assays which are used for culture confirmation assays.

Others have developed DNA-based tests for the detection and identification of bacterial pathogens which are objects of the present invention, for example: *Staphylococcus* sp. (US patent serial no. 5,437,978), *Neisseria* sp. (US patent serial no. 5,162,199 and European patent serial no. 0,337,896,131) and *Listeria monocytogenes* (US patent serial nos. 5,389,513 and 5,089,386). However, the diagnostic tests described in these patents are based either on rRNA genes or on genetic targets different from those described in the present invention. To our knowledge there are only four patents published by others mentioning the use of

any of the four highly conserved gene targets described in the present invention for diagnostic purposes (PCT international publication number WO92/03455 and WO00/14274, European patent publication number 0 133 671 B1, and European patent publication number 0 133 288 A2). WO92/03455 is focused on the inhibition of *Candida* species for therapeutic purposes. It describes antisense oligonucleotide probes hybridizing to *Candida* messenger RNA. Two of the numerous mRNA proposed as targets are coding for translation elongation factor 1 (tef1) and the beta subunit of ATPase. DNA amplification or hybridization are not under the scope of their invention and although diagnostic use is briefly mentioned in the body of the application, no specific claim is made regarding diagnostics. WO00/14274 describes the use of bacterial *recA* gene for identification and speciation of bacteria of the *Burkholderia cepacia* complex. Specific claims are made on a method for obtaining nucleotide sequence information for the *recA* gene from the target bacteria and a following comparison with a standard library of nucleotide sequence information (claim 1), and on the use of PCR for amplification of the *recA* gene in a sample of interest (claims 4 to 7, and 13). However, the use of a discriminatory restriction enzyme in a RFLP procedure is essential to fulfill the speciation and WO00/14274 did not mention that multiple *recA* probes could be used simultaneously. Patent EP 0 133 288 A2 describes and claims the use of bacterial *tuf* (and *fus*) sequence for diagnostics based on hybridization of a *tuf* (or *fus*) probe with bacterial DNA. DNA amplification is not under the scope of EP 0 133 288 A2. Nowhere it is mentioned that multiple *tuf* (or *fus*) probes could be used simultaneously. No mention is made regarding speciation using *tuf* (or *fus*) DNA nucleic acids and/or sequences. The sensitivities of the *tuf* hybridizations reported are 1×10^6 bacteria or 1-100 ng of DNA. This is much less sensitive than what is achieved by our assays using nucleic acid amplification technologies.

Although there are phenotypic identification methods which have been used for more than 125 years in clinical microbiology laboratories, these methods do not provide information fast enough to be useful in the initial management of patients.

There is a need to increase the speed of the diagnosis of commonly encountered bacterial, fungal and parasitical infections. Besides being much faster, DNA-based diagnostic tests are more accurate than standard biochemical tests presently used for diagnosis because the microbial genotype (e.g. DNA level) is more stable than the phenotype (e.g. physiologic level).

Bacteria, fungi and parasites encompass numerous well-known microbial pathogens. Other microorganisms could also be pathogens or associated with human diseases. For example, achlorophylous algae of the *Prototheca* genus can infect humans. Archae, especially methanogens, are present in the gut flora of humans (Reeve, J.H., 1999, *J. Bacteriol.* **181**:3613-3617). However, methanogens have been associated to pathologic manifestations in the colon, vagina, and mouth (Belay *et al.*, 1988, *Appl. Enviro. Microbiol.* **54**:600-603; Belay *et al.*, 1990, *J. Clin. Microbiol.* **28**:1666-1668; Weaver *et al.*, 1986, *Gut* **27**:698-704).

In addition to the identification of the infectious agent, it is often desirable to identify harmful toxins and/or to monitor the sensitivity of the microorganism to antimicrobial agents. As revealed in this invention, genetic identification of the microorganism could be performed simultaneously with toxin and antimicrobial agents resistance genes.

Knowledge of the genomic sequences of algal, archaeal, bacterial, fungal and parasitical species continuously increases as testified by the number of sequences available from public databases such as GenBank. From the sequences readily available from those public databases, there is no indication therefrom as to their potential for diagnostic purposes. For determining good candidates for diagnostic purposes, one could select sequences for DNA-based assays for (i) the species-specific detection and identification of commonly encountered bacterial, fungal and parasitical pathogens, (ii) the genus-specific detection and identification of commonly encountered bacterial, fungal or parasitical pathogens, (iii) the family-specific detection and identification of commonly encountered bacterial, fungal or parasitical pathogens, (iv) the group-specific detection and identification of commonly encountered bacterial, fungal or parasitical pathogens, (v) the

universal detection of algal, archaeal, bacterial, fungal or parasitical pathogens, and/or (vi) the specific detection and identification of antimicrobial agents resistance genes, and/or (vii) the specific detection and identification of bacterial toxin genes. All of the above types of DNA-based assays may be performed directly from any type of clinical specimens or from a microbial culture.

In our assigned U.S. patent 6,001,564 and our WO98/20157 patent publication, we described DNA sequences suitable for (i) the species-specific detection and identification of clinically important bacterial pathogens, (ii) the universal detection of bacteria, and (iii) the detection of antimicrobial agents resistance genes.

The WO98/20157 patent publication describes proprietary *tuf* DNA sequences as well as *tuf* sequences selected from public databases (in both cases, fragments of at least 100 base pairs), as well as oligonucleotide probes and amplification primers derived from these sequences. All the nucleic acid sequences described in that patent publication can enter in the composition of diagnostic kits or products and methods capable of a) detecting the presence of bacteria and fungi b) detecting specifically at the species, genus, family or group levels, the presence of bacteria and fungi and antimicrobial agents resistance genes associated with these pathogens. However, these methods and kits need to be improved, since the ideal kit and method should be capable of diagnosing close to 100% of microbial pathogens and associated antimicrobial agents resistance genes and toxins genes. For example, infections caused by *Enterococcus faecium* have become a clinical problem because of its resistance to many antibiotics. Both the detection of these bacteria and the evaluation of their resistance profiles are desirable. Besides that, novel DNA sequences (probes and primers) capable of recognizing the same and other microbial pathogens or the same and additional antimicrobial agents resistance genes are also desirable to aim at detecting more target genes and complement our earlier patent applications.

The present invention improves the assigned application by disclosing new proprietary *tuf* nucleic acids and/or sequences as well as describing new ways to

obtain *tuf* nucleic acids and/or sequences. In addition we disclose new proprietary *atpD* and *recA* nucleic acids and/or sequences. In addition, new uses of *tuf*, *atpD* and *recA* DNA nucleic acids and/or sequences selected from public databases (Table 11) are disclosed.

Highly conserved genes for identification and diagnostics

Highly conserved genes are useful for identification of microorganisms. For bacteria, the most studied genes for identification of microorganisms are the universally conserved ribosomal RNA genes (rRNA). Among those, the principal targets used for identification purposes are the small subunit (SSU) ribosomal 16S rRNA genes (in prokaryotes) and 18S rRNA genes (in eukaryotes) (Relman and Persing, Genotyping Methods for Microbial Identification, *In:* D.H. Persing, 1996, PCR Protocols for Emerging Infectious Diseases, ASM Press, Washington D.C.). The rRNA genes are also the most commonly used targets for universal detection of bacteria (Chen *et al.*, 1988, FEMS Microbiol. Lett. **57**:19-24; McCabe *et al.*, 1999, Mol. Genet. Metabol. **66**:205-211) and fungi (Van Burik *et al.*, 1998, J. Clin. Microbiol. **36**:1169-1175).

However, it may be difficult to discriminate between closely related species when using primers derived from the 16S rRNA. In some instances, 16S rRNA sequence identity may not be sufficient to guarantee species identity (Fox *et al.*, 1992, Int. J. Syst. Bacteriol. **42**:166-170) and it has been shown that inter-operon sequence variation as well as strain to strain variation could undermine the application of 16S rRNA for identification purposes (Clayton *et al.*, 1995, Int. J. Syst. Bacteriol. **45**:595-599). The heat shock proteins (HSP) are another family of very conserved proteins. These ubiquitous proteins in bacteria and eukaryotes are expressed in answer to external stress agents. One of the most described of these HSP is HSP 60. This protein is very conserved at the amino acid level, hence it has been useful for phylogenetic studies. Similar to 16S rRNA, it would be difficult to

discriminate between species using the HSP 60 nucleotide sequences as a diagnostic tool. However, Goh *et al.* identified a highly conserved region flanking a variable region in HSP 60, which led to the design of universal primers amplifying this variable region (Goh *et al.*, US patent serial no. 5,708,160). The sequence variations in the resulting amplicons were found useful for the design of species-specific assays.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a specific, ubiquitous and sensitive method using probes and/or amplification primers for determining the presence and/or amount of nucleic acids:

- from any algal, archaeal, bacterial, fungal or parasitical species in any sample suspected of containing said nucleic acids, and optionally,
- from specific microbial species or genera selected from the group consisting of the species or genera listed in Table 4, and optionally,
- from an antimicrobial agents resistance gene selected from the group consisting of the genes listed in Table 5, and optionally,
- from a toxin gene selected from the group consisting of the genes listed in Table 6,

wherein each of said nucleic acids or a variant or part thereof comprises a selected target region hybridizable with said probes or primers;

said method comprising the steps of contacting said sample with said probes or primers and detecting the presence and/or amount of hybridized probes or amplified products as an indication of the presence and/or amount of said any

microbial species, specific microbial species or genus or family or group and antimicrobial agents resistance gene and/or toxin gene.

In a specific embodiment, a similar method directed to each specific microbial species or genus or family or group detection and identification, antimicrobial agents resistance genes detection, toxin genes detection, and universal bacterial detection, separately, is provided.

In a more specific embodiment, the method makes use of DNA fragments from conserved genes (proprietary sequences and sequences obtained from public databases), selected for their capacity to sensitively, specifically and ubiquitously detect the targeted algal, archaeal, bacterial, fungal or parasitical nucleic acids.

In a particularly preferred embodiment, oligonucleotides of at least 12 nucleotides in length have been derived from the longer DNA fragments, and are used in the present method as probes or amplification primers. To be a good diagnostic candidate, an oligonucleotide of at least 12 nucleotides should be capable of hybridizing with nucleic acids from given microorganism(s), and with substantially all strains and representatives of said microorganism(s); said oligonucleotide being species-, or genus-, or family-, or group-specific or universal.

In another particularly preferred embodiment, oligonucleotides primers and probes of at least 12 nucleotides in length are designed for their specificity and ubiquity based upon analysis of our databases of *tuf*, *atpD* and *recA* sequences. These databases are generated using both proprietary and public sequence information. Altogether, these databases form a sequence repertory useful for the design of primers and probes for the detection and identification of algal, archaeal, bacterial, fungal and parasitical microorganisms. The repertory can also be subdivided into subrepertoires for sequence analysis leading to the design of various primers and probes.

The *tuf*, *atpD* and *recA* sequences databases as a product to assist the design of oligonucleotides primers and probes for the detection and identification of algal, archaeal, bacterial, fungal and parasitical microorganisms are also covered.

The proprietary oligonucleotides (probes and primers) are also another object of this invention.

Diagnostic kits comprising probes or amplification primers such as those for the detection of a microbial species or genus or family or phylum or group selected from the following list consisting of *Abiotrophia adiacens*, *Acinetobacter baumanii*, *Actinomycetae*, *Bacteroides*, *Cytophaga* and *Flexibacter* phylum, *Bacteroides fragilis*, *Bordetella pertussis*, *Bordetella* sp., *Campylobacter jejuni* and *C. coli*, *Candida albicans*, *Candida dubliniensis*, *Candida glabrata*, *Candida guilliermondii*, *Candida krusei*, *Candida lusitaniae*, *Candida parapsilosis*, *Candida tropicalis*, *Candida zeylanoides*, *Candida* sp., *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium* sp., *Corynebacterium* sp., *Cryptococcus neoformans*, *Cryptococcus* sp., *Cryptosporidium parvum*, *Entamoeba* sp., *Enterobacteriaceae* group, *Enterococcus casseliflavus-flavescens-gallinarum* group, *Enterococcus faecalis*, *Enterococcus faecium*, *Enterococcus gallinarum*, *Enterococcus* sp., *Escherichia coli* and *Shigella* sp. group, *Gemella* sp., *Giardia* sp., *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Legionella* sp., *Leishmania* sp., *Mycobacteriaceae* family, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, platelets contaminants group (see Table 14), *Pseudomonas aeruginosa*, *Pseudomonads* group, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Staphylococcus hominis*, *Staphylococcus saprophyticus*, *Staphylococcus* sp., *Streptococcus agalactiae*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Streptococcus* sp., *Trypanosoma brucei*, *Trypanosoma cruzi*, *Trypanosoma* sp., *Trypanosomatidae* family, are also objects of the present invention.

Diagnostic kits further comprising probes or amplification primers for the detection of an antimicrobial agents resistance gene selected from the group listed in Table 5 are also objects of this invention.

Diagnostic kits further comprising probes or amplification primers for the detection of a toxin gene selected from the group listed in Table 6 are also objects of this invention.

Diagnostic kits further comprising probes or amplification primers for the detection of any other algal, archaeal, bacterial, fungal or parasitical species than those specifically listed herein, comprising or not comprising those for the detection of the specific microbial species or genus or family or group listed above, and further comprising or not comprising probes and primers for the antimicrobial agents resistance genes listed in Table 5, and further comprising or not comprising probes and primers for the toxin genes listed in Table 6 are also objects of this invention.

In a preferred embodiment, such a kit allows for the separate or the simultaneous detection and identification of the above-listed microbial species or genus or family or group; or universal detection of algae, archaea, bacteria, fungi or parasites; or antimicrobial agents resistance genes; or toxin genes; or for the detection of any microorganism (algae, archaea, bacteria, fungi or parasites).

In the above methods and kits, probes and primers are not limited to nucleic acids and may include, but are not restricted to analogs of nucleotides such as: inosine, 3-nitropyrrole nucleosides (Nichols *et al.*, 1994, *Nature* 369:492-493), Linked Nucleic Acids (LNA) (Koskin *et al.*, 1998, *Tetrahedron* 54:3607-3630), and Peptide Nucleic Acids (PNA) (Egholm *et al.*, 1993, *Nature* 365:566-568).

In the above methods and kits, amplification reactions may include but are not restricted to: a) polymerase chain reaction (PCR), b) ligase chain reaction (LCR), c) nucleic acid sequence-based amplification (NASBA), d) self-sustained sequence replication (3SR), e) strand displacement amplification (SDA), f) branched DNA signal amplification (bDNA), g) transcription-mediated amplification (TMA), h) cycling probe technology (CPT), i) nested PCR, j) multiplex PCR, k) solid phase amplification (SPA), l) nuclease dependent signal amplification (NDSA), m) rolling circle amplification technology (RCA), n) Anchored strand displacement amplification, o) Solid-phase (immobilized) rolling circle amplification.

In the above methods and kits, detection of the nucleic acids of target genes may include real-time or post-amplification technologies. These detection

technologies can include, but are not limited to, fluorescence resonance energy transfer (FRET)-based methods such as adjacent hybridization to FRET probes (including probe-probe and probe-primer methods), TaqMan, Molecular Beacons, scorpions, nanoparticle probes and Sunrise (Amplifluor). Other detection methods include target genes nucleic acids detection via immunological methods, solid phase hybridization methods on filters, chips or any other solid support, whether the hybridization is monitored by fluorescence, chemiluminescence, potentiometry, mass spectrometry, plasmon resonance, polarimetry, colorimetry, or scanometry. Sequencing, including sequencing by dideoxy termination or sequencing by hybridization, e.g. sequencing using a DNA chip, is another possible method to detect and identify the nucleic acids of target genes.

In a preferred embodiment, a PCR protocol is used for nucleic acid amplification, in diagnostic method as well as in method of construction of a repertory of nucleic acids and deduced sequences.

In a particularly preferred embodiment, a PCR protocol is provided, comprising, an initial denaturation step of 1-3 minutes at 95 °C, followed by an amplification cycle including a denaturation step of one second at 95 °C and an annealing step of 30 seconds at 45-65°C, without any time allowed specifically for the elongation step. This PCR protocol has been standardized to be suitable for PCR reactions with most selected primer pairs, which greatly facilitates the testing because each clinical sample can be tested with universal, species-specific, genus-specific, antimicrobial agents resistance gene and toxin gene PCR primers under uniform cycling conditions. Furthermore, various combinations of primer pairs may be used in multiplex PCR assays.

It is also an object of the present invention that *tuf*, *atpD* and *recA* sequences could serve as drug targets and these sequences and means to obtain them revealed in the present invention can assist the screening, design and modeling of these drugs.

It is also an object of the present invention that *tuf*, *atpD* and *recA* sequences could serve for vaccine purposes and these sequences and means to obtain them

revealed in the present invention can assist the screening, design and modeling of these vaccines.

We aim at developing a universal DNA-based test or kit to screen out rapidly samples which are free of algal, archaeal, bacterial, fungal or parasitical cells. This test could be used alone or combined with more specific identification tests to detect and identify the above algal and/or archaeal and/or bacterial and/or fungal and/or parasitical species and/or genera and/or family and/or group and to determine rapidly the bacterial resistance to antibiotics and/or presence of bacterial toxins. Although the sequences from the selected antimicrobial agents resistance genes are available from public databases and have been used to develop DNA-based tests for their detection, our approach is unique because it represents a major improvement over current diagnostic methods based on bacterial cultures. Using an amplification method for the simultaneous or independent or sequential microbial detection-identification and antimicrobial resistance genes detection, there is no need for culturing the clinical sample prior to testing. Moreover, a modified PCR protocol has been developed to detect all target DNA sequences in approximately one hour under uniform amplification conditions. This procedure should save lives by optimizing treatment, should diminish antimicrobial agents resistance because less antibiotics will be prescribed, should reduce the use of broad spectrum antibiotics which are expensive, decrease overall health care costs by preventing or shortening hospitalizations, and side effects of drugs, and decrease the time and costs associated with clinical laboratory testing.

In another embodiment, sequence repertoires and ways to obtain them for other gene targets are also an object of this invention, such is the case for the *hexA* nucleic acids and/or sequences of Streptococci.

In yet another embodiment, for the detection of mutations associated with antibiotic resistance genes, we built repertoires to distinguish between point mutations reflecting only gene diversity and point mutations involved in resistance. Such repertoires and ways to obtain them for *pbp1a*, *pbp2b* and *pbp2x* genes of sensitive and penicillin-resistant *Streptococcus pneumoniae* and also for *gyrA* and

parC gene fragments from various bacterial species are also an object of the present invention.

The diagnostic kits, primers and probes mentioned above can be used to identify algae, archaea, bacteria, fungi, parasites, antimicrobial agents resistance genes and toxin genes on any type of sample, whether said diagnostic kits, primers and probes are used for *in vitro* or *in situ* applications. The said samples may include but are not limited to: any clinical sample, any environment sample, any microbial culture, any microbial colony, any tissue, and any cell line.

It is also an object of the present invention that said diagnostic kits, primers and probes can be used alone or in conjunction with any other assay suitable to identify microorganisms, including but not limited to: any immunoassay, any enzymatic assay, any biochemical assay, any lysotypic assay, any serological assay, any differential culture medium, any enrichment culture medium, any selective culture medium, any specific assay medium, any identification culture medium, any enumeration culture medium, any cellular stain, any culture on specific cell lines, and any infectivity assay on animals.

In the methods and kits described herein below, the oligonucleotide probes and amplification primers have been derived from larger sequences (i.e. DNA fragments of at least 100 base pairs). All DNA fragments have been obtained either from proprietary fragments or from public databases. DNA fragments selected from public databases are newly used in a method of detection according to the present invention, since they have been selected for their diagnostic potential.

In another embodiment, the amino acid sequences translated from the repertory of *tuf*, *atpD* and *recA* nucleic acids and/or sequences are also an object of the present invention.

It is clear to the individual skilled in the art that other oligonucleotide sequences appropriate for (i) the universal detection of algae, archaea, bacteria, fungi or parasites, (ii) the detection and identification of the above microbial species or genus or family or group, and (iii) the detection of antimicrobial agents resistance genes, and (iv) the detection of toxin genes, other than those listed in

Annexes I to III, XXI to XXII, XXXII to XXXVII, XXXIX to XLI, and XLIII to LIV may also be derived from the proprietary fragments or selected public database sequences. For example, the oligonucleotide primers or probes may be shorter or longer than the ones chosen; they may also be selected anywhere else in the proprietary DNA fragments or in the sequences selected from public databases; they may be also variants of the same oligonucleotide. If the target DNA or a variant thereof hybridizes to a given oligonucleotide, or if the target DNA or a variant thereof can be amplified by a given oligonucleotide PCR primer pair, the converse is also true; a given target DNA may hybridize to a variant oligonucleotide probe or be amplified by a variant oligonucleotide PCR primer. Alternatively, the oligonucleotides may be designed from any DNA fragment sequences for use in amplification methods other than PCR. Consequently, the core of this invention is the identification of universal, species-specific, genus-specific, family-specific, group-specific, resistance gene-specific, toxin gene-specific genomic or non-genomic DNA fragments which are used as a source of specific and ubiquitous oligonucleotide probes and/or amplification primers. Although the selection and evaluation of oligonucleotides suitable for diagnostic purposes requires much effort, it is quite possible for the individual skilled in the art to derive, from the selected DNA fragments, oligonucleotides other than the ones listed in Annexes I to III, XXI to XXII, XXXII to XXXVII, XXXIX to XLI, and XLIII to LIV which are suitable for diagnostic purposes. When a proprietary fragment or a public databases sequence is selected for its specificity and ubiquity, it increases the probability that subsets thereof will also be specific and ubiquitous.

Since a high percentage of clinical specimens are negative for bacteria (Table 3), DNA fragments having a high potential for the selection of universal oligonucleotide probes or primers were selected from proprietary and public database sequences. The amplification primers were selected from genes highly conserved in algae, archaea, bacteria, fungi and parasites, and are used to detect the presence of any algal, archaeal, bacterial, fungal or parasitical pathogen in clinical specimens in order to determine rapidly whether it is positive or negative for algae,

archaea, bacteria, fungi or parasites. The selected genes, designated *tuf*, *fus*, *atpD* and *recA*, encode respectively 2 proteins (elongation factors Tu and G) involved in the translational process during protein synthesis, a protein (beta subunit) responsible for the catalytic activity of proton pump ATPase and a protein responsible for the homologous recombination of genetic material. The alignments of *tuf*, *atpD* and *recA* sequences used to derive the universal primers include both proprietary and public database sequences. The universal primer strategy allows the rapid screening of the numerous negative clinical specimens (around 80% of the specimens received, see Table 3) submitted for microbiological testing.

Table 4 provides a list of the archaeal, bacterial, fungal and parasitical species for which *tuf* and/or *atpD* and/or *recA* nucleic acids and/or sequences are revealed in the present invention. Tables 5 and 6 provide a list of antimicrobial agents resistance genes and toxin genes selected for diagnostic purposes. Table 7 provides the origin of *tuf*, *atpD* and *recA* nucleic acids and/or sequences listed in the sequence listing. Tables 8-10 and 12-14 provide lists of species used to test the specificity, ubiquity and sensitivity of some assays described in the examples. Table 11 provides a list of microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases. Table 15 lists the microorganisms identified by commercial systems. Tables 16-18 are part of Example 42, whereas Tables 19-20 are part of Example 43. Tables 21-22 illustrate Example 44, whereas Tables 23-25 illustrate Example 45.

In accordance with the present invention is provided a method for generating a repertory of nucleic acids of *tuf*, *fus*, *atpD* and/or *recA* genes from which are derived probes or primers, or both, useful for the detection of one, more than one related microorganisms, or substantially all microorganisms of a group selected from algae, archaea, bacteria, fungi and parasites, which comprises the step of:

- amplifying the nucleic acids of a plurality of determined algal, archaeal, bacterial, fungal and parasitical species with any combination of the primer pairs defined in SEQ ID NOs.: 558-561, 562-574, 636-655, 664, 681-683, 696-697, 699-700, 708, 812-815, 911-917, 919-922, 935-938, 1203-1207, 1212-1213, 1221-1229, 1605-1606, 1974-1984, 1999- 2003, 2282-2285.

The terms "related microorganisms" are intended to cover microorganisms that share a common evolutive profile up to the speciation e.g. those that belong to a species, a genus, a family or a phylum. The same terms are also intended to cover a group of different species that are grouped for a specific reason, for example, because they all have a common host tissue or cell. In one specific example, a group of microorganisms potentially found in platelet preparations are grouped together and are considered "related" organisms for the purpose of their simultaneous detection in that particular type of sample.

The repertoires *per se* of nucleic acids and of sequences derived therefrom are also provided, as well as "gene banks" comprising these repertoires.

For generating sequences of probes or primers, the above method is reproduced or one may start from the sequence repertory or gene bank itself, and the following steps are added:

- aligning a subset of nucleic acid sequences of said repertory,
- locating nucleic acid stretches that are present in the nucleic acids of strains or representatives of said one, more than one related microorganisms, or substantially all microorganisms of said group, and not present in the nucleic acid sequences of other microorganisms, and

deriving consensus nucleic acid sequences useful as probes or primers from said stretches.

Once the sequences of probes or primers are designed, they are converted into real molecules by nucleic acid synthesis.

From the above methods and resulting repertoires, probes and primers for the universal detection of any one of alga, archaeon, bacterium, fungus and parasite are obtainable.

More specifically, the following probes or primers having the sequence defined in SEQ ID NOs.: 543, 556-574, 636-655, 658-661, 664, 681-683, 694, 696, 697, 699, 700, 708, 812-815, 911-917, 919-922, 935-938, 1203-1207, 1212-1213, 1221-1229, 1605-1606, 1974-1984, 1999-2000, 2282-2285 or any variant of at least 12 nucleotides capable of hybridizing with the targeted microorganism(s) and these sequences and a diagnostic method using the same are provided.

Further, probes or primers having specific and ubiquitous properties for the detection and identification of any one of an algal, archaeal, bacterial, fungal and parasitital species, genus, family and group are also designed and derived from the same methods and repertoires.

More specifically, are provided definite probes or primers having specific and ubiquitous properties for the detection and identification of microorganisms.

Indeed, a general method is provided for detecting the presence in a test sample of any microorganism that is an alga, archaeum, bacterium, fungus or parasite, which comprises:

a) putting in contact any test sample *tuf* or *atpD* or *recA* sequences and nucleic acid primers and/or probes, said primers and/or probes having been selected to be sufficiently complementary to hybridize to

one or more *tuf* or *atpD* or *recA* sequences that are specific to said microorganism:

- b) allowing the primers and/or probes and any test sample *tuf* or *atpD* or *recA* sequences to hybridize under specified conditions such as said primers and/or probes hybridize to the *tuf* or *atpD* or *recA* sequences of said microorganism and does not detectably hybridize to *tuf* or *atpD* or *recA* sequences from other microorganisms; and,
- c) testing for hybridization of said primers and/or probes to any test sample *tuf* or *atpD* or *recA* sequences.

In the latter, step c) is based on a nucleic acid target amplification method, or on a signal amplification method.

The terms "sufficiently complementary" cover perfect and imperfect complementarity.

In addition to the universal or the specific detection and/or identification of microorganisms, the simultaneous detection of antimicrobial agent resistance gene or of a toxin gene is provided in compositions of matter as well as in diagnostic methods. Such detection is brought by using probes or primers having at least 12 nucleotides in length capable of hybridizing with an antimicrobial agent resistance gene and/or toxin gene, a definite set thereof being particularly provided.

Of course, any proprietary nucleic acid and nucleotide sequence derived therefrom, and any variant of at least 12 nucleotides capable of a selective hybridization with the following nucleic acids are within the scope of this invention as well as derived recombinant vectors and hosts:

SEQ ID NOs.: 1-73, 75-241, 399-457, 498-529, 612-618, 621-624, 675, 677, 717-736, 779-792, 840-855, 865, 868-888, 897-910, 932, 967-989 992, 1266-1297, 1518-1526, 1561-1575, 1578-1580, 1662-1664, 1666-1667, 1669-1670, 1673-1683, 1685-1689, 1786-1843, 1874-1881, 1956-1960, 2183-2185, 2187-2188, 2193-2201, 2214-2249, 2255-2272, which are all *tuf* sequences;

SEQ ID NOs.: 242-270, 272-398, 458-497, 530-538, 663, 667, 673-676, 678-680, 737-778, 827-832, 834-839, 856-862, 866-867, 889-896, 929-931, 941-966, 1245-1254, 1256-1265, 1527, 1576-1577, 1600-1604, 1638-1647, 1649-1660, 1671, 1684, 1844-1848, 1849-1865, 2189-2192, which are all *atpD* sequences;

SEQ ID NOs.: 990-991, 1003, 1288-1289, 1714, 1756-1763, 1866-1873 and 2202-2212, which are all *recA* sequences; and

SEQ ID NOs.: 1004-1075, 1255, 1607-1608, 1648, 1764-1785, 2013-2014, 2056-2064, 2273-2280, which are antimicrobial agent resistance or toxin gene sequences found to be suitable for the detection and identification of microbial species.

To complement the following repertoires, another one comprising *hexA* nucleic acids and derived sequences have been construed through amplification of nucleic acids of any streptococcal species with any combination of primers SEQ ID NOs.: 1179, 1181, 1182 and 1184 to 1191. From this particular repertoire, primers and/or probes for detecting *Streptococcus pneumoniae* have been designed and obtained. Particularly, a nucleic acid sequence of at least 12 nucleotides capable of hybridizing with *Streptococcus pneumoniae* and with any one of SEQ ID NOs.: 1184 to 1187 or with SEQ ID NOs.: 1179, 1180, 1181 or 1182 are provided.

The remarkable sequence diversity of nucleic acids that encode proteins also provides diversity of peptide sequences which constitute another repertoire that is also within the scope of this invention. From the protein and nucleic acid sequence repertoires is derived a use therefrom for the design of a therapeutic agent effective against a target microorganism, for example, an antibiotic, a vaccine or a genic therapeutic agent.

Due to the constant evolution in the diagnostic methods, here is finally provided a method for the identification of a microorganism in a test sample, comprising the steps of:

- a) obtaining a nucleic acid sequence from a *tuf*, *fus*, *atpD*, and/or *recA* genes of said microorganisms, and

- b) comparing said nucleic acid sequence with the nucleic acid sequences of a bank as defined in claim 5, said repertory comprising a nucleic acid sequence obtained from the nucleic acids of said microorganism, whereby said microorganism is identify when there is a match between the sequences.

In this method, any way by which the specified given sequence is obtained is contemplated, and this sequence is simply compared to the sequences of a bank or a repertory. If the comparison results in a match, e.g. if bank comprises the nucleic acid sequence of interest, the identification of the microorganism is provided.

DETAILED DESCRIPTION OF THE INVENTION

HIGHLY CONSERVED GENES AND THEIR USE TO GENERATE SPECIES-SPECIFIC, GENUS-SPECIFIC, FAMILY-SPECIFIC, GROUP-SPECIFIC AND UNIVERSAL NUCLEIC ACID PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY ALGAL, ARCHAEOAL, BACTERIAL, FUNGAL AND PARASITICAL MICROORGANISMS FROM CLINICAL SPECIMENS FOR DIAGNOSIS

The present inventors reasoned that comparing the published *Haemophilus influenzae* and *Mycoplasma genitalium* genomes and searching for conserved genes could provide targets to develop useful diagnostic primers and probes. This sequence comparison is highly informative as these two bacteria are distantly related and most genes present in the minimal genome of *M. genitalium* are likely to be present in every bacterium. Therefore genes conserved between these two bacteria are likely to be conserved in all other bacteria.

Following the genomic comparison, it was found that several protein-coding genes were conserved in evolution. Highly conserved proteins included the translation elongation factors G (EF-G) and Tu (EF-Tu) and the β subunit of F₀F₁ type ATP-synthase, and to a lesser extent, the RecA recombinase. These four proteins coding genes were selected amongst the 20 most conserved genes on the basis that they all possess at least two highly conserved regions suitable for the design of universal amplification and sequencing primers. Moreover, within the fragment amplified by these primers, highly conserved and more variable regions are also present hence suggesting it might be possible to rapidly obtain sequence information from various microbial species to design universal as well as species-, genus-, family-, or group-specific primers and probes of potential use for the detection and identification and/or quantification of microorganisms.

Translation elongation factors are members of a family of GTP-binding proteins which intervene in the interactions of tRNA molecules with the ribosome machinery during essential steps of protein synthesis. The role of elongation factor Tu is to facilitate the binding of aminoacylated tRNA molecules to the A site of the ribosome. The eukaryotic, archaeal (archaeabacterial) and algal homolog of EF-Tu is called elongation factor 1 alpha (EF-1 α). All protein synthesis factors originated from a common ancestor via gene duplications and fusions (Cousineau *et al.*, 1997, J. Mol. Evol. 45:661-670). In particular, elongation factor G (EF-G), although having a functional role in promoting the translocation of aminoacyl-tRNA molecules from the A site to the P site of the ribosome, shares sequence homologies with EF-Tu and is thought to have arisen from the duplication and fusion of an ancestor of the EF-Tu gene.

In addition, EF-Tu is known to be the target for antibiotics belonging to the elfamycin's group as well as to other structural classes (Anborgh and Parmeggiani, 1991, EMBO J. 10:779-784; Luiten *et al.*, 1992, European patent application serial No. EP 0 466 251 A1). EF-G for its part, is the target of the antibiotic fusidic acid. In addition to its crucial activities in translation, EF-Tu has chaperone-like functions in protein folding, protection against heat denaturation of proteins and interactions with unfolded proteins (Caldas *et al.*, 1998, J. Biol. Chem. 273:11478-11482). Interestingly, a form of the EF-Tu protein has been identified as a dominant component of the periplasm of *Neisseria gonorrhoeae* (Porcella *et al.*, 1996, Microbiology 142:2481-2489), hence suggesting that at least in some bacterial species, EF-Tu might be an antigen with vaccine potential.

F₀F₁ type ATP-synthase belongs to a superfamily of proton-translocating ATPases divided in three major families: P, V and F (Nelson and Taiz, 1989, TIBS 14:113-116). P-ATPases (or E₁-E₂ type) operate via a phosphorylated intermediate and are not evolutionarily related to the other two families. V-ATPases (or V₀V₁ type) are present on the vacuolar and other endomembranes of eukaryotes, on the plasma membrane of archaea (archaeabacteria) and algae, and also on the plasma membrane of some eubacteria especially species belonging to the order

Spirochaetales as well as to the *Chlamydiaceae* and *Deinococcaceae* families. F-ATPases (or F₀F₁ type) are found on the plasma membrane of most eubacteria, on the inner membrane of mitochondria and on the thylakoid membrane of chloroplasts. They function mainly in ATP synthesis. They are large multimeric enzymes sharing numerous structural and functional features with the V-ATPases. F and V-type ATPases have diverged from a common ancestor in an event preceding the appearance of eukaryotes. The β subunit of the F-ATPases is the catalytic subunit and it possesses low but significant sequence homologies with the catalytic A subunit of V-ATPases.

The translation elongation factors EF-Tu, EF-G and EF-1 α , and the catalytic subunit of F or V-types ATP-synthase, are highly conserved proteins sometimes used for phylogenetic analysis and their genes are also known to be highly conserved-(Iwabe *et al.*, 1989, Proc. Natl. Acad. Sci. USA **86**:9355-9359, Gogarten *et al.*, 1989, Proc. Natl. Acad. Sci. USA **86**:6661-6665, Ludwig *et al.*, 1993, Antonie van Leeuwenhoek **64**:285-305). A recent BLAST (Altschul *et al.*, 1997, J. Mol. Biol. **215**:403-410) search performed by the present inventors on the GenBank, European Molecular Biology Laboratory (EMBL), DNA Database of Japan (DDBJ) and specific genome project databases indicated that throughout bacteria, the EF-Tu and the β subunit of F₀F₁ type ATP-synthase genes may be more conserved than other genes that are well conserved between *H. influenzae* and *M. genitalium*.

The RecA recombinase is a multifunctional protein encoded by the *recA* gene. It plays a central role in homologous recombination, it is critical for the repair of DNA damage and it is involved in the regulation of the SOS system by promoting the proteolytic digestion of the LexA repressor. It is highly conserved in bacteria and could serve as a useful genetic marker to reconstruct bacterial phylogeny (Miller and Kokjohn, 1990, Annu. Rev. Microbiol. **44**:365-394). Although RecA possesses some highly conserved sequence segments that we used to design universal primers aimed at sequencing the *recA* fragments, it is clearly not as well conserved EF-G, EF-Tu and β subunit of F₀F₁ type ATP-synthase.

Hence, RecA may not be optimal for universal detection of bacteria with high sensitivity but it was chosen because preliminary data indicated that EF-G, EF-Tu and β subunit of F₀F₁ type ATP-synthase may sometimes be too closely related to find specific primer pairs that could discriminate between certain very closely related species and genera. While RecA, EF-G, EF-Tu and β subunit of F₀F₁ type ATP-synthase genes, possesses highly conserved regions suitable for the design of universal sequencing primers, the less conserved region between primers should be divergent enough to allow species-specific and genus-specific primers in those cases.

Thus, as targets to design primers and probes for the genetic detection of microorganisms, the present inventors have focused on the genes encoding these four proteins: *tuf*, the gene for elongation factor Tu (EF-Tu); *fus*, the gene for the elongation-factor G (EF-G); *atpD*, the gene for β subunit of F₀F₁ type ATP-synthase; and *recA*, the gene encoding the RecA recombinase. In several bacterial genomes *tuf* is often found in two highly similar duplicated copies named *tufA* and *tufB* (Filer and Furano, 1981, J. Bacteriol. 148:1006-1011, Sela *et al.*, 1989, J. Bacteriol. 171:581-584). In some particular cases, more divergent copies of the *tuf* genes can exist in some bacterial species such as some actinomycetes (Luiten *et al.* European patent application publication No. EP 0 446 251 A1; Vijgenboom *et al.*, 1994, Microbiology 140:983-998) and, as revealed as part of this invention, in several enterococcal species. In several bacterial species, *tuf* is organized in an operon with its homolog gene for the elongation factor G (EF-G) encoded by the *fusA* gene (Figure 3). This operon is often named the *str* operon. The *tuf*, *fus*, *atpD* and *recA* genes were chosen as they are well conserved in evolution and have highly conserved stretches as well as more variable segments. Moreover, these four genes have eukaryotic orthologs which are described in the present invention as targets to identify fungi and parasites. The eukaryotic homolog of elongation factor Tu is called elongation factor 1-alpha (EF-1 α) (gene name: *tef*, *tef1*, *efl*, *ef-1* or *EF-1*). In fungi, the gene for EF-1 α occurs sometimes in two or more highly

similar duplicated copies (often named *tef1*, *tef2*, *tef3*...). In addition, eukaryotes have a copy of elongation factor Tu which is originating from their organelle genome ancestry (gene name: *tuf1*, *tufM* or *tufA*). For the purpose of the current invention, the genes for these four functionally and evolutionarily linked elongation factors (bacterial EF-Tu and EF-G, eukaryotic EF-1 α , and organellar EF-Tu) will hereafter be designated as «*tuf* nucleic acids and/or sequences». The eukaryotic (mitochondrial) F0F1 type ATP-synthase beta subunit gene is named *atp2* in yeast. For the purpose of the current invention, the genes of catalytic sub-unit of either F or V-type ATP-synthase will hereafter be designated as «*atpD* nucleic acids and/or sequences». The eukaryotic homologs of RecA are distributed in two families, typified by the Rad51 and Dmc1 proteins. Archaeal homologs of RecA are called RadA. For the purpose of the current invention, the genes corresponding to the latter proteins will hereafter be designated as «*recA* nucleic acids and/or sequences».

In the description of this invention, the terms «nucleic acids» and «sequences» might be used interchangeably. However, «nucleic acids» are chemical entities while «sequences» are the pieces of information derived from (inherent to) these «nucleic acids». Both nucleic acids and sequences are equivalently valuable sources of information for the matter pertaining to this invention.

Analysis of multiple sequence alignments of *tuf* and *atpD* sequences permitted the design of oligonucleotide primers (and probes) capable of amplifying (or hybridizing to) segments of *tuf* (and/or *fus*) and *atpD* genes from a wide variety of bacterial species (see Examples 1 to 4, 24 and 26, and Table 7). Sequencing and amplification primer pairs for *tuf* nucleic acids and/or sequences are listed in Annex I and hybridization probes are listed in Annexes III and XLVII. Sequencing and amplification primer pairs for *atpD* nucleic acids and/or sequences are listed in Annex II. Analysis of the main subdivisions of *tuf* and *atpD* sequences (see Figures 1 and 2) permitted to design sequencing primers amplifying specifically each of these subdivisions. It should be noted that these sequencing primers could also be used as universal primers. However, since some of these sequencing primers

include several variable sequence (degenerated) positions, their sensitivity could be lower than that of universal primers developed for diagnostic purposes. Further subdivisions could be done on the basis of the various phyla where these genes are encountered.

Similarly, analysis of multiple sequence alignments of *recA* sequences present in the public databases permitted the design of oligonucleotide primers capable of amplifying segments of *recA* genes from a wide variety of bacterial species. Sequencing and amplification primer pairs for *recA* sequences are listed in Annex XXI. The main subdivisions of *recA* nucleic acids and/or sequences comprise *recA*, *radA*, *rad51* and *dmc1*. Further subdivisions could be done on the basis of the various phyla where these genes are encountered.

The present inventor's strategy is to get as much sequence data information from the four conserved genes (*tuf*, *fus*, *atpD* and *recA*). This ensemble of sequence data forming a repertory (with subrepertoires corresponding to each target gene and their main sequence subdivisions) and then using the sequence information of the sequence repertory (or subrepertoires) to design primer pairs that could permit either universal detection of algae or archaea or bacteria or fungi or parasites, detection of a family or group of microorganism (e.g. *Enterobacteriaceae*), detection of a genus (e.g. *Streptococcus*) or finally a specific species (e.g. *Staphylococcus aureus*). It should be noted that for the purpose of the present invention a group of microorganisms is defined depending on the needs of the particular diagnostic test. It does not need to respect a particular taxonomical grouping or phylum. See Example 12 where primers were designed to amplify a group of bacteria consisting of the 17 major bacterial species encountered as contaminants of platelet concentrates. Also remark that in that Example, the primers are not only able to sensitively and rapidly detect at least the 17 important bacterial species, but could also detect other species as well, as shown in Table 14. In these circumstances the primers shown in Example 12 are considered universal for platelet-contaminating bacteria. To develop an assay specific for the latter, one or more primers or probes specific to each species could be designed. Another

example of primers and/or probes for group detection is given by the Pseudomonad group primers. These primers were designed based upon alignment of *tuf* sequences from real *Pseudomonas* species as well as from former *Pseudomonas* species such as *Stenotrophomonas maltophilia*. The resulting primers are able to amplify all *Pseudomonas* species tested as well as several species belonging to different genera, hence as being specific for a group including *Pseudomonas* and other species, we defined that group as Pseudomonads, as several members were former *Pseudomonas*.

For certain applications, it may be possible to develop a universal, group, family or genus-specific reaction and to proceed to species identification using sequence information within the amplicon to design species-specific internal probes or primers, or alternatively, to proceed directly by sequencing the amplicon. The various strategies will be discussed further below.

The ensembles formed by public and proprietary *tuf*, *atpD* and *recA* nucleic acids and/or sequences are used in a novel fashion so they constitute three databases containing useful information for the identification of microorganisms.

Sequence repertoires of other gene targets were also built to solve some specific identification problems especially for microbial species genetically very similar to each other such as *E. coli* and *Shigella* (see Example 23). Based on *tuf*, *atpD* and *recA* sequences, *Streptococcus pneumoniae* is very difficult to differentiate from the closely related species *S. oralis* and *S. mitis*. Therefore, we elected to build a sequence repertoire from *hexA* sequences (Example 19), a gene much more variable than our highly conserved *tuf*, *atpD* and *recA* nucleic acids and/or sequences.

For the detection of mutations associated with antibiotic resistance genes, we also built repertoires to distinguish between point mutations reflecting only gene diversity and point mutations involved in resistance. This was done for *pbp1a*, *pbp2b* and *pbp2x* genes of penicillin-resistant and sensitive *Streptococcus pneumoniae* (Example 18) and also for *gyrA* and *parC* gene fragments of various bacterial species for which quinolone resistance is important to monitor.

Oligonucleotide primers and probes design and synthesis

The *tuf*, *fus*, *atpD* and *recA* DNA fragments sequenced by us and/or selected from public databases (GenBank and EMBL) were used to design oligonucleotides primers and probes for diagnostic purposes. Multiple sequence alignments were made using subsets of the *tuf* or *atpD* or *recA* sequences repertory. Subsets were chosen to encompass as much as possible of the targetted microorganism(s) DNA sequence data and also include sequence data from phylogenetically related microorganisms from which the targetted microorganism(s) should be distinguished. Regions suitable for primers and probes should be conserved for the targetted microorganism(s) and divergent for the microorganisms from which the targetted microorganism(s) should be distinguished. The large amount of *tuf* or *atpD*-or-*recA* sequences data in our repertory permits to reduce trial and errors in obtaining specific and ubiquitous primers and probes. We also relied on the corresponding peptide sequences of *tuf*, *fus*, *atpD* and *recA* nucleic acids and/or sequences to facilitate the identification of regions suitable for primers and probes design. As part of the design rules, all oligonucleotides (probes for hybridization and primers for DNA amplification by PCR) were evaluated for their suitability for hybridization or PCR amplification by computer analysis using standard programs (i.e. the Genetics Computer Group (GCG) programs and the primer analysis software Oligo™ 5.0). The potential suitability of the PCR primer pairs was also evaluated prior to the synthesis by verifying the absence of unwanted features such as long stretches of one nucleotide and a high proportion of G or C residues at the 3' end (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.). Oligonucleotide probes and amplification primers were synthesized using an automated DNA synthesizer (Perkin-Elmer Corp., Applied Biosystems Division).

The oligonucleotide sequence of primers or probes may be derived from either strand of the duplex DNA. The primers or probes may consist of the bases

A, G, C, or T or analogs and they may be degenerated at one or more chosen nucleotide position(s). The primers or probes may be of any suitable length and may be selected anywhere within the DNA sequences from proprietary fragments or from selected database sequences which are suitable for (i) the universal detection of algae or archaea or bacteria or fungi or parasites, (ii) the species-specific detection and identification of any microorganism, including but not limited to: *Abiotrophia adiacens*, *Bacteroides fragilis*, *Bordetella pertussis*, *Candida albicans*, *Candida dubliniensis*, *Candida glabrata*, *Candida guilliermondii*, *Candida krusei*, *Candida lusitaniae*, *Candida parapsilosis*, *Candida tropicalis*, *Candida zeylanoides*, *Campylobacter jejuni* and *C. coli*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Cryptococcus neoformans*, *Cryptosporidium parvum*, *Enterococcus faecalis*, *Enterococcus faecium*, *Enterococcus gallinarum*, *Escherichia coli*, *Haemophilus influenzae*, *Legionella pneumophila*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Staphylococcus hominis*, *Staphylococcus saprophyticus*, *Streptococcus agalactiae*, *Streptococcus pneumoniae*, *Trypanosoma brucei*, *Trypanosoma cruzi*, (iii) the genus-specific detection of *Bordetella* species, *Candida* species, *Clostridium* species, *Corynebacterium* species, *Cryptococcus* species, *Entamoeba* species, *Enterococcus* species, *Gemella* species, *Giardia* species, *Legionella* species, *Leishmania* species, *Staphylococcus* species, *Streptococcus* species, *Trypanosoma* species, (iv) the family-specific detection of *Enterobacteriaceae* family members, *Mycobacteriaceae* family members, *Trypanosomatidae* family members, (v) the detection of *Enterococcus casseliflavus-flavescens-gallinarum* group, *Enterococcus*, *Gemella* and *Abiotrophia adiacens* group, Pseudomonads extended group, Platelet-contaminating bacteria group, (vi) the detection of clinically important antimicrobial agents resistance genes listed in Table 5, (vii) the detection of clinically important toxin genes listed in Table 6.

Variants for a given target microbial gene are naturally occurring and are attributable to sequence variation within that gene during evolution (Watson *et al.*, 1987, Molecular Biology of the Gene, 4th ed., The Benjamin/Cummings Publishing Company, Menlo Park, CA; Lewin, 1989, Genes IV, John Wiley & Sons, New York, NY). For example, different strains of the same microbial species may have a single or more nucleotide variation(s) at the oligonucleotide hybridization site. The person skilled in the art is well aware of the existence of variant algal, archaeal, bacterial, fungal or parasitical DNA nucleic acids and/or sequences for a specific gene and that the frequency of sequence variations depends on the selective pressure during evolution on a given gene product. The detection of a variant sequence for a region between two PCR primers may be demonstrated by sequencing the amplification product. In order to show the presence of sequence variants at the primer hybridization site, one has to amplify a larger DNA target with PCR primers outside that hybridization site. Sequencing of this larger fragment will allow the detection of sequence variation at this site. A similar strategy may be applied to show variants at the hybridization site of a probe. Insofar as the divergence of the target nucleic acids and/or sequences or a part thereof does not affect the specificity and ubiquity of the amplification primers or probes, variant microbial DNA is under the scope of this invention. Variants of the selected primers or probes may also be used to amplify or hybridize to a variant DNA.

Sequencing of *tuf* nucleic acids and/or sequences from a variety of archaeal, bacterial, fungal and parasitical species

The nucleotide sequence of a portion of *tuf* nucleic acids and/or sequences was determined for a variety of archaeal, bacterial, fungal and parasitical species. The amplification primers (SEQ ID NOs. 664 and 697), which amplify a *tuf* gene portion of approximately 890 bp, were used along with newly designed sequencing primer pairs (See Annex I for the sequencing primers for *tuf* nucleic acids and/or

sequences). Most primer pairs can amplify different copies of *tuf* genes (*tufA* and *tufB*). This is not surprising since it is known that for several bacterial species these two genes are nearly identical. For example, the entire *tufA* and *tufB* genes from *E. coli* differ at only 13 nucleotide positions (Neidhardt *et al.*, 1996, *Escherichia coli* and *Salmonella*: Cellular and Molecular Biology, 2nd ed., American Society for Microbiology Press, Washington, D.C.). Similarly, some fungi are known to have two nearly identical copies of *tuf* nucleic acids and/or sequences (EF-1 α). These amplification primers are degenerated at several nucleotide positions and contain inosines in order to allow the amplification of a wide range of *tuf* nucleic acids and/or sequences. The strategy used to select these amplification primers is similar to that illustrated in Annex I for the selection of universal primers. The *tuf* sequencing primers even sometimes amplified highly divergent copies of *tuf* genes (*tufC*) as illustrated in the case of some enterococcal species (SEQ ID NOs.: 73, 75, 76, 614 to 618, 621 and 987 to 989). To prove this, we have determined the enterococcal *tuf* nucleic acids and/or sequences from PCR amplicons cloned into a plasmid vector. Using the sequence data from the cloned amplicons, we designed new sequencing primers specific to the divergent (*tufC*) copy of enterococci (SEQ ID NOs.: 658-659 and 661) and then sequenced directly the *tufC* amplicons. The amplification primers (SEQ ID NOs.: 543, 556, 557, 643-645, 660, 664, 694, 696 and 697) could be used to amplify the *tuf* nucleic acids and/or sequences from any bacterial species. The amplification primers (SEQ ID NOs.: 558, 559, 560, 653, 654, 655, 813, 815, 1974-1984, 1999-2003) could be used to amplify the *tuf* (EF-1 α) genes from any fungal and/or parasitical species. The amplification primers SEQ ID NOs. 1221-1228 could be used to amplify bacterial *tuf* nucleic acids and/or sequences of the EF-G subdivision (*fusA*) (Figure 3). The amplification primers SEQ ID NOs. 1224, and 1227-1229 could be used to amplify bacterial *tuf* nucleic acids and/or sequences comprising the end of EF-G (*fusA*) and the beginning of EF-Tu (*tuf*), including the intergenic region, as shown in Figure 3. Most *tuf* fragments to be sequenced were amplified using the following amplification protocol: One μ l of cell suspension (or of purified genomic DNA

0.1-100 ng/ μ l) was transferred directly to 19 μ l of a PCR reaction mixture. Each PCR reaction contained 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM MgCl₂, 1 μ M of each of the 2 primers, 200 μ M of each of the four dNTPs, 0.5 unit of *Taq* DNA polymerase (Promega Corp., Madison, WI). PCR reactions were subjected to cycling using a PTC-200 thermal cycler (MJ Research Inc., Watertown, Mass.) as follows: 3 min at 94-96 °C followed by 30-45 cycles of 1 min at 95 °C for the denaturation step, 1 min at 50-55 °C for the annealing step and 1 min at 72 °C for the extension step. Subsequently, twenty microliters of the PCR-amplified mixture were resolved by electrophoresis in a 1.5% agarose gel. The amplicons were then visualized by staining with methylene blue (Flores *et al.*, 1992, Biotechniques, 13:203-205). The size of the amplification products was estimated by comparison with a 100-bp molecular weight ladder. The band corresponding to the specific amplification product was excised from the agarose gel and purified using the QIAquick™ gel extraction kit (QIAGEN Inc., Chatsworth, CA). The gel-purified DNA fragment was then used directly in the sequencing protocol. Both strands of the *tuf* genes amplification product were sequenced by the dideoxynucleotide chain termination sequencing method by using an Applied Biosystems automated DNA sequencer (model 377) with their Big Dye™ Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA). The sequencing reactions were performed by using the same amplification primers and 10 ng/100 bp of the gel-purified amplicon per reaction. For the sequencing of long amplicons such as those of eukaryotic *tuf* (EF-1 α) nucleic acids and/or sequences, we designed internal sequencing primers (SEQ ID NOS.: 654, 655 and 813) to be able to obtain sequence data on both strands for most of the fragment length. In order to ensure that the determined sequence did not contain errors attributable to the sequencing of PCR artefacts, we have sequenced two preparations of the gel-purified *tuf* amplification product originating from two independent PCR amplifications. For most target microbial species, the sequences determined for both amplicon preparations were identical. In case of discrepancies, amplicons from a third independent PCR amplification

were sequenced. Furthermore, the sequences of both strands were 100% complementary thereby confirming the high accuracy of the determined sequence. The *tuf* nucleic acids and/or sequences determined using the above strategy are described in the Sequence Listing. Table 7 gives the originating microbial species and the source for each *tuf* sequence in the Sequence Listing.

The alignment of the *tuf* sequences determined by us or selected from databases revealed clearly that the length of the sequenced portion of the *tuf* genes is variable. There may be insertions or deletions of several amino acids. In addition, in several fungi introns were observed. Intron nucleic acids and/or sequences are part of *tuf* nucleic acids and/or sequences and could be useful in the design of species-specific primers and probes. This explains why the size of the sequenced *tuf* amplification products was variable from one fungal species to another. Consequently, the nucleotide positions indicated on top of each of Annexes IV to XX, XXIII to XXXI, XXXVIII and XLII do not correspond for sequences having insertions or deletions.

It should also be noted that the various *tuf* nucleic acids and/or sequences determined by us occasionally contain base ambiguities. These degenerated nucleotides correspond to sequence variations between *tufA* and *tufB* genes (or copies of the EF-G subdivision of *tuf* nucleic acids and/or sequences, or copies of EF-1 α subdivision of *tuf* nucleic acids and/or sequences for fungi and parasites) because the amplification primers amplify both *tuf* genes. These nucleotide variations were not attributable to nucleotide misincorporations by the *Taq* DNA polymerase because the sequence of both strands was identical and also because the sequences determined with both preparations of the gel-purified *tuf* amplicons obtained from two independent PCR amplifications were identical.

The selection of amplification primers from *tuf* nucleic acids and/or sequences

The *tuf* sequences determined by us or selected from public databases were used to select PCR primers for universal detection of bacteria, as well as for genus-

specific, species-specific family-specific or group-specific detection and identification. The strategy used to select these PCR primers was based on the analysis of multiple sequence alignments of various *tuf* sequences. For more details about the selection of PCR primers from *tuf* sequences please refer to Examples 5, 7-14, 17, 22, 24, 28, 30-31, 33, 36, and 38-40, and to Annexes VI-IX, XI-XIX and XXV.

Sequencing of *atpD* and *recA* nucleic acids and/or sequences from a variety of archaeal, bacterial, fungal and parasitical species

The method used to obtain *atpD* and *recA* nucleic acids and/or sequences is similar to that described above for *tuf* nucleic acids and/or sequences.

The selection of amplification primers from *atpD* or *recA* nucleic acids and/or sequences

The comparison of the nucleotide sequence for the *atpD* or *recA* genes from various archaeal, bacterial, fungal and parasitical species allowed the selection of PCR primers (refer to Examples 6, 13, 29, 34 and 37, and to Annexes IV, V, X, and XX).

DNA amplification

For DNA amplification by the widely used PCR (polymerase chain reaction) method, primer pairs were derived from proprietary DNA fragments or from database sequences. Prior to synthesis, the potential primer pairs were analyzed by using the Oligo™ 5.0 software to verify that they were good candidates for PCR amplification.

During DNA amplification by PCR, two oligonucleotide primers binding respectively to each strand of the heat-denatured target DNA from the microbial

genome are used to amplify exponentially *in vitro* the target DNA by successive thermal cycles allowing denaturation of the DNA, annealing of the primers and synthesis of new targets at each cycle (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.).

Briefly, the PCR protocols were as follows: Treated clinical specimens or standardized bacterial or fungal or parasitical suspensions (see below) or purified genomic DNA from bacteria, fungi or parasites were amplified in a 20 μ l PCR reaction mixture. Each PCR reaction contained 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 2.5 mM MgCl₂, 0.4 μ M of each primer, 200 μ M of each of the four dNTPs and 0.5 unit of *Taq* DNA polymerase (Promega) combined with the TaqStartTM antibody (Clontech Laboratories Inc., Palo Alto, CA). The TaqStartTM antibody, which is a neutralizing monoclonal antibody to *Taq* DNA polymerase, was added to all PCR reactions to enhance the specificity and the sensitivity of the amplifications (Kellogg *et al.*, 1994, Biotechniques 16:1134-1137). The treatment of the clinical specimens varies with the type of specimen tested, since the composition and the sensitivity level required are different for each specimen type. It consists in a rapid protocol to lyse the microbial cells and eliminate or neutralize PCR inhibitors. For amplification from bacterial or fungal or parasitical cultures or from purified genomic DNA, the samples were added directly to the PCR amplification mixture without any pre-treatment step. An internal control was derived from sequences not found in the target microorganisms or in the human genome. The internal control was integrated into all amplification reactions to verify the efficiency of the PCR assays and to ensure that significant PCR inhibition was absent. Alternatively, an internal control derived from rRNA was also useful to monitor the efficiency of microbial lysis protocols.

PCR reactions were then subjected to thermal cycling (3 min at 94-96°C followed by 30 cycles of 1 second at 95°C for the denaturation step and 30 seconds at 50-65°C for the annealing-extension step) using a PTC-200 thermal cycler (MJ Research Inc.). The number of cycles performed for the PCR assays varies

according to the sensitivity level required. For example, the sensitivity level required for microbial detection directly from clinical specimens is higher for blood specimens than for urine specimens because the concentration of microorganisms associated with a septicemia can be much lower than that associated with a urinary tract infection. Consequently, more sensitive PCR assays having more thermal cycles are probably required for direct detection from blood specimens. Similarly, PCR assays performed directly from bacterial or fungal or parasitical cultures may be less sensitive than PCR assays performed directly from clinical specimens because the number of target organisms is normally much lower in clinical specimens than in microbial cultures.

The person skilled in the art of DNA amplification knows the existence of other rapid amplification procedures such as ligase chain reaction (LCR), transcription-mediated amplification (TMA), self-sustained sequence replication (3SR), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), branched DNA (bDNA), cycling probe technology (CPT), solid phase amplification (SPA), rolling circle amplification technology (RCA), solid phase RCA, anchored SDA and nuclease dependent signal amplification (NDSA) (Lee *et al.*, 1997, Nucleic Acid Amplification Technologies: Application to Disease Diagnosis, Eaton Publishing, Boston, MA; Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.; Westin *et al.*, 2000, Nat. Biotechnol. 18:199-204). The scope of this invention is not limited to the use of amplification by PCR, but rather includes the use of any rapid nucleic acid amplification method or any other procedure which may be used to increase the sensitivity and/or the rapidity of nucleic acid-based diagnostic tests. The scope of the present invention also covers the use of any nucleic acids amplification and detection technology including real-time or post-amplification detection technologies, any amplification technology combined with detection, any hybridization nucleic acid chips or arrays technologies, any amplification chips or combination of amplification and

hybridization chips technologies. Detection and identification by any sequencing method is also under the scope of the present invention.

Any oligonucleotide suitable for the amplification of nucleic acids by approaches other than PCR or for DNA hybridization which are derived from the species-specific, genus-specific and universal DNA fragments as well as from selected antimicrobial agents resistance or toxin gene sequences included in this document are also under the scope of this invention.

Detection of amplification products

Classically, detection of amplification is performed by standard ethidium bromide-stained agarose gel electrophoresis. It is clear that other methods for the detection of specific amplification products, which may be faster and more practical for routine diagnosis, may be used. Such methods may be based on the detection of fluorescence after or during amplification. One simple method for monitoring amplified DNA is to measure its rate of formation by measuring the increase in fluorescence of intercalating agents such as ethidium bromide or SYBR® Green I (Molecular Probes). If more specific detection is required, fluorescence-based technologies can monitor the appearance of a specific product during the reaction. The use of dual-labeled fluorogenic probes such as in the TaqMan™ system (Applied Biosystems) which utilizes the 5'-3' exonuclease activity of the *Taq* polymerase is a good example (Livak K.J. *et al.* 1995, PCR Methods Appl. 4:357-362). TaqMan™ can be performed during amplification and this "real-time" detection can be done in a single closed tube hence eliminating post-PCR sample handling and consequently preventing the risk of amplicon carryover. Several other fluorescence-based detection methods can be performed in real-time. Fluorescence resonance energy transfer (FRET) is the principle behind the use of adjacent hybridization probes (Wittwer, C.T. *et al.* 1997. BioTechniques 22:130-138), molecular beacons (Tyagi S. and Kramer F.R. 1996. Nature Biotechnology 14:303-308) and scorpions (Whitcomb *et al.* 1999. Nature

Biotechnology 17:804-807). Adjacent hybridization probes are designed to be internal to the amplification primers. The 3' end of one probe is labelled with a donor fluorophore while the 5' end of an adjacent probe is labelled with an acceptor fluorophore. When the two probes are specifically hybridized in close proximity (spaced by 1 to 5 nucleotides) the donor fluorophore which has been excited by an external light source emits light that is absorbed by a second acceptor that emit more fluorescence and yields a FRET signal. Molecular beacons possess a stem-and-loop structure where the loop is the probe and at the bottom of the stem a fluorescent moiety is at one end while a quenching moiety is at the other end. The beacons undergo a fluorogenic conformational change when they hybridize to their targets hence separating the fluorochrome from its quencher. The FRET principle is also used in an air thermal cycler with a built-in fluorometer (Wittwer, C.T. *et al.* 1997. BioTechniques 22:130-138). The amplification and detection are extremely rapid as reactions are performed in capillaries: it takes only 18 min to complete 45 cycles. Those techniques are suitable especially in the case where few pathogens are searched for. Boehringer-Roche Inc. sells the LightCycler™, and Cepheid makes the SmartCycler. These two apparatus are capable of rapid cycle PCR combined with fluorescent SYBR® Green I or FRET detection. We recently demonstrated in our laboratory, real-time detection of 10 CFU in less than 40 minutes using adjacent hybridization probes on the LightCycler™. Methods based on the detection of fluorescence are particularly promising for utilization in routine diagnosis as they are very rapid, quantitative and can be automated.

Microbial pathogens detection and identification may also be performed by solid support or liquid hybridization using species-specific internal DNA probes hybridizing to an amplification product. Such probes may be generated from any sequence from our repertory and designed to specifically hybridize to DNA amplification products which are objects of the present invention. Alternatively, the internal probes for species or genus or family or group detection and identification may be derived from the amplicons produced by a universal, family-, group-, genus- or species-specific amplification assay(s). The oligonucleotide

probes may be labeled with biotin or with digoxigenin or with any other reporter molecule (for more details see below the section on hybrid capture). Hybridization on a solid support is amendable to miniaturization.

At present the oligonucleotide nucleic acid microarray technology is appealing. Currently, available low to medium density arrays (Heller *et al.*, An integrated microelectronics hybridization system for genomic research and diagnostic applications. *In:* Harrison, D.J., and van den Berg, A., 1998, Micro total analysis systems '98, Kluwer Academic Publisher, Dordrecht.) could specifically capture fluorescent-labelled amplicons. Detection methods for hybridization are not limited to fluorescence; potentiometry, colorimetry and plasmon resonance are some examples of alternative detection methods. In addition to detection by hybridization, nucleic acid microarrays could be used to perform rapid sequencing by hybridization. Mass spectrometry could also be applicable for rapid identification of the amplicon or even for sequencing of the amplification products (Chiu and Cantor, 1999, Clinical Chemistry **45**:1578; Berkenkamp *et al.*, 1998, Science **281**:260).

For the future of our assay format, we also consider the major challenge of molecular diagnostics tools, *i.e.:* integration of the major steps including sample preparation, genetic amplification, detection, data analysis and presentation (Anderson *et al.*, Advances in integrated genetic analysis. *In:* Harrison, D.J., and van den Berg, A., 1998, Micro total analysis systems '98, Kluwer Academic Publisher, Dordrecht.).

To ensure PCR efficiency, glycerol, dimethyl sulfoxide (DMSO) or other related solvents can be used to increase the sensitivity of the PCR and to overcome problems associated with the amplification of a target DNA having a high GC content or forming strong secondary structures (Dieffenbach and Dveksler, 1995, PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Plainview, New York). The concentration ranges for glycerol and DMSO are 5-15% (v/v) and 3-10% (v/v), respectively. For the PCR reaction mixture, the concentration ranges for the amplification primers and MgCl₂ are 0.1-1.5 μM and

1.0-10.0 mM, respectively. Modifications of the standard PCR protocol using external and nested primers (i.e. nested PCR) or using more than one primer pair (i.e. multiplex PCR) may also be used (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.). For more details about the PCR protocols and amplicon detection methods, see Examples.

Hybrid capture and chemiluminescence detection of amplification products

Hybridization and detection of amplicons by chemiluminescence were adapted from Nikiforov *et al.* (1994, PCR Methods and Applications 3:285-291 and 1995, Anal. Biochem. 227:201-209) and from the DIG™ system protocol of Boehringer Mannheim. Briefly, 50 µl of a 25 picomoles solution of capture probe diluted in EDC {1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride} are immobilized in each well of 96-wells plates (Microlite™ 2, Dynex) by incubation overnight at room temperature. The next day, the plates are incubated with a solution of 1% BSA diluted into TNTw (10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.05% Tween™ 20) for 1 hour at 37 °C. The plates are then washed on a Wellwash Ascent™ (Labsystems) with TNTw followed by Washing Buffer (100 mM maleic acid pH7.5; 150 mM NaCl; 0.3% Tween™ 20).

The amplicons were labelled with DIG-11-dUTP during PCR using the PCR DIG Labelling Mix from Boehringer Mannheim according to the manufacturer's instructions. Hybridization of the amplicons to the capture probes is performed in triplicate at stringent temperature (generally, probes are designed to allow hybridization at 55 °C, the stringent temperature) for 30 minutes in 1.5 M NaCl; 10 mM EDTA. It is followed by two washes in 2 X SSC; 0.1% SDS, then by four washes in 0.1X SSC; 0.1% SDS at the stringent temperature (55 °C). Detection with 1,2 dioxetane chemiluminescent alkaline phosphatase substrates like CSPD® (Tropix Inc.) is performed according to the manufacturer's instructions but with shorter incubations times and a different antibody concentration. The plates are

agitated at each step, the blocking incubation is performed for only 5 minutes, the anti-DIG-AP1 is used at a 1:1000 dilution, the incubation with antibody lasts 15 minutes, the plates are washed twice for only 5 minutes. Finally, after a 2 minutes incubation into the detection buffer, the plates are incubated 5 minutes with CSPD® at room temperature followed by a 10 minutes incubation at 37 °C without agitation. Luminous signal detection is performed on a Dynex Microtiter Plate Luminometer using RLU (Relative Light Units).

Specificity, ubiquity and sensitivity tests for oligonucleotide primers and probes

The specificity of oligonucleotide primers and probes was tested by amplification of DNA or by hybridization with bacterial or fungal or parasitical species selected from a panel comprising closely related species and species sharing the same anatomo-pathological site (see Annexes and Examples). All of the bacterial, fungal and parasitical species tested were likely to be pathogens associated with infections or potential contaminants which can be isolated from clinical specimens. Each target DNA could be released from microbial cells using standard chemical and/or physical treatments to lyse the cells (Sambrook *et al.*, 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) or alternatively, genomic DNA purified with the GNOME™ DNA kit (Bio101, Vista, CA) was used. Subsequently, the DNA was subjected to amplification with the primer pairs. Specific primers or probes amplified only the target microbial species, genus, family or group.

Oligonucleotides primers found to amplify specifically the target species, genus, family or group were subsequently tested for their ubiquity by amplification (i.e. ubiquitous primers amplified efficiently most or all isolates of the target species or genus or family or group). Finally, the sensitivity of the primers or probes was determined by using 10-fold or 2-fold dilutions of purified genomic DNA from the targeted microorganism. For most assays, sensitivity levels in the

range of 1-100 copies were obtained. The specificity, ubiquity and sensitivity of the PCR assays using the selected amplification primer pairs were tested either directly from cultures of microbial species or from purified microbial genomic DNA.

Probes were tested in hybrid capture assays as described above. An oligonucleotide probe was considered specific only when it hybridized solely to DNA from the species or genus or family or group from which it was selected. Oligonucleotide probes found to be specific were subsequently tested for their ubiquity (i.e. ubiquitous probes detected efficiently most or all isolates of the target species or genus or family or group) by hybridization to microbial DNAs from different clinical isolates of the species or genus or family or group of interest including ATCC reference strains. Similarly, oligonucleotide primers and probes could be derived from antimicrobial agents resistance or toxin genes which are objects of the present invention.

Reference strains

The reference strains used to build proprietary *tuf*, *atpD* and *recA* sequence data subrepertoires, as well as to test the amplification and hybridization assays were obtained from (i) the American Type Culture Collection (ATCC), (ii) the Laboratoire de santé publique du Québec (LSPQ), (iii) the Centers for Disease Control and Prevention (CDC), (iv) the National Culture Type Collection (NCTC) and (v) several other reference laboratories throughout the world. The identity of our reference strains was confirmed by phenotypic testing and reconfirmed by analysis of *tuf*, *atpD* and *recA* sequences (see Example 13).

Antimicrobial agents resistance genes

Antimicrobial resistance complicates treatment and often leads to therapeutic failures. Furthermore, overuse of antibiotics inevitably leads to the emergence of

microbial resistance. Our goal is to provide clinicians, in approximately one hour, the needed information to prescribe optimal treatments. Besides the rapid identification of negative clinical specimens with DNA-based tests for universal algal, archaeal, bacterial, fungal or parasitical detection and the identification of the presence of a specific pathogen in the positive specimens with species- and/or genus- and/or family- and/or group-specific DNA-based tests, clinicians also need timely information about the ability of the microbial pathogen to resist antibiotic treatments. We feel that the most efficient strategy to evaluate rapidly microbial resistance to antimicrobials is to detect directly from the clinical specimens the most common and clinically important antimicrobial agents resistance genes (i.e. DNA-based tests for the specific detection of antimicrobial agents resistance genes). Since the sequence from the most important and common antimicrobial agents resistance genes are available from public databases, our strategy is to use the sequence from a portion or from the entire resistance gene to design specific oligonucleotide primers or probes which will be used as a basis for the development of sensitive and rapid DNA-based tests. The list of each of the antimicrobial agents resistance genes selected on the basis of their clinical relevance (i.e. high incidence and importance) is given in Table 5; descriptions of the designed amplification primers and internal probes are given in Annexes XXXIV-XXXVII, XXXIX, XLV, and L-LI. Our approach is unique because the antimicrobial agents resistance genes detection and the microbial detection and identification can be performed simultaneously, or independently, or sequentially in multiplex or parallel or sequential assays under uniform PCR amplification conditions. These amplifications can also be done separately.

Toxin genes

Toxin identification is often very important to prescribe optimal treatments. Besides the rapid identification of negative clinical specimens with DNA-based tests for universal bacterial detection and the identification of the presence of a

specific pathogen in the positive specimens with species- and/or genus- and/or family- and/or group-specific DNA-based tests, clinicians sometimes need timely information about the ability of certain bacterial pathogens to produce toxins. Since the sequence from the most important and common bacterial toxin genes are available from public databases, our strategy is to use the sequence from a portion or from the entire toxin gene to design specific oligonucleotide primers or probes which will be used as a basis for the development of sensitive and rapid DNA-based tests. The list of each of the bacterial toxin genes selected on the basis of their clinical relevance (i.e. high incidence and importance) is given in Table 6; descriptions of the designed amplification primers and internal probes are given in Annexes XXII, XXXII and XXXIII. Our approach is unique because the toxin genes detection and the bacterial detection and identification can be performed simultaneously, or independently, or sequentially, in multiplex or parallel or sequential assays under uniform PCR amplification conditions. These amplifications can also be done separately.

Universal bacterial detection

In the routine microbiology laboratory, a high percentage of clinical specimens sent for bacterial identification are negative by culture. Testing clinical samples with universal amplification primers or universal probes to detect the presence of bacteria prior to specific identification and screening out the numerous negative specimens is thus useful as it reduces costs and may rapidly orient the clinical management of the patients. Several amplification primers and probes were therefore synthesized from highly conserved portions of bacterial sequences from the *tuf*, *atpD* and *recA* nucleic acids and/or sequences. The universal primers selection was based on a multiple sequence alignment constructed with sequences from our repertory.

All computer analysis of amino acid and nucleotide sequences were performed by using the GCG programs. Subsequently, optimal PCR primers for

the universal amplification of bacteria were selected with the help of the Oligo™ program. The selected primers are degenerated at several nucleotide positions and contain several inosines in order to allow the amplification of all clinically relevant bacterial species. Inosine is a nucleotide analog able to specifically bind to any of the four nucleotides A, C, G or T. Degenerated oligonucleotides consist of an oligonucleotide mix having two or more of the four nucleotides A, C, G or T at the site of mismatches. The inclusion of inosine and/or of base ambiguities in the amplification primers allow mismatch tolerance thereby permitting the amplification of a wider array of target nucleotide sequences (Dieffenbach and Dveksler, 1995 PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Plainview, NY).

The amplification conditions with the universal primers are very similar to those used for the species- and genus-specific amplification assays except that the annealing temperature is slightly lower. The original universal PCR assay described in our assigned WO98/20157 (SEQ ID NOS. 23-24 of the latter application) was specific and nearly ubiquitous for the detection of bacteria. The specificity for bacteria was verified by amplifying genomic DNA isolated from the 12 fungal species as well as genomic DNA from *Leishmania donovani*, *Saccharomyces cerevisiae* and human lymphocytes. None of the above eukaryotic DNA preparations could be amplified by the universal assay, thereby suggesting that this test is specific for bacteria. The ubiquity of the universal assay was verified by amplifying genomic DNAs from 116 reference strains which represent 95 of the most clinically relevant bacterial species. These species have been selected from the bacterial species listed in Table 4. We found that at least 104 of these strains could be amplified. However, the assay could be improved since bacterial species which could not be amplified with the original *tuf* nucleic acids and/or sequences-based assay included species belonging to the following genera: *Corynebacterium* (11 species) and *Stenotrophomonas* (1 species). Sequencing of the *tuf* genes from these bacterial species and others has been performed in the scope of the present invention in order to improve the universal assay. This

sequencing data has been used to select new universal primers which may be more ubiquitous and more sensitive. Also, we improved our primer and probes design strategy by taking into consideration the phylogeny observed in analysing our repertory of *tuf*, *atpD* and *recA* sequences. Data from each of the 3 main subrepertoires (*tuf*, *atpD* and *recA*) was subjected to a basic phylogenetic analysis using the Pileup command from version 10 of the GCG package (Genetics Computer Group, inc.). This analysis indicated the main branches or phyla reflecting the relationships between sequences. Instead of trying to design primers or probes able to hybridize to all phyla, we designed primers or probes able to hybridize to the main phyla while trying to use the largest phylum possible. This strategy should allow less degenerated primers hence improving sensitivity and by combining primers in a multiplex assay, improve ubiquity. Universal primers SEQ ID NOS. 643-645 based on *tuf* sequences have been designed to amplify most pathogenic bacteria except *Actinomycetaceae*, *Clostridiaceae* and the *Cytophaga*, *Flexibacter* and *Bacteroides* phylum (pathogenic bacteria of this phylum include mostly *Bacteroides*, *Porphyromonas* and *Prevotella* species). Primers to fill these gaps have been designed for *Actinomycetaceae* (SEQ ID NOS. 646-648), *Clostridiaceae* (SEQ ID NOS. 796-797, 808-811), and the *Cytophaga*, *Flexibacter* and *Bacteroides* phylum (SEQ ID NOS. 649-651), also derived from *tuf* nucleic acids and/or sequences. These primers sets could be used alone or in conjunction to render the universal assay more ubiquitous.

Universal primers derived from *atpD* sequences include SEQ ID NOS. 562-565. Combination of these primers does not amplify human DNA but should amplify almost all pathogenic bacterial species except proteobacteria belonging to the epsilon subdivision (*Campylobacter* and *Helicobacter*), the bacteria from the *Cytophaga*, *Flexibacter* and *Bacteroides* group and some actinomycetes and corynebacteria. By analysing *atpD* sequences from the latter species, primers and probes to specifically fill these gaps could be designed and used in conjunction with primers SEQ ID NOS. 562-565, also derived from *atpD* nucleic acids and/or sequences.

In addition, universality of the assay could be expanded by mixing *atpD* sequences-derived primers with *tuf* sequences-derived primers. Ultimately, even *recA* sequences-derived primers could be added to fill some gaps in the universal assay.

It is important to note that the 95 bacterial species selected to test the ubiquity of the universal assay include all of the most clinically relevant bacterial species associated with a variety of human infections acquired in the community or in hospitals (nosocomial infections). The most clinically important bacterial and fungal pathogens are listed in Tables 1 and 2.

Amino acid sequences derived from *tuf*, *atpD* and *recA* nucleic acids and/or sequences

The amino acid sequences translated from the repertory of *tuf*, *atpD* and *recA* nucleic acids and/or sequences are also an object of the present invention. The amino acid sequence data will be particularly useful for homology modeling of three-dimensional (3D) structure of the elongation factor Tu, elongation factor G, elongation factor 1 α , ATPase subunit beta and RecA recombinase. For all these proteins, at least one structure model has been published using X-ray diffraction data from crystals. Based on those structural informations it is possible to use computer software to build 3D model structures for any other protein having peptide sequence homologies with the known structure (Greer, 1991, Methods in Enzymology, 202:239-252; Taylor, 1994, Trends Biotechnol., 12(5):154-158; Sali, 1995, Curr. Opin. Biotechnol. 6:437-451; Sanchez and Sali, 1997, Curr. Opin. Struct. Biol. 7:206-214; Fischer and Eisenberg, 1999, Curr. Opin. Struct. Biol. 9:208-211; Guex *et al.*, 1999, Trends Biochem. Sci. 24: 364-367). Model structures of target proteins are used for the design or to predict the behavior of ligands and inhibitors such as antibiotics. Since EF-Tu and EF-G are already known as antibiotic targets (see above) and since the beta subunit of ATPase and RecA recombinase are essential to the survival of the microbial cells in natural

conditions of infection, all four proteins could be considered antibiotic targets. Sequence data, especially the new data generated by us could be very useful to assist the creation of new antibiotic molecules with desired spectrum of activity. In addition, model structures could be used to improve protein function for commercial purposes such as improving antibiotic production by microbial strains or increasing biomass.

The following detailed embodiments and appended drawings are provided as illustrative examples of his invention, with no intention to limit the scope thereof.

DESCRIPTION OF THE DRAWINGS

Figures 1 and 2 illustrate the principal subdivisions of the *tuf* and *atpD* sequences repertoires, respectively. For the design of primers and probes, depending on the needs, one may want to use the complete data set illustrated on the top of the pyramid or use only a subset illustrated by the different branching points. Smaller subdivisions, representing groups, families, genus and species, could even be made to extend to the bottom of the pyramid. Because the *tuf* and *atpD* sequences are highly conserved and evolved with each species, the design of primers and probes does not need to include all the sequences within the database or its subdivisions. As illustrated in Annexes IV to XX, XXIII to XXXI, XXXVIII and XLII, depending on the use, sequences from a limited number of species can be carefully selected to represent: i) only the main phylogenetic branches from which the intended probes and primers need to be differentiating, and ii) only the species for which they need to be matching. However, for ubiquity purposes, and especially for primers and probes identifying large groups of species (genus, family, group or universal, or sequencing primers), the more data is included into the sequence analysis, the better the probes and primers will be suitable for each particular intended use. Similarly, for specificity purposes, a larger data set (or repertory) ensures optimal primers and probes design by reducing the chance of employing nonspecific oligonucleotides.

Figure 3 illustrates the approach used to design specific amplification primers from *fusA* as well as from the region between the end of *fusA* and the beginning of *tuf* in the streptomycin (*str*) operon (referred to as the *fusA-tuf* intergenic spacer in Table 7).

Figures 4 to 6 are illustrations to Example 42, whereas Figures 7 to 10 illustrate Example 43. Figures 11 and 12 illustrate Example 44.

FIGURE LEGENDS

Figure 3. Schematic organization of universal amplification primers (SEQ ID NOs. 1221-1229) in the *str* operon. Amplicon sizes are given in bases pairs. Drawing not to scale, as the *fusA-tuf* intergenic spacer size varies depending on the bacterial species. Indicated amplicon lengths are for *E. coli*.

Figure 4. Abridged multiple amino acid sequence alignment of the partial *tuf* gene products from selected species illustrated using the program Alscript. Residues highly conserved in bacteria are boxed in grey and gaps are represented with dots. Residues in reverse print are unique to the enterococcal *tufB* as well as to streptococcal and lactococcal *tuf* gene products. Numbering is based on *E. coli* EF-Tu and secondary structure elements of *E. coli* EF-Tu are represented by cylinders (α -helices) and arrows (β -strands).

Figure 5. Distance matrix tree of bacterial EF-Tu based on amino acid sequence homology. The tree was constructed by the neighbor-joining method. The tree was rooted using archeal and eukaryotic EF-1 α genes as the outgroup. The scale bar represents 5% changes in amino acid sequence, as determined by taking the sum of all of the horizontal lines connecting two species.

Figure 6. Southern hybridization of *Bgl*II/*Xba*I digested genomic DNAs of some enterococci (except for *E. casseliflavus* and *E. gallinarum* whose genomic DNA was digested with *Bam*HI/*Pvu*II) using the *tufA* gene fragment of *E. faecium* as probes. The sizes of hybridizing fragments are shown in kilobases. Strains tested are listed in Table 16.

Figure 7. *Pantoea* and *Tatumella* species specific signature indel in *atpD* genes. The nucleotide positions given are for *E. coli* *atpD* sequence (GenBank accession no. V00267). Numbering starts from the first base of the initiation codon.

Figure 8: Trees based on sequence data from *tuf* (left side) and *atpD* (right side). The phylogenetic analysis was performed using the Neighbor-Joining method calculated using the Kimura two-parameter method. The value on each branch indicates the occurrence (%) of the branching order in 750 bootstrapped trees.

Figure 9: Phylogenetic tree of members of the family *Enterobacteriaceae* based on *tuf* (a), *atpD* (b), and 16S rDNA (c) genes. Trees were generated by neighbor-joining method calculated using the Kimura two-parameter method. The value on each branch is the percentage of bootstrap replications supporting the branch. 750 bootstrap replications were calculated.

Figure 10: Plot of *tuf* distances versus 16S rDNA distances (a), *atpD* distances versus 16S rDNA distances (b), and *atpD* distances versus *tuf* distances (c). Symbols: ○, distances between pairs of strains belonging to the same species; ●, distances between *E. coli* strains and *Shigella* strains; □, distances between pairs belonging to the same genus; ■, distances between pairs belonging to different genera; Δ, distances between pairs belonging to different families.

EXAMPLES AND ANNEXES

For sake of clarity, here is a list of Examples and Annexes:

- Example 1: Sequencing of bacterial *atpD* (F-type and V-type) gene fragments.
- Example 2: Sequencing of eukaryotic *atpD* (F-type and V-type) gene fragments.
- Example 3: Sequencing of eukaryotic *tuf* (EF-1) gene fragments.

- Example 4: Sequencing of eukaryotic *tuf* (organelle origin, M) gene fragments.
- Example 5: Specific detection and identification of *Streptococcus agalactiae* using *tuf* sequences.
- Example 6: Specific detection and identification of *Streptococcus agalactiae* using *atpD* sequences.
- Example 7: Development of a PCR assay for detection and identification of staphylococci at genus and species levels.
- Example 8: Differentiating between the two closely related yeast species *Candida albicans* and *Candida dubliniensis*.
- Example 9: Specific detection and identification of *Entamoeba histolytica*.
- Example 10: Sensitive detection and identification of *Chlamydia trachomatis*.
- Example 11: Genus-specific detection and identification of enterococci.
- Example 12: Detection and identification of the major bacterial platelets contaminants using *tuf* sequences with a multiplex PCR test.
- Example 13: The resolving power of the *tuf* and *atpD* sequences databases is comparable to the biochemical methods for bacterial identification.
- Example 14: Detection of group B streptococci from clinical specimens.
- Example 15: Simultaneous detection and identification of *Streptococcus pyogenes* and its pyrogenic exotoxin A.
- Example 16: Real-time detection and identification of Shiga toxin-producing bacteria.
- Example 17: Development of a PCR assay for the detection and identification of staphylococci at genus and species levels and its associated *mecA* gene.
- Example 18: Sequencing of *pbp1a*, *pbp2b* and *pbp2x* genes of *Streptococcus pneumoniae*.
- Example 19: Sequencing of *hexA* genes of *Streptococcus* species.
- Example 20: Development of a multiplex PCR assay for the detection of *Streptococcus pneumoniae* and its penicillin resistance genes.

- Example 21: Sequencing of the vancomycin resistance *vanA*, *vanC1*, *vanC2* and *vanC3* genes.
- Example 22: Development of a PCR assay for the detection and identification of enterococci at genus and species levels and its associated resistance genes *vanA* and *vanB*.
- Example 23: Development of a multiplex PCR assay for detection and identification of vancomycin-resistant *Enterococcus faecalis*, *Enterococcus faecium*, *Enterococcus gallinarum*, *Enterococcus casseliflavus*, and *Enterococcus flavesiens*.
- Example 24: Universal amplification involving the EF-G (*fusA*) subdivision of *tuf* sequences.
- Example 25: DNA fragment isolation from *Staphylococcus saprophyticus* by arbitrarily primed PCR.
- Example 26: Sequencing of prokaryotic *tuf* gene fragments.
- Example 27: Sequencing of procaryotic *recA* gene fragments.
- Example 28: Specific detection and identification of *Escherichia coli/Shigella* sp. using *tuf* sequences.
- Example 29: Specific detection and identification of *Klebsiella pneumoniae* using *atpD* sequences.
- Example 30: Specific detection and identification of *Acinetobacter baumanii* using *tuf* sequences.
- Example 31: Specific detection and identification of *Neisseria gonorrhoeae* using *tuf* sequences.
- Example 32: Sequencing of bacterial *gyrA* and *parC* gene fragments.
- Example 33: Development of a PCR assay for the specific detection and identification of *Staphylococcus aureus* and its quinolone resistance genes *gyrA* and *parC*.
- Example 34: Development of a PCR assay for the detection and identification of *Klebsiella pneumoniae* and its quinolone resistance genes *gyrA* and *parC*.

- Example 35: Development of a PCR assay for the detection and identification of *Streptococcus pneumoniae* and its quinolone resistance genes *gyrA* and *parC*.
- Example 36: Detection of extended-spectrum TEM-type β -lactamases in *Escherichia coli*.
- Example 37: Detection of extended-spectrum SHV-type β -lactamases in *Klebsiella pneumoniae*.
- Example 38: Development of a PCR assay for the detection and identification of *Neisseria gonorrhoeae* and its associated tetracycline resistance gene *tetM*.
- Example 39: Development of a PCR assay for the detection and identification of *Shigella* sp. and their associated trimethoprim resistance gene *dhfr1a*.
- Example 40: Development of a PCR assay for the detection and identification of *Acinetobacter baumanii* and its associated aminoglycoside resistance gene *aph(3')-VIa*.
- Example 41: Specific detection and identification of *Bacteroides fragilis* using *atpD* (V-type) sequences.
- Example 42: Evidence for horizontal gene transfer in the evolution of the elongation factor Tu in Enterococci.
- Example 43: Elongation factor Tu (*tuf*) and the F-ATPase beta-subunit (*atpD*) as phylogenetic tools for species of the family *Enterobacteriaceae*.
- Example 44: Testing new pairs of PCR primers selected from two species-specific genomic DNA fragments which are objects of US patent 6,001,564.
- Example 45: Testing modified versions of PCR primers derived from the sequence of several primers which are objects of US patent 6,001,564.

The various Annexes show the strategies used for the selection of a variety of DNA amplification primers, nucleic acid hybridization probes and molecular beacon internal probes:

- (i) Annex I shows the amplification primers used for nucleic acid amplification from *tuf* sequences.
- (ii) Annex II shows the amplification primers used for nucleic acid amplification from *atpD* sequences.
- (iii) Annex III shows the internal hybridization probes for detection of *tuf* sequences.
- (iv) Annex IV illustrates the strategy used for the selection of the amplification primers specific for *atpD* sequences of the F-type.
- (v) Annex V illustrates the strategy used for the selection of the amplification primers specific for *atpD* sequences of the V-type.
- (vi) Annex VI illustrates the strategy used for the selection of the amplification primers specific for the *tuf* sequences of organelle lineage (M, the letter M is used to indicate that in most cases, the organelle is the mitochondria).
- (vii) Annex VII illustrates the strategy used for the selection of the amplification primers specific for the *tuf* sequences of eukaryotes (EF-1).
- (viii) Annex VIII illustrates the strategy for the selection of *Streptococcus agalactiae*-specific amplification primers from *tuf* sequences.
- (ix) Annex IX illustrates the strategy for the selection of *Streptococcus agalactiae*-specific hybridization probes from *tuf* sequences.
- (x) Annex X illustrates the strategy for the selection of *Streptococcus agalactiae*-specific amplification primers from *atpD* sequences.
- (xi) Annex XI illustrates the strategy for the selection from *tuf* sequences of *Candida albicans/dubliniensis*-specific amplification primers, *Candida albicans*-specific hybridization probe and *Candida dubliniensis*-specific hybridization probe.

- (xii) Annex XII illustrates the strategy for the selection of *Staphylococcus*-specific amplification primers from *tuf* sequences.
- (xiii) Annex XIII illustrates the strategy for the selection of the *Staphylococcus*-specific hybridization probe from *tuf* sequences.
- (xiv) Annex XIV illustrates the strategy for the selection of *Staphylococcus saprophyticus*-specific and *Staphylococcus haemolyticus*-specific hybridization probes from *tuf* sequences.
- (xv) Annex XV illustrates the strategy for the selection of *Staphylococcus aureus*-specific and *Staphylococcus epidermidis*-specific hybridization probes from *tuf* sequences.
- (xvi) Annex XVI illustrates the strategy for the selection of the *Staphylococcus hominis*-specific hybridization probe from *tuf* sequences.
- (xvii) Annex XVII illustrates the strategy for the selection of the *Enterococcus*-specific amplification primers from *tuf* sequences.
- (xviii) Annex XVIII illustrates the strategy for the selection of the *Enterococcus faecalis*-specific hybridization probe, of the *Enterococcus faecium*-specific hybridization probe and of the *Enterococcus casseliflavus-flavescens-gallinarum* group-specific hybridization probe from *tuf* sequences.
- (xix) Annex XIX illustrates the strategy for the selection of primers from *tuf* sequences for the identification of platelets contaminants.
- (xx) Annex XX illustrates the strategy for the selection of the universal amplification primers from *atpD* sequences.
- (xxi) Annex XXI shows the amplification primers used for nucleic acid amplification from *recA* sequences.
- (xxii) Annex XXII shows the specific and ubiquitous primers for nucleic acid amplification from *speA* sequences.
- (xxiii) Annex XXIII illustrates the first strategy for the selection of *Streptococcus pyogenes*-specific amplification primers from *speA* sequences.

- (xxiv) Annex XXIV illustrates the second strategy for the selection of *Streptococcus pyogenes*-specific amplification primers from *speA* sequences.
- (xxv) Annex XXV illustrates the strategy for the selection of *Streptococcus pyogenes*-specific amplification primers from *tuf* sequences.
- (xxvi) Annex XXVI illustrates the strategy for the selection of *stx₁*-specific amplification primers and hybridization probe.
- (xxvii) Annex XXVII illustrates the strategy for the selection of *stx₂*-specific amplification primers and hybridization probe.
- (xxviii) Annex XXVIII illustrates the strategy for the selection of *vanA*-specific amplification primers from *van* sequences.
- (xxix) Annex XXIX illustrates the strategy for the selection of *vanB*-specific amplification primers from *van* sequences.
- (xxx) Annex XXX illustrates the strategy for the selection of *vanC*-specific amplification primers from *vanC* sequences.
- (xxxi) Annex XXXI illustrates the strategy for the selection of *Streptococcus pneumoniae*-specific amplification primers and hybridization probes from *pbp1a* sequences.
- (xxxii) Annex XXXII shows the specific and ubiquitous primers for nucleic acid amplification from toxin gene sequences.
- (xxxiii) Annex XXXIII shows the molecular beacon internal hybridization probes for specific detection of toxin sequences.
- (xxxiv) Annex XXXIV shows the specific and ubiquitous primers for nucleic acid amplification from *van* sequences.
- (xxxv) Annex XXXV shows the internal hybridization probes for specific detection of *van* sequences.
- (xxxvi) Annex XXXVI shows the specific and ubiquitous primers for nucleic acid amplification from *pbp* sequences.
- (xxxvii) Annex XXXVII shows the internal hybridization probes for specific detection of *pbp* sequences.

- (xxxviii) Annex XXXVIII illustrates the strategy for the selection of *vanAB*-specific amplification primers and *vanA*- and *vanB*- specific hybridization probes from *van* sequences.
- (xxxix) Annex XXXIX shows the internal hybridization probe for specific detection of *mecA*.
- (xli) Annex XL shows the specific and ubiquitous primers for nucleic acid amplification from *hexA* sequences.
- (xli) Annex XLI shows the internal hybridization probe for specific detection of *hexA*.
- (xlii) Annex XLII illustrates the strategy for the selection of *Streptococcus pneumoniae* species-specific amplification primers and hybridization probe from *hexA* sequences.
- (xliii) Annex XLIII shows the specific and ubiquitous primers for nucleic acid amplification from *pcp* sequences.
- (xliv) Annex XLIV shows specific and ubiquitous primers for nucleic acid amplification of *S. saprophyticus* sequences of unknown coding potential.
- (xlv) Annex XLV shows the molecular beacon internal hybridization probes for specific detection of antimicrobial agents resistance gene sequences.
- (xlvi) Annex XLVI shows the molecular beacon internal hybridization probe for specific detection of *S. aureus* gene sequences of unknown coding potential.
- (xlvii) Annex XLVII shows the molecular beacon hybridization internal probe for specific detection of *tuf* sequences.
- (xlviii) Annex XLVIII shows the molecular beacon internal hybridization probes for specific detection of *ddl* and *mtl* sequences.
- (xlix) Annex XLIX shows the internal hybridization probe for specific detection of *S. aureus* sequences of unknown coding potential.
- (l) Annex L shows the amplification primers used for nucleic acid amplification from antimicrobial agents resistance genes sequences.

- (li) Annex LI shows the internal hybridization probes for specific detection of antimicrobial agents resistance genes sequences.
- (lii) Annex LII shows the molecular beacon internal hybridization probes for specific detection of *atpD* sequences.
- (liii) Annex LIII shows the internal hybridization probes for specific detection of *atpD* sequences.
- (liv) Annex LIVI shows the internal hybridization probes for specific detection of *ddl* and *mtl* sequences.

As shown in these Annexes, the selected amplification primers may contain inosines and/or base ambiguities. Inosine is a nucleotide analog able to specifically bind to any of the four nucleotides A, C, G or T. Alternatively, degenerated oligonucleotides which consist of an oligonucleotide mix having two or more of the four nucleotides A, C, G or T at the site of mismatches were used. The inclusion of inosine and/or of degeneracies in the amplification primers allows mismatch tolerance thereby permitting the amplification of a wider array of target nucleotide sequences (Dieffenbach and Dveksler, 1995 PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Plainview, New York).

EXAMPLES

EXAMPLE 1:

Sequencing of bacterial *atpD* (F-type and V-type) gene fragments. As shown in Annex IV, the comparison of publicly available *atpD* (F-type) sequences from a variety of bacterial species revealed conserved regions allowing the design of PCR primers able to amplify *atpD* sequences (F-type) from a wide range of bacterial species. Using primers pairs SEQ ID NOs. 566 and 567, 566 and 814, 568 and 567, 570 and 567, 572 and 567, 569 and 567, 571 and 567, 700 and 567, it was possible to amplify and sequence *atpD* sequences SEQ ID NOs. 242-270, 272-398, 673-

674, 737-767, 866-867, 942-955, 1245-1254, 1256-1265, 1527, 1576, 1577, 1600-1604, 1640-1646, 1649, 1652, 1655, 1657, 1659-1660, 1671, 1844-1845, and 1849-1865.

Similarly, Annex V shows the strategy to design the PCR primers able to amplify *atpD* sequences of the V-type from a wide range of archaeal and bacterial species. Using primers SEQ ID NOs. 681-683, it was possible to amplify and sequence *atpD* sequences SEQ ID NOs. 827-832, 929-931, 958 and 966. As the gene was difficult to amplify for several species, additional amplification primers were designed inside the original amplicon (SEQ ID NOs. 1203-1207) in order to obtain sequence information for these species. Other primers (SEQ ID NO. 1212, 1213, 2282-2285) were also designed to amplify regions of the *atpD* gene (V-type) in archaeabacteria.

EXAMPLE 2:

Sequencing of eukaryotic *atpD* (F-type and V-type) gene fragments. The comparison of publicly available *atpD* (F-type) sequences from a variety of fungal and parasitical species revealed conserved regions allowing the design of PCR primers able to amplify *atpD* sequences from a wide range of fungal and parasitical species. Using primers pairs SEQ ID NOs. 568 and 573, 574 and 573, 574 and 708, and 566 and 567, it was possible to amplify and sequence *atpD* sequences SEQ ID NOs. 458-497, 530-538, 663, 667, 676, 678-680, 768-778, 856-862, 889-896, 941, 1638-1639, 1647, 1650-1651, 1653-1654, 1656, 1658, 1684, 1846-1848, and 2189-2192.

In the same manner, the primers described in Annex V (SEQ ID NOs. 681-683) could amplify the *atpD* (V-type) gene from various fungal and parasitical species. This strategy allowed to obtain SEQ ID NOs. 834-839, 956-957, and 959-965.

EXAMPLE 3:

Sequencing of eukaryotic *tuf* (EF-1) gene fragments. As shown in Annex VII, the comparison of publicly available *tuf* (EF-1) sequences from a variety of fungal and parasitical species revealed conserved regions allowing the design of PCR primers able to amplify *tuf* sequences from a wide range of fungal and parasitical species. Using primers pairs SEQ ID NOs. 558 and 559, 813 and 559, 558 and 815, 560 and 559, 653 and 559, 558 and 655, and 654 and 559, 1999 and 2000, 2001 and 2003, 2002 and 2003, it was possible to amplify and sequence *tuf* sequences SEQ ID NOs. 399-457, 509-529, 622-624, 677, 779-790, 840-842, 865, 897-903, 1266-1287, 1561-1571 and 1685.

EXAMPLE 4:

Sequencing of eukaryotic *tuf* (organelle origin, M) gene fragments. As shown in Annex VI, the comparison of publicly available *tuf* (organelle origin, M) sequences from a variety of fungal and parasitical organelles revealed conserved regions allowing the design of PCR primers able to amplify *tuf* sequences of several organelles belonging to a wide range fungal and parasitical species. Using primers pairs SEQ ID NOs. 664 and 652, 664 and 561, 911 and 914, 912 and 914, 913 and 915, 916 and 561, 664 and 917, it was possible to amplify and sequence *tuf* sequences SEQ ID NOs. 498-508, 791-792, 843-855, 904-910, 1664, 1666-1667, 1669-1670, 1673-1683, 1686-1689, 1874-1876, 1879, 1956-1960, and 2193-2199.

EXAMPLE 5:

Specific detection and identification of *Streptococcus agalactiae* using *tuf* sequences. As shown in Annex VIII, the comparison of *tuf* sequences from a variety of bacterial species allowed the selection of PCR primers specific for *S. agalactiae*. The strategy used to design the PCR primers was based on the analysis

of a multiple sequence alignment of various *tuf* sequences. The multiple sequence alignment includes the *tuf* sequences of four bacterial strains from the target species as well as *tuf* sequences from other species and bacterial genera, especially representatives of closely related species. A careful analysis of this alignment allowed the selection of oligonucleotide sequences which are conserved within the target species but which discriminate sequences from other species and genera, especially from the closely related species, thereby permitting the species-specific, ubiquitous and sensitive detection and identification of the target bacterial species.

The chosen primer pair, oligos SEQ ID NO. 549 and SEQ ID NO. 550, gives an amplification product of 252 bp. Standard PCR was carried out using 0.4 μ M of each primer, 2.5 mM MgCl₂, BSA 0.05 mM, 1X Taq Buffer (Promega), dNTP 0.2 mM (Pharmacia), 0.5 U *Taq* DNA polymerase (Promega) coupled with TaqStartTM antibody (Clontech Laboratories Inc., Palo Alto), 1 μ l of genomic DNA sample in a final volume of 20 μ l using a PTC-200 thermocycler (MJ Research Inc.). The optimal cycling conditions for maximum sensitivity and specificity were 3 minutes at 95 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 62 °C, followed by terminal extension at 72 °C for 2 minutes. Detection of the PCR products was made by electrophoresis in agarose gels (2 %) containing 0.25 μ g/ml of ethidium bromide.

Specificity of the assay was tested by adding into the PCR reactions, 0.1 ng of genomic DNA from each of the bacterial species listed in Table 8. Efficient amplification was observed only for the 5 *S. agalactiae* strains listed. Of the other bacterial species, including 32 species representative of the vaginal flora and 27 other streptococcal species, only *S. acidominimus* yielded amplification. The signal with 0.1 ng of *S. acidominimus* genomic DNA was weak and the detection limit for this species was 10 pg (corresponding to more than 4000 genome copies) while the detection limit for *S. agalactiae* was 2.5 fg (corresponding to one genome copy) of genomic DNA.

To increase the specificity of the assay, internal probes were designed for FRET (Fluorescence Resonance Energy Transfer) detection using the LightCycler™ (Idaho Technology). As illustrated in Annex IX, a multiple sequence alignment of streptococcal *tuf* sequence fragments corresponding to the 252 bp region amplified by primers SEQ ID NO. 549 and SEQ ID NO. 550, was used for the design of internal probes TSagHF436 (SEQ ID NO. 582) and TSagHF465 (SEQ ID NO. 583). The region of the amplicon selected for internal probes contained sequences unique and specific to *S. agalactiae*. SEQ ID NO. 583, the more specific probe, is labelled with fluorescein in 3', while SEQ ID NO. 582, the less discriminant probe, is labelled with CY5 in 5' and blocked in 3' with a phosphate group. However, since the FRET signal is only emitted if both probes are adjacently hybridized on the same target amplicon, detection is highly specific.

Real-time detection of PCR products using the LightCycler™ was carried out using 0.4 μM of each primer (SEQ ID NO. 549-550), 0.2 μM of each probe (SEQ ID NO. 582-583), 2.5 mM MgCl₂, BSA 450 μg/ml, 1X PC2 Buffer (AB Peptides, St-Louis, MO), dNTP 0.2 mM (Pharmacia), 0.5 U KlenTaq1™ DNA polymerase (AB Peptides) coupled with TaqStart™ antibody (Clontech Laboratories Inc., Palo Alto), 0.7 μl of genomic DNA sample in a final volume of 7 μl using a LightCycler thermocycler (Idaho Technology). The optimal cycling conditions for maximum sensitivity and specificity were 3 minutes at 94 °C for initial denaturation, then forty cycles of three steps consisting of 0 second (this setting meaning the LightCycler will reach the target temperature and stay at it for its minimal amount of time) at 94 °C, 10 seconds at 64 °C, 20 seconds at 72 °C. Amplification was monitored during each annealing steps using the fluorescence ratio. The streptococcal species having close sequence homologies with the *tuf* sequence of *S. agalactiae* (*S. acidominimus*, *S. anginosus*, *S. bovis*, *S. dysgalactiae*, *S. equi*, *S. ferus*, *S. gordonii*, *S. intermedius*, *S. parasanguis*, *S. parauberis*, *S. salivarius*, *S. sanguis*, *S. suis*) as well as *S. agalactiae* were tested in the

LightCycler with 0.07 ng of genomic DNA per reaction. Only *S. agalactiae* yielded an amplification signal, hence demonstrating that the assay is species-specific. With the LightCycler™ assay using the internal FRET probes, the detection limit for *S. agalactiae* was 1-2 genome copies of genomic DNA.

EXAMPLE 6:

Specific detection and identification of *Streptococcus agalactiae* using *atpD* sequences. As shown in Annex X, the comparison of *atpD* sequences from a variety of bacterial species allowed the selection of PCR primers specific for *S. agalactiae*. The primer design strategy is similar to the strategy described in the preceding Example except that *atpD* sequences were used in the alignment.

Four primers were selected, ASag42 (SEQ ID NO. 627), ASag52 (SEQ ID NO. 628), ASag206 (SEQ ID NO. 625) and ASag371 (SEQ ID NO. 626). The following combinations of these four primers give four amplicons; SEQ ID NO. 627 + SEQ ID NO. 625 = 190 bp, SEQ ID NO. 628 + SEQ ID NO. 625 = 180 bp, SEQ ID NO. 627 + SEQ ID NO. 626 = 355 bp, and SEQ ID NO. 628 + SEQ ID NO. 626 = 345 bp.

Standard PCR was carried out on PTC-200 thermocyclers (MJ Research Inc) using 0.4 μM of each primers pair, 2.5 mM MgCl₂, BSA 0.05 mM, 1X *taq* Buffer (Promega), dNTP 0.2 mM (Pharmacia), 0.5 U *Taq* DNA polymerase (Promega) coupled with TaqStart™ antibody (Clontech Laboratories Inc., Palo Alto), 1 μL of genomic DNA sample in a final volume of 20 μL. The optimal cycling conditions for maximum sensitivity and specificity were adjusted for each primer pair. Three minutes at 95 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at the optimal annealing temperature specified below were followed by terminal extension at 72 °C for 2 minutes. Detection of the PCR products was made by electrophoresis in agarose gels (2 %) containing

0.25 µg/ml of ethidium bromide. Since *atpD* sequences are relatively more specific than *tuf* sequences, only the most closely related species namely, the streptococcal species listed in Table 9, were tested.

All four primer pairs only amplified the six *S. agalactiae* strains. With an annealing temperature of 63 °C, the primer pair SEQ ID NO. 627 + SEQ ID NO. 625 had a sensitivity of 1-5 fg (equivalent to 1-2 genome copies). At 55 °C, the primer pair SEQ ID NO. 628 + SEQ ID NO. 625 had a sensitivity of 2.5 fg (equivalent to 1 genome copy). At 60 °C, the primer pair SEQ ID NO. 627 + SEQ ID NO. 626 had a sensitivity of 10 fg (equivalent to 4 genome copies). At 58 °C, the primer pair SEQ ID NO. 628 + SEQ ID NO. 626 had a sensitivity of 2.5-5 fg (equivalent to 1-2 genome copies). This proves that all four primer pairs can detect *S. agalactiae* with high specificity and sensitivity. Together with Example 5, this example demonstrates that both *tuf* and *atpD* sequences are suitable and flexible targets for the identification of microorganisms at the species level. The fact that 4 different primer pairs based on *atpD* sequences led to efficient and specific amplification of *S. agalactiae* demonstrates that the challenge is to find target genes suitable for diagnostic purposes, rather than finding primer pairs from these target sequences.

EXAMPLE 7:

Development of a PCR assay for detection and identification of staphylococci at genus and species levels.

Materials and Methods

Bacterial strains. The specificity of the PCR assay was verified by using a panel of ATCC (America Type Culture Collection) and DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH; German Collection of

Microorganisms and Cell Cultures) reference strains consisting of 33 gram-negative and 47 gram-positive bacterial species (Table 12). In addition, 295 clinical isolates representing 11 different species of staphylococci from the microbiology laboratory of the Centre Hospitalier Universitaire de Québec, Pavillon Centre Hospitalier de l'Université Laval (CHUL) (Ste-Foy, Québec, Canada) were also tested to further validate the *Staphylococcus*-specific PCR assay. These strains were all identified by using (i) conventional methods or (ii) the automated MicroScan Autoscanner system equipped with the Positive BP Combo Panel Type 6 (Dade Diagnostics, Mississauga, Ontario, Canada). Bacterial strains from frozen stocks kept at -80 °C in brain heart infusion (BHI) broth containing 10% glycerol were cultured on sheep blood agar or in BHI broth (Quelab Laboratories Inc, Montréal, Québec, Canada).

PCR primers and internal probes. Based on multiple sequence alignments, regions of the *tuf* gene unique to staphylococci were identified. *Staphylococcus*-specific PCR primers TStaG422 (SEQ ID NO. 553) and TStaG765 (SEQ ID NO. 575) were derived from these regions (Annex XII). These PCR primers are displaced by two nucleotide positions compared to original *Staphylococcus*-specific PCR primers described in our patent publication WO98/20157 (SEQ ID NOs. 17 and 20 in the said patent publication). These modifications were done to ensure specificity and ubiquity of the primer pair, in the light of new *tuf* sequence data revealed in the present patent application for several additional staphylococcal species and strains.

Similarly, sequence alignment analysis were performed to design genus and species-specific internal probes (see Annexes XIII to XVI). Two internal probes specific for *Staphylococcus* (SEQ ID NOs. 605-606), five specific for *S. aureus* (SEQ ID NOs. 584-588), five specific for *S. epidermidis* (SEQ ID NO. 589-593), two specific for *S. haemolyticus* (SEQ ID NOs. 594-595), three specific for *S. hominis* (SEQ ID NOs. 596-598), four specific for *S. saprophyticus* (SEQ ID NOs. 599-601 and 695), and two specific for coagulase-negative *Staphylococcus* species including

S. epidermidis, *S. hominis*, *S. saprophyticus*, *S. auricularis*, *S. capitis*, *S. haemolyticus*, *S. lugdunensis*, *S. simulans*, *S. cohnii* and *S. warneri* (SEQ ID NOS. 1175-1176) were designed. The range of mismatches between the *Staphylococcus*-specific 371-bp amplicon and each of the 20-mer species-specific internal probes was from 1 to 5, in the middle of the probe when possible. No mismatches were present in the two *Staphylococcus*-specific probes for the 11 species analyzed: *S. aureus*, *S. auricularis*, *S. capitis*, *S. cohnii*, *S. epidermidis*, *S. haemolyticus*, *S. hominis*, *S. lugdunensis*, *S. saprophyticus*, *S. simulans* and *S. warneri*. In order to verify the intra-specific sequence conservation of the nucleotide sequence, sequences were obtained for the 371-bp amplicon from five unrelated ATCC and clinical strains for each of the species *S. aureus*, *S. epidermidis*, *S. haemolyticus*, *S. hominis* and *S. saprophyticus*. The OligoTM (version 5.0) primer analysis software (National Biosciences, Plymouth, Minn.) was used to confirm the absence of self-complementary regions within and between the primers or probes. When required, the primers contained inosines or degenerated nucleotides at one or more variable positions. Oligonucleotide primers and probes were synthesized on a model 394 DNA synthesizer (Applied Biosystems, Mississauga, Ontario, Canada). Detection of the hybridization was performed with the DIG-labeled dUTP incorporated during amplification with the *Staphylococcus*-specific PCR assay, and the hybridization signal was detected with a luminometer (Dynex Technologies) as described above in the section on luminescent detection of amplification products. Annexes XIII to XVI illustrate the strategy for the selection of several internal probes.

PCR amplification. For all bacterial species, amplification was performed from purified genomic DNA or from a bacterial suspension whose turbidity was adjusted to that of a 0.5 McFarland standard, which corresponds to approximately 1.5×10^8 bacteria per ml. One nanogram of genomic DNA or 1 μ l of the standardized bacterial suspension was transferred directly to a 19 μ l PCR mixture. Each PCR reaction contained 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM

$MgCl_2$, 0.2 μM (each) of the two *Staphylococcus* genus-specific primers (SEQ ID NOs. 553 and 575), 200 μM (each) of the four deoxynucleoside triphosphates (Pharmacia Biotech), 3.3 $\mu g/\mu l$ bovine serum albumin (BSA) (Sigma-Aldrich Canada Ltd, Oakville, Ontario, Canada), and 0.5 U *Taq* polymerase (Promega) coupled with *TaqStart*TM Antibody (Clontech). The PCR amplification was performed as follows: 3 min. at 94 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 55 °C, plus a terminal extension at 72 °C for 2 minutes. Detection of the PCR products was made by electrophoresis in agarose gels (2 %) containing 0.25 $\mu g/ml$ of ethidium bromide. Visualization of the PCR products was made under UV at 254 nm.

For determination of the sensitivities of the PCR assays, two-fold dilutions of purified genomic DNA were used to determine the minimal number of genome copies which can be detected.

Results

Amplifications with the *Staphylococcus* genus-specific PCR assay. The specificity of the assay was assessed by performing 30-cycle and 40-cycle PCR amplifications with the panel of gram-positive (47 species from 8 genera) and gram-negative (33 species from 22 genera) bacterial species listed in Table 12. The PCR assay was able to detect efficiently 27 of 27 staphylococcal species tested in both 30-cycle and 40-cycle regimens. For 30-cycle PCR, all bacterial species tested other than staphylococci were negative. For 40-cycle PCR, *Enterococcus faecalis* and *Macrococcus caseolyticus* were slightly positive for the *Staphylococcus*-specific PCR assay. The other species tested remained negative. Ubiquity tests performed on a collection of 295 clinical isolates provided by the microbiology laboratory of the Centre Hospitalier Universitaire de Québec, Pavillon Centre Hospitalier de l'Université Laval (CHUL), including *Staphylococcus aureus* (n=34), *S. auricularis* (n=2), *S. capitis* (n=19), *S. cohnii* (n=5), *S. epidermidis* (n=18), *S. haemolyticus*

(n=21), *S. hominis* (n=73), *S. lugdunensis* (n=17), *S. saprophyticus* (n=6), *S. simulans* (n=3), *S. warneri* (n=32) and *Staphylococcus* sp. (n=65), showed a uniform amplification signal with the 30-cycle PCR assays and a perfect relation between the genotype and classical identification schemes.

The sensitivity of the *Staphylococcus*-specific assay with 30-cycle and 40-cycle PCR protocols was determined by using purified genomic DNA from the 11 staphylococcal species previously mentioned. For PCR with 30 cycles, a detection limit of 50 copies of genomic DNA was consistently obtained. In order to enhance the sensitivity of the assay, the number of cycles was increased. For 40-cycle PCR assays, the detection limit was lowered to a range of 5-10 genome copies, depending on the staphylococcal species tested.

Hybridization between the *Staphylococcus*-specific 371-bp amplicon and species-specific or genus-specific internal probes. Inter-species polymorphism was sufficient to generate species-specific internal probes for each of the principal species involved in human diseases (*S. aureus*, *S. epidermidis*, *S. haemolyticus*, *S. hominis* and *S. saprophyticus*). In order to verify the intra-species sequence conservation of the nucleotide sequence, sequence comparisons were performed on the 371-bp amplicon from five unrelated ATCC and clinical strains for each of the 5 principal staphylococcal species: *S. aureus*, *S. epidermidis*, *S. haemolyticus*, *S. hominis* and *S. saprophyticus*. Results showed a high level of conservation of nucleotide sequence between different unrelated strains from the same species. This sequence information allowed the development of staphylococcal species identification assays using species-specific internal probes hybridizing to the 371-bp amplicon. These assays are specific and ubiquitous for those five staphylococcal species. In addition to the species-specific internal probes, the genus-specific internal probes were able to recognize all or most *Staphylococcus* species tested.

EXAMPLE 8:

Differentiating between the two closely related yeast species *Candida albicans* and *Candida dubliniensis*. It is often useful for the clinician to be able to differentiate between two very closely related species of microorganisms. *Candida albicans* is the most important cause of invasive human mycose. In recent years, a very closely related species, *Candida dubliniensis*, was isolated in immunosuppressed patients. These two species are difficult to distinguish by classic biochemical methods. This example demonstrates the use of *tuf* sequences to differentiate *Candida albicans* and *Candida dubliniensis*. PCR primers SEQ ID NOs. 11-12, from previous patent publication WO98/20157, were selected for their ability to specifically amplify a *tuf* (elongation factor 1 alpha type) fragment from both species (see Annex XI for primer positions). Within this *tuf* fragment, a region differentiating *C. albicans* and *C. dubliniensis* by two nucleotides was selected and used to design two internal probes (see Annex XI for probe design, SEQ ID NOs. 577 and 578) specific for each species. Amplification of genomic DNA from *C. albicans* and *C. dubliniensis* was carried out using DIG-11-dUTP as described above in the section on chemiluminescent detection of amplification products. Internal probes SEQ ID NOs. 577 and 578 were immobilized on the bottom of individual microtiter plates and hybridization was carried out as described above in the above section on chemiluminescent detection of amplification products. Luminometer data showed that the amplicon from *C. albicans* hybridized only to probe SEQ ID NO. 577 while the amplicon from *C. dubliniensis* hybridized only to probe SEQ ID NO. 578, thereby demonstrating that each probe was species-specific.

EXAMPLE 9:

Specific identification of *Entamoeba histolytica*. Upon analysis of *tuf* (elongation factor 1 alpha) sequence data, it was possible to find four regions where

Entamoeba histolytica sequences remained conserved while other parasitical and eukaryotic species have diverged. Primers TEntG38 (SEQ ID NO. 703), TEntG442 (SEQ ID NO. 704), TEntG534 (SEQ ID NO. 705), and TEntG768 (SEQ ID NO. 706) were designed so that SEQ ID NO. 703 could be paired with the three other primers. On PTC-200 thermocyclers (MJ Research), the cycling conditions for initial sensitivity and specificity testing were 3 min. at 94 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 55 °C, followed by terminal extension at 72 °C for 2 minutes. Detection of the PCR products was made by electrophoresis in agarose gels (2 %) containing 0.25 µg/ml of ethidium bromide. The three primer pairs could detect the equivalent of less than 200 *E. histolytica* genome copies. Specificity was tested using 0.5 ng of purified genomic DNA from a panel of microorganisms including *Babesia bovis*, *Babesia microti*, *Candida albicans*, *Crithidia fasciculata*, *Leishmania major*, *Leishmania hertigi* and *Neospora caninum*. Only *E. histolytica* DNA could be amplified, thereby suggesting that the assay was species-specific.

EXAMPLE 10:

Sensitive identification of *Chlamydia trachomatis*. Upon analysis of *tuf* sequence data, it was possible to find two regions where *Chlamydia trachomatis* sequences remained conserved while other species have diverged. Primers Ctr82 (SEQ ID NO. 554) and Ctr249 (SEQ ID NO. 555) were designed. With the PTC-200 thermocyclers (MJ Research), the optimal cycling conditions for maximum sensitivity and specificity were determined to be 3 min. at 94 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 60 °C, followed by terminal extension at 72 °C for 2 minutes. Detection of the PCR products was made by electrophoresis in agarose gels (2 %) containing 0.25 µg/ml of ethidium bromide. The assay could detect the equivalent of 8 *C. trachomatis* genome copies. Specificity was tested with 0.1 ng of purified genomic DNA from a panel of microorganisms including 22 species commonly encountered

in the vaginal flora (*Bacillus subtilis*, *Bacteroides fragilis*, *Candida albicans*, *Clostridium difficile*, *Corynebacterium cervicis*, *Corynebacterium urealyticum*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Fusobacterium nucleatum*, *Gardnerella vaginalis*, *Haemophilus influenzae*, *Klebsiella oxytoca*, *Lactobacillus acidophilus*, *Peptococcus niger*, *Peptostreptococcus prevotii*, *Porphyromonas asaccharolytica*, *Prevotella melaninogenica*, *Propionibacterium acnes*, *Staphylococcus aureus*, *Streptococcus acidominimus*, and *Streptococcus agalactiae*). Only *C. trachomatis* DNA could be amplified, thereby suggesting that the assay was species-specific.

EXAMPLE 11:

Genus-specific detection and identification of enterococci. Upon analysis of *tuf* sequence data and comparison with the repertory of *tuf* sequences, it was possible to find two regions where *Enterococcus* sequences remained conserved while other genera have diverged (Annex XVII). Primer pair Encg313dF and Encg599c (SEQ ID NOs. 1137 and 1136) was tested for its specificity by using purified genomic DNA from a panel of bacteria listed in Table 10. Using the PTC-200 thermocycler (MJ Research), the optimal cycling conditions for maximum sensitivity and specificity were determined to be 3 min. at 94 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 55 °C, followed by terminal extension at 72 °C for 2 minutes. Detection of the PCR products was made by electrophoresis in agarose gels (2 %) containing 0.25 µg/ml of ethidium bromide. Visualization of the PCR products was made under UV at 254 nm. The 18 enterococcal species listed in Table 10 were all amplified efficiently. The only other species amplified were *Abiotrophia adiacens*, *Gemella haemolysans* and *Gemella morbillorum*, three gram-positive species. Sensitivity tested with several strains of *E. casseliflavus*, *E. faecium*, *E. faecalis*, *E. flavescentis* and *E. gallinarum* and with one strain of each other *Enterococcus* species listed in Table 10 ranged from 1 to 10 copies of genomic DNA. The sequence variation

within the 308-bp amplicon was sufficient so that internal probes could be used to speciate the amplicon and differentiate enterococci from *Abiotrophia adiacens*, *Gemella haemolysans* and *Gemella morbillorum*, thereby allowing to achieve excellent specificity. Species-specific internal probes were generated for each of the clinically important species, *E. faecalis* (SEQ ID NO. 1174), *E. faecium* (SEQ ID NO. 602), and the group including *E. casseliflavus*, *E. flavescentis* and *E. gallinarum* (SEQ ID NO. 1122) (Annex XVIII). The species-specific internal probes were able to differentiate their respective *Enterococcus* species from all other *Enterococcus* species. These assays are sensitive, specific and ubiquitous for those five *Enterococcus* species.

EXAMPLE 12:

Identification of the major bacterial platelets contaminants using *tuf* sequences with a multiplex PCR test. Blood platelets preparations need to be monitored for bacterial contaminations. The *tuf* sequences of 17 important bacterial contaminants of platelets were aligned. As shown in Annex XIX, analysis of these sequences allowed the design of PCR primers. Since in the case of contamination of platelet concentrates, detecting all species (not just the more frequently encountered ones) is desirable, perfect specificity of primers was not an issue in the design. However, sensitivity is important. That is why, to avoid having to put too much degeneracy, only the most frequent contaminants were included in primer design, knowing that the selected primers would anyway be able to amplify more species than the 17 used in the design because they target highly conserved regions of *tuf* sequences. Oligonucleotide sequences which are conserved in these 17 major bacterial contaminants of platelet concentrates were chosen (oligos Tplaq 769 and Tplaq 991, respectively SEQ ID NOs. 636 and 637) thereby permitting the detection of these bacterial species. However, sensitivity was slightly deficient with staphylococci. To ensure maximal sensitivity in the detection of all the more frequent bacterial contaminants, a multiplex assay also including oligonucleotide

primers targetting the *Staphylococcus* genera (oligos Stag 422, SEQ ID NO. 553; and Stag 765, SEQ ID NO. 575) was developed. The bacterial species detected with the assay are listed in Table 14.

The primer pairs, oligos SEQ ID NO. 636 and SEQ ID NO. 637 that give an amplification product of 245 pb, and oligos SEQ ID NO. 553 and SEQ ID NO. 575 that give an amplification product of 368 pb, were used simultaneously in the multiplex PCR assay. Detection of these PCR products was made on the LightCycler thermocycler (Idaho Technology) using SYBR® Green I (Molecular Probe Inc.). SYBR® Green I is a fluorescent dye that binds specifically to double-stranded DNA.

Fluorogenic detection of PCR products with the LightCycler was carried out using 1.0 μ M of both Tplaq primers (SEQ ID NOs. 636-637) and 0.4 μ M of both TStaG primers (SEQ ID NOs. 553 and 575), 2.5 mM MgCl₂, BSA 7.5 μ M , dNTP 0.2 mM (Pharmacia), 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 0.5 U *Taq* DNA polymerase (Boehringer Mannheim) coupled with TaqStart™ antibody (Clontech), and 0.07 ng of genomic DNA sample in a final volume of 7 μ l. The optimal cycling conditions for maximum sensitivity and specificity were 1 minute at 94 °C for initial denaturation, then forty-five cycles of three steps consisting of 0 second at 95 °C, 5 seconds at 60 °C and 9 seconds at 72 °C. Amplification was monitored during each elongation cycle by measuring the level of SYBR® Green I. However, real analysis takes place after PCR. Melting curves are done for each sample and transformation of the melting peak allows determination of Tm. Thus primer-dimer and specific PCR product are discriminated. With this assay, all prominent bacterial contaminants of platelet concentrates listed in Annex XIX and Table 14 were detected. Sensitivity tests were performed on the 9 most frequent bacterial contaminants of platelets. The detection limit was less than 20 genome copies for *E. cloacae*, *B. cereus*, *S. choleraesuis* and *S. marcescens*; less than 15 genome copies for *P. aeruginosa*; and 2 to 3 copies were detected for *S. aureus*, *S.*

epidermidis, *E. coli* and *K. pneumoniae*. Further refinements of assay conditions should increase sensitivity levels.

EXAMPLE 13:

The resolving power of the *tuf* and *atpD* sequences databases is comparable to the biochemical methods for bacterial identification. The present gold standard for bacterial identification is mainly based on key morphological traits and batteries of biochemical tests. Here we demonstrate that the use of *tuf* and *atpD* sequences combined with simple phylogenetic analysis of databases formed by these sequences is comparable to the gold standard. In the process of acquiring data for the *tuf* sequences, we sequenced the *tuf* gene of a strain that was given to us labelled as *Staphylococcus hominis* ATCC 35982. That *tuf* sequence (SEQ ID NO. 192) was incorporated into the *tuf* sequences database and subjected to a basic phylogenetic analysis using the Pileup command from version 10 of the GCG package (Genetics Computer Group). This analysis indicated that SEQ ID NO. 192 is not associated with other *S. hominis* strains but rather with the *S. warneri* strains. The ATCC 35982 strain was sent to the reference laboratory of the Laboratoire de santé publique du Québec (LSPQ). They used the classic identification scheme for staphylococci (Kloos and Schleifer, 1975., J. Clin. Microbiol. 1:82-88). Their results shown that although the colonial morphology could correspond to *S. hominis*, the more precise biochemical assays did not. These assays included discriminant mannitol, mannose and ribose acidification tests as well as rapid and dense growth in deep thioglycolate agar. The LSPQ report identified strain ATCC 35982 as *S. warneri* which confirms our database analysis. The same thing happened for *S. warneri* (SEQ ID NO. 187) which had initially been identified as *S. haemolyticus* by a routine clinical laboratory using a low resolving power automated system (MicroScan, AutoScan-4TM). Again, the *tuf* and LSPQ analysis agreed on its identification as *S. warneri*. In numerous other instances, in the course of acquiring *tuf* and *atpD* sequence data from various species and genera,

analysis of our *tuf* and/or *atpD* sequence databases permitted the exact identification of mislabelled or erroneously identified strains. These results clearly demonstrate the usefulness and the high resolving power of our sequence-based identification assays using the *tuf* and *atpD* sequences databases.

EXAMPLE 14:

Detection of group B streptococci from clinical specimens.

Introduction

Streptococcus agalactiae, the group B streptococcus (GBS), is responsible for a severe illness affecting neonate infants. The bacterium is passed from the healthy carrier mother to the baby during delivery. To prevent this infection, it is recommended to treat expectant mothers susceptible of carrying GBS in their vaginal/anal flora. Carrier status is often a transient condition and rigorous monitoring requires cultures and classic bacterial identification weeks before delivery. To improve the detection and identification of GBS we developed a rapid, specific and sensitive PCR test fast enough to be performed right at delivery.

Materials and Methods

GBS clinical specimens. A total of 66 duplicate vaginal/anal swabs were collected from 41 consenting pregnant women admitted for delivery at the Centre Hospitalier Universitaire de Québec, Pavillon Saint-François d'Assise following the CDC recommendations. The samples were obtained either before or after rupture of membranes. The swab samples were tested at the Centre de Recherche en Infectiologie de l'Université Laval within 24 hours of collection. Upon receipt, one swab was cut and then the tip of the swab was added to GNS selective broth for identification of group B streptococci (GBS) by the standard culture methods

recommended by the CDC. The other swab was processed following the instruction of the IDI DNA extraction kit (Infectio Diagnostics (IDI) Inc.) prior to PCR amplification.

Oligonucleotides. PCR primers, Tsag340 (SEQ ID NO. 549) and Tsag552 (SEQ ID NO. 550) complementary to the regions of the *tuf* gene unique for GBS were designed based upon a multiple sequence alignment using our repertory of *tuf* sequences. Oligo primer analysis software (version 5.0) (National Biosciences) was used to analyse primers annealing temperature, secondary structure potential as well as mispriming and dimerization potential. The primers were synthesized using a model 391 DNA synthesizer (Applied Biosystems).

A pair of fluorescently labeled adjacent hybridization probes Sag465-F (SEQ ID NO. 583) and Sag436-C (SEQ ID NO. 582) were synthesized and purified by Operon Technologies. They were designed to meet the recommendations of the manufacturer (Idaho Technology) and based upon multiple sequence alignment analysis using our repertory of *tuf* sequences to be specific and ubiquitous for GBS. These adjacent probes, which are separated by one nucleotide, allow fluorescence resonance energy transfer (FRET), generating an increased fluorescence signal when both hybridized simultaneously to their target sequences. The probe SEQ ID NO. 583 was labeled with FITC in 3' prime while SEQ ID NO. 582 was labeled with Cy5 in 5' prime. The Cy5-labeled probes contained a 3'-blocking phosphate group to prevent extension of the probes during the PCR reactions.

PCR amplification. Conventional amplifications were performed either from 2 μ l of a purified genomic DNA preparation or cell lysates of vaginal/anal specimens. The 20 μ l PCR mixture contained 0.4 μ M of each GBS-specific primer (SEQ ID NOS. 549-550), 200 μ M of each deoxyribonucleotide (Pharmacia Biotech), 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 0.1% Triton X-100, 2.5 mM MgCl₂, 3.3 mg/ml bovine serum albumin (BSA) (Sigma), and 0.5 U of *Taq* polymerase (Promega) combined with the TaqStartTM antibody (Clontech). The TaqStartTM antibody, which is a neutralizing monoclonal antibody of *Taq* DNA

polymerase, was added to all PCR reactions to enhance the efficiency of the amplification. The PCR mixtures were subjected to thermal cycling (3 min at 95 °C and then 40 cycles of 1 s at 95 °C, and 30 s at 62 °C with a 2-min final extension at 72 °C) with a PTC-200 DNA Engine thermocycler (MJ research). The PCR-amplified reaction mixture was resolved by agarose gel electrophoresis.

The LightCycler™ PCR amplifications were performed with 1 µl of a purified genomic DNA preparation or cell lysates of vaginal/anal specimens. The 10µl amplification mixture consisted of 0.4 µM each GBS-specific primer (SEQ ID NOs. 549-550), 200 µM each dNTP, 0.2 µM each fluorescently labeled probe (SEQ ID NOs. 582-583), 300 µg/ml BSA (Sigma), and 1 µl of 10x PC2 buffer (containing 50 mM Tris-HCl (pH 9.1), 16 mM ammonium sulfate, 3.5 mM Mg²⁺, and 150 µg/ml BSA) and 0.5 U KlenTaq1™ (AB Peptides) coupled with TaqStart™ antibody (Clontech). KlenTaq1™ is a highly active and more heat-stable DNA polymerase without 5'-exonuclease activity. This prevents hydrolysis of hybridized probes by the 5' to 3' exonuclease activity. A volume of 7 µl of the PCR mixture was transferred into a composite capillary tube (Idaho Technology). The tubes were then centrifuged to move the reaction mixture to the tips of the capillaries and then cleaned with optical-grade methanol. Subsequently the capillaries were loaded into the carousel of a LC32 LightCycler™ (Idaho Technology), an instrument that combines rapid-cycle PCR with fluorescence analysis for continuous monitoring during amplification. The PCR reaction mixtures were subjected to a denaturation step at 94 °C for 3 min followed by 45 cycles of 0 s at 94 °C, 20 s at 64 °C and 10 s at 72 °C with a temperature transition rate of 20 °C/s. Fluorescence signals were obtained at each cycle by sequentially positioning each capillary on the carousel at the focus of optical elements affiliated to the built-in fluorimeter for 100 milliseconds. Complete amplification and analysis required about 35 min.

Specificity and sensitivity tests. The specificity of the conventional and LightCycler™ PCR assays was verified by using purified genomic DNA (0.1 ng/reaction) from a battery of ATCC reference strains representing 35 clinically

relevant gram-positive species (*Abiotrophia defectiva* ATCC 49176, *Bifidobacterium breve* ATCC 15700, *Clostridium difficile* ATCC 9689, *Corynebacterium urealyticum* ATCC 43042, *Enterococcus casseliflavus* ATCC 25788, *Enterococcus durans* ATCC 19432, *Enterococcus faecalis* ATCC 29212, *Enterococcus faecium* ATCC 19434, *Enterococcus gallinarum* ATCC 49573, *Enterococcus raffinosus* ATCC 49427, *Lactobacillus reuteri* ATCC 23273, *Lactococcus lactis* ATCC 19435, *Listeria monocytogenes* ATCC 15313, *Peptococcus niger* ATCC 27731, *Peptostreptococcus anaerobius* ATCC 27337, *Peptostreptococcus prevotii* ATCC 9321, *Staphylococcus aureus* ATCC 25923, *Staphylococcus epidermidis* ATCC 14990, *Staphylococcus haemolyticus* ATCC 29970, *Staphylococcus saprophyticus* ATCC 15305, *Streptococcus agalactiae* ATCC 27591, *Streptococcus anginosus* ATCC 33397, *Streptococcus bovis* ATCC 33317, *Streptococcus constellatus* ATCC 27823, *Streptococcus dysgalactiae* ATCC 43078, *Streptococcus gordonii* ATCC 10558, *Streptococcus mitis* ATCC 33399, *Streptococcus mutans* ATCC 25175, *Streptococcus oralis* ATCC 35037, *Streptococcus parauberis* ATCC 6631, *Streptococcus pneumoniae* ATCC 6303, *Streptococcus pyogenes* ATCC 19615, *Streptococcus salivarius* ATCC 7073, *Streptococcus sanguinis* ATCC 10556, *Streptococcus uberis* ATCC 19436). These microbial species included 15 species of streptococci and many members of the normal vaginal and anal floras. In addition, 40 GBS isolates of human origin, whose identification was confirmed by a latex agglutination test (Streptex, Murex), were also used to evaluate the ubiquity of the assay.

For determination of the sensitivities (i.e., the minimal number of genome copies that could be detected) for conventional and LightCycler™ PCR assays, serial 10-fold or 2-fold dilutions of purified genomic DNA from 5 GBS ATCC strains were used.

Results

Evaluation of the GBS-specific conventional and LightCycler™ PCR assays. The specificity of the two assays demonstrated that only DNAs from GBS

strains could be amplified. Both PCR assays did not amplify DNAs from any other bacterial species tested including 14 streptococcal species other than GBS as well as phylogenetically related species belonging to the genera *Enterococcus*, *Pepostreptococcus* and *Lactococcus*. Important members of the vaginal or anal flora, including coagulase-negative staphylococci, *Lactobacillus* sp., and *Bacterioides* sp. were also negative with the GBS-specific PCR assay. The LightCyclerTM PCR assays detected only GBS DNA by producing an increased fluorescence signal which was interpreted as a positive PCR result. Both PCR methods were able to amplify all of 40 GBS clinical isolates, showing a perfect correlation with the phenotypic identification methods.

The sensitivity of the assay was determined by using purified genomic DNA from the 5 ATCC strains of GBS. The detection limit for all of these 5 strains was one genome copy of GBS. The detection limit of the assay with the LightCyclerTM was 3.5 fg of genomic DNA (corresponding to 1-2 genome copies of GBS). These results confirmed the high sensitivity of our GBS-specific PCR assay.

Direct Detection of GBS from vaginal/anal specimens. Among 66 vaginal/anal specimens tested, 11 were positive for GBS by both culture and PCR. There was one sample positive by culture only. The sensitivity of both PCR methods with vaginal/anal specimens for identifying colonization status in pregnant women at delivery was 91.7% when compared to culture results. The specificity and positive predictive values were both 100% and the negative predictive value was 97.8%. The time for obtaining results was approximately 45 min for LightCyclerTM PCR, approximately 100 min for conventional PCR and 48 hours for culture.

Conclusion

We have developed two PCR assays (conventional and LightCyclerTM) for the detection of GBS, which are specific (i.e., no amplification of DNA from a variety of bacterial species other than GBS) and sensitive (i.e., able to detect around 1

genome copy for several reference ATCC strains of GBS). Both PCR assays are able to detect GBS directly from vaginal/anal specimens in a very short turnaround time. Using the real-time PCR assay on LightCyclerTM, we can detect GBS carriage in pregnant women at delivery within 45 minutes.

EXAMPLE 15:

Simultaneous detection and identification of *Streptococcus pyogenes* and its pyrogenic exotoxin A. The rapid detection of *Streptococcus pyogenes* and of its pyrogenic exotoxin A is of clinical importance. We developed a multiplex assay which permits the detection of strains of *S. pyogenes* carrying the pyrogenic toxin A gene, which is associated with scarlet fever and other pathologies. In order to specifically detect *S. pyogenes*, nucleotide sequences of the pyrrolidone carboxylyl peptidase (*pcp*) gene were aligned to design PCR primers Spy291 (SEQ ID NO. 1211) and Spy473 (SEQ ID NO. 1210). Next, we designed primers for the specific detection of the pyrogenic exotoxin A. Nucleotide sequences of the *speA* gene, carried on the bacteriophage T12, were aligned as shown in Annex XXIII to design PCR primers Spytx814 (SEQ ID NO. 994) and Spytx 927 (SEQ ID NO. 995).

The primer pairs: oligos SEQ ID NOs. 1210-1211, yielding an amplification product of 207 bp, and oligos SEQ ID NOs. 994-995, yielding an amplification product of 135 bp, were used in a multiplex PCR assay.

PCR amplification was carried out using 0.4 μ M of both pairs of primers, 2.5 mM MgCl₂, BSA 0.05 μ M , dNTP 0.2 μ M (Pharmacia), 10mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM MgCl₂, 0.5 U *Taq* DNA polymerase (Promega) coupled with TaqStartTM antibody (Clontech Laboratories Inc.), and 1 μ l of genomic DNA sample in a final volume of 20 μ l. PCR amplification was performed using a PTC-200 thermal cycler (MJ Research). The optimal cycling conditions for maximum specificity and sensitivity were 3 minutes at 94 °C for

initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 63 °C, followed by a final step of 2 minutes at 72 °C. Detection of the PCR products was made by electrophoresis in agarose gels (2 %) containing 0.25 µg/ml of ethidium bromide. Visualization of the PCR products was made under UV at 254 nm.

The detection limit was less than 5 genome copies for both *S. pyogenes* and its pyrogenic exotoxin A. The assay was specific for pyrogenic exotoxin A-producing *S. pyogenes*: strains of the 27 other species of *Streptococcus* tested, as well as 20 strains of various gram-positive and gram-negative bacterial species were all negative.

A similar approach was used to design an alternative set of *speA*-specific primers (SEQ ID NOs. 996 to 998, see Annex XXIV). In addition, another set of primers based on the *tuf* gene (SEQ ID NOs. 999 to 1001, see Annex XXV) could be used to specifically detect *Streptococcus pyogenes*.

EXAMPLE 16:

Real-time detection and identification of Shiga toxin-producing bacteria. Shiga toxin-producing *Escherichia coli* and *Shigella dysenteriae* cause bloody diarrhea. Currently, identification relies mainly on the phenotypic identification of *S. dysenteriae* and *E. coli* serotype O157:H7. However, other serotypes of *E. coli* are increasingly found to be producers of type 1 and/or type 2 Shiga toxins. Two pairs of PCR primers targeting highly conserved regions present in each of the Shiga toxin genes *stx₁* and *stx₂* were designed to amplify all variants of those genes (see Annexes XXVI and XXVII). The first primer pair, oligonucleotides 1SLT224 (SEQ ID NO. 1081) and 1SLT385 (SEQ ID NO. 1080), yields an amplification product of 186 bp from the *stx₁* gene. For this amplicon, the 1SLTB1-Fam (SEQ ID NO. 1084) molecular beacon was designed for the specific detection of *stx₁*.

using the fluorescent label 6-carboxy-fluorescein. The 1SltS1-FAM (SEQ ID NO. 2012) molecular scorpion was also designed as an alternate way for the specific detection of *stx*₁. A second pair of PCR primers, oligonucleotides 2SLT537 (SEQ ID NO. 1078) and 2SLT678b (SEQ ID NO. 1079), yields an amplification product of 160 bp from the *stx*₂ gene. Molecular beacon 2SLTB1-Tet (SEQ ID NO. 1085) was designed for the specific detection of *stx*₂ using the fluorescent label 5-tetrachloro-fluorescein. Both primer pairs were combined in a multiplex PCR assay.

PCR amplification was carried out using 0.8 μ M of primer pair SEQ ID NOs. 1080-1081, 0.5 μ M of primer pair SEQ ID NOs. 1078-1079, 0.3 μ M of each molecular beacon, 8 mM MgCl₂, 490 μ g/mL BSA, 0.2 mM dNTPs (Pharmacia), 50 mM Tris-HCl, 16 mM NH₄SO₄, 1X TaqMaster (Eppendorf), 2.5 U KlenTaqI DNA polymerase (AB Peptides) coupled with TaqStartTM antibody (Clontech Laboratories Inc.), and 1 μ l of genomic DNA sample in a final volume of 25 μ l. PCR amplification was performed using a SmartCycler thermal cycler (Cepheid). The optimal cycling conditions for maximum sensitivity and specificity were 60 seconds at 95 °C for initial denaturation, then 45 cycles of three steps consisting of 10 seconds at 95 °C, 15 seconds at 56 °C and 5 seconds at 72 °C. Detection of the PCR products was made in real-time by measuring the fluorescent signal emitted by the molecular beacon when it hybridizes to its target at the end of the annealing step at 56 °C.

The detection limit was the equivalent of less than 5 genome copies. The assay was specific for the detection of both toxins, as demonstrated by the perfect correlation between PCR results and the phenotypic characterization performed using antibodies specific for each Shiga toxin type. The assay was successfully performed on several Shiga toxin-producing strains isolated from various geographic areas of the world, including 10 O157:H7 *E. coli*, 5 non-O157:H7 *E. coli* and 4 *S. dysenteriae*.

EXAMPLE 17:

Development of a PCR assay for the detection and identification of staphylococci at genus and species levels and its associated *mecA* gene. The *Staphylococcus*-specific PCR primers described in Example 7 (SEQ ID NOs. 553 and 575) were used in multiplex with the *mecA*-specific PCR primers and the *S. aureus*-specific primers described in our assigned US patent no. 5,994,066 (SEQ ID NOs. 261 and 262 for *mecA* and SEQ ID NOs. 152 and 153 for *S. aureus* in the said patent). Sequence alignment analysis of 10 publicly available *mecA* gene sequences allowed to design an internal probe specific to *mecA* (SEQ ID NO. 1177). An internal probe was also designed for the *S. aureus*-specific amplicon (SEQ ID NO 1234). PCR amplification and agarose gel electrophoresis of the amplified products were performed as described in Example 7, with the exception that 0.4 μ M (each) of the two *Staphylococcus*-specific primers (SEQ ID NOs. 553 and 575) and 0.4 μ M (each) of the *mecA*-specific primers and 0.4 μ M (each) of the *S. aureus*-specific primers were used in the PCR mixture. The specificity of the multiplex assay with 40-cycle PCR protocols was verified by using purified genomic DNA from five methicillin-resistant and fifteen methicillin-sensitive staphylococcal strains. The sensitivity of the multiplex assay with 40-cycle PCR protocols was determined by using purified genomic DNA from twenty-three methicillin-resistant and twenty-eight methicillin-sensitive staphylococcal strains. The detection limit was 2 to 10 genome copies of genomic DNA, depending on the staphylococcal species tested. Furthermore, the *mecA*-specific internal probe, the *S. aureus*-specific internal probe and the coagulase-negative staphylococci-specific internal probe (described in Example 7) were able to recognize twenty-three methicillin-resistant staphylococcal strains and twenty-eight methicillin-sensitive staphylococcal strains with high sensitivity and specificity.

The format of the assay is not limited to the one described above. A person skilled in the art could adapt the assay for different formats such as PCR with real-time detection using molecular beacon probes. Molecular beacon probes designed to be used in this assay include, but are not limited to, SEQ ID NO. 1232 for detection of the *S. aureus*-specific amplicon, SEQ ID NO. 1233 for detection of coagulase-negative staphylococci and SEQ ID NO. 1231 for detection of *mecA*.

Alternatively, a multiplex PCR assay containing the *Staphylococcus*-specific PCR primers described in Example 7 (SEQ ID NOs. 553 and 575) and the *mecA*-specific PCR primers described in our assigned US patent no. 5,994,066 (SEQ ID NOs. 261 and 262 in the said patent) were developed. PCR amplification and agarose gel electrophoresis of the amplified products were performed as described in Example 7, with the exception that 0.4 μ M (each) of the *Staphylococcus*-specific primers (SEQ ID NOs. 553 and 575), and 0.4 μ M (each) of the *mecA*-specific primers described in our assigned US patent no. 5,994,066 (SEQ ID NOs. 261 and 262 in the said patent) were used in the PCR mixture. The sensitivity of the multiplex assay with 40-cycle PCR protocols was determined by using purified genomic DNA from two methicillin-resistant and five methicillin-sensitive staphylococcal strains. The detection limit was 2 to 5 copies of genomic DNA, depending on the staphylococcal species tested. The specificity of the multiplex PCR assay coupled with capture-probe hybridization was tested with two strains of methicillin-resistant *S. aureus*, two strains of methicillin-sensitive *S. aureus* and seven strains of methicillin-sensitive coagulase-negative staphylococci. The *mecA*-specific internal probe (SEQ ID NO. 1177) and the *S. aureus*-specific internal probe (SEQ ID NO. 587) described in Example 7 were able to recognize all the strains with high specificity showing a perfect correlation with susceptibility to methicillin. The sensitivity of the PCR assay coupled with capture-probe hybridization was tested with one strain of methicillin-resistant *S. aureus*. The detection limit was around 10 copies of genomic DNA.

EXAMPLE 18:Sequencing of *pbp1a*, *pbp2b* and *pbp2x* genes of *Streptococcus pneumoniae*.

Penicillin resistance in *Streptococcus pneumoniae* involves the sequential alteration of up to five penicillin-binding proteins (PBPs) 1A, 1B, 2A, 2X and 2B in such a way that their affinity is greatly reduced toward the antibiotic molecule. The altered PBP genes have arisen as the result of interspecies recombination events from related streptococcal species. Among the PBPs usually found in *S. pneumoniae*, PBPs 1A, 2B, and 2X play the most important role in the development of penicillin resistance. Alterations in PBP 2B and 2X mediate low-level resistance to penicillin while additional alterations in PBP 1A plays a significant role in full penicillin resistance.

In order to generate a database for *pbp* sequences that can be used for design of primers and/or probes for the specific and ubiquitous detection of β -lactam resistance in *S. pneumoniae*, *pbp1a*, *pbp2b* and *pbp2x* DNA fragments sequenced by us or selected from public databases (GenBank and EMBL) from a variety of *S. pneumoniae* strains were used to design oligonucleotide primers. This database is essential for the design of specific and ubiquitous primers and/or probes for detection of β -lactam resistance in *S. pneumoniae* since the altered PBP 1A, PBP 2B and PBP 2X of β -lactam resistant *S. pneumoniae* are encoded by mosaic genes with numerous sequence variations among resistant isolates. The PCR primers were located in conserved regions of *pbp* genes and were able to amplify *pbp1a*, *pbp2b*, and *pbp2x* sequences of several strains of *S. pneumoniae* having various levels of resistance to penicillin and third-generation cephalosporins. Using primer pairs SEQ ID NOs. 1125 and 1126, SEQ ID NOs. 1142 and 1143, SEQ ID NOs. 1146 and 1147, it was possible to amplify and determine *pbp1a* sequences SEQ ID NOs. 1004-1018, 1648, 2056-2060 and 2062-2064, *pbp2b* sequences SEQ ID NOs. 1019-1033, and *pbp2x* sequences SEQ ID NOs. 1034-1048. Six other PCR primers

(SEQ ID NOs. 1127-1128, 1144-1145, 1148-1149) were also designed and used to complete the sequencing of *pbp1a*, *pbp2b* and *pbp2x* amplification products. The described primers (SEQ ID NOs. 1125 and 1126, SEQ ID NOs. 1142 and 1143, SEQ ID NOs. 1146 and 1147, SEQ ID NOs. 1127-1128, 1144-1145, 1148-1149) represent a powerful tool for generating new *pbp* sequences for design of primers and/or probes for detection of β-lactam resistance in *S. pneumoniae*.

EXAMPLE 19:

Sequencing of hexA genes of *Streptococcus* species. The *hexA* sequence of *S. pneumoniae* described in our assigned US patent no. 5,994,066 (SEQ ID NO. 31 in the said patent, SEQ ID NO. 1183 in the present application) allowed the design of a PCR primer (SEQ ID NO. 1182) which was used with primer Spn1401 described in our assigned US patent no. 5,994,066 (SEQ ID NO. 156 in the said patent, SEQ ID NO. 1179 in the present application) to generate a database for *hexA* sequences that can be used to design primers and/or probes for the specific identification and detection of *S. pneumoniae* (Annex XLII). Using primers SEQ ID NO. 1179 and SEQ ID NO. 1182 (Annex XLII), it was possible to amplify and determine the *hexA* sequence from *S. pneumoniae* (4 strains) (SEQ ID NOs. 1184-1187), *S. mitis* (three strains) (SEQ ID NOs. 1189-1191) and *S. oralis* (SEQ ID NO. 1188).

EXAMPLE 20:

Development of multiplex PCR assays coupled with capture probe hybridization for the detection and identification of *Streptococcus pneumoniae* and its penicillin resistance genes.

Two different assays were developed to identify *S. pneumoniae* and its susceptibility to penicillin.

ASSAY I:

Bacterial strains. The specificity of the multiplex PCR assay was verified by using a panel of ATCC (American Type Culture Collection) reference strains consisting of 33 gram-negative and 67 gram-positive bacterial species (Table 13). In addition, a total of 98 strains of *S. pneumoniae*, 16 strains of *S. mitis* and 3 strains of *S. oralis* from the American Type Culture Collection, the microbiology laboratory of the Centre Hospitalier Universitaire de Québec, Pavillon Centre Hospitalier de l'Université Laval (CHUL), (Ste-Foy, Québec, Canada), the Laboratoire de santé publique du Québec, (Sainte-Anne-de-Bellevue, Québec, Canada), the Sunnybrook and Women's College Health Sciences Centre (Toronto, Canada), the Infectious Diseases Section, Department of Veterans Affairs Medical Center, (Houston, USA) were also tested to further validate the *Streptococcus pneumoniae*-specific PCR assay. The penicillin MICs (minimal inhibitory concentrations) were measured by the broth dilution method according to the recommended protocol of NCCLS.

PCR primers and internal probes. The analysis of *hexA* sequences from a variety of streptococcal species from the publicly available *hexA* sequence and from the database described in Example 19 (SEQ ID NOS. 1184-1191) allowed the selection of a PCR primer specific to *S. pneumoniae*, SEQ ID NO. 1181. This primer was used with the *S. pneumoniae*-specific primer SEQ ID NO. 1179 to generate an amplification product of 241 bp (Annex XLII). The PCR primer SEQ ID NO. 1181 is located 127 nucleotides downstream on the *hexA* sequence compared to the original *S. pneumoniae*-specific PCR primer Spn1515 described in our assigned US patent no. 5,994,066 (SEQ ID NO. 157 in the said patent). These modifications were done to ensure the design of the *S. pneumoniae*-specific internal probe according to the new *hexA* sequences of several streptococcal species from the database described in Example 19 (SEQ ID NOS. 1184-1191).

The analysis of *pbp1a* sequences from *S. pneumoniae* strains with various levels of penicillin resistance from public databases and from the database described in Example 18 allowed the identification of amino acid substitutions Ile-459 to Met and Ser-462 to Ala that occur in isolates with high-level penicillin resistance (MICs $\geq 1\mu\text{g}/\text{ml}$), and amino acid substitutions Ser-575 to Thr, Gln-576 to Gly and Phe-577 to Tyr that are common to all penicillin-resistant isolates with MICs $\geq 0.25\mu\text{g}/\text{ml}$. As shown in Annex XXXI, PCR primer pair SEQ ID NOs. 1130 and 1131 were designed to detect high-level penicillin resistance (MICs $\geq 1\mu\text{g}/\text{ml}$), whereas PCR primer pair SEQ ID NOs. 1129 and 1131 were designed to detect intermediate- and high-level penicillin resistance (MICs $\geq 0.25\mu\text{g}/\text{ml}$).

The analysis of *hexA* sequences from the publicly available *hexA* sequence and from the database described in Example 19 allowed the design of an internal probe specific to *S. pneumoniae* (SEQ ID NO. 1180) (Annex XLII). The range of mismatches between the *S. pneumoniae*-specific 241-bp amplicon was from 2 to 5, in the middle of the 19-bp probe. The analysis of *pbp1a* sequences from public databases and from the database described in Example 18 allowed the design of five internal probes containing all possible mutations to detect the high-level penicillin resistance 383-bp amplicon (SEQ ID NOs. 1197, 1217-1220). Alternatively, two other internal probes (SEQ ID NOs. 2024-2025) can also be used to detect the high-level penicillin resistance 383-bp amplicon. Five internal probes containing all possible mutations to detect the 157-bp amplicon which includes intermediate- and high-level penicillin resistance were also designed (SEQ ID NOs. 1094, 1192-1193, 1214 and 1216). Design and synthesis of primers and probes, and detection of the probe hybridization were performed as described in Example 7. Annex XXXI illustrates one of the internal probe for detection of the high-level penicillin resistance 383-bp amplicon (SEQ ID NO. 1197) and one of the internal probe for detection of the intermediate- and high-level penicillin resistance 157-bp amplicon (SEQ ID NO. 1193).

PCR amplification. For all bacterial species, amplification was performed from purified genomic DNA using a PTC-200 thermocycler (MJ Research). 1 μ l of genomic DNA at 0.1 ng/ μ l, or 1 μ l of a bacterial lysate, was transferred to a 19 μ l PCR mixture. Each PCR reaction contained 50 mM KCl, 10 mM Tris-HCl (H 9.0), 0.1% Triton X-100, 2.5 mM MgCl₂, 0.1 μ M (each) of the *S. pneumoniae*-specific primers SEQ ID NO. 1179 and SEQ ID NO. 1181, 0.2 μ M of primer SEQ ID NO. 1129, 0.7 μ M of primer SEQ ID NO. 1131, and 0.6 μ M of primer SEQ ID NO. 1130, 0.05 mM bovine serum albumin (BSA), and 0.5 U *Taq* polymerase (Promega) coupled with TaqStartTM antibody. In order to generate Digoxigenin (DIG)-labeled amplicons for capture probe hybridization, 0.1X PCR DIG labeling four deoxynucleoside triphosphates mix (Boehringer Mannheim GmbH) was used for amplification.

For determination of the sensitivity of the PCR assays, 10-fold dilutions of purified genomic DNA were used to determine the minimal number of genome copies which can be detected.

Capture probe hybridization. The DIG-labeled amplicons were hybridized to the capture probes bound to 96-well plates. The plates were incubated with anti-DIG-alkaline phosphatase and the chemiluminescence was measured by using a luminometer (MLX, Dynex Technologies Inc.) after incubation with CSPD and recorded as Relative Light Unit (RLU). The RLU ratio of tested sample with and without capture probes was then calculated. A ratio \geq 2.0 was defined as a positive hybridization signal. All reactions were performed in duplicate.

Results

Amplifications with the multiplex PCR assay. The specificity of the assay was assessed by performing 40-cycle PCR amplifications with the panel of gram-positive (67 species from 12 genera) and gram-negative (33 species from 17

genera) bacterial species listed in Table 13. All bacterial species tested other than *S. pneumoniae* were negative except *S. mitis* and *S. oralis*. Ubiquity tests were performed using a collection of 98 *S. pneumoniae* strains including high-level penicillin resistance ($n=53$), intermediate resistance ($n=12$) and sensitive ($n=33$) strains. There was a perfect correlation between PCR and standard susceptibility testing for 33 penicillin-sensitive isolates. Among 12 *S. pneumoniae* isolates with intermediate penicillin resistance based on susceptibility testing, 11 had intermediate resistance based on PCR, but one *S. pneumoniae* isolate with penicillin MIC of $0.25 \mu\text{g/ml}$ showed a high-level penicillin resistance based on genotyping. Among 53 isolates with high-level penicillin resistance based on susceptibility testing, 51 had high-level penicillin resistance based on PCR but two isolates with penicillin MIC $> 1 \mu\text{g/ml}$ showed an intermediate penicillin resistance based on genotyping. In general, there was a good correlation between the genotype and classical culture method for bacterial identification and susceptibility testing.

The sensitivity of the *S. pneumoniae*-specific assay with 40-cycle PCR protocols was determined by using purified genomic DNA from 9 isolates of *S. pneumoniae*. The detection limit was around 10 copies of genomic DNA for all of them.

Post-PCR hybridization with internal probes. The specificity of the multiplex PCR assay coupled with capture-probe hybridization was tested with 98 strains of *S. pneumoniae*, 16 strains of *S. mitis* and 3 strains of *S. oralis*. The internal probe specific to *S. pneumoniae* (SEQ ID NO. 1180) detected all 98 *S. pneumoniae* strains but did not hybridize to the *S. mitis* and *S. oralis* amplicons. The five internal probes specific to the high-level resistance amplicon (SEQ ID NOs. 1197, 1217-1220) detected all amplification patterns corresponding to high-level resistance. The two *S. pneumoniae* strains with penicillin MIC $> 1 \mu\text{g/ml}$ that showed an intermediate penicillin resistance based on PCR amplification were also intermediate resistance based on probe hybridization. Similarly, among 12 strains

with intermediate-penicillin resistance based on susceptibility testing, 11 showed intermediate-penicillin resistance based on hybridization with the five internal probes specific to the intermediate and high-level resistance amplicon (SEQ ID NOs. 1094, 1192-1193, 1214 and 1216). The strain described above having a penicillin MIC of 0.25 µg/ml which was high-level penicillin resistance based on PCR amplification was also high-level resistance based on probe hybridization. In summary, the combination of the multiplex PCR and hybridization assays results in a highly specific test for the detection of penicillin-resistant *Streptococcus pneumoniae*.

ASSAY II:

Bacterial strains. The specificity of the multiplex PCR assay was verified by using the same strains as those used for the development of Assay I. The penicillin MICs (minimal inhibitory concentrations) were measured by the broth dilution method according to the recommended protocol of NCCLS.

PCR primers and internal probes. The analysis of *pbp1a* sequences from *S. pneumoniae* strains with various levels of penicillin resistance from public databases and from the database described in Example 18 allowed the design of two primers located in the constant region of *pbp1a*. PCR primer pair (SEQ ID NOs. 2015 and 2016) was designed to amplify a 888-bp variable region of *pbp1a* from all *S. pneumoniae* strains. A series of internal probes were designed for identification of the *pbp1a* mutations associated with penicillin resistance in *S. pneumoniae*. For detection of high-level penicillin resistance (MICs \geq 1µg/ml), three internal probes were designed (SEQ ID NOs. 2017-2019). Alternatively, ten other internal probes were designed that can also be used for detection of high-level resistance within the 888-bp *pbp1a* amplicon: (1) three internal probes for identification of the amino acid substitutions Thr-371 to Ser or Ala within the motif S370TMK (SEQ ID NOs. 2031-2033); (2) two internal probes for detection

of the amino acid substitutions Ile-459 to Met and Ser-462 to Ala near the motif S428RN (SEQ ID NOs. 1135 and 2026); (3) two internal probes for identification of the amino acid substitutions Asn-443 to Asp (SEQ ID NOs. 1134 and 2027); and (4) three internal probes for detection of all sequence variations within another region (SEQ ID NOs. 2028-2030). For detection of high-level and intermediate penicillin resistance (MICs \geq 0.25 μ g/ml), four internal probes were designed (SEQ ID NOs. 2020-2023). Alternatively, six other internal probes were designed for detection of the four consecutive amino acid substitutions T574SQF to A574TGY near the motif K557TG (SEQ ID NOs. 2034-2039) that can also be used for detection of intermediate- and high-level resistance within the 888-bp *pbp1a* amplicon.

PCR amplification. For all bacterial species, amplification was performed from purified genomic DNA using a PTC-200 thermocycler (MJ Research). 1 μ l of genomic DNA at 0.1 ng/ μ l, or 1 μ l of a bacterial lysate, was transferred to a 19 μ l PCR mixture. Each PCR reaction contained 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM MgCl₂, 0.08 μ M (each) of the *S. pneumoniae*-specific primers SEQ ID NO. 1179 and SEQ ID NO. 1181, 0.4 μ M of the *pbp1a*-specific primer SEQ ID NO. 2015, 1.2 μ M of *pbp1a*-specific primer SEQ ID NO. 2016, 0.05 mM bovine serum albumin (BSA), and 0.5 U *Taq* polymerase (Promega) coupled with TaqStartTM antibody. In order to generate Digoxigenin (DIG)-labeled amplicons for capture probe hybridization, 0.1X PCR DIG labeling four deoxynucleoside triphosphates mix (Boehringer Mannheim GmbH) was used for amplification.

For determination of the sensitivities of the PCR assays, 10-fold dilutions of purified genomic DNA were used to determine the minimal number of genome copies which can be detected.

Capture probe hybridization. The DIG-labeled amplicons were hybridized to the capture probes bound to 96-well plates as described for Assay I.

Results

Amplifications with the multiplex PCR assay. The specificity of the assay was assessed by performing 40-cycle PCR amplifications with the panel of gram-positive (67 species from 12 genera) and gram-negative (33 species from 17 genera) bacterial species listed in Table 13. All bacterial species tested other than *S. pneumoniae* were negative except *S. mitis* and *S. oralis*. Ubiquity tests were performed using a collection of 98 *S. pneumoniae* strains including high-level penicillin resistance (n=53), intermediate resistance (n=12) and sensitive (n=33) strains. All the above *S. pneumoniae* strains produced the 888-bp amplicon corresponding to *pbp1a* and the 241-bp fragment corresponding to *hexA*.

The sensitivity of the *S. pneumoniae*-specific assay with 40-cycle PCR protocols was determined by using purified genomic DNA from 9 isolates of *S. pneumoniae*. The detection limit was around 10 copies of genomic DNA for all of them.

Post-PCR hybridization with internal probes. The specificity of the multiplex PCR assay coupled with capture-probe hybridization was tested with 98 strains of *S. pneumoniae*, 16 strains of *S. mitis* and 3 strains of *S. oralis*. The internal probe specific to *S. pneumoniae* (SEQ ID NO. 1180) detected all 98 *S. pneumoniae* strains but did not hybridize to the *S. mitis* and *S. oralis* amplicons. The three internal probes (SEQ ID NOs 2017-2019) specific to high-level resistance detected all the 43 strains with high-level penicillin resistance based on susceptibility testing. Among 12 isolates with intermediate-penicillin resistance based on susceptibility testing, 11 showed intermediate-penicillin resistance based on hybridization with 4 internal probes (SEQ ID NOs. 2020-2023) and one strain

having penicillin MIC of 0.25 µg/ml was misclassified as high-level penicillin resistance. In summary, the combination of the multiplex PCR and hybridization assays results in a highly specific test for the detection of penicillin-resistant *Streptococcus pneumoniae*.

EXAMPLE 21:

Sequencing of the vancomycin resistance vanA, vanC1, vanC2 and vanC3 genes. The publicly available sequences of the vanH-vanA-vanX-vanY locus of transposon Tn1546 from *E. faecalis*, vanC1 sequence from one strain of *E. gallinarum*, vanC2 and vanC3 sequences from a variety of *E. casseliflavus* and *E. flavescentis* strains, respectively, allowed the design of PCR primers able to amplify the vanA, vanC1, vanC2 and vanC3 sequences of several *Enterococcus* species. Using primer pairs van6877 and van9106 (SEQ ID NOs. 1150 and 1155), vanC1-122 and vanC1-1315 (SEQ ID NOs. 1110 and 1109), and vanC2C3-1 and vanC2C3-1064 (SEQ ID NOs. 1108 and 1107), it was possible to amplify and determine vanA sequences SEQ ID NOs. 1049-1057, vanC1 sequences SEQ ID NOs. 1058-1059, vanC2 sequences SEQ ID NOs. 1060-1063 and vanC3 sequences SEQ ID NOs. 1064-1066, respectively. Four other PCR primers (SEQ ID NOs. 1151-1154) were also designed and used to complete the sequencing of vanA amplification products.

EXAMPLE 22:

Development of a PCR assay for the detection and identification of enterococci at genus and species levels and its associated resistance genes vanA and vanB. The comparison of vanA and vanB sequences revealed conserved regions allowing the design of PCR primers specific to both vanA and vanB sequences (Annex XXXVIII). The PCR primer pair vanAB459 and vanAB830R (SEQ ID NOs. 1112 and 1111) was used in multiplex with the *Enterococcus*-specific primers Encg313dF and Encg599c (SEQ ID NOs. 1137 and 1136) described in Example

11. Sequence alignment analysis of *vanA* and *vanB* sequences revealed regions suitable for the design of internal probes specific to *vanA* (SEQ ID NO. 1170) and *vanB* (SEQ ID NO. 1171). PCR amplification and agarose gel electrophoresis of the amplified products were performed as described in Example 11. The optimal cycling conditions for maximum sensitivity and specificity were found to be 3 min. at 94 °C, followed by forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 62°C, plus a terminal extension at 72 °C for 2 minutes. The specificity of the multiplex assay with 40-cycle PCR was verified by using 0.1 nanogram of purified genomic DNA from a panel of bacteria listed in Table 10. The sensitivity of the multiplex assay with 40-cycle PCR was verified with three strains of *E. casseliflavus*, eight strains of *E. gallinarum*, two strains of *E. flavescentis*, two vancomycin-resistant strains of *E. faecalis* and one vancomycin-sensitive strain of *E. faecalis*, three vancomycin-resistant strains of *E. faecium*, one vancomycin-sensitive strain of *E. faecium* and one strain of each of the other enterococcal species listed in Table 10. The detection limit was 1 to 10 copies of genomic DNA, depending on the enterococcal species tested. The *vanA*- and *vanB*-specific internal probes (SEQ ID NOs. 1170 and 1171), as well as the *E. faecalis*- and *E. faecium*-specific internal probes (SEQ ID NOs. 1174 and 602) and the internal probe specific to the group including *E. casseliflavus*, *E. gallinarum* and *E. flavescentis* (SEQ ID NO. 1122) described in Example 11, were able to recognize vancomycin-resistant enterococcal species with high sensitivity, specificity and ubiquity showing a perfect correlation between the genotypic and phenotypic analysis.

The format of the assay is not limited to the one described above. A person skilled in the art could adapt the assay for different formats such as PCR with real-time detection using molecular beacon probes. Molecular beacon probes designed to be used in this assay include, but are not limited to, SEQ ID NO. 1236 for the detection of *E. faecalis*, SEQ ID NO. 1235 for the detection of *E. faecium*, SEQ ID NO. 1240 for the detection of *vanA*, and SEQ ID NO. 1241 for the detection of *vanB*.

EXAMPLE 23:

Development of a multiplex PCR assay for detection and identification of vancomycin-resistant *Enterococcus faecalis*, *Enterococcus faecium* and the group including *Enterococcus gallinarum*, *Enterococcus casseliflavus*, and *Enterococcus flavesiens*. The analysis of *vanA* and *vanB* sequences revealed conserved regions allowing design of a PCR primer pair (SEQ ID NOs. 1089 and 1090) specific to *vanA* sequences (Annex XXVIII) and a PCR primer pair (SEQ ID NOs. 1095 and 1096) specific to *vanB* sequences (Annex XXIX). The *vanA*-specific PCR primer pair (SEQ ID NOs. 1089 and 1090) was used in multiplex with the *vanB*-specific PCR primer pair described in our assigned US patent 5,994,066 (SEQ ID NOs. 1095 and 1096 in the present patent and SEQ ID NOs. 231 and 232 in the said patent). The comparison of *vanC1*, *vanC2* and *vanC3* sequences revealed conserved regions allowing design of PCR primers (SEQ ID NOs. 1101 and 1102) able to generate a 158-bp amplicon specific to the group including *E. gallinarum*, *E. casseliflavus* and *E. flavesiens* (Annex XXX). The *vanC*-specific PCR primer pair (SEQ ID NOs. 1101 and 1102) was used in multiplex with the *E. faecalis*-specific PCR primer pair described in our assigned US patent 5,994,066 (SEQ ID NOs. 40 and 41 in the said patent) and with the *E. faecium*-specific PCR primer pair described in our patent publication WO98/20157 (SEQ ID NOs. 1 and 2 in the said publication). For both multiplexes, the optimal cycling conditions for maximum sensitivity and specificity were found to be 3 min. at 94 °C, followed by forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 58 °C, plus a terminal extension at 72 °C for 2 minutes. Detection of the PCR products was made by electrophoresis in agarose gels (2 %) containing 0.25 µg/ml of ethidium bromide. The *vanA*-specific PCR primer pair (SEQ ID NOs. 1089 and 1090), the *vanB*-specific primer pair (SEQ ID NOs. 1095 and 1096) and the *vanC*-specific primer pair (SEQ ID NOs. 1101 and 1102) were tested for their specificity by using 0.1 nanogram of purified genomic DNA from a panel of 5 vancomycin-

sensitive *Enterococcus* species, 3 vancomycin-resistant *Enterococcus* species, 13 other gram-positive bacteria and one gram-negative bacterium. Specificity tests were performed with the *E. faecium*-specific PCR primer pair described in our patent publication WO98/20157 (SEQ ID NOs. 1 and 2 in the said publication) and with the *E. faecalis*-specific PCR primer pair described in our assigned US patent 5,994,066 (SEQ ID NOs. 40 and 41 in the said patent) on a panel of 37 gram-positive bacterial species. All *Enterococcus* strains were amplified with high specificity showing a perfect correlation between the genotypic and phenotypic analysis. The sensitivity of the assays was determined for several strains of *E. gallinarum*, *E. casseliflavus*, *E. flavesiensis* and vancomycin-resistant *E. faecalis* and *E. faecium*. Using each of the *E. faecalis*- and *E. faecium*-specific PCR primer pairs as well as *vanA*-, *vanB*- and *vanC*-specific PCR primers used alone or in multiplex as described above, the sensitivity ranged from 1 to 10 copies of genomic DNA.

The format of the assay is not limited to the one described above. A person skilled in the art could adapt the assay for different formats such as PCR with real-time detection using molecular beacon probes. Molecular beacon probes designed to be used in this assay include, but are not limited to, SEQ ID NO. 1238 for the detection of *E. faecalis*, SEQ ID NO. 1237 for the detection of *E. faecium*, SEQ ID NO. 1239 for the detection of *vanA*, and SEQ ID NO. 1241 for the detection of *vanB*.

Alternatively, another PCR assay was developed for the detection of vancomycin-resistant *E. faecium* and vancomycin-resistant *E. faecalis*. This assay included two multiplex: (1) the first multiplex contained the *vanA*-specific primer pair (SEQ ID NOs. 1090-1091) and the *vanB*-specific PCR primer pair described in our assigned US patent 5,994,066 (SEQ ID NOs. 1095 and 1096 in the present patent and SEQ ID NOs. 231 and 232 in the said patent), and (2) the second multiplex contained the *E. faecalis*-specific PCR primer pair described in our assigned US patent 5,994,066 (SEQ ID NOs. 40 and 41 in the said patent) and the *E. faecium*-specific PCR primer pair described in our patent publication WO98/20157 (SEQ ID NOs. 1

and 2 in the said publication). For both multiplexes, the optimal cycling conditions for maximum sensitivity and specificity were found to be 3 min. at 94 °C, followed by forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 58 °C, plus a terminal extension at 72 °C for 2 minutes. Detection of the PCR products was made by electrophoresis in agarose gels (2 %) containing 0.25 µg/ml of ethidium bromide. The two multiplexes were tested for their specificity by using 0.1 nanogram of purified genomic DNA from a panel of two vancomycin-sensitive *E. faecalis* strains, two vancomycin-resistant *E. faecalis* strains, two vancomycin-sensitive *E. faecium* strains, two vancomycin-resistant *E. faecium* strains, 16 other enterococcal species and 31 other gram-positive bacterial species. All the *E. faecium* and *E. faecalis* strains were amplified with high specificity showing a perfect correlation between the genotypic analysis and the susceptibility to glycopeptide antibiotics (vancomycin and teicoplanin). The sensitivity of the assay was determined for two vancomycin-resistant *E. faecalis* strains and two vancomycin-resistant *E. faecium* strains. The detection limit was 5 copies of genomic DNA for all the strains.

This multiplex PCR assay was coupled with capture-probe hybridization. Four internal probes were designed: one specific to the *vanA* amplicon (SEQ ID NO. 2292), one specific to the *vanB* amplicon (SEQ ID NO. 2294), one specific to the *E. faecalis* amplicon (SEQ ID NO. 2291) and one specific to the *E. faecium* amplicon (SEQ ID NO. 2287). Each of the internal probes detected their specific amplicons with high specificity and sensitivity.

EXAMPLE 24:

Universal amplification involving the EF-G (*fusA*) subdivision of *tuf* sequences. As shown in Figure 3, primers SEQ ID NOs. 1228 and 1229 were designed to amplify the region between the end of *fusA* and the beginning of *tuf* genes in the *str* operon. Genomic DNAs from a panel of 35 strains were tested for PCR amplification with those primers. In the initial experiment, the following strains showed a positive

result: *Abiotrophia adiacens* ATCC 49175, *Abiotrophia defectiva* ATCC 49176, *Bacillus subtilis* ATCC 27370, *Closridium difficile* ATCC 9689, *Enterococcus avium* ATCC 14025, *Enterococcus casseliflavus* ATCC 25788, *Enterococcus cecorum* ATCC 43198, *Enterococcus faecalis* ATCC 29212, *Enterococcus faecium* ATCC 19434, *Enterococcus flavescentis* ATCC 49996, *Enterococcus gallinarum* ATCC 49573, *Enterococcus solitarius* ATCC 49428, *Escherichia coli* ATCC 11775, *Haemophilus influenzae* ATCC 9006, *Lactobacillus acidophilus* ATCC 4356, *Peptococcus niger* ATCC 27731, *Proteus mirabilis* ATCC 25933, *Staphylococcus aureus* ATCC 43300, *Staphylococcus auricularis* ATCC 33753, *Staphylococcus capitis* ATCC 27840, *Staphylococcus epidemidis* ATCC 14990, *Staphylococcus haemolyticus* ATCC 29970, *Staphylococcus hominis* ATCC 27844, *Staphylococcus lugdunensis* ATCC 43809, *Staphylococcus saprophyticus* ATCC 15305, *Staphylococcus simulans* ATCC 27848, and *Staphylococcus warneri* ATCC 27836. This primer pair could amplify additional bacterial species; however, there was no amplification for some species, suggesting that the PCR cycling conditions could be optimized or the primers modified. For example, SEQ ID NO. 1227 was designed to amplify a broader range of species.

In addition to other possible primer combinations to amplify the region covering *fusA* and *tuf*, Figure 3 illustrates the positions of amplification primers SEQ ID NOs. 1221-1227 which could be used for universal amplification of *fusA* segments. All of the above mentioned primers (SEQ ID NOs. 1221-1229) could be useful for the universal and/or the specific detection of bacteria.

Moreover, different combinations of primers SEQ ID NOs. 1221-1229, sometimes in combination with *tuf* sequencing primer SEQ ID NO. 697, were used to sequence portions of the *str* operon, including the intergenic region. In this manner, the following sequences were generated: SEQ ID NOs. 1518-1526, 1578-1580, 1786-1821, 1822-1834, 1838-1843, 2184, 2187, 2188, 2214-2249, and 2255-2269.

EXAMPLE 25:

DNA fragment isolation from *Staphylococcus saprophyticus* by arbitrarily primed PCR. DNA sequences of unknown coding potential for the species-specific detection and identification of *Staphylococcus saprophyticus* were obtained by the method of arbitrarily primed PCR (AP-PCR).

AP-PCR is a method which can be used to generate specific DNA probes for microorganisms (Fani *et al.*, 1993, Molecular Ecology 2:243-250). A description of the AP-PCR protocol used to isolate a species-specific genomic DNA fragment from *Staphylococcus saprophyticus* follows. Twenty different oligonucleotide primers of 10 nucleotides in length (all included in the AP-PCR kit OPAD (Operon Technologies, Inc., Alameda, CA)) were tested systematically with DNAs from 5 bacterial strains of *Staphylococcus saprophyticus* as well as with bacterial strains of 27 other staphylococcal (non-*S. saprophyticus*) species. For all bacterial species, amplification was performed directly from one μ L (0.1 ng/ μ L) of purified genomic DNA. The 25 μ L PCR reaction mixture contained 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM MgCl₂, 1.2 μ M of only one of the 20 different AP-PCR primers OPAD, 200 μ M of each of the four dNTPs, 0.5 U of Taq DNA polymerase (Promega Corp., Madison, Wis.) coupled with TaqStartTM antibody (Clontech Laboratories Inc., Palo Alto, CA). PCR reactions were subjected to cycling using a MJ Research PTC-200 thermal cycler as follows: 3 min at 96 °C followed by 42 cycles of 1 min at 94 °C for the denaturation step, 1 min at 31 °C for the annealing step and 2 min at 72 °C for the extension step. A final extension step of 7 min at 72 °C followed the 42 cycles to ensure complete extension of PCR products. Subsequently, twenty microliters of the PCR-amplified mixture were resolved by electrophoresis on a 1.5 % agarose gel containing 0.25 μ g/ml of ethidium bromide. The size of the amplification products was estimated by comparison with a 50-bp molecular weight ladder.

Amplification patterns specific for *Staphylococcus saprophyticus* were observed with the AP-PCR primer OPAD-16 (sequence: 5'-AACGGGCGTC-3'). Amplification with this primer consistently showed a band corresponding to a

DNA fragment of approximately 380 bp for all *Staphylococcus saprophyticus* strains tested but not for any of the other staphylococcal species tested.

The band corresponding to the 380 bp amplicon, specific and ubiquitous for *S. saprophyticus* based on AP-PCR, was excised from the agarose gel and purified using the QIAquick™ gel extraction kit (QIAGEN Inc.). The gel-purified DNA fragment was cloned into the T/A cloning site of the pCR 2.1™ plasmid vector (Invitrogen Inc.) using T4 DNA ligase (New England BioLabs). Recombinant plasmids were transformed into *E. coli* DH5α competent cells using standard procedures. All reactions were performed according to the manufacturer's instructions. Plasmid DNA isolation was done by the method of Birnboim and Doly (Nucleic Acid Res., 1979, 7:1513-1523) for small-scale preparations. All plasmid DNA preparations were digested with the EcoRI restriction endonuclease to ensure the presence of the approximately 380 bp AP-PCR insert into the plasmid. Subsequently, a large-scale and highly purified plasmid DNA preparation was performed from two selected clones shown to carry the AP-PCR insert by using the QIAGEN plasmid purification kit (midi format). These large-scale plasmid preparations were used for automated DNA sequencing.

The 380 bp nucleotide sequence was determined for three strains of *S. saprophyticus* (SEQ ID NOs. 74, 1093, and 1198). Both strands of the AP-PCR insert from the two selected clones were sequenced by the dideoxynucleotide chain termination sequencing method with SP6 and T7 sequencing primers by using the Applied Biosystems automated DNA sequencer (model 373A) with their PRISM™ Sequenase^{RTM} Terminator Double-stranded DNA Sequencing Kit (Applied Biosystems, Foster City, CA).

Optimal species-specific amplification primers (SEQ ID NOs. 1208 and 1209) have been selected from the sequenced AP-PCR *Staphylococcus saprophyticus* DNA fragments with the help of the primer analysis software OligoTM 5.0 (National BioSciences Inc.). The selected primers were tested in PCR assays to verify their specificity and ubiquity. Data obtained with DNA preparations from reference ATCC strains of 49 gram-positive and 31 gram-negative bacterial

species, including 28 different staphylococcal species, indicate that the selected primer pairs are specific for *Staphylococcus saprophyticus* since no amplification signal has been observed with DNAs from the other staphylococcal or bacterial species tested. This assay was able to amplify efficiently DNA from all 60 strains of *S. saprophyticus* from various origins tested. The sensitivity level achieved for three *S. saprophyticus* reference ATCC strains was around 6 genome copies.

EXAMPLE 26:

Sequencing of prokaryotic *tuf* gene fragments. The comparison of publicly available *tuf* sequences from a variety of bacterial species revealed conserved regions, allowing the design of PCR primers able to amplify *tuf* sequences from a wide range of bacterial species. Using primer pair SEQ ID NOs. 664 and 697, it was possible to amplify and determine *tuf* sequences SEQ ID NOs.: 1-73, 75-241, 607-618, 621, 662, 675, 717-736, 868-888, 932, 967-989, 992, 1002, 1572-1575, 1662-1663, 1715-1733, 1835-1837, 1877-1878, 1880-1881, 2183, 2185, 2200, 2201, and 2270-2272.

EXAMPLE 27:

Sequencing of prokaryotic *recA* gene fragments. The comparison of publicly available *recA* sequences from a variety of bacterial species revealed conserved regions, allowing the design of PCR primers able to amplify *recA* sequences from a wide range of bacterial species. Using primer pairs SEQ ID NOs. 921-922 and 1605-1606, it was possible to amplify and determine *recA* sequences SEQ ID NOs.: 990-991, 1003, 1288-1289, 1714, 1756-1763, 1866-1873 and 2202-2212.

EXAMPLE 28:

Specific detection and identification of *Escherichia coli/Shigella* sp. using *tuf* sequences. The analysis of *tuf* sequences from a variety of bacterial species allowed the selection of PCR primers (SEQ ID NOs. 1661 and 1665) and of an internal probe (SEQ ID NO. 2168) specific to *Escherichia coli/Shigella* sp. The strategy used to design the PCR primers was based on the analysis of a multiple sequence alignment of various *tuf* sequences. The multiple sequence alignment included the *tuf* sequences of *Escherichia coli/Shigella* sp. as well as *tuf* sequences from other species and bacterial genera, especially representatives of closely related species. A careful analysis of this alignment allowed the selection of oligonucleotide sequences which are conserved within the target species but which discriminate sequences from other species, especially from the closely related species, thereby permitting the species-specific and ubiquitous detection and identification of the target bacterial species.

The chosen primer pair, oligos SEQ ID NOs. 1661 and 1665, gives an amplification product of 219 bp. Standard PCR was carried out using 0.4 μ M of each primer, 2.5 mM MgCl₂, BSA 0.05 mM, 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1 % Triton X-100, dNTPs 0.2 mM (Pharmacia), 0.5 U *Taq* DNA polymerase (Promega) coupled with TaqStartTM antibody (Clontech Laboratories Inc.), 1 μ l of genomic DNA sample in a final volume of 20 μ l using a PTC-200 thermocycler (MJ Research). The optimal cycling conditions for maximum sensitivity and specificity were 3 minutes at 95 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 60 °C, followed by terminal extension at 72 °C for 2 minutes. Detection of the PCR products was made by electrophoresis in agarose gels (2 %) containing 0.25 μ g/ml of ethidium bromide. Visualization of the PCR products was made under UV at 254 nm.

Specificity of the assay was tested by adding to the PCR reactions 0.1 ng of genomic DNA from each of the following bacterial species: *Escherichia coli* (7

strains), *Shigella sonnei*, *Shigella flexneri*, *Shigella dysenteriae*, *Salmonella typhimurium*, *Salmonella typhi*, *Salmonella enteritidis*, *Tatumella ptyseos*, *Klebsiella pneumoniae* (2 strains), *Enterobacter aerogenes*, *Citrobacter farmeri*, *Campylobacter jejuni*, *Serratia marcescens*. Amplification was observed only for the *Escherichia coli* and *Shigella* sp. strains listed and *Escherichia fergusonii*. The sensitivity of the assay with 40-cycle PCR was verified with one strain of *E. coli* and three strains of *Shigella* sp. The detection limit for *E. coli* and *Shigella* sp. was 1 to 10 copies of genomic DNA, depending on the strains tested.

EXAMPLE 29:

Specific detection and identification of *Klebsiella pneumoniae* using *atpD* sequences. The analysis of *atpD* sequences from a variety of bacterial species allowed the selection of PCR primers specific to *K. pneumoniae*. The primer design strategy is similar to the strategy described in Example 28 except that *atpD* sequences were used in the alignment.

Two *K. pneumoniae*-specific primers were selected, (SEQ ID NOS. 1331 and 1332) which give an amplification product of 115 bp. Standard PCR was carried out on PTC-200 thermocyclers (MJ Research) using 0.4 μ M of each primer as described in Example 28. The optimal cycling conditions for maximum sensitivity and specificity were as follow: three minutes at 95 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 55°C, followed by terminal extension at 72 °C for 2 minutes.

Specificity of the assay was tested by adding to the PCR reactions 0.1 ng of genomic DNA from each of the following bacterial species: *Klebsiella pneumoniae* (2 strains), *Klebsiella ornitholytica*, *Klebsiella oxytoca* (2 strains), *Klebsiella planticola*, *Klebsiella terrigena*, *Citrobacter freundii*, *Escherichia coli*, *Salmonella cholerasuis typhi*, *Serratia marcescens*, *Enterobacter aerogenes*, *Proteus vulgaris*,

Kluyvera ascorbata, *Kluyvera georgiana*, *Kluyvera cryocrescens* and *Yersinia enterolitica*. Amplification was detected for the two *K. pneumoniae* strains, *K. planticola*, *K. terrigena* and the three *Kluyvera* species tested. Analysis of the multiple alignment sequence of the *atpD* gene allowed the design of an internal probe SEQ ID NO. 2167 which can discriminate *Klebsiella pneumoniae* from other *Klebsiella* sp. and *Kluyvera* sp. The sensitivity of the assay with 40-cycle PCR was verified with one strain of *K. pneumoniae*. The detection limit for *K. pneumoniae* was around 10 copies of genomic DNA.

EXAMPLE 30:

Specific detection and identification of *Acinetobacter baumannii* using *atpD* sequences. The analysis of *atpD* sequences from a variety of bacterial species allowed the selection of PCR primers specific to *Acinetobacter baumannii*. The primer design strategy is similar to the strategy described in Example 28.

Two *A. baumannii*-specific primers were selected, SEQ ID NOs. 1690 and 1691, which give an amplification product of 233 bp. Standard PCR was carried out on PTC-200 thermocyclers (MJ Research) using 0.4 µM of each primer as described in Example 28. The optimal cycling conditions for maximum sensitivity and specificity were as follow: three minutes at 95 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 60°C, followed by terminal extension at 72 °C for 2 minutes.

Specificity of the assay was tested by adding to the PCR reactions 0.1 ng of genomic DNA from each of the following bacterial species: *Acinetobacter baumannii* (3 strains), *Acinetobacter anitratus*, *Acinetobacter lwoffi*, *Serratia marcescens*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, *Psychrobacter phenylpyruvicus*, *Neisseria gonorrhoeae*, *Haemophilus haemoliticus*, *Yersinia enterolitica*, *Proteus vulgaris*, *Eikenella corrodens*,

Escherichia coli. Amplification was detected only for *A. baumannii*, *A. anitratus* and *A. lwoffii*. The sensitivity of the assay with 40-cycle PCR was verified with two strains of *A. baumannii*. The detection limit for the two *A. baumannii* strains tested was 5 copies of genomic DNA. Analysis of the multiple alignment sequence of the *atpD* gene allowed the design of a *A. baumannii*-specific internal probe (SEQ ID NO. 2169).

EXAMPLE 31:

Specific detection and identification of *Neisseria gonorrhoeae* using *tuf* sequences.

The analysis of *tuf* sequences from a variety of bacterial species allowed the selection of PCR primers specific to *Neisseria gonorrhoeae*. The primer design strategy is similar to the strategy described in Example 28.

Two *N. gonorrhoeae*-specific primers were selected, SEQ ID NOs. 551 and 552, which give an amplification product of 139 bp. PCR amplification was carried out on PTC-200 thermocyclers (MJ Research) using 0.4 μ M of each primer as described in Example 28. The optimal cycling conditions for maximum sensitivity and specificity were as follow: three minutes at 95 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 65°C, followed by terminal extension at 72 °C for 2 minutes.

Specificity of the assay was tested by adding into the PCR reactions, 0.1 ng of genomic DNA from each of the following bacterial species: *Neisseria gonorrhoeae* (19 strains), *Neisseria meningitidis* (2 strains), *Neisseria lactamica*, *Neisseria flavaescens*, *Neisseria animalis*, *Neisseria canis*, *Neisseria cuniculi*, *Neisseria elongata*, *Neisseria mucosa*, *Neisseria polysaccharea*, *Neisseria sicca*, *Neisseria subflava*, *Neisseria weaveri*. Amplification was detected only for *N. gonorrhoeae*, *N. sicca* and *N. polysaccharea*. The sensitivity of the assay with 40-cycle PCR was verified with two strains of *N. gonorrhoeae*. The detection limit for the *N.*

gonorrhoeae strains tested was 5 copies of genomic DNA. Analysis of the multiple alignment sequence of the *tuf* gene allowed the design of an internal probe, SEQ ID NO. 2166, which can discriminate *N. gonorrhoeae* from *N. sicca* and *N. polysaccharea*.

EXAMPLE 32:

Sequencing of bacterial *gyrA* and *parC* gene fragments. Sequencing of bacterial *gyrA* and *parC* fragments. One of the major mechanism of resistance to quinolone in various bacterial species is mediated by target changes (DNA gyrase and/or topoisomerase IV). These enzymes control DNA topology and are vital for chromosome function and replication. Each of these enzymes is a tetramer composed of two subunits: GyrA and GyrB forming A₂B₂ complex in DNA gyrase; and ParC and ParE forming and C₂E₂ complex in DNA topoisomerase IV. It has been shown that they are hotspots, called the quinolone-resistance-determining region (QRDR) for mutations within *gyrA* that encodes for the GyrA subunit of DNA gyrase and within *parC* that encodes the *parC* subunit of topoisomerase IV.

In order to generate a database for *gyrA* and *parC* sequences that can be used for design of primers and/or probes for the specific detection of quinolone resistance in various bacterial species, *gyrA* and *parC* DNA fragments selected from public database (GenBank and EMBL) from a variety of bacterial species were used to design oligonucleotide primers.

Using primer pair SEQ ID NOs. 1297 and 1298, it was possible to amplify and determine *gyrA* sequences from *Klebsiella oxytoca* (SEQ ID NO. 1764), *Klebsiella pneumoniae* subsp. *ozaneae* (SEQ ID NO. 1765), *Klebsiella planticola* (SEQ ID NO. 1766), *Klebsiella pneumoniae* (SEQ ID NO. 1767), *Klebsiella pneumoniae* subsp. *pneumoniae* (two strains) (SEQ ID NOs. 1768-1769), *Klebsiella*

pneumoniae subsp. *rhinoscleromatis* (SEQ ID NO. 1770), *Klebsiella terrigena* (SEQ ID NO. 1771), *Kluyvera ascorbata* (SEQ ID NO. 2013), *Kluyvera georgiana* (SEQ ID NO. 2014) and *Escherichia coli* (4 strains) (SEQ ID NOs. 2277-2280). Using primer pair SEQ ID NOs. 1291 and 1292, it was possible to amplify and determine *gyrA* sequences from *Legionella pneumophila* subsp. *pneumophila* (SEQ ID NO. 1772), *Proteus mirabilis* (SEQ ID NO. 1773), *Providencia rettgeri* (SEQ ID NO. 1774), *Proteus vulgaris* (SEQ ID NO. 1775) and *Yersinia enterolitica* (SEQ ID NO. 1776). Using primer pair SEQ ID NOs. 1340 and 1341, it was possible to amplify and determine *gyrA* sequence from *Staphylococcus aureus* (SEQ ID NO. 1255).

Using primers SEQ ID NOs. 1318 and 1319, it was possible to amplify and determine *parC* sequences from *K. oxytoca* (two strains) (SEQ ID NOs. 1777-1778), *Klebsiella pneumoniae* subsp. *ozaenae* (SEQ ID NO. 1779), *Klebsiella planticola* (SEQ ID NO. 1780), *Klebsiella pneumoniae* (SEQ ID NO. 1781), *Klebsiella pneumoniae* subsp. *pneumoniae* (two strains) (SEQ ID NOs. 1782-1783), *Klebsiella pneumoniae* subsp. *rhinoscleromatis* (SEQ ID NO. 1784) and *Klebsiella terrigena* (SEQ ID NO. 1785).

EXAMPLE 33:

Development of a PCR assay for the specific detection and identification of *Staphylococcus aureus* and its quinolone resistance genes *gyrA* and *parC*. The analysis of *gyrA* and *parC* sequences from a variety of bacterial species revealed conserved regions allowing the design of PCR primers specific to the quinolone-resistance-determining region (QRDR) of *gyrA* and *parC* from *Staphylococcus aureus*. PCR primer pair SEQ ID NOs. 1340 and 1341 was designed to amplify the *gyrA* sequence of *S. aureus*, whereas PCR primer pair SEQ ID NOs. 1342 and 1343 was designed to amplify *S. aureus parC*. The comparison of *gyrA* and *parC* sequences from *S. aureus* strains with various levels of quinolone resistance

allowed the identification of amino acid substitutions Ser-84 to Leu, Glu-88 to Gly or Lys in the GyrA subunit of DNA gyrase encoded by *gyrA* and amino acid changes Ser-80 to Phe or Tyr and Ala-116 to Glu in the ParC subunit of topoisomerase IV encoded by *parC*. These amino acid substitutions in GyrA and ParC subunits occur in isolates with intermediate- or high-level quinolone resistance. Internal probes for the specific detection of wild-type *S. aureus gyrA* (SEQ ID NO. 1940) and wild-type *S. aureus parC* (SEQ ID NO. 1941) as well as internal probes for the specific detection of each of the *gyrA* (SEQ ID NOs. 1333-1335) and *parC* mutations identified in quinolone-resistant *S. aureus* (SEQ ID NOs. 1336-1339) were designed.

The *gyrA*- and *parC*-specific primer pairs (SEQ ID NOs. 1340-1341 and SEQ ID NOs. 1342-1343) were used in multiplex. PCR amplification was carried out on PTC-200 thermocyclers (MJ Research) using 0.3, 0.3, 0.6 and 0.6 µM of each primers, respectively, as described in Example 28. The optimal cycling conditions for maximum sensitivity and specificity were 3 minutes at 95 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 62 °C, followed by terminal extension at 72 °C for 2 minutes. Detection of the PCR products was made by electrophoresis in agarose gels (2 %) containing 0.25 µg/ml of ethidium bromide. The specificity of the multiplex assay with 40-cycle PCR was verified by using 0.1 ng of purified genomic DNA from a panel of gram-positive bacteria. The list included the following: *Abiotrophia adiacens*, *Abiotrophia defectiva*, *Bacillus cereus*, *Bacillus mycoides*, *Enterococcus faecalis* (2 strains), *Enterococcus flavescentis*, *Gemella morbillorum*, *Lactococcus lactis*, *Listeria innocua*, *Listeria monocytogenes*, *Staphylococcus aureus* (5 strains), *Staphylococcus auricalis*, *Staphylococcus capitis* subsp. *urealyticus*, *Staphylococcus carnosus*, *Staphylococcus chromogenes*, *Staphylococcus epidermidis* (3 strains), *Staphylococcus gallinarum*, *Staphylococcus haemolyticus* (2 strains), *Staphylococcus hominis*, *Staphylococcus hominis* subsp. *hominis*, *Staphylococcus lentus*, *Staphylococcus lugdunensis*, *Staphylococcus*

saccharolyticus, *Staphylococcus saprophyticus* (3 strains), *Staphylococcus simulans*, *Staphylococcus warneri*, *Staphylococcus xylosus*, *Streptococcus agalactiae*, *Streptococcus pneumoniae*. Strong amplification of both *gyrA* and *parC* genes was only detected for the *S. aureus* strains tested. The sensitivity of the multiplex assay with 40-cycle PCR was verified with one quinolone-sensitive and four quinolone-resistant strains of *S. aureus*. The detection limit was 2 to 10 copies of genomic DNA, depending on the strains tested.

Detection of the hybridization with the internal probes was performed as described in Example 7. The internal probes specific to wild-type *gyrA* and *parC* of *S. aureus* and to the *gyrA* and *parC* variants of *S. aureus* were able to recognize two quinolone-resistant and one quinolone-sensitive *S. aureus* strains showing a perfect correlation with the susceptibility to quinolones.

The complete assay for the specific detection of *S. aureus* and its susceptibility to quinolone contains the *Staphylococcus*-specific primers (SEQ ID NOs. 553 and 575) described in Example 7 and the multiplex containing the *S. aureus* *gyrA*- and *parC*-specific primer pairs (SEQ ID NOs. 1340-1341 and SEQ ID NOs. 1342-1343). Amplification is coupled with post-PCR hybridization with the internal probe specific to *S. aureus* (SEQ ID NO. 587) described in Example 7 and the internal probes specific to wild-type *S. aureus* *gyrA* and *parC* (SEQ ID NOs. 1940-1941) and to the *S. aureus* *gyrA* and *parC* variants (SEQ ID NOs. 1333-1338).

An assay was also developed for the detection of quinolone-resistant *S. aureus* using the SmartCycler (Cepheid). Real-time detection is based on the use of *S. aureus* *parC*-specific primers (SEQ ID NOs. 1342 and 1343) and the *Staphylococcus*-specific primers (SEQ ID NOs. 553 and 575) described in Example 7. Internal probes were designed for molecular beacon detection of the wild-type *S. aureus* *parC* (SEQ ID NO.1939), for detection of the Ser-80 to Tyr or

Phe amino acid substitutions in the ParC subunit encoded by *S. aureus parC* (SEQ ID NOs. 1938 and 1955) and for detection of *S. aureus* (SEQ ID NO. 2282).

EXAMPLE 34:

Development of a PCR assay for the detection and identification of *Klebsiella pneumoniae* and its quinolone resistance genes *gyrA* and *parC*. The analysis of *gyrA* and *parC* sequences from a variety of bacterial species from the public databases and from the database described in Example 32 revealed conserved regions allowing the design of PCR primers specific to the quinolone-resistance-determining region (QRDR) of *gyrA* and *parC* from *K. pneumoniae*. PCR primer pair SEQ ID NOs. 1936 and 1937, or pair SEQ ID NOs. 1937 and 1942, were designed to amplify the *gyrA* sequence of *K. pneumoniae*, whereas PCR primer pair SEQ ID NOs. 1934 and 1935 was designed to amplify *K. pneumoniae parC* sequence. An alternative pair, SEQ ID NOs. 1935 and 1936, can also amplify *K. pneumoniae parC*. The comparison of *gyrA* and *parC* sequences from *K. pneumoniae* strains with various levels of quinolone resistance allowed the identification of amino acid substitutions Ser-83 to Tyr or Phe and Asp-87 to Gly or Ala and Asp-87 to Asn in the GyrA subunit of DNA gyrase encoded by *gyrA* and amino acid changes Ser-80 to Ile or Arg and Glu-84 to Gly or Lys in the ParC subunit of topoisomerase IV encoded by *parC*. These amino acid substitutions in the GyrA and ParC subunits occur in isolates with intermediate- or high-level quinolone resistance. Internal probes for the specific detection of wild-type *K. pneumoniae gyrA* (SEQ ID NO. 1943) and wild-type *K. pneumoniae parC* (SEQ ID NO. 1944) as well as internal probes for the specific detection of each of the *gyrA* (SEQ ID NOs. 1945-1949) and *parC* mutations identified in quinolone-resistant *K. pneumoniae* (SEQ ID NOs. 1950-1953) were designed.

Two multiplex using the *K. pneumoniae gyrA*- and *parC*-specific primer pairs were used: the first multiplex contained *K. pneumoniae gyrA*-specific primers (SEQ ID

NOs. 1937 and 1942) and *K. pneumoniae* *parC*-specific primers (SEQ ID NOs. 1934 and 1935) and the second multiplex contained *K. pneumoniae* *gyrA*/*parC*-specific primer (SEQ ID NOs. 1936), *K. pneumoniae* *gyrA*-specific primer (SEQ ID NO. 1937) and *K. pneumoniae* *parC*-specific primer (SEQ ID NO. 1935). Standard PCR was carried out on PTC-200 thermocyclers (MJ Research) using for the first multiplex 0.6, 0.6, 0.4, 0.4 μ M of each primer, respectively, and for the second multiplex 0.8, 0.4, 0.4 μ M of each primer, respectively. PCR amplification and agarose gel electrophoresis of the amplified products were performed as described in Example 28. The optimal cycling conditions for maximum sensitivity and specificity were 3 minutes at 95 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 62 °C, followed by terminal extension at 72 °C for 2 minutes. The specificity of the two multiplex assays with 40-cycle PCR was verified by using 0.1 ng of purified genomic DNA from a panel of gram-negative bacteria. The list included: *Acinetobacter baumannii*, *Citrobacter freundii*, *Eikenella corrodens*, *Enterobacter aerogenes*, *Enterobacter cancerogenes*, *Enterobacter cloacae*, *Escherichia coli* (10 strains), *Haemophilus influenzae*, *Klebsiella pneumoniae*, *Klebsiella ornitholytica*, *Klebsiella oxytoca* (2 strains), *Klebsiella planticola*, *Klebsiella terrigena*, *Kluyvera ascorbata*, *Kluyvera cryocrescens*, *Kluyvera georgiana*, *Neisseria gonorrhoeae*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Salmonella choleraesuis* subsp. *typhimurium*, *Salmonella enteritidis*, *Serratia liquefaciens*, *Serratia marcescens* and *Yersinia enterocolytica*. For both multiplex, strong amplification of both *gyrA* and *parC* was observed only for the *K. pneumoniae* strain tested. The sensitivity of the two multiplex assays with 40-cycle PCR was verified with one quinolone-sensitive strain of *K. pneumoniae*. The detection limit was around 10 copies of genomic DNA.

The complete assay for the specific detection of *K. pneumoniae* and its susceptibility to quinolone contains the *Klebsiella*-specific primers (SEQ ID NOs. 1331 and 1332) described in Example 29 and either the multiplex containing the *K.*

K. pneumoniae *gyrA*- and *parC*-specific primers (SEQ ID NOs. 1935, 1936, 1937) or the multiplex containing the *K. pneumoniae* *gyrA*- and *parC*-specific primers (SEQ ID NOs. 1934, 1937, 1939, 1942). Amplification is coupled with post-PCR hybridization with the internal probe specific to *K. pneumoniae* (SEQ ID NO. 2167) described in Example 29 and the internal probes specific to wild-type *K. pneumoniae* *gyrA* and *parC* (SEQ ID NOs. 1943, 1944) and to the *K. pneumoniae* *gyrA* and *parC* variants (SEQ ID NOs. 1945-1949 and 1950-1953).

An assay was also developed for the detection of quinolone-resistant *K. pneumoniae* using the SmartCycler (Cepheid). Real-time detection is based on the use of resistant *K. pneumoniae* *gyrA*-specific primers (SEQ ID NOs. 1936 and 1937) and the *K. pneumoniae*-specific primers (SEQ ID NOs. 1331 and 1332) described in Example 29. Internal probes were designed for molecular beacon detection of the wild-type *K. pneumoniae* *gyrA* (SEQ ID NO. 2251), for detection of the Ser-83 to Tyr or Phe and/or Asp-87 to Gly or Asn in the GyrA subunit of DNA gyrase encoded by *gyrA* (SEQ ID NOs. 2250) and for detection of *K. pneumoniae* (SEQ ID NO. 2281).

EXAMPLE 35:

Development of a PCR assay for detection and identification of *S. pneumoniae* and its quinolone resistance genes *gyrA* and *parC*. The analysis of *gyrA* and *parC* sequences from a variety of bacterial species revealed conserved regions allowing the design of PCR primers able to amplify the quinolone-resistance-determining region (QRDR) of *gyrA* and *parC* from all *S. pneumoniae* strains. PCR primer pair SEQ ID NOs. 2040 and 2041 was designed to amplify the QRDR of *S. pneumoniae* *gyrA*, whereas PCR primer pair SEQ ID NOs. 2044 and 2045 was designed to amplify the QRDR of *S. pneumoniae* *parC*. The comparison of *gyrA* and *parC* sequences from *S. pneumoniae* strains with various levels of quinolone resistance allowed the identification of amino acid substitutions Ser-81 to Phe or

Tyr in the GyrA subunit of DNA gyrase encoded by *gyrA* and amino acid changes Ser-79 to Phe in the ParC subunit of topoisomerase IV encoded by *parC*. These amino acid substitutions in the GyrA and ParC subunits occur in isolates with intermediate- or high-level quinolone resistance. Internal probes for the specific detection of each of the *gyrA* (SEQ ID NOs. 2042 and 2043) and *parC* (SEQ ID NO. 2046) mutations identified in quinolone-resistant *S. pneumoniae* were designed.

For all bacterial species, amplification was performed from purified genomic DNA. 1 μ l of genomic DNA at 0.1 ng/ μ L was transferred directly to a 19 μ l PCR mixture. Each PCR reaction contained 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM MgCl₂, 0.4 μ M (each) of the above primers SEQ ID NOs. 2040, 2041, 2044 and 2045, 0.05 mM bovine serum albumin (BSA) and 0.5 U *Taq* polymerase coupled with TaqStartTM antibody. The optimal cycling conditions for maximum sensitivity and specificity were 3 minutes at 95 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 58 °C, followed by terminal extension at 72 °C for 2 minutes. In order to generate Digoxigenin (DIG)-labeled amplicons for capture probe hybridization, 0.1X PCR DIG labeling four deoxynucleoside triphosphates mix (Boehringer Mannheim GmbH) was used for amplification.

The DIG-labeled amplicons were hybridized to the capture probes bound to 96-well plates. The plates were incubated with anti-DIG-alkaline phosphatase and the chemiluminescence was measured by using a luminometer (MLX, Dynex Technologies Inc.) after incubation with CSPD and recorded as Relative Light Unit (RLU). The RLU ratio of tested sample with and without captures probes was then calculated. A ratio \geq 2.0 was defined as a positive hybridization signal. All reactions were performed in duplicate.

The specificity of the multiplex assay with 40-cycle PCR was verified by using 0.1 ng of purified genomic DNA from a panel of bacteria listed in Table 13. Strong amplification of both *gyrA* and *parC* was detected only for the *S. pneumoniae* strains tested. Weak amplification of both *gyrA* and *parC* genes was detected for *Staphylococcus simulans*. The detection limit tested with purified genomic DNA from 5 strains of *S. pneumoniae* was 1 to 10 genome copies. In addition, 5 quinolone-resistant and 2 quinolone-sensitive clinical isolates of *S. pneumoniae* were tested to further validate the developed multiplex PCR coupled with capture probe hybridization assays. There was a perfect correlation between detection of *S. pneumoniae* *gyrA* and *parC* mutations and the susceptibility to quinolone.

The complete assay for the specific detection of *S. pneumoniae* and its susceptibility to quinolone contains the *S. pneumoniae*-specific primers (SEQ ID NOS. 1179 and 1181) described in Exemple 20 and the multiplex containing the *S. pneumoniae* *gyrA*-specific and *parC*-specific primer pairs (SEQ ID NOS. 2040 and 2041 and SEQ ID NOS. 2044 and 2045). Amplification is coupled with post-PCR hybridization with the internal probe specific to *S. pneumoniae* (SEQ ID NO. 1180) described in Example and the internal probes specific to each of the *S. pneumoniae* *gyrA* and *parC* variants (SEQ ID NOS. 2042, 2043 and 2046).

EXAMPLE 36:

Detection of extended-spectrum TEM-type β-lactamases in *Escherichia coli*. The analysis of TEM sequences which confer resistance to third-generation cephalosporins and to β-lactamase inhibitors allowed the identification of amino acid substitutions Met-69 to Ile or Leu or Val, Ser-130 to Gly, Arg-164 to Ser or His, Gly-238 to Ser, Glu-240 to Lys and Arg-244 to Ser or Cys or Thr or His or Leu. PCR primers SEQ ID NOS. 1907 and 1908 were designed to amplify TEM sequences. Internal probes for the specific detection of wild-type TEM (SEQ ID NO. 2141) and for each of the amino acid substitutions (SEQ ID NOS. 1909-1926) identified in TEM variants were designed to detect resistance to third-generation

cephalosporins and to β -lactamase inhibitors. Design and synthesis of primers and probes, and detection of the hybridization were performed as described in Example 7.

For all bacterial species, amplification was performed from purified genomic DNA. One μ l of genomic DNA at 0.1ng/ μ l was transferred directly to a 19 μ l PCR mixture. Each PCR reaction contained 50 mM KCl, 10 mM Tris-HCl (pH 9.0); 0.1% Triton X-100, 2.5 mM MgCl₂, 0.4 μ M of the TEM-specific primers SEQ ID NOs. 1907 and 1908, 200 μ M (each) of the four deoxynucleoside triphosphates, 0.05 mM bovine serum albumin (BSA) and 0.5 U *Taq* polymerase (Promega) coupled with TaqStartTM antibody. PCR amplification and agarose gel analysis of the amplified products were performed as described in Example 28. The optimal cycling conditions for maximum sensitivity and specificity were 3 minutes at 95 °C for initial denaturation, then forty cycles of three steps consisting of 5 seconds at 95 °C, 30 seconds at 55 °C and 30 seconds at 72 °C, followed by terminal extension at 72 °C for 2 minutes.

The specificity of the TEM-specific primers with 40-cycle PCR was verified by using 0.1 ng of purified genomic from the following bacteria: three third-generation cephalosporin-resistant *Escherichia coli* strains (one with TEM-10, one with TEM-28 and the other with TEM-49), two third-generation cephalosporin-sensitive *Escherichia coli* strain (one with TEM-1 and the other without TEM), one third-generation cephalosporin-resistant *Klebsiella pneumoniae* strain (with TEM-47), and one β -lactamase-inhibitor-resistant *Proteus mirabilis* strain (with TEM-39). Amplification with the TEM-specific primers was detected only for strains containing TEM.

The sensitivity of the assay with 40-cycle PCR was verified with three *E. coli* strains containing TEM-1 or TEM-10 or TEM-49, one *K. pneumoniae* strain containing TEM-47 and one *P. mirabilis* strain containing TEM-39. The detection

limit was 5 to 100 copies of genomic DNA, depending on the TEM-containing strains tested.

The TEM-specific primers SEQ ID NOs. 1907 and 1908 were used in multiplex with the *Escherichia coli/Shigella* sp.-specific primers SEQ ID NOs. 1661 and 1665 described in Example 28 to allow the complete identification of *Escherichia coli/Shigella* sp. and the susceptibility to β -lactams. PCR amplification with 0.4 μ M of each of the primers and agarose gel analysis of the amplified products was performed as described above.

The specificity of the multiplex with 40-cycle PCR was verified by using 0.1 ng of purified genomic DNA from the following bacteria: three third-generation cephalosporin-resistant *Escherichia coli* strains (one with TEM-10, one with TEM-28 and the other with TEM-49), two third-generation cephalosporin-sensitive *Escherichia coli* strain (one with TEM-1 and the other without TEM), one third-generation cephalosporin-resistant *Klebsiella pneumoniae* strain (with TEM-47), and one β -lactamase-inhibitor-resistant *Proteus mirabilis* strain (with TEM-39). The multiplex was highly specific to *Escherichia coli* strains containing TEM.

The complete assay for detection of TEM-type β -lactamases in *E. coli* includes PCR amplification using the multiplex containing the TEM-specific primers (SEQ ID NOs. 1907 and 1908) and the *Escherichia coli/Shigella* sp.-specific primers (SEQ ID NOs. 1661 and 1665) coupled with post PCR-hybridization with the internal probes specific to wild-type TEM (SEQ ID NO. 2141) and to the TEM variants (SEQ ID NOs. 1909-1926).

EXAMPLE 37:

Detection of extended-spectrum SHV-type β -lactamases in *Klebsiella pneumoniae*.

The comparison of SHV sequences, which confer resistance to third-generation

cephalosporins and to β -lactamase inhibitors, allowed the identification of amino acid substitutions Ser-130 to Gly, Asp-179 to Ala or Asn, Gly-238 to Ser , and Glu-240 to Lys. PCR primer pair SEQ ID NOs. 1884 and 1885 was designed to amplify SHV sequences. Internal probes for the specific identification of wild-type SHV (SEQ ID NO. 1896) and for each of the amino acid substitutions (SEQ ID NOs. 1886-1895 and 1897-1898) identified in SHV variants were designed to detect resistance to third-generation cephalosporins and to β -lactamase inhibitors. Design and synthesis of primers and probes, and detection of the hybridization were performed as described in Example 7.

For all bacterial species, amplification was performed from purified genomic DNA. One μ l of genomic DNA at 0.1ng/ μ l was transferred directly to a 19 μ l PCR mixture. Each PCR reaction contained 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM MgCl₂, 0.4 μ M of the SHV-specific primers SEQ ID NO. 1884 and 1885, 200 μ M (each) of the four deoxynucleoside triphosphates, 0.05 mM bovine serum albumin (BSA) and 0.5 U *Taq* polymerase (Promega) coupled with TaqStartTM antibody. PCR amplification and agarose gel analysis of the amplified products were performed as described in Example 28. The optimal cycling conditions for maximum sensitivity and specificity were 3 minutes at 95 °C for initial denaturation, then forty cycles of three steps consisting of 5 seconds at 95 °C, 30 seconds at 55 °C and 30 seconds at 72 °C, followed by terminal extension at 72 °C for 2 minutes.

The specificity of the SHV-specific primers with 40-cycle PCR was verified by using 0.1 ng of purified genomic from the following bacteria: two third-generation cephalosporin-resistant *Klebsiella pneumoniae* strains (one with SHV-2a and the other with SHV-12), one third-generation cephalosporin-sensitive *Klebsiella pneumoniae* strain (with SHV-1), two third-generation cephalosporin-resistant *Escherichia coli* strains (one with SHV-8 and the other with SHV-7), and two third-generation cephalosporin-sensitive *Escherichia coli* strains (one with SHV-1

and the other without any SHV). Amplification with the SHV-specific primers was detected only for strains containing SHV.

The sensitivity of the assay with 40-cycle PCR was verified with four strains containing SHV. The detection limit was 10 to 100 copies of genomic DNA, depending on the SHV-containing strains tested.

The amplification was coupled with post-PCR hybridization with the internal probes specific for identification of wild-type SHV (SEQ ID NO. 1896) and for each of the amino acid substitutions (SEQ ID NOs. 1886-1895 and 1897-1898) identified in SHV variants. The specificity of the probes was verified with six strains containing various SHV enzymes, one *Klebsiella pneumoniae* strain containing SHV-1, one *Klebsiella pneumoniae* strain containing SHV-2a, one *Klebsiella pneumoniae* strain containing SHV-12, one *Escherichia coli* strain containing SHV-1, one *Escherichia coli* strain containing SHV-7 and one *Escherichia coli* strain containing SHV-8. The probes correctly detected each of the SHV genes and their specific mutations. There was a perfect correlation between the SHV genotype of the strains and the susceptibility to β -lactam antibiotics.

The SHV-specific primers SEQ ID NOs. 1884 and 1885 were used in multiplex with the *K. pneumoniae*-specific primers SEQ ID NOs. 1331 and 1332 described in Example 29 to allow the complete identification of *K. pneumoniae* and the susceptibility to β -lactams. PCR amplification with 0.4 μ M of each of the primers and agarose gel analysis of the amplified products were performed as described above.

The specificity of the multiplex with 40-cycle PCR was verified by using 0.1 ng of purified genomic DNA from the following bacteria: three *K. pneumoniae* strains containing SHV-1, one *Klebsiella pneumoniae* strain containing SHV-2a, one

Klebsiella pneumoniae strain containing SHV-12, one *K. rhinoscleromatis* strain containing SHV-1, one *Escherichia coli* strain without SHV. The multiplex was highly specific to *Klebsiella pneumoniae* strain containing SHV.

EXAMPLE 38:

Development of a PCR assay for the detection and identification of *Neisseria gonorrhoeae* and its associated tetracycline resistance gene *tetM*. The analysis of publicly available *tetM* sequences revealed conserved regions allowing the design of PCR primers specific to *tetM* sequences. The PCR primer pair SEQ ID NOs. 1588 and 1589 was used in multiplex with the *Neisseria gonorrhoeae*-specific primers SEQ ID NOs. 551 and 552 described in Example 31. Sequence alignment analysis of *tetM* sequences revealed regions suitable for the design of an internal probe specific to *tetM* (SEQ ID NO. 2254). PCR amplification was carried out on PTC-200 thermocyclers (MJ Research) using 0.4 μ M of each primer pair as described in Example 28. The optimal cycling conditions for maximum sensitivity and specificity were as follow: three minutes at 95 °C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95 °C and 30 seconds at 60°C, followed by terminal extension at 72 °C for 2 minutes.

The specificity of the multiplex PCR assay with 40-cycle PCR was verified by using 0.1 ng of purified genomic DNA from the following bacteria: two tetracycline-resistant *Escherichia coli* strains (one containing the tetracycline-resistant gene *tetB* and the other containing the tetracycline-resistant gene *tetC*), one tetracycline-resistant *Pseudomonas aeruginosa* strain (containing the tetracycline-resistant gene *tetA*), nine tetracycline-resistant *Neisseria gonorrhoeae* strains, two tetracycline-sensitive *Neisseria meningitidis* strains, one tetracycline-sensitive *Neisseria polysaccharea* strain, one tetracycline-sensitive *Neisseria sicca* strain and one tetracycline-sensitive *Neisseria subflava* strain. Amplification with both the *tetM*-specific and *Neisseria gonorrhoeae*-specific primers was detected

only for *N. gonorrhoeae* strains containing *tetM*. There was a weak amplification signal using *Neisseria gonorrhoeae*-specific primers for the following species: *Neisseria sicca*, *Neisseria polysaccharea* and *Neisseria meningitidis*. There was a perfect correlation between the *tetM* genotype and the tetracycline susceptibility pattern of the *Neisseria gonorrhoeae* strains tested. The internal probe specific to *N. gonorrhoeae* SEQ ID NO. 2166 described in Example 31 can discriminate *Neisseria gonorrhoeae* from the other *Neisseria* sp.

The sensitivity of the assay with 40-cycle PCR was verified with two tetracycline resistant strains of *N. gonorrhoeae*. The detection limit was 5 copies of genomic DNA for both strains.

EXAMPLE 39:

Development of a PCR assay for the detection and identification of *Shigella* sp. and their associated trimethoprim resistance gene *dhfrIa*. The analysis of publicly available *dhfrIa* and other *dhfr* sequences revealed regions allowing the design of PCR primers specific to *dhfrIa* sequences. The PCR primer pair (SEQ ID NOs. 1459 and 1460) was used in multiplex with the *Escherichia coli/Shigella* sp.-specific primers SEQ ID NOs. 1661 and 1665 described in Example 28. Sequence alignment analysis of *dhfrIa* sequences revealed regions suitable for the design of an internal probe specific to *dhfrIa* (SEQ ID NO. 2253). PCR amplification and agarose gel analysis of the amplified products were performed as described in Example 28 with an annealing temperature of 60 °C. The specificity of the multiplex assay with 40-cycle PCR was verified by using 0.1 ng of purified genomic DNA from a panel of bacteria. The list included the following trimethoprim-sensitive strains, *Salmonella typhimurium*, *Salmonella typhi*, *Salmonella enteritidis*, *Tatumella ptyseos*, *Klebsiella pneumoniae*, *Enterobacter aerogenes*, *Citrobacter farmeri*, *Campylobacter jejuni*, *Serratia marcescens*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, six trimethoprim-resistant *Escherichia coli* strains (containing *dhfrIa* or *dhfrV* or *dhfrVII* or *dhfrXII* or

dhfrXIII or *dhfrXV*), four trimethoprim-resistant strains containing *dhfrIa* (*Shigella sonnei*, *Shigella flexneri*, *Shigella dysenteriae* and *Escherichia coli*). There was a perfect correlation between the *dhfrIa* genotype and the trimethoprim susceptibility pattern of the *Escherichia coli* and *Shigella* sp. strains tested. The *dhfrIa* primers were specific to the *dhfrIa* gene and did not amplify any of the other trimethoprim-resistant *dhfr* genes tested. The sensitivity of the multiplex assay with 40-cycle PCR was verified with three strains of trimethoprim-resistant strains of *Shigella* sp. The detection limit was 5 to 10 genome copies of DNA, depending on the *Shigella* sp. strains tested.

EXAMPLE 40:

Development of a PCR assay for the detection and identification of *Acinetobacter baumannii* and its associated aminoglycoside resistance gene *aph(3')-VIa*. The comparison of publicly available *aph(3')-VIa* sequence revealed regions allowing the design of PCR primers specific to *aph(3')-VIa*. The PCR primer pair (SEQ ID NOS. 1404 and 1405) was used in multiplex with the *Acinetobacter baumannii*-specific primers SEQ ID NOS. 1692 and 1693 described in Example 30. Analysis of the *aph(3')-VIa* sequence revealed region suitable for the design of an internal probe specific to *aph(3')-VIa* (SEQ ID NO. 2252). PCR amplification and agarose gel analysis of the amplified products were performed as described in Example 28. The specificity of the multiplex assay with 40-cycle PCR was verified by using 0.1 ng of purified genomic DNA from a panel of bacteria including: two aminoglycoside-resistant *A. baumannii* strains (containing *aph(3')-VIa*), one aminoglycoside-sensitive *A. baumani* strain, one of each of the following aminoglycoside-resistant bacteria, one *Serratia marcescens* strain containing the aminoglycoside-resistant gene *aacC1*, one *Serratia marcescens* strain containing the aminoglycoside-resistant gene *aacC4*, one *Enterobacter cloacae* strain containing the aminoglycoside-resistant gene *aacC2*, one *Enterococcus faecalis* containing the aminoglycoside-resistant gene *aacA-aphD*, one *Pseudomonas*

aeruginosa strain containing the aminoglycoside-resistant gene *aac6Ila* and one of each of the following aminoglycoside-sensitive bacterial species, *Acinetobacter anitratus*, *Acinetobacter lwoffi*, *Psychobacter phenylpyruvian*, *Neisseria gonorrhoeae*, *Haemophilus haemolyticus*, *Haemophilus influenzae*, *Yersinia enterolitica*, *Proteus vulgaris*, *Eikenella corrodens*, *Escherichia coli*. There was a perfect correlation between the *aph(3')-Vla* genotype and the aminoglycoside susceptibility pattern of the *A. baumannii* strains tested. The *aph(3')-Vla*-specific primers were specific to the *aph(3')-Vla* gene and did not amplify any of the other aminoglycoside-resistant genes tested. The sensitivity of the multiplex assay with 40-cycle PCR was verified with two strains of aminoglycoside-resistant strains of *A. baumannii*. The detection limit was 5 genome copies of DNA for both *A. baumannii* strains tested.

EXAMPLE 41:

Specific identification of *Bacteroides fragilis* using *atpD* (V-type) sequences. The comparison of *atpD* (V-type) sequences from a variety of bacterial species allowed the selection of PCR primers for *Bacteroides fragilis*. The strategy used to design the PCR primers was based on the analysis of a multiple sequence alignment of various *atpD* sequences from *B. fragilis*, as well as *atpD* sequences from the related species *B. dispar*, bacterial genera and archaea, especially representatives with phylogenetically related *atpD* sequences. A careful analysis of this alignment allowed the selection of oligonucleotide sequences which are conserved within the target species but which discriminate sequences from other species, especially from closely related species *B. dispar*, thereby permitting the species-specific and ubiquitous detection and identification of the target bacterial species.

The chosen primer pair, SEQ ID NOs. 2134-2135, produces an amplification product of 231 bp. Standard PCR was carried out on PTC-200 thermocyclers (MJ Research Inc.) using 0.4 μ M of each primers pair as described in Example 28. The

optimal cycling conditions for maximum sensitivity and specificity were as follows: three minutes at 95°C for initial denaturation, then forty cycles of two steps consisting of 1 second at 95°C and 30 seconds at 60°C, followed by terminal extension at 72°C for 2 minutes.

The format of this assay is not limited to the one described above. A person skilled in the art could adapt the assay for different formats such as PCR with real-time detection using molecular beacon probes. Molecular beacon probes designed to be used in this assay include, but are not limited to, SEQ ID NO. 2136 for the detection of the *B. fragilis* amplicon.

EXAMPLE 42:

Evidence for horizontal gene transfer in the evolution of the elongation factor Tu in Enterococci.

ABSTRACT

The elongation factor Tu, encoded by *tuf* genes, is a GTP binding protein that plays a central role in protein synthesis. One to three *tuf* genes per genome are present depending on the bacterial species. Most low G+C gram-positive bacteria carry only one *tuf* gene. We have designed degenerate PCR primers derived from consensus sequences of the *tuf* gene to amplify partial *tuf* sequences from 17 enterococcal species and other phylogenetically related species. The amplified DNA fragments were sequenced either by direct sequencing or by sequencing cloned inserts containing putative amplicons. Two different *tuf* genes (*tufA* and *tufB*) were found in 11 enterococcal species, including *Enterococcus avium*, *E. casseliflavus*, *E. dispar*, *E. durans*, *E. faecium*, *E. gallinarum*, *E. hirae*, *E. malodoratus*, *E. mundtii*, *E. pseudoavium*, and *E. raffinosus*. For the other six enterococcal species (*E. cecorum*, *E. columbae*, *E. faecalis*, *E. sulfureus*, *E.*

saccharolyticus, and *E. solitarius*), only the *tufA* gene was present. Based on 16S rRNA gene sequence analysis, the 11 species having two *tuf* genes all share a common ancestor, while the six species having only one copy diverged from the enterococcal lineage before that common ancestor. The presence of one or two copies of the *tuf* gene in enterococci was confirmed by Southern hybridization. Phylogenetic analysis of *tuf* sequences demonstrated that the enterococcal *tufA* gene branches with the *Bacillus*, *Listeria* and *Staphylococcus* genera, while the enterococcal *tufB* gene clusters with the genera *Streptococcus* and *Lactococcus*. Primary structure analysis showed that four amino acid residues within the sequenced regions are conserved and unique to the enterococcal *tufB* genes and the *tuf* genes of streptococci and *L. lactis*. The data suggest that an ancestral streptococcus or a streptococcus-related species may have horizontally transferred a *tuf* gene to the common ancestor of the 11 enterococcal species which now carry two *tuf* genes.

INTRODUCTION

The elongation factor Tu (EF-Tu) is a GTP binding protein playing a central role in protein synthesis. It mediates the recognition and transport of aminoacyl-tRNAs and their positioning to the A-site of the ribosome. The highly conserved function and ubiquitous distribution render the elongation factor a valuable phylogenetic marker among eubacteria and even throughout the archaeabacterial and eukaryotic kingdoms. The *tuf* genes encoding elongation factor Tu are present in various copy numbers per bacterial genome. Most gram-negative bacteria contain two *tuf* genes. As found in *Escherichia coli*, the two genes, while being almost identical in sequence, are located in different parts of the bacterial chromosome. However, recently completed microbial genomes revealed that only one *tuf* gene is found in *Helicobacter pylori* as well as in some obligate parasitic bacteria, such as *Borrelia burgdorferi*, *Rickettsia prowazekii*, and *Treponema pallidum*, and in some cyanobacteria. In most gram-positive bacteria studied so far, only one *tuf* gene was found. However, Southern hybridization showed that there are two *tuf* genes in

some clostridia as well as in *Streptomyces coelicolor* and *S. lividans*. Up to three *tuf*-like genes have been identified in *S. ramocissimus*.

Although massive prokaryotic gene transfer is suggested to be one of the factors responsible for the evolution of bacterial genomes, the genes encoding components of the translation machinery are thought to be highly conserved and difficult to be transferred horizontally due to the complexity of their interactions. However, a few recent studies demonstrated evidence that horizontal gene transfer has also occurred in the evolution of some genes coding for the translation apparatus, namely, 16S rRNA and some aminoacyl-tRNA synthetases. No further data suggest that such a mechanism is involved in the evolution of the elongation factors. Previous studies concluded that the two copies of *tuf* genes in the genomes of some bacteria resulted from an ancient event of gene duplication. Moreover, a study of the *tuf* gene in *R. prowazekii* suggested that intrachromosomal recombination has taken place in the evolution of the genome of this organism.

To date, little is known about the *tuf* genes of enterococcal species. In this study, we analyzed partial sequences of *tuf* genes in 17 enterococcal species, namely, *E. avium*, *E. casseliflavus*, *E. cecorum*, *E. columbae*, *E. dispar*, *E. durans*, *E. faecalis*, *E. faecium*, *E. gallinarum*, *E. hirae*, *E. malodoratus*, *E. mundtii*, *E. pseudoavium*, *E. raffinosus*, *E. saccharolyticus*, *E. solitarius*, and *E. sulfureus*. We report here the presence of two divergent copies of *tuf* genes in 11 of these enterococcal species. The 6 other species carried a single *tuf* gene. The evolutionary implications are discussed.

MATERIALS AND METHODS

Bacterial strains. Seventeen enterococcal strains and other gram-positive bacterial strains obtained from the American Type Culture Collection (ATCC, Manassas, Va.) were used in this study (Table 16). All strains were grown on sheep blood agar or in brain-heart infusion broth prior to DNA isolation.

DNA isolation. Bacterial DNAs were prepared using the G NOME DNA extraction kit (Bio101, Vista, Calif.) as previously described.

Sequencing of putative *tuf* genes. In order to obtain the *tuf* gene sequences of enterococci and other gram-positive bacteria, two sequencing approaches were used: 1) sequencing of cloned PCR products and 2) direct sequencing of PCR products. A pair of degenerate primers (SEQ ID NOs. 664 and 697) were used to amplify an 886-bp portion of the *tuf* genes from enterococcal species and other gram-positive bacteria as previously described. For *E. avium*, *E. casseliflavus*, *E. dispar*, *E. durans*, *E. faecium*, *E. gallinarum*, *E. hirae*, *E. mundtii*, *E. pseudoavium*, and *E. raffinosus*, the amplicons were cloned using the Original TA cloning kit (Invitrogen, Carlsbad, Calif.) as previously described. Five clones for each species were selected for sequencing. For *E. cecorum*, *E. faecalis*, *E. saccharolyticus*, and *E. solitarius* as well as the other gram-positive bacteria, the sequences of the 886-bp amplicons were obtained by direct sequencing. Based on the results obtained from the earlier rounds of sequencing, two pairs of primers were designed for obtaining the partial *tuf* sequences from the other enterococcal species by direct sequencing. One pair of primers (SEQ ID NOs. 543 and 660) were used to amplify the enterococcal *tuf* gene fragments from *E. columbae*, *E. malodoratus*, and *E. sulfureus*. Another pair of primers (SEQ ID NOs. 664 and 661) were used to amplify the second *tuf* gene fragments from *E. avium*, *E. malodoratus*, and *E. pseudoavium*.

Prior to direct sequencing, PCR products were electrophoresed on 1% agarose gel at 120V for 2 hours. The gel was then stained with 0.02% methylene blue for 30 minutes and washed twice with autoclaved distilled water for 15 minutes. The gel slices containing PCR products of the expected sizes were cut out and purified with the QIAquick gel extraction kit (QIAGen Inc., Mississauga, Ontario, Canada) according to the manufacturer's instructions. PCR mixtures for sequencing were prepared as described previously. DNA sequencing was carried out with the Big DyeTM Terminator Ready Reaction cycle sequencing kit using a 377 DNA sequencer (PE Applied Biosystems, Foster City, Calif.). Both strands of the

amplified DNA were sequenced. The sequence data were verified using the Sequencer™ 3.0 software (Gene Codes Corp., Ann Arbor, Mich.).

Sequence analysis and phylogenetic study. Nucleotide sequences of the *tuf* genes and their respective flanking regions for *E. faecalis*, *Staphylococcus aureus*, and *Streptococcus pneumoniae*, were retrieved from the TIGR microbial genome database and *S. pyogenes* from the University of Oklahoma database. DNA sequences and deduced protein sequences obtained in this study were compared with those in all publicly available databases using the BLAST and FASTA programs. Unless specified, sequence analysis was conducted with the programs from GCG package (Version 10; Genetics Computer Group, Madison, Wisc.). Sequence alignment of the *tuf* genes from 74 species representing all three kingdoms of life (Tables 16 and 17) were carried out by use of Pileup and corrected upon visual analysis. The N- and C-termini extremities of the sequences were trimmed to yield a common block of 201 amino acids sequences and equivocal residues were removed. Phylogenetic analysis was performed with the aid of PAUP 4.0b4 written by Dr. David L. Swofford (Sinauer Associates, Inc., Publishers, Sunderland, Mass.). The distance matrix and maximum parsimony were used to generate phylogenetic trees and bootstrap resampling procedures were performed using 500 and 100 replications in each analysis, respectively.

Protein structure analysis. The crystal structures of (i)*Thermus aquaticus* EF-Tu in complex with Phe-tRNA^{Phe} and a GTP analog and (ii) *E. coli* EF-Tu in complex with GDP served as templates for constructing the equivalent models for enterococcal EF-Tu. Homology modeling of protein structure was performed using the SWISS-MODEL server and inspected using the SWISS-PDB viewer version 3.1.

Southern hybridization. In a previous study, we amplified and cloned an 803-bp PCR product of the *tuf* gene fragment from *E. faecium*. Two divergent sequences of the inserts, which we assumed to be *tufA* and *tufB* genes, were obtained. The recombinant plasmid carrying either *tufA* or *tufB* sequence was used to generate two probes labeled with Digoxigenin (DIG)-11-dUTP by PCR

incorporation following the instructions of the manufacturer (Boehringer Mannheim, Laval, Québec, Canada). Enterococcal genomic DNA samples (1-2 µg) were digested to completion with restriction endonucleases *Bgl*II and *Xba*I as recommended by the supplier (Amersham Pharmacia Biotech, Mississauga, Ontario, Canada). These restriction enzymes were chosen because no restriction sites were observed within the amplified *tuf* gene fragments of most enterococci. Southern blotting and filter hybridization were performed using positively charged nylon membranes (Boehringer Mannheim) and QuikHyb hybridization solution (Stratagene Cloning Systems, La Jolla, Calif.) according to the manufacturers' instructions with modifications. Twenty µl of each digestion were electrophoresed for 2 h at 120V on a 0.8% agarose gel. The DNA fragments were denatured with 0.5 M NaOH and transferred by Southern blotting onto a positively charged nylon membrane (Boehringer Mannheim). The filters were pre-hybridized for 15 min and then hybridized for 2 h in the QuikHyb solution at 68°C with either DIG-labeled probe. Posthybridization washings were performed twice with 0.5x SSC, 1% SDS at room temperature for 15 min and twice in the same solution at 60°C for 15 min. Detection of bound probes was achieved using disodium 3- (4-methoxyspiro (1,2-dioxetane-3,2'- (5'-chloro) tricyclo(3.3.1.1^{3,7}) decan)-4-yl) phenyl phosphate (CSPD) (Boehringer Mannheim) as specified by the manufacturer.

GenBank submission. The GenBank accession numbers for partial *tuf* gene sequences generated in this study are given in Table 16.

RESULTS

Sequencing and nucleotide sequence analysis. In this study, all gram-positive bacteria other than enterococci yielded a single *tuf* sequence of 886 bp using primers SEQ ID NOs. 664 and 697 (Table 16). Each of four enterococcal species including *E. cecorum*, *E. faecalis*, *E. saccharolyticus*, and *E. solitarius* also yielded one 886-bp *tuf* sequence. On the other hand, for *E. avium*, *E. casseliflavus*, *E. dispar*, *E. durans*, *E. faecium*, *E. gallinarum*, *E. hirae*, *E. mundtii*, *E. pseudoavium*,

and *E. raffinosus*, direct sequencing of the 886-bp fragments revealed overlapping peaks according to their sequence chromatograms, suggesting the presence of additional copies of the *tuf* gene. Therefore, the *tuf* gene fragments of these 10 species were cloned first and then sequenced. Sequencing data revealed that two different types of *tuf* sequences (*tufA* and *tufB*) are found in eight of these species including *E. casseliflavus*, *E. dispar*, *E. durans*, *E. faecium*, *E. gallinarum*, *E. hirae*, *E. mundtii*, and *E. raffinosus*. Five clones from *E. avium* and *E. pseudoavium* yielded only a single *tuf* sequence. These new sequence data allowed the design of new primers specific for the enterococcal *tufA* or *tufB* sequences. Primers SEQ ID NOs. 543 and 660 were designed to amplify only enterococcal *tufA* sequences and a 694-bp fragment was amplified from all 17 enterococcal species. The 694-bp sequences of *tufA* genes from *E. columbae*, *E. malodoratus*, and *E. sulfureus* were obtained by direct sequencing using these primers. Primers SEQ ID NOs. 664 and 661 were designed for the amplification of 730-bp portion of *tufB* genes and yielded the expected fragments from 11 enterococcal species, including *E. malodoratus* and the 10 enterococcal species in which heterogeneous *tuf* sequences were initially found. The sequences of the *tufB* fragments for *E. avium*, *E. malodoratus* and *E. pseudoavium* were determined by direct sequencing using the primers SEQ ID NOs. 664 and 661. Overall, *tufA* gene fragments were obtained from all 17 enterococcal species but *tufB* gene fragments were obtained with only 11 enterococcal species (Table 16).

The identities between *tufA* and *tufB* for each enterococcal species were 68-79% at the nucleotide level and 81 to 89% at the amino acid level. The *tufA* gene is highly conserved among all enterococcal species with identities varying from 87% to 99% for DNA and 93% to 99% for amino acid sequences, while the identities among *tufB* genes of enterococci varies from 77% to 92% for DNA and 91% to 99% for amino acid sequences, indicating their different origins and evolution (Table 18). Since *E. solitarius* has been transferred to the genus *Tetragenococcus*, which is also a low G+C gram-positive bacterium, our sequence comparison did not include this species as an enterococcus. G+C content of enterococcal *tufA*

sequences ranged from 40.8% to 43.1%, while that of enterococcal *tufB* sequences varied from 37.8% to 46.3%. Based on amino acid sequence comparison, the enterococcal *tufA* gene products share higher identities with those of *Abiotrophia adiacens*, *Bacillus subtilis*, *Listeria monocytogenes*, *S. aureus*, and *S. epidermidis*. On the other hand, the enterococcal *tufB* gene products share higher percentages of amino acid identity with the *tuf* genes of *S. pneumoniae*, *S. pyogenes* and *Lactococcus lactis* (Table 18).

In order to elucidate whether the two enterococcal *tuf* sequences encode genuine EF-Tu, the deduced amino acid sequences of both genes were aligned with other EF-Tu sequences available in SWISSPROT (Release 38). Sequence alignment demonstrated that both gene products are highly conserved and carry all conserved residues present in this portion of prokaryotic EF-Tu (Figure 4). Therefore, it appears that both gene products could fulfill the function of EF-Tu. The partial *tuf* gene sequences encode the portion of EF-Tu from residues 117 to 317, numbered as in *E. coli*. This portion makes up of the last four α -helices and two β -strands of domain I, the entire domain II and the N-terminal part of domain III on the basis of the determined structures of *E. coli* EF-Tu.

Based on the deduced amino acid sequences, the enterococcal *tufB* genes have unique conserved residues Lys129, Leu140, Ser230, and Asp234 (*E. coli* numbering) that are also conserved in streptococci and *L. lactis*, but not in the other bacteria (Figure 4). All these residues are located in loops except for Ser230. In other bacteria the residue Ser230 is substituted for highly conserved Thr, which is the 5th residue of the third β -strand of domain II. This region is partially responsible for the interaction between the EF-Tu and aminoacyl-tRNA by the formation of a deep pocket for any of the 20 naturally occurring amino acids. According to our three-dimensional model (data not illustrated), the substitution Thr230→Ser in domain II of EF-Tu may have little impact on the capability of the pocket to accommodate any amino acid. However, the high conservation of Thr230 comparing to the unique Ser substitution found only in streptococci and 11 enterococci could suggest a subtle functional role for this residue.

The *tuf* gene sequences obtained for *E. faecalis*, *S. aureus*, *S. pneumoniae* and *S. pyogenes* were compared with their respective incomplete genome sequence. Contigs with more than 99% identity were identified. Analysis of the *E. faecalis* genome data revealed that the single *E. faecalis* *tuf* gene is located within an *str* operon where *tuf* is preceded by *fus* that encodes the elongation factor G. This *str* operon is present in *S. aureus* and *B. subtilis* but not in the two streptococcal genomes examined. The 700-bp or so sequence upstream the *S. pneumoniae* *tuf* gene has no homology with any known gene sequences. In *S. pyogenes*, the gene upstream of *tuf* is similar to a cell division gene, *ftsW*, suggesting that the *tuf* genes in streptococci are not arranged in a *str* operon.

Phylogenetic analysis. Phylogenetic analysis of the *tuf* amino acid sequences with representatives of eubacteria, archeabacteria, and eukaryotes using neighbor-joining and maximum parsimony methods showed three major clusters representing the three kingdoms of life. Both methods gave similar topologies consistent with the rRNA gene data (data not shown). Within the bacterial clade, the tree is polyphyletic but *tufA* genes from all enterococcal species always clustered with those from other low G+C gram-positive bacteria (except for streptococci and lactococci), while the *tufB* genes of the 11 enterococcal species form a distinct cluster with streptococci and *L. lactis* (Figure 5). Duplicated genes from the same organism do not cluster together, thereby not suggesting evolution by recent gene duplication.

Southern hybridization. Southern hybridization of *Bgl*II/*Xba*I digested genomic DNA from 12 enterococcal species tested with the *tufA* probe (DIG-labeled *tufA* fragment from *E. faecium*) yielded two bands of different sizes in 9 species, which also carried two divergent *tuf* sequences according to their sequencing data. For *E. faecalis* and *E. solitarius*, a single band was observed indicating that one *tuf* gene is present (Figure 6). A single band was also found when digested genomic DNA from *S. aureus*, *S. pneumoniae*, and *S. pyogenes* were hybridized with the *tufA* probe (data not shown). For *E. faecium*, the presence of three bands can be explained by the existence of a *Xba*I restriction site in the

middle of the *tufA* sequence, which was confirmed by sequencing data. Hybridization with the *tufB* probe (DIG-labeled *tufB* fragment of *E. faecium*) showed a banding profile similar to the one obtained with the *tufA* probe (data not shown).

DISCUSSION

In this study, we have shown that two divergent copies of genes encoding the elongation factor Tu are present in some enterococcal species. Sequence data revealed that both genes are highly conserved at the amino acid level. One copy (*tufA*) is present in all enterococcal species, while the other (*tufB*) is present only in 11 of the 17 enterococcal species studied. Based on 16S rRNA sequence analysis, these 11 species are members of three different enterococcal subgroups (*E. avium*, *E. faecium*, and *E. gallinarum* species groups) and a distinct species (*E. dispar*). Moreover, 16S rDNA phylogeny suggests that these 11 species possessing 2 *tuf* genes all share a common ancestor before they further evolved to become the modern species. Since the six other species having only one copy diverged from the enterococcal lineage before that common ancestor, it appears that the presence of one *tuf* gene in these six species is not attributable to gene loss.

Two clusters of low G+C gram-positive bacteria were observed in the phylogenetic tree of the *tuf* genes: one contains a majority of low G+C gram-positive bacteria and the other contains lactococci and streptococci. This is similar to the finding on the basis of phylogenetic analysis of the 16S rRNA gene and the *hrcA* gene coding for a unique heat-shock regulatory protein. The enterococcal *tufA* genes branched with most of the low G+C gram-positive bacteria, suggesting that they originated from a common ancestor. On the other hand, the enterococcal *tufB* genes branched with the genera *Streptococcus* and *Lactococcus* that form a distinct lineage separated from other low G+C gram-positive bacteria (Figure 5). The finding that these EF-Tu proteins share some conserved amino acid residues unique to this branch also supports the idea that they may share a common ancestor. Although these conserved residues might result from convergent

evolution upon a specialized function, such convergence at the sequence level, even for a few residues, seems to be rare, making it an unlikely event. Moreover, no currently known selective pressure, if any, would account for keeping one versus two *tuf* genes in bacteria. The G+C contents of enterococcal *tufA* and *tufB* sequences are similar, indicating that they both originated from low G+C gram-positive bacteria, in accordance with the phylogenetic analysis.

The *tuf* genes are present in various copy numbers in different bacteria. Furthermore, the two *tuf* genes are normally associated with characteristic flanking genes. The two *tuf* gene copies commonly encountered within gram-negative bacteria are part of the bacterial *str* operon and tRNA-*tufB* operon, respectively. The arrangement of *tufA* in the *str* operon was also found in a variety of bacteria, including *Thermotoga maritima*, the most ancient bacteria sequenced so far, *Aquifex aeolicus*, cyanobacteria, *Bacillus* sp., *Micrococcus luteus*, *Mycobacterium tuberculosis*, and *Streptomyces* sp. Furthermore, the tRNA-*tufB* operon has also been identified in *Aquifex aeolicus*, *Thermus thermophilus*, and *Chlamydia trachomatis*. The two widespread *tuf* gene arrangements argue in favor of their ancient origins. It is noteworthy that most obligate intracellular parasites, such as *Mycoplasma* sp., *R. prowazekii*, *B. burgdorferi*, and *T. pallidum*, contain only one *tuf* gene. Their flanking sequences are distinct from the two conserved patterns as a result of selection for effective propagation by an extensive reduction in genome size by intragenomic recombination and rearrangement.

Most gram-positive bacteria with low G+C content sequenced to date contain only a single copy of the *tuf* gene as a part of the *str* operon. This is the case for *B. subtilis*, *S. aureus* and *E. faecalis*. PCR amplification using a primer targeting a conserved region of the *fus* gene and the *tufA*-specific primer SEQ ID NO. 660, but not the *tufB*-specific primer SEQ ID NO. 661, yielded the expected amplicons for all 17 enterococcal species tested, indicating the presence of the *fus-tuf* organization in all enterococci (data not shown). However, in the genomes of *S. pneumoniae* and *S. pyogenes*, the sequences flanking the *tuf* genes varies although the *tuf* gene itself remains highly conserved. The enterococcal *tufB* genes are

clustered with streptococci, but at present we do not have enough data to identify the genes flanking the enterococcal *tufB* genes. Furthermore, the functional role of the enterococcal *tufB* genes remains unknown. One can only postulate that the two divergent gene copies are expressed under different conditions.

The amino acid sequence identities between the enterococcal *tufA* and *tufB* genes are lower than either i) those between the enterococcal *tufA* and the *tuf* genes from other low G+C gram-positive bacteria (streptococci and lactococci excluded) or ii) those between the enterococcal *tufB* and streptococcal and lactococcal *tuf* genes. These findings suggest that the enterococcal *tufA* genes share a common ancestor with other low G+C gram-positive bacteria via the simple scheme of vertical evolution, while the enterococcal *tufB* genes are more closely related to those of streptococci and lactococci. The facts that some enterococci possess an additional *tuf* gene and that the single streptococcal *tuf* gene is not clustered with other low G+C gram-positive bacteria cannot be explained by the mechanism of gene duplication or intrachromosomal recombination. According to sequence and phylogenetic analysis, we propose that the presence of the additional copy of the *tuf* genes in 11 enterococcal species is due to horizontal gene transfer. The common ancestor of the 11 enterococcal species now carrying *tufB* genes acquired a *tuf* gene from an ancestral streptococcus or a streptococcus-related species during enterococcal evolution through gene transfer before the diversification of modern enterococci. Further study of the flanking regions of the gene may provide more clues for the origin and function of this gene in enterococci.

Recent studies of genes and genomes have demonstrated that considerable horizontal transfer occurred in the evolution of aminoacyl-tRNA synthetases in all three kingdoms of life. The heterogeneity of 16S rRNA is also attributable to horizontal gene transfer in some bacteria, such as *Streptomyces*, *Thermomonospora chromogena* and *Mycobacterium celatum*. In this study, we provide the first example in support of a likely horizontal transfer of the *tuf* gene encoding the elongation factor Tu. This may be an exception since stringent functional constraints do not allow for frequent horizontal transfer of the *tuf* gene as with

other genes. However, enterococcal *tuf* genes should not be the only such exception as we have noticed that the phylogeny of *Streptomyces tuf* genes is equally or more complex than that of enterococci. For example, the three *tuf*-like genes in a high G+C gram-positive bacterium, *S. ramocissimus*, branched with the *tuf* genes of phylogenetically divergent groups of bacteria (Figure 5). Another example may be the *tuf* genes in clostridia, which represent a phylogenetically very broad range of organisms and form a plethora of lines and groups of various complexities and depths. Four species belonging to three different clusters within the genus *Clostridium* have been shown by Southern hybridization to carry two copies of the *tuf* gene. Further sequence data and phylogenetic analysis may help interpreting the evolution of the elongation factor Tu in these gram-positive bacteria. Since the *tuf* genes and 16S rRNA genes are often used for phylogenetic study, the existence of duplicate genes originating from horizontal gene transfer may alter the phylogeny of microorganisms when the laterally acquired copy of the gene is used for such analysis. Hence, caution should be taken in interpreting phylogenetic data. In addition, the two *tuf* genes in enterococci have evolved separately and are distantly related to each other phylogenetically. The enterococcal *tufB* genes are less conserved and unique to the 11 enterococcal species only. We previously demonstrated that the enterococcal *tufA* genes could serve as a target to develop a DNA-based assay for identification of enterococci. The enterococcal *tufB* genes would also be useful in identification of these 11 enterococcal species.

EXAMPLE 43:

Elongation Factor Tu (*tuf*) and the F-ATPase beta-subunit (*atpD*) as phylogenetic tools for species of the family Enterobacteriaceae.

SUMMARY

The phylogeny of enterobacterial species commonly found in clinical samples was analyzed by comparing partial sequences of their elongation factor Tu (*tuf*) genes and their F-ATPase beta-subunit (*atpD*) genes. A 884-bp fragment for *tuf* and a 884- or 871-bp fragment for *atpD* were sequenced for 88 strains of 72 species from 25 enterobacterial genera. The *atpD* sequence analysis revealed a specific indel to *Pantoea* and *Tatumella* species showing for the first time a tight phylogenetic affiliation between these two genera. Comprehensive *tuf* and *atpD* phylogenetic trees were constructed and are in agreement with each other. Monophyletic genera are *Yersinia*, *Pantoea*, *Edwardsiella*, *Cedecea*, *Salmonella*, *Serratia*, *Proteus*, and *Providencia*. Analogous trees were obtained based on available 16S rDNA sequences from databases. *tuf* and *atpD* phylogenies are in agreement with the 16S rDNA analysis despite the smaller resolution power for the latter. In fact, distance comparisons revealed that *tuf* and *atpD* genes provide a better resolution for pairs of species belonging to the family *Enterobacteriaceae*. However, 16S rDNA distances are better resolved for pairs of species belonging to different families. In conclusion, *tuf* and *atpD* conserved genes are sufficiently divergent to discriminate different species inside the family *Enterobacteriaceae* and offer potential for the development of diagnostic tests based on DNA to identify enterobacterial species.

INTRODUCTION

Members of the family *Enterobacteriaceae* are facultatively anaerobic gram-negative rods, catalase-positive and oxydase-positive (Brenner, 1984). They are found in soil, water, plants, and in animals from insects to man. Many enterobacteria are opportunistic pathogens. In fact, members of this family are responsible for about 50 % of nosocomial infections in the United States (Brenner, 1984). Therefore, this family is of considerable clinical importance.

Major classification studies on the family *Enterobacteriaceae* are based on phenotypic traits (Brenner *et al.*, 1999; Brenner *et al.*, 1980; Dickey & Zumoff,

1988; Farmer III *et al.*, 1980; Farmer III *et al.*, 1985b; Farmer III *et al.*, 1985a) such as biochemical reactions and physiological characteristics. However, phenotypically distinct strains may be closely related by genotypic criteria and may belong to the same genospecies (Bercovier *et al.*, 1980; Hartl & Dykhuizen, 1984). Also, phenotypically close strains (biogroups) may belong to different genospecies, like *Klebsiella pneumoniae* and *Enterobacter aerogenes* (Brenner, 1984) for example. Consequently, identification and classification of certain species may be ambiguous with techniques based on phenotypic tests (Janda *et al.*, 1999; Kitch *et al.*, 1994; Sharma *et al.*, 1990).

More advances in the classification of members of the family *Enterobacteriaceae* have come from DNA-DNA hybridization studies (Brenner *et al.*, 1993; Brenner *et al.*, 1986; Brenner, *et al.*, 1980; Farmer III, *et al.*, 1980; Farmer III, *et al.*, 1985b; Izard *et al.*, 1981; Steigerwalt *et al.*, 1976). Furthermore, the phylogenetic significance of bacterial classification based on 16S rDNA sequences has been recognized by many workers (Stackebrandt & Goebel, 1994; Wayne *et al.*, 1987). However, members of the family *Enterobacteriaceae* have not been subjected to extensive phylogenetic analysis of 16S rDNA (Sproer *et al.*, 1999). In fact, this molecule was not thought to solve taxonomic problems concerning closely related species because of its very high degree of conservation (Brenner, 1992; Sproer, *et al.*, 1999). Another drawback of the 16S rDNA gene is that it is found in several copies within the genome (seven in *Escherichia coli* and *Salmonella typhimurium*) (Hill & Harnish, 1981). Due to sequence divergence between the gene copies, direct sequencing of PCR products is often not suitable to achieve a representative sequence (Cilia *et al.*, 1996; Hill & Harnish, 1981). Other genes such as *gap* and *ompA* (Lawrence *et al.*, 1991), *rpoB* (Mollet *et al.*, 1997), and *infB* (Hedegaard *et al.*, 1999) were used to resolve the phylogeny of enterobacteria. However, none of these studies covered an extensive number of species.

tuf and *atpD* are the genes encoding the elongation factor Tu (EF-Tu) and the F-ATPase beta-subunit, respectively. EF-Tu is involved in peptide chain formation (Ludwig *et al.*, 1990). The two copies of the *tuf* gene (*tufA* and *tufB*) found in enterobacteria (Sela *et al.*, 1989) share high identity level (99 %) in *Salmonella typhimurium* and in *E. coli*. The recombination phenomenon could explain sequence homogenization between the two copies (Abdulkarim & Hughes, 1996; Grunberg-Manago, 1996). F-ATPase is present on the plasma membranes of eubacteria (Nelson & Taiz, 1989). It functions mainly in ATP synthesis (Nelson & Taiz, 1989) and the beta-subunit contains the catalytic site of the enzyme. EF-Tu and F-ATPase are highly conserved throughout evolution and shows functional constancy (Amann *et al.*, 1988; Ludwig, *et al.*, 1990). Recently, phylogenies based on protein sequences from EF-Tu and F-ATPase beta-subunit showed good agreement with each other and with the rDNA data (Ludwig *et al.*, 1993).

We elected to sequence 884-bp fragments of *tuf* and *atpD* from 88 clinically relevant enterobacterial strains representing 72 species from 25 genera. These sequences were used to create phylogenetic trees that were compared with 16S rDNA trees. These trees revealed good agreement with each others and demonstrated the high resolution of *tuf* and *atpD* phylogenies at the species level.

MATERIALS AND METHODS

Bacterial strains and genomic material. All bacterial strains used in this study were obtained from the American Type Culture Collection (ATCC) or the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ). These enterobacteria can all be recovered from clinical specimens, but not all are pathogens. Whenever possible, we choose type strains. Identification of all strains was confirmed by classical biochemical tests using the automated system MicroScan WalkAway-96 system equipped with a Negative BP Combo Panel Type 15 (Dade Behring Canada). Genomic DNA was purified using the G NOME

DNA kit (Bio 101). Genomic DNA from *Yersinia pestis* was kindly provided by Dr. Robert R. Brubaker. Strains used in this study and their descriptions are shown in Table 19.

PCR primers. The eubacterial *tuf* and *atpD* gene sequences available from public databases were analyzed using the GCG package (version 8.0) (Genetics Computer Group). Based on multiple sequence alignments, two highly conserved regions were chosen for each genes, and PCR primers were derived from these regions with the help of Oligo primer analysis software (version 5.0) (National Biosciences). A second 5' primer was design to amplify the gene *atpD* for few enterobacteria difficult to amplify with the first primer set. When required, the primers contained inosines or degeneracies to account for variable positions. Oligonucleotide primers were synthesized with a model 394 DNA/RNA synthesizer (PE Applied Biosystems). PCR primers used in this study are listed in Table 20.

DNA sequencing. An 884-bp portion of the *tuf* gene and an 884-bp portion (or alternatively an 871-bp portion for a few enterobacterial strains) of the *atpD* gene were sequenced for all enterobacteria listed in the first strain column of Table 19. Amplification was performed with 4 ng of genomic DNA. The 40- μ l PCR mixtures used to generate PCR products for sequencing contained 1.0 μ M each primer, 200 μ M each deoxyribonucleoside triphosphate (Pharmacia Biotech), 10 mM Tris-HCl (pH 9.0 at 25 °C), 50 mM KCl, 0.1 % (w/v) Triton X-100, 2.5 mM MgCl₂, 0.05 mM BSA, 0.3 U of *Taq* DNA polymerase (Promega) coupled with TaqStart™ antibody (Clontech Laboratories). The TaqStart™ neutralizing monoclonal antibody for *Taq* DNA polymerase was added to all PCR mixtures to enhance efficiency of amplification (Kellogg *et al.*, 1994). The PCR mixtures were subjected to thermal cycling (3 min at 95 °C and then 35 cycles of 1 min at 95 °C, 1 min at 55 °C for *tuf* or 50 °C for *atpD*, and 1 min at 72 °C, with a 7-min final extension at 72 °C) using a PTC-200 DNA Engine thermocycler (MJ Research).

PCR products having the predicted sizes were recovered from an agarose gel stained for 15 min with 0·02 % of methylene blue followed by washing in sterile distilled water for 15 min twice (Flores *et al.*, 1992). Subsequently, PCR products having the predicted sizes were recovered from gels using the QIAquick gel extraction kit (QIAGEN).

Both strands of the purified amplicons were sequenced using the ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems) on an automated DNA sequencer (Model 377). Amplicons from two independant PCR amplifications were sequenced for each strain to ensure the absence of sequencing errors attributable to nucleotide miscorporations by the *Taq* DNA polymerase. Sequence assembly was performed with the aid of Sequencher 3.0 software (Gene Codes).

Phylogenetic analysis. Multiple sequence alignments were performed using PileUp from the GCG package (Version 10.0) (Genetics Computer Group) and checked by eye with the editor SeqLab to edit sequences if necessary and to note which regions were to be excluded for phylogenetic analysis. *Vibrio cholerae* and *Shewanella putrefaciens* were used as outgroups. Bootstrap subsets (750 sets) and phylogenetic trees were generated with the Neighbor Joining algorithm from Dr. David Swofford's PAUP (Phylogenetic Analysis Using Parsimony) Software version 4.0b4 (Sinauer Associates) and with tree-bisection branch-swapping. The distance model used was Kimura (1980) two-parameter. Relative rate test was performed with the aid of Phyltest program version 2.0 (c).

RESULTS AND DISCUSSION

DNA amplification, sequencing and sequence alignments

A PCR product of the expected size of 884 bp was obtained for *tuf* and of 884 or 871 bp for *atpD* from all bacterial strains tested. After subtracting for biased

primer regions and ambiguous single strand data, sequences of at least 721 bp for *tuf* and 713 bp for *atpD* were submitted to phylogenetic analyses. These sequences were aligned with *tuf* and *atpD* sequences available in databases to verify that the nucleotide sequences indeed encoded a part of tested genes. Gaps were excluded to perform phylogenetic analysis.

Signature sequences

From the sequence alignments obtained from both tested genes, only one insertion was observed. This five amino acids insertion is located between the positions 325 and 326 of *atpD* gene of *E. coli* strain K-12 (Saraste *et al.*, 1981) and can be considered a signature sequence of *Tatumella ptyseos* and *Pantoea* species (Fig. 7). The presence of a conserved indel of defined length and sequence and flanked by conserved regions could suggest a common ancestor, particularly when members of a given taxa share this indel (Gupta, 1998). To our knowledge, high relatedness between the genera *Tatumella* and *Pantoea* is demonstrated for the first time.

Enterobacter agglomerans ATCC 27989 sequence does not possess the five amino acid indel (Fig. 7). This indel could represent a useful marker to help resolve the *Enterobacter agglomerans* and *Pantoea* classification. Indeed, the transfer of *Enterobacter agglomerans* to *Pantoea agglomerans* was proposed in 1989 by Gavini *et al.* (Gavini *et al.*, 1989). However, some strains are provisionally classified as *Pantoea* sp. until their interrelatedness is elucidated (Gavini, *et al.*, 1989). Since the transfer was proposed, the change of nomenclature has not yet been made for all *Enterobacter agglomerans* in the ATCC database. The absence of the five amino acids indel suggests that some strains of *Enterobacter agglomerans* most likely do not belong to the genus *Pantoea*.

Phylogenetic trees based on partial *tuf* sequences, *atpD* sequences, and published 16S rDNA data of members of the *Enterobacteriaceae*.

Representative trees constructed from *tuf* and *atpD* sequences with the neighbor-joining method are shown in Fig. 8. The phylogenetic trees generated from partial *tuf* sequences and *atpD* sequences are very similar. Nevertheless, *atpD* tree shows more monophyletic groups corresponding to species that belong to the same genus. These groups are more consistent with the actual taxonomy. For both genes, some genera are not monophyletic. These results support previous phylogenies based on the genes *gap* and *ompA* (Lawrence, *et al.*, 1991), *rpoB* (Mollet, *et al.*, 1997), and *infB* (Hedegaard, *et al.*, 1999) which all showed that the genera *Escherichia* and *Klebsiella* are polyphyletic. There were few differences in branching between *tuf* and *atpD* genes.

Even though *Pantoea agglomerans* and *Pantoea dispersa* indels were excluded for phylogenetic analysis, these two species grouped together and were distant from *Enterobacter agglomerans* ATCC 27989, adding another evidence that the latter species is heterogenous and that not all members of this species belong to the genus *Pantoea*. In fact, the *E. agglomerans* strain ATCC 27989 exhibits branch lengths similar to others *Enterobacter* species with both genes. Therefore, we suggest that this strain belong to the genus *Enterobacter* until further reclassification of that genus.

tuf and *atpD* trees exhibit very short genetic distances between taxa belonging to the same genetic species including species segregated for clinical considerations. This first concern *E. coli* and *Shigella* species that were confirmed to be the same genetic species by hybridization studies (Brenner *et al.*, 1972; Brenner *et al.*, 1972; Brenner *et al.*, 1982) and phylogenies based on 16S rDNA (Wang *et al.*, 1997) and *rpoB* genes (Mollet, *et al.*, 1997). Hybridization studies (Bercovier, *et al.*, 1980) and phylogeny based on 16S rDNA genes (Ibrahim *et al.*, 1994) demonstrated also that *Yersinia pestis* and *Y. pseudotuberculosis* are the same genetic species. Among

Yersinia pestis and *Y. pseudotuberculosis*, the three *Klebsiella pneumoniae* subspecies, *E. coli-Shigella* species, and *Salmonella choleraesuis* subspecies, *Salmonella* is a less tightly knit species than the other genetic species. The same is true for *E. coli* and *Shigella* species.

Escherichia fergusonii is very close to *E. coli-Shigella* genetic species. This observation is corroborated by 16S rDNA phylogeny (McLaughlin *et al.*, 2000) but not by DNA hybridization values. In fact, *E. fergusonii* is only 49% to 63% related to *E. coli-Shigella* (Farmer III, *et al.*, 1985b). It was previously observed that very recently diverged species may not be recognizable based on 16S rDNA sequences although DNA hybridization established them as different species (Fox *et al.*, 1992). Therefore, *E. fergusonii* could be a new “quasi-species”.

atpD phylogeny revealed *Salmonella* subspecies divisions consistent with the actual taxonomy. This result was already observed by Christensen *et al.* (Christensen & Olsen, 1998). Nevertheless, *tuf* partial sequences discriminate less than *atpD* between *Salmonella* subspecies.

Overall, *tuf* and *atpD* phylogenies exhibit enough divergence between species to ensure efficient discrimination. Therefore, it could be easy to distinguish phenotypically close enterobacteria belonging to different genetic species such as *Klebsiella pneumoniae* and *Enterobacter aerogenes*.

Phylogenetic relationships between *Salmonella*, *E. coli* and *C. freundii* are not well defined. 16S rDNA and 23S rDNA sequence data reveals a closer relationship between *Salmonella* and *E. coli* than between *Salmonella* and *C. freundii* (Christensen *et al.*, 1998), while DNA homology studies (Selander *et al.*, 1996) and *infB* phylogeny (Hedegaard, *et al.*, 1999) showed that *Salmonella* is more closely related to *C. freundii* than to *E. coli*. In that regard, *tuf* and *atpD* phylogenies are coherent with 16S rDNA and 23S rDNA sequence analysis.

Phylogenetic analyses were also performed using amino acids sequences. *tuf* tree based on amino acids is characterized by a better resolution between taxa outgroup and taxa ingroup (enterobacteria) than tree based on nucleic acids whereas *atpD* trees based on amino acids and nucleic acids give almost the same resolution between taxa outgroup and ingroup (data not shown).

Relative rate test (or two cluster test (Takezaki *et al.*, 1995)) evaluates if evolution is constant between two taxa. Before to apply the test, the topology of a tree is determined by tree-building method without the assumption of rate constancy. Therefore, two taxa (or two groups of taxa) are compared with a third taxon that is an outgroup of the first two taxa (Takezaki, *et al.*, 1995). Few pairs of taxa that exhibited a great difference between their branch lengths at particular nodes were chosen to perform the test. This test reveals that *tuf* and *atpD* are not constant in their evolution within the family *Enterobacteriaceae*. For *tuf*, for example, the hypothesis of rate constancy is rejected (Z value higher than 1.96) between *Yersinia* species. The same is true for *Proteus* species. For *atpD*, for example, evolution is not constant between *Proteus* species, between *Proteus* species and *Providencia* species, and between *Yersinia* species and *Escherichia coli*. For 16S rDNA, for example, evolution is not constant between two *E. coli*, between *E. coli* and *Enterobacter aerogenes*, and between *E. coli* and *Proteus vulgaris*. These results suggest that *tuf*, *atpD* and 16S rDNA could not serve as a molecular clock for the entire family *Enterobacteriaceae*.

Since the number and the nature of taxa can influence topology of trees, phylogenetic trees from *tuf* and *atpD* were reconstructed using sequences corresponding to strains for which 16S rDNA genes were published in GenEMBL. These trees were similar to those generated using 16S rDNA (Fig. 9). Nevertheless, 16S rDNA tree gave poorer resolution power than *tuf* and *atpD* gene trees. Indeed, these latter exhibited less multifurcation (polytomy) than the 16S rDNA tree.

Comparison of distances based on *tuf*, *atpD*, and 16S rDNA data.

tuf, *atpD*, and 16S rDNA distances (i.e. the number of differences per nucleotide site) were compared with each other for each pair of strains. We found that the *tuf* and *atpD* distances were respectively 2.268 ± 0.965 and 2.927 ± 0.896 times larger than 16S rDNA distances (Fig. 10a and b). *atpD* distances were 1.445 ± 0.570 times larger than *tuf* distances (Fig. 10c). Figure 10 also shows that the *tuf*, *atpD*, and 16S rDNA distances between members of different species of the same genus (0.053 ± 0.034 , 0.060 ± 0.020 , and 0.024 ± 0.010 , respectively) were in mean smaller than the distances between members of different genera belonging to the same family (0.103 ± 0.053 , 0.129 ± 0.051 , and 0.044 ± 0.013 , respectively). However, the overlap exhibits with standard deviations add to a focus of evidences that some enterobacterial genera are not well defined (Brenner, 1984). In fact, many distances for pairs of species especially belonging to the genera *Escherichia*, *Shigella*, *Enterobacter*, *Citrobacter*, *Klebsiella*, and *Kluyvera* overlap distances for pairs of species belonging to the same genus (Fig. 10). For example, distances for pairs composed by species of *Citrobacter* and species of *Klebsiella* overlap distances for pairs composed by two *Citrobacter* or by two *Klebsiella*.

Observing the distance distributions, 16S rDNA distances reveal a clear separation between the families *Enterobacteriaceae* and *Vibrionaceae* despite the fact that the family *Vibrionaceae* is genetically very close to the *Enterobacteriaceae* (Fig. 10a and b). Nevertheless, *tuf* and *atpD* show higher discriminating power below the family level (Fig. 10a and b).

There were some discrepancies in the relative distances for the same pairs of taxa between the two genes studied. First, distances between *Yersinia* species are at least two times lower for *atpD* than for *tuf* (Fig. 10c). Also, distances at the family level (between *Enterobacteriaceae* and *Vibrionaceae*) show that *Enterobacteriaceae* is a tighter knit family with *atpD* gene (*Proteus* genus

excepted) than with *tuf* gene. Both genes well delineate taxa belonging to the same species. There is one exception with *atpD*: *Klebsiella planticola* and *K. ornithinolithica* belong to the same genus but fit with taxa belonging to the same species (Fig. 10a and c). These two species are also very close genotypically with *tuf* gene. This suggest that *Klebsiella planticola* and *K. ornithinolithica* could be two newborn species. *tuf* and *atpD* genes exhibit little distances between *Escherichia fergusonii* and *E. coli-Shigella* species. Unfortunately, comparison with 16S rDNA could not be achieved because the *E. fergusonii* 16S rDNA sequence is not yet accessible in GenEMBL database. Therefore, the majority of phenotypically close enterobacteria could be easily discriminated genotypically using *tuf* and *atpD* gene sequences.

In conclusion, *tuf* and *atpD* genes exhibit phylogenies consistent with 16S rDNA genes phylogeny. For example, they reveal that the family *Enterobacteriaceae* is monophyletic. Moreover, *tuf* and *atpD* distances provide a higher discriminating power than 16S rDNA distances. In fact, *tuf* and *atpD* genes discriminate well between different genospecies and are conserved between strains of the same genetic species in such a way that primers and molecular probes for diagnostic purposes could be designed. Preliminary studies support these observations and diagnostic tests based on *tuf* and *atpD* sequence data to identify enterobacteria are currently under development.

EXAMPLE 44:

Testing new pairs of PCR primers selected from two species-specific genomic DNA fragments which are objects of our assigned US patent 6,001,564

Objective: The goal of these experiments is to demonstrate that it is relatively easy for a person skilled in the art to find other PCR primer pairs from the species-specific

fragments used as targets for detection and identification of a variety of microorganisms. In fact, we wish to prove that the PCR primers previously tested by our group and which are objects of the present patent application are not the only possible good choices for diagnostic purposes. For this example, we used diagnostic targets described in our assigned US patent 6,001,564.

Experimental strategy: We have selected randomly two species-specific genomic DNA fragments for this experiment. The first one is the 705-bp fragment specific to *Staphylococcus epidermidis* (SEQ ID NO: 36 from US patent 6,001,564) while the second one is the 466-bp fragment specific to *Moraxella catarrhalis* (SEQ ID NO: 29 from US patent 6,001,564). Subsequently, we have selected from these two fragments a number of PCR primer pairs other than those previously tested. We have chosen 5 new primer pairs from each of these two sequences which are well dispersed along the DNA fragment (Figures 11 and 12). We have tested these primers for their specificity and compared them with the original primers previously tested. For the specificity tests, we have tested all bacterial species closely related to the target species based on phylogenetic analysis with three conserved genes (rRNA genes, *tuf* and *atpD*). The rational for selecting a restricted number of bacterial species to evaluate the specificity of the new primer pairs is based on the fact that the lack of specificity of a DNA-based assay is attributable to the detection of closely related species which are more similar at the nucleotide level. Based on the phylogenetic analysis, we have selected (i) species from the closely related genus *Staphylococcus*, *Enterococcus*, *Streptococcus* and *Listeria* to test the specificity of the *S. epidermidis*-specific PCR assays and (ii) species from the closely related genus *Moraxella*, *Kingella* and *Neisseria* to test the specificity of the *M. catarrhalis*-specific PCR assays.

Materials and methods

Bacterial strains. All bacterial strains used for these experiments were obtained from the American Type Culture Collection (ATCC, Rockville, MD).

Genomic DNA isolation. Genomic DNA was purified from the ATCC reference strains by using the G-nome DNA kit (Bio 101 Inc., Vista, CA).

Oligonucleotide design and synthesis. PCR primers were designed with the help of the OligoTM primer analysis software Version 4.0 (National Biosciences Inc., Plymouth, Minn.) and synthesized using a model 391 DNA synthesizer (Applied Biosystems, Foster City, CA).

PCR assays. All PCR assays were performed by using genomic DNA purified from reference strains obtained from the ATCC. One μ l of purified DNA preparation (containing 0.01 to 1 ng of DNA per μ l) was added directly into the PCR reaction mixture. The 20 μ L PCR reactions contained final concentrations of 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.1% Triton X-100, 2.5 mM MgCl₂, 0.4 μ M of each primer, 200 μ M of each of the four dNTPs and 0.5 unit of *Taq* DNA polymerase (Promega, Madison, WI) combined with the TaqStartTM antibody (Clontech Laboratories Inc., Palo Alto, CA). An internal control was integrated into all amplification reactions to verify the efficiency of the amplification reaction as well as to ensure that significant PCR inhibition was absent. Primers amplifying a region of 252 bp from a control plasmid added to each amplification reaction were used to provide the internal control. PCR reactions were then subjected to thermal cycling (3 min at 95°C followed by 30 cycles of 1 second at 95°C for the denaturation step and 30 seconds at 50 to 65°C for the annealing-extension step) using a PTC-200 thermal cycler (MJ Research Inc., Watertown, MA). PCR amplification products were then analyzed by standard agarose gel (2%) electrophoresis. Amplification products were visualized in agarose gels containing 0.25 μ g/mL of ethidium bromide under UV at 254 nm.

Results

Tables 21 and 22 show the results of specificity tests with the 5 new primer pairs selected from SEQ ID NO: 29 (specific to *M. catarrhalis* from US patent 6,001,564) and SEQ ID NO: 36 (specific to *S. epidermidis* from US patent 6,001,564), respectively. In order to evaluate the performance of these new primers pairs, we compared them in parallel with the original primer pairs previously tested.

For *M. catarrhalis*, all of the 5 selected PCR primer pairs were specific for the target species because none of the closely related species could be amplified (Table 21). In fact, the comparison with the original primer pair SEQ ID NO: 118 + SEQ ID NO: 119 (from US patent 6,001,564) revealed that all new pairs showed identical results in terms of specificity and sensitivity thereby suggesting their suitability for diagnostic purposes.

For *S. epidermidis*, 4 of the 5 selected PCR primer pairs were specific for the target species (Table 22). It should be noted that for 3 of these four primer pairs the annealing temperature had to be increased from 55 °C to 60 or 65 °C to attain specificity for *S. epidermidis*. Again the comparison with the original primer pair SEQ ID NO: 145 + SEQ ID NO: 146 (from US patent 6,001,564) revealed that these four primer pairs were as good as the original pair. Increasing the annealing temperature for the PCR amplification is well known by persons skilled in the art to be a very effective way to improve the specificity of a PCR assay (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.; Ehrlich and Greenberg, 1994, PCR-based Diagnostics in Infectious Disease, Blackwell Scientific Publications, Boston, MA). In fact, those skilled in the art are well aware of the fact that the annealing temperature is critical for the optimization of PCR assays. Only the primer pair VBsep3 + VBsep4 amplified bacterial species other than *S. epidermidis* including the staphylococcal species *S. capitis*, *S. cohnii*, *S. aureus*, *S. haemolyticus* and *S. hominis* (Table 22). For this non-specific primer pair, increasing the annealing temperature

from 55 to 65 °C was not sufficient to attain the desired specificity. One possible explanation for the fact that it appears slightly easier to select species-specific primers for *M. catarrhalis* than for *S. epidermidis* is that *M. catarrhalis* is more isolated in phylogenetic trees than *S. epidermidis*. The large number of coagulase negative staphylococcal species such as *S. epidermidis* is largely responsible for this phylogenetic clustering.

Conclusion

These experiments clearly show that it is relatively easy for a person skilled in the art to select, from the species-specific DNA fragments selected as target for identification, PCR primer pairs suitable for diagnostic purposes other than those previously tested. The amplification conditions can be optimized by modifying critical variables such as the annealing temperature to attain the desired specificity and sensitivity. Consequently, we consider that it is legitimate to claim any possible primer sequences selected from the species-specific fragment and that it would be unfair to grant only the claims dealing with the primer pairs previously tested. By extrapolation, these results strongly suggest that it is also relatively easy for a person skilled in the art to select, from the species-specific DNA fragments, DNA probes suitable for diagnostic purposes other than those previously tested.

EXAMPLE 45:

Testing modified versions of PCR primers derived from the sequence of several primers which are objects of US patent 6,001,564.

Objective: The purpose of this project is to verify the efficiency of amplification by modified PCR primers derived from primers previously tested. The types of primer modifications to be tested include (i) variation of the sequence at one or more nucleotide positions and (ii) increasing or reducing the length of the primers. For this example, we used diagnostic targets described in US patent 6,001,564.

Experimental strategy:

a) Testing primers with nucleotide changes

We have designed 13 new primers which are derived from the *S. epidermidis*-specific SEQ ID NO: 146 from US patent 6,001,564 (Table 23). These primers have been modified at one or more nucleotide positions. As shown in Table 23, the nucleotide changes were introduced all along the primer sequence. Furthermore, instead of modifying the primer at any nucleotide position, the nucleotide changes were introduced at the third position of each codon to better reflect potential genetic variations *in vivo*. It should be noted that no nucleotide changes were introduced at the 3' end of the oligonucleotide primers because those skilled in the art are well aware of the fact that mismatches at the 3' end should be avoided (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.). All of these modified primers were tested in PCR assays in combination with SEQ ID NO: 145 from US patent 6,001,564 and the efficiency of the amplification was compared with the original primer pair SEQ ID NO: 145 + SEQ ID NO: 146 previously tested in US patent 6,001,564.

b) Testing shorter or longer versions of primers

We have designed shorter and longer versions of the original *S. epidermidis*-specific PCR primer pair SEQ ID NO: 145 + 146 from US patent 6,001,564 (Table 24) as well as shorter versions of the original *P. aeruginosa*-specific primer pair SEQ ID NO: 83 + 84 from US patent 6,001,564 (Table 25). As shown in Tables 24 and 25, both primers of each pair were shortened or lengthened to the same length. Again, those skilled in the art know that the melting temperature of both primers from a pair should be similar to avoid preferential binding at one primer binding site which is

detrimental in PCR (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.; Ehrlich and Greenberg, 1994, PCR-based Diagnostics in Infectious Disease, Blackwell Scientific Publications, Boston, MA). All of these shorter or longer primer versions were tested in PCR assays and the efficiency of the amplification was compared with the original primer pair SEQ ID NOs 145 and 146.

Materials and methods

See the Materials and methods section of Example 44.

Results

a) Testing primers with nucleotide changes

The results of the PCR assays with the 13 modified versions of SEQ ID NO: 146 from US patent 6,001,564 are shown in Table 23. The 8 modified primers having a single nucleotide variation showed an efficiency of amplification identical to the original primer pair based on testing with 3 different dilutions of genomic DNA. The four primers having two nucleotide variations and primer VBmut12 having 3 nucleotide changes also showed PCR results identical to those obtained with the original pair. Finally, primer VBmut13 with four nucleotide changes showed a reduction in sensitivity by approximately one log as compared with the original primer pair. However, reducing the annealing temperature from 55 to 50 °C gave an efficiency of amplification very similar to that observed with the original primer pair (Table 23). In fact, reducing the annealing temperature of PCR cycles represents an effective way to reduce the stringency of hybridization for the primers and consequently allows the binding of probes with mismatches (Persing *et al.*, 1993, Diagnostic Molecular Microbiology: Principles and Applications, American Society for Microbiology, Washington, D.C.). Subsequently, we have confirmed the

specificity of the PCR assays with each of these 13 modified versions of SEQ ID NO: 146 from US patent 6,001,564 by performing amplifications from all bacterial species closely related to *S. epidermidis* which are listed in Table 22.

b) Testing shorter or longer versions of primers

For these experiments, two primer pairs were selected: i) SEQ ID NO: 145 + 146 from US patent 6,001,564 (specific to *S. epidermidis*) which are AT rich and ii) SEQ ID NO: 83 + 84 (specific to *P. aeruginosa*) which are GC rich. For the AT rich sequence, primers of 15 to 30 nucleotide in length were designed (Table 24) while for the GC rich sequences, primers of 13 to 19 nucleotide in length were designed (Table 25).

Table 24 shows that, for an annealing temperature of 55 °C, the 30- 25-, 20- and 17-nucleotide versions of SEQ ID NO: 145 and 146 from US patent 6,001,564 all showed identical results as compared with the original primer pair except that the 17-nucleotide version amplified slightly less efficiently the *S. epidermidis* DNA. Reducing the annealing temperature from 55 to 45 °C for the 17-nucleotide version allowed to increase the amplification efficiency to a level very similar to that with the original primer pair (SEQ ID NO: 145 + 146 from US patent 6,001,564). Regarding the 15-nucleotide version, there was amplification of *S. epidermidis* DNA only when the annealing temperature was reduced to 45 °C. Under those PCR conditions the assay remained *S. epidermidis*-specific but the amplification signal with *S. epidermidis* DNA was slightly lower as compared with the original primer pair. Subsequently, we have further confirmed the specificity of the shorter or longer versions by amplifying DNA from all bacterial species closely related to *S. epidermidis* which are listed in Table 22.

Table 25 shows that, for an annealing temperature of 55 °C, all shorter versions of SEQ ID NO: 83 and 84 from US patent 6,001,564 showed identical PCR results as

compared with the original primer pair. As expected, these results show that it is simpler to reduce the length of GC rich as compared with AT rich. This is attributable to the fact that GC binding is more stable than AT binding.

Conclusion

a) Testing primers with nucleotide changes

The above experiments clearly show that PCR primers may be modified at one or more nucleotide positions without affecting the specificity and the sensitivity of the PCR assay. These results strongly suggest that a given oligonucleotide can detect variant genomic sequences from the target species. In fact, the nucleotide changes in the selected primers were purposely introduced at the third position of each codon to mimic nucleotide variation in genomic DNA. Thus we conclude that it is justified to claim "a variant thereof" for i) the SEQ IDs of the fragments and oligonucleotides which are object of the present patent application and ii) genomic variants of the target species.

b) Testing shorter or longer versions of primers

The above experiments clearly show that PCR primers may be shorter or longer without affecting the specificity and the sensitivity of the PCR assay. We have showed that oligonucleotides ranging in sizes from 13 to 30 nucleotides may be as specific and sensitive as the original primer pair from which they were derived. Consequently, these results suggest that it is not exaggerated to claim sequences having at least 12 nucleotide in length.

This invention has been described herein above, and it is readily apparent that modifications can be made thereto without departing from the spirit of this invention. These modifications are under the scope of this invention, as defined in the appended claims.

Table 1. Distribution (%) of nosocomial pathogens for various human infections in USA (1990-1992).

Pathogen	UTI ²	SSI ³	BSI ⁴	Pneumonia	CSF ⁵
<i>Escherichia coli</i>	27	9	5	4	2
<i>Staphylococcus aureus</i>	2	21	17	21	2
<i>Staphylococcus epidermidis</i>	2	6	20	0	1
<i>Enterococcus faecalis</i>	16	12	9	2	0
10 <i>Enterococcus faecium</i>	1	1	0	0	0
<i>Pseudomonas aeruginosa</i>	12	9	3	18	0
<i>Klebsiella pneumoniae</i>	7	3	4	9	0
<i>Proteus mirabilis</i>	5	3	1	2	0
<i>Streptococcus pneumoniae</i>	0	0	3	1	18
15 Group B Streptococci	1	1	2	1	6
Other streptococci	3	5	2	1	3
<i>Haemophilus influenzae</i>	0	0	0	6	45
<i>Neisseria meningitidis</i>	0	0	0	0	14
<i>Listeria monocytogenes</i>	0	0	0	0	3
20 Other enterococci	1	1	0	0	0
Other staphylococci	2	8	13	2	0
<i>Candida albicans</i>	9	3	5	5	0
Other <i>Candida</i>	2	1	3	1	0
<i>Enterobacter</i> sp.	5	7	4	12	2
25 <i>Acinetobacter</i> sp.	1	1	2	4	2
<i>Citrobacter</i> sp.	2	1	1	1	0
<i>Serratia marcescens</i>	1	1	1	3	1
Other <i>Klebsiella</i>	1	1	1	2	1
Others	0	6	4	5	0

30 ¹ Data recorded by the National Nosocomial Infections Surveillance (NNIS) from 80 hospitals (Emori and Gaynes, 1993, *Clin. Microbiol. Rev.*, 6:428-442).

² Urinary tract infection.

³ Surgical site infection.

35 ⁴ Bloodstream infection.

⁵ Cerebrospinal fluid.

Table 2. Distribution (%) of bloodstream infection pathogens in Quebec (1995), Canada (1992), UK (1969-1988) and USA (1990-1992).

5	Organism	Quebec ¹		Canada ²		Community-acquired	Hospital-acquired	USA ⁴
		Quebec ¹	Canada ²	UK ³	Hospital-acquired			
	<i>E. coli</i>	/ 15.6	53.8	24.8	20.3	5.0		
10	<i>S. epidermidis</i> and other CoNS ⁵	25.8	-	0.5	7.2	31.0		
	<i>S. aureus</i>	9.6	-	9.7	19.4	16.0		
	<i>S. pneumoniae</i>	6.3	-	22.5	2.2	-		
	<i>E. faecalis</i>	3.0	-	1.0	4.2	-		
15	<i>E. faecium</i>	2.6	-	0.2	0.5	-		
	<i>Enterococcus</i> sp.	-	-	- -	9.0			
	<i>H. influenzae</i>	1.5	-	3.4	0.4	-		
	<i>P. aeruginosa</i>	1.5	8.2	1.0	8.2	3.0		
	<i>K. pneumoniae</i>	3.0	11.2	3.0	9.2	4.0		
20	<i>P. mirabilis</i>	-	3.9	2.8	5.3	1.0		
	<i>S. pyogenes</i>	-	-	1.9	0.9	-		
	<i>Enterobacter</i> sp.	4.1	5.5	0.5	2.3	4.0		
	<i>Candida</i> sp.	8.5	-	-	1.0	8.0		
	<i>Others</i>	18.5	17.4	28.7	18.9	19.0		

25 ¹ Data obtained for 270 isolates collected at the Centre Hospitalier de l'Université Laval (CHUL) during a 5 month period (May to October 1995).

2 ² Data from 10 hospitals throughout Canada representing 941 gram-negative isolates. (Chamberland *et al.*, 1992, *Clin. Infect. Dis.*, **15**:615-628).

30 ³ Data from a 20-year study (1969-1988) for nearly 4000 isolates. (Eykyn *et al.*, 1990, *J. Antimicrob. Chemother.*, Suppl. C, **25**:41-58).

4 ⁴ Data recorded by the National Nosocomial Infections Surveillance (NNIS) from 80 hospitals (Emori and Gaynes, 1993, *Clin. Microbiol. Rev.*, **6**:428-442).

5 ⁵ Coagulase-negative staphylococci.

Table 3. Distribution of positive and negative clinical specimens tested at the microbiology laboratory of the CHUL (February 1994 – January 1995).

	Clinical specimens and/or sites	No. of samples tested (%)	% of positive specimens	% of negative specimens
5	Urine	17,981 (54.5)	19.4	80.6
	Blood culture/marrow	10,010 (30.4)	6.9	93.1
	Sputum	1,266 (3.8)	68.4	31.6
10	Superficial pus	1,136 (3.5)	72.3	27.7
	Cerebrospinal fluid	553 (1.7)	1.0	99.0
	Synovial fluid	523 (1.6)	2.7	97.3
	Respiratory tract	502 (1.5)	56.6	43.4
	Deep pus	473 (1.4)	56.8	43.2
15	Ears	289 (0.9)	47.1	52.9
	Pleural and pericardial fluid	132 (0.4)	1.0	99.0
	Peritoneal fluid	101(0.3)	28.6	71.4
Total:		32,966 (100.0)	20.0	80.0

Table 4. Example of microbial species for which *tuf* and/or *atpD* and/or *recA* nucleic acids and/or sequences are used in the present invention.

5	Bacterial species
	<i>Abiotrophia adiacens</i>
	<i>Abiotrophia defectiva</i>
10	<i>Achromobacter xylosoxidans</i> subsp. <i>denitrificans</i>
	<i>Acetobacterium woodi</i>
	<i>Acetobacter aceti</i>
	<i>Acetobacter altoacetigenes</i>
	<i>Acetobacter polyoxogenes</i>
	<i>Acholeplasma laidlawii</i>
15	<i>Acidothermus cellulolyticus</i>
	<i>Acidiphilum facilis</i>
	<i>Acinetobacter baumannii</i>
	<i>Acinetobacter calcoaceticus</i>
20	<i>Acinetobacter lwoffii</i>
	<i>Actinomyces meyeri</i>
	<i>Aerococcus viridans</i>
	<i>Aeromonas hydrophila</i>
	<i>Aeromonas salmonicida</i>
25	<i>Agrobacterium radiobacter</i>
	<i>Agrobacterium tumefaciens</i>
	<i>Alcaligenes faecalis</i> subsp. <i>faecalis</i>
	<i>Allochromatium vinosum</i>
	<i>Anabaena variabilis</i>
30	<i>Anacystis nidulans</i>
	<i>Anaerorhabdus furcosus</i>
	<i>Aquifex aeolicus</i>
	<i>Aquifex pyrophilus</i>
	<i>Arcanobacterium haemolyticum</i>
35	<i>Archaeoglobus fulgidus</i>
	<i>Azotobacter vinelandii</i>
	<i>Bacillus anthracis</i>
	<i>Bacillus cereus</i>
	<i>Bacillus firmus</i>
	<i>Bacillus halodurans</i>
40	<i>Bacillus megaterium</i>
	<i>Bacillus mycoides</i>
	<i>Bacillus pseudomycoides</i>
	<i>Bacillus stearothermophilus</i>
	<i>Bacillus subtilis</i>
45	<i>Bacillus thuringiensis</i>
	<i>Bacillus weihenstephanensis</i>
	<i>Bacteroides distasonis</i>
	<i>Bacteroides fragilis</i>
	<i>Bacteroides forsythus</i>
50	<i>Bacteroides ovatus</i>
	<i>Bacteroides vulgatus</i>
	<i>Bartonella henselae</i>
	<i>Bifidobacterium adolescentis</i>
	<i>Bifidobacterium breve</i>
55	<i>Bifidobacterium dentium</i>
	<i>Bifidobacterium longum</i>
	<i>Blastochloris viridis</i>
	<i>Borrelia burgdorferi</i>
	<i>Bordetella pertussis</i>
60	<i>Bordetella bronchiseptica</i>
	<i>Brucella abortus</i>
	<i>Brevibacterium linens</i>
	<i>Brevibacterium flavum</i>
	<i>Brevundimonas diminuta</i>
	<i>Buchnera aphidicola</i>
	<i>Budvicia aquatica</i>
	<i>Burkholderia cepacia</i>
	<i>Burkholderia mallei</i>
	<i>Burkholderia pseudomallei</i>
70	<i>Butiauxella agrestis</i>
	<i>Butyrivibrio fibrisolvens</i>
	<i>Campylobacter coli</i>
	<i>Campylobacter curvus</i>
	<i>Campylobacter fetus</i> subsp. <i>fetus</i>
	<i>Campylobacter fetus</i> subsp. <i>venerealis</i>
	<i>Campylobacter gracilis</i>
	<i>Campylobacter jejuni</i>
	<i>Campylobacter jejuni</i> subsp. <i>doylei</i>
	<i>Campylobacter jejuni</i> subsp. <i>jejuni</i>
	<i>Campylobacter lari</i>
	<i>Campylobacter rectus</i>
	<i>Campylobacter sputorum</i> subsp. <i>sputorum</i>
	<i>Campylobacter upsaliensis</i>
	<i>Cedecea davisae</i>
	<i>Cedecea lapagei</i>
	<i>Cedecea neteri</i>
	<i>Chlamydia pneumoniae</i>
	<i>Chlamydia psittaci</i>
	<i>Chlamydia trachomatis</i>
90	<i>Chlorobium vibrioforme</i>
	<i>Chloroflexus aurantiacus</i>
	<i>Chryseobacterium meningosepticum</i>
	<i>Citrobacter amalonaticus</i>
	<i>Citrobacter braakii</i>
	<i>Citrobacter farmeri</i>
	<i>Citrobacter freundii</i>
	<i>Citrobacter koseri</i>
	<i>Citrobacter sedlakii</i>
	<i>Citrobacter werkmanii</i>
	<i>Citrobacter youngae</i>
100	<i>Clostridium acetobutylicum</i>
	<i>Clostridium beijerinckii</i>
	<i>Clostridium bifermentans</i>
	<i>Clostridium botulinum</i>
	<i>Clostridium difficile</i>
	<i>Clostridium innocuum</i>
	<i>Clostridium histolyticum</i>
	<i>Clostridium novyi</i>
	<i>Clostridium septicum</i>
110	<i>Clostridium perfringens</i>
	<i>Clostridium ramosum</i>
	<i>Clostridium sordellii</i>
	<i>Clostridium tertium</i>
	<i>Clostridium tetani</i>
	<i>Comamonas acidovorans</i>
	<i>Corynebacterium accolens</i>
	<i>Corynebacterium bovis</i>
	<i>Corynebacterium cervicis</i>

Table 4. Example of microbial species for which *tuf* and/or *atpD* and/ or *recA* nucleic acids and/or sequences are used in the present invention (continued).

	Bacterial species (continued)
5	
	<i>Corynebacterium diphtheriae</i>
	<i>Corynebacterium flavescentis</i>
	<i>Corynebacterium genitalium</i>
	<i>Corynebacterium glutamicum</i>
10	<i>Corynebacterium jeikeium</i>
	<i>Corynebacterium kutscheri</i>
	<i>Corynebacterium minutissimum</i>
	<i>Corynebacterium mycetoides</i>
	<i>Corynebacterium pseudodiphtheriticum</i>
15	<i>Corynebacterium pseudogenitalium</i>
	<i>Corynebacterium pseudotuberculosis</i>
	<i>Corynebacterium renale</i>
	<i>Corynebacterium striatum</i>
	<i>Corynebacterium ulcerans</i>
20	<i>Corynebacterium urealyticum</i>
	<i>Corynebacterium xerosis</i>
	<i>Coxiella burnetii</i>
	<i>Cytophaga lytica</i>
	<i>Deinococcus radiodurans</i>
25	<i>Deinonema</i> sp.
	<i>Edwardsiella hoshinae</i>
	<i>Edwardsiella tarda</i>
	<i>Ehrlichia canis</i>
	<i>Ehrlichia risticii</i>
30	<i>Eikenella corrodens</i>
	<i>Enterobacter aerogenes</i>
	<i>Enterobacter agglomerans</i>
	<i>Enterobacter amnigenus</i>
	<i>Enterobacter asburiae</i>
35	<i>Enterobacter cancerogenus</i>
	<i>Enterobacter cloacae</i>
	<i>Enterobacter gergoviae</i>
	<i>Enterobacter hormaechei</i>
	<i>Enterobacter sakazakii</i>
40	<i>Enterococcus avium</i>
	<i>Enterococcus casseliflavus</i>
	<i>Enterococcus cecorum</i>
	<i>Enterococcus columbae</i>
	<i>Enterococcus dispar</i>
45	<i>Enterococcus durans</i>
	<i>Enterococcus faecalis</i>
	<i>Enterococcus faecium</i>
	<i>Enterococcus flavescens</i>
	<i>Enterococcus gallinarum</i>
50	<i>Enterococcus hirae</i>
	<i>Enterococcus malodoratus</i>
	<i>Enterococcus mundtii</i>
	<i>Enterococcus pseudoavium</i>
	<i>Enterococcus raffinosus</i>
55	<i>Enterococcus saccharolyticus</i>
	<i>Enterococcus solitarius</i>
	<i>Enterococcus sulfureus</i>
	<i>Erwinia amylovora</i>
	<i>Erwinia carotovora</i>
60	<i>Escherichia coli</i>
	<i>Escherichia fergusonii</i>
	<i>Escherichia hermannii</i>
	<i>Escherichia vulneris</i>
	<i>Eubacterium lentum</i>
65	<i>Eubacterium nodatum</i>
	<i>Ewingella americana</i>
	<i>Francisella tularensis</i>
	<i>Frankia alni</i>
	<i>Fervidobacterium islandicum</i>
70	<i>Fibrobacter succinogenes</i>
	<i>Flavobacter ferrugineum</i>
	<i>Flexistipes sinusarabici</i>
	<i>Fusobacterium gonidiaformans</i>
	<i>Fusobacterium necrophorum</i> subsp. <i>necrophorum</i>
75	<i>Fusobacterium nucleatum</i> subsp. <i>polymorphum</i>
	<i>Gardnerella vaginalis</i>
	<i>Gemella haemolysans</i>
	<i>Gemella morbillorum</i>
	<i>Globicatella sanguis</i>
80	<i>Gloeobacter violaceus</i>
	<i>Gloeothece</i> sp.
	<i>Gluconobacter oxydans</i>
	<i>Haemophilus actinomycetemcomitans</i>
	<i>Haemophilus aphrophilus</i>
85	<i>Haemophilus ducreyi</i>
	<i>Haemophilus haemolyticus</i>
	<i>Haemophilus influenzae</i>
	<i>Haemophilus parahaemolyticus</i>
90	<i>Huemophilus parainfluenzae</i>
	<i>Haemophilus paraphrophilus</i>
	<i>Haemophilus segnis</i>
	<i>Hafnia alvei</i>
	<i>Halobacterium marismortui</i>
	<i>Halobacterium salinarum</i>
95	<i>Haloferax volcanii</i>
	<i>Helicobacter pylori</i>
	<i>Herpetosiphon aurantiacus</i>
	<i>Kingella kingae</i>
	<i>Klebsiella ornithinolytica</i>
100	<i>Klebsiella oxytoca</i>
	<i>Klebsiella planticola</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>ozaenae</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>rhinoscleromatis</i>
	<i>Klebsiella terrigena</i>
	<i>Kluyvera ascorbata</i>
	<i>Kluyvera cryocrescens</i>
	<i>Kluyvera georgiana</i>
110	<i>Kocuria kristinae</i>
	<i>Lactobacillus acidophilus</i>
	<i>Lactobacillus garvieae</i>
	<i>Lactobacillus paracasei</i>
115	<i>Lactobacillus casei</i> subsp. <i>casei</i>
	<i>Lactococcus garvieae</i>
	<i>Lactococcus lactis</i>
	<i>Lactococcus lactis</i> subsp. <i>lactis</i>
	<i>Leclercia adecarboxylata</i>
	<i>Legionella micdadei</i>

Table 4. Example of microbial species for which *tuf* and/or *atpD* and/or *recA* nucleic acids and/ or sequences are used in the present invention (continued).

	Bacterial species (continued)
5	
	<i>Legionella pneumophila</i> subsp. <i>pneumophila</i>
	<i>Leminorella grimontii</i>
	<i>Leminorella richardii</i>
10	<i>Leptospira biflexa</i>
	<i>Leptospira interrogans</i>
	<i>Leuconostoc mesenteroides</i> subsp. <i>dextranicum</i>
	<i>Listeria innocua</i>
15	<i>Listeria ivanovii</i>
	<i>Listeria monocytogenes</i>
	<i>Listeria seeligeri</i>
	<i>Macrococcus caseolyticus</i>
	<i>Magnetospirillum magnetotacticum</i>
20	<i>Megamonas hypermegale</i>
	<i>Methanobacterium thermoautotrophicum</i>
	<i>Methanococcus jannaschii</i>
	<i>Methanococcus vannielii</i>
	<i>Methanosarcina barkeri</i>
25	<i>Methanosarcina jannaschii</i>
	<i>Methyllobacillus flagellatum</i>
	<i>Methylomonas clara</i>
	<i>Micrococcus luteus</i>
	<i>Micrococcus tylae</i>
30	<i>Mitsuokella multacidus</i>
	<i>Mobiluncus curtisi</i> subsp. <i>holmesii</i>
	<i>Moellerella thermoacetica</i>
	<i>Moellerella wisconsensis</i>
	<i>Moorella thermoacetica</i>
35	<i>Moraxella catarrhalis</i>
	<i>Moraxella osloensis</i>
	<i>Morganella morganii</i> subsp. <i>morganii</i>
	<i>Mycobacterium avium</i>
	<i>Mycobacterium bovis</i>
40	<i>Mycobacterium gordoneae</i>
	<i>Mycobacterium kansasii</i>
	<i>Mycobacterium leprae</i>
	<i>Mycobacterium terrae</i>
	<i>Mycobacterium tuberculosis</i>
45	<i>Mycoplasma capricolum</i>
	<i>Mycoplasma gallisepticum</i>
	<i>Mycoplasma genitalium</i>
	<i>Mycoplasma hominis</i>
	<i>Mycoplasma pirum</i>
50	<i>Mycoplasma mycoides</i>
	<i>Mycoplasma pneumoniae</i>
	<i>Mycoplasma pulmonis</i>
	<i>Mycoplasma salivarium</i>
	<i>Myxococcus xanthus</i>
55	<i>Neisseria animalis</i>
	<i>Neisseria canis</i>
	<i>Neisseria cinerea</i>
	<i>Neisseria cuniculi</i>
	<i>Neisseria elongata</i> subsp. <i>elongata</i>
60	<i>Neisseria elongata</i> subsp. <i>intermedia</i>
	<i>Neisseria flava</i>
	<i>Neisseria flavescens</i>
	<i>Neisseria gonorrhoeae</i>
	<i>Neisseria lactamica</i>
	<i>Neisseria meningitidis</i>
	<i>Neisseria mucosa</i>
	<i>Neisseria perflava</i>
	<i>Neisseria pharyngis</i> var. <i>flava</i>
	<i>Neisseria polysaccharea</i>
	<i>Neisseria sicca</i>
	<i>Neisseria subflava</i>
	<i>Neisseria weaveri</i>
	<i>Obesumbacterium proteus</i>
	<i>Ochrobactrum anthropi</i>
	<i>Pantoea agglomerans</i>
	<i>Pantoea dispersa</i>
	<i>Paracoccus denitrificans</i>
	<i>Pasteurella multocida</i>
	<i>Pectinatus frisingensis</i>
	<i>Peptococcus niger</i>
	<i>Peptostreptococcus anaerobius</i>
	<i>Peptostreptococcus asaccharolyticus</i>
	<i>Peptostreptococcus prevotii</i>
	<i>Phormidium ectocarpi</i>
	<i>Pirellula marina</i>
	<i>Planobispora rosea</i>
	<i>Plesiomonas shigelloides</i>
	<i>Plectonema boryanum</i>
	<i>Porphyromonas asaccharolytica</i>
	<i>Porphyromonas gingivalis</i>
	<i>Pragia fontium</i>
	<i>Prevotella buccalis</i>
	<i>Prevotella melaninogenica</i>
	<i>Prevotella oralis</i>
	<i>Prevotella ruminocola</i>
	<i>Prochlorothrix hollandica</i>
	<i>Propionibacterium acnes</i>
	<i>Propionigenium modestum</i>
	<i>Proteus mirabilis</i>
	<i>Proteus penneri</i>
	<i>Proteus vulgaris</i>
	<i>Providencia alcalifaciens</i>
	<i>Providencia rettgeri</i>
	<i>Providencia rustigianii</i>
	<i>Providencia stuartii</i>
	<i>Pseudomonas aeruginosa</i>
	<i>Pseudomonas fluorescens</i>
	<i>Pseudomonas putida</i>
	<i>Pseudomonas stutzeri</i>
	<i>Psychrobacter phenylpyruvicum</i>
	<i>Pyrococcus abyssi</i>
	<i>Rahnella aquatilis</i>
	<i>Rickettsia prowazekii</i>
	<i>Rhizobium leguminosarum</i>
	<i>Rhizobium phaseoli</i>
	<i>Rhodobacter capsulatus</i>
	<i>Rhodobacter sphaeroides</i>

Table 4. Example of microbial species for which *tuf* and/or *atpD* and/or *recA* nucleic acids and/or sequences are used in the present invention (continued).

5	Bacterial species (continued)
10	<i>Rhodopseudomonas palustris</i> <i>Rhodospirillum rubrum</i> <i>Ruminococcus albus</i> <i>Ruminococcus bromii</i> <i>Salmonella bongori</i> <i>Salmonella choleraesuis</i> subsp. <i>arizonae</i> <i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> <i>Salmonella choleraesuis</i> subsp. <i>diarizonae</i> <i>Salmonella choleraesuis</i> subsp. <i>houtenae</i> <i>Salmonella choleraesuis</i> subsp. <i>indica</i> <i>Salmonella choleraesuis</i> subsp. <i>salamae</i> <i>Serpulina hyoilectariae</i> <i>Serratia ficaria</i> <i>Serratia fonticola</i> 25 <i>Serratia grimesii</i> <i>Serratia liquefaciens</i> <i>Serratia marcescens</i> <i>Serratia odorifera</i> <i>Serratia plymuthica</i> <i>Serratia rubidaea</i> <i>Shewanella putrefaciens</i> <i>Shigella boydii</i> <i>Shigella dysenteriae</i> 35 <i>Shigella flexneri</i> <i>Shigella sonnei</i> <i>Sinorhizobium meliloti</i> <i>Spirochaeta aurantia</i> <i>Staphylococcus aureus</i> 40 <i>Staphylococcus aureus</i> subsp. <i>aureus</i> <i>Staphylococcus auricularis</i> <i>Staphylococcus capitis</i> subsp. <i>capitis</i> <i>Staphylococcus cohnii</i> subsp. <i>cohnii</i> <i>Staphylococcus epidermidis</i> <i>Staphylococcus haemolyticus</i> 45 <i>Staphylococcus hominis</i> <i>Staphylococcus hominis</i> subsp. <i>hominis</i> <i>Staphylococcus lugdunensis</i> <i>Staphylococcus saprophyticus</i> <i>Staphylococcus sciuri</i> subsp. <i>sciuri</i> 50 <i>Staphylococcus simulans</i> <i>Staphylococcus warneri</i> <i>Stigmatella aurantiaca</i> <i>Stenotrophomonas maltophilia</i> <i>Streptococcus acidominimus</i> 55 <i>Streptococcus agalactiae</i> <i>Streptococcus anginosus</i> <i>Streptococcus bovis</i> <i>Streptococcus cricetus</i> <i>Streptococcus cristatus</i> 60 <i>Streptococcus downei</i> <i>Streptococcus dysgalactiae</i> <i>Streptococcus equi</i> subsp. <i>equi</i> <i>Streptococcus ferus</i>
65	<i>Streptococcus gordonii</i> <i>Streptococcus macacae</i> <i>Streptococcus mitis</i> <i>Streptococcus mutans</i> <i>Streptococcus oralis</i> <i>Streptococcus parasanguinis</i> 70 <i>Streptococcus pneumoniae</i> <i>Streptococcus pyogenes</i> <i>Streptococcus ratti</i> <i>Streptococcus salivarius</i> <i>Streptococcus salivarius</i> subsp. <i>thermophilus</i> <i>Streptococcus sanguinis</i> <i>Streptococcus sobrinus</i> <i>Streptococcus suis</i> <i>Streptococcus uberis</i> 75 <i>Streptococcus vestibularis</i> <i>Streptomyces anbofaciens</i> <i>Streptomyces aureofaciens</i> <i>Streptomyces cinnamoneus</i> <i>Streptomyces coelicolor</i> <i>Streptomyces collinus</i> 80 <i>Streptomyces lividans</i> <i>Streptomyces netropsis</i> <i>Streptomyces ramocissimus</i> <i>Streptomyces rimosus</i> <i>Streptomyces venezuelae</i> 85 <i>Succinivibrio dextrinosolvens</i> <i>Synechococcus</i> sp. <i>Synechocystis</i> sp. <i>Tatumella ptyseos</i> <i>Taxobacter occetus</i> 90 <i>Tetragenococcus halophilus</i> <i>Thermoplasma acidophilum</i> <i>Thermotoga maritima</i> <i>Thermus aquaticus</i> <i>Thermus thermophilus</i> 95 <i>Thiobacillus ferrooxidans</i> <i>Thiomonas cuprina</i> <i>Trabulsiella guamensis</i> <i>Treponema pallidum</i> <i>Ureaplasma urealyticum</i> 100 <i>Veillonella parvula</i> <i>Vibrio alginolyticus</i> <i>Vibrio anguillarum</i> <i>Vibrio cholerae</i> <i>Vibrio mimicus</i> 105 <i>Wolinella succinogenes</i> <i>Xanthomonas citri</i> <i>Xanthomonas oryzae</i> <i>Xenorhabdus bovieni</i> <i>Xenorhabdus nematophilus</i> 110 <i>Yersinia bercovieri</i> <i>Yersinia enterocolitica</i> <i>Yersinia frederiksenii</i> <i>Yersinia intermedia</i> <i>Yersinia pestis</i>

Table 4. Example of microbial species for which *tuf* and/or *atpD* and/or *recA* nucleic acids and/or sequences are used in the present invention (continued).

5	Bacterial species (continued)
	<i>Yersinia pseudotuberculosis</i>
	<i>Yersinia rohdei</i>
	<i>Yokenella regensburgei</i>
10	<i>Zoogloea ramigera</i>

Table 4. Example of microbial species for which *tuf* and/or *atpD* and/or *recA* nucleic acids and/or sequences are used in the present invention (continued).

	Fungal species
5	
10	<i>Absidia corymbifera</i> <i>Absidia glauca</i> <i>Alternaria alternata</i> <i>Arxula adeninivorans</i> <i>Aspergillus flavus</i> <i>Aspergillus fumigatus</i> <i>Aspergillus nidulans</i> <i>Aspergillus niger</i> <i>Aspergillus oryzae</i> <i>Aspergillus terreus</i> <i>Aspergillus versicolor</i> <i>Aureobasidium pullulans</i> <i>Basidiobolus ranarum</i> <i>Bipolaris hawaiiensis</i> <i>Bilophila wadsworthia</i> <i>Blastoschizomyces capitatus</i> <i>Blastomycetes dermatitidis</i> <i>Candida albicans</i> <i>Candida catenulata</i> <i>Candida dubliniensis</i> <i>Candida famata</i> <i>Candida glabrata</i> <i>Candida guilliermondii</i> <i>Candida haemulonii</i> <i>Candida inconspicua</i> <i>Candida kefyr</i> <i>Candida krusei</i> <i>Candida lambica</i> <i>Candida lusitaniae</i> <i>Candida norvegica</i> <i>Candida norvegensis</i> <i>Candida parapsilosis</i> <i>Candida rugosa</i> <i>Candida sphaerica</i> <i>Candida tropicalis</i> <i>Candida utilis</i> <i>Candida viswanathii</i> <i>Candida zeylanoides</i> <i>Cladophialophora carriionii</i> <i>Coccidioides immitis</i> <i>Coprinus cinereus</i> <i>Cryptococcus albidus</i> <i>Cryptococcus humicolus</i> <i>Cryptococcus laurentii</i> <i>Cryptococcus neoformans</i> <i>Cunninghamella bertholletiae</i> <i>Curvularia lunata</i> <i>Emericella nidulans</i> <i>Emmonsia parva</i> <i>Eremothecium gossypii</i> <i>Exophiala dermatitidis</i> <i>Exophiala jeanselmei</i> <i>Exophiala moniliae</i> <i>Exserohilum rostratum</i> <i>Eremothecium gossypii</i> <i>Fonsecaea pedrosoi</i>
15	<i>Fusarium moniliforme</i> <i>Fusarium oxysporum</i> <i>Fusarium solani</i> <i>Geotrichum sp.</i> <i>Histoplasma capsulatum</i> <i>Hortaea werneckii</i> <i>Issatchenkia orientalis Kudrjanzev</i> <i>Kluyveromyces lactis</i> <i>Malassezia furfur</i> <i>Malassezia pachydermatis</i> <i>Malbranchea filamentosa</i> <i>Metschnikowia pulcherrima</i> <i>Microsporum audouinii</i> <i>Microsporum canis</i> <i>Mucor circinelloides</i> <i>Neurospora crassa</i> <i>Paecilomyces lilacinus</i> <i>Paracoccidioides brasiliensis</i> <i>Penicillium marneffei</i> <i>Phialaphora verrucosa</i> <i>Pichia anomala</i> <i>Piedraia hortai</i> <i>Podospora anserina</i> <i>Podospora curvicolla</i> <i>Puccinia graminis</i> <i>Pseudallescheria boydii</i> <i>Reclinomonas americana</i> <i>Rhizomucor racemosus</i> <i>Rhizopus oryzae</i> <i>Rhodotorula minuta</i> <i>Rhodotorula mucilaginosa</i> <i>Saccharomyces cerevisiae</i> <i>Saksenaea vasiformis</i> <i>Schizosaccharomyces pombe</i> <i>Scopulariopsis koningii</i> <i>Sordaria macrospora</i> <i>Sporobolomyces salmonicolor</i> <i>Sporothrix schenckii</i> <i>Stephanoascus ciferrii</i> <i>Syncephalastrum racemosum</i> <i>Trichoderma reesei</i> <i>Trichophyton mentagrophytes</i> <i>Trichophyton rubrum</i> <i>Trichophyton tonsurans</i> <i>Trichosporon cutaneum</i> <i>Ustilago maydis</i> <i>Wangiella dermatitidis</i> <i>Yarrowia lipolytica</i>
20	65
25	70
30	75
35	80
40	85
45	90
50	95
55	100
60	105
	110

Table 4. Example of microbial species for which *tuf* and/or *atpD* and/or *recA* nucleic acids and/or sequences are used in the present invention (continued).

	Parasitical species
5	<i>Babesia bigemina</i> <i>Babesia bovis</i> <i>Babesia microti</i> <i>Blastocystis hominis</i>
10	<i>Crithidia fasciculata</i> <i>Cryptosporidium parvum</i> <i>Entamoeba histolytica</i> <i>Giardia lamblia</i>
15	<i>Kentrophoros</i> sp. <i>Leishmania aethiopica</i> <i>Leishmania amazonensis</i> <i>Leishmania braziliensis</i> <i>Leishmania donovani</i> <i>Leishmania infantum</i>
20	<i>Leishmania enriettii</i> <i>Leishmania gerbilli</i> <i>Leishmania guyanensis</i> <i>Leishmania hertigi</i> <i>Leishmania major</i>
25	<i>Leishmania mexicana</i> <i>Leishmania panamensis</i> <i>Leishmania tarentolae</i> <i>Leishmania tropica</i> <i>Neospora caninum</i>
30	<i>Onchocerca volvulus</i> <i>Plasmodium berghei</i> <i>Plasmodium falciparum</i> <i>Plasmodium knowlesi</i>
35	<i>Porphyra purpurea</i> <i>Toxoplasma gondii</i> <i>Treponema pallidum</i> <i>Trichomonas tenax</i> <i>Trichomonas vaginalis</i>
40	<i>Trypanosoma brucei</i> <i>Trypanosoma brucei</i> subsp. <i>brucei</i> <i>Trypanosoma congoense</i> <i>Trypanosoma cruzi</i>

Table 5. Antimicrobial agents resistance genes selected for diagnostic purposes.

	Gene	Antimicrobial agent	Bacteria ¹	ACCESSION NO.	SEQ ID NO.
5	<i>aac(3)-Ib</i> ²	Aminoglycosides	<i>Enterobacteriaceae</i> <i>Pseudomonads</i>	L06157	
	<i>aac(3)-IIb</i> ²	Aminoglycosides	<i>Enterobacteriaceae,</i> <i>Pseudomonads</i>	M97172	
10	<i>aac(3)-IVa</i> ²	Aminoglycosides	<i>Enterobacteriaceae</i>	X01385	
	<i>aac(3)-Vla</i> ²	Aminoglycosides	<i>Enterobacteriaceae,</i> Pseudomonads	M88012	
	<i>aac(2')-Ia</i> ²	Aminoglycosides	<i>Enterobacteriaceae,</i> Pseudomonads	X04555	
15	<i>aac(6')-aph(2'')</i> ²	Aminoglycosides	<i>Enterococcus</i> sp., <i>Staphylococcus</i> sp.		83-86 ³
	<i>aac(6')-Ia</i> ²	Aminoglycosides	<i>Enterobacteriaceae,</i> Pseudomonads	M18967	
	<i>aac(6')-Ic</i> ²	Aminoglycosides	<i>Enterobacteriaceae,</i> Pseudomonads	M94066	
20	<i>aac(6')-IIa</i> ²	Aminoglycosides	Pseudomonads		112 ⁴
	<i>aadB [ant(2")-Ia</i> ²]	Aminoglycosides	<i>Enterobacteriaceae</i>		53-54 ³
	<i>aacC1 [aac(3)-Ia</i> ²]	Aminoglycosides	Pseudomonads		55-56 ³
	<i>aacC2 [aac(3)-IIa</i> ²]	Aminoglycosides	Pseudomonads		57-58 ³
	<i>aacC3 [aac(3)-III</i> ²]	Aminoglycosides	Pseudomonads		59-60 ³
25	<i>aacA4 [aac(6')-Ib</i> ²]	Aminoglycosides	Pseudomonads		65-66 ³
	<i>ant(3")-Ia</i> ²	Aminoglycosides	<i>Enterobacteriaceae,</i> <i>Enterococcus</i> sp., <i>Staphylococcus</i> sp.	X02340 M10241	
30	<i>ant(4')-Ia</i> ²	Aminoglycosides	<i>Staphylococcus</i> sp.	V01282	
	<i>aph(3')-Ia</i> ²	Aminoglycosides	<i>Enterobacteriaceae,</i> Pseudomonads	J01839	
	<i>aph(3')-IIa</i> ²	Aminoglycosides	<i>Enterobacteriaceae,</i> Pseudomonads	V00618	
35	<i>aph(3')-IIIa</i> ²	Aminoglycosides	<i>Enterococcus</i> sp., <i>Staphylococcus</i> sp.	V01547	
	<i>aph(3')-VIa</i> ²	Aminoglycosides	<i>Enterobacteriaceae,</i> Pseudomonads	X07753	
	<i>rpsL</i> ²	Streptomycin	<i>M. tuberculosis,</i> <i>M. avium complex</i>	X80120 U14749 X70995 L08011	
40					
	<i>blaOXA</i> ^{5,6}	β-lactams	<i>Enterobacteriaceae,</i> Pseudomonads	Y10693 AJ238349 AJ009819 X06046 X03037 X07260 U13880 X75562 AF034958 J03427 Z22590 U59183 L38523 U63835 AF043100 AF060206 U85514 AF043381 AF024602 AF064820	110 ⁴
45					
50					
55					
60					
65	<i>blaROB</i> ⁵	β-lactams	<i>Haemophilus</i> sp. <i>Pasteurella</i> sp.		45-48 ³

Table 5. Antimicrobial agents resistance genes selected for diagnostic purposes (continued).

Gene	Antimicrobial agent	Bacteria ¹	ACCESSION NO.	SEQ ID NO.	
5	<i>blaSHV</i> ^{5,6}	β-lactams	<i>Enterobacteriaceae,</i> <i>Pseudomonas aeruginosa</i>	AF124984 AF148850 M59181 X98099 M33655 AF148851 X53433 L47119 AF074954 X53817 AF096930 X55640 Y11069 U20270 U92041 S82452 X98101 X98105 AF164577 AJ011428 AF116855 AB023477 AF293345 AF227204 AF208796 AF132290	41-44 ³
10					
15					
20					
25					
30	<i>blaTEM</i> ^{5,6}	β-lactams	<i>Enterobacteriaceae,</i> <i>Neisseria</i> sp., <i>Haemophilus</i> sp.	AF012911 U48775 AF093512 AF052748 X64523 Y13612 X57972 AF157413 U31280 U36911 U48775 V00613 X97254 AJ012256 X04515 AF126482 U09188 M88143 Y14574 AF188200 AJ251946 Y17581 Y17582 Y17583 M88143 U37195 Y17584 X64523 U95363 Y10279 Y10280 Y10281 AF027199 AF104441 AF104442 AF062386 X57972 AF047171 AF188199 AF157553 AF190694 AF190695 AF190693 AF190692	37-40 ³
35					
40					
45					
50					
55					
60					
65					
70					
75					

Table 5. Antimicrobial agents resistance genes selected for diagnostic purposes (continued).

	Gene	Antimicrobial agent	Bacteria ¹	ACCESSION NO.	SEQ ID NO.
5	<i>blaCARB</i> ⁵	β-lactams	<i>Pseudomonas</i> sp., <i>Enterobacteriaceae</i>	J05162 S46063 M69058 U14749 D86225 D13210 Z18955 AF071555 AF153200 AF030945	
10					
15	<i>blaCTX-M-1</i> ⁵	β-lactams	<i>Enterobacteriaceae</i>	X92506	
20	<i>blaCTX-M-2</i> ⁵	β-lactams	<i>Enterobacteriaceae</i>	X92507	
	<i>blaCMY-2</i> ⁷	β-lactams	<i>Enterobacteriaceae</i>	X91840 AJ007826 AJ011293 AJ011291 Y17716 Y16783	
25				Y16781 Y15130 U77414 S83226 Y15412	
30	<i>blaIMP</i> ⁵	β-lactams	<i>Enterobacteriaceae,</i> <i>Pseudomonas aeruginosa</i>	AJ223604 S71932 D50438 D29636 X98393	
35				AB010417 D78375	
	<i>blaPER-1</i> ⁵	β-lactams	<i>Enterobacteriaceae,</i> <i>Pseudomonadaceae</i>	Z21957	
40	<i>blaPER-2</i> ⁷	β-lactams	<i>Enterobacteriaceae</i>	X93314	
	<i>blaZ</i> ¹²	β-lactams	<i>Enterococcus</i> sp., <i>Staphylococcus</i> sp.		111 ⁴
	<i>mecA</i> ¹²	β-lactams	<i>Staphylococcus</i> sp.		97-98 ³

Table 5. Antimicrobial agents resistance genes selected for diagnostic purposes (continued).

Gene	Antimicrobial agent	Bacteria ¹	ACCESSION NO.	SEQ ID NO.	
5 <i>pbp1a</i> ¹³	β-lactams	<i>Streptococcus pneumoniae</i>	M90527 X67872 AB006868 AB006874 X67873 AB006878 AB006875 AB006877 AB006879 AF046237 AF046235 AF026431 AF046232 AF046233 AF046236 X67871 Z49095 AF046234 AB006873 X67866 X67868 AB006870 AB006869 AB006872 X67870 AB006871 X67867 X67869 AB006876 AF046230 AF046238 Z49094	1004-1018, 1648,2056-2064, 2273-2276	
10					
15					
20					
25					
30					
35					
40 <i>pbp2b</i> ¹³	β-lactams	<i>Streptococcus pneumoniae</i>	X16022 M25516 M25518 M25515 U20071 U20084 U20082 U20067 U20079 Z22185 U20072 U20083 U20081 M25522 U20075 U20070 U20077 U20068 Z22184 U20069 U20078 M25521 M25525 M25519 Z21981 M25523 M25526 U20076 U20074 M25520 M25517 M25524 Z22230 U20073 U20080	1019-1033	
45					
50 <i>pbp2b</i> ¹³	β-lactams	<i>Streptococcus pneumoniae</i>	U20083 U20081 M25522 U20075 U20070 U20077 U20068 Z22184 U20069 U20078 M25521 M25525 M25519 Z21981 M25523 M25526 U20076 U20074 M25520 M25517 M25524 Z22230 U20073 U20080		
55					
60					
65					
70					
75					

Table 5. Antimicrobial agents resistance genes selected for diagnostic purposes (continued).

Gene	Antimicrobial agent	Bacteria ¹	ACCESSION NO.	SEQ ID NO.
5 <i>pbp2x</i> ¹³	β-lactams	<i>Streptococcus pneumoniae</i>		1034-1048
			X16367	
			X65135	
10			AB011204	
			AB011209	
			AB011199	
			AB011200	
			AB011201	
			AB011202	
15			AB011198	
			AB011208	
			AB011205	
			AB015852	
20			AB011210	
			AB015849	
			AB015850	
			AB015851	
			AB015847	
25			AB015846	
			AB011207	
			AB015848	
			Z49096	
	<i>int</i>	-lactams, trimethoprim	<i>Enterobacteriaceae</i> ,	99-102 ³
30	<i>sul</i>	aminoglycosides, antiseptic,	Pseudomonads	103-106 ³
	<i>ermA</i> ¹⁴	chloramphenicol	<i>Staphylococcus</i> sp.	113 ⁴
35	<i>ermB</i> ¹⁴	Macrolides, lincosamides, streptogramin B	<i>Enterobacteriaceae</i> , <i>Staphylococcus</i> sp.	114 ⁴
		Macrolides,	<i>Enterococcus</i> sp.	
40	<i>ermC</i> ¹⁴	lincosamides, streptogramin B	<i>Streptococcus</i> sp.	115 ⁴
		Macrolides,	<i>Enterobacteriaceae</i> ,	
		lincosamides,	<i>Staphylococcus</i> sp.	
45	<i>ereA</i> ¹²	Macrolides	<i>Enterobacteriaceae</i> , <i>Staphylococcus</i> sp.	M11277
	<i>ereB</i> ¹²	Macrolides	<i>Enterobacteriaceae</i>	E01199
50	<i>mraA</i> ¹²	Macrolides	<i>Staphylococcus</i> sp.	AF099140
	<i>mefA</i> , <i>mefE</i> ⁸	Macrolides	<i>Staphylococcus</i> sp.	A15097
	<i>mphA</i> ⁸	Macrolides	<i>Enterobacteriaceae</i> , <i>Staphylococcus</i> sp.	X03988
55	<i>linA</i> / <i>linA'</i> ⁹	Lincosamides	<i>Staphylococcus</i> sp.	77-80 ³
			J03947	
60	<i>linB</i> ¹⁰	Lincosamides	<i>Enterococcus faecium</i>	M14039
			A15070	
			E01245	
			AF110130	
			AJ238249	
65	<i>vga</i> ¹⁵	Streptogramin	<i>Staphylococcus</i> sp.	M90056
	<i>vgb</i> ¹⁵	Streptogramin	<i>Staphylococcus</i> sp.	U82085
			M36022	
			M20219	
			AF015628	

Table 5. Antimicrobial agents resistance genes selected for diagnostic purposes (continued).

	Gene	Antimicrobial agent	Bacteria ¹	ACCESSION NO.	SEQ ID NO.
5	<i>val</i> 15 <i>valB</i> 15	Streptogramin Streptogramin	<i>Staphylococcus</i> sp. <i>Staphylococcus</i> sp.	L07778 U19459 L38809	87-88 ³
10	<i>satA</i> 15 <i>mupA</i> 12	Streptogramin Mupirocin	<i>Enterococcus faecium</i> <i>Staphylococcus aureus</i>	L12033 X75439 X59478 X59477	81-82 ³
15	<i>gyrA</i> 16	Quinolones	Gram-positive and gram-negative bacteria	X95718 X06744 X57174 X16817 X71437	1255, 1607-1608, 1764-1776, 2013-2014, 2277-2280
20	<i>parC/grlA</i> 16	Quinolones	Gram-positive and gram-negative bacteria	AF065152 AF060881 D32252 AB005036 AF056287 X95717 AF129764 AB017811 AF065152	1777-1785
25	<i>parE/grlB</i> 16	Quinolones	Gram-positive bacteria	X95717 AF065153 AF058920	
30	<i>norA</i> 16	Quinolones	<i>Staphylococcus</i> sp.	D90119 M80252 M97169	
35	<i>mexR</i> (<i>palB</i>) 16 <i>nfxB</i> 16 <i>cat</i> 12	Quinolones Quinolones Chloramphenicol	<i>Pseudomonas aeruginosa</i> <i>Pseudomonas aeruginosa</i> Gram-positive and gram-negative bacteria	U23763 X65646 M55620 X15100 A24651 M28717	
40				A00568 A00569 X74948 Y00723	
45				A24362 A00569 M93113 M62822 M58516 V01277	
50				X02166 M77169 X53796 J01841 X07848	
55	<i>ppflo</i> -like <i>embB</i> 17 <i>pncA</i> 17	Chloramphenicol Ethambutol Pyrazinamide	<i>Mycobacterium tuberculosis</i> <i>Mycobacterium tuberculosis</i>	AF071555 U68480 U59967	
60	<i>rpoB</i> 17	Rifampin	<i>Mycobacterium tuberculosis</i>	AF055891 AF055892 S71246 L27989 AF055893 AF106077 U02492	
65	<i>inhA</i> 17	Isoniazid	<i>Mycobacterium tuberculosis</i>		

Table 5. Antimicrobial agents resistance genes selected for diagnostic purposes (continued).

	Gene	Antimicrobial agent	Bacteria ¹	ACCESSION NO.	SEQ ID NO.
5	<i>vanA</i> ¹²	Vancomycin	<i>Enterococcus</i> sp.		67-70 ³
	<i>vanB</i> ¹²	Vancomycin	<i>Enterococcus</i> sp.		1049-1057
10	<i>vanC1</i> ¹²	Vancomycin	<i>Enterococcus gallinarum</i>		116 ⁴
	<i>vanC2</i> ¹²	Vancomycin	<i>Enterococcus casseliflavus</i>		117 ⁴
					1058-1059
					1060-1063
15				U94521 U94522 U94523 U94524 U94525 L29638	
	<i>vanC3</i> ¹²	Vancomycin	<i>Enterococcus flavescentis</i>		1064-1066
20	<i>vanD</i> ¹⁸	Vancomycin	<i>Enterococcus faecium</i>	L29639	
	<i>vanE</i> ¹²	Vancomycin	<i>Enterococcus faecium</i>	U72706	
	<i>tetB</i> ¹⁹	Tetracycline	Gram-negative bacteria	AF130997 AF136925 J01830 AF162223 AP000342 S83213 U81141 V00611	
25				X52632 AF116348 U50983 X92947 M211136 U08812 X04388	
30	<i>teiM</i> ¹⁹	Tetracycline	Gram-negative and Gram-positive bacteria	M36657 AF017389 AF017391 AJ238350 X17477 K00052 U09476 X00926	
35	<i>sul II</i> ²⁰	Sulfonamides	Gram-negative bacteria	Z50805 Z50804	
40	<i>dhfrIa</i> ²⁰	Trimethoprim	Gram-negative bacteria	X12868 Z86002 U31119 AF139109	
45	<i>dhfrIb</i> ²⁰	Trimethoprim	Gram-negative bacteria	X58425 U10186 U09273	
	<i>dhfrV</i> ²⁰	Trimethoprim	Gram-negative bacteria	X57730 Z21672	
	<i>dhfrVI</i> ²⁰	Trimethoprim	Gram-negative bacteria	AF175203 AF180731	
	<i>dhfrVII</i> ²⁰	Trimethoprim	Gram-negative bacteria	M84522	
50	<i>dhfrVIII</i> ²⁰	Trimethoprim	Gram-negative bacteria	Z50802 Z83331	
	<i>dhfrIX</i> ²⁰	Trimethoprim	Gram-negative bacteria	AF170088	
55	<i>dhfrXII</i> ²⁰	Trimethoprim	Gram-negative bacteria	AF180469 AF169041	
	<i>dhfrXIII</i> ²⁰	Trimethoprim	Gram-negative bacteria		
	<i>dhfrXV</i> ²⁰	Trimethoprim	Gram-negative bacteria		
60	<i>dhfrXVII</i> ²⁰	Trimethoprim	Gram-negative bacteria		

Table 5. Antimicrobial agents resistance genes selected for diagnostic purposes (continued).

Gene	Antimicrobial agent	Bacteria ¹	ACCESSION NO.	SEQ ID NO.
5 <i>dfra</i> ²⁰	Trimethoprim	<i>Staphylococcus</i> sp.	AF045472 U40259 AF051916 X13290 Y07536 Z16422 Z48233	
10				
15				
20	1 Bacteria having high incidence for the specified antibiotic resistance gene. The presence of the antibiotic resistance genes in other bacteria is not excluded. 2 Shaw, K. J., P. N. Rather, R. S. Hare, and G. H. Miller. 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. <i>Microbiol. Rev.</i> 57:138-163. 3 Antibiotic resistance genes from our assigned US patent no. 6,001,564 for which we have selected PCR primer pairs. 4 These SEQ ID NOs. refer to a previous patent (publication WO98/20157). 5 Bush, K., G.A. Jacoby and A. Medeiros. 1995. A functional classification scheme for β -lactamase and its correlation with molecular structure. <i>Antimicrob. Agents. Chemother.</i> 39:1211-1233. 6 Nucleotide mutations in blaSHV, blaTEM, and blaOXA, are associated with extended-spectrum β -lactamase or inhibitor-resistant β -lactamase. 7 Bauerfeind, A., Y. Chong, and K. Lee. 1998. Plasmid-encoded AmpC beta-lactamases: how far have we gone 10 ears after discovery? <i>Yonsei Med. J.</i> 39:520-525. 8 Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. <i>Antimicrob. Agent Chemother.</i> 40:2562-2566. 9 Leclerc, R., A., Brisson-Noël, J. Duval, and P. Courvalin. 1991. Phenotypic expression and genetic heterogeneity of lincosamide inactivation in <i>Staphylococcus</i> sp. <i>Antimicrob. Agents. Chemother.</i> 35:1887-1891.			
25	10 Bozdogan, B., L. Berrezouga, M.-S. Kuo, D. A. Yurek, K. A. Farley, B. J. Stockman, and R. Leclercq. 1999. A new gene, linB, conferring resistance to lincosamides by nucleotidylation in <i>Enterococcus faecium</i> HM1025. <i>Antimicrob. Agents. Chemother.</i> 43:925-929. 11 Cockerill III, F.R. 1999. Genetic methods for assessing antimicrobial resistance. <i>Antimicrob. Agents. Chemother.</i> 43:199-212. 12 Tenover, F. C., T. Popovic, and O Olsvik. 1996. Genetic methods for detecting antibacterial resistance genes. pp. 1368-1378. In Murray, P. R., E. J. Baron, M. A. Pfaffer, F. C. Tenover, R. H. Yolken (eds). <i>Manual of clinical microbiology</i> . 6th ed., ASM Press, Washington, D.C. USA 13 Dowson, C. G., T. J. Tracey, and B. G. Spratt. 1994. Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to β -lactam antibiotics. <i>Trends Molec. Microbiol.</i> 2: 361-366.			
30	14 Jensen, L. B., N. Frimodt-Møller, F. M. Aarestrup. 1999. Presence of erm gene classes in Gram-positive bacteria of animal and human origin in Denmark. <i>FEMS Microbiol.</i> 170:151-158. 15 Thal, L. A., and M. J. Zervos. 1999. Occurrence and epidemiology of resistance to virginiamycin and streptogramins. <i>J. Antimicrob. Chemother.</i> 43:171-176.			
35	16 Martinez J. L., A. Alonso, J. M. Gomez-Gomez, and F. Baquero. 1998. Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg? <i>J. Antimicrob. Chemother.</i> 42:683-688 17 Cockerill III, F.R. 1999. Genetic methods for assessing antimicrobial resistance. <i>Antimicrob. Agents. Chemother.</i> 43:199-212. 18 Casadewall, B. and P. Courvalin. 1999 Characterization of the vanD glycopeptide resistance gene cluster from <i>Enterococcus faecium</i> BM 4339. <i>J. Bacteriol.</i> 181:3644-3648.			
40	19 Roberts, M.C. 1999. Genetic mobility and distribution of tetracycline resistance determinants. <i>Ciba Found. Symp.</i> 207:206-222. 20 Huovinen, P., L. Sundström, G. Swedberg, and O. Sköld. 1995. Trimethoprim and sulfonamide resistance. <i>Antimicrob. Agent Chemother.</i> 39:279-289.			
45				
50				
55				
60				

Table 6. List of bacterial toxins selected for diagnostic purposes.

Organism	Toxin	Accession number
5 <i>Actinobacillus actinomycetemcomitans</i>	Cytotoxic distending toxin (<i>cdtA</i> , <i>cdtB</i> , <i>cdtC</i>)	AF006830
10 <i>Actinomyces pyogenes</i>	Leukotoxin (<i>ltxA</i>)	M27399
10 <i>Aeromonas hydrophila</i>	Hemolysin (<i>pyolysin</i>)	U84782
10	Aerolysin (<i>aerA</i>)	M16495
10	Haemolysin (<i>hlyA</i>)	U81555
15 <i>Bacillus anthracis</i>	Cytotonic enterotoxin (<i>alt</i>)	L77573
15 <i>Bacillus cereus</i>	Anthrax toxin (<i>cya</i>)	M23179
	Enterotoxin (<i>bceT</i>)	D17312
		AF192766, AF192767
20	Enterotoxic hemolysin BL	AJ237785
20 <i>Bacillus mycoides</i>	Non-haemolytic enterotoxins A,B and C (<i>nhe</i>)	Y19005
20 <i>Bacillus pseudomycoides</i>	Hemolytic enterotoxin HBL	AJ243150 to AJ243153
20 <i>Bacteroides fragilis</i>	Hemolytic enterotoxin HBL	AJ243154 to AJ243156
	Enterotoxin (<i>bftP</i>)	U67735
25	Matrix metalloprotease/enterotoxin (fragilysin)	S75941, AF038459
	Metalloprotease toxin-2	U90931 AF081785
30	Metalloprotease toxin-3	AF056297
	Adenylate cyclase hemolysin (<i>cyaA</i>)	Z37112, U22953
	Dermonecrotic toxin (<i>dnt</i>)	U59687 AB020025
35 <i>Bordetella pertussis</i>	Pertussis toxin (S1 subunit, <i>tox</i>)	AJ006151 AJ006153 AJ006155 AJ006157 AJ006159 AJ007363 M14378, M16494 AJ007364 M13223 X16347
40		
45	Adenyl cyclase (<i>cya</i>)	18323
50 <i>Campylobacter jejuni</i>	Dermonecrotic toxin (<i>dnt</i>)	U10527
50 <i>Citrobacter freundii</i>	Cytotoxic distending toxin (<i>cdtA</i> , <i>cdtB</i> , <i>cdtC</i>)	U51121
	Shiga-like toxin (<i>slt-IIcA</i>)	X67514, S53206
	Botulism toxin (BoNT) (A,B,E and F serotypes are neurotoxic for humans; the other serotypes have not been considered)	X52066, X52088 X73423 M30196 X70814 X70819 X71343 Z11934 X70817 M81186 X70818 X70815 X62089 X62683 S76749 X81714 X70816
55		
60		
65		

Table 6. List of bacterial toxins selected for diagnostic purposes (continued).

Organism	Toxin	Accession number	
5 <i>Clostridium botulinum</i> (continued)		X70820 X70281 L35496 M92906	
10 <i>Clostridium difficile</i>	A toxin (enterotoxin) (<i>tcdA</i>) (<i>cdtA</i>)	AB012304 AF053400 Y12616 X51797 X17194 M30307	
15	B toxin (cytotoxin) (<i>toxB</i>) (<i>cdtB</i>)	Z23277 X53138	
20	<i>Clostridium perfringens</i>	Alpha (phospholipase C) (<i>cpa</i>) L43545 L43546 L43547 L43548 X13608 X17300 D10248	
25	Beta (dermonecrotic protein) (<i>cpb</i>)	L13198 X83275 L77965	
30	Enterotoxin (<i>cpe</i>)	AJ000766 M98037 X81849 X71844 Y16009	
35	Enterotoxin pseudogene (not expressed)	AF037328 AF037329 AF037330	
40	Epsilon toxin (<i>etxD</i>)	M80837 M95206 X60694	
45	Iota (Ia and Ib)	X73562	
50	<i>Clostridium sordellii</i>	Lambda (metalloprotease)	D45904
	<i>Clostridium tetani</i>	Theta (perfringolysin O) Cytotoxin L Tetanospasmin	M36704 X82638 X06214 X04436
55	<i>Corynebacterium diphtheriae</i>	Diphtheriae toxin	X00703
	<i>Corynebacterium pseudotuberculosis</i>	Phospholipase C	A21336
60	<i>Eikenella corrodens</i> <i>Enterobacter cloacae</i> <i>Enterococcus faecalis</i> <i>Escherichia coli</i> (EHEC)	lysine decarboxylase (<i>cada</i>) Shiga-like toxin II Cytolysin B (<i>cylB</i>) Hemolysin toxin (<i>hlyA</i> and <i>ehxA</i>)	U89166 Z50754, U33502 M38052 AF043471 X94129 X79839 X86087 AB011549 AF074613

Table 6. List of bacterial toxins selected for diagnostic purposes (continued).

Organism	Toxin	Accession number	
5 <i>Escherichia coli</i> (EHEC)	Shiga-like (Vero cytotoxin) (<i>stx</i>)	X81418, M36727 M14107, E03962 M10133, E03959 M12863, X07865 X81417, Y10775 X81416, Z50754 X81415, X67515 Z36900, AF043627 L11078, M19473 L04539, M17358 L11079, M19437 X65949, M24352 M21534, X07903 M29153, Z36899 Z37725 Z36901 X61283 AB017524 U72191 X61283	X81418, M36727 M14107, E03962 M10133, E03959 M12863, X07865 X81417, Y10775 X81416, Z50754 X81415, X67515 Z36900, AF043627 L11078, M19473 L04539, M17358 L11079, M19437 X65949, M24352 M21534, X07903 M29153, Z36899 Z37725 Z36901 X61283 AB017524 U72191 X61283
10			
15			
20			
25 <i>Escherichia coli</i> (ETEC)	Enterotoxin (heat-labile) (<i>eltB</i>)	M17874 M17873 J01605 AB011677	
30	Enterotoxin (heat-stable) (<i>astA</i>) (<i>estA1</i>)	L11241 M58746 M29255 V00612 J01831	
35 <i>Escherichia coli</i> (other)	<i>Cytotoxic-distending toxin</i> (<i>cdt</i>) (3 genes)	U03293 U04208 U89305	
40			
45 <i>Haemophilus ducreyi</i> <i>Helicobacter pylori</i>	Cytotoxic necrotizing factor 1 (<i>cnf1</i>) Microcin 24 (<i>mfs</i>) Autotransporter enterotoxin (<i>Per</i>) (cytotoxin) Cytotoxic distending toxin (<i>cdtA</i> , <i>cdtB</i> , <i>cdtC</i>) Vacuolating toxin (<i>vacA</i>)	U42629 U47048 AF056581 U53215 U07145 U80067 U80068 AF077938 AF077939 AF077940 AF077941 AF057703 X15127 M24199 X60035 U25452 U25443 U25446 U25449	
50			
55 <i>Legionella pneumophila</i> <i>Listeria monocytogenes</i>	Structural toxin protein (<i>rtxA</i>) Listeriolysin O (<i>lisA</i> , <i>hlyA</i>)	AF057703 X15127 M24199 X60035 U25452 U25443 U25446 U25449	
60 <i>Pasteurella multocida</i>	Mitogenic toxin (dermonecrotic toxin)	X57775, Z28388 X51512 X52478	
65 <i>Proteus mirabilis</i> <i>Pseudomonas aeruginosa</i> <i>Salmonella typhimurium</i>	Hemolysin (<i>hpmA</i>) Cytotoxin (Enterotoxin A) Calmodulin-sensitive adenylate cyclase toxin (<i>cya</i>) Cytolysin (<i>salmolysin</i>) (<i>slyA</i>) Enterotoxin (<i>stn</i>)	M30186 X14956 AF060869 U03842 L16014	

Table 6. List of bacterial toxins selected for diagnostic purposes (continued).

Organism	Toxin	Accession number	
5 <i>Serratia marcescens</i>	Hemolysin (<i>shlA</i>)	M22618	
5 <i>Shigella dysenteriae</i> type 1	Shiga toxin (<i>stxA</i> and <i>stxB</i>)	X07903, M32511 M19437 M24352, M21947	
10 <i>Shigella flexneri</i>	ShET2 enterotoxin (<i>senA</i>)	Z54211 Z47381	
	Enterotoxin 1 (<i>set1A</i> and <i>set1B</i>)	U35656	
15 <i>Shigella sonnei</i>	Hemolysin E (<i>hlyE</i> , <i>clvA</i> , <i>sheA</i>)	AF200955	
	Shiga toxin (<i>stxA</i> and <i>stxB</i>)	AJ132761	
	Beta-hemolysin (<i>hlyA</i>)	L01270	
	Gamma-hemolysin (<i>hlg2</i>)	D42143 L01055	
20	Enterotoxin	U93688	
	Enterotoxin A (<i>sea</i>)	L22565, L22566 M18970	
25	Enterotoxin B	M11118	
	Enterotoxin C1 (<i>entC1</i>)	X05815	
30	Enterotoxin C2 (<i>entC2</i>)	P34071	
	Enterotoxin C3 (<i>entC3</i>)	X51661	
	Enterotoxin D (<i>sed</i>)	M94872	
35	Enterotoxin E	M21319	
	Enterotoxin G (<i>seg</i>)	AF064773	
	Enterotoxin H (<i>seh</i>)	U11702	
40	Enterotoxin I (<i>sei</i>)	AF064774	
	Enterotoxin J	AF053140	
45	Exfoliative toxin A (ETA, Epidermolytic toxin A)	M17347 M17357 L25372, M20371	
	Exfoliative toxin B (ETB)	M17348, M13775	
50	Leukocidin R (F and S component, <i>lukF</i> and <i>lukS</i> ; Hemolysin B and C)	X64389, S53213 X72700 L01055	
55	Toxic shock syndrome toxin 1 (TSST-1, alpha toxin, alpha hemolysin)	X01645 M90536 J02615 U93688	
60	<i>Staphylococcus epidermidis</i>	Delta toxin (<i>hld</i>)	AF068634
	<i>Staphylococcus intermedius</i>	Enterotoxin 1	U91526
	Leukocidin R (F and S component, <i>lukF</i> and <i>lukS</i> ; synergohymenotropic toxin)	X79188	
65 <i>Streptococcus pneumoniae</i>	Pneumolysin	X52474	

Table 6. List of bacterial toxins selected for diagnostic purposes (continued).

Organism	Toxin	Accession number
5 <i>Streptococcus pyogenes</i>	<i>Streptococcus</i> pyrogenic exotoxin A (<i>speA</i>)	X61553 to X61573 X03929 U40453, M19350
	Pyrogenic exotoxin B (<i>speB</i>) M86905, M35110	U63134
10 <i>Vibrio cholerae</i>	Cholerae toxin (<i>ctxA</i> and <i>ctxB</i> subunits)	X00171 X76390 X58786 X58785, S55782 D30052 D30053 K02679 AF175708
	Accessory cholera enterotoxin (<i>ace</i>)	Z22569, AF175708
20 <i>Vibrio parahaemolyticus</i>	Heat-stable enterotoxin (<i>sto</i>)	X74108, M85198 M97591, L03220
	<i>Zonula occludens</i> toxin (<i>zot</i>)	M83563, AF175708
25 <i>Vibrio vulnificus</i>	Thermostable direct hemolysin (<i>tdh</i>)	S67841
	Cytolysin (<i>vvhA</i>)	M34670
	<i>Yersinia enterocolitica</i>	U09235, X65999
30 <i>Yersinia kristensenii</i>	Heat-stable enterotoxin type B (<i>ystB</i>)	D88145
	Heat-stable enterotoxin type C (<i>ystC</i>)	D63578
	Enterotoxin X69218	
<i>Yersinia pestis</i>	Toxin	X92727

35

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing.

SEQ ID NO.		Archaeal, bacterial, fungal or parasitical species	Source Gene*
5	1	<i>Acinetobacter baumannii</i>	This patent <i>tuf</i>
	2	<i>Actinomyces meyeri</i>	This patent <i>tuf</i>
	3	<i>Aerococcus viridans</i>	This patent <i>tuf</i>
	4	<i>Achromobacter xylosoxidans</i> subsp. <i>denitrificans</i>	This patent <i>tuf</i>
	5	<i>Anaerorhabdus furcosus</i>	This patent <i>tuf</i>
10	6	<i>Bacillus anthracis</i>	This patent <i>tuf</i>
	7	<i>Bacillus cereus</i>	This patent <i>tuf</i>
	8	<i>Bacteroides distasonis</i>	This patent <i>tuf</i>
	9	<i>Enterococcus casseliflavus</i>	This patent <i>tuf</i>
	10	<i>Staphylococcus saprophyticus</i>	This patent <i>tuf</i>
15	11	<i>Bacteroides ovatus</i>	This patent <i>tuf</i>
	12	<i>Bartonella henselae</i>	This patent <i>tuf</i>
	13	<i>Bifidobacterium adolescentis</i>	This patent <i>tuf</i>
	14	<i>Bifidobacterium dentium</i>	This patent <i>tuf</i>
	15	<i>Brucella abortus</i>	This patent <i>tuf</i>
20	16	<i>Burkholderia cepacia</i>	This patent <i>tuf</i>
	17	<i>Cedecea davisae</i>	This patent <i>tuf</i>
	18	<i>Cedecea neteri</i>	This patent <i>tuf</i>
	19	<i>Cedecea lapagei</i>	This patent <i>tuf</i>
	20	<i>Chlamydia pneumoniae</i>	This patent <i>tuf</i>
25	21	<i>Chlamydia psittaci</i>	This patent <i>tuf</i>
	22	<i>Chlamydia trachomatis</i>	This patent <i>tuf</i>
	23	<i>Chryseobacterium meningosepticum</i>	This patent <i>tuf</i>
	24	<i>Citrobacter amalonaticus</i>	This patent <i>tuf</i>
	25	<i>Citrobacter braakii</i>	This patent <i>tuf</i>
30	26	<i>Citrobacter koseri</i>	This patent <i>tuf</i>
	27	<i>Citrobacter farmeri</i>	This patent <i>tuf</i>
	28	<i>Citrobacter freundii</i>	This patent <i>tuf</i>
	29	<i>Citrobacter sedlakii</i>	This patent <i>tuf</i>
	30	<i>Citrobacter werkmanii</i>	This patent <i>tuf</i>
35	31	<i>Citrobacter youngae</i>	This patent <i>tuf</i>
	32	<i>Clostridium perfringens</i>	This patent <i>tuf</i>
	33	<i>Comamonas acidovorans</i>	This patent <i>tuf</i>
	34	<i>Corynebacterium bovis</i>	This patent <i>tuf</i>
	35	<i>Corynebacterium cervicis</i>	This patent <i>tuf</i>
40	36	<i>Corynebacterium flavescentis</i>	This patent <i>tuf</i>
	37	<i>Corynebacterium kutscheri</i>	This patent <i>tuf</i>
	38	<i>Corynebacterium minutissimum</i>	This patent <i>tuf</i>
	39	<i>Corynebacterium mycetoides</i>	This patent <i>tuf</i>
	40	<i>Corynebacterium pseudogenitalium</i>	This patent <i>tuf</i>
45	41	<i>Corynebacterium renale</i>	This patent <i>tuf</i>
	42	<i>Corynebacterium ulcerans</i>	This patent <i>tuf</i>
	43	<i>Corynebacterium urealyticum</i>	This patent <i>tuf</i>
	44	<i>Corynebacterium xerosis</i>	This patent <i>tuf</i>
	45	<i>Coxiella burnetii</i>	This patent <i>tuf</i>
50	46	<i>Edwardsiella hoshinae</i>	This patent <i>tuf</i>
	47	<i>Edwardsiella tarda</i>	This patent <i>tuf</i>
	48	<i>Eikenella corrodens</i>	This patent <i>tuf</i>
	49	<i>Enterobacter aerogenes</i>	This patent <i>tuf</i>
	50	<i>Enterobacter agglomerans</i>	This patent <i>tuf</i>
55	51	<i>Enterobacter amnigenus</i>	This patent <i>tuf</i>
	52	<i>Enterobacter asburiae</i>	This patent <i>tuf</i>
	53	<i>Enterobacter cancerogenus</i>	This patent <i>tuf</i>
	54	<i>Enterobacter cloacae</i>	This patent <i>tuf</i>
	55	<i>Enterobacter gergoviae</i>	This patent <i>tuf</i>
60	56	<i>Enterobacter hormaechei</i>	This patent <i>tuf</i>
	57	<i>Enterobacter sakazakii</i>	This patent <i>tuf</i>
	58	<i>Enterococcus casseliflavus</i>	This patent <i>tuf</i>
	59	<i>Enterococcus cecorum</i>	This patent <i>tuf</i>
	60	<i>Enterococcus dispar</i>	This patent <i>tuf</i>
65	61	<i>Enterococcus durans</i>	This patent <i>tuf</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
62	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
63	<i>Enterococcus faecium</i>	This patent	<i>tuf</i>
64	<i>Enterococcus flavescentis</i>	This patent	<i>tuf</i>
65	<i>Enterococcus gallinarum</i>	This patent	<i>tuf</i>
10	<i>Enterococcus hirae</i>	This patent	<i>tuf</i>
66	<i>Enterococcus mundtii</i>	This patent	<i>tuf</i>
67	<i>Enterococcus pseudoavium</i>	This patent	<i>tuf</i>
68	<i>Enterococcus raffinosus</i>	This patent	<i>tuf</i>
69	<i>Enterococcus saccharolyticus</i>	This patent	<i>tuf</i>
70	<i>Enterococcus solitarius</i>	This patent	<i>tuf</i>
15	<i>Enterococcus casseliflavus</i>	This patent	<i>tuf (C)</i>
71	<i>Staphylococcus saprophyticus</i>	This patent	unknown
72	<i>Enterococcus flavescentis</i>	This patent	<i>tuf (C)</i>
73	<i>Enterococcus gallinarum</i>	This patent	<i>tuf (C)</i>
74	<i>Ehrlichia canis</i>	This patent	<i>tuf</i>
75	<i>Escherichia fergusonii</i>	This patent	<i>tuf</i>
20	<i>Escherichia hermannii</i>	This patent	<i>tuf</i>
76	<i>Escherichia vulneris</i>	This patent	<i>tuf</i>
77	<i>Eubacterium luentum</i>	This patent	<i>tuf</i>
78	<i>Eubacterium nodatum</i>	This patent	<i>tuf</i>
79	<i>Ewingella americana</i>	This patent	<i>tuf</i>
80	<i>Francisella tularensis</i>	This patent	<i>tuf</i>
25	<i>Fusobacterium nucleatum</i> subsp. <i>polymorphum</i>	This patent	<i>tuf</i>
81	<i>Gemella haemolysans</i>	This patent	<i>tuf</i>
82	<i>Gemella morbillorum</i>	This patent	<i>tuf</i>
83	<i>Haemophilus actinomycetemcomitans</i>	This patent	<i>tuf</i>
84	<i>Haemophilus aphrophilus</i>	This patent	<i>tuf</i>
85	<i>Haemophilus ducreyi</i>	This patent	<i>tuf</i>
30	<i>Haemophilus haemolyticus</i>	This patent	<i>tuf</i>
86	<i>Haemophilus parahaemolyticus</i>	This patent	<i>tuf</i>
87	<i>Haemophilus parainfluenzae</i>	This patent	<i>tuf</i>
88	<i>Haemophilus paraphrophilus</i>	This patent	<i>tuf</i>
89	<i>Haemophilus segnis</i>	This patent	<i>tuf</i>
35	<i>Hafnia alvei</i>	This patent	<i>tuf</i>
90	<i>Kingella kingae</i>	This patent	<i>tuf</i>
91	<i>Klebsiella ornithinolytica</i>	This patent	<i>tuf</i>
92	<i>Klebsiella oxytoca</i>	This patent	<i>tuf</i>
93	<i>Klebsiella planticola</i>	This patent	<i>tuf</i>
94	<i>Klebsiella pneumoniae</i> subsp. <i>ozaenae</i>	This patent	<i>tuf</i>
95	<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i>	This patent	<i>tuf</i>
96	<i>Klebsiella pneumoniae</i> subsp. <i>rhinoscleromatis</i>	This patent	<i>tuf</i>
40	<i>Kluyvera ascorbata</i>	This patent	<i>tuf</i>
97	<i>Kluyvera cryocrescens</i>	This patent	<i>tuf</i>
98	<i>Kluyvera georgiana</i>	This patent	<i>tuf</i>
99	<i>Lactobacillus casei</i> subsp. <i>casei</i>	This patent	<i>tuf</i>
100	<i>Lactococcus lactis</i> subsp. <i>lactis</i>	This patent	<i>tuf</i>
101	<i>Leclercia adecarboxylata</i>	This patent	<i>tuf</i>
45	<i>Legionella micdadei</i>	This patent	<i>tuf</i>
102	<i>Legionella pneumophila</i> subsp. <i>pneumophila</i>	This patent	<i>tuf</i>
103	<i>Leminorella grimontii</i>	This patent	<i>tuf</i>
104	<i>Leminorella richardii</i>	This patent	<i>tuf</i>
105	<i>Leptospira interrogans</i>	This patent	<i>tuf</i>
50	<i>Megamonas hypermegale</i>	This patent	<i>tuf</i>
106	<i>Mitsuokella multacidus</i>	This patent	<i>tuf</i>
107	<i>Mobiluncus curtisi</i> subsp. <i>holmesii</i>	This patent	<i>tuf</i>
108	<i>Moellerella wisconsensis</i>	This patent	<i>tuf</i>
109	<i>Moraxella catarrhalis</i>	This patent	<i>tuf</i>
110	<i>Morganella morganii</i> subsp. <i>morganii</i>	This patent	<i>tuf</i>
55	<i>Mycobacterium tuberculosis</i>	This patent	<i>tuf</i>
111			
112			
113			
114			
115			
116			
117			
118			
119			
120			
121			
122			

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Neisseria cinerea</i>	This patent	tuf
123	<i>Neisseria elongata</i> subsp. <i>elongata</i>	This patent	tuf
124	<i>Neisseria flavescens</i>	This patent	tuf
125	<i>Neisseria gonorrhoeae</i>	This patent	tuf
126	<i>Neisseria lactamica</i>	This patent	tuf
127	<i>Neisseria meningitidis</i>	This patent	tuf
10	<i>Neisseria mucosa</i>	This patent	tuf
128	<i>Neisseria sicca</i>	This patent	tuf
129	<i>Neisseria subflava</i>	This patent	tuf
130	<i>Neisseria weaveri</i>	This patent	tuf
15	<i>Ochrobactrum anthropi</i>	This patent	tuf
133	<i>Pantoea agglomerans</i>	This patent	tuf
134	<i>Pantoea dispersa</i>	This patent	tuf
135	<i>Pasteurella multocida</i>	This patent	tuf
136	<i>Peptostreptococcus anaerobius</i>	This patent	tuf
20	<i>Peptostreptococcus asaccharolyticus</i>	This patent	tuf
138	<i>Peptostreptococcus prevotii</i>	This patent	tuf
139	<i>Porphyromonas asaccharolytica</i>	This patent	tuf
140	<i>Porphyromonas gingivalis</i>	This patent	tuf
141	<i>Pragia fontium</i>	This patent	tuf
25	<i>Prevotella melaninogenica</i>	This patent	tuf
143	<i>Prevotella oralis</i>	This patent	tuf
144	<i>Propionibacterium acnes</i>	This patent	tuf
145	<i>Proteus mirabilis</i>	This patent	tuf
146	<i>Proteus penneri</i>	This patent	tuf
30	<i>Proteus vulgaris</i>	This patent	tuf
148	<i>Providencia alcalifaciens</i>	This patent	tuf
149	<i>Providencia rettgeri</i>	This patent	tuf
150	<i>Providencia rustigianii</i>	This patent	tuf
151	<i>Providencia stuartii</i>	This patent	tuf
35	<i>Pseudomonas aeruginosa</i>	This patent	tuf
153	<i>Pseudomonas fluorescens</i>	This patent	tuf
154	<i>Pseudomonas stutzeri</i>	This patent	tuf
155	<i>Psychrobacter phenylpyruvicum</i>	This patent	tuf
156	<i>Rahnella aquatilis</i>	This patent	tuf
40	<i>Salmonella choleraesuis</i> subsp. <i>arizona</i>	This patent	tuf
158	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i>	This patent	tuf
159	serotype <i>Choleraesuis</i>	This patent	tuf
160	<i>Salmonella choleraesuis</i> subsp. <i>diarizonae</i>	This patent	tuf
45	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i>	This patent	tuf
161	serotype <i>Heidelberg</i>	This patent	tuf
162	<i>Salmonella choleraesuis</i> subsp. <i>houtenae</i>	This patent	tuf
163	<i>Salmonella choleraesuis</i> subsp. <i>indica</i>	This patent	tuf
164	<i>Salmonella choleraesuis</i> subsp. <i>salamae</i>	This patent	tuf
50	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype <i>Typhi</i>	This patent	tuf
165	<i>Serratia fonticola</i>	This patent	tuf
166	<i>Serratia liquefaciens</i>	This patent	tuf
167	<i>Serratia marcescens</i>	This patent	tuf
168	<i>Serratia odorifera</i>	This patent	tuf
169	<i>Serratia plymuthica</i>	This patent	tuf
55	<i>Serratia rubidaea</i>	This patent	tuf
170	<i>Shigella boydii</i>	This patent	tuf
171	<i>Shigella dysenteriae</i>	This patent	tuf
172	<i>Shigella flexneri</i>	This patent	tuf
173	<i>Shigella sonnei</i>	This patent	tuf
60	<i>Staphylococcus aureus</i>	This patent	tuf
176	<i>Staphylococcus aureus</i>	This patent	tuf
177	<i>Staphylococcus aureus</i>	This patent	tuf
178	<i>Staphylococcus aureus</i>	This patent	tuf
179	<i>Staphylococcus aureus</i>	This patent	tuf
65	<i>Staphylococcus aureus</i> subsp. <i>aureus</i>	This patent	tuf
180	<i>Staphylococcus auricularis</i>	This patent	tuf
181	<i>Staphylococcus capitis</i> subsp. <i>capitis</i>	This patent	tuf
182			

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Macroccoccus caseolyticus</i>	This patent	<i>tuf</i>
183	<i>Staphylococcus cohnii</i> subsp. <i>cohnii</i>	This patent	<i>tuf</i>
184	<i>Staphylococcus epidermidis</i>	This patent	<i>tuf</i>
185	<i>Staphylococcus haemolyticus</i>	This patent	<i>tuf</i>
186	<i>Staphylococcus warneri</i>	This patent	<i>tuf</i>
187	<i>Staphylococcus haemolyticus</i>	This patent	<i>tuf</i>
10	<i>Staphylococcus haemolyticus</i>	This patent	<i>tuf</i>
188	<i>Staphylococcus haemolyticus</i>	This patent	<i>tuf</i>
189	<i>Staphylococcus haemolyticus</i>	This patent	<i>tuf</i>
190	<i>Staphylococcus hominis</i> subsp. <i>hominis</i>	This patent	<i>tuf</i>
191	<i>Staphylococcus hominis</i> subsp. <i>hominis</i>	This patent	<i>tuf</i>
192	<i>Staphylococcus warneri</i>	This patent	<i>tuf</i>
15	<i>Staphylococcus hominis</i>	This patent	<i>tuf</i>
193	<i>Staphylococcus hominis</i>	This patent	<i>tuf</i>
194	<i>Staphylococcus hominis</i>	This patent	<i>tuf</i>
195	<i>Staphylococcus hominis</i>	This patent	<i>tuf</i>
196	<i>Staphylococcus hominis</i>	This patent	<i>tuf</i>
197	<i>Staphylococcus lugdunensis</i>	This patent	<i>tuf</i>
20	<i>Staphylococcus saprophyticus</i>	This patent	<i>tuf</i>
198	<i>Staphylococcus saprophyticus</i>	This patent	<i>tuf</i>
199	<i>Staphylococcus saprophyticus</i>	This patent	<i>tuf</i>
200	<i>Staphylococcus saprophyticus</i>	This patent	<i>tuf</i>
201	<i>Staphylococcus sciuri</i> subsp. <i>sciuri</i>	This patent	<i>tuf</i>
202	<i>Staphylococcus warneri</i>	This patent	<i>tuf</i>
25	<i>Staphylococcus warneri</i>	This patent	<i>tuf</i>
203	<i>Bifidobacterium longum</i>	This patent	<i>tuf</i>
204	<i>Stenotrophomonas maltophilia</i>	This patent	<i>tuf</i>
205	<i>Streptococcus acidominimus</i>	This patent	<i>tuf</i>
206	<i>Streptococcus agalactiae</i>	This patent	<i>tuf</i>
30	<i>Streptococcus agalactiae</i>	This patent	<i>tuf</i>
207	<i>Streptococcus agalactiae</i>	This patent	<i>tuf</i>
208	<i>Streptococcus agalactiae</i>	This patent	<i>tuf</i>
209	<i>Streptococcus agalactiae</i>	This patent	<i>tuf</i>
210	<i>Streptococcus agalactiae</i>	This patent	<i>tuf</i>
211	<i>Streptococcus anginosus</i>	This patent	<i>tuf</i>
212	<i>Streptococcus bovis</i>	This patent	<i>tuf</i>
35	<i>Streptococcus anginosus</i>	This patent	<i>tuf</i>
213	<i>Streptococcus cricetus</i>	This patent	<i>tuf</i>
214	<i>Streptococcus cristatus</i>	This patent	<i>tuf</i>
215	<i>Streptococcus downei</i>	This patent	<i>tuf</i>
216	<i>Streptococcus dysgalactiae</i>	This patent	<i>tuf</i>
40	<i>Streptococcus equi</i> subsp. <i>equi</i>	This patent	<i>tuf</i>
217	<i>Streptococcus ferus</i>	This patent	<i>tuf</i>
218	<i>Streptococcus gordoni</i>	This patent	<i>tuf</i>
219	<i>Streptococcus anginosus</i>	This patent	<i>tuf</i>
220	<i>Streptococcus macacae</i>	This patent	<i>tuf</i>
45	<i>Streptococcus gordoni</i>	This patent	<i>tuf</i>
221	<i>Streptococcus mutans</i>	This patent	<i>tuf</i>
222	<i>Streptococcus parasanguinis</i>	This patent	<i>tuf</i>
223	<i>Streptococcus ratti</i>	This patent	<i>tuf</i>
50	<i>Streptococcus sanguinis</i>	This patent	<i>tuf</i>
224	<i>Streptococcus sobrinus</i>	This patent	<i>tuf</i>
225	<i>Streptococcus suis</i>	This patent	<i>tuf</i>
226	<i>Streptococcus uberis</i>	This patent	<i>tuf</i>
227	<i>Streptococcus vestibularis</i>	This patent	<i>tuf</i>
55	<i>Tatumella ptyeos</i>	This patent	<i>tuf</i>
228	<i>Trabulsiella guamensis</i>	This patent	<i>tuf</i>
229	<i>Veillonella parvula</i>	This patent	<i>tuf</i>
230	<i>Yersinia enterocolitica</i>	This patent	<i>tuf</i>
231	<i>Yersinia frederiksenii</i>	This patent	<i>tuf</i>
232	<i>Yersinia intermedia</i>	This patent	<i>tuf</i>
60	<i>Yersinia pestis</i>	This patent	<i>tuf</i>
233	<i>Yersinia pseudotuberculosis</i>	This patent	<i>tuf</i>
234	<i>Yersinia rohdei</i>	This patent	<i>tuf</i>
235	<i>Yokenella regensburgei</i>	This patent	<i>tuf</i>
236	<i>Achromobacter xylosoxidans</i> subsp. <i>denitrificans</i>	This patent	<i>aipD</i>
65	<i>Acinetobacter baumannii</i>	This patent	<i>aipD</i>
237	<i>Acinetobacter lwoffii</i>	This patent	<i>aipD</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

	SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	245	<i>Staphylococcus saprophyticus</i>	This patent	<i>atpD</i>
	246	<i>Alcaligenes faecalis</i> subsp. <i>faecalis</i>	This patent	<i>atpD</i>
	247	<i>Bacillus anthracis</i>	This patent	<i>atpD</i>
	248	<i>Bacillus cereus</i>	This patent	<i>atpD</i>
	249	<i>Bacteroides distasonis</i>	This patent	<i>atpD</i>
10	250	<i>Bacteroides ovatus</i>	This patent	<i>atpD</i>
	251	<i>Leclercia adecarboxylata</i>	This patent	<i>atpD</i>
	252	<i>Stenotrophomonas maltophilia</i>	This patent	<i>atpD</i>
	253	<i>Bartonella henselae</i>	This patent	<i>atpD</i>
15	254	<i>Bifidobacterium adolescentis</i>	This patent	<i>atpD</i>
	255	<i>Brucella abortus</i>	This patent	<i>atpD</i>
	256	<i>Cedecea davisae</i>	This patent	<i>atpD</i>
	257	<i>Cedecea lapagei</i>	This patent	<i>atpD</i>
	258	<i>Cedecea neteri</i>	This patent	<i>atpD</i>
	259	<i>Chryseobacterium meningosepticum</i>	This patent	<i>atpD</i>
20	260	<i>Citrobacter amalonaticus</i>	This patent	<i>atpD</i>
	261	<i>Citrobacter braakii</i>	This patent	<i>atpD</i>
	262	<i>Citrobacter koseri</i>	This patent	<i>atpD</i>
	263	<i>Citrobacter farmeri</i>	This patent	<i>atpD</i>
	264	<i>Citrobacter freundii</i>	This patent	<i>atpD</i>
25	265	<i>Citrobacter koseri</i>	This patent	<i>atpD</i>
	266	<i>Citrobacter sedlakii</i>	This patent	<i>atpD</i>
	267	<i>Citrobacter werkmanii</i>	This patent	<i>atpD</i>
	268	<i>Citrobacter youngae</i>	This patent	<i>atpD</i>
	269	<i>Clostridium innocuum</i>	This patent	<i>atpD</i>
30	270	<i>Clostridium perfringens</i>	This patent	<i>atpD</i>
	272	<i>Corynebacterium diphtheriae</i>	This patent	<i>atpD</i>
	273	<i>Corynebacterium pseudodiphtheriticum</i>	This patent	<i>atpD</i>
	274	<i>Corynebacterium ulcerans</i>	This patent	<i>atpD</i>
	275	<i>Corynebacterium urealyticum</i>	This patent	<i>atpD</i>
35	276	<i>Coxiella burnetii</i>	This patent	<i>atpD</i>
	277	<i>Edwardsiella hoshinae</i>	This patent	<i>atpD</i>
	278	<i>Edwardsiella tarda</i>	This patent	<i>atpD</i>
	279	<i>Eikenella corrodens</i>	This patent	<i>atpD</i>
	280	<i>Enterobacter agglomerans</i>	This patent	<i>atpD</i>
40	281	<i>Enterobacter amnigenus</i>	This patent	<i>atpD</i>
	282	<i>Enterobacter asburiae</i>	This patent	<i>atpD</i>
	283	<i>Enterobacter cancerogenus</i>	This patent	<i>atpD</i>
	284	<i>Enterobacter cloacae</i>	This patent	<i>atpD</i>
	285	<i>Enterobacter gergoviae</i>	This patent	<i>atpD</i>
45	286	<i>Enterobacter hormaechei</i>	This patent	<i>atpD</i>
	287	<i>Enterobacter sakazakii</i>	This patent	<i>atpD</i>
	288	<i>Enterococcus avium</i>	This patent	<i>atpD</i>
	289	<i>Enterococcus casseliflavus</i>	This patent	<i>atpD</i>
	290	<i>Enterococcus durans</i>	This patent	<i>atpD</i>
50	291	<i>Enterococcus faecalis</i>	This patent	<i>atpD</i>
	292	<i>Enterococcus faecium</i>	This patent	<i>atpD</i>
	293	<i>Enterococcus gallinarum</i>	This patent	<i>atpD</i>
	294	<i>Enterococcus saccharolyticus</i>	This patent	<i>atpD</i>
	295	<i>Escherichia fergusonii</i>	This patent	<i>atpD</i>
55	296	<i>Escherichia hermannii</i>	This patent	<i>atpD</i>
	297	<i>Escherichia vulneris</i>	This patent	<i>atpD</i>
	298	<i>Eubacterium lentum</i>	This patent	<i>atpD</i>
	299	<i>Ewingella americana</i>	This patent	<i>atpD</i>
	300	<i>Francisella tularensis</i>	This patent	<i>atpD</i>
60	301	<i>Fusobacterium gonatiformans</i>	This patent	<i>atpD</i>
	302	<i>Fusobacterium necrophorum</i> subsp. <i>necrophorum</i>	This patent	<i>atpD</i>
	303	<i>Fusobacterium nucleatum</i> subsp. <i>polymorphum</i>	This patent	<i>atpD</i>
	304	<i>Gardnerella vaginalis</i>	This patent	<i>atpD</i>
	305	<i>Gemella haemolysans</i>	This patent	<i>atpD</i>
65	306	<i>Gemella morbillorum</i>	This patent	<i>atpD</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

	SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	307	<i>Haemophilus ducreyi</i>	This patent	<i>aipD</i>
	308	<i>Haemophilus haemolyticus</i>	This patent	<i>aipD</i>
	309	<i>Haemophilus parahaemolyticus</i>	This patent	<i>aipD</i>
	310	<i>Haemophilus parainfluenzae</i>	This patent	<i>aipD</i>
	311	<i>Hafnia alvei</i>	This patent	<i>aipD</i>
10	312	<i>Kingella kingae</i>	This patent	<i>aipD</i>
	313	<i>Klebsiella pneumoniae</i> subsp. <i>ozaenae</i>	This patent	<i>aipD</i>
	314	<i>Klebsiella ornithinolytica</i>	This patent	<i>aipD</i>
	315	<i>Klebsiella oxytoca</i>	This patent	<i>aipD</i>
	316	<i>Klebsiella planticola</i>	This patent	<i>aipD</i>
15	317	<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i>	This patent	<i>aipD</i>
	318	<i>Kluyvera ascorbata</i>	This patent	<i>aipD</i>
	319	<i>Kluyvera cryocrescens</i>	This patent	<i>aipD</i>
	320	<i>Kluyvera georgiana</i>	This patent	<i>aipD</i>
	321	<i>Lactobacillus acidophilus</i>	This patent	<i>aipD</i>
20	322	<i>Legionella pneumophila</i> subsp. <i>pneumophila</i>	This patent	<i>aipD</i>
	323	<i>Leminorella grimontii</i>	This patent	<i>aipD</i>
	324	<i>Listeria monocytogenes</i>	This patent	<i>aipD</i>
	325	<i>Micrococcus lyliae</i>	This patent	<i>aipD</i>
	326	<i>Moellerella wisconsensis</i>	This patent	<i>aipD</i>
25	327	<i>Moraxella catarrhalis</i>	This patent	<i>aipD</i>
	328	<i>Moraxella osloensis</i>	This patent	<i>aipD</i>
	329	<i>Morganella morganii</i> subsp. <i>morganii</i>	This patent	<i>aipD</i>
	330	<i>Pantoea agglomerans</i>	This patent	<i>aipD</i>
	331	<i>Pantoea dispersa</i>	This patent	<i>aipD</i>
30	332	<i>Pasteurella multocida</i>	This patent	<i>aipD</i>
	333	<i>Pragia fontium</i>	This patent	<i>aipD</i>
	334	<i>Proteus mirabilis</i>	This patent	<i>aipD</i>
	335	<i>Proteus vulgaris</i>	This patent	<i>aipD</i>
	336	<i>Providencia alcalifaciens</i>	This patent	<i>aipD</i>
35	337	<i>Providencia rettgeri</i>	This patent	<i>aipD</i>
	338	<i>Providencia rustigianii</i>	This patent	<i>aipD</i>
	339	<i>Providencia stuartii</i>	This patent	<i>aipD</i>
	340	<i>Psychrobacter phenylpyruvicum</i>	This patent	<i>aipD</i>
	341	<i>Rahnella aquatilis</i>	This patent	<i>aipD</i>
40	342	<i>Salmonella choleraesuis</i> subsp. <i>arizonaee</i>	This patent	<i>aipD</i>
	343	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Choleraesuis	This patent	<i>aipD</i>
	344	<i>Salmonella choleraesuis</i> subsp. <i>diarizonae</i>	This patent	<i>aipD</i>
	345	<i>Salmonella choleraesuis</i> subsp. <i>houtenae</i>	This patent	<i>aipD</i>
45	346	<i>Salmonella choleraesuis</i> subsp. <i>indica</i>	This patent	<i>aipD</i>
	347	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Paratyphi A	This patent	<i>aipD</i>
	348	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Paratyphi B	This patent	<i>aipD</i>
50	349	<i>Salmonella choleraesuis</i> subsp. <i>salamae</i>	This patent	<i>aipD</i>
	350	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Typhi	This patent	<i>aipD</i>
	351	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Typhimurium	This patent	<i>aipD</i>
55	352	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Virchow	This patent	<i>aipD</i>
	353	<i>Serratia ficaria</i>	This patent	<i>aipD</i>
	354	<i>Serratia fonticola</i>	This patent	<i>aipD</i>
	355	<i>Serratia grimesii</i>	This patent	<i>aipD</i>
	356	<i>Serratia liquefaciens</i>	This patent	<i>aipD</i>
60	357	<i>Serratia marcescens</i>	This patent	<i>aipD</i>
	358	<i>Serratia odorifera</i>	This patent	<i>aipD</i>
	359	<i>Serratia plymuthica</i>	This patent	<i>aipD</i>
	360	<i>Serratia rubidaea</i>	This patent	<i>aipD</i>
	361	<i>Pseudomonas putida</i>	This patent	<i>aipD</i>
65	362	<i>Shigella boydii</i>	This patent	<i>aipD</i>
	363	<i>Shigella dysenteriae</i>	This patent	<i>aipD</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source Gene*
5	<i>Shigella flexneri</i>	This patent <i>atpD</i>
364	<i>Shigella sonnei</i>	This patent <i>atpD</i>
365	<i>Staphylococcus aureus</i>	This patent <i>atpD</i>
366	<i>Staphylococcus auricularis</i>	This patent <i>atpD</i>
367	<i>Staphylococcus capitis</i> subsp. <i>capitis</i>	This patent <i>atpD</i>
368	<i>Staphylococcus cohnii</i> subsp. <i>cohnii</i>	This patent <i>atpD</i>
10	<i>Staphylococcus epidermidis</i>	This patent <i>atpD</i>
369	<i>Staphylococcus haemolyticus</i>	This patent <i>atpD</i>
370	<i>Staphylococcus hominis</i> subsp. <i>hominis</i>	This patent <i>atpD</i>
371	<i>Staphylococcus hominis</i>	This patent <i>atpD</i>
372	<i>Staphylococcus lugdunensis</i>	This patent <i>atpD</i>
15	<i>Staphylococcus saprophyticus</i>	This patent <i>atpD</i>
373	<i>Staphylococcus simulans</i>	This patent <i>atpD</i>
374	<i>Staphylococcus warneri</i>	This patent <i>atpD</i>
20	<i>Streptococcus acidominimus</i>	This patent <i>atpD</i>
378	<i>Streptococcus agalactiae</i>	This patent <i>atpD</i>
379	<i>Streptococcus agalactiae</i>	This patent <i>atpD</i>
380	<i>Streptococcus agalactiae</i>	This patent <i>atpD</i>
381	<i>Streptococcus agalactiae</i>	This patent <i>atpD</i>
382	<i>Streptococcus agalactiae</i>	This patent <i>atpD</i>
25	<i>Streptococcus agalactiae</i>	This patent <i>atpD</i>
383	<i>Streptococcus dysgalactiae</i>	This patent <i>atpD</i>
384	<i>Streptococcus equi</i> subsp. <i>equi</i>	This patent <i>atpD</i>
385	<i>Streptococcus equi</i> subsp. <i>equi</i>	This patent <i>atpD</i>
386	<i>Streptococcus anginosus</i>	This patent <i>atpD</i>
387	<i>Streptococcus salivarius</i>	This patent <i>atpD</i>
30	<i>Streptococcus suis</i>	This patent <i>atpD</i>
388	<i>Streptococcus uberis</i>	This patent <i>atpD</i>
389	<i>Tatumella ptyeos</i>	This patent <i>atpD</i>
390	<i>Trabulsiella guamensis</i>	This patent <i>atpD</i>
391	<i>Yersinia bercovieri</i>	This patent <i>atpD</i>
392	<i>Yersinia enterocolitica</i>	This patent <i>atpD</i>
35	<i>Yersinia frederiksenii</i>	This patent <i>atpD</i>
393	<i>Yersinia intermedia</i>	This patent <i>atpD</i>
394	<i>Yersinia pseudotuberculosis</i>	This patent <i>atpD</i>
395	<i>Yersinia rohdei</i>	This patent <i>atpD</i>
396	<i>Yokenella regensburgei</i>	This patent <i>atpD</i>
40	<i>Yarrowia lipolytica</i>	This patent <i>tuf</i> (EF-1)
399	<i>Absidia corymbifera</i>	This patent <i>tuf</i> (EF-1)
400	<i>Alternaria alternata</i>	This patent <i>tuf</i> (EF-1)
401	<i>Aspergillus flavus</i>	This patent <i>tuf</i> (EF-1)
402	<i>Aspergillus fumigatus</i>	This patent <i>tuf</i> (EF-1)
45	<i>Aspergillus fumigatus</i>	This patent <i>tuf</i> (EF-1)
403	<i>Aspergillus niger</i>	This patent <i>tuf</i> (EF-1)
404	<i>Blastoschizomyces capitatus</i>	This patent <i>tuf</i> (EF-1)
405	<i>Candida albicans</i>	This patent <i>tuf</i> (EF-1)
406	<i>Candida albicans</i>	This patent <i>tuf</i> (EF-1)
407	<i>Candida albicans</i>	This patent <i>tuf</i> (EF-1)
50	<i>Candida albicans</i>	This patent <i>tuf</i> (EF-1)
408	<i>Candida albicans</i>	This patent <i>tuf</i> (EF-1)
409	<i>Candida albicans</i>	This patent <i>tuf</i> (EF-1)
410	<i>Candida albicans</i>	This patent <i>tuf</i> (EF-1)
411	<i>Candida albicans</i>	This patent <i>tuf</i> (EF-1)
412	<i>Candida dubliniensis</i>	This patent <i>tuf</i> (EF-1)
55	<i>Candida catenulata</i>	This patent <i>tuf</i> (EF-1)
413	<i>Candida dubliniensis</i>	This patent <i>tuf</i> (EF-1)
414	<i>Candida dubliniensis</i>	This patent <i>tuf</i> (EF-1)
415	<i>Candida dubliniensis</i>	This patent <i>tuf</i> (EF-1)
416	<i>Candida famata</i>	This patent <i>tuf</i> (EF-1)
417	<i>Candida glabrata</i>	WO98/20157 <i>tuf</i> (EF-1)
60	<i>Candida guilliermondii</i>	This patent <i>tuf</i> (EF-1)
418	<i>Candida haemulonii</i>	This patent <i>tuf</i> (EF-1)
419	<i>Candida inconspecta</i>	This patent <i>tuf</i> (EF-1)
420	<i>Candida kefyr</i>	This patent <i>tuf</i> (EF-1)
421	<i>Candida krusei</i>	WO98/20157 <i>tuf</i> (EF-1)
422	<i>Candida lambica</i>	This patent <i>tuf</i> (EF-1)
65	<i>Candida lusitaniae</i>	This patent <i>tuf</i> (EF-1)
423	<i>Candida norvegensis</i>	This patent <i>tuf</i> (EF-1)
424		
425		

Table 7. Origin of the nucleic acids and/ r sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Candida parapsilosis</i>	WO98/20157	<i>tuf</i> (EF-1)
426	<i>Candida rugosa</i>	This patent	<i>tuf</i> (EF-1)
427	<i>Candida sphaerica</i>	This patent	<i>tuf</i> (EF-1)
428	<i>Candida tropicalis</i>	WO98/20157	<i>tuf</i> (EF-1)
429	<i>Candida utilis</i>	This patent	<i>tuf</i> (EF-1)
10	<i>Candida viswanathii</i>	This patent	<i>tuf</i> (EF-1)
430	<i>Candida zeylanoides</i>	This patent	<i>tuf</i> (EF-1)
431	<i>Coccidioides immitis</i>	This patent	<i>tuf</i> (EF-1)
432	<i>Cryptococcus albidus</i>	This patent	<i>tuf</i> (EF-1)
433	<i>Exophiala jeanselmei</i>	This patent	<i>tuf</i> (EF-1)
15	<i>Fusarium oxysporum</i>	This patent	<i>tuf</i> (EF-1)
434	<i>Geotrichum sp.</i>	This patent	<i>tuf</i> (EF-1)
435	<i>Histoplasma capsulatum</i>	This patent	<i>tuf</i> (EF-1)
436	<i>Issatchenka orientalis</i> Kudrjanzev	This patent	<i>tuf</i> (EF-1)
437	<i>Malassezia furfur</i>	This patent	<i>tuf</i> (EF-1)
20	<i>Malassezia pachydermatis</i>	This patent	<i>tuf</i> (EF-1)
440	<i>Malbranchea filamentosa</i>	This patent	<i>tuf</i> (EF-1)
441	<i>Metschnikowia pulcherrima</i>	This patent	<i>tuf</i> (EF-1)
442	<i>Paecilomyces lilacinus</i>	This patent	<i>tuf</i> (EF-1)
443	<i>Paracoccidioides brasiliensis</i>	This patent	<i>tuf</i> (EF-1)
25	<i>Penicillium marneffei</i>	This patent	<i>tuf</i> (EF-1)
446	<i>Pichia anomala</i>	This patent	<i>tuf</i> (EF-1)
447	<i>Pichia anomala</i>	This patent	<i>tuf</i> (EF-1)
448	<i>Pseudallescheria boydii</i>	This patent	<i>tuf</i> (EF-1)
449	<i>Rhizopus oryzae</i>	This patent	<i>tuf</i> (EF-1)
30	<i>Rhodotorula minuta</i>	This patent	<i>tuf</i> (EF-1)
450	<i>Sporobolomyces salmonicolor</i>	This patent	<i>tuf</i> (EF-1)
451	<i>Sporothrix schenckii</i>	This patent	<i>tuf</i> (EF-1)
452	<i>Stephanoascus ciferrii</i>	This patent	<i>tuf</i> (EF-1)
453	<i>Trichophyton mentagrophytes</i>	This patent	<i>tuf</i> (EF-1)
35	<i>Trichosporon cutaneum</i>	This patent	<i>tuf</i> (EF-1)
455	<i>Wangiella dermatitidis</i>	This patent	<i>tuf</i> (EF-1)
456	<i>Aspergillus fumigatus</i>	This patent	<i>atpD</i>
457	<i>Blastoschizomyces capitatus</i>	This patent	<i>atpD</i>
458	<i>Candida albicans</i>	This patent	<i>atpD</i>
459	<i>Candida dubliniensis</i>	This patent	<i>atpD</i>
460	<i>Candida famata</i>	This patent	<i>atpD</i>
40	<i>Candida glabrata</i>	This patent	<i>atpD</i>
461	<i>Candida guilliermondii</i>	This patent	<i>atpD</i>
462	<i>Candida haemulonii</i>	This patent	<i>atpD</i>
463	<i>Candida inconspecta</i>	This patent	<i>atpD</i>
464	<i>Candida kefyr</i>	This patent	<i>atpD</i>
465	<i>Candida krusei</i>	This patent	<i>atpD</i>
45	<i>Candida lambica</i>	This patent	<i>atpD</i>
466	<i>Candida lusitaniae</i>	This patent	<i>atpD</i>
467	<i>Candida norvegensis</i>	This patent	<i>atpD</i>
50	<i>Candida parapsilosis</i>	This patent	<i>atpD</i>
471	<i>Candida rugosa</i>	This patent	<i>atpD</i>
472	<i>Candida sphaerica</i>	This patent	<i>atpD</i>
473	<i>Candida tropicalis</i>	This patent	<i>atpD</i>
55	<i>Candida utilis</i>	This patent	<i>atpD</i>
476	<i>Candida viswanathii</i>	This patent	<i>atpD</i>
477	<i>Candida zeylanoides</i>	This patent	<i>atpD</i>
478	<i>Coccidioides immitis</i>	This patent	<i>atpD</i>
479	<i>Cryptococcus albidus</i>	This patent	<i>atpD</i>
60	<i>Fusarium oxysporum</i>	This patent	<i>atpD</i>
481	<i>Geotrichum sp.</i>	This patent	<i>atpD</i>
482	<i>Histoplasma capsulatum</i>	This patent	<i>atpD</i>
483	<i>Malassezia furfur</i>	This patent	<i>atpD</i>
484	<i>Malassezia pachydermatis</i>	This patent	<i>atpD</i>
65	<i>Metschnikowia pulcherrima</i>	This patent	<i>atpD</i>
485	<i>Penicillium marneffei</i>	This patent	<i>atpD</i>
486			
487			

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.		Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	488	<i>Pichia anomala</i>	This patent	<i>atpD</i>
	489	<i>Pichia anomala</i>	This patent	<i>atpD</i>
	490	<i>Rhodotorula minuta</i>	This patent	<i>atpD</i>
	491	<i>Rhodotorula mucilaginosa</i>	This patent	<i>atpD</i>
	492	<i>Sporobolomyces salmonicolor</i>	This patent	<i>atpD</i>
10	493	<i>Sporothrix schenckii</i>	This patent	<i>atpD</i>
	494	<i>Stephanoascus ciferrii</i>	This patent	<i>atpD</i>
	495	<i>Trichophyton mentagrophytes</i>	This patent	<i>atpD</i>
	496	<i>Wangiella dermatitidis</i>	This patent	<i>atpD</i>
	497	<i>Yarrowia lipolytica</i>	This patent	<i>atpD</i>
15	498	<i>Aspergillus fumigatus</i>	This patent	<i>tuf (M)</i>
	499	<i>Blastoschizomyces capitatus</i>	This patent	<i>tuf (M)</i>
	500	<i>Candida rugosa</i>	This patent	<i>tuf (M)</i>
	501	<i>Coccidioides immitis</i>	This patent	<i>tuf (M)</i>
	502	<i>Fusarium oxysporum</i>	This patent	<i>tuf (M)</i>
20	503	<i>Histoplasma capsulatum</i>	This patent	<i>tuf (M)</i>
	504	<i>Paracoccidioides brasiliensis</i>	This patent	<i>tuf (M)</i>
	505	<i>Penicillium marneffei</i>	This patent	<i>tuf (M)</i>
	506	<i>Pichia anomala</i>	This patent	<i>tuf (M)</i>
	507	<i>Trichophyton mentagrophytes</i>	This patent	<i>tuf (M)</i>
25	508	<i>Yarrowia lipolytica</i>	This patent	<i>tuf (M)</i>
	509	<i>Babesia bigemina</i>	This patent	<i>tuf (EF-1)</i>
	510	<i>Babesia bovis</i>	This patent	<i>tuf (EF-1)</i>
	511	<i>Crithidia fasciculata</i>	This patent	<i>tuf (EF-1)</i>
	512	<i>Entamoeba histolytica</i>	This patent	<i>tuf (EF-1)</i>
30	513	<i>Giardia lamblia</i>	This patent	<i>tuf (EF-1)</i>
	514	<i>Leishmania tropica</i>	This patent	<i>tuf (EF-1)</i>
	515	<i>Leishmania aethiopica</i>	This patent	<i>tuf (EF-1)</i>
	516	<i>Leishmania tropica</i>	This patent	<i>tuf (EF-1)</i>
	517	<i>Leishmania donovani</i>	This patent	<i>tuf (EF-1)</i>
35	518	<i>Leishmania infantum</i>	This patent	<i>tuf (EF-1)</i>
	519	<i>Leishmania enriettii</i>	This patent	<i>tuf (EF-1)</i>
	520	<i>Leishmania gerbilli</i>	This patent	<i>tuf (EF-1)</i>
	521	<i>Leishmania hertigi</i>	This patent	<i>tuf (EF-1)</i>
	522	<i>Leishmania major</i>	This patent	<i>tuf (EF-1)</i>
40	523	<i>Leishmania amazonensis</i>	This patent	<i>tuf (EF-1)</i>
	524	<i>Leishmania mexicana</i>	This patent	<i>tuf (EF-1)</i>
	525	<i>Leishmania tarentolae</i>	This patent	<i>tuf (EF-1)</i>
	526	<i>Leishmania tropica</i>	This patent	<i>tuf (EF-1)</i>
	527	<i>Neospora caninum</i>	This patent	<i>tuf (EF-1)</i>
45	528	<i>Trichomonas vaginalis</i>	This patent	<i>tuf (EF-1)</i>
	529	<i>Trypanosoma brucei</i> subsp. <i>brucei</i>	This patent	<i>tuf (EF-1)</i>
	530	<i>Crithidia fasciculata</i>	This patent	<i>atpD</i>
	531	<i>Leishmania tropica</i>	This patent	<i>atpD</i>
	532	<i>Leishmania aethiopica</i>	This patent	<i>atpD</i>
50	533	<i>Leishmania donovani</i>	This patent	<i>atpD</i>
	534	<i>Leishmania infantum</i>	This patent	<i>atpD</i>
	535	<i>Leishmania gerbilli</i>	This patent	<i>atpD</i>
	536	<i>Leishmania hertigi</i>	This patent	<i>atpD</i>
	537	<i>Leishmania major</i>	This patent	<i>atpD</i>
55	538	<i>Leishmania amazonensis</i>	This patent	<i>atpD</i>
	607	<i>Enterococcus faecalis</i>	WO98/20157	<i>tuf</i>
	608	<i>Enterococcus faecium</i>	WO98/20157	<i>tuf</i>
	609	<i>Enterococcus gallinarum</i>	WO98/20157	<i>tuf</i>
	610	<i>Haemophilus influenzae</i>	WO98/20157	<i>tuf</i>
60	611	<i>Staphylococcus epidermidis</i>	WO98/20157	<i>tuf</i>
	612	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Paratyphi A	This patent	<i>tuf</i>
	613	<i>Serraria ficaria</i>	This patent	<i>tuf</i>
	614	<i>Enterococcus malodoratus</i>	This patent	<i>tuf (C)</i>
65	615	<i>Enterococcus durans</i>	This patent	<i>tuf (C)</i>
	616	<i>Enterococcus pseudoavium</i>	This patent	<i>tuf (C)</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Enterococcus dispar</i>	This patent	<i>tuf</i> (C)
617	<i>Enterococcus avium</i>	This patent	<i>tuf</i> (C)
618	<i>Saccharomyces cerevisiae</i>	Database	<i>tuf</i> (M)
619	<i>Enterococcus faecium</i>	This patent	<i>tuf</i> (C)
621	<i>Saccharomyces cerevisiae</i>	This patent	<i>tuf</i> (EF-1)
622	<i>Cryptococcus neoformans</i>	This patent	<i>tuf</i> (EF-1)
10	<i>Candida albicans</i>	WO98/20157	<i>tuf</i> (EF-1)
623	<i>Corynebacterium diphtheriae</i>	WO98/20157	<i>tuf</i>
624	<i>Candida catenulata</i>	This patent	<i>atpD</i>
663	<i>Saccharomyces cerevisiae</i>	Database	<i>tuf</i> (EF-1)
15	<i>Saccharomyces cerevisiae</i>	Database	<i>atpD</i>
665	<i>Trypanosoma cruzi</i>	This patent	<i>atpD</i>
666	<i>Corynebacterium glutamicum</i>	Database	<i>tuf</i>
667	<i>Escherichia coli</i>	Database	<i>atpD</i>
668	<i>Helicobacter pylori</i>	Database	<i>atpD</i>
20	<i>Clostridium acetobutylicum</i>	Database	<i>atpD</i>
671	<i>Cytophaga lytica</i>	Database	<i>atpD</i>
672	<i>Ehrlichia risticii</i>	This patent	<i>atpD</i>
673	<i>Vibrio cholerae</i>	This patent	<i>atpD</i>
674	<i>Vibrio cholerae</i>	This patent	<i>tuf</i>
25	<i>Leishmania enriettii</i>	This patent	<i>atpD</i>
676	<i>Babesia microti</i>	This patent	<i>tuf</i> (EF-1)
677	<i>Cryptococcus neoformans</i>	This patent	<i>atpD</i>
678	<i>Cryptococcus neoformans</i>	This patent	<i>atpD</i>
30	<i>Cunninghamella bertholletiae</i>	This patent	<i>atpD</i>
680	<i>Candida tropicalis</i>	Database	<i>atpD</i> (V)
684	<i>Enterococcus hirae</i>	Database	<i>atpD</i> (V)
685	<i>Chlamydia pneumoniae</i>	Database	<i>atpD</i> (V)
686	<i>Halobacterium salinarum</i>	Database	<i>atpD</i> (V)
687	<i>Homo sapiens</i>	Database	<i>atpD</i> (V)
35	<i>Plasmodium falciparum</i>	Database	<i>atpD</i> (V)
688	<i>Saccharomyces cerevisiae</i>	Database	<i>atpD</i> (V)
689	<i>Schizosaccharomyces pombe</i>	Database	<i>atpD</i> (V)
690	<i>Trypanosoma congolense</i>	Database	<i>atpD</i> (V)
691	<i>Thermus thermophilus</i>	Database	<i>atpD</i> (V)
40	<i>Escherichia coli</i>	WO98/20157	<i>tuf</i>
693	<i>Borrelia burgdorferi</i>	Database	<i>atpD</i> (V)
698	<i>Treponema pallidum</i>	Database	<i>atpD</i> (V)
709	<i>Chlamydia trachomatis</i>	Genome project	<i>atpD</i> (V)
710	<i>Enterococcus faecalis</i>	Genome project	<i>atpD</i> (V)
45	<i>Methanoscincus jannaschii</i>	Database	<i>atpD</i> (V)
712	<i>Porphyromonas gingivalis</i>	Genome project	<i>atpD</i> (V)
713	<i>Streptococcus pneumoniae</i>	Genome project	<i>atpD</i> (V)
714	<i>Burkholderia mallei</i>	This patent	<i>tuf</i>
50	<i>Burkholderia pseudomallei</i>	This patent	<i>tuf</i>
718	<i>Clostridium beijerinckii</i>	This patent	<i>tuf</i>
719	<i>Clostridium innocuum</i>	This patent	<i>tuf</i>
720	<i>Clostridium novyi</i>	This patent	<i>tuf</i>
721	<i>Clostridium septicum</i>	This patent	<i>tuf</i>
55	<i>Clostridium tertium</i>	This patent	<i>tuf</i>
723	<i>Clostridium tetani</i>	This patent	<i>tuf</i>
724	<i>Enterococcus malodoratus</i>	This patent	<i>tuf</i>
725	<i>Enterococcus sulfureus</i>	This patent	<i>tuf</i>
726	<i>Lactococcus garvieae</i>	This patent	<i>tuf</i>
60	<i>Mycoplasma pirum</i>	This patent	<i>tuf</i>
728	<i>Mycoplasma salivarium</i>	This patent	<i>tuf</i>
729	<i>Neisseria polysaccharea</i>	This patent	<i>tuf</i>
730	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i>	This patent	<i>tuf</i>
731	serotype Enteritidis		

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Gallinarum	This patent	<i>tuf</i>
	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Paratyphi B	This patent	<i>tuf</i>
10	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Virchow	This patent	<i>tuf</i>
	<i>Serratia grimesii</i>	This patent	<i>tuf</i>
	<i>Clostridium difficile</i>	This patent	<i>tuf</i>
	<i>Burkholderia pseudomallei</i>	This patent	<i>atpD</i>
15	<i>Clostridium bifermentans</i>	This patent	<i>atpD</i>
	<i>Clostridium beijerinckii</i>	This patent	<i>atpD</i>
	<i>Clostridium difficile</i>	This patent	<i>atpD</i>
	<i>Clostridium ramosum</i>	This patent	<i>atpD</i>
	<i>Clostridium septicum</i>	This patent	<i>atpD</i>
20	<i>Clostridium tertium</i>	This patent	<i>atpD</i>
	<i>Comamonas acidovorans</i>	This patent	<i>atpD</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>rhinoscleromatis</i>	This patent	<i>atpD</i>
	<i>Neisseria canis</i>	This patent	<i>atpD</i>
	<i>Neisseria cinerea</i>	This patent	<i>atpD</i>
25	<i>Neisseria cuniculi</i>	This patent	<i>atpD</i>
	<i>Neisseria elongata</i> subsp. <i>elongata</i>	This patent	<i>atpD</i>
	<i>Neisseria flavescens</i>	This patent	<i>atpD</i>
	<i>Neisseria gonorrhoeae</i>	This patent	<i>atpD</i>
	<i>Neisseria gonorrhoeae</i>	This patent	<i>atpD</i>
30	<i>Neisseria lactamica</i>	This patent	<i>atpD</i>
	<i>Neisseria meningitidis</i>	This patent	<i>atpD</i>
	<i>Neisseria mucosa</i>	This patent	<i>atpD</i>
	<i>Neisseria subflava</i>	This patent	<i>atpD</i>
	<i>Neisseria weaveri</i>	This patent	<i>atpD</i>
35	<i>Neisseria animalis</i>	This patent	<i>atpD</i>
	<i>Proteus penneri</i>	This patent	<i>atpD</i>
	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Enteritidis	This patent	<i>atpD</i>
	<i>Yersinia pestis</i>	This patent	<i>atpD</i>
40	<i>Burkholderia mallei</i>	This patent	<i>atpD</i>
	<i>Clostridium sordellii</i>	This patent	<i>atpD</i>
	<i>Clostridium novyi</i>	This patent	<i>atpD</i>
	<i>Clostridium botulinum</i>	This patent	<i>atpD</i>
	<i>Clostridium histolyticum</i>	This patent	<i>atpD</i>
45	<i>Peptostreptococcus prevotii</i>	This patent	<i>atpD</i>
	<i>Absidia corymbifera</i>	This patent	<i>atpD</i>
	<i>Alternaria alternata</i>	This patent	<i>atpD</i>
	<i>Aspergillus flavus</i>	This patent	<i>atpD</i>
	<i>Mucor circinelloides</i>	This patent	<i>atpD</i>
50	<i>Piedraia hortai</i>	This patent	<i>atpD</i>
	<i>Pseudallescheria boydii</i>	This patent	<i>aipD</i>
	<i>Rhizopus oryzae</i>	This patent	<i>aipD</i>
	<i>Scopulariopsis kongnigii</i>	This patent	<i>aipD</i>
	<i>Trichophyton mentagrophytes</i>	This patent	<i>aipD</i>
55	<i>Trichophyton tonsurans</i>	This patent	<i>aipD</i>
	<i>Trichosporon cutaneum</i>	This patent	<i>aipD</i>
	<i>Cladophialophora carrionii</i>	This patent	<i>tuf</i> (EF-1)
	<i>Cunninghamella bertholletiae</i>	This patent	<i>tuf</i> (EF-1)
	<i>Curvularia lunata</i>	This patent	<i>tuf</i> (EF-1)
60	<i>Fonsecaea pedrosoi</i>	This patent	<i>tuf</i> (EF-1)
	<i>Microsporum audouinii</i>	This patent	<i>tuf</i> (EF-1)
	<i>Mucor circinelloides</i>	This patent	<i>tuf</i> (EF-1)
	<i>Phialophora verrucosa</i>	This patent	<i>tuf</i> (EF-1)
	<i>Saksenaea vasiformis</i>	This patent	<i>tuf</i> (EF-1)
65	<i>Syncephalastrum racemosum</i>	This patent	<i>tuf</i> (EF-1)
	<i>Trichophyton tonsurans</i>	This patent	<i>tuf</i> (EF-1)
	<i>Trichophyton mentagrophytes</i>	This patent	<i>tuf</i> (EF-1)

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Bipolaris hawaiiensis</i>	This patent	<i>tuf</i> (EF-1)
790	<i>Aspergillus fumigatus</i>	This patent	<i>tuf</i> (M)
791	<i>Trichophyton mentagrophytes</i>	This patent	<i>tuf</i> (M)
792	<i>Clostridium novyi</i>	This patent	<i>aipD</i> (V)
827	<i>Clostridium difficile</i>	This patent	<i>aipD</i> (V)
828	<i>Clostridium septicum</i>	This patent	<i>aipD</i> (V)
10	<i>Clostridium botulinum</i>	This patent	<i>aipD</i> (V)
829	<i>Clostridium perfringens</i>	This patent	<i>aipD</i> (V)
830	<i>Clostridium tetani</i>	This patent	<i>aipD</i> (V)
831	<i>Streptococcus pyogenes</i>	Database	<i>aipD</i> (V)
15	<i>Babesia bovis</i>	This patent	<i>aipD</i> (V)
834	<i>Cryptosporidium parvum</i>	This patent	<i>aipD</i> (V)
835	<i>Leishmania infantum</i>	This patent	<i>aipD</i> (V)
836	<i>Leishmania major</i>	This patent	<i>aipD</i> (V)
837	<i>Leishmania tarentolae</i>	This patent	<i>aipD</i> (V)
20	<i>Trypanosoma brucei</i>	This patent	<i>aipD</i> (V)
839	<i>Trypanosoma cruzi</i>	This patent	<i>tuf</i> (EF-1)
840	<i>Trypanosoma cruzi</i>	This patent	<i>tuf</i> (EF-1)
841	<i>Trypanosoma cruzi</i>	This patent	<i>tuf</i> (EF-1)
842	<i>Babesia bovis</i>	This patent	<i>tuf</i> (M)
25	<i>Leishmania aethiopica</i>	This patent	<i>tuf</i> (M)
844	<i>Leishmania amazonensis</i>	This patent	<i>tuf</i> (M)
845	<i>Leishmania donovani</i>	This patent	<i>tuf</i> (M)
846	<i>Leishmania infantum</i>	This patent	<i>tuf</i> (M)
847	<i>Leishmania enriettii</i>	This patent	<i>tuf</i> (M)
30	<i>Leishmania gerbilli</i>	This patent	<i>tuf</i> (M)
849	<i>Leishmania major</i>	This patent	<i>tuf</i> (M)
850	<i>Leishmania mexicana</i>	This patent	<i>tuf</i> (M)
851	<i>Leishmania tarentolae</i>	This patent	<i>tuf</i> (M)
852	<i>Trypanosoma cruzi</i>	This patent	<i>tuf</i> (M)
35	<i>Trypanosoma cruzi</i>	This patent	<i>tuf</i> (M)
854	<i>Trypanosoma cruzi</i>	This patent	<i>tuf</i> (M)
855	<i>Babesia bigemina</i>	This patent	<i>tuf</i> (M)
856	<i>Babesia bovis</i>	This patent	<i>aipD</i>
857	<i>Babesia microti</i>	This patent	<i>aipD</i>
40	<i>Leishmania guyanensis</i>	This patent	<i>aipD</i>
859	<i>Leishmania mexicana</i>	This patent	<i>aipD</i>
860	<i>Leishmania tropica</i>	This patent	<i>aipD</i>
861	<i>Leishmania tropica</i>	This patent	<i>aipD</i>
862	<i>Bordetella pertussis</i>	Database	<i>tuf</i>
45	<i>Trypanosoma brucei brucei</i>	Database	<i>tuf</i> (EF-1)
864	<i>Cryptosporidium parvum</i>	This patent	<i>tuf</i> (EF-1)
865	<i>Staphylococcus saprophyticus</i>	This patent	<i>aipD</i>
866	<i>Zoogloea ramigera</i>	This patent	<i>aipD</i>
867	<i>Staphylococcus saprophyticus</i>	This patent	<i>tuf</i>
50	<i>Enterococcus casseliflavus</i>	This patent	<i>tuf</i>
868	<i>Enterococcus casseliflavus</i>	This patent	<i>tuf</i>
869	<i>Enterococcus flavescens</i>	This patent	<i>tuf</i>
870	<i>Enterococcus gallinarum</i>	This patent	<i>tuf</i>
871	<i>Enterococcus gallinarum</i>	This patent	<i>tuf</i>
55	<i>Staphylococcus haemolyticus</i>	This patent	<i>tuf</i>
872	<i>Staphylococcus epidermidis</i>	This patent	<i>tuf</i>
873	<i>Staphylococcus epidermidis</i>	This patent	<i>tuf</i>
874	<i>Staphylococcus epidermidis</i>	This patent	<i>tuf</i>
875	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
876	<i>Pseudomonas aeruginosa</i>	This patent	<i>tuf</i>
877	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
60	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
878	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
879	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
880	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
881	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
882	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
65	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
883	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
884	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
885	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Enterococcus faecium</i>	This patent	<i>tuf</i>
886	<i>Zoogloea ramigera</i>	This patent	<i>tuf</i>
887	<i>Enterococcus faecalis</i>	This patent	<i>tuf</i>
888	<i>Aspergillus fumigatus</i>	This patent	<i>atpD</i>
889	<i>Penicillium marneffei</i>	This patent	<i>atpD</i>
890	<i>Paecilomyces lilacinus</i>	This patent	<i>atpD</i>
10	<i>Penicillium marneffei</i>	This patent	<i>atpD</i>
891	<i>Sporothrix schenckii</i>	This patent	<i>atpD</i>
892	<i>Malbrancheda filamentosa</i>	This patent	<i>atpD</i>
893	<i>Paecilomyces lilacinus</i>	This patent	<i>atpD</i>
894	<i>Aspergillus niger</i>	This patent	<i>atpD</i>
15	<i>Aspergillus fumigatus</i>	This patent	<i>tuf (EF-1)</i>
895	<i>Penicillium marneffei</i>	This patent	<i>tuf (EF-1)</i>
896	<i>Piedraia hortai</i>	This patent	<i>tuf (EF-1)</i>
897	<i>Paecilomyces lilacinus</i>	This patent	<i>tuf (EF-1)</i>
898	<i>Aspergillus niger</i>	This patent	<i>tuf (M)</i>
899	<i>Paracoccidioides brasiliensis</i>	This patent	<i>tuf (M)</i>
900	<i>Sporothrix schenckii</i>	This patent	<i>tuf (M)</i>
20	<i>Penicillium marneffei</i>	This patent	<i>tuf (M)</i>
901	<i>Curvularia lunata</i>	This patent	<i>tuf (M)</i>
902	<i>Alternaria alternata</i>	This patent	<i>tuf (M)</i>
903	<i>Penicillium marneffei</i>	This patent	<i>tuf (M)</i>
904	<i>Aspergillus flavus</i>	This patent	<i>tuf (M)</i>
25	<i>Bipolaris hawaiiensis</i>	This patent	<i>tuf (M)</i>
905	<i>Alternaria alternata</i>	This patent	<i>tuf (M)</i>
906	<i>Penicillium marneffei</i>	This patent	<i>tuf (M)</i>
907	<i>Penicillium marneffei</i>	This patent	<i>tuf (M)</i>
908	<i>Penicillium marneffei</i>	This patent	<i>tuf (M)</i>
909	<i>Penicillium marneffei</i>	This patent	<i>tuf (M)</i>
30	<i>Penicillium marneffei</i>	Database	<i>recA</i>
910	<i>Escherichia coli</i>	This patent	<i>atpD (V)</i>
918	<i>Bacteroides fragilis</i>	This patent	<i>atpD (V)</i>
929	<i>Bacteroides distasonis</i>	This patent	<i>atpD (V)</i>
930	<i>Porphyromonas asaccharolytica</i>	This patent	<i>atpD (V)</i>
931	<i>Listeria monocytogenes</i>	This patent	<i>tuf</i>
35	<i>Saccharomyces cerevisiae</i>	Database	<i>recA (Rad51)</i>
932	<i>Saccharomyces cerevisiae</i>	Database	<i>recA (Dmc1)</i>
939	<i>Cryptococcus humicolus</i>	This patent	<i>atpD</i>
940	<i>Escherichia coli</i>	This patent	<i>atpD</i>
941	<i>Escherichia coli</i>	This patent	<i>atpD</i>
40	<i>Escherichia coli</i>	This patent	<i>atpD</i>
942	<i>Escherichia coli</i>	This patent	<i>atpD</i>
943	<i>Escherichia coli</i>	This patent	<i>atpD</i>
944	<i>Escherichia coli</i>	This patent	<i>atpD</i>
945	<i>Escherichia coli</i>	This patent	<i>atpD</i>
946	<i>Neisseria polysaccharea</i>	This patent	<i>atpD</i>
947	<i>Neisseria sicca</i>	This patent	<i>atpD</i>
45	<i>Streptococcus mitis</i>	This patent	<i>atpD</i>
948	<i>Streptococcus mitis</i>	This patent	<i>atpD</i>
949	<i>Streptococcus mitis</i>	This patent	<i>atpD</i>
950	<i>Streptococcus mitis</i>	This patent	<i>atpD</i>
951	<i>Streptococcus oralis</i>	This patent	<i>atpD</i>
952	<i>Streptococcus pneumoniae</i>	This patent	<i>atpD</i>
50	<i>Streptococcus pneumoniae</i>	This patent	<i>atpD</i>
953	<i>Streptococcus pneumoniae</i>	This patent	<i>atpD</i>
954	<i>Streptococcus pneumoniae</i>	This patent	<i>atpD</i>
955	<i>Streptococcus pneumoniae</i>	This patent	<i>atpD</i>
956	<i>Babesia microti</i>	This patent	<i>atpD (V)</i>
957	<i>Entamoeba histolytica</i>	This patent	<i>atpD (V)</i>
55	<i>Fusobacterium nucleatum subsp. polymorphum</i>	This patent	<i>atpD (V)</i>
958	<i>Leishmania aethiopica</i>	This patent	<i>atpD (V)</i>
959	<i>Leishmania tropica</i>	This patent	<i>atpD (V)</i>
960	<i>Leishmania guyanensis</i>	This patent	<i>atpD (V)</i>
961	<i>Leishmania donovani</i>	This patent	<i>atpD (V)</i>
962	<i>Leishmania hertigi</i>	This patent	<i>atpD (V)</i>
60	<i>Leishmania mexicana</i>	This patent	<i>atpD (V)</i>
963	<i>Leishmania tropica</i>	This patent	<i>atpD (V)</i>
964	<i>Peptostreptococcus anaerobius</i>	This patent	<i>atpD (V)</i>
965	<i>Bordetella pertussis</i>	This patent	<i>tuf</i>
966	<i>Bordetella pertussis</i>	This patent	<i>tuf</i>
967	<i>Enterococcus columbae</i>	This patent	<i>tuf</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Enterococcus flavesiens</i>	This patent	<i>tuf</i>
970	<i>Streptococcus pneumoniae</i>	This patent	<i>tuf</i>
971	<i>Escherichia coli</i>	This patent	<i>tuf</i>
972	<i>Escherichia coli</i>	This patent	<i>tuf</i>
973	<i>Escherichia coli</i>	This patent	<i>tuf</i>
974	<i>Escherichia coli</i>	This patent	<i>tuf</i>
10	<i>Escherichia coli</i>	This patent	<i>tuf</i>
975	<i>Mycobacterium avium</i>	This patent	<i>tuf</i>
976	<i>Streptococcus pneumoniae</i>	This patent	<i>tuf</i>
977	<i>Mycobacterium gordonaee</i>	This patent	<i>tuf</i>
978	<i>Streptococcus pneumoniae</i>	This patent	<i>tuf</i>
15	<i>Mycobacterium tuberculosis</i>	This patent	<i>tuf</i>
980	<i>Staphylococcus warneri</i>	This patent	<i>tuf</i>
981	<i>Streptococcus mitis</i>	This patent	<i>tuf</i>
982	<i>Streptococcus mitis</i>	This patent	<i>tuf</i>
983	<i>Streptococcus mitis</i>	This patent	<i>tuf</i>
20	<i>Streptococcus mitis</i>	This patent	<i>tuf</i>
984	<i>Streptococcus oralis</i>	This patent	<i>tuf</i>
985	<i>Streptococcus pneumoniae</i>	This patent	<i>tuf</i>
986	<i>Enterococcus hirae</i>	This patent	<i>tuf (C)</i>
987	<i>Enterococcus mundtii</i>	This patent	<i>tuf (C)</i>
25	<i>Enterococcus raffinosus</i>	This patent	<i>tuf (C)</i>
990	<i>Bacillus anthracis</i>	This patent	<i>recA</i>
991	<i>Prevotella melaninogenica</i>	This patent	<i>recA</i>
992	<i>Enterococcus casseliflavus</i>	This patent	<i>tuf</i>
993	<i>Streptococcus pyogenes</i>	Database	<i>speA</i>
30	<i>Streptococcus pyogenes</i>	WO98/20157	<i>tuf</i>
1002	<i>Bacillus cereus</i>	This patent	<i>recA</i>
1003	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1004	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1005	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1006	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
35	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1007	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1008	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1009	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1010	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1011	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
40	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1012	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1013	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1014	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1015	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1016	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1017	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
45	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1018	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1a</i>
1019	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1020	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1021	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
50	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1022	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1023	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1024	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1025	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1026	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
55	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1027	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1028	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1029	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1030	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1031	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
60	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1032	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1033	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2b</i>
1034	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1035	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1036	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
65	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1038	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1039	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1040	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1041	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1042	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
10	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1043	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1044	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1045	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1046	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1047	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
15	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1048	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp2x</i>
1049	<i>Enterococcus faecium</i>	This patent	<i>vana</i>
1050	<i>Enterococcus gallinarum</i>	This patent	<i>vana</i>
1051	<i>Enterococcus faecium</i>	This patent	<i>vana</i>
1052	<i>Enterococcus faecium</i>	This patent	<i>vana</i>
20	<i>Enterococcus faecium</i>	This patent	<i>vana</i>
1053	<i>Enterococcus faecium</i>	This patent	<i>vana</i>
1054	<i>Enterococcus faecalis</i>	This patent	<i>vana</i>
1055	<i>Enterococcus gallinarum</i>	This patent	<i>vana</i>
1056	<i>Enterococcus faecium</i>	This patent	<i>vana</i>
1057	<i>Enterococcus flavescens</i>	This patent	<i>vana</i>
25	<i>Enterococcus gallinarum</i>	This patent	<i>vancI</i>
1058	<i>Enterococcus gallinarum</i>	This patent	<i>vancI</i>
1059	<i>Enterococcus gallinarum</i>	This patent	<i>vancI</i>
1060	<i>Enterococcus casseliflavus</i>	This patent	<i>vanc2</i>
1061	<i>Enterococcus casseliflavus</i>	This patent	<i>vanc2</i>
1062	<i>Enterococcus casseliflavus</i>	This patent	<i>vanc2</i>
30	<i>Enterococcus casseliflavus</i>	This patent	<i>vanc2</i>
1063	<i>Enterococcus casseliflavus</i>	This patent	<i>vanc2</i>
1064	<i>Enterococcus flavescens</i>	This patent	<i>vanc3</i>
1065	<i>Enterococcus flavescens</i>	This patent	<i>vanc3</i>
1066	<i>Enterococcus flavescens</i>	This patent	<i>vanc3</i>
1067	<i>Enterococcus faecium</i>	This patent	<i>vanXY</i>
35	<i>Enterococcus faecium</i>	This patent	<i>vanXY</i>
1068	<i>Enterococcus faecium</i>	This patent	<i>vanXY</i>
1069	<i>Enterococcus faecium</i>	This patent	<i>vanXY</i>
1070	<i>Enterococcus faecalis</i>	This patent	<i>vanXY</i>
1071	<i>Enterococcus gallinarum</i>	This patent	<i>vanXY</i>
1072	<i>Enterococcus faecium</i>	This patent	<i>vanXY</i>
40	<i>Enterococcus flavescens</i>	This patent	<i>vanXY</i>
1073	<i>Enterococcus faecium</i>	This patent	<i>vanXY</i>
1074	<i>Enterococcus faecium</i>	This patent	<i>vanXY</i>
1075	<i>Enterococcus gallinarum</i>	This patent	<i>vanXY</i>
1076	<i>Escherichia coli</i>	Database	<i>stx1</i>
1077	<i>Escherichia coli</i>	Database	<i>stx2</i>
45	<i>Staphylococcus saprophyticus</i>	This patent	unknown
1093	<i>Staphylococcus saprophyticus</i>	Database	<i>vanB</i>
1117	<i>Enterococcus faecium</i>	Database	<i>vanc1</i>
1138	<i>Enterococcus gallinarum</i>	Database	<i>vana</i>
1139	<i>Enterococcus faecium</i>	Database	<i>vanc2</i>
1140	<i>Enterococcus casseliflavus</i>	Database	<i>vanHAXY</i>
50	<i>Enterococcus faecium</i>	Database	<i>vanHAXY</i>
1141	<i>Enterococcus faecium</i>	Database	<i>vanHAXY</i>
1169	<i>Streptococcus pneumoniae</i>	Database	<i>pbp1a</i>
1172	<i>Streptococcus pneumoniae</i>	Database	<i>pbp2b</i>
1173	<i>Streptococcus pneumoniae</i>	Database	<i>pbp2x</i>
1178	<i>Staphylococcus aureus</i>	Database	<i>mecA</i>
55	<i>Streptococcus pneumoniae</i>	Database	<i>hexA</i>
1183	<i>Streptococcus pneumoniae</i>	This patent	<i>hexA</i>
1184	<i>Streptococcus pneumoniae</i>	This patent	<i>hexA</i>
1185	<i>Streptococcus pneumoniae</i>	This patent	<i>hexA</i>
1186	<i>Streptococcus pneumoniae</i>	This patent	<i>hexA</i>
1187	<i>Streptococcus pneumoniae</i>	This patent	<i>hexA</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	1188 <i>Streptococcus oralis</i>	This patent	<i>hexA</i>
	1189 <i>Streptococcus mitis</i>	This patent	<i>hexA</i>
	1190 <i>Streptococcus mitis</i>	This patent	<i>hexA</i>
	1191 <i>Streptococcus mitis</i>	This patent	<i>hexA</i>
	1198 <i>Staphylococcus saprophyticus</i>	This patent	unknown
10	1215 <i>Streptococcus pyogenes</i>	Database	<i>pcp</i>
	1230 <i>Escherichia coli</i>	Database	<i>tuf (EF-G)</i>
	1242 <i>Enterococcus faecium</i>	Database	<i>ddl</i>
	1243 <i>Enterococcus faecalis</i>	Database	<i>mtlF, mtlD</i>
	1244 <i>Staphylococcus aureus</i> subsp. <i>aureus</i>	This patent	unknown
15	1245 <i>Bacillus anthracis</i>	This patent	<i>atpD</i>
	1246 <i>Bacillus mycoides</i>	This patent	<i>atpD</i>
	1247 <i>Bacillus thuringiensis</i>	This patent	<i>atpD</i>
	1248 <i>Bacillus thuringiensis</i>	This patent	<i>atpD</i>
	1249 <i>Bacillus thuringiensis</i>	This patent	<i>atpD</i>
20	1250 <i>Bacillus weihenstephanensis</i>	This patent	<i>atpD</i>
	1251 <i>Bacillus thuringiensis</i>	This patent	<i>atpD</i>
	1252 <i>Bacillus thuringiensis</i>	This patent	<i>atpD</i>
	1253 <i>Bacillus cereus</i>	This patent	<i>atpD</i>
	1254 <i>Bacillus cereus</i>	This patent	<i>atpD</i>
25	1255 <i>Staphylococcus aureus</i>	This patent	<i>gyrA</i>
	1256 <i>Bacillus weihenstephanensis</i>	This patent	<i>atpD</i>
	1257 <i>Bacillus anthracis</i>	This patent	<i>atpD</i>
	1258 <i>Bacillus thuringiensis</i>	This patent	<i>atpD</i>
	1259 <i>Bacillus cereus</i>	This patent	<i>atpD</i>
30	1260 <i>Bacillus cereus</i>	This patent	<i>atpD</i>
	1261 <i>Bacillus thuringiensis</i>	This patent	<i>atpD</i>
	1262 <i>Bacillus thuringiensis</i>	This patent	<i>atpD</i>
	1263 <i>Bacillus thuringiensis</i>	This patent	<i>atpD</i>
	1264 <i>Bacillus thuringiensis</i>	This patent	<i>atpD</i>
35	1265 <i>Bacillus anthracis</i>	This patent	<i>atpD</i>
	1266 <i>Paracoccidioides brasiliensis</i>	This patent	<i>tuf (EF-1)</i>
	1267 <i>Blastomyces dermatitidis</i>	This patent	<i>tuf (EF-1)</i>
	1268 <i>Histoplasma capsulatum</i>	This patent	<i>tuf (EF-1)</i>
	1269 <i>Trichophyton rubrum</i>	This patent	<i>tuf (EF-1)</i>
40	1270 <i>Microsporum canis</i>	This patent	<i>tuf (EF-1)</i>
	1271 <i>Aspergillus versicolor</i>	This patent	<i>tuf (EF-1)</i>
	1272 <i>Exophiala moniliae</i>	This patent	<i>tuf (EF-1)</i>
	1273 <i>Hortaea wemeckii</i>	This patent	<i>tuf (EF-1)</i>
	1274 <i>Fusarium solani</i>	This patent	<i>tuf (EF-1)</i>
45	1275 <i>Aureobasidium pullulans</i>	This patent	<i>tuf (EF-1)</i>
	1276 <i>Blastomyces dermatitidis</i>	This patent	<i>tuf (EF-1)</i>
	1277 <i>Exophiala dermatitidis</i>	This patent	<i>tuf (EF-1)</i>
	1278 <i>Fusarium moniliiforme</i>	This patent	<i>tuf (EF-1)</i>
	1279 <i>Aspergillus terreus</i>	This patent	<i>tuf (EF-1)</i>
50	1280 <i>Aspergillus fumigatus</i>	This patent	<i>tuf (EF-1)</i>
	1281 <i>Cryptococcus laurentii</i>	This patent	<i>tuf (EF-1)</i>
	1282 <i>Emmonsia parva</i>	This patent	<i>tuf (EF-1)</i>
	1283 <i>Fusarium solani</i>	This patent	<i>tuf (EF-1)</i>
	1284 <i>Sporothrix schenckii</i>	This patent	<i>tuf (EF-1)</i>
55	1285 <i>Aspergillus nidulans</i>	This patent	<i>tuf (EF-1)</i>
	1286 <i>Cladophialophora carmionii</i>	This patent	<i>tuf (EF-1)</i>
	1287 <i>Exserohilum rostratum</i>	This patent	<i>tuf (EF-1)</i>
	1288 <i>Bacillus thuringiensis</i>	This patent	<i>recA</i>
	1289 <i>Bacillus thuringiensis</i>	This patent	<i>recA</i>
60	1299 <i>Staphylococcus aureus</i>	Database	<i>gyrA</i>
	1300 <i>Escherichia coli</i>	Database	<i>gyrA</i>
	1307 <i>Staphylococcus aureus</i>	Database	<i>gyrB</i>
	1320 <i>Escherichia coli</i>	Database	<i>parC (grlA)</i>
	1321 <i>Staphylococcus aureus</i>	Database	<i>parC (grlA)</i>
65	1328 <i>Staphylococcus aureus</i>	Database	<i>parE (grlB)</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	1348 unidentified bacterium	Database	<i>aac2Ia</i>
	1351 <i>Pseudomonas aeruginosa</i>	Database	<i>aac3Ib</i>
	1356 <i>Serratia marcescens</i>	Database	<i>aac3IIb</i>
	1361 <i>Escherichia coli</i>	Database	<i>aac3IVa</i>
	1366 <i>Enterobacter cloacae</i>	Database	<i>aac3VIa</i>
10	1371 <i>Citrobacter koseri</i>	Database	<i>aac6Ia</i>
	1376 <i>Serratia marcescens</i>	Database	<i>aac6Ic</i>
	1381 <i>Escherichia coli</i>	Database	<i>ant3Ia</i>
	1386 <i>Staphylococcus aureus</i>	Database	<i>ant4Ia</i>
	1391 <i>Escherichia coli</i>	Database	<i>aph3Ia</i>
15	1396 <i>Escherichia coli</i>	Database	<i>aph3IIIa</i>
	1401 <i>Enterococcus faecalis</i>	Database	<i>aph3IIIa</i>
	1406 <i>Acinetobacter baumannii</i>	Database	<i>aph3Vla</i>
	1411 <i>Pseudomonas aeruginosa</i>	Database	<i>blaCARB</i>
	1416 <i>Klebsiella pneumoniae</i>	Database	<i>blaCMY-2</i>
20	1423 <i>Escherichia coli</i>	Database	<i>blaCTX-M-1</i>
	1428 <i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Typhimurium	Database	<i>blaCTX-M-2</i>
	1433 <i>Pseudomonas aeruginosa</i>	Database	<i>blaIMP</i>
	1438 <i>Escherichia coli</i>	Database	<i>blaOXA2</i>
25	1439 <i>Pseudomonas aeruginosa</i>	Database	<i>blaOXA10</i>
	1442 <i>Pseudomonas aeruginosa</i>	Database	<i>blaPER1</i>
	1445 <i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Typhimurium	Database	<i>blaPER2</i>
	1452 <i>Staphylococcus epidermidis</i>	Database	<i>dfrA</i>
30	1461 <i>Escherichia coli</i>	Database	<i>dfrIA</i>
	1470 <i>Escherichia coli</i>	Database	<i>dfrIB</i>
	1475 <i>Escherichia coli</i>	Database	<i>dfrV</i>
	1480 <i>Proteus mirabilis</i>	Database	<i>dfrVI</i>
	1489 <i>Escherichia coli</i>	Database	<i>dfrVII</i>
35	1494 <i>Escherichia coli</i>	Database	<i>dfrVIII</i>
	1499 <i>Escherichia coli</i>	Database	<i>dfrIX</i>
	1504 <i>Escherichia coli</i>	Database	<i>dfrXII</i>
	1507 <i>Escherichia coli</i>	Database	<i>dfrXIII</i>
	1512 <i>Escherichia coli</i>	Database	<i>dfrXV</i>
40	1517 <i>Escherichia coli</i>	Database	<i>dfrXVII</i>
	1518 <i>Acinetobacter lwoffii</i>	This patent	<i>fusA</i>
	1519 <i>Acinetobacter lwoffii</i>	This patent	<i>fusA-tuf spacer</i>
	1520 <i>Acinetobacter lwoffii</i>	This patent	<i>tuf</i>
	1521 <i>Haemophilus influenzae</i>	This patent	<i>fusA</i>
45	1522 <i>Haemophilus influenzae</i>	This patent	<i>fusA-tuf spacer</i>
	1523 <i>Haemophilus influenzae</i>	This patent	<i>tuf</i>
	1524 <i>Proteus mirabilis</i>	This patent	<i>fusA</i>
	1525 <i>Proteus mirabilis</i>	This patent	<i>fusA-tuf spacer</i>
	1526 <i>Proteus mirabilis</i>	This patent	<i>tuf</i>
50	1527 <i>Campylobacter curvus</i>	This patent	<i>atpD</i>
	1530 <i>Escherichia coli</i>	Database	<i>ereA</i>
	1535 <i>Escherichia coli</i>	Database	<i>ereB</i>
	1540 <i>Staphylococcus haemolyticus</i>	Database	<i>linA</i>
	1545 <i>Enterococcus faecium</i>	Database	<i>linB</i>
55	1548 <i>Streptococcus pyogenes</i>	Database	<i>melA</i>
	1551 <i>Streptococcus pneumoniae</i>	Database	<i>melE</i>
	1560 <i>Escherichia coli</i>	Database	<i>mphA</i>
	1561 <i>Candida albicans</i>	This patent	<i>tuf (EF-1)</i>
	1562 <i>Candida dubliniensis</i>	This patent	<i>tuf (EF-1)</i>
60	1563 <i>Candida famata</i>	This patent	<i>tuf (EF-1)</i>
	1564 <i>Candida glabrata</i>	This patent	<i>tuf (EF-1)</i>
	1565 <i>Candida guilliermondii</i>	This patent	<i>tuf (EF-1)</i>
	1566 <i>Candida haemulonii</i>	This patent	<i>tuf (EF-1)</i>
	1567 <i>Candida kefyr</i>	This patent	<i>tuf (EF-1)</i>
65	1568 <i>Candida lusitaniae</i>	This patent	<i>tuf (EF-1)</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Candida sphaerica</i>	This patent	<i>tuf</i> (EF-1)
1569	<i>Candida tropicalis</i>	This patent	<i>tuf</i> (EF-1)
1570	<i>Candida viswanathii</i>	This patent	<i>tuf</i> (EF-1)
1571	<i>Alcaligenes faecalis</i> subsp. <i>faecalis</i>	This patent	<i>tuf</i>
1572	<i>Prevotella buccalis</i>	This patent	<i>tuf</i>
1573	<i>Succinivibrio dextrinosolvens</i>	This patent	<i>tuf</i>
10	<i>Tetragenococcus halophilus</i>	This patent	<i>tuf</i>
1574	<i>Campylobacter jejuni</i> subsp. <i>jejuni</i>	This patent	<i>atpD</i>
1575	<i>Campylobacter rectus</i>	This patent	<i>atpD</i>
1576	<i>Enterococcus casseliflavus</i>	This patent	<i>fusA</i>
1577	<i>Enterococcus gallinarum</i>	This patent	<i>fusA</i>
15	<i>Streptococcus mitis</i>	This patent	<i>fusA</i>
1579	<i>Enterococcus faecium</i>	Database	<i>satG</i>
1580	Cloning vector pFW16	Database	<i>telM</i>
1585	<i>Enterococcus faecium</i>	Database	<i>vanD</i>
1590	<i>Enterococcus faecalis</i>	Database	<i>vanE</i>
1594	<i>Campylobacter jejuni</i> subsp. <i>doulei</i>	This patent	<i>atpD</i>
20	<i>Enterococcus sulfureus</i>	This patent	<i>atpD</i>
1599	<i>Enterococcus solitarius</i>	This patent	<i>atpD</i>
1600	<i>Campylobacter sputorum</i> subsp. <i>sputorum</i>	This patent	<i>atpD</i>
1601	<i>Enterococcus pseudoavium</i>	This patent	<i>gyrA</i>
25	<i>Klebsiella ornithinolytica</i>	This patent	<i>gyrA</i>
1607	<i>Klebsiella oxytoca</i>	Database	<i>vatB</i>
1608	<i>Staphylococcus aureus</i>	Database	<i>vatC</i>
1613	<i>Staphylococcus cohnii</i>	Database	<i>vga</i>
30	<i>Staphylococcus aureus</i>	Database	<i>vgaB</i>
1623	<i>Staphylococcus aureus</i>	Database	<i>vgb</i>
1628	<i>Aspergillus fumigatus</i>	This patent	<i>atpD</i>
1633	<i>Aspergillus fumigatus</i>	This patent	<i>atpD</i>
1638	<i>Bacillus mycoides</i>	This patent	<i>atpD</i>
35	<i>Bacillus mycoides</i>	This patent	<i>atpD</i>
1641	<i>Bacillus mycoides</i>	This patent	<i>atpD</i>
1642	<i>Bacillus mycoides</i>	This patent	<i>atpD</i>
1643	<i>Bacillus pseudomycoides</i>	This patent	<i>atpD</i>
1644	<i>Bacillus pseudomycoides</i>	This patent	<i>atpD</i>
40	<i>Budvicia aquatica</i>	This patent	<i>atpD</i>
1645	<i>Buttiauxella agrestis</i>	This patent	<i>atpD</i>
1646	<i>Candida norvegica</i>	This patent	<i>atpD</i>
1647	<i>Streptococcus pneumoniae</i>	This patent	<i>ppb1a</i>
1648	<i>Campylobacter lari</i>	This patent	<i>atpD</i>
45	<i>Coccidioides immitis</i>	This patent	<i>atpD</i>
1650	<i>Emmonsia parva</i>	This patent	<i>atpD</i>
1651	<i>Erwinia amylovora</i>	This patent	<i>atpD</i>
1652	<i>Fonsecaea pedrosoi</i>	This patent	<i>atpD</i>
1653	<i>Fusarium moniliforme</i>	This patent	<i>atpD</i>
50	<i>Klebsiella oxytoca</i>	This patent	<i>atpD</i>
1655	<i>Microsporum audouinii</i>	This patent	<i>atpD</i>
1656	<i>Obesumbacterium proteus</i>	This patent	<i>atpD</i>
1657	<i>Paracoccidioides brasiliensis</i>	This patent	<i>atpD</i>
1658	<i>Plesiomonas shigelloides</i>	This patent	<i>atpD</i>
55	<i>Shewanella putrefaciens</i>	This patent	<i>atpD</i>
1660	<i>Campylobacter curvus</i>	This patent	<i>tuf</i>
1662	<i>Campylobacter rectus</i>	This patent	<i>tuf</i>
1663	<i>Fonsecaea pedrosoi</i>	This patent	<i>tuf</i>
1664	<i>Microsporum audouinii</i>	This patent	<i>tuf</i>
60	<i>Piedraia hortai</i>	This patent	<i>tuf</i>
1667	<i>Escherichia coli</i>	Database	<i>tuf</i>
1668	<i>Saksenaea vasiformis</i>	This patent	<i>tuf</i>
1669	<i>Trichophyton tonsurans</i>	This patent	<i>tuf</i>
1670	<i>Enterobacter aerogenes</i>	This patent	<i>atpD</i>
65	<i>Bordetella pertussis</i>	Database	<i>atpD</i>
1672	<i>Arcanobacterium haemolyticum</i>	This patent	<i>tuf</i>
1673			

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Butyrivibrio fibrisolvens</i>	This patent	<i>tuf</i>
	<i>Campylobacter jejuni</i> subsp. <i>doylei</i>	This patent	<i>tuf</i>
	<i>Campylobacter lari</i>	This patent	<i>tuf</i>
	<i>Campylobacter sputorum</i> subsp. <i>sputorum</i>	This patent	<i>tuf</i>
	<i>Campylobacter upsaliensis</i>	This patent	<i>tuf</i>
10	<i>Globicatella sanguis</i>	This patent	<i>tuf</i>
	<i>Lactobacillus acidophilus</i>	This patent	<i>tuf</i>
	<i>Leuconostoc mesenteroides</i> subsp. <i>dextranicum</i>	This patent	<i>tuf</i>
	<i>Prevotella buccalis</i>	This patent	<i>tuf</i>
	<i>Ruminococcus bromii</i>	This patent	<i>tuf</i>
15	<i>Paracoccidioides brasiliensis</i>	This patent	<i>alpD</i>
	<i>Candida norvegica</i>	This patent	<i>tuf</i> (EF-1)
	<i>Aspergillus nidulans</i>	This patent	<i>tuf</i>
	<i>Aspergillus terreus</i>	This patent	<i>tuf</i>
	<i>Candida norvegica</i>	This patent	<i>tuf</i>
20	<i>Candida parapsilosis</i>	This patent	<i>tuf</i>
	<i>Streptococcus gordonii</i>	WO98/20157	<i>recA</i>
	<i>Streptococcus mutans</i>	WO98/20157	<i>recA</i>
	<i>Streptococcus pneumoniae</i>	WO98/20157	<i>recA</i>
	<i>Streptococcus pyogenes</i>	WO98/20157	<i>recA</i>
25	<i>Streptococcus salivarius</i> subsp. <i>thermophilus</i>	WO98/20157	<i>recA</i>
	<i>Escherichia coli</i>	WO98/20157	<i>oxa</i>
	<i>Enterococcus faecalis</i>	WO98/20157	<i>blaZ</i>
	<i>Pseudomonas aeruginosa</i>	WO98/20157	<i>aac6'-Ila</i>
	<i>Staphylococcus aureus</i>	WO98/20157	<i>ermA</i>
30	<i>Escherichia coli</i>	WO98/20157	<i>ermB</i>
	<i>Staphylococcus aureus</i>	WO98/20157	<i>ermC</i>
	<i>Enterococcus faecalis</i>	WO98/20157	<i>vanB</i>
	<i>Campylobacter jejuni</i> subsp. <i>jejuni</i>	This patent	<i>recA</i>
	<i>Abiotrophia adiacens</i>	WO98/20157	<i>tuf</i>
35	<i>Abiotrophia defectiva</i>	WO98/20157	<i>tuf</i>
	<i>Corynebacterium accolens</i>	WO98/20157	<i>tuf</i>
	<i>Corynebacterium genitalium</i>	WO98/20157	<i>tuf</i>
	<i>Corynebacterium jeikeium</i>	WO98/20157	<i>tuf</i>
	<i>Corynebacterium pseudodiphtheriticum</i>	WO98/20157	<i>tuf</i>
40	<i>Corynebacterium striatum</i>	WO98/20157	<i>tuf</i>
	<i>Enterococcus avium</i>	WO98/20157	<i>tuf</i>
	<i>Gardnerella vaginalis</i>	WO98/20157	<i>tuf</i>
	<i>Listeria innocua</i>	WO98/20157	<i>tuf</i>
	<i>Listeria ivanovii</i>	WO98/20157	<i>tuf</i>
45	<i>Listeria monocytogenes</i>	WO98/20157	<i>tuf</i>
	<i>Listeria seeligeri</i>	WO98/20157	<i>tuf</i>
	<i>Staphylococcus aureus</i>	WO98/20157	<i>tuf</i>
	<i>Staphylococcus saprophyticus</i>	WO98/20157	<i>tuf</i>
	<i>Staphylococcus simulans</i>	WO98/20157	<i>tuf</i>
50	<i>Streptococcus agalactiae</i>	WO98/20157	<i>tuf</i>
	<i>Streptococcus pneumoniae</i>	WO98/20157	<i>tuf</i>
	<i>Streptococcus salivarius</i>	WO98/20157	<i>tuf</i>
	<i>Agrobacterium radiobacter</i>	WO98/20157	<i>tuf</i>
	<i>Bacillus subtilis</i>	WO98/20157	<i>tuf</i>
55	<i>Bacteroides fragilis</i>	WO98/20157	<i>tuf</i>
	<i>Borrelia burgdorferi</i>	WO98/20157	<i>tuf</i>
	<i>Brevibacterium linens</i>	WO98/20157	<i>tuf</i>
	<i>Chlamydia trachomatis</i>	WO98/20157	<i>tuf</i>
	<i>Fibrobacter succinogenes</i>	WO98/20157	<i>tuf</i>
60	<i>Flavobacterium terrigineum</i>	WO98/20157	<i>tuf</i>
	<i>Helicobacter pylori</i>	WO98/20157	<i>tuf</i>
	<i>Micrococcus luteus</i>	WO98/20157	<i>tuf</i>
	<i>Mycobacterium tuberculosis</i>	WO98/20157	<i>tuf</i>
	<i>Mycoplasma genitalium</i>	WO98/20157	<i>tuf</i>
65	<i>Neisseria gonorrhoeae</i>	WO98/20157	<i>tuf</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Rickettsia prowazekii</i>	WO98/20157	<i>tuf</i>
	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i>	WO98/20157	<i>tuf</i>
	serotype Typhimurium		
	<i>Shewanella putrefaciens</i>	WO98/20157	<i>tuf</i>
10	<i>Stigmatella aurantiaca</i>	WO98/20157	<i>tuf</i>
	<i>Thiomonas cuprina</i>	WO98/20157	<i>tuf</i>
	<i>Treponema pallidum</i>	WO98/20157	<i>tuf</i>
	<i>Ureaplasma urealyticum</i>	WO98/20157	<i>tuf</i>
	<i>Wolinella succinogenes</i>	WO98/20157	<i>tuf</i>
15	<i>Burkholderia cepacia</i>	WO98/20157	<i>tuf</i>
	<i>Bacillus anthracis</i>	This patent	<i>recA</i>
	<i>Bacillus anthracis</i>	This patent	<i>recA</i>
	<i>Bacillus cereus</i>	This patent	<i>recA</i>
	<i>Bacillus cereus</i>	This patent	<i>recA</i>
20	<i>Bacillus mycoides</i>	This patent	<i>recA</i>
	<i>Bacillus pseudomycoides</i>	This patent	<i>recA</i>
	<i>Bacillus thuringiensis</i>	This patent	<i>recA</i>
	<i>Bacillus thuringiensis</i>	This patent	<i>recA</i>
	<i>Klebsiella oxytoca</i>	This patent	<i>gyrA</i>
25	<i>Klebsiella pneumoniae</i> subsp. <i>ozaenae</i>	This patent	<i>gyrA</i>
	<i>Klebsiella planticola</i>	This patent	<i>gyrA</i>
	<i>Klebsiella pneumoniae</i>	This patent	<i>gyrA</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i>	This patent	<i>gyrA</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i>	This patent	<i>gyrA</i>
30	<i>Klebsiella pneumoniae</i> subsp. <i>rhinoscleromatis</i>	This patent	<i>gyrA</i>
	<i>Klebsiella terrigena</i>	This patent	<i>gyrA</i>
	<i>Legionella pneumophila</i> subsp. <i>pneumophila</i>	This patent	<i>gyrA</i>
	<i>Proteus mirabilis</i>	This patent	<i>gyrA</i>
	<i>Providencia rettgeri</i>	This patent	<i>gyrA</i>
35	<i>Proteus vulgaris</i>	This patent	<i>gyrA</i>
	<i>Yersinia enterocolitica</i>	This patent	<i>parC (grlA)</i>
	<i>Klebsiella oxytoca</i>	This patent	<i>parC (grlA)</i>
	<i>Klebsiella oxytoca</i>	This patent	<i>parC (grlA)</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>ozaenae</i>	This patent	<i>parC (grlA)</i>
40	<i>Klebsiella planticola</i>	This patent	<i>parC (grlA)</i>
	<i>Klebsiella pneumoniae</i>	This patent	<i>parC (grlA)</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i>	This patent	<i>parC (grlA)</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i>	This patent	<i>parC (grlA)</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>rhinoscleromatis</i>	This patent	<i>parC (grlA)</i>
45	<i>Klebsiella terrigena</i>	This patent	<i>parC (grlA)</i>
	<i>Bacillus cereus</i>	This patent	<i>fusA</i>
	<i>Bacillus cereus</i>	This patent	<i>fusA</i>
	<i>Bacillus anthracis</i>	This patent	<i>fusA</i>
	<i>Bacillus cereus</i>	This patent	<i>fusA</i>
50	<i>Bacillus anthracis</i>	This patent	<i>fusA</i>
	<i>Bacillus pseudomycoides</i>	This patent	<i>fusA</i>
	<i>Bacillus cereus</i>	This patent	<i>fusA</i>
	<i>Bacillus anthracis</i>	This patent	<i>fusA</i>
	<i>Bacillus cereus</i>	This patent	<i>fusA</i>
55	<i>Bacillus weihenstephanensis</i>	This patent	<i>fusA</i>
	<i>Bacillus mycoides</i>	This patent	<i>fusA</i>
	<i>Bacillus thuringiensis</i>	This patent	<i>fusA</i>
	<i>Bacillus weihenstephanensis</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Bacillus thuringiensis</i>	This patent	<i>fusA-tuf spacer</i>
60	<i>Bacillus anthracis</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Bacillus pseudomycoides</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Bacillus anthracis</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Bacillus cereus</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Bacillus cereus</i>	This patent	<i>fusA-tuf spacer</i>
65	<i>Bacillus mycoides</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Bacillus cereus</i>	This patent	<i>fusA-tuf spacer</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Bacillus cereus</i>	This patent	<i>fusA-tuf</i> spacer
	<i>Bacillus cereus</i>	This patent	<i>fusA-tuf</i> spacer
	<i>Bacillus anthracis</i>	This patent	<i>fusA-tuf</i> spacer
	<i>Bacillus mycoides</i>	This patent	<i>tuf</i>
	<i>Bacillus thuringiensis</i>	This patent	<i>tuf</i>
10	<i>Bacillus cereus</i>	This patent	<i>tuf</i>
	<i>Bacillus weihenstephanensis</i>	This patent	<i>tuf</i>
	<i>Bacillus anthracis</i>	This patent	<i>tuf</i>
	<i>Bacillus cereus</i>	This patent	<i>tuf</i>
	<i>Bacillus cereus</i>	This patent	<i>tuf</i>
15	<i>Bacillus anthracis</i>	This patent	<i>tuf</i>
	<i>Bacillus cereus</i>	This patent	<i>tuf</i>
	<i>Bacillus anthracis</i>	This patent	<i>tuf</i>
	<i>Bacillus pseudomycoides</i>	This patent	<i>tuf</i>
	<i>Bacillus cereus</i>	This patent	<i>tuf</i>
20	<i>Streptococcus oralis</i>	This patent	<i>fusA</i>
	<i>Budvicia aquatica</i>	This patent	<i>fusA</i>
	<i>Buttiauxella agrestis</i>	This patent	<i>fusA</i>
	<i>Klebsiella oxytoca</i>	This patent	<i>fusA</i>
	<i>Plesiomonas shigelloides</i>	This patent	<i>fusA</i>
25	<i>Shewanella putrefaciens</i>	This patent	<i>fusA</i>
	<i>Obesumbacterium proteus</i>	This patent	<i>fusA</i>
	<i>Klebsiella oxytoca</i>	This patent	<i>fusA-tuf</i> spacer
	<i>Budvicia aquatica</i>	This patent	<i>fusA-tuf</i> spacer
	<i>Plesiomonas shigelloides</i>	This patent	<i>fusA-tuf</i> spacer
30	<i>Obesumbacterium proteus</i>	This patent	<i>fusA-tuf</i> spacer
	<i>Shewanella putrefaciens</i>	This patent	<i>fusA-tuf</i> spacer
	<i>Buttiauxella agrestis</i>	This patent	<i>fusA-tuf</i> spacer
	<i>Campylobacter coli</i>	This patent	<i>tuf</i>
	<i>Campylobacter fetus subsp. fetus</i>	This patent	<i>tuf</i>
35	<i>Campylobacter fetus subsp. venerealis</i>	This patent	<i>tuf</i>
	<i>Buttiauxella agrestis</i>	This patent	<i>tuf</i>
	<i>Klebsiella oxytoca</i>	This patent	<i>tuf</i>
	<i>Plesiomonas shigelloides</i>	This patent	<i>tuf</i>
	<i>Shewanella putrefaciens</i>	This patent	<i>tuf</i>
40	<i>Obesumbacterium proteus</i>	This patent	<i>tuf</i>
	<i>Budvicia aquatica</i>	This patent	<i>tuf</i>
	<i>Abiotrophia adiacens</i>	This patent	<i>atpD</i>
	<i>Arcanobacterium haemolyticum</i>	This patent	<i>atpD</i>
	<i>Basidiobolus ranarum</i>	This patent	<i>atpD</i>
45	<i>Blastomyces dermatitidis</i>	This patent	<i>atpD</i>
	<i>Blastomyces dermatitidis</i>	This patent	<i>atpD</i>
	<i>Campylobacter coli</i>	This patent	<i>atpD</i>
	<i>Campylobacter fetus subsp. fetus</i>	This patent	<i>atpD</i>
	<i>Campylobacter fetus subsp. venerealis</i>	This patent	<i>atpD</i>
50	<i>Campylobacter gracilis</i>	This patent	<i>atpD</i>
	<i>Campylobacter jejuni subsp. jejuni</i>	This patent	<i>atpD</i>
	<i>Enterococcus cecorum</i>	This patent	<i>atpD</i>
	<i>Enterococcus columbae</i>	This patent	<i>atpD</i>
	<i>Enterococcus dispar</i>	This patent	<i>atpD</i>
55	<i>Enterococcus malodoratus</i>	This patent	<i>atpD</i>
	<i>Enterococcus mundtii</i>	This patent	<i>atpD</i>
	<i>Enterococcus raffinosus</i>	This patent	<i>atpD</i>
	<i>Globicatella sangulis</i>	This patent	<i>atpD</i>
	<i>Lactococcus garvieae</i>	This patent	<i>atpD</i>
60	<i>Lactococcus lactis</i>	This patent	<i>atpD</i>
	<i>Listeria ivanovii</i>	This patent	<i>atpD</i>
	<i>Succinivibrio dextrinosolvens</i>	This patent	<i>atpD</i>
	<i>Tetragenococcus halophilus</i>	This patent	<i>atpD</i>
	<i>Campylobacter fetus subsp. fetus</i>	This patent	<i>recA</i>
65	<i>Campylobacter fetus subsp. venerealis</i>	This patent	<i>recA</i>
	<i>Campylobacter jejuni subsp. jejuni</i>	This patent	<i>recA</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Enterococcus avium</i>	This patent	<i>recA</i>
1869	<i>Enterococcus faecium</i>	This patent	<i>recA</i>
1870	<i>Listeria monocytogenes</i>	This patent	<i>recA</i>
1871	<i>Streptococcus mitis</i>	This patent	<i>recA</i>
1872	<i>Streptococcus oralis</i>	This patent	<i>recA</i>
1873	<i>Aspergillus fumigatus</i>	This patent	<i>tuf (M)</i>
10	<i>Aspergillus versicolor</i>	This patent	<i>tuf (M)</i>
1874	<i>Basidiobolus ranarum</i>	This patent	<i>tuf (M)</i>
1875	<i>Campylobacter gracilis</i>	This patent	<i>tuf</i>
1876	<i>Campylobacter jejuni</i> subsp. <i>jejuni</i>	This patent	<i>tuf</i>
1877	<i>Coccidioides immitis</i>	This patent	<i>tuf (M)</i>
15	<i>Erwinia amylovora</i>	This patent	<i>tuf</i>
1878	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype <i>Typhimurium</i>	This patent	<i>tuf</i>
1879	<i>Klebsiella pneumoniae</i>	Database	<i>blaSHV</i>
1880	<i>Klebsiella pneumoniae</i>	Database	<i>blaSHV</i>
1881	<i>Escherichia coli</i>	Database	<i>blaSHV</i>
20	<i>Klebsiella pneumoniae</i>	Database	<i>blaSHV</i>
1899	<i>Klebsiella pneumoniae</i>	Database	<i>blaSHV</i>
1900	<i>Klebsiella pneumoniae</i>	Database	<i>blaSHV</i>
1901	<i>Escherichia coli</i>	Database	<i>blaSHV</i>
1902	<i>Klebsiella pneumoniae</i>	Database	<i>blaSHV</i>
1903	<i>Klebsiella pneumoniae</i>	Database	<i>blaSHV</i>
25	<i>Escherichia coli</i>	Database	<i>blaSHV</i>
1904	<i>Pseudomonas aeruginosa</i>	Database	<i>blaSHV</i>
1905	<i>Neisseria meningitidis</i>	Database	<i>blaTEM</i>
1927	<i>Escherichia coli</i>	Database	<i>blaTEM</i>
1928	<i>Klebsiella oxytoca</i>	Database	<i>blaTEM</i>
1929	<i>Escherichia coli</i>	Database	<i>blaTEM</i>
30	<i>Escherichia coli</i>	Database	<i>blaTEM</i>
1931	<i>Escherichia coli</i>	Database	<i>blaTEM</i>
1932	<i>Escherichia coli</i>	Database	<i>blaTEM</i>
1933	<i>Escherichia coli</i>	Database	<i>blaTEM</i>
1954	<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i>	Database	<i>gyrA</i>
1956	<i>Candida inconspicua</i>	This patent	<i>tuf (M)</i>
35	<i>Candida utilis</i>	This patent	<i>tuf (M)</i>
1957	<i>Candida zeylanoides</i>	This patent	<i>tuf (M)</i>
1958	<i>Candida catenulata</i>	This patent	<i>tuf (M)</i>
1959	<i>Candida krusei</i>	This patent	<i>tuf (M)</i>
1960	Plasmid pGS05	Database	<i>sull</i>
40	Transposon Tn10	Database	<i>tetB</i>
1970	<i>Cryptococcus neoformans</i>	Database	<i>tuf (EF-1)</i>
1985	<i>Cryptococcus neoformans</i>	Database	<i>tuf (EF-1)</i>
1986	<i>Saccharomyces cerevisiae</i>	Database	<i>tuf (EF-1)</i>
1987	<i>Saccharomyces cerevisiae</i>	Database	<i>tuf (EF-1)</i>
45	<i>Eremothecium gossypii</i>	Database	<i>tuf (EF-1)</i>
1988	<i>Eremothecium gossypii</i>	Database	<i>tuf (EF-1)</i>
1989	<i>Aspergillus oryzae</i>	Database	<i>tuf (EF-1)</i>
1990	<i>Aureobasidium pullulans</i>	Database	<i>tuf (EF-1)</i>
1991	<i>Histoplasma capsulatum</i>	Database	<i>tuf (EF-1)</i>
50	<i>Neurospora crassa</i>	Database	<i>tuf (EF-1)</i>
1994	<i>Podospora anserina</i>	Database	<i>tuf (EF-1)</i>
1995	<i>Podospora curvicerca</i>	Database	<i>tuf (EF-1)</i>
1996	<i>Sordaria macrospora</i>	Database	<i>tuf (EF-1)</i>
1997	<i>Trichoderma reesei</i>	Database	<i>tuf (EF-1)</i>
55	<i>Candida albicans</i>	Database	<i>tuf (M)</i>
2004	<i>Schizosaccharomyces pombe</i>	Database	<i>tuf (M)</i>
2005	<i>Klebsiella pneumoniae</i>	Database	<i>blaTEM</i>
2010	<i>Klebsiella pneumoniae</i>	Database	<i>blaTEM</i>
2011	<i>Kluyvera ascorbata</i>	This patent	<i>gyrA</i>
60	<i>Kluyvera georgiana</i>	This patent	<i>gyrA</i>
2013	<i>Streptococcus pneumoniae</i>	Database	<i>ppb1A</i>
2047	<i>Streptococcus pneumoniae</i>	Database	<i>ppb1A</i>
2048	<i>Streptococcus pneumoniae</i>	Database	<i>ppb1A</i>
2049	<i>Streptococcus pneumoniae</i>	Database	<i>ppb1A</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Streptococcus pneumoniae</i>	Database	<i>pbp1A</i>
	<i>Streptococcus pneumoniae</i>	Database	<i>pbp1A</i>
	<i>Streptococcus pneumoniae</i>	Database	<i>pbp1A</i>
	<i>Streptococcus pneumoniae</i>	Database	<i>pbp1A</i>
	<i>Streptococcus pneumoniae</i>	Database	<i>gyrA</i>
10	<i>Streptococcus pneumoniae</i>	Database	<i>parC</i>
	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1A</i>
	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1A</i>
	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1A</i>
	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1A</i>
15	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1A</i>
	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1A</i>
	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1A</i>
	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1A</i>
20	<i>Streptococcus pneumoniae</i>	This patent	<i>pbp1A</i>
	<i>Mycobacterium tuberculosis</i>	Database	<i>rpoB</i>
	<i>Mycoplasma pneumoniae</i>	Database	<i>tuf</i>
	<i>Mycobacterium tuberculosis</i>	Database	<i>inhA</i>
	<i>Mycobacterium tuberculosis</i>	Database	<i>embB</i>
25	<i>Clostridium difficile</i>	Database	<i>cdtA</i>
	<i>Clostridium difficile</i>	Database	<i>cdtB</i>
	<i>Pseudomonas putida</i>	Genome project	<i>tuf</i>
	<i>Pseudomonas aeruginosa</i>	Genome project	<i>tuf</i>
	<i>Campylobacter jejuni</i>	Database	<i>atpD</i>
30	<i>Streptococcus pneumoniae</i>	Database	<i>pbp1a</i>
	<i>Staphylococcus aureus</i>	Database	<i>mupA</i>
	<i>Escherichia coli</i>	Database	<i>catI</i>
	<i>Escherichia coli</i>	Database	<i>catII</i>
	<i>Shigella flexneri</i>	Database	<i>catIII</i>
35	<i>Clostridium perfringens</i>	Database	<i>catP</i>
	<i>Staphylococcus aureus</i>	Database	<i>cat</i>
	<i>Staphylococcus aureus</i>	Database	<i>ppf1o-like</i>
	<i>Salmonella typhimurium</i>	Database	<i>tuf</i>
	<i>Alcaligenes faecalis</i> subsp. <i>faecalis</i>	This patent	<i>fusA</i>
40	<i>Campylobacter coli</i>	This patent	<i>tuf</i>
	<i>Succinivibrio dextrinosolvens</i>	This patent	<i>tuf</i>
	<i>Tetragenococcus halophilus</i>	This patent	<i>tuf</i>
	<i>Campylobacter jejuni</i> subsp. <i>jejuni</i>	This patent	<i>fusA</i>
	<i>Campylobacter jejuni</i> subsp. <i>jejuni</i>	This patent	<i>fusA</i>
45	<i>Leishmania guyanensis</i>	This patent	<i>atpD</i>
	<i>Trypanosoma brucei brucei</i>	This patent	<i>atpD</i>
	<i>Aspergillus nidulans</i>	This patent	<i>atpD</i>
	<i>Leishmania panamensis</i>	This patent	<i>atpD</i>
	<i>Aspergillus nidulans</i>	This patent	<i>tuf (M)</i>
50	<i>Aureobasidium pullulans</i>	This patent	<i>tuf (M)</i>
	<i>Emmonsia parva</i>	This patent	<i>tuf (M)</i>
	<i>Exserohilum rostratum</i>	This patent	<i>tuf (M)</i>
	<i>Fusarium moniliforme</i>	This patent	<i>tuf (M)</i>
	<i>Fusarium solani</i>	This patent	<i>tuf (M)</i>
55	<i>Histoplasma capsulatum</i>	This patent	<i>tuf (M)</i>
	<i>Kocuria kristinae</i>	This patent	<i>tuf</i>
	<i>Vibrio mimicus</i>	This patent	<i>tuf</i>
	<i>Citrobacter freundii</i>	This patent	<i>recA</i>
	<i>Clostridium botulinum</i>	This patent	<i>recA</i>
	<i>Francisella tularensis</i>	This patent	<i>recA</i>
60	<i>Peptostreptococcus anaerobius</i>	This patent	<i>recA</i>
	<i>Peptostreptococcus asaccharolyticus</i>	This patent	<i>recA</i>
	<i>Providencia stuartii</i>	This patent	<i>recA</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Paratyphi A	This patent	<i>recA</i>
	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype Typhimurium	This patent	<i>recA</i>
10	<i>Staphylococcus saprophyticus</i>	This patent	<i>recA</i>
	<i>Yersinia pseudotuberculosis</i>	This patent	<i>recA</i>
	<i>Zoogloea ramigera</i>	This patent	<i>recA</i>
	<i>Abiotrophia adiacens</i>	This patent	<i>fusA</i>
	<i>Acinetobacter baumannii</i>	This patent	<i>fusA</i>
15	<i>Actinomyces meyeri</i>	This patent	<i>fusA</i>
	<i>Clostridium difficile</i>	This patent	<i>fusA</i>
	<i>Corynebacterium diphtheriae</i>	This patent	<i>fusA</i>
	<i>Enterobacter cloacae</i>	This patent	<i>fusA</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i>	This patent	<i>fusA</i>
20	<i>Listeria monocytogenes</i>	This patent	<i>fusA</i>
	<i>Mycobacterium avium</i>	This patent	<i>fusA</i>
	<i>Mycobacterium gordonaee</i>	This patent	<i>fusA</i>
	<i>Mycobacterium kansasii</i>	This patent	<i>fusA</i>
	<i>Mycobacterium terrae</i>	This patent	<i>fusA</i>
25	<i>Neisseria polysaccharea</i>	This patent	<i>fusA</i>
	<i>Staphylococcus epidermidis</i>	This patent	<i>fusA</i>
	<i>Staphylococcus haemolyticus</i>	This patent	<i>fusA</i>
	<i>Succinivibrio dextrinosolvens</i>	This patent	<i>fusA</i>
	<i>Tetragenococcus halophilus</i>	This patent	<i>fusA</i>
30	<i>Veillonella parvula</i>	This patent	<i>fusA</i>
	<i>Yersinia pseudotuberculosis</i>	This patent	<i>fusA</i>
	<i>Zoogloea ramigera</i>	This patent	<i>fusA</i>
	<i>Aeromonas hydrophila</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Abiotrophia adiacens</i>	This patent	<i>fusA-tuf spacer</i>
35	<i>Acinetobacter baumannii</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Actinomyces meyeri</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Clostridium difficile</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Corynebacterium diphtheriae</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Enterobacter cloacae</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i>	This patent	<i>fusA-tuf spacer</i>
40	<i>Listeria monocytogenes</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Mycobacterium avium</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Mycobacterium gordonaee</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Mycobacterium kansasii</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Mycobacterium terrae</i>	This patent	<i>fusA-tuf spacer</i>
45	<i>Neisseria polysaccharea</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Staphylococcus epidermidis</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Staphylococcus haemolyticus</i>	This patent	<i>fusA-tuf spacer</i>
	<i>Abiotrophia adiacens</i>	This patent	<i>tuf</i>
50	<i>Acinetobacter baumannii</i>	This patent	<i>tuf</i>
	<i>Actinomyces meyeri</i>	This patent	<i>tuf</i>
	<i>Clostridium difficile</i>	This patent	<i>tuf</i>
	<i>Corynebacterium diphtheriae</i>	This patent	<i>tuf</i>
	<i>Enterobacter cloacae</i>	This patent	<i>tuf</i>
	<i>Klebsiella pneumoniae</i> subsp. <i>pneumoniae</i>	This patent	<i>tuf</i>
55	<i>Listeria monocytogenes</i>	This patent	<i>tuf</i>
	<i>Mycobacterium avium</i>	This patent	<i>tuf</i>
	<i>Mycobacterium gordonaee</i>	This patent	<i>tuf</i>
	<i>Mycobacterium kansasii</i>	This patent	<i>tuf</i>
	<i>Mycobacterium terrae</i>	This patent	<i>tuf</i>
60	<i>Neisseria polysaccharea</i>	This patent	<i>tuf</i>
	<i>Staphylococcus epidermidis</i>	This patent	<i>tuf</i>
	<i>Staphylococcus haemolyticus</i>	This patent	<i>tuf</i>
	<i>Aeromonas hydrophila</i>	This patent	<i>tuf</i>
	<i>Bilophila wadsworthia</i>	This patent	<i>tuf</i>
65	<i>Brevundimonas diminuta</i>	This patent	<i>tuf</i>
	<i>Streptococcus mitis</i>	This patent	<i>ppb1a</i>

Table 7. Origin of the nucleic acids and/or sequences in the sequence listing (continued).

SEQ ID NO.	Archaeal, bacterial, fungal or parasitical species	Source	Gene*
5	2274 <i>Streptococcus mitis</i>	This patent	<i>pbp1a</i>
	2275 <i>Streptococcus mitis</i>	This patent	<i>pbp1a</i>
	2276 <i>Streptococcus oralis</i>	This patent	<i>pbp1a</i>
	2277 <i>Escherichia coli</i>	This patent	<i>gyrA</i>
10	2278 <i>Escherichia coli</i>	This patent	<i>gyrA</i>
	2279 <i>Escherichia coli</i>	This patent	<i>gyrA</i>
	2280 <i>Escherichia coli</i>	This patent	<i>gyrA</i>
	2288 <i>Enterococcus faecium</i>	Database	<i>ddl</i>
	2293 <i>Enterococcus faecium</i>	Database	<i>vanA</i>
15	2296 <i>Enterococcus faecalis</i>	Database	<i>vanB</i>

* *tuf* indicates *tuf* sequences, *tuf* (C) indicates *tuf* sequences divergent from main (usually A and B) copies of the elongation factor-Tu, *tuf* (EF-1) indicates *tuf* sequences of the eukaryotic type (elongation factor 1α), *tuf* (M) indicates *tuf* sequences from organellar (mostly mitochondrial) origin.

fusA indicates *fusA* sequences; *fusA-tuf* spacer indicates the intergenic region between *fusA* and *tuf*.

atpD indicates *atpD* sequences of the F-type, *atpD* (V) indicates *atpD* sequences of the V-type.

recA indicates *recA* sequences, *recA*(Rad51) indicates *rad51* sequences or homologs and *recA*(Dmc1) indicates *dmc1* sequences or homologs.

Table 8. Bacterial species used to test the specificity of the *Streptococcus agalactiae*-specific amplification primers derived from *tuf* sequences.

	Strain	Reference number	Strain	Reference number
5	<i>Streptococcus acidominimus</i>	ATCC 51726	<i>Bacteroides caccae</i>	ATCC 43185
	<i>Streptococcus agalactiae</i>	ATCC 12403	<i>Bacteroides vulgatus</i>	ATCC 8482
	<i>Streptococcus agalactiae</i>	ATCC 12973	<i>Bacteroides fragilis</i>	ATCC 25285
	<i>Streptococcus agalactiae</i>	ATCC 13813	<i>Candida albicans</i>	ATCC 11006
	<i>Streptococcus agalactiae</i>	ATCC 27591	<i>Clostridium innoculum</i>	ATCC 14501
	<i>Streptococcus agalactiae</i>	CDCs 1073	<i>Clostridium ramosum</i>	ATCC 25582
	<i>Streptococcus anginosus</i>	ATCC 27335	<i>Lactobacillus casei</i> subsp. <i>casei</i>	ATCC 393
	<i>Streptococcus anginosus</i>	ATCC 33397	<i>Clostridium septicum</i>	ATCC 12464
	<i>Streptococcus bovis</i>	ATCC 33317	<i>Corynebacterium cervicis</i>	NCTC 10604
	<i>Streptococcus anginosus</i>	ATCC 27823	<i>Corynebacterium genitalium</i>	ATCC 33031
10	<i>Streptococcus cricetus</i>	ATCC 19642	<i>Corynebacterium urealyticum</i>	ATCC 43042
	<i>Streptococcus cristatus</i>	ATCC 51100	<i>Enterococcus faecalis</i>	ATCC 29212
	<i>Streptococcus downei</i>	ATCC 33748	<i>Enterococcus faecium</i>	ATCC 19434
	<i>Streptococcus dysgalactiae</i>	ATCC 43078	<i>Eubacterium lentum</i>	ATCC 43055
	<i>Streptococcus equi</i> subsp. <i>equi</i>	ATCC 9528	<i>Eubacterium nodutum</i>	ATCC 33099
	<i>Streptococcus ferus</i>	ATCC 33477	<i>Gardnerella vaginalis</i>	ATCC 14018
	<i>Streptococcus gordonii</i>	ATCC 10558	<i>Lactobacillus acidophilus</i>	ATCC 4356
	<i>Streptococcus macacae</i>	ATCC 35911	<i>Lactobacillus crispatus</i>	ATCC 33820
	<i>Streptococcus mitis</i>	ATCC 49456	<i>Lactobacillus gasseri</i>	ATCC 33323
	<i>Streptococcus mutans</i>	ATCC 25175	<i>Lactobacillus johnsonii</i>	ATCC 33200
15	<i>Streptococcus oralis</i>	ATCC 35037	<i>Lactococcus lactis</i> subsp. <i>lactis</i>	ATCC 19435
	<i>Streptococcus parasanguinis</i>	ATCC 15912	<i>Lactococcus lactis</i> subsp. <i>lactis</i>	ATCC 11454
	<i>Streptococcus parauberis</i>	DSM 6631	<i>Listeria innocua</i>	ATCC 33090
	<i>Streptococcus pneumoniae</i>	ATCC 27336	<i>Micrococcus luteus</i>	ATCC 9341
	<i>Streptococcus pyogenes</i>	ATCC 19615	<i>Escherichia coli</i>	ATCC 25922
	<i>Streptococcus ratti</i>	ATCC 19645	<i>Micrococcus lylae</i>	ATCC 27566
	<i>Streptococcus salivarius</i>	ATCC 7073	<i>Porphyromonas asaccharolytica</i>	ATCC 25260
	<i>Streptococcus sanguinis</i>	ATCC 10556	<i>Prevotella corporis</i>	ATCC 33547
	<i>Streptococcus sobrinus</i>	ATCC 27352	<i>Prevotella melanogenica</i>	ATCC 25845
	<i>Streptococcus suis</i>	ATCC 43765	<i>Staphylococcus aureus</i>	ATCC 13301
20	<i>Streptococcus uberis</i>	ATCC 19436	<i>Staphylococcus epidermidis</i>	ATCC 14990
	<i>Streptococcus vestibularis</i>	ATCC 49124	<i>Staphylococcus saprophyticus</i>	ATCC 15305

Table 9. Bacterial species used to test the specificity of the *Streptococcus agalactiae*-specific amplification primers derived from *atpD* sequences.

	Strain	Reference number	Strain	Reference number
5	<i>Streptococcus acidominimus</i>	ATCC 51726	<i>Streptococcus gordoni</i>	ATCC 10558
	<i>Streptococcus agalactiae</i>	ATCC 12400	<i>Streptococcus macacae</i>	ATCC 35911
	<i>Streptococcus agalactiae</i>	ATCC 12403	<i>Streptococcus mitis</i>	ATCC 49456
	<i>Streptococcus agalactiae</i>	ATCC 12973	<i>Streptococcus mutans</i>	ATCC 25175
	<i>Streptococcus agalactiae</i>	ATCC 13813	<i>Streptococcus oralis</i>	ATCC 35037
	<i>Streptococcus agalactiae</i>	ATCC 27591	<i>Streptococcus parasanguinis</i>	ATCC 15912
	<i>Streptococcus agalactiae</i>	CDCs-1073	<i>Streptococcus parauberis</i>	DSM 6631
	<i>Streptococcus anginosus</i>	ATCC 27335	<i>Streptococcus pneumoniae</i>	ATCC 27336
	<i>Streptococcus anginosus</i>	ATCC 27823	<i>Streptococcus pyogenes</i>	ATCC 19615
	<i>Streptococcus bovis</i>	ATCC 33317	<i>Streptococcus ratti</i>	ATCC 19645
10	<i>Streptococcus cricetus</i>	ATCC 19642	<i>Streptococcus salivarius</i>	ATCC 7073
	<i>Streptococcus cristatus</i>	ATCC 51100	<i>Streptococcus sanguinis</i>	ATCC 10556
	<i>Streptococcus downei</i>	ATCC 33748	<i>Streptococcus sobrinus</i>	ATCC 27352
	<i>Streptococcus dysgalactiae</i>	ATCC 43078	<i>Streptococcus suis</i>	ATCC 43765
	<i>Streptococcus equi</i> subsp. <i>equi</i>	ATCC 9528	<i>Streptococcus uberis</i>	ATCC 19436
15	<i>Streptococcus ferus</i>	ATCC 33477	<i>Streptococcus vestibularis</i>	ATCC 49124
20				

Table 10. Bacterial species used to test the specificity of the *Enterococcus*-specific amplification primers derived from *tuf* sequences.

	Strain	Reference number	Strain	Reference number
5 Gram-positive species (n=74)				
	<i>Abiotrophia adiacens</i>	ATCC 49176	<i>Listeria innocua</i>	ATCC 33090
	<i>Abiotrophia defectiva</i>	ATCC 49175	<i>Listeria ivanovii</i>	ATCC 19119
	<i>Bacillus cereus</i>	ATCC 14579	<i>Listeria monocytogenes</i>	ATCC 15313
	<i>Bacillus subtilis</i>	ATCC 27370	<i>Listeria seeligeri</i>	ATCC 35967
10	<i>Bifidobacterium adolescentis</i>	ATCC 27534	<i>Micrococcus luteus</i>	ATCC 9341
	<i>Bifidobacterium breve</i>	ATCC 15700	<i>Pediococcus acidilacti</i>	ATCC 33314
	<i>Bifidobacterium dentium</i>	ATCC 27534	<i>Pediococcus pentosaceus</i>	ATCC 33316
	<i>Bifidobacterium longum</i>	ATCC 15707	<i>Peptococcus niger</i>	ATCC 27731
	<i>Clostridium perfringens</i>	ATCC 3124	<i>Peptostreptococcus anaerobius</i>	ATCC 27337
15	<i>Clostridium septicum</i>	ATCC 12464	<i>Peptostreptococcus indolicus</i>	ATCC 29247
	<i>Corynebacterium aquaticus</i>	ATCC 14665	<i>Peptostreptococcus micros</i>	ATCC 33270
	<i>Corynebacterium pseudodiphtheriticum</i>	ATCC 10700	<i>Propionibacterium acnes</i>	ATCC 6919
	<i>Enterococcus avium</i>	ATCC 14025	<i>Staphylococcus aureus</i>	ATCC 43300
20	<i>Enterococcus casseliflavus</i>	ATCC 25788	<i>Staphylococcus capitis</i>	ATCC 27840
	<i>Enterococcus cecorum</i>	ATCC 43199	<i>Staphylococcus epidermidis</i>	ATCC 14990
	<i>Enterococcus columbae</i>	ATCC 51263	<i>Staphylococcus haemolyticus</i>	ATCC 29970
	<i>Enterococcus dispar</i>	ATCC 51266	<i>Staphylococcus hominis</i>	ATCC 27844
	<i>Enterococcus durans</i>	ATCC 19432	<i>Staphylococcus lugdunensis</i>	ATCC 43809
25	<i>Enterococcus faecalis</i>	ATCC 29212	<i>Staphylococcus saprophyticus</i>	ATCC 15305
	<i>Enterococcus faecium</i>	ATCC 19434	<i>Staphylococcus simulans</i>	ATCC 27848
	<i>Enterococcus flavescentis</i>	ATCC 49996	<i>Staphylococcus warneri</i>	ATCC 27836
	<i>Enterococcus gallinarum</i>	ATCC 49573	<i>Streptococcus agalactiae</i>	ATCC 13813
	<i>Enterococcus hirae</i>	ATCC 8044	<i>Streptococcus anginosus</i>	ATCC 33397
30	<i>Enterococcus malodoratus</i>	ATCC 43197	<i>Streptococcus bovis</i>	ATCC 33317
	<i>Enterococcus mundtii</i>	ATCC 43186	<i>Streptococcus constellatus</i>	ATCC 27823
	<i>Enterococcus pseudoavium</i>	ATCC 49372	<i>Streptococcus cristatus</i>	ATCC 51100
	<i>Enterococcus raffinosus</i>	ATCC 49427	<i>Streptococcus intermedius</i>	ATCC 27335
	<i>Enterococcus saccharolyticus</i>	ATCC 43076	<i>Streptococcus mitis</i>	ATCC 49456
35	<i>Enterococcus solitarius</i>	ATCC 49428	<i>Streptococcus mitis</i>	ATCC 3639
	<i>Enterococcus sulfureus</i>	ATCC 49903	<i>Streptococcus mutans</i>	ATCC 27175
	<i>Eubacterium lentum</i>	ATCC 49903	<i>Streptococcus parasanguinis</i>	ATCC 15912
	<i>Gemella haemolysans</i>	ATCC 10379	<i>Streptococcus pneumoniae</i>	ATCC 27736
	<i>Gemella morbillorum</i>	ATCC 27842	<i>Streptococcus pneumoniae</i>	ATCC 6303
40	<i>Lactobacillus acidophilus</i>	ATCC 4356	<i>Streptococcus pyogenes</i>	ATCC 19615
	<i>Leuconostoc mesenteroides</i>	ATCC 19225	<i>Streptococcus salivarius</i>	ATCC 7073
	<i>Listeria grayi</i>	ATCC 19120	<i>Streptococcus sanguinis</i>	ATCC 10556
	<i>Listeria grayi</i>	ATCC 19123	<i>Streptococcus suis</i>	ATCC 43765

Table 10. Bacterial species used to test the specificity of the *Enterococcus*-specific amplification primers derived from *tuf* sequences (continued).

	Strain	Reference number	Strain	Reference number
5 Gram-negative species (n=39)				
	<i>Acidominococcus fermentans</i>	ATCC 2508	<i>Hafnia alvei</i>	ATCC 13337
	<i>Acinetobacter baumannii</i>	ATCC 19606	<i>Klebsiella oxytoca</i>	ATCC 13182
	<i>Alcaligenes faecalis</i>	ATCC 8750	<i>Meganomonas hypermegas</i>	ATCC 25560
	<i>Anaerobiospirillum succiniproducens</i>	ATCC 29305	<i>Mitsukoella multiacidus</i>	ATCC 27723
10	<i>Anaerohabdus furcosus</i>	ATCC 25662	<i>Moraxella catarrhalis</i>	ATCC 43628
	<i>Bacteroides distasonis</i>	ATCC 8503	<i>Morganella morganii</i>	ATCC 25830
	<i>Bacteroides thetaiotaomicron</i>	ATCC 29741	<i>Neisseria meningitidis</i>	ATCC 13077
	<i>Bacteroides vulgaris</i>	ATCC 8482	<i>Pasteurella aerogenes</i>	ATCC 27883
15	<i>Bordetella pertussis</i>	LSPQ 3702	<i>Proteus vulgaris</i>	ATCC 13315
	<i>Bulkholderia cepacia</i>	LSPQ 2217	<i>Providencia alcalifaciens</i>	ATCC 9886
	<i>Butyvibrio fibrinosolvens</i>	ATCC 19171	<i>Providencia rettgeri</i>	ATCC 9250
	<i>Cardiobacterium hominis</i>	ATCC 15826	<i>Pseudomonas aeruginosa</i>	ATCC 27853
	<i>Citrobacter freundii</i>	ATCC 8090	<i>Salmonella typhimurium</i>	ATCC 14028
20	<i>Desulfovibrio vulgaris</i>	ATCC 29579	<i>Serratia marcescens</i>	ATCC 13880
	<i>Edwardsiellae tarda</i>	ATCC 15947	<i>Shigella flexneri</i>	ATCC 12022
	<i>Enterobacter cloacae</i>	ATCC 13047	<i>Shigella sonnei</i>	ATCC 29930
	<i>Escherichia coli</i>	ATCC 25922	<i>Succinivibrio dextrinosolvens</i>	ATCC 19716
	<i>Fusobacterium russii</i>	ATCC 25533	<i>Tissierella praeacuta</i>	ATCC 25539
25	<i>Haemophilus influenzae</i>	ATCC 9007	<i>Veillonella parvula</i>	ATCC 10790
			<i>Yersinia enterocolitica</i>	ATCC 9610

Table 11. Microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases.

	Species	Strain	Accession number	Coding gene*
<u><i>tuf</i> sequences</u>				
Bacteria				
5	<i>Actinobacillus actinomycetemcomitans</i>	HK1651	Genome project ²	<i>tuf</i>
	<i>Actinobacillus actinomycetemcomitans</i>	HK1651	Genome project ²	<i>tuf</i> (EF-G)
	<i>Agrobacterium tumefaciens</i>		X99673	<i>tuf</i>
	<i>Agrobacterium tumefaciens</i>		X99673	<i>tuf</i> (EF-G)
	<i>Agrobacterium tumefaciens</i>		X99674	<i>tuf</i>
10	<i>Anacystis nidulans</i>	PCC 6301	X17442	<i>tuf</i>
	<i>Aquifex aeolicus</i>	VF5	AE000669	<i>tuf</i>
	<i>Aquifex aeolicus</i>	VF5	AE000669	<i>tuf</i> (EF-G)
	<i>Aquifex pyrophilus</i>		Genome project ²	<i>tuf</i> (EF-G)
	<i>Aquifex pyrophilus</i>		Y15787	<i>tuf</i>
15	<i>Bacillus anthracis</i>	Ames	Genome project ²	<i>tuf</i>
	<i>Bacillus anthracis</i>	Ames	Genome project ²	<i>tuf</i> (EF-G)
	<i>Bacillus halodurans</i>	C-125	AB017508	<i>tuf</i>
	<i>Bacillus halodurans</i>	C-125	AB017508	<i>tuf</i> (EF-G)
	<i>Bacillus stearothermophilus</i>	CCM 2184	AJ000260	<i>tuf</i>
20	<i>Bacillus subtilis</i>	168	D64127	<i>tuf</i>
	<i>Bacillus subtilis</i>	168	D64127	<i>tuf</i> (EF-G)
	<i>Bacillus subtilis</i>	DSM 10	Z99104	<i>tuf</i>
	<i>Bacillus subtilis</i>	DSM 10	Z99104	<i>tuf</i> (EF-G)
	<i>Bacteroides forsythus</i>	ATCC 43037	AB035466	<i>tuf</i>
25	<i>Bacteroides fragilis</i>	DSM 1151	'	<i>tuf</i>
	<i>Bordetella bronchiseptica</i>	RB50	Genome project ²	<i>tuf</i>
	<i>Bordetella pertussis</i>	Tohama 1	Genome project ²	<i>tuf</i>
	<i>Bordetella pertussis</i>	Tohama 1	Genome project ²	<i>tuf</i> (EF-G)
	<i>Borrelia burgdorferi</i>	B31	U78193	<i>tuf</i>
30	<i>Borrelia burgdorferi</i>		AE001155	<i>tuf</i> (EF-G)
	<i>Brevibacterium linens</i>	DSM 20425	X76863	<i>tuf</i>
	<i>Buchnera aphidicola</i>	Ap	Y12307	<i>tuf</i>
	<i>Burkholderia pseudomallei</i>	K96243	Genome project ²	<i>tuf</i> (EF-G)
	<i>Campylobacter jejuni</i>	NCTC 11168	Y17167	<i>tuf</i>
35	<i>Campylobacter jejuni</i>	NCTC 11168	CJ11168X2	<i>tuf</i> (EF-G)
	<i>Chlamydia pneumoniae</i>	CWL029	AE001592	<i>tuf</i>
	<i>Chlamydia pneumoniae</i>	CWL029	AE001639	<i>tuf</i> (EF-G)
	<i>Chlamydia trachomatis</i>		M74221	<i>tuf</i>
	<i>Chlamydia trachomatis</i>	D/UW-3/CX	AE001317	<i>tuf</i> (EF-G)
40	<i>Chlamydia trachomatis</i>	D/UW-3/CX	AE001305	<i>tuf</i>
	<i>Chlamydia trachomatis</i>	F/IC-Cal-13	L22216	<i>tuf</i>
	<i>Chlorobium vibrioforme</i>	DSM 263	X77033	<i>tuf</i>
	<i>Chloroflexus aurantiacus</i>	DSM 636	X76865	<i>tuf</i>
	<i>Clostridium acetobutylicum</i>	ATCC 824	Genome project ²	<i>tuf</i>
45	<i>Clostridium difficile</i>	630	Genome project ²	<i>tuf</i>
	<i>Clostridium difficile</i>	630	Genome project ²	<i>tuf</i> (EF-G)
	<i>Corynebacterium diphtheriae</i>	NCTC 13129	Genome project ²	<i>tuf</i>
	<i>Corynebacterium diphtheriae</i>	NCTC 13129	Genome project ²	<i>tuf</i> (EF-G)
	<i>Corynebacterium glutamicum</i>	ASO 19	X77034	<i>tuf</i>
50	<i>Corynebacterium glutamicum</i>	MJ-233	E09634	<i>tuf</i>
	<i>Coxiella burnetii</i>	Nine Mile phase I	AF136604	<i>tuf</i>
	<i>Cytophaga lytica</i>	DSM 2039	X77035	<i>tuf</i>
	<i>Deinococcus radiodurans</i>	R1	AE001891	<i>tuf</i> (EF-G)
	<i>Deinococcus radiodurans</i>	R1	AE180092	<i>tuf</i>

Table 11. Microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases (continued).

	Species	Strain	Accession number	Coding gene*
	<i>Deinococcus radiodurans</i>	R1	AE002041	<i>tuf</i>
	<i>Deinonema</i> sp.		1	<i>tuf</i>
	<i>Eikenella corrodens</i>	ATCC 23834	Z12610	<i>tuf</i>
5	<i>Eikenella corrodens</i>	ATCC 23834	Z12610	<i>tuf</i> (EF-G)
	<i>Enterococcus faecalis</i>		Genome project ²	<i>tuf</i> (EF-G)
	<i>Escherichia coli</i>		J01690	<i>tuf</i>
	<i>Escherichia coli</i>		J01717	<i>tuf</i>
	<i>Escherichia coli</i>		X00415	<i>tuf</i> (EF-G)
	<i>Escherichia coli</i>		X57091	<i>tuf</i>
10	<i>Escherichia coli</i>	K-12 MG1655	U00006	<i>tuf</i>
	<i>Escherichia coli</i>	K-12 MG1655	U00096	<i>tuf</i>
	<i>Escherichia coli</i>	K-12 MG1655	AE000410	<i>tuf</i> (EF-G)
	<i>Fervidobacterium islandicum</i>	DSM 5733	Y15788	<i>tuf</i>
	<i>Fibrobacter succinogenes</i>	S85	X76866	<i>tuf</i>
15	<i>Flavobacterium fermentum</i>	DSM 13524	X76867	<i>tuf</i>
	<i>Flexistipes sinusarabici</i>		X59461	<i>tuf</i>
	<i>Gloeobacter violaceus</i>	PCC 7421	U09433	<i>tuf</i>
	<i>Gloeothece</i> sp.	PCC 6501	U09434	<i>tuf</i>
	<i>Haemophilus actinomycetemcomitans</i>	HK1651	Genome project ²	<i>tuf</i>
20	<i>Haemophilus ducreyi</i>	35000	AF087414	<i>tuf</i> (EF-G)
	<i>Haemophilus influenzae</i>	Rd	U32739	<i>tuf</i>
	<i>Haemophilus influenzae</i>	Rd	U32746	<i>tuf</i>
	<i>Haemophilus influenzae</i>	Rd	U32739	<i>tuf</i> (EF-G)
	<i>Helicobacter pylori</i>	26695	AE000511	<i>tuf</i>
25	<i>Helicobacter pylori</i>	J99	AE001539	<i>tuf</i> (EF-G)
	<i>Helicobacter pylori</i>	J99	AE001541	<i>tuf</i>
	<i>Herpetosiphon aurantiacus</i>	Hpga1	X76868	<i>tuf</i>
	<i>Klebsiella pneumoniae</i>	M6H 78578	Genome project ²	<i>tuf</i>
	<i>Klebsiella pneumoniae</i>	M6H 78578	Genome project ²	<i>tuf</i> (EF-G)
30	<i>Lactobacillus paracasei</i>		E13922	<i>tuf</i>
	<i>Legionella pneumophila</i>	Philadelphia-1	Genome project ²	<i>tuf</i>
	<i>Leptospira interrogans</i>		AF115283	<i>tuf</i>
	<i>Leptospira interrogans</i>		AF115283	<i>tuf</i> (EF-G)
	<i>Micrococcus luteus</i>	IFO 3333	M17788	<i>tuf</i> (EF-G)
35	<i>Micrococcus luteus</i>	IFO 3333	M17788	<i>tuf</i>
	<i>Moraxella</i> sp.	TAC II 25	AJ249258	<i>tuf</i>
	<i>Mycobacterium avium</i>	104	Genome project ²	<i>tuf</i>
	<i>Mycobacterium avium</i>	104	Genome project ²	<i>tuf</i> (EF-G)
	<i>Mycobacterium bovis</i>	AF2122/97	Genome project ²	<i>tuf</i>
40	<i>Mycobacterium bovis</i>	AF2122/97	Genome project ²	<i>tuf</i> (EF-G)
	<i>Mycobacterium leprae</i>		L13276	<i>tuf</i>
	<i>Mycobacterium leprae</i>		Z14314	<i>tuf</i>
	<i>Mycobacterium leprae</i>		Z14314	<i>tuf</i> (EF-G)
	<i>Mycobacterium leprae</i>	Thai 53	D13869	<i>tuf</i>
45	<i>Mycobacterium tuberculosis</i>	Erdmann	S40925	<i>tuf</i>
	<i>Mycobacterium tuberculosis</i>	H37Rv	AL021943	<i>tuf</i> (EF-G)
	<i>Mycobacterium tuberculosis</i>	H37Rv	Z84395	<i>tuf</i>
	<i>Mycobacterium tuberculosis</i>	y42	AD000005	<i>tuf</i>
	<i>Mycobacterium tuberculosis</i>	CSU#93	Genome project ²	<i>tuf</i>
50	<i>Mycobacterium tuberculosis</i>	CSU#93	Genome project ²	<i>tuf</i> (EF-G)
	<i>Mycoplasma capricolum</i>	PG-31	X16462	<i>tuf</i>
	<i>Mycoplasma genitalium</i>	G37	U39732	<i>tuf</i>
	<i>Mycoplasma genitalium</i>	G37	U39689	<i>tuf</i> (EF-G)
	<i>Mycoplasma hominis</i>		X57136	<i>tuf</i>
55	<i>Mycoplasma hominis</i>	PG21	M57675	<i>tuf</i>

Table 11. Microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases (continued).

	Species	Strain	Accession number	Coding gene*
	<i>Mycoplasma pneumoniae</i>	M129	AE000019	<i>tuf</i>
	<i>Mycoplasma pneumoniae</i>	M129	AE000058	<i>tuf</i> (EF-G)
	<i>Neisseria gonorrhoeae</i>	MS11	L36380	<i>tuf</i>
	<i>Neisseria gonorrhoeae</i>	MS11	L36380	<i>tuf</i> (EF-G)
5	<i>Neisseria meningitidis</i>	Z2491	Genome project ²	<i>tuf</i> (EF-G)
	<i>Neisseria meningitidis</i>	Z2491	Genome project ²	<i>tuf</i>
	<i>Pasteurella multocida</i>	Pm70	Genome project ²	<i>tuf</i>
	<i>Peptococcus niger</i>	DSM 20745	X76869	<i>tuf</i>
	<i>Phormidium ectocarpi</i>	PCC 7375	U09443	<i>tuf</i>
10	<i>Planobispora rosea</i>	ATCC 53773	U67308	<i>tuf</i>
	<i>Planobispora rosea</i>	ATCC 53733	X98830	<i>tuf</i>
	<i>Planobispora rosea</i>	ATCC 53733	X98830	<i>tuf</i> (EF-G)
	<i>Plectonema boryanum</i>	PCC 73110	U09444	<i>tuf</i>
	<i>Porphyromonas gingivalis</i>	W83	Genome project ²	<i>tuf</i>
15	<i>Porphyromonas gingivalis</i>	W83	Genome project ²	<i>tuf</i> (EF-G)
	<i>Porphyromonas gingivalis</i>	FDC 381	AB035461	<i>tuf</i>
	<i>Porphyromonas gingivalis</i>	W83	AB035462	<i>tuf</i>
	<i>Porphyromonas gingivalis</i>	SUNY 1021	AB035463	<i>tuf</i>
	<i>Porphyromonas gingivalis</i>	A7A1-28	AB035464	<i>tuf</i>
20	<i>Porphyromonas gingivalis</i>	ATCC 33277	AB035465	<i>tuf</i>
	<i>Porphyromonas gingivalis</i>	ATCC 33277	AB035471	<i>tuf</i> (EF-G)
	<i>Prochlorothrix hollandica</i>		U09445	<i>tuf</i>
	<i>Pseudomonas aeruginosa</i>	PAO-1	Genome project ²	<i>tuf</i>
	<i>Pseudomonas putida</i>		Genome project ²	<i>tuf</i>
25	<i>Rickettsia prowazekii</i>	Madrid E	AJ235272	<i>tuf</i>
	<i>Rickettsia prowazekii</i>	Madrid E	AJ235270	<i>tuf</i> (EF-G)
	<i>Rickettsia prowazekii</i>	Madrid E	Z54171	<i>tuf</i> (EF-G)
	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype <i>Typhimurium</i>		X64591	<i>tuf</i> (EF-G)
30	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype <i>Typhimurium</i>	LT2 trpE91	X55116	<i>tuf</i>
	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype <i>Typhimurium</i>	LT2 trpE91	X55117	<i>tuf</i>
	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype <i>Typhimurium</i>	B204	U51635	<i>tuf</i>
35	<i>Serpulina hyodysenteriae</i>		AF058451	<i>tuf</i>
	<i>Serratia marcescens</i>	DSM 50426		<i>tuf</i>
	<i>Shewanella putrefaciens</i>	MR-1	Genome project ²	<i>tuf</i>
	<i>Shewanella putrefaciens</i>	DSM 1902	X76874	<i>tuf</i>
	<i>Spirochaeta aurantia</i>			<i>tuf</i>
	<i>Staphylococcus aureus</i>		AJ237696	<i>tuf</i> (EF-G)
40	<i>Staphylococcus aureus</i>	EMRSA-16	Genome project ²	<i>tuf</i>
	<i>Staphylococcus aureus</i>	NCTC 8325	Genome project ²	<i>tuf</i>
	<i>Staphylococcus aureus</i>	COL	Genome project ²	<i>tuf</i>
	<i>Staphylococcus aureus</i>	EMRSA-16	Genome project ²	<i>tuf</i> (EF-G)
	<i>Stigmatella aurantiaca</i>	DW4	X82820	<i>tuf</i>
45	<i>Stigmatella aurantiaca</i>	Sg a1	X76870	<i>tuf</i>
	<i>Streptococcus mutans</i>	GS-5 Kuramitsu	U75481	<i>tuf</i>
	<i>Streptococcus mutans</i>	UAB159	Genome project ²	<i>tuf</i>
	<i>Streptococcus oralis</i>	NTCC 11427	P331701	<i>tuf</i>
	<i>Streptococcus pyogenes</i>		Genome project ²	<i>tuf</i> (EF-G)
50	<i>Streptococcus pyogenes</i>	M1-GAS	Genome project ²	<i>tuf</i>
	<i>Streptomyces aureofaciens</i>	ATCC 10762	AF007125	<i>tuf</i>
	<i>Streptomyces cinnamoneus</i>	Tue89	X98831	<i>tuf</i>
	<i>Streptomyces coelicolor</i>	A3(2)	AL031013	<i>tuf</i> (EF-G)
	<i>Streptomyces coelicolor</i>	A3(2)	X77039	<i>tuf</i> (EF-G)
55	<i>Streptomyces coelicolor</i>	M145	X77039	<i>tuf</i>

Table 11. Microbial species for which *tuf* and/ or *atpD* and/ or *recA* sequences are available in public databases (continued).

	Species	Strain	Accession number	Coding gene*
	<i>Streptomyces collinus</i>	BSM 40733	S79408	<i>tuf</i>
	<i>Streptomyces netropsis</i>	Tu1063	AF153618	<i>tuf</i>
	<i>Streptomyces ramocissimus</i>		X67057	<i>tuf</i>
	<i>Streptomyces ramocissimus</i>		X67058	<i>tuf</i>
5	<i>Streptomyces ramocissimus</i>		X67057	<i>tuf</i> (EF-G)
	<i>Synechococcus</i> sp.	PCC 6301	X17442	<i>tuf</i> (EF-G)
	<i>Synechococcus</i> sp.	PCC 6301	X17442	<i>tuf</i>
	<i>Synechocystis</i> sp.	PCC 6803	D90913	<i>tuf</i> (EF-G)
	<i>Synechocystis</i> sp.	PCC 6803	D90913	<i>tuf</i>
10	<i>Synechocystis</i> sp.	PCC 6803	X65159	<i>tuf</i> (EF-G)
	<i>Taxeobacter occetus</i>	Myx 2105	X77036	<i>tuf</i>
	<i>Thermotoga maritima</i>		Genome project ²	<i>tuf</i> (EF-G)
	<i>Thermotoga maritima</i>		M27479	<i>tuf</i>
	<i>Thermus aquaticus</i>	EP 00276	X66322	<i>tuf</i>
15	<i>Thermus thermophilus</i>	HB8	X16278	<i>tuf</i> (EF-G)
	<i>Thermus thermophilus</i>	HB8	X05977	<i>tuf</i>
	<i>Thermus thermophilus</i>	HB8	X06657	<i>tuf</i>
	<i>Thiomonas cuprina</i>	DSM 5495	U78300	<i>tuf</i>
	<i>Thiomonas cuprina</i>	DSM 5495	U78300	<i>tuf</i> (EF-G)
20	<i>Thiomonas cuprina</i>	Hoe5	X76871	<i>tuf</i>
	<i>Treponema denticola</i>		Genome project ²	<i>tuf</i>
	<i>Treponema denticola</i>		Genome project ²	<i>tuf</i> (EF-G)
	<i>Treponema pallidum</i>		AE001202	<i>tuf</i>
	<i>Treponema pallidum</i>		AE001222	<i>tuf</i> (EF-G)
25	<i>Treponema pallidum</i>		AE001248	<i>tuf</i> (EF-G)
	<i>Ureaplasma urealyticum</i>	ATCC 33697	Z34275	<i>tuf</i>
	<i>Ureaplasma urealyticum</i>	serovar 3 biovar 1	AE002151	<i>tuf</i>
	<i>Ureaplasma urealyticum</i>	serovar 3 biovar 1	AE002151	<i>tuf</i> (EF-G)
	<i>Vibrio cholerae</i>	N16961	Genome project ²	<i>tuf</i>
30	<i>Wolinella succinogenes</i>	DSM 1740	X76872	<i>tuf</i>
	<i>Yersinia pestis</i>	CO-92	Genome project ²	<i>tuf</i>
	<i>Yersinia pestis</i>	CO-92	Genome project ²	<i>tuf</i> (EF-G)
35	Archaeabacteria			
	<i>Archaeoglobus fulgidus</i>		Genome project ²	<i>tuf</i> (EF-G)
	<i>Halobacterium marismortui</i>		X16677	<i>tuf</i>
	<i>Methanobacterium thermoautrophicum</i>	delta H	AE000877	<i>tuf</i>
40	<i>Methanococcus jannaschii</i>	ATCC 43067	U67486	<i>tuf</i>
	<i>Methanococcus vannielii</i>		X05698	<i>tuf</i>
	<i>Pyrococcus abyssi</i>	Orsay	AJ248285	<i>tuf</i>
	<i>Thermoplasma acidophilum</i>	DSM 1728	X53866	<i>tuf</i>
45	Fungi			
	<i>Absidia glauca</i>	CBS 101.48	X54730	<i>tuf</i> (EF-1)
	<i>Arxula adeninivorans</i>	Ls3	Z47379	<i>tuf</i> (EF-1)
50	<i>Aspergillus oryzae</i>	KBN616	AB007770	<i>tuf</i> (EF-1)
	<i>Aureobasidium pullulans</i>	R106	U19723	<i>tuf</i> (EF-1)
	<i>Candida albicans</i>	SC5314	Genome project ²	<i>tuf</i> (M)
	<i>Candida albicans</i>	SC5314	M29934	<i>tuf</i> (EF-1)
	<i>Candida albicans</i>	SC5314	M29935	<i>tuf</i> (EF-1)
55	<i>Cryptococcus neoformans</i>	B3501	U81803	<i>tuf</i> (EF-1)

Table 11. Microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases (continued).

	Species	Strain	Accession number	Coding gene*
	<i>Cryptococcus neoformans</i>	M1-106	U81804	<i>tuf</i> (EF-1)
	<i>Eremothecium gossypii</i>	ATCC 10895	X73978	<i>tuf</i> (EF-1)
	<i>Eremothecium gossypii</i>		A29820	<i>tuf</i> (EF-1)
	<i>Fusarium oxysporum</i>	NRRL 26037	AF008498	<i>tuf</i> (EF-1)
5	<i>Histoplasma capsulatum</i>	186AS	U14100	<i>tuf</i> (EF-1)
	<i>Podospora anserina</i>		X74799	<i>tuf</i> (EF-1)
	<i>Podospora curvicolla</i>	VLV	X96614	<i>tuf</i> (EF-1)
	<i>Protothece wickerhamii</i>	263-11	AJ245645	<i>tuf</i> (EF-1)
	<i>Puccinia graminis</i>	race 32	X73529	<i>tuf</i> (EF-1)
10	<i>Reclinomonas americana</i>	ATCC 50394	AF007261	<i>tuf</i> (M)
	<i>Rhizomucor racemosus</i>	ATCC 1216B	X17475	<i>tuf</i> (EF-1)
	<i>Rhizomucor racemosus</i>	ATCC 1216B	J02605	<i>tuf</i> (EF-1)
	<i>Rhizomucor racemosus</i>	ATCC 1216B	X17476	<i>tuf</i> (EF-1)
	<i>Rhodotorula mucilaginosa</i>		AF016239	<i>tuf</i> (EF-1)
15	<i>Saccharomyces cerevisiae</i>		K00428	<i>tuf</i> (M)
	<i>Saccharomyces cerevisiae</i>		M59369	<i>tuf</i> (EF-G)
	<i>Saccharomyces cerevisiae</i>		X00779	<i>tuf</i> (EF-1)
	<i>Saccharomyces cerevisiae</i>		X01638	<i>tuf</i> (EF-1)
	<i>Saccharomyces cerevisiae</i>		M10992	<i>tuf</i> (EF-1)
20	<i>Saccharomyces cerevisiae</i>	Alpha S288	X78993	<i>tuf</i> (EF-1)
	<i>Saccharomyces cerevisiae</i>		M15666	<i>tuf</i> (EF-1)
	<i>Saccharomyces cerevisiae</i>		Z35987	<i>tuf</i> (EF-1)
	<i>Saccharomyces cerevisiae</i>	S288C (AB972)	U51033	<i>tuf</i> (EF-1)
	<i>Schizophyllum commune</i>	1-40	X94913	<i>tuf</i> (EF-1)
25	<i>Schizosaccharomyces pombe</i>	972h-	AL021816	<i>tuf</i> (EF-1)
	<i>Schizosaccharomyces pombe</i>	972h-	AL021813	<i>tuf</i> (EF-1)
	<i>Schizosaccharomyces pombe</i>	972h-	D82571	<i>tuf</i> (EF-1)
	<i>Schizosaccharomyces pombe</i>		U42189	<i>tuf</i> (EF-1)
	<i>Schizosaccharomyces pombe</i>	PR745	D89112	<i>tuf</i> (EF-1)
30	<i>Sordaria macrospora</i>	OOO	X96615	<i>tuf</i> (EF-1)
	<i>Trichoderma reesei</i>	QM9414	Z23012	<i>tuf</i> (EF-1)
	<i>Yarrowia lipolytica</i>		AF054510	<i>tuf</i> (EF-1)
35	Parasites			
	<i>Blastocystis hominis</i>	HE87-1	D64080	<i>tuf</i> (EF-1)
	<i>Cryptosporidium parvum</i>		U69697	<i>tuf</i> (EF-1)
	<i>Eimeria tenella</i>	LS18	AI755521	<i>tuf</i> (EF-1)
40	<i>Entamoeba histolytica</i>	HM1:IMSS	X83565	<i>tuf</i> (EF-1)
	<i>Entamoeba histolytica</i>	NIH 200	M92073	<i>tuf</i> (EF-1)
	<i>Giardia lamblia</i>		D14342	<i>tuf</i> (EF-1)
	<i>Kentrophoros</i> sp.		AF056101	<i>tuf</i> (EF-1)
	<i>Leishmania amazonensis</i>	IFLA/BR/67/PH8	M92653	<i>tuf</i> (EF-1)
45	<i>Leishmania braziliensis</i>		U72244	<i>tuf</i> (EF-1)
	<i>Onchocerca volvulus</i>		M64333	<i>tuf</i> (EF-1)
	<i>Porphyra purpurea</i>	Avonport	U08844	<i>tuf</i> (EF-1)
	<i>Plasmodium berghii</i>	ANKA	AJ224150	<i>tuf</i> (EF-1)
	<i>Plasmodium falciparum</i>	K1	X60488	<i>tuf</i> (EF-1)
50	<i>Plasmodium knowlesi</i>	line H	AJ224153	<i>tuf</i> (EF-1)
	<i>Toxoplasma gondii</i>	RH	Y11431	<i>tuf</i> (EF-1)
	<i>Trichomonas tenax</i>	ATCC 30207	D78479	<i>tuf</i> (EF-1)
	<i>Trypanosoma brucei</i>	LVH/75/ USAMRU-K/18	U10562	<i>tuf</i> (EF-1)
55	<i>Trypanosoma cruzi</i>	Y	L76077	<i>tuf</i> (EF-1)

Table 11. Microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases (continued).

	Species	Strain	Accession number	Coding gene*
Human and plants				
5	<i>Arabidopsis thaliana</i>	Columbia	X89227	<i>tuf</i> (EF-1)
	<i>Glycine max</i>	Ceresia	X89058	<i>tuf</i> (EF-1)
	<i>Glycine max</i>	Ceresia	Y15107	<i>tuf</i> (EF-1)
	<i>Glycine max</i>	Ceresia	Y15108	<i>tuf</i> (EF-1)
	<i>Glycine max</i>	Maple Arrow	X66062	<i>tuf</i> (EF-1)
10	<i>Homo sapiens</i>		X03558	<i>tuf</i> (EF-1)
	<i>Pyramimonas disomata</i>		AB008010	<i>tuf</i>
<u>atpD sequences</u>				
15	Bacteria			
	<i>Acetobacterium woodii</i>	DSM 1030	U10505	<i>atpD</i>
	<i>Actinobacillus actinomycetemcomitans</i>	HK1651	Genome project ²	<i>atpD</i>
	<i>Bacillus anthracis</i>	Ames	Genome project ²	<i>atpD</i>
20	<i>Bacillus firmus</i>	OF4	M60117	<i>atpD</i>
	<i>Bacillus megaterium</i>	QM B1551	M20255	<i>atpD</i>
	<i>Bacillus stearothermophilus</i>		D38058	<i>atpD</i>
	<i>Bacillus stearothermophilus</i>	IFO1035	D38060	<i>atpD</i>
	<i>Bacillus subtilis</i>	168	Z28592	<i>atpD</i>
25	<i>Bacteroides fragilis</i>	DSM 2151	M22247	<i>atpD</i>
	<i>Bordetella bronchiseptica</i>	RB50	Genome project ²	<i>atpD</i>
	<i>Bordetella pertussis</i>	Tohama 1	Genome project ²	<i>atpD</i>
	<i>Borrelia burgdorferi</i>	B31	AE001122	<i>atpD</i> (V)
	<i>Burkholderia cepacia</i>	DSM50181	X76877	<i>atpD</i>
30	<i>Burkholderia pseudomallei</i>	K96243	Genome project ²	<i>atpD</i>
	<i>Campylobacter jejuni</i>	NCTC 11168	CJ11168X1	<i>atpD</i>
	<i>Chlamydia pneumoniae</i>	MoPn	Genome project ²	<i>atpD</i> (V)
	<i>Chlamydia trachomatis</i>	DSM 263	Genome project ²	<i>atpD</i> (V)
	<i>Chlorobium vibrioforme</i>	JEO503	X76873	<i>atpD</i>
35	<i>Citrobacter freundii</i>	ATCC 824	AF037156	<i>atpD</i>
	<i>Clostridium acetobutylicum</i>	DSM 792	Genome project ²	<i>atpD</i>
	<i>Clostridium acetobutylicum</i>	630	AF101055	<i>atpD</i>
	<i>Clostridium difficile</i>	NCTC13129	Genome project ²	<i>atpD</i>
40	<i>Corynebacterium diphtheriae</i>	ASO 19	X76875	<i>atpD</i>
	<i>Corynebacterium glutamicum</i>	MJ-233	E09634	<i>atpD</i>
	<i>Corynebacterium glutamicum</i>	DSM 2039	M22535	<i>atpD</i>
	<i>Cytophaga lytica</i>	DSM 30053	³	<i>atpD</i>
	<i>Enterobacter aerogenes</i>	V583	Genome project ²	<i>atpD</i> (V)
	<i>Enterococcus faecalis</i>		M90060	<i>atpD</i>
45	<i>Enterococcus hirae</i>	ATCC 9790	D17462	<i>atpD</i> (V)
	<i>Enterococcus hirae</i>		J01594	<i>atpD</i>
	<i>Escherichia coli</i>		M25464	<i>atpD</i>
	<i>Escherichia coli</i>		V00267	<i>atpD</i>
50	<i>Escherichia coli</i>	K12 MG1655	V00311	<i>atpD</i>
	<i>Escherichia coli</i>	DSM 13524	L10328	<i>atpD</i>
	<i>Flavobacterium ferrugineum</i>		³	<i>atpD</i>
	<i>Haemophilus actinomycetemcomitans</i>		Genome project ²	<i>atpD</i>
	<i>Haemophilus influenzae</i>	Rd	U32730	<i>atpD</i>
55	<i>Helicobacter pylori</i>	NCTC 11638	AF004014	<i>atpD</i>

Table 11. Microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases (continued).

	Species	Strain	Accession number	Coding gene*
	<i>Helicobacter pylori</i>	26695	Genome project ²	<i>atpD</i>
	<i>Helicobacter pylori</i>	J99	Genome project ²	<i>atpD</i>
	<i>Klebsiella pneumoniae</i>	M6H 78578	Genome project ²	<i>atpD</i>
5	<i>Lactobacillus casei</i>	DSM 20021	X64542	<i>atpD</i>
	<i>Legionella pneumophila</i>	Philadelphia-1	Genome project ²	<i>atpD</i>
	<i>Moorella thermoacetica</i>	ATCC 39073	U64318	<i>atpD</i>
	<i>Mycobacterium avium</i>	104	Genome project ²	<i>atpD</i>
	<i>Mycobacterium bovis</i>	AF2122/97	Genome project ²	<i>atpD</i>
	<i>Mycobacterium leprae</i>		U15186	<i>atpD</i>
10	<i>Mycobacterium leprae</i>		Genome project ²	<i>atpD</i>
	<i>Mycobacterium tuberculosis</i>	H37Rv	Z73419	<i>atpD</i>
	<i>Mycobacterium tuberculosis</i>	CSU#93	Genome project ²	<i>atpD</i>
	<i>Mycoplasma gallisepticum</i>		X64256	<i>atpD</i>
	<i>Mycoplasma genitalium</i>	G37	U39725	<i>atpD</i>
15	<i>Mycoplasma pneumoniae</i>	M129	U43738	<i>atpD</i>
	<i>Neisseria gonorrhoeae</i>	FA 1090	Genome project ²	<i>atpD</i>
	<i>Neisseria meningitidis</i>	Z2491	Genome project ²	<i>atpD</i>
	<i>Pasteurella multocida</i>	Pm70	Genome project ²	<i>atpD</i>
	<i>Pectinatus frisingensis</i>	DSM 20465	X64543	<i>atpD</i>
20	<i>Peptococcus niger</i>	DSM 20475	X76878	<i>atpD</i>
	<i>Pirellula marina</i>	IFAM 1313	X57204	<i>atpD</i>
	<i>Porphyromonas gingivalis</i>	W83	Genome project ²	<i>atpD (V)</i>
	<i>Propionigenium modestum</i>	DSM 2376	X58461	<i>atpD</i>
	<i>Pseudomonas aeruginosa</i>	PAO1	Genome project ²	<i>atpD</i>
25	<i>Pseudomonas putida</i>		Genome project ²	<i>atpD</i>
	<i>Rhodobacter capsulatus</i>	B100	X99599	<i>atpD</i>
	<i>Rhodospirillum rubrum</i>		X02499	<i>atpD</i>
	<i>Rickettsia prowazekii</i>	F-12	AF036246	<i>atpD</i>
	<i>Rickettsia prowazekii</i>	Madrid	Genome project ²	<i>atpD</i>
30	<i>Ruminococcus albus</i>	7ATCC	AB006151	<i>atpD</i>
	<i>Salmonella bongori</i>	JEO4162	AF037155	<i>atpD</i>
	<i>Salmonella bongori</i>	BR1859	AF037154	<i>atpD</i>
	<i>Salmonella choleraesuis</i> subsp. <i>arizonaee</i>	S83769	AF037146	<i>atpD</i>
35	<i>Salmonella choleraesuis</i> subsp. <i>arizonaee</i>	u24	AF037147	<i>atpD</i>
	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype <i>Dublin</i>	K228	AF037140	<i>atpD</i>
	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype <i>Dublin</i>	K771	AF037139	<i>atpD</i>
40	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype <i>Infantis</i>	Div36-86	AF037142	<i>atpD</i>
	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype <i>Tennessee</i>	Div95-86	AF037143	<i>atpD</i>
45	<i>Salmonella choleraesuis</i> subsp. <i>choleraesuis</i> serotype <i>Typhimurium</i>	LT2	AF037141	<i>atpD</i>
	<i>Salmonella choleraesuis</i> subsp. <i>diarizonae</i>	DS210/89	AF037149	<i>atpD</i>
	<i>Salmonella choleraesuis</i> subsp. <i>diarizonae</i>	JEO307	AF037148	<i>atpD</i>
50	<i>Salmonella choleraesuis</i> subsp. <i>diarizonae</i>	S109671	AF037150	<i>atpD</i>
	<i>Salmonella choleraesuis</i> subsp. <i>houtenae</i>	S84366	AF037151	<i>atpD</i>
55	<i>Salmonella choleraesuis</i>	S84098	AF037152	<i>atpD</i>

Table 11. Microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases (continued).

	Species	Strain	Accession number	Coding gene*
	<i>subsp. houtenae</i>			
	<i>Salmonella choleraesuis</i>	BR2047	AF037153	<i>atpD</i>
	<i>subsp. indica</i>			
	<i>Salmonella choleraesuis</i>	NSC72	AF037144	<i>atpD</i>
5	<i>subsp. salamae</i>			
	<i>Salmonella choleraesuis</i>	S114655	AF037145	<i>atpD</i>
	<i>subsp. salamae</i>			
	<i>Shewanella putrefaciens</i>	MR-1	Genome project ²	<i>atpD</i>
	<i>Staphylococcus aureus</i>	COL	Genome project ²	<i>atpD</i>
10	<i>Stigmatella aurantiaca</i>	Sga1	X76879	<i>atpD</i>
	<i>Streptococcus bovis</i>	JB-1	AB009314	<i>atpD</i>
	<i>Streptococcus mutans</i>	GS-5	U31170	<i>atpD</i>
	<i>Streptococcus mutans</i>	UAB159	Genome project ²	<i>atpD</i>
	<i>Streptococcus pneumoniae</i>	Type 4	Genome project ²	<i>atpD (V)</i>
15	<i>Streptococcus pneumoniae</i>	Type 4	Genome project ²	<i>atpD</i>
	<i>Streptococcus pyogenes</i>	M1-GAS	Genome project ²	<i>atpD (V)</i>
	<i>Streptococcus pyogenes</i>	M1-GAS	Genome project ²	<i>atpD</i>
	<i>Streptococcus sanguinis</i>	10904	AF001955	<i>atpD</i>
	<i>Streptomyces lividans</i>	1326	Z22606	<i>atpD</i>
20	<i>Thermus thermophilus</i>	HB8	D63799	<i>atpD (V)</i>
	<i>Thiobacillus ferrooxidans</i>	ATCC 33020	M81087	<i>atpD</i>
	<i>Treponema pallidum</i>	Nichols	AE001228	<i>atpD (V)</i>
	<i>Vibrio alginolyticus</i>		X16050	<i>atpD</i>
	<i>Vibrio cholerae</i>	N16961	Genome project ²	<i>atpD</i>
25	<i>Wolinella succinogenes</i>	DSM 1470	X76880	<i>atpD</i>
	<i>Yersinia enterocolitica</i>	NCTC 10460	AF037157	<i>atpD</i>
	<i>Yersinia pestis</i>	CO-92	Genome project ²	<i>atpD</i>
30	Archaeabacteria			
	<i>Archaeoglobus fulgidus</i>	DSM 4304	AE001023	<i>atpD (V)</i>
	<i>Halobacterium salinarum</i>		S56356	<i>atpD (V)</i>
	<i>Haloferax volcanii</i>	WR 340	X79516	<i>atpD</i>
35	<i>Methanococcus jannaschii</i>	DSM 2661	U67477	<i>atpD (V)</i>
	<i>Methanosaarcina barkeri</i>	DSM 800	J04836	<i>atpD (V)</i>
40	Fungi			
	<i>Candida albicans</i>	SC5314	Genome project ²	<i>atpD</i>
	<i>Candida tropicalis</i>		M64984	<i>atpD (V)</i>
	<i>Kluyveromyces lactis</i>	2359/152	U37764	<i>atpD</i>
	<i>Neurospora crassa</i>		X53720	<i>atpD</i>
45	<i>Saccharomyces cerevisiae</i>		M12082	<i>atpD</i>
	<i>Saccharomyces cerevisiae</i>	X2180-1A	J05409	<i>atpD (V)</i>
	<i>Schizosaccharomyces pombe</i>	972 h-	S47814	<i>atpD (V)</i>
	<i>Schizosaccharomyces pombe</i>	972 h-	M57956	<i>atpD</i>
50	Parasites			
	<i>Giardia lamblia</i>	WB	U18938	<i>atpD</i>
	<i>Plasmodium falciparum</i>	3D7	L08200	<i>atpD (V)</i>
55	<i>Trypanosoma congoense</i>	IL3000	Z25814	<i>atpD (V)</i>

Table 11. Microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases (continued).

	Species	Strain	Accession number	Coding gene*
Human and plants				
5	<i>Homo sapiens</i>		L09234	<i>atpD</i> (V)
	<i>Homo sapiens</i>		M27132	<i>atpD</i>
<u>recA</u> sequences				
10	Bacteria			
	<i>Acetobacter aceti</i>	no. 1023	S60630	<i>recA</i>
	<i>Acetobacter altoacetigenes</i>	MH-24	E05290	<i>recA</i>
15	<i>Acetobacter polyoxogenes</i>	NBI 1028	D13183	<i>recA</i>
	<i>Acholeplasma laidlawii</i>	8195	M81465	<i>recA</i>
	<i>Acidiphilium facilis</i>	ATCC 35904	D16538	<i>recA</i>
	<i>Acidothermus cellulolyticus</i>	ATCC 43068	AJ006705	<i>recA</i>
	<i>Acinetobacter calcoaceticus</i>	BD413/ADP1	L26100	<i>recA</i>
20	<i>Actinobacillus actinomycetemcomitans</i>	HK1651	Genome project ²	<i>recA</i>
	<i>Aeromonas salmonicida</i>	A449	U83688	<i>recA</i>
	<i>Agrobacterium tumefaciens</i>	C58	L07902	<i>recA</i>
	<i>Allochromatium vinosum</i>		AJ000677	<i>recA</i>
	<i>Aquifex aeolicus</i>	VF5	AE000775	<i>recA</i>
25	<i>Aquifex pyrophilus</i>	Kol5a	L23135	<i>recA</i>
	<i>Azotobacter vinelandii</i>		S96898	<i>recA</i>
	<i>Bacillus stearothermophilus</i>	10	Genome project ²	<i>recA</i>
	<i>Bacillus subtilis</i>	PB1831	U87792	<i>recA</i>
	<i>Bacillus subtilis</i>	168	Z99112	<i>recA</i>
30	<i>Bacteroides fragilis</i>		M63029	<i>recA</i>
	<i>Bifidobacterium breve</i>	NCFB 2258	AF094756	<i>recA</i>
	<i>Blastochloris viridis</i>	DSM 133	AF022175	<i>recA</i>
	<i>Bordetella pertussis</i>	165	X53457	<i>recA</i>
	<i>Bordetella pertussis</i>	Tohama I	Genome project ²	<i>recA</i>
35	<i>Borrelia burgdorferi</i>	Sh-2-82	U23457	<i>recA</i>
	<i>Borrelia burgdorferi</i>	B31	AE001124	<i>recA</i>
	<i>Brevibacterium flavum</i>	MJ-233	E10390	<i>recA</i>
	<i>Brucella abortus</i>	2308	L00679	<i>recA</i>
	<i>Burkholderia cepacia</i>	ATCC 17616	U70431	<i>recA</i>
40	<i>Burkholderia cepacia</i>		D90120	<i>recA</i>
	<i>Burkholderia pseudomallei</i>	K96243	Genome project ²	<i>recA</i>
	<i>Campylobacter fetus</i> subsp. <i>fetus</i>	23D	AF020677	<i>recA</i>
	<i>Campylobacter jejuni</i>	81-176	U03121	<i>recA</i>
	<i>Campylobacter jejuni</i>	NCTC 11168	AL139079	<i>recA</i>
45	<i>Chlamydia trachomatis</i>	L2	U16739	<i>recA</i>
	<i>Chlamydia trachomatis</i>	D/UW-3/CX	AE001335	<i>recA</i>
	<i>Chlamydophila pneumoniae</i>	CWL029	AE001658	<i>recA</i>
	<i>Chloroflexus aurantiacus</i>	J-10-II	AF037259	<i>recA</i>
	<i>Clostridium acetobutylicum</i>		M94057	<i>recA</i>
50	<i>Clostridium perfringens</i>	13	U61497	<i>recA</i>
	<i>Corynebacterium diphtheriae</i>	NCTC13129	Genome project ²	<i>recA</i>
	<i>Corynebacterium glutamicum</i>	AS019	U14965	<i>recA</i>
	<i>Corynebacterium pseudotuberculosis</i>	C231	U30387	<i>recA</i>
	<i>Deinococcus radiodurans</i>	KD8301	AB005471	<i>recA</i>
55	<i>Deinococcus radiodurans</i>	R1	U01876	<i>recA</i>

Table 11. Microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases (continued).

	Species	Strain	Accession number	Coding gene*
	<i>Enterobacter agglomerans</i>	339	L03291	<i>recA</i>
	<i>Enterococcus faecalis</i>	OGIX	M81466	<i>recA</i>
	<i>Erwinia carotovora</i>		X55554	<i>recA</i>
	<i>Escherichia coli</i>		J01672	<i>recA</i>
5	<i>Escherichia coli</i>		X55552	<i>recA</i>
	<i>Escherichia coli</i>	K-12	AE000354	<i>recA</i>
	<i>Frankia alni</i>	Arl3	AJ006707	<i>recA</i>
	<i>Gluconobacter oxydans</i>		U21001	<i>recA</i>
	<i>Haemophilus influenzae</i>	Rd	U32687	<i>recA</i>
10	<i>Haemophilus influenzae</i>	Rd	U32741	<i>recA</i>
	<i>Haemophilus influenzae</i>	Rd	L07529	<i>recA</i>
	<i>Helicobacter pylori</i>	69A	Z35478	<i>recA</i>
	<i>Helicobacter pylori</i>	26695	AE000536	<i>recA</i>
	<i>Helicobacter pylori</i>	J99	AE001453	<i>recA</i>
15	<i>Klebsiella pneumoniae</i>	M6H 78578	Genome project ²	<i>recA</i>
	<i>Lactococcus lactis</i>	ML3	M88106	<i>recA</i>
	<i>Legionella pneumophila</i>		X55453	<i>recA</i>
	<i>Leptospira biflexa</i>	serovar patoc	U32625	<i>recA</i>
	<i>Leptospira interrogans</i>	serovar pomona	U29169	<i>recA</i>
20	<i>Magnetospirillum magnetotacticum</i>	MS-1	X17371	<i>recA</i>
	<i>Methylobacillus flagellatus</i>	MFK1	M35325	<i>recA</i>
	<i>Methylomonas clara</i>	ATCC 31226	X59514	<i>recA</i>
	<i>Mycobacterium avium</i>	104	Genome project ²	<i>recA</i>
	<i>Mycobacterium bovis</i>	AF122/97	Genome project ²	<i>recA</i>
25	<i>Mycobacterium leprae</i>		X73822	<i>recA</i>
	<i>Mycobacterium tuberculosis</i>	H37Rv	X58485	<i>recA</i>
	<i>Mycobacterium tuberculosis</i>	CSU#93	Genome project ²	<i>recA</i>
	<i>Mycoplasma genitalium</i>	G37	U39717	<i>recA</i>
	<i>Mycoplasma mycoides</i>	GM9	L22073	<i>recA</i>
30	<i>Mycoplasma pneumoniae</i>	ATCC 29342	MPAE000033	<i>recA</i>
	<i>Mycoplasma pulmonis</i>	KD735	L22074	<i>recA</i>
	<i>Myxococcus xanthus</i>		L40368	<i>recA</i>
	<i>Myxococcus xanthus</i>		L40367	<i>recA</i>
	<i>Neisseria animalis</i>	NCTC 10212	U57910	<i>recA</i>
35	<i>Neisseria cinerea</i>	LCDC 81-176	AJ223869	<i>recA</i>
	<i>Neisseria cinerea</i>	LNP 1646	U57906	<i>recA</i>
	<i>Neisseria cinerea</i>	NCTC 10294	AJ223871	<i>recA</i>
	<i>Neisseria cinerea</i>	Vedros M601	AJ223870	<i>recA</i>
	<i>Neisseria elongata</i>	CCUG 2131	AJ223882	<i>recA</i>
40	<i>Neisseria elongata</i>	CCUG 4165A	AJ223880	<i>recA</i>
	<i>Neisseria elongata</i>	NCTC 10660	AJ223881	<i>recA</i>
	<i>Neisseria elongata</i>	NCTC 11050	AJ223878	<i>recA</i>
	<i>Neisseria elongata</i>	NHITCC 2376	AJ223877	<i>recA</i>
	<i>Neisseria elongata</i>	CCUG 4557	AJ223879	<i>recA</i>
45	<i>subsp. intermedia</i>			
	<i>Neisseria flava</i>	Bangor 9	AJ223873	<i>recA</i>
	<i>Neisseria flavescens</i>	LNP 444	U57907	<i>recA</i>
	<i>Neisseria gonorrhoeae</i>	CH95	U57902	<i>recA</i>
	<i>Neisseria gonorrhoeae</i>	FA19	X64842	<i>recA</i>
50	<i>Neisseria gonorrhoeae</i>	MS11	X17374	<i>recA</i>
	<i>Neisseria gonorrhoeae</i>		Genome project ²	<i>recA</i>
	<i>Neisseria lactamica</i>	CCUC 7757	AJ223866	<i>recA</i>
	<i>Neisseria lactamica</i>	CCUG 7852	Y11819	<i>recA</i>
	<i>Neisseria lactamica</i>	LCDC 77-143	Y11818	<i>recA</i>
55	<i>Neisseria lactamica</i>	LCDC 80-111	AJ223864	<i>recA</i>

Table 11. Microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases (continued).

	Species	Strain	Accession number	Coding gene*
	<i>Neisseria lactamica</i>	LCDC 845	AJ223865	<i>recA</i>
	<i>Neisseria lactamica</i>	NCTC 10617	U57905	<i>recA</i>
	<i>Neisseria lactamica</i>	NCTC 10618	AJ223863	<i>recA</i>
5	<i>Neisseria meningitidis</i>	44/46	X64849	<i>recA</i>
	<i>Neisseria meningitidis</i>	Bangor 13	AJ223868	<i>recA</i>
	<i>Neisseria meningitidis</i>	HF116	X64848	<i>recA</i>
	<i>Neisseria meningitidis</i>	HF130	X64844	<i>recA</i>
	<i>Neisseria meningitidis</i>	HF46	X64847	<i>recA</i>
10	<i>Neisseria meningitidis</i>	M470	X64850	<i>recA</i>
	<i>Neisseria meningitidis</i>	N94II	X64846	<i>recA</i>
	<i>Neisseria meningitidis</i>	NCTC 8249	AJ223867	<i>recA</i>
	<i>Neisseria meningitidis</i>	P63	X64845	<i>recA</i>
	<i>Neisseria meningitidis</i>	S3446	U57903	<i>recA</i>
15	<i>Neisseria meningitidis</i>	FAM18	Genome project ²	<i>recA</i>
	<i>Neisseria mucosa</i>	LNP 405	U57908	<i>recA</i>
	<i>Neisseria mucosa</i>	Vedros M1801	AJ223875	<i>recA</i>
	<i>Neisseria perflava</i>	CCUG 17915	AJ223876	<i>recA</i>
	<i>Neisseria perflava</i>	LCDC 85402	AJ223862	<i>recA</i>
20	<i>Neisseria pharyngis</i> var. <i>flava</i>	NCTC 4590	U57909	<i>recA</i>
	<i>Neisseria polysaccharea</i>	CCUG 18031	Y11815	<i>recA</i>
	<i>Neisseria polysaccharea</i>	CCUG 24845	Y11816	<i>recA</i>
	<i>Neisseria polysaccharea</i>	CCUG 24846	Y11814	<i>recA</i>
	<i>Neisseria polysaccharea</i>	INS MA 3008	Y11817	<i>recA</i>
25	<i>Neisseria polysaccharea</i>	NCTC 11858	U57904	<i>recA</i>
	<i>Neisseria sicca</i>	NRL 30016	AJ223872	<i>recA</i>
	<i>Neisseria subflava</i>	NRL 30017	AJ223874	<i>recA</i>
	<i>Paracoccus denitrificans</i>	DSM 413	U59631	<i>recA</i>
	<i>Pasteurella multocida</i>		X99324	<i>recA</i>
30	<i>Porphyromonas gingivalis</i>	W83	U70054	<i>recA</i>
	<i>Prevotella ruminicola</i>	JCM 8958	U61227	<i>recA</i>
	<i>Proteus mirabilis</i>	pG1300	X14870	<i>recA</i>
	<i>Proteus vulgaris</i>		X55555	<i>recA</i>
	<i>Pseudomonas aeruginosa</i>		X05691	<i>recA</i>
35	<i>Pseudomonas aeruginosa</i>	PAM 7	X52261	<i>recA</i>
	<i>Pseudomonas fluorescens</i>	PAO12	D13090	<i>recA</i>
	<i>Pseudomonas putida</i>	OE 28.3	M96558	<i>recA</i>
	<i>Pseudomonas putida</i>		L12684	<i>recA</i>
40	<i>Rhizobium leguminosarum</i>	PpS145	U70864	<i>recA</i>
	<i>biov variae</i>	VF39	X59956	<i>recA</i>
	<i>Rhizobium phaseoli</i>	CNPAF512	X62479	<i>recA</i>
	<i>Rhodobacter capsulatus</i>	J50	X82183	<i>recA</i>
	<i>Rhodobacter sphaeroides</i>	2.4.1	X72705	<i>recA</i>
45	<i>Rhodopseudomonas palustris</i>	N 7	D84467	<i>recA</i>
	<i>Rickettsia prowazekii</i>	Madrid E	AJ235273	<i>recA</i>
	<i>Rickettsia prowazekii</i>	Madrid E	U01959	<i>recA</i>
	<i>Serratia marcescens</i>		M22935	<i>recA</i>
	<i>Shigella flexneri</i>		X55553	<i>recA</i>
50	<i>Shigella sonnei</i>	KNIH104S	AF101227	<i>recA</i>
	<i>Sinorhizobium meliloti</i>	2011	X59957	<i>recA</i>
	<i>Staphylococcus aureus</i>		L25893	<i>recA</i>
	<i>Streptococcus gordonii</i>	Challis V288	L20574	<i>recA</i>
	<i>Streptococcus mutans</i>	UA96	M81468	<i>recA</i>
55	<i>Streptococcus mutans</i>	GS-5	M61897	<i>recA</i>
	<i>Streptococcus pneumoniae</i>		Z17307	<i>recA</i>

Table 11. Microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases (continued).

	Species	Strain	Accession number	Coding gene*
	<i>Streptococcus pneumoniae</i>	R800	Z34303	<i>recA</i>
	<i>Streptococcus pyogenes</i>	NZ131	U21934	<i>recA</i>
	<i>Streptococcus pyogenes</i>	D471	M81469	<i>recA</i>
	<i>Streptococcus salivarius</i>		M94062	<i>recA</i>
5	<i>subsp. thermophilus</i>			
	<i>Streptomyces ambofaciens</i>	DSM 40697	Z30324	<i>recA</i>
	<i>Streptomyces coelicolor</i>	A3(2)	AL020958	<i>recA</i>
	<i>Streptomyces lividans</i>	TK24	X76076	<i>recA</i>
	<i>Streptomyces rimosus</i>	R6	X94233	<i>recA</i>
10	<i>Streptomyces venezuelae</i>	ATCC10712	U04837	<i>recA</i>
	<i>Synechococcus</i> sp.	PR6	M29495	<i>recA</i>
	<i>Synechocystis</i> sp.	PCC6803	D90917	<i>recA</i>
	<i>Thermotoga maritima</i>		L23425	<i>recA</i>
	<i>Thermotoga maritima</i>		AE001823	<i>recA</i>
15	<i>Thermus aquaticus</i>		L20095	<i>recA</i>
	<i>Thermus thermophilus</i>	HB8	D17392	<i>recA</i>
	<i>Thiobacillus ferrooxidans</i>		M26933	<i>recA</i>
	<i>Treponema denticola</i>		Genome project ²	<i>recA</i>
	<i>Treponema pallidum</i>	Nichols	AE001243	<i>recA</i>
20	<i>Vibrio anguillarum</i>		M80525	<i>recA</i>
	<i>Vibrio cholerae</i>	017	X71969	<i>recA</i>
	<i>Vibrio cholerae</i>	2740-80	U10162	<i>recA</i>
	<i>Vibrio cholerae</i>	569B	L42384	<i>recA</i>
	<i>Vibrio cholerae</i>	M549	AF117881	<i>recA</i>
25	<i>Vibrio cholerae</i>	M553	AF117882	<i>recA</i>
	<i>Vibrio cholerae</i>	M645	AF117883	<i>recA</i>
	<i>Vibrio cholerae</i>	M793	AF117878	<i>recA</i>
	<i>Vibrio cholerae</i>	M794	AF117880	<i>recA</i>
	<i>Vibrio cholerae</i>	M967	AF117879	<i>recA</i>
30	<i>Xanthomonas citri</i>	XW47	AF006590	<i>recA</i>
	<i>Xanthomonas oryzae</i>		AF013600	<i>recA</i>
	<i>Xenorhabdus bovienii</i>	T228/1	U87924	<i>recA</i>
	<i>Xenorhabdus nematophilus</i>	AN6	AF127333	<i>recA</i>
	<i>Yersinia pestis</i>	231	X75336	<i>recA</i>
35	<i>Yersinia pestis</i>	CO-92	Genome project ²	<i>recA</i>

Fungi, parasites, human and plants

40	<i>Anabaena variabilis</i>	ATCC 29413	M29680	<i>recA</i>
	<i>Arabidopsis thaliana</i>		U43652	<i>recA</i> (Rad51)
	<i>Candida albicans</i>		U39808	<i>recA</i> (Dmc1)
	<i>Coprinus cinereus</i>	Okayama-7	U21905	<i>recA</i> (Rad51)
	<i>Emericella nidulans</i>		Z80341	<i>recA</i> (Rad51)
45	<i>Gallus gallus</i>		L09655	<i>recA</i> (Rad51)
	<i>Homo sapiens</i>		D13804	<i>recA</i> (Rad51)
	<i>Homo sapiens</i>		D63882	<i>recA</i> (Dmc1)
	<i>Leishmania major</i>	Friedlin	AF062379	<i>recA</i> (Rad51)
	<i>Leishmania major</i>	Friedlin	AF062380	<i>recA</i> (Dmc1)
50	<i>Mus musculus</i>		D58419	<i>recA</i> (Dmc1)
	<i>Neurospora crassa</i>	74-OR23-1A	D29638	<i>recA</i> (Rad51)
	<i>Saccharomyces cerevisiae</i>		D10023	<i>recA</i> (Rad51)
	<i>Schizosaccharomyces pombe</i>		Z22691	<i>recA</i> (Rad51)
	<i>Schizosaccharomyces pombe</i>	972h-PB9R	AL021817	<i>recA</i> (Dmc1)
55	<i>Tetrahymena thermophila</i>		AF064516	<i>recA</i> (Rad51)

Table 11. Microbial species for which *tuf* and/or *atpD* and/or *recA* sequences are available in public databases (continued).

Species	Strain	Accession number	Coding gene*
<i>Trypanosoma brucei</i>	stock 427	Y13144	<i>recA</i> (Rad51)
<i>Ustilago maydis</i>		U62484	<i>recA</i> (Rad51)
<i>Xenopus laevis</i>		D38488	<i>recA</i> (Rad51)
5 <i>Xenopus laevis</i>		D38489	<i>recA</i> (Rad51)

* *tuf* indicates *tuf* sequences, including *tuf* genes, *fusA* genes and *fusA-tuf* intergenic spacers.

tuf (C) indicates *tuf* sequences divergent from main (usually A and B) copies of the elongation factor-Tu

10 *tuf* (EF-1) indicates *tuf* sequences of the eukaryotic type (elongation factor 1α)

tuf (M) indicates *tuf* sequences from organellar (mostly mitochondrial) origin

atpD indicates *atpD* sequences of the F-type

atpD (V) indicates *atpD* sequences of the V-Type

recA indicates *recA* sequences

15 *recA* (Rad51) indicates *rad51* sequences or homologs

recA (Dmc1) indicates *dmc1* sequences or homologs

¹ Nucleotides sequences published in Arch. Microbiol. 1990 153:241-247

² These sequences are from the TIGR database (<http://www.tigr.org/tdb/tdb.html>)

³ Nucleotides sequences published in FEMS Microbiology Letters 1988 50:101-106

Table 12. Bacterial species used to test the specificity of the *Staphylococcus*-specific amplification primers derived from *tuf* sequences.

	Strain	Reference number	Strain	Reference number	
5					
	Staphylococcal species (n=27)			Other Gram-positive bacteria (n=20)	
	<i>Staphylococcus arlettae</i>	ATCC 43957	<i>Bacillus subtilis</i>	ATCC 27370	
	<i>Staphylococcus aureus</i>	ATCC 35844	<i>Enterococcus avium</i>	ATCC 14025	
	subsp. <i>anaerobius</i>				
10	<i>Staphylococcus aureus</i>	ATCC 43300	<i>Enterococcus durans</i>	ATCC 19432	
	subsp. <i>aureus</i>				
	<i>Staphylococcus auricularis</i>	ATCC 33753	<i>Enterococcus faecalis</i>	ATCC 19433	
	<i>Staphylococcus capitis</i>	ATCC 27840	<i>Enterococcus faecium</i>	ATCC 19434	
	subsp. <i>capitis</i>				
15	<i>Staphylococcus caprae</i>	ATCC 35538	<i>Enterococcus flavescentis</i>	ATCC 49996	
	<i>Staphylococcus carnosus</i>	ATCC 51365	<i>Enterococcus gallinarum</i>	ATCC 49573	
	<i>Staphylococcus chromogenes</i>	ATCC 43764	<i>Lactobacillus acidophilus</i>	ATCC 4356	
	<i>Staphylococcus cohnii</i>	DSM 20260	<i>Lactococcus lactis</i>	ATCC 11454	
	subsp. <i>urealyticum</i>				
20	<i>Staphylococcus delphini</i>	ATCC 49171	<i>Listeria innocua</i>	ATCC 33090	
	<i>Staphylococcus epidermidis</i>	ATCC 14990	<i>Listeria ivanovii</i>	ATCC 19119	
	<i>Staphylococcus equorum</i>	ATCC 43958	<i>Listeria monocytogenes</i>	ATCC 15313	
	<i>Staphylococcus felis</i>	ATCC 49168	<i>Macrococcus caseolyticus</i>	ATCC 13548	
	<i>Staphylococcus gallinarum</i>	ATCC 35539	<i>Streptococcus agalactiae</i>	ATCC 13813	
25	<i>Staphylococcus haemolyticus</i>	ATCC 29970	<i>Streptococcus anginosus</i>	ATCC 33397	
	<i>Staphylococcus hominis</i>	ATCC 27844	<i>Streptococcus bovis</i>	ATCC 33317	
	<i>Staphylococcus hyicus</i>	ATCC 11249	<i>Streptococcus mutans</i>	ATCC 25175	
	<i>Staphylococcus intermedius</i>	ATCC 29663	<i>Streptococcus pneumoniae</i>	ATCC 6303	
	<i>Staphylococcus kloosii</i>	ATCC 43959	<i>Streptococcus pyogenes</i>	ATCC 19615	
30	<i>Staphylococcus lento</i>	ATCC 29070	<i>Streptococcus salivarius</i>	ATCC 7073	
	<i>Staphylococcus lugdunensis</i>	ATCC 43809			
	<i>Staphylococcus saprophyticus</i>	ATCC 15305			
	<i>Staphylococcus schleiferi</i>	ATCC 49545			
	subsp. <i>coagulans</i>				
35	<i>Staphylococcus sciuri</i>	ATCC 29060			
	subsp. <i>sciuri</i>				
	<i>Staphylococcus simulans</i>	ATCC 27848			
	<i>Staphylococcus warneri</i>	ATCC 27836			
	<i>Staphylococcus xylosus</i>	ATCC 29971			
40	Gram-negative bacteria (n=33)				
	<i>Acinetobacter baumannii</i>	ATCC 19606	<i>Morganella morganii</i>	ATCC 25830	
	<i>Bacteroides distasonis</i>	ATCC 8503	<i>Neisseria gonorrhoeae</i>	ATCC 35201	
	<i>Bacteroides fragilis</i>	ATCC 25285	<i>Neisseria meningitidis</i>	ATCC 13077	
	<i>Bulkholderia cepacia</i>	ATCC 25416	<i>Proteus mirabilis</i>	ATCC 25933	
45	<i>Bordetella pertussis</i>	ATCC 9797	<i>Proteus vulgaris</i>	ATCC 13315	
	<i>Citrobacter freundii</i>	ATCC 8090	<i>Providencia rettgeri</i>	ATCC 9250	
	<i>Enterobacter aerogenes</i>	ATCC 13048	<i>Providencia stuartii</i>	ATCC 29914	
	<i>Enterobacter cloacae</i>	ATCC 13047	<i>Pseudomonas aeruginosa</i>	ATCC 27853	
	<i>Escherichia coli</i>	ATCC 25922	<i>Pseudomonas fluorescens</i>	ATCC 13525	
50	<i>Haemophilus influenzae</i>	ATCC 8907	<i>Salmonella choleraesuis</i>	ATCC 7001	
	<i>Haemophilus parahaemolyticus</i>	ATCC 10014	<i>Salmonella typhimurium</i>	ATCC 14028	
	<i>Haemophilus parainfluenzae</i>	ATCC 7901	<i>Serratia marcescens</i>	ATCC 8100	
	<i>Hafnia alvei</i>	ATCC 13337	<i>Shigella flexneri</i>	ATCC 12022	
	<i>Kingella indologenes</i>	ATCC 25869	<i>Shigella sonnei</i>	ATCC 29930	
55	<i>Klebsiella oxytoca</i>	ATCC 13182	<i>Stenotrophomonas maltophilia</i>	ATCC 13843	
	<i>Klebsiella pneumoniae</i>	ATCC 13883	<i>Yersinia enterocolitica</i>	ATCC 9610	
	<i>Moraxella catarrhalis</i>	ATCC 25240			

Table 13. Bacterial species used to test the specificity of the penicillin-resistant *Streptococcus pneumoniae* assay.

	Strain	Reference number	Strain	Reference number
5	Gram-positive species (n=67)			
10	<i>Abiotrophia adiacens</i>	ATCC 49175	<i>Staphylococcus hominis</i>	ATCC 27844
	<i>Abiotrophia defectiva</i>	ATCC 49176	<i>Staphylococcus lugdunensis</i>	ATCC 43809
	<i>Actinomyces pyogenes</i>	ATCC 19411	<i>Staphylococcus saprophyticus</i>	ATCC 15305
15	<i>Bacillus anthracis</i>	ATCC 4229	<i>Staphylococcus simulans</i>	ATCC 27848
	<i>Bacillus cereus</i>	ATCC 14579	<i>Staphylococcus warneri</i>	ATCC 27836
	<i>Bifidobacterium breve</i>	ATCC 15700	<i>Streptococcus acidominimus</i>	ATCC 51726
	<i>Clostridium difficile</i>	ATCC 9689	<i>Streptococcus agalactiae</i>	ATCC 12403
20	<i>Enterococcus avium</i>	ATCC 14025	<i>Streptococcus anginosus</i>	ATCC 33397
	<i>Enterococcus casseliflavus</i>	ATCC 25788	<i>Streptococcus bovis</i>	ATCC 33317
	<i>Enterococcus dispar</i>	ATCC 51266	<i>Streptococcus constellatus</i>	ATCC 27823
	<i>Enterococcus durans</i>	ATCC 19432	<i>Streptococcus cricetus</i>	ATCC 19624
	<i>Enterococcus faecalis</i>	ATCC 29212	<i>Streptococcus cristatus</i>	ATCC 51100
	<i>Enterococcus faecium</i>	ATCC 19434	<i>Streptococcus downei</i>	ATCC 33748
25	<i>Enterococcus flavescentis</i>	ATCC 49996	<i>Streptococcus dysgalactiae</i>	ATCC 43078
	<i>Enterococcus gallinarum</i>	ATCC 49573	<i>Streptococcus equi</i>	ATCC 9528
	<i>Enterococcus hirae</i>	ATCC 8043	<i>Streptococcus ferus</i>	ATCC 33477
	<i>Enterococcus mundtii</i>	ATCC 43186	<i>Streptococcus gordonii</i>	ATCC 10558
	<i>Enterococcus raffinosus</i>	ATCC 49427	<i>Streptococcus intermedius</i>	ATCC 27335
30	<i>Lactobacillus lactis</i>	ATCC 19435	<i>Streptococcus mitis</i>	ATCC 903
	<i>Lactobacillus monocytogenes</i>	ATCC 15313	<i>Streptococcus mitis</i>	LSPQ 2583
	<i>Mobiluncus curtisi</i>	ATCC 35242	<i>Streptococcus mitis</i>	ATCC 49456
	<i>Peptococcus niger</i>	ATCC 27731	<i>Streptococcus mutans</i>	ATCC 27175
35	<i>Peptostreptococcus acones</i>	ATCC 6919	<i>Streptococcus oralis</i>	ATCC 10557
	<i>Peptostreptococcus anaerobius</i>	ATCC 27337	<i>Streptococcus oralis</i>	ATCC 9811
	<i>Peptostreptococcus asaccharolyticus</i>	ATCC 2639	<i>Streptococcus oralis</i>	ATCC 35037
	<i>Peptostreptococcus lactolyticus</i>	ATCC 51172	<i>Streptococcus parasanguinis</i>	ATCC 15912
	<i>Peptostreptococcus magnus</i>	ATCC 15794	<i>Streptococcus parauberis</i>	ATCC 6631
40	<i>Peptostreptococcus prevotii</i>	ATCC 9321	<i>Streptococcus rattus</i>	ATCC 15912
	<i>Peptostreptococcus tetradius</i>	ATCC 35098	<i>Streptococcus salivarius</i>	ATCC 7073
	<i>Staphylococcus aureus</i>	ATCC 25923	<i>Streptococcus sanguinis</i>	ATCC 10556
	<i>Staphylococcus capitis</i>	ATCC 27840	<i>Streptococcus suis</i>	ATCC 43765
	<i>Staphylococcus epidermidis</i>	ATCC 14990	<i>Streptococcus uberis</i>	ATCC 19436
	<i>Staphylococcus haemolyticus</i>	ATCC 29970	<i>Streptococcus vestibularis</i>	ATCC 49124
Gram-negative species (n=33)				
45	<i>Actinetobacter baumannii</i>	ATCC 19606	<i>Moraxella morganii</i>	ATCC 13077
	<i>Bordetella pertussis</i>	ATCC 9797	<i>Neisseria gonorrhoeae</i>	ATCC 35201
	<i>Citrobacter diversus</i>	ATCC 27028	<i>Neisseria meningitidis</i>	ATCC 13077
	<i>Citrobacter freundii</i>	ATCC 8090	<i>Proteus mirabilis</i>	ATCC 25933
50	<i>Enterobacter aerogenes</i>	ATCC 13048	<i>Proteus vulgaris</i>	ATCC 13315
	<i>Enterobacter agglomerans</i>	ATCC 27155	<i>Providencia alcalifaciens</i>	ATCC 9886
	<i>Enterobacter cloacae</i>	ATCC 13047	<i>Providencia rettgeri</i>	ATCC 9250
	<i>Escherichia coli</i>	ATCC 25922	<i>Providencia rustigianii</i>	ATCC 33673
55	<i>Haemophilus ducreyi</i>	ATCC 33940	<i>Providencia stuartii</i>	ATCC 33672
	<i>Haemophilus haemolyticus</i>	ATCC 33390	<i>Pseudomonas aeruginosa</i>	ATCC 35554
	<i>Haemophilus influenzae</i>	ATCC 9007	<i>Pseudomonas fluorescens</i>	ATCC 13525
	<i>Haemophilus parainfluenzae</i>	ATCC 7901	<i>Pseudomonas stutzeri</i>	ATCC 17588
	<i>Hafnia alvei</i>	ATCC 13337	<i>Salmonella typhimurium</i>	ATCC 14028
	<i>Klebsiella oxytoca</i>	ATCC 13182	<i>Serratia marcescens</i>	ATCC 13880
	<i>Klebsiella pneumoniae</i>	ATCC 13883	<i>Shigella flexneri</i>	ATCC 12022
	<i>Moraxella atlantae</i>	ATCC 29525	<i>Yersina enterocolitica</i>	ATCC 9610
	<i>Moraxella catarrhalis</i>	ATCC 43628		

Table 14. Bacterial species (n=104) detected by the platelet contaminants assay. Bold characters indicate the major bacterial contaminants found in platelet concentrates.

5	<i>Abiotrophia adiacens</i>	<i>Klebsiella oxytoca</i>	<i>Staphylococcus simulans</i>
	<i>Abiotrophia defectiva</i>	<i>Klebsiella pneumoniae</i>	<i>Staphylococcus warneri</i>
	<i>Acinetobacter baumannii</i>	<i>Legionella pneumophila</i>	<i>Stenotrophomonas maltophilia</i>
	<i>Acinetobacter lwoffii</i>	<i>Megamonas hypermegale</i>	80 <i>Streptococcus acidominimus</i>
	<i>Aerococcus viridans</i>	<i>Moraxella atlantae</i>	Streptococcus agalactiae
10	<i>Bacillus anthracis</i>	<i>Moraxella catarrhalis</i>	<i>Streptococcus anginosus</i>
	<i>Bacillus cereus</i>	<i>Morganella morganii</i>	<i>Streptococcus bovis</i>
	<i>Bacillus subtilis</i>	<i>Neisseria gonorrhoeae</i>	<i>Streptococcus constellatus</i>
	<i>Brucella abortus</i>	<i>Neisseria meningitidis</i>	85 <i>Streptococcus cricetus</i>
	<i>Burkholderia cepacia</i>	<i>Pasteurella aerogenes</i>	<i>Streptococcus cristatus</i>
15	<i>Citrobacter diversus</i>	<i>Pasteurella multocida</i>	<i>Streptococcus dysgalactiae</i>
	<i>Citrobacter freundii</i>	<i>Peptostreptococcus magnus</i>	<i>Streptococcus equi</i>
	<i>Enterobacter aerogenes</i>	<i>Proteus mirabilis</i>	<i>Streptococcus ferus</i>
	<i>Enterobacter agglomerans</i>	<i>Providencia alcalifaciens</i>	90 <i>Streptococcus gordonii</i>
	<i>Enterobacter cloacae</i>	<i>Providencia rettgeri</i>	<i>Streptococcus intermedius</i>
20	<i>Enterococcus avium</i>	<i>Providencia rustigianii</i>	<i>Streptococcus macacae</i>
	<i>Enterococcus casseliflavus</i>	<i>Providencia stuartii</i>	<i>Streptococcus mitis</i>
	<i>Enterococcus dispar</i>	<i>Pseudomonas aeruginosa</i>	<i>Streptococcus mutans</i>
	<i>Enterococcus durans</i>	<i>Pseudomonas fluorescens</i>	95 <i>Streptococcus oralis</i>
	<i>Enterococcus faecalis</i>	<i>Pseudomonas stutzeri</i>	<i>Streptococcus parasanguinis</i>
25	<i>Enterococcus faecium</i>	<i>Salmonella bongori</i>	<i>Streptococcus parauberis</i>
	<i>Enterococcus flavescentis</i>	<i>Salmonella choleraesuis</i>	<i>Streptococcus pneumoniae</i>
	<i>Enterococcus gallinarum</i>	<i>Salmonella enteritidis</i>	<i>Streptococcus pyogenes</i>
	<i>Enterococcus mundtii</i>	<i>Salmonella gallinarum</i>	100 <i>Streptococcus ratti</i>
	<i>Enterococcus raffinosus</i>	<i>Salmonella typhimurium</i>	<i>Streptococcus salivarius</i>
30	<i>Enterococcus solitarius</i>	<i>Serratia liquefaciens</i>	<i>Streptococcus sanguinis</i>
	<i>Escherichia coli</i>	<i>Serratia marcescens</i>	<i>Streptococcus sobrinus</i>
	<i>Gemella morbillorum</i>	<i>Shigella flexneri</i>	<i>Streptococcus uberis</i>
	<i>Haemophilus ducreyi</i>	<i>Shigella sonnei</i>	105 <i>Streptococcus vestibularis</i>
	<i>Haemophilus haemolyticus</i>	<i>Staphylococcus aureus</i>	<i>Vibrio cholerae</i>
35	<i>Haemophilus influenzae</i>	<i>Staphylococcus capitis</i>	<i>Yersinia enterocolitica</i>
	<i>Haemophilus parahaemolyticus</i>	<i>Staphylococcus epidermidis</i>	<i>Yersinia pestis</i>
	<i>Haemophilus parainfluenzae</i>	<i>Staphylococcus haemolyticus</i>	<i>Yersinia pseudotuberculosis</i>
	<i>Hafnia alvei</i>	<i>Staphylococcus hominis</i>	
40	<i>Kingella kingae</i>	<i>Staphylococcus lugdunensis</i>	
		<i>Staphylococcus saprophyticus</i>	

Table 15. Microorganisms identified by commercial systems¹.

		<i>Alcaligenes xylosoxidans</i> subsp. <i>xylosoxidans</i>	75	<i>Brevibacterium</i> species
		<i>Allobiococcus otitis</i>		<i>Brevundimonas (Pseudomonas)</i>
		<i>Anaerobiospirillum succiniciproducens</i>		<i>diminuta</i>
		<i>Anaerovibrio lipolytica</i>		<i>Brevundimonas (Pseudomonas)</i>
		<i>Arachnia propionica</i>		<i>vesicularis</i>
5	<i>Achromobacter</i> species	<i>Arcanobacterium (Actinomyces)</i>	80	<i>Brevundimonas species</i>
	<i>Acidaminococcus fermentans</i>	<i>bemardiae</i>		<i>Brochotrich thermosphacta</i>
	<i>Acinetobacter alcaligenes</i>	<i>Arcanobacterium (Actinomyces)</i>	155	<i>Brucella abortus</i>
	<i>Acinetobacter anitratus</i>	<i>pyogenes</i>		<i>Brucella canis</i>
	<i>Acinetobacter baumannii</i>	<i>Arcanobacterium haemolyticum</i>	160	<i>Brucella melitensis</i>
10	<i>Acinetobacter calcoaceticus</i>	<i>Arcobacter cryoerophilus</i>		<i>Brucella ovis</i>
	<i>Acinetobacter calcoaceticus</i> biovar <i>anitratus</i>	<i>(Campylobacter cryoerophila)</i>		<i>Brucella suis</i>
	<i>Acinetobacter calcoaceticus</i> biovar <i>Iwoffii</i>	<i>Arthrobacter globiformis</i>	85	<i>Budvicia aquatica</i>
15	<i>Acinetobacter genomospecies</i>	<i>Arthrobacter species</i>		<i>Burkholderia (Pseudomonas) cepacia</i>
	<i>Acinetobacter haemolyticus</i>	<i>Axiozyma telluris (Torulopsis</i>	90	<i>Burkholderia (Pseudomonas) gladioli</i>
	<i>Acinetobacter johnsonii</i>	<i>pintolopesii)</i>	165	<i>Burkholderia (Pseudomonas) mallei</i>
	<i>Acinetobacter junii</i>	<i>Atopobium minutum (Lactobacillus</i>		<i>Burkholderia (Pseudomonas)</i>
	<i>Acinetobacter Iwoffii</i>	<i>minutus)</i>		<i>pseudomallei</i>
20	<i>Acinetobacter radioresistens</i>	<i>Aureobacterium</i> species	95	<i>Burkholderia species</i>
	<i>Acinetobacter species</i>	<i>Bacillus amyloliquefaciens</i>		<i>Buttiauxella agrestis</i>
	<i>Actinobacillus actinomycetemcomitans</i>	<i>Bacillus anthracis</i>	170	<i>Campylobacter coli</i>
	<i>Actinobacillus capsulatus</i>	<i>Bacillus badius</i>		<i>Campylobacter concisus</i>
	<i>Actinobacillus equuli</i>	<i>Bacillus cereus</i>		<i>Campylobacter fetus</i>
25	<i>Actinobacillus hominis</i>	<i>Bacillus circulans</i>	100	<i>Campylobacter fetus subsp. fetus</i>
	<i>Actinobacillus lignieresii</i>	<i>Bacillus coagulans</i>		<i>Campylobacter fetus subsp.</i>
	<i>Actinobacillus pleuropneumoniae</i>	<i>Bacillus firmus</i>	175	<i>venerealis</i>
	<i>Actinobacillus species</i>	<i>Bacillus lentus</i>		<i>Campylobacter hyoilealis</i>
30	<i>Actinobacillus suis</i>	<i>Bacillus licheniformis</i>		<i>Campylobacter jejuni subsp. doylei</i>
	<i>Actinobacillus ureae</i>	<i>Bacillus megaterium</i>	105	<i>Campylobacter jejuni subsp. jejuni</i>
	<i>Actinomyces bovis</i>	<i>Bacillus mycoides</i>		<i>Campylobacter larv</i>
	<i>Actinomyces israelii</i>	<i>Bacillus pantothenticus</i>	180	<i>Campylobacter larv subsp. UPTC</i>
	<i>Actinomyces meyeri</i>	<i>Bacillus pumilus</i>		<i>Campylobacter mucosalis</i>
35	<i>Actinomyces naeslundii</i>	<i>Bacillus species</i>		<i>Campylobacter species</i>
	<i>Actinomyces neuii</i> subsp. <i>anitratus</i>	<i>Bacillus sphaericus</i>	110	<i>Campylobacter sputorum</i>
	<i>Actinomyces neuii</i> subsp. <i>neuii</i>	<i>Bacillus stearothermophilus</i>		<i>Campylobacter sputorum subsp.</i>
	<i>Actinomyces odontolyticus</i>	<i>Bacillus subtilis</i>	185	<i>bubulus</i>
	<i>Actinomyces pyogenes</i>	<i>Bacillus thuringiensis</i>		<i>Campylobacter sputorum subsp.</i>
40	<i>Actinomyces radingae</i>	<i>Bacteroides cacciae</i>		<i>fecalis</i>
	<i>Actinomyces species</i>	<i>Bacteroides capillosus</i>	115	<i>Campylobacter sputorum subsp.</i>
	<i>Actinomyces turicensis</i>	<i>Bacteroides distasonis</i>		<i>sputorum</i>
	<i>Actinomyces viscosus</i>	<i>Bacteroides eggerthii</i>	190	<i>Campylobacter upsaliensis</i>
	<i>Aerococcus species</i>	<i>Bacteroides fragilis</i>		<i>Candida (Clavispora) lusitaniae</i>
	<i>Aerococcus viridans</i>	<i>Bacteroides merdae</i>		<i>Candida (Pichia) guilliermondii</i>
45	<i>Aeromonas caviae</i>	<i>Bacteroides ovatus</i>	120	<i>Candida (Torulopsis) glabrata</i>
	<i>Aeromonas hydrophila</i>	<i>Bacteroides species</i>		<i>Candida albicans</i>
	<i>Aeromonas hydrophila</i> group	<i>Bacteroides splanchnicus</i>	195	<i>Candida boldinii</i>
	<i>Aeromonas jandaei</i>	<i>Bacteroides stercoris</i>		<i>Candida catenulata</i>
50	<i>Aeromonas salmonicida</i>	<i>Bacteroides thetaiotaomicron</i>		<i>Candida ciferri</i>
	<i>Aeromonas salmonicida</i> subsp. <i>achromogenes</i>	<i>Bacteroides uniformis</i>	125	<i>Candida colliculos</i>
	<i>Aeromonas salmonicida</i> subsp. <i>masouci</i>	<i>Bacteroides ureolyticus (B. corradiens)</i>		<i>Candida conglobata</i>
	<i>Aeromonas salmonicida</i> subsp. <i>salmonicida</i>	<i>Bacteroides vulgaris</i>	200	<i>Candida curvata (Cryptococcus</i>
55	<i>Aeromonas schuberti</i>	<i>Bergeyella (Weeksella) zoohelcum</i>		<i>curvatus)</i>
	<i>Aeromonas sobria</i>	<i>Bifidobacterium adolescentis</i>		<i>Candida dattile</i>
	<i>Aeromonas species</i>	<i>Bifidobacterium bifidum</i>		<i>Candida dubliniensis</i>
	<i>Aeromonas trota</i>	<i>Bifidobacterium breve</i>	130	<i>Candida tamata</i>
60	<i>Aeromonas veronii</i>	<i>Bifidobacterium dentium</i>		<i>Candida globosa</i>
	<i>Aeromonas veronii</i> biovar <i>sobria</i>	<i>Bifidobacterium infantis</i>	205	<i>Candida hellenica</i>
	<i>Aeromonas veronii</i> biovar <i>veronii</i>	<i>Bifidobacterium species</i>		<i>Candida holmii</i>
	<i>Agrobacterium radiobacter</i>	<i>Blastoschizomyces (Dipodascus)</i>	135	<i>Candida humicola</i>
	<i>Agrobacterium species</i>	<i>capitatus</i>		<i>Candida inconspicua</i>
65	<i>Agrobacterium tumefaciens</i>	<i>Bordetella avium</i>		<i>Candida intermedia</i>
	<i>Alcaligenes denitrificans</i>	<i>Bordetella bronchiseptica</i>		<i>Candida ketyl</i>
	<i>Alcaligenes faecalis</i>	<i>Bordetella parapertussis</i>	140	<i>Candida krusei</i>
	<i>Alcaligenes odorans</i>	<i>Bordetella pertussis</i>		<i>Candida lambica</i>
70	<i>Alcaligenes odorans</i> (<i>Alcaligenes</i> <i>faecalis</i>)	<i>Bordetella species</i>		<i>Candida magnoliae</i>
	<i>Alcaligenes species</i>	<i>Borelia species</i>	215	<i>Candida maris</i>
	<i>Alcaligenes xylosoxidans</i>	<i>Branhamella (Moraxella) catarrhalis</i>		<i>Candida melibiosica</i>
	<i>Alcaligenes xylosoxidans</i> subsp. <i>denitrificans</i>	<i>Branhamella species</i>		<i>Candida membranaefaciens</i>
		<i>Brevibacillus brevis</i>	145	<i>Candida norvegensis</i>
		<i>Brevibacillus laterosporus</i>		<i>Candida norvegica</i>
		<i>Brevibacterium casei</i>	220	<i>Candida parapsilosis</i>
		<i>Brevibacterium epidermidis</i>		<i>Candida paratropicalis</i>
		<i>Brevibacterium linens</i>		<i>Candida pelliculosa</i>

Table 15. Microorganism identified by commercial systems (continued)

	<i>Candida pseudotropicalis</i>		<i>Clostridium hastiforme</i>		<i>Corynebacterium urealyticum</i> (group D2)
	<i>Candida pulcherrima</i>	80	<i>Clostridium histolyticum</i>		<i>Corynebacterium xerosis</i>
	<i>Candida ravautil</i>		<i>Clostridium innocuum</i>	160	<i>Cryptococcus albidus</i>
	<i>Candida rugosa</i>		<i>Clostridium limosum</i>		<i>Cryptococcus atter</i>
5	<i>Candida sake</i>		<i>Clostridium novyi</i>		<i>Cryptococcus cereanus</i>
	<i>Candida silvicola</i>	85	<i>Clostridium novyi A</i>		<i>Cryptococcus gastricus</i>
	<i>Candida species</i>		<i>Clostridium paraputreficum</i>		<i>Cryptococcus humiculus</i>
	<i>Candida sphaerica</i>		<i>Clostridium perfringens</i>	165	<i>Cryptococcus lactativorus</i>
10	<i>Candida stellatoidea</i>		<i>Clostridium putreficum</i>		<i>Cryptococcus laurentii</i>
	<i>Candida tenuis</i>		<i>Clostridium ramosum</i>		<i>Cryptococcus luteolus</i>
	<i>Candida tropicalis</i>	90	<i>Clostridium septicum</i>		<i>Cryptococcus melibiosum</i>
	<i>Candida utilis</i>		<i>Clostridium sordellii</i>		<i>Cryptococcus neoformans</i>
	<i>Candida valida</i>		<i>Clostridium species</i>	170	<i>Cryptococcus species</i>
	<i>Candida vini</i>		<i>Clostridium sphenoides</i>		<i>Cryptococcus terrae</i>
15	<i>Candida viswanathii</i>		<i>Clostridium sporogenes</i>		<i>Cryptococcus uniguttulatus</i>
	<i>Candida zeylanoides</i>		<i>Clostridium subterminalae</i>		<i>Debaromyces hansenii</i>
	<i>Capnocytophaga gingivalis</i>	95	<i>Clostridium tertium</i>		<i>Debaromyces marama</i>
	<i>Capnocytophaga ochracea</i>		<i>Clostridium tetani</i>	175	<i>Debaromyces polymorphus</i>
20	<i>Capnocytophaga species</i>		<i>Clostridium tyrobutyricum</i>		<i>Debaromyces species</i>
	<i>Capnocytophaga sputigena</i>		<i>Comamonas (Pseudomonas) acidovorans</i>		<i>Dermabacter hominis</i>
	<i>Cardiobacterium hominis</i>	100	<i>Comamonas (Pseudomonas) testosteroni</i>		<i>Demacoccus (Micrococcus) nishinomiyaensis</i>
	<i>Carmobacterium divergens</i>		<i>Comamonas species</i>	180	<i>Dietzia species</i>
	<i>Carmobacterium piscicola</i>		<i>Corynebacterium accolens</i>		<i>Edwardsiella hoshiae</i>
	CDC group ED-2		<i>Corynebacterium afermentans</i>		<i>Edwardsiella ictaluri</i>
25	CDC group EF4 (<i>Pasteurella</i> sp.)	105	<i>Corynebacterium amycolatum</i>		<i>Edwardsiella species</i>
	CDC group EF-4A		<i>Corynebacterium aquaticum</i>	185	<i>Edwardsiella tarda</i>
	CDC group EF-4B		<i>Corynebacterium argentoratense</i>		<i>Eikenella corrodens</i>
	CDC group EQ-Z		<i>Corynebacterium auris</i>		<i>Empedobacter brevis</i> (<i>Flavobacterium breve</i>)
30	CDC group HB-5		<i>Corynebacterium bovis</i>		<i>Enterobacter aerogenes</i>
	CDC group II K-2	110	<i>Corynebacterium coyleae</i>	190	<i>Enterobacter agglomerans</i>
	CDC group IV C-2 (<i>Bordetella</i> -like)		<i>Corynebacterium cystitidis</i>		<i>Enterobacter ammigenus</i>
	CDC group M5		<i>Corynebacterium diphtheriae</i>		<i>Enterobacter ammigenus asburiae</i>
	CDC group M6		<i>Corynebacterium diphtheriae</i> biotype <i>belanti</i>		(CDC enteric group 17)
35	<i>Cedecaea deviseae</i>	115	<i>Corynebacterium diphtheriae</i> biotype <i>gravis</i>		<i>Enterobacter ammigenus</i> biogroup 1
	<i>Cedecaea lapagei</i>		<i>Corynebacterium diphtheriae</i> biotype <i>intermedius</i>	195	<i>Enterobacter ammigenus</i> biogroup 2
	<i>Cedecaea neteri</i>		<i>Corynebacterium diphtheriae</i> biotype <i>mitis</i>		<i>Enterobacter asburiae</i>
	<i>Cedecaea species</i>	120	<i>Corynebacterium flavescens</i>		<i>Enterobacter cancerogenus</i>
	<i>Cellulomonas (Oerskovia) turbata</i>		<i>Corynebacterium glucuronolyticum</i>		<i>Enterobacter cloacae</i>
40	<i>Cellulomonas species</i>		<i>Corynebacterium glucuronolyticum-seminalis</i>		<i>Enterobacter gergoviae</i>
	<i>Chlamydia species</i>		<i>Corynebacterium group A</i>	200	<i>Enterobacter hormaechei</i>
	<i>Chromobacterium violaceum</i>		<i>Corynebacterium group A-4</i>		<i>Enterobacter intermedius</i>
	<i>Chryseobacterium (Flavobacterium) indologenes</i>		<i>Corynebacterium group A-5</i>		<i>Enterobacter sakazakii</i>
45	<i>Chryseobacterium (Flavobacterium) meningosepticum</i>	125	<i>Corynebacterium group ANF</i>		<i>Enterobacter species</i>
	<i>Chryseobacterium gleum</i>		<i>Corynebacterium group B</i>		<i>Enterobacter taylorae</i>
	<i>Chryseobacterium species</i>		<i>Corynebacterium group B-3</i>	210	<i>Enterobacter taylorae</i> (CDC enteric group 19)
	<i>Chryseomonas (Oerskovia) turbata</i>		<i>Corynebacterium group F</i>		<i>Enterococcus (Streptococcus) cecorum</i>
50	<i>Cellulomonas species</i>		<i>Corynebacterium group F-1</i>		<i>Enterococcus (Streptococcus) faecalis</i> (Group D)
	<i>Chryseobacterium (Flavobacterium) meningosepticum</i>		<i>Corynebacterium group F-2</i>		<i>Enterococcus (Streptococcus) faecium</i> (Group D)
	<i>Chryseobacterium gleum</i>		<i>Corynebacterium group G</i>	215	<i>Enterococcus (Streptococcus) saccharolyticus</i>
	<i>Chryseobacterium species</i>		<i>Corynebacterium group G-1</i>		<i>Enterococcus avium</i> (Group D)
55	<i>Citrobacter freundii</i>	130	<i>Corynebacterium group G-2</i>		<i>Enterococcus casseliflavus</i> (<i>Streptococcus faecium</i> subsp. <i>casseliflavus</i>)
	<i>Citrobacter freundii complex</i>		<i>Corynebacterium group I</i>		<i>Enterococcus durans</i> (<i>Streptococcus faecium</i> subsp. <i>durans</i>) (Group D)
	<i>Citrobacter koseri</i>	135	<i>Corynebacterium group I-2</i>		<i>Enterococcus gallinarum</i>
	<i>Citrobacter sedlakii</i>		<i>Corynebacterium jeikeium</i> (group JK)		<i>Enterococcus hirae</i>
	<i>Citrobacter species</i>		<i>Corynebacterium kutscheri</i> (<i>C. murium</i>)	220	<i>Enterococcus malodoratus</i>
60	<i>Citrobacter werkmanii</i>		<i>Corynebacterium macginleyi</i>		<i>Enterococcus mundil</i>
	<i>Citrobacter youngae</i>		<i>Corynebacterium minutissimum</i>		<i>Enterococcus raffinosus</i>
	<i>Clostridium acetobutylicum</i>	140	<i>Corynebacterium pilosum</i>	225	<i>Enterococcus species</i>
	<i>Clostridium baratii</i>		<i>Corynebacterium propinquum</i>		<i>Erwinia amylovora</i>
	<i>Clostridium beijerinckii</i>		<i>Corynebacterium pseudodiphtheriticum</i>		<i>Erwinia carotovora</i>
	<i>Clostridium bifementans</i>		<i>Corynebacterium pseudotuberculosis</i>		<i>Erwinia carotovora</i> subsp. <i>atroseptica</i>
65	<i>Clostridium botulinum</i>		<i>Corynebacterium pyogenes</i>	230	<i>Erwinia carotovora</i> subsp. <i>betavascularum</i>
	<i>Clostridium botulinum</i> (NP) B&F	145	<i>Corynebacterium renale</i>		<i>Erwinia carotovora</i> subsp. <i>carotovora</i>
	<i>Clostridium botulinum</i> (NP) E		<i>Corynebacterium renale</i> group		<i>Erwinia chrysanthemi</i>
	<i>Clostridium botulinum</i> (P) A&H		<i>Corynebacterium seminale</i>		<i>Erwinia cypripedi</i>
	<i>Clostridium botulinum</i> (P) F		<i>Corynebacterium species</i>		<i>Erwinia mellitivora</i>
70	<i>Clostridium botulinum</i> G1		<i>Corynebacterium stiatum</i> (<i>C. flavidum</i>)		
	<i>Clostridium botulinum</i> G2		<i>Corynebacterium ulcerans</i>		
	<i>Clostridium butyricum</i>	150			
	<i>Clostridium cedaveris</i>				
	<i>Clostridium chauvoei</i>				
75	<i>Clostridium clostridiforme</i>				
	<i>Clostridium difficile</i>	155			
	<i>Clostridium fallax</i>				
	<i>Clostridium glycolicum</i>				

Table 15. Microorganisms identified by commercial systems (continued)

	<i>Erwinia nigrifaciens</i>	80	VII	<i>Lactobacillus paracasei</i> subsp. <i>paracasei</i>
	<i>Erwinia quercina</i>		VIII	<i>Lactobacillus pentosus</i>
	<i>Erwinia rhamontici</i>			<i>Lactobacillus plantarum</i>
	<i>Erwinia rubrifaciens</i>			<i>Lactobacillus salivarius</i>
5	<i>Erwinia salicis</i>			<i>Lactobacillus salivarius</i> var. <i>salicinius</i>
	<i>Erwinia species</i>	85		<i>Lactobacillus species</i>
	<i>Erysipelothrix rhusiopathiae</i>			<i>Lactococcus diacilactis</i>
	<i>Erysipelothrix species</i>			<i>Lactococcus garvieae</i>
	<i>Escherichia blattae</i>			<i>Lactococcus lactis</i> subsp. <i>cremoris</i>
10	<i>Escherichia coli</i>			<i>Lactococcus lactis</i> subsp. <i>diacilactis</i>
	<i>Escherichia coli A-D</i>			<i>Lactococcus lactis</i> subsp. <i>hordiae</i>
	<i>Escherichia coli O157:H7</i>	90		<i>Lactococcus lactis</i> subsp. <i>lactis</i>
	<i>Escherichia fergusonii</i>			<i>Lactococcus plantarum</i>
	<i>Escherichia hermannii</i>			<i>Lactococcus raffinolactis</i>
15	<i>Escherichia species</i>			<i>Leclercia adecarboxylata</i>
	<i>Escherichia vulneris</i>			<i>Legionella species</i>
	<i>Eubacterium aerofaciens</i>	95		<i>Leminorella species</i>
	<i>Eubacterium alactolyticum</i>			<i>Leptospira species</i>
	<i>Eubacterium lentum</i>			<i>Leptotrichia buccalis</i>
20	<i>Eubacterium limosum</i>			<i>Leuconostoc (Weissella) parmesenteroides</i>
	<i>Eubacterium species</i>	100		<i>Leuconostoc carnosum</i>
	<i>Ewingella americana</i>			<i>Leuconostoc citreum</i>
	<i>Filobasidiella neoformans</i>			<i>Leuconostoc gelidum</i>
	<i>Filobasidium floriforme</i>			<i>Leuconostoc lactis</i>
25	<i>Filobasidium uniguttatum</i>			<i>Leuconostoc mesenteroides</i>
	<i>Flavimonas oryzihabitans</i>			<i>Leuconostoc mesenteroides</i> subsp. <i>cremoris</i>
	<i>Flavobacterium gleum</i>	105		<i>Leuconostoc mesenteroides</i> subsp. <i>dextranicum</i>
	<i>Flavobacterium indologenes</i>			<i>Leuconostoc mesenteroides</i> subsp. <i>mesenteroides</i>
	<i>Flavobacterium odoratum</i>			<i>Leuconostoc species</i>
30	<i>Flavobacterium species</i>			<i>Listeria grayi</i>
	<i>Francisella novicida</i>	110		<i>Listeria innocua</i>
	<i>Francisella philomiragia</i>			<i>Listeria ivanovii</i>
	<i>Francisella species</i>			<i>Listeria monocytogenes</i>
	<i>Francisella tularensis</i>			<i>Listeria murrayi</i>
35	<i>Fusobacterium mortiferum</i>			<i>Listeria seeligeri</i>
	<i>Fusobacterium necrogenes</i>			<i>Listeria species</i>
	<i>Fusobacterium necrophorum</i>	115		<i>Listeria welshimeri</i>
	<i>Fusobacterium nucleatum</i>			<i>Megasphaera elsdenii</i>
	<i>Fusobacterium species</i>			<i>Methylobacterium mesophilicum</i>
40	<i>Fusobacterium varium</i>			<i>Metschnikowia pulcherrima</i>
	<i>Gaffkya species</i>			<i>Microbacterium species</i>
	<i>Gardnerella vaginalis</i>	120		<i>Micrococcus luteus</i>
	<i>Gemella haemolysans</i>			<i>Micrococcus lys</i>
	<i>Gemella morbillorum</i>			<i>Micrococcus species</i>
45	<i>Gemella species</i>			<i>Mobiluncus curtisi</i>
	<i>Geotrichum candidum</i>			<i>Mobiluncus mulieris</i>
	<i>Geotrichum fermentans</i>	125		<i>Moellerella wisconsensis</i>
	<i>Geotrichum penicillarium</i>			<i>Moraxella (Branhamella) catarrhalis</i>
	<i>Geotrichum penicillatum</i>			<i>Moraxella atlantae</i>
50	<i>Geotrichum species</i>			<i>Moraxella bovis</i>
	<i>Gordonia species</i>			<i>Moraxella lacunata</i>
	<i>Haemophilus aegyptius</i>	130		<i>Moraxella nonliquefaciens</i>
	<i>Haemophilus aphrophilus</i>			<i>Moraxella osloensis</i>
	<i>Haemophilus ducreyi</i>			<i>Moraxella phenylpyruvica</i>
55	<i>Haemophilus haemoglobinophilus</i>			<i>Moraxella species</i>
	<i>Haemophilus haemolyticus</i>			<i>Morganella morganii</i>
	<i>Haemophilus influenzae</i>			<i>Morganella morganii</i> subsp. <i>morganii</i>
	<i>Haemophilus influenzae</i> biotype I	135		<i>Morganella morganii</i> subsp. <i>sibonii</i>
	<i>Haemophilus influenzae</i> biotype II			<i>Mycobacterium africanum</i>
60	<i>Haemophilus influenzae</i> biotype III			<i>Mycobacterium asiaticum</i>
	<i>Haemophilus influenzae</i> biotype IV			<i>Mycobacterium avium</i>
	<i>Haemophilus influenzae</i> biotype V	140		<i>Mycobacterium bovis</i>
	<i>Haemophilus influenzae</i> biotype VI			<i>Mycobacterium chelonae</i>
	<i>Haemophilus influenzae</i> biotype VII			<i>Mycobacterium fortuitum</i>
65	<i>Haemophilus influenzae</i> biotype VIII			<i>Mycobacterium gordonaiae</i>
	<i>Haemophilus paragallinarum</i>			<i>Mycobacterium kansasii</i>
	<i>Haemophilus parahaemolyticus</i>	145		<i>Mycobacterium malmoense</i>
	<i>Haemophilus parainfluenzae</i>			<i>Mycobacterium marinum</i>
	<i>Haemophilus parainfluenzae</i> biotype I			<i>Mycobacterium phlei</i>
70	<i>Haemophilus parainfluenzae</i> biotype II			<i>Mycobacterium scrofulaceum</i>
	<i>Haemophilus parainfluenzae</i> biotype III	150		<i>Mycobacterium smegmatis</i>
	<i>Haemophilus parainfluenzae</i> biotype IV			<i>Mycobacterium species</i>
75	<i>Haemophilus parainfluenzae</i> biotype V			
	<i>Haemophilus parainfluenzae</i> biotype VI	155		
	<i>Haemophilus parainfluenzae</i> biotype VII			

Table 15. Microorganisms identified by commercial systems (continued)¹

5	<i>Mycobacterium tuberculosis</i>	<i>Pichia fermentans</i>	<i>Saccharomyces exiguum</i>
	<i>Mycobacterium ulcerans</i>	<i>Pichia membranefaciens</i>	<i>Saccharomyces kluyveri</i>
	<i>Mycobacterium xenopi</i>	<i>Pichia norvegensis</i>	<i>Saccharomyces species</i>
	<i>Mycoplasma fermentans</i>	<i>Pichia ohmeri</i>	<i>Sakaguchia dacryoides</i>
5	<i>Mycoplasma hominis</i>	<i>Pichia spartinae</i>	<i>(Rhodospirillum dacryoidum)</i>
	<i>Mycoplasma orale</i>	<i>Pichia species</i>	<i>Salmonella anzoneae</i>
	<i>Mycoplasma pneumoniae</i>	<i>Plesiomonas shigelloides</i>	<i>Salmonella choleraesuis</i>
	<i>Mycoplasma species</i>	<i>Porphyromonas asaccharolytica</i>	<i>Salmonella enteritidis</i>
	<i>Myroides species</i>	<i>Porphyromonas endodontalis</i>	<i>Salmonella gallinarum</i>
10	<i>Neisseria cinerea</i>	<i>Porphyromonas gingivalis</i>	<i>Salmonella paratyphi A</i>
	<i>Neisseria elongata</i> subsp. <i>elongata</i>	<i>Porphyromonas levii</i>	<i>Salmonella paratyphi B</i>
	<i>Neisseria flava</i>	<i>Prevotella (Bacteroides) buccae</i>	<i>Salmonella pullorum</i>
	<i>Neisseria flavescens</i>	<i>Prevotella (Bacteroides) buccalis</i>	<i>Salmonella species</i>
	<i>Neisseria gonorrhoeae</i>	<i>Prevotella (Bacteroides) corporis</i>	<i>Salmonella typhi</i>
15	<i>Neisseria lactamica</i>	<i>Prevotella (Bacteroides) dentale</i>	<i>Salmonella typhimurium</i>
	<i>Neisseria meningitidis</i>	<i>Prevotella (Bacteroides) foecis</i>	<i>Salmonella typhisuis</i>
	<i>Neisseria mucosa</i>	<i>Prevotella (Bacteroides) oralis</i>	<i>Salmonella/Arizona</i>
	<i>Neisseria perflava</i>	<i>Prevotella (Bacteroides) disiens</i>	<i>Serratia ficaria</i>
	<i>Neisseria polysacccharea</i>	<i>Prevotella (Bacteroides) oris</i>	<i>Serratia fonticola</i>
20	<i>Neisseria saprophytes</i>	<i>Prevotella bivia (Bacteroides bivius)</i>	<i>Serratia grimesii</i>
	<i>Neisseria sicca</i>	<i>Prevotella intermedia (Bacteroides intermedius)</i>	<i>Serratia liquefaciens</i>
	<i>Neisseria subflava</i>	<i>Prevotella melaninogenica</i>	<i>Serratia marcescens</i>
	<i>Neisseria weaveri</i>	<i>(Bacteroides melaninogenicus)</i>	<i>Serratia odorifera</i>
	<i>Neisseria weaveri</i> (CDC group M5)	<i>Prevotella ruminicola</i>	<i>Serratia odorifera type 1</i>
25	<i>Nocardia species</i>	<i>Propionibacterium acnes</i>	<i>Serratia odorifera type 2</i>
	<i>Ochrobactrum anthropi</i>	<i>Propionibacterium avidum</i>	<i>Serratia plymuthica</i>
	<i>Oerskovia species</i>	<i>Propionibacterium granulosum</i>	<i>Serratia proteamaculans</i>
	<i>Oerskovia xanthinolytica</i>	<i>Propionibacterium propionicum</i>	<i>Serratia proteamaculans subsp. proteamaculans</i>
30	<i>Oligella species</i>	<i>Propionibacterium species</i>	<i>Serratia proteamaculans subsp. quinovora</i>
	<i>Oligella ureolytica</i>	<i>Proteus mirabilis</i>	<i>Serratia rubidaea</i>
	<i>Paenibacillus alvei</i>	<i>Proteus penneri</i>	<i>Serratia species</i>
	<i>Paenibacillus macerans</i>	<i>Proteus species</i>	<i>Shewanella (Pseudomonas, Alteromonas) putrefaciens</i>
	<i>Paenibacillus polymyxa</i>	<i>Proteus vulgaris</i>	<i>Shigella boydii</i>
35	<i>Pantoea agglomerans</i>	<i>Prototheca species</i>	<i>Shigella dysenteriae</i>
	<i>Pantoea ananas</i> (<i>Erwinia uredovora</i>)	<i>Prototheca wickerhamii</i>	<i>Shigella flexneri</i>
	<i>Pantoea dispersa</i>	<i>Prototheca zopfii</i>	<i>Shigella sonnei</i>
	<i>Pantoea species</i>	<i>Providencia alcalifaciens</i>	<i>Shigella species</i>
	<i>Pantoea stewartii</i>	<i>Providencia heimbachae</i>	<i>Sphingobacterium multivorum</i>
40	<i>Pasteurella (Haemophilus) avium</i>	<i>Providencia reitgeri</i>	<i>Sphingobacterium species</i>
	<i>Pasteurella aerogenes</i>	<i>Providencia rustigianii</i>	<i>Sphingobacterium spiritivorum</i>
	<i>Pasteurella gallinarum</i>	<i>Providencia species</i>	<i>Sphingobacterium thalpophilum</i>
	<i>Pasteurella haemolytica</i>	<i>Providencia stuartii</i>	<i>Sphingomonas (Pseudomonas) paucimobilis</i>
	<i>Pasteurella haemolyticus</i>	<i>Providencia stuartii urea +</i>	<i>Sporidiobolus salmonicolor</i>
45	<i>Pasteurella multocida</i>	<i>Pseudomonas (Chryseomonas) luteola</i>	<i>Sporobolomyces roseus</i>
	<i>Pasteurella multocida</i> SF	<i>Pseudomonas acidovorans</i>	<i>Sporobolomyces salmonicolor</i>
	<i>Pasteurella multocida</i> subsp. <i>multocida</i>	<i>Pseudomonas aeruginosa</i>	<i>Sporobolomyces species</i>
	<i>Pasteurella multocida</i> subsp. <i>septica</i>	<i>Pseudomonas alcaligenes</i>	<i>Staphylococcus (Peptococcus) saccharolyticus</i>
50	<i>Pasteurella pneumotropica</i>	<i>Pseudomonas cepacia</i>	<i>Staphylococcus arletiae</i>
	<i>Pasteurella species</i>	<i>Pseudomonas chlororaphis</i> (<i>P. aureofaciens</i>)	<i>Staphylococcus aureus</i>
	<i>Pasteurella ureae</i>	<i>Pseudomonas fluorescens</i>	<i>Staphylococcus aureus</i> (Coagulase-negative)
	<i>Pediococcus acidilactici</i>	<i>Pseudomonas fluorescens</i> group	<i>Staphylococcus auricularis</i>
	<i>Pediococcus damnosus</i>	<i>Pseudomonas mendocina</i>	<i>Staphylococcus capitis</i>
55	<i>Pediococcus pentosaceus</i>	<i>Pseudomonas pseudoalcaligenes</i>	<i>Staphylococcus capitis</i> subsp. <i>capitis</i>
	<i>Pediococcus species</i>	<i>Pseudomonas putida</i>	<i>Staphylococcus capitis</i> subsp. <i>ureolyticus</i>
	<i>Pepioccoccus niger</i>	<i>Pseudomonas species</i>	<i>Staphylococcus caprae</i>
	<i>Pepioccoccus species</i>	<i>Pseudomonas stutzeri</i>	<i>Staphylococcus carnosus</i>
	<i>Pepioccoccus anaerobius</i>	<i>Pseudomonas testosteroni</i>	<i>Staphylococcus caseolyticus</i>
60	<i>Peptostreptococcus asaccharolyticus</i>	<i>Pseudomonas vesicularis</i>	<i>Staphylococcus chromogenes</i>
	<i>Peptostreptococcus indolicus</i>	<i>Pseudoramibacter (Eubacterium) alactolyticus</i>	<i>Staphylococcus cohnii</i>
	<i>Peptostreptococcus magnus</i>	<i>Rahnella aquatilis</i>	<i>Staphylococcus cohnii</i> subsp. <i>cohnii</i>
	<i>Peptostreptococcus micros</i>	<i>Ralstonia (Pseudomonas, Burkholderia) picketti</i>	<i>Staphylococcus cohnii</i> subsp. <i>urealyticum</i>
65	<i>Peptostreptococcus parvulus</i>	<i>Rhodococcus (Corynebacterium) equi</i>	<i>Staphylococcus epidermidis</i>
	<i>Peptostreptococcus prevotii</i>	<i>Rhodococcus species</i>	<i>Staphylococcus equorum</i>
	<i>Peptostreptococcus productus</i>	<i>Rhodospirillum toruloides</i>	<i>Staphylococcus gallinarum</i>
	<i>Peptostreptococcus species</i>	<i>Rhodotorula glutinis</i>	<i>Staphylococcus haemolyticus</i>
	<i>Peptostreptococcus tetradius</i>	<i>Rhodotorula minuta</i>	<i>Staphylococcus hominis</i>
	<i>Phaeococcomyces exophialiae</i>	<i>Rhodotorula mucilaginosa</i> (<i>R. rubra</i>)	<i>Staphylococcus hominis</i> subsp. <i>hominis</i>
70	<i>Photobacterium damselaе</i>	<i>Rhodotorula species</i>	<i>Staphylococcus hominis</i> subsp. <i>novobiophageicus</i>
	<i>Pichia (Hansenula) anomala</i>	<i>Rickettsia species</i>	
	<i>Pichia (Hansenula) jadinii</i>	<i>Rothia dentocanosa</i>	
	<i>Pichia (Hansenula) petersonii</i>	<i>Saccharomyces cerevisiae</i>	
75	<i>Pichia angusta</i> (<i>Hansenula</i> polymorpha)		
	<i>Pichia carsonii</i> (<i>P. vin</i>)		
	<i>Pichia etchellsii</i>		
	<i>Pichia farinosa</i>		

Table 15. Microorganisms identified by commercial systems (continued)¹.

5	<i>Staphylococcus hyicus</i>	60	<i>Streptococcus Gamma (non)-hemolytic</i>	120	<i>Tetragenococcus (Pediococcus) halophilus</i>
	<i>Staphylococcus intermedius</i>		<i>Streptococcus gordoni</i>		<i>Torulopsis delbrueckii (Saccharomyces rosei)</i>
	<i>Staphylococcus kloosii</i>		<i>Streptococcus Group B</i>		<i>Torulopsis candida</i>
	<i>Staphylococcus lentus</i>	65	<i>Streptococcus Group C</i>		<i>Torulopsis haemulonii</i>
	<i>Staphylococcus lugdunensis</i>		<i>Streptococcus Group D</i>	125	<i>Torulopsis inconspicua</i>
	<i>Staphylococcus saprophyticus</i>		<i>Streptococcus Group E</i>		<i>Treponema species</i>
10	<i>Staphylococcus schleiferi</i>		<i>Streptococcus Group F</i>		<i>Trichosporon asahii</i>
	<i>Staphylococcus sciuri</i>		<i>Streptococcus Group G</i>		<i>Trichosporon asteroides</i>
	<i>Staphylococcus simulans</i>	70	<i>Streptococcus Group L</i>		<i>Trichosporon beigelii</i>
	<i>Staphylococcus species</i>		<i>Streptococcus Group P</i>	130	<i>Trichosporon cutaneum</i>
	<i>Staphylococcus warneri</i>		<i>Streptococcus Group U</i>		<i>Trichosporon inkin</i>
	<i>Staphylococcus xylosus</i>		<i>Streptococcus intermedius</i>		<i>Trichosporon mucoides</i>
15	<i>Stenotrophomonas (Xanthomonas) maltophilia</i>		<i>Streptococcus intermedius (Streptococcus milleri II)</i>		<i>Trichosporon ovoides</i>
	<i>Stephanoascus citerri</i>	75	<i>Streptococcus intermedius (viridans Streptococcus)</i>	135	<i>Trichosporon pullulans</i>
	<i>Stomatococcus mucilaginosus</i>		<i>Streptococcus milleri group</i>		<i>Trichosporon species</i>
	<i>Streptococcus acidominimus</i>		<i>Streptococcus mitis</i>		<i>Turicella otitidis</i>
20	<i>Streptococcus agalactiae</i>	80	<i>Streptococcus mitis (viridans Streptococcus)</i>	140	<i>Ureaplasma species</i>
	<i>Streptococcus agalactiae (Group B)</i>		<i>Streptococcus mitis group</i>		<i>Ureaplasma urealyticum</i>
	<i>Streptococcus agalactiae hemolytic</i>		<i>Streptococcus mutans</i>		<i>Veillonella parvula (V. alcalescens)</i>
	<i>Streptococcus agalactiae non-hemolytic</i>		<i>Streptococcus mutans (viridans Streptococcus)</i>		<i>Veillonella species</i>
25	<i>Streptococcus alactolyticus</i>	85	<i>Streptococcus oralis</i>	145	<i>Vibrio alginolyticus</i>
	<i>Streptococcus anginosus</i>		<i>Streptococcus parasanguis</i>		<i>Vibrio cholerae</i>
	<i>Streptococcus anginosus (Group D, nonenterococci)</i>		<i>Streptococcus pneumoniae</i>		<i>Vibrio damsela</i>
	<i>Streptococcus beta-hemolytic group A</i>		<i>Streptococcus porcinus</i>		<i>Vibrio fluvialis</i>
30	<i>Streptococcus beta-hemolytic non-group A or B</i>	90	<i>Streptococcus pyogenes</i>	150	<i>Vibrio fumissii</i>
	<i>Streptococcus beta-hemolytic non-group A</i>		<i>Streptococcus pyogenes (Group A)</i>		<i>Vibrio harveyi</i>
	<i>Streptococcus beta-hemolytic</i>		<i>Streptococcus salivarius</i>		<i>Vibrio holisae</i>
35	<i>Streptococcus bovis (Group D, nonenterococci)</i>	95	<i>Streptococcus salivarius (viridans Streptococcus)</i>		<i>Vibrio metschnikovii</i>
	<i>Streptococcus bovis I</i>		<i>Streptococcus salivarius subsp.</i>		<i>Vibrio mimicus</i>
	<i>Streptococcus bovis II</i>		<i>Streptococcus salivarius subsp. thermophilus</i>	155	<i>Vibrio parahaemolyticus</i>
	<i>Streptococcus canis</i>		<i>Streptococcus sanguis</i>		<i>Vibrio species</i>
40	<i>Streptococcus constellatus</i>	100	<i>Streptococcus sanguis I (viridans Streptococcus)</i>	160	<i>Vibrio species SF</i>
	<i>Streptococcus constellatus (Streptococcus milleri I)</i>		<i>Streptococcus sanguis II</i>		<i>Vibrio vulnificus</i>
	<i>Streptococcus constellatus (viridans Streptococcus)</i>		<i>Streptococcus sanguis II (viridans Streptococcus)</i>		<i>Weeksella (Bergeyella) virosa</i>
	<i>Streptococcus downei</i>		<i>Streptococcus sobrinus</i>	155	<i>Weeksella species</i>
45	<i>Streptococcus dysgalactiae subsp. dysgalactiae</i>	105	<i>Streptococcus species</i>		<i>Weeksella virosa</i>
	<i>Streptococcus dysgalactiae subsp. equisimilis</i>		<i>Streptococcus suis I</i>		<i>Williopsis (Hansenula) satumus</i>
	<i>Streptococcus equi (Group C/Group G Streptococcus)</i>		<i>Streptococcus suis II</i>		<i>Xanthomonas campestris</i>
50	<i>Streptococcus equi subsp. equi</i>	110	<i>Streptococcus uberis</i>		<i>Xanthomonas species</i>
	<i>Streptococcus equi subsp. zooepidemicus</i>		<i>Streptococcus species</i>	160	<i>Yarrowia (Candida) lipolytica</i>
	<i>Streptococcus equinus</i>		<i>Streptococcus vestibularis</i>		<i>Yersinia aldovae</i>
55	<i>Streptococcus equinus (Group D, nonenterococci)</i>	115	<i>Streptococcus zooepidemicus</i>	165	<i>Yersinia enterocolitica</i>
	<i>Streptococcus equisimilis</i>		<i>Streptococcus zooepidemicus (Group C)</i>		<i>Yersinia enterocolitica group</i>
	<i>Streptococcus equisimilis (Group C/Group G Streptococcus)</i>		<i>Streptomyces somaliensis</i>		<i>Yersinia frederiksenii</i>
			<i>Streptomyces species</i>		<i>Yersinia intermedia</i>
			<i>Suttonella (Kingella) indologenes</i>		<i>Yersinia intermedius</i>
			<i>Tatumella physeos</i>	170	<i>Yersinia kristensenii</i>
					<i>Yersinia pestis</i>
					<i>Yersinia pseudotuberculosis</i>
					<i>Yersinia pseudotuberculosis SF</i>
					<i>Yersinia ruckeri</i>
					<i>Yersinia species</i>
					<i>Yokenella regensburgae</i>
					<i>Yokenella regensburgae (Koserella trabulis)</i>
				175	<i>Zygoascus hellenicus</i>
					<i>Zygosaccharomyces species</i>

¹ The list includes microorganisms that may be identified by API identification test systems and VITEK® automated identification system from bioMérieux Inc., or by the MicroScan - WalkAway® automated systems from Dade Behring. Identification relies on classical identification methods using batteries of biochemical and other phenotypical tests.

Table 16. *tuf* gene sequences obtained in our laboratory (Example 42).

Species	Strain no.	Gene	GenBank Accession no.*
<i>Abiotrophia adiacens</i>	ATCC49175	<i>tuf</i>	AF124224
<i>Enterococcus avium</i>	ATCC14025	<i>tufA</i>	AF124220
		<i>tufB</i>	AF274715
<i>Enterococcus casseliflavus</i>	ATCC25788	<i>tufA</i>	AF274716
		<i>tufB</i>	AF274717
<i>Enterococcus cecorum</i>	ATCC43198	<i>tuf</i>	AF274718
<i>Enterococcus columbae</i>	ATCC51263	<i>tuf</i>	AF274719
<i>Enterococcus dispar</i>	ATCC51266	<i>tufA</i>	AF274720
		<i>tufB</i>	AF274721
<i>Enterococcus durans</i>	ATCC19432	<i>tufA</i>	AF274722
		<i>tufB</i>	AF274723
<i>Enterococcus faecalis</i>	ATCC29212	<i>tuf</i>	AF124221
<i>Enterococcus faecium</i>	ATCC 19434	<i>tufA</i>	AF124222
		<i>tufB</i>	AF274724
<i>Enterococcus gallinarum</i>	ATCC49573	<i>tufA</i>	AF124223
		<i>tufB</i>	AF274725
<i>Enterococcus hirae</i>	ATCC8043	<i>tufA</i>	AF274726
		<i>tufB</i>	AF274727
<i>Enterococcus malodoratus</i>	ATCC43197	<i>tufA</i>	AF274728
		<i>tufB</i>	AF274729
<i>Enterococcus mundtii</i>	ATCC43186	<i>tufA</i>	AF274730
		<i>tufB</i>	AF274731
<i>Enterococcus pseudoavium</i>	ATCC49372	<i>tufA</i>	AF274732
		<i>tufB</i>	AF274733
<i>Enterococcus raffinosus</i>	ATCC49427	<i>tufA</i>	AF274734
		<i>tufB</i>	AF274735
<i>Enterococcus saccharolyticus</i>	ATCC43076	<i>tuf</i>	AF274736
<i>Enterococcus solitarius</i>	ATCC49428	<i>tuf</i>	AF274737
<i>Enterococcus sulfureus</i>	ATCC49903	<i>tuf</i>	AF274738
<i>Lactococcus lactis</i>	ATCC11154	<i>tuf</i>	AF274745
<i>Listeria monocytogenes</i>	ATCC15313	<i>tuf</i>	AF274746
<i>Listeria seeligeni</i>	ATCC35967	<i>tuf</i>	AF274747
<i>Staphylococcus aureus</i>	ATCC25923	<i>tuf</i>	AF274739
<i>Staphylococcus epidermidis</i>	ATCC14990	<i>tuf</i>	AF274740
<i>Streptococcus mutans</i>	ATCC25175	<i>tuf</i>	AF274741
<i>Streptococcus pneumoniae</i>	ATCC6303	<i>tuf</i>	AF274742
<i>Streptococcus pyogenes</i>	ATCC19615	<i>tuf</i>	AF274743
<i>Streptococcus suis</i>	ATCC43765	<i>tuf</i>	AF274744

*Corresponding sequence ID NO. for the above ATCC strains are given in table 7.

Table 17. *tuf* gene sequences selected from databases for Example 42.

Species	Gene	Accession no.*
<i>Agrobacterium tumefaciens</i>	<i>tufA</i>	X99673
	<i>tufB</i>	X99674
<i>Anacystis nidulans</i>	<i>tuf</i>	X17442
<i>Aquifex aeolicus</i>	<i>tufA</i>	AE000657
	<i>tufB</i>	AE000657
<i>Bacillus stearothermophilus</i>	<i>tuf</i>	AJ000260
<i>Bacillus subtilis</i>	<i>tuf</i>	AL009126
<i>Bacteroides fragilis</i>	<i>tuf</i>	P33165
<i>Borrelia burgdorferi</i>	<i>tuf</i>	AE000783
<i>Brevibacterium linens</i>	<i>tuf</i>	X76863
<i>Bulkholderia cepacia</i>	<i>tuf</i>	P33167
<i>Campylobacter jejuni</i>	<i>tufB</i>	Y17167
<i>Chlamydia pneumoniae</i>	<i>tuf</i>	AE001363
<i>Chlamydia trachomatis</i>	<i>tuf</i>	M74221
<i>Corynebacterium glutamicum</i>	<i>tuf</i>	X77034
<i>Cytophaga lytica</i>	<i>tuf</i>	X77035
<i>Deinococcus radiodurans</i>	<i>tuf</i>	AE000513
<i>Escherichia coli</i>	<i>tufA</i>	J01690
	<i>tufB</i>	J01717
<i>Fervidobacterium islandicum</i>	<i>tuf</i>	Y15788
<i>Haemophilus influenzae</i>	<i>tufA</i>	L42023
	<i>tufB</i>	L42023
<i>Helicobacter pylori</i>	<i>tuf</i>	AE000511
<i>Homo sapiens</i> (Human)	<i>EF-1α</i>	X03558
<i>Methanococcus jannaschii</i>	<i>EF-1α</i>	U67486
<i>Mycobacterium leprae</i>	<i>tuf</i>	D13869
<i>Mycobacterium tuberculosis</i>	<i>tuf</i>	X63539
<i>Mycoplasma genitalium</i>	<i>tuf</i>	L43967
<i>Mycoplasma pneumoniae</i>	<i>tuf</i>	U00089
<i>Neisseria gonorrhoeae</i>	<i>tufA</i>	L36380
<i>Nicotiana tabacum</i> (Tobacco)	<i>EF-1α</i>	U04632
<i>Peptococcus niger</i>	<i>tuf</i>	X76869
<i>Planobispora rosea</i>	<i>tuf1</i>	U67308
<i>Saccharomyces cerevisiae</i> (Yeast)	<i>EF-1α</i>	X00779
<i>Salmonella typhimurium</i>	<i>tufA</i>	X55116
	<i>tufB</i>	X55117
<i>Shewanella putrefaciens</i>	<i>tuf</i>	P33169
<i>Spirochaeta aurantia</i>	<i>tuf</i>	X76874
<i>Spirulina platensis</i>	<i>tufA</i>	X15646
<i>Streptomyces aureofaciens</i>	<i>tuf1</i>	AF007125
<i>Streptomyces cinnamoneus</i>	<i>tuf1</i>	X98831
<i>Streptomyces coelicolor</i>	<i>tuf1</i>	X77039
	<i>tuf3</i>	X77040
<i>Streptomyces coeliginosus</i>	<i>tuf1</i>	S79408
<i>Streptomyces ramocissimus</i>	<i>tuf1</i>	X67057
	<i>tuf2</i>	X67058
	<i>tuf3</i>	X67059
<i>Synechocystis</i> sp.	<i>tuf</i>	AB001339
<i>Taxeobacter ocellatus</i>	<i>tuf</i>	X77036
<i>Thermotoga maritima</i>	<i>tuf</i>	AE000512
<i>Thermus aquaticus</i>	<i>tuf</i>	X66322
<i>Thermus thermophilus</i>	<i>tuf</i>	X06657
<i>Thiobacillus cuprinus</i>	<i>tuf</i>	U78300
<i>Treponema pallidum</i>	<i>tuf</i>	AE000520
<i>Wolinella succinogenes</i>	<i>tuf</i>	X76872

* Sequence data were obtained from GenBank, EMBL, and SWISSPROT databases. Genes were designated as appeared in the references.

Table 18. Nucleotide and amino acid sequence identities of EF-Tu between different enterococci and other low G+C gram-positive bacteria.

The upper right triangle represents the deduced amino acid sequence identities of gram-positive bacterial EF-Tu, while the lower left triangle represents the DNA sequence identities of the corresponding *tuf* genes. The sequence identities between different enterococcal *tufA* genes are boxed while those between enterococcal *tufB* genes are shaded.

Bacterial <i>tuf</i> gene	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39
1. <i>E. avium</i> <i>tufA</i>	96	98	96	96	96	96	97	95	98	99	95	95	96	94	96	93	86	87	85	88	88	86	85	85	87	87	88	92	91	90	80	80	82	83	84	82	83		
2. <i>E. casseliflavus</i> <i>tufA</i>	90	97	96	98	96	99	95	96	96	96	95	95	96	96	94	93	87	88	88	87	87	85	87	87	87	87	87	87	84	81	80	81	91	92	85	87	85	85	85
3. <i>E. dispers</i> <i>tufA</i>	93	90	95	95	95	95	95	97	97	91	90	85	85	85	85	83	83	86	87	85	87	87	87	87	87	87	87	87	83	80	80	82	85	86	84	85	84		
4. <i>E. durans</i> <i>tufA</i>	90	89	90	98	96	99	93	99	95	96	90	91	94	95	94	92	87	87	88	86	86	86	87	87	87	88	87	94	90	90	90	91	85	86	84	84	84		
5. <i>E. faecium</i> <i>tufA</i>	88	90	89	96	96	98	92	68	95	96	89	91	82	94	93	92	87	88	87	86	87	87	86	87	87	88	87	94	92	91	91	91	93	85	86	84	84	84	
6. <i>E. gallinarum</i> <i>tufA</i>	90	97	89	19	63	96	93	95	96	96	88	89	89	96	93	92	87	87	86	87	87	86	87	87	88	87	94	92	90	80	83	85	86	84	83	84			
7. <i>E. hirae</i> <i>tufA</i>	90	90	89	99	98	89	93	99	95	96	91	91	83	95	94	92	86	87	88	85	86	85	86	87	87	87	84	80	80	80	91	85	85	84	84	84	84		
8. <i>E. meliloti</i> <i>tufA</i>	96	91	94	90	89	89	92	97	97	89	89	90	93	96	92	86	85	82	85	85	85	85	85	85	85	85	85	83	82	82	82	82	82	82	82	82			
9. <i>E. mundtii</i> <i>tufA</i>	89	89	84	96	93	93	96	88	84	95	88	88	88	94	94	92	87	87	88	88	87	88	87	88	87	84	80	80	80	89	91	85	86	84	84	84			
10. <i>E. pseudaurum</i> <i>tufA</i>	97	92	93	90	89	91	89	97	89	98	90	90	91	95	96	92	86	85	85	85	85	85	85	85	85	85	85	85	85	85	85	85	85	85	85	85	85		
11. <i>E. refinans</i> <i>tufA</i>	97	91	93	90	89	89	97	98	87	91	90	90	94	95	93	93	88	87	85	86	86	85	85	85	85	85	85	84	84	84	84	84	84	84	84	84	84		
12. <i>E. cecorum</i> <i>tufA</i>	90	90	95	96	95	95	96	92	95	95	95	95	95	95	95	98	95	95	95	95	95	95	95	95	95	95	95	95	95	95	95	95	95	95	95	95	95		
13. <i>E. columbae</i> <i>tufA</i>	90	90	95	96	97	96	95	93	95	95	95	97	95	94	94	92	94	92	89	88	88	87	87	87	87	87	87	87	87	87	87	87	87	87	87	87	87		
14. <i>E. faecalis</i> <i>tufA</i>	91	91	89	98	97	94	94	94	95	96	90	89	94	94	94	93	87	87	88	87	88	87	87	88	87	87	87	87	87	87	87	87	87	87	87	87	87		
15. <i>E. saecharolyticus</i> <i>tufA</i>	91	91	90	87	80	89	91	89	82	91	89	89	82	94	91	91	91	85	85	85	85	85	85	85	85	85	85	85	85	85	85	85	85	85	85	85	85		
16. <i>E. surfacei</i> <i>tufA</i>	91	89	80	91	88	90	91	89	92	91	88	89	91	94	91	91	91	85	85	84	84	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	
17. <i>E. sartorii</i> <i>tuf</i>	83	83	83	83	83	82	82	84	83	84	84	84	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	83	
18. <i>E. taurinus</i> <i>tufB</i>	77	78	78	76	77	78	76	77	78	78	78	78	78	78	78	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	
19. <i>E. caseifaciens</i> <i>tufB</i>	71	71	72	72	72	70	72	70	71	72	72	72	70	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	
20. <i>E. chaperi</i> <i>tufB</i>	76	78	77	77	77	76	77	76	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	
21. <i>E. durans</i> <i>tufB</i>	77	78	78	78	77	78	77	78	77	78	77	78	78	78	78	75	82	80	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	
22. <i>E. trecom</i> <i>tufB</i>	76	75	76	75	75	76	76	75	76	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	
23. <i>E. gallinarum</i> <i>tufB</i>	72	73	72	73	72	74	72	72	72	72	73	72	73	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	72	
24. <i>E. hirae</i> <i>tufB</i>	75	74	76	75	75	75	76	75	74	74	75	75	74	75	74	75	74	75	74	76	79	79	83	79	93	87	87	87	87	87	87	87	87	87	87	87	87	87	87
25. <i>E. mesilotolerans</i> <i>tufB</i>	76	76	76	77	77	77	77	74	76	76	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	
26. <i>E. mundtii</i> <i>tufB</i>	74	74	74	73	73	74	74	74	74	74	74	75	73	73	73	73	73	73	73	73	73	73	73	73	73	73	73	73	73	73	73	73	73	73	73	73	73	73	
27. <i>E. pseudaurum</i> <i>tufB</i>	77	77	78	77	78	77	77	77	76	77	78	77	78	77	78	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	
28. <i>E. raffinovorus</i> <i>tufB</i>	78	79	78	77	77	78	77	79	79	78	78	79	77	79	79	79	79	80	79	80	81	77	81	77	81	77	81	77	81	77	81	77	81	77	81	77	81	77	
29. <i>A. adiacens</i> <i>tuf</i>	88	87	86	88	88	86	86	88	88	87	88	88	88	89	89	82	77	77	78	77	76	76	76	76	76	76	76	76	76	76	76	76	76	76	76	76	76	76	
30. <i>B. subtilis</i> <i>tuf</i>	81	80	79	80	80	79	79	78	80	81	80	81	81	80	78	73	69	73	73	71	70	71	72	71	74	78	76	76	76	76	76	76	76	76	76	76	76		
31. <i>L. monocytogenes</i> <i>tuf</i>	82	81	82	82	82	82	81	81	81	82	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	81	
32. <i>L. longigenum</i> <i>tuf</i>	82	81	82	82	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	82	81	
33. <i>S. enterica</i> <i>tuf</i>	84	84	83	83	84	84	82	84	83	84	86	86	86	84	82	81	79	75	75	75	75	75	75	75	75	75	75	75	75	75	75	75	75	75	75	75	75	75	
34. <i>S. epidermidis</i> <i>tuf</i>	83	85	83	84	83	84	84	82	84	83	85	87	85	85	82	82	79	75	69	75	75	75	75	75	75	75	75	75	75	75	75	75	75	75	75	75	75	75	
35. <i>S. mutans</i> <i>tuf</i>	76	77	76	76	76	76	75	76	76	77	76	77	76	77	76	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	77	
36. <i>S. pneumoniae</i> <i>tuf</i>	76	77	76	77	77	77	77	77	77	77	76	77	76	77	77																								

Table 19. Strains analyzed in Example 43.

Taxon	Strain*	Strain†	16S rDNA sequence accession number
<i>Cedecea</i>	ATCC 33431 ^T		
<i>Cedecea lapagei</i>	ATCC 33432 ^T		
<i>Cedecea neteri</i>	ATCC 33855 ^T		
<i>Citrobacter amalonaticus</i>	ATCC 25405 ^T	CDC 9020-77 ^T	AF025370
<i>Citrobacter braakii</i>	ATCC 43162		
		CDC 080-58 ^T	AF025368
<i>Citrobacter farmeri</i>	ATCC 51112 ^T	CDC 2991-81 ^T	AF025371
<i>Citrobacter freundii</i>	ATCC 8090 ^T	DSM 30039 ^T	AJ233408
<i>Citrobacter koseri</i>	ATCC 27156 ^T		
<i>Citrobacter sedlakii</i>	ATCC 51115 ^T	CDC 4696-86 ^T	AF025364
<i>Citrobacter werkmanii</i>	ATCC 51114 ^T	CDC 0876-58 ^T	AF025373
<i>Citrobacter youngae</i>	ATCC 29935 ^T		
<i>Edwardsiella hoshinae</i>	ATCC 33379 ^T		
<i>Edwardsiella tarda</i>	ATCC 15947 ^T		
		CDC 4411-68	AF015259
<i>Enterobacter aerogenes</i>	ATCC 13048 ^T	JCM 1235 ^T	AB004750
<i>Enterobacter agglomerans</i>	ATCC 27989		
<i>Enterobacter amnigenus</i>	ATCC 33072 ^T	JCM 1237 ^T	AB004749
<i>Enterobacter asburiae</i>	ATCC 35953 ^T	JCM 6051 ^T	AB004744
<i>Enterobacter cancerogenus</i>	ATCC 35317 ^T		
<i>Enterobacter cloacae</i>	ATCC 13047 ^T		
<i>Enterobacter gergoviae</i>	ATCC 33028 ^T	JCM 1234 ^T	AB004748
<i>Enterobacter hormaechei</i>	ATCC 49162 ^T		
<i>Enterobacter sakazakii</i>	ATCC 29544 ^T	JCM 1233 ^T	AB004746
<i>Escherichia coli</i>	ATCC 11775 ^T	ATCC 11775 ^T	X80725
<i>Escherichia coli</i>	ATCC 25922	ATCC 25922	X80724
<i>Escherichia coli</i> (ETEC)	ATCC 35401		
<i>Escherichia coli</i> (O157:H7)	ATCC 43895	ATCC 43895	Z83205
<i>Escherichia fergusonii</i>	ATCC 35469 ^T		
<i>Escherichia hermanii</i>	ATCC 33650 ^T		
<i>Escherichia vulneris</i>	ATCC 33821 ^T	ATCC 33821 ^T	X80734
<i>Ewingella americana</i>	ATCC 33852 ^T		
		NCPPB 3905	X88848
<i>Hafnia alvei</i>	ATCC 13337 ^T	ATCC 13337 ^T	M59155
<i>Klebsiella ornithinolytica</i>	ATCC 31898		
		CIP 103.364	U78182
<i>Klebsiella oxytoca</i>	ATCC 33496	ATCC 13182 ^T	U78183
<i>Klebsiella planticola</i>	ATCC 33531 ^T	JCM 7251 ^T	AB004755
<i>Klebsiella pneumoniae</i>			
subsp. <i>pneumoniae</i>	ATCC 13883 ^T	DSM 30104 ^T	AJ233420
subsp. <i>ozaenae</i>	ATCC 11296 ^T	ATCC 11296 ^T	Y17654
subsp. <i>rhinoscleromatis</i>	ATCC 13884 ^T		

Table 19. Strains analyzed in Example 43 (continued).

Taxon	Strain*	Strain†	16S rDNA sequence accession number
<i>Kluyvera ascorbata</i>	ATCC 33433 ^T	ATCC 14236	Y07650
<i>Kluyvera cryocrescens</i>	ATCC 33435 ^T		
<i>Kluyvera georgiana</i>	ATCC 51603 ^T		
<i>Leclercia ede carboxylata</i>	ATCC 23216 ^T		
<i>Leminorella grimontii</i>	ATCC 33999 ^T	DSM 5078 ^T	AJ233421
<i>Moellerella wisconsensis</i>	ATCC 35017 ^T		
<i>Morganella morganii</i>	ATCC 25830 ^T		
<i>Pantoea agglomerans</i>	ATCC 27155 ^T	DSM 3493 ^T	AJ233423
<i>Pantoea dispersa</i>	ATCC 14589 ^T		
<i>Plesiomonas shigelloides</i>	ATCC 14029 ^T		
<i>Pragia fontium</i>	ATCC 49100 ^T	DSM 5563 ^T	AJ233424
<i>Proteus mirabilis</i>	ATCC 25933		
<i>Proteus penneri</i>	ATCC 33519 ^T		
<i>Proteus vulgaris</i>	ATCC 13315 ^T	DSM 30118 ^T	AJ233425
<i>Providencia alcalifaciens</i>	ATCC 9886 ^T		
<i>Providencia rettgeri</i>	ATCC 9250		
<i>Providencia rustigianii</i>	ATCC 33673 ^T		
<i>Providencia stuartii</i>	ATCC 33672		
<i>Rahnella aquatilis</i>	ATCC 33071 ^T	DSM 4594 ^T	AJ233426
<i>Salmonella choleraesuis</i> subsp. <i>arizonaee</i>	ATCC 13314 ^T		
<i>Salmonella choleraesuis</i> serotype Choleraesuis	ATCC 7001		
<i>Salmonella choleraesuis</i> serotype Enteritidis‡	ATCC 13076 ^T	SE22	SE22
serotype Gallinarum	ATCC 9184		
serotype Heidelberg	ATCC 8326		
serotype Paratyphi A	ATCC 9150		
serotype Paratyphi B	ATCC 8759		
serotype Typhi‡	ATCC 10749	St111	U88545
serotype Typhimurium‡	ATCC 14028		
serotype Virchow	ATCC 51955		
subsp. <i>dianizonae</i>	ATCC 43973 ^T		
subsp. <i>houtenae</i>	ATCC 43974 ^T		
subsp. <i>indica</i>	ATCC 43976 ^T		
subsp. <i>salamae</i>	ATCC 43972 ^T		
<i>Serratia fonticola</i>	DSM 4576 ^T	DSM 4576 ^T	AJ233429
<i>Serratia grimesii</i>	ATCC 14460 ^T	DSM 30063 ^T	AJ233430
<i>Serratia liquefaciens</i>	ATCC 27592 ^T		
<i>Serratia marcescens</i>	ATCC 13880 ^T	DSM 30121 ^T	AJ233431
<i>Serratia odorifera</i>	ATCC 33077 ^T	DSM 4582 ^T	AJ233432
<i>Serratia plymuthica</i>	DSM 4540 ^T	DSM 4540 ^T	AJ233433
<i>Serratia rubidaea</i>	DSM 4480 ^T	DSM 4480 ^T	AJ233436
<i>Shigella boydii</i>	ATCC 9207	ATCC 9207	X96965
<i>Shigella dysenteriae</i>	ATCC 11835	ATCC 13313 ^T	X96966
		ATCC 25931	X96964

Table 19. Strains analyzed in Example 43 (continued).

Taxon	Strain*	Strain†	16S rDNA sequence accession number
<i>Shigella flexneri</i>	ATCC 12022	ATCC 12022	X96963
<i>Shigella sonnei</i>	ATCC 29930 ^T		
<i>Tatumella ptyseos</i>	ATCC 33301 ^T	DSM 5000 ^T	AJ233437
<i>Trabulsiella guamensis</i>	ATCC 49490 ^T		
<i>Yersinia enterocolitica</i>	ATCC 9610 ^T	ATCC 9610 ^T	M59292
<i>Yersinia frederiksenii</i>	ATCC 33641 ^T		
<i>Yersinia intermedia</i>	ATCC 29909 ^T		
<i>Yersinia pestis</i>	RRB KIMD27		
		ATCC 19428 ^T	X75274
<i>Yersinia pseudotuberculosis</i>	ATCC 29833 ^T		
<i>Yersinia rohdei</i>	ATCC 43380 ^T	ER-2935 ^T	X75276
<i>Shewanella putrefaciens</i>	ATCC 8071 ^T		
<i>Vibrio cholerae</i>	ATCC 25870		
		ATCC 14035 ^T	X74695

T Type strain

5 *Strains used in this study for sequencing of partial *tuf* and *atpD* genes. SEQ ID NOs. for *tuf* and *atpD* sequences corresponding to the above reference strains are given in table 7.

†Strains used in other studies for sequencing of 16S rDNA gene. When both strain numbers are on the same row, both strains are considered to be the same although strain numbers may be different.

‡Phylogenetic serotypes considered species by the Bacteriological Code (1990 Revision).

Table 20. PCR primer pairs used in this study

Primer SEQ ID NO.	Sequence	Nucleotide positions*	Amplicon length (bp)
<i>tuf</i>			
664	5'-AAYATGATIACIGGGCIGCICARATGGA- 3'	271-299	884
697	5'-CCIACTICKICCRCCYTCRCG-3'	1132-1156	
<i>atpD</i>			
568	5'-RTIATIGGIGCIGTIRTIGAYGT-3'	25-47	884
567	5'-TCRTCIGCIGGIACRTAIAYIGCYTG-3'	883-908	
700	5'-TIRTIGAYGTCGARTTCCCTCARG-3'	38-61	871
567	5'-TCRTCIGCIGGIACRTAIAYIGCYTG-3'	883-908	

5 *The nucleotide positions given are for *E. coli* *tuf* and *atpD* sequences (GenBank accession no. AE000410 and V00267, respectively). Numbering starts from the first base of the initiation codon.

Table 21. Selection of *M. catarrhalis*-specific primer pairs from SEQ ID NO: 29¹ (466 pb DNA fragment) other than those previously tested².

Primer	Sequence	Amplicon size (bp)	<i>Moraxella catarrhalis</i> ATCC 43628	<i>Moraxella catarrhalis</i> ATCC 53879	<i>Moraxella osloensis</i>	<i>Moraxella albilans</i>	<i>Moraxella phenylpyruvica</i>	<i>Kingella kingae</i>	<i>Nelsseria meningitidis</i>	<i>Nelsseria gonorrhoeae</i>	<i>Escherichia coli</i>	<i>Staphylococcus aureus</i>
SEQ ID NO:118	CGCTGACGGCTTGTGTACCA	118	+	+	-	-	-	-	-	-	-	-
SEQ ID NO:119	TGTTTGAGCTTTATTTTGA				-	-	-	-	-	-	-	-
VBmcat1	TGTTTAAGATTCACTCTGCCATT	93	+	+	-	-	-	-	-	-	-	-
VBmcat2	TAAGTCGCTGACGGCTTGT				-	-	-	-	-	-	-	-
VBmcat3	CCTGGACCACAAAGTCATCAT				-	-	-	-	-	-	-	-
VBmcat4	AATTCAACCAAAATGTCAAAGC	140	+	+	-	-	-	-	-	-	-	-
VBmcat5	AATGATAAACCGTCAAGCAAGC	219	+	+	-	-	-	-	-	-	-	-
VBmcat6	GTTGCATGGTATTGTAAAAA				-	-	-	-	-	-	-	-
VBmcat7	GTTGGGTTCACTTTACAAT				-	-	-	-	-	-	-	-
VBmcat8	GCTTTAAGCTGATGATGAGAG	160	+	+	-	-	-	-	-	-	-	-
VBmcat9	TGACCATGCACACCCATT				-	-	-	-	-	-	-	-
VBmcat10	TCAATTGGATGAAAGTATGTT	167	+	+	-	-	-	-	-	-	-	-

¹ SEQ ID NO. from US patent 6,001,564.² All PCR assays were performed with 1 ng of purified genomic DNA by using an annealing temperature of 55°C and 30 cycles of amplification. The genomic DNA from the various bacterial species above was always isolated from reference strains obtained from ATCC.³ All positive results showed a strong amplification signal with genomic DNA from the target species *M. catarrhalis*.

Table 22. Selection of *S. epidermidis*-specific primer pairs from SEQ ID NO: 36¹ (705 pb DNA fragment) other than those previously tested.

Primer	Sequence (all 25 nucleotides)	Amplicon size (bp)	Annealing temperature ² (°C)
SEQ ID NO:145	ATCAAAAGTTGGCGAACCTTTCA	125	+ ³
SEQ ID NO:146	CAAAGAGGGGAGAAAAAGTATCA	208	+
VBsep3	CATAGTGTGATTGGCTCAAAGTCTTG	208	+
VBsep4	GCGAATAGTGAACTAACATTCTGTTG	208	+
VBsep5	CACGCTCTTTTGCAATTTCATTTGA	208	+
VBsep6	GRAGCAAAATTCAAATGGACCCAG	208	+
VBsep7	AAAGTCTTTGCTTTCAGATTCA	177	+
VBsep8	GTGTTCACAGGTATGGATGGCTTTA	177	+
VBsep9	GAGCATCCATAACCTGTGAACACAGA	153	+
VBsep10	TTTTCCAATTACAAGAGACATCAGT	153	+
VBsep11	TTTGAATTTCGCATGTACTTGTGTTG	135	+
VBsep12	CCCCGGGTTCGAAATCGATAAAAAG	135	+

¹ SEQ ID NO. from US patent 6,001,564.² All PCR assays were performed with 1 ng of purified genomic DNA by using an annealing temperature of 55 to 65°C and 30 cycles of amplification. The genomic DNA from the various bacterial species above was always isolated from reference strains obtained from ATCC.³ All positive results showed a strong amplification signal with genomic DNA from the target species *S. epidermidis*. The intensity of the positive amplification signal with species other than *S. epidermidis* was variable.
NT = not tested.

Tabl 23. Influence of nucleotide variation(s) on the efficiency of the PCR amplification: Example with SEQ ID NO: 146 from *S. epidermidis*.

Primer ¹	Sequence (all 25 nucleotides)	Number of mutation	50°C			55°C			50°C		
			1	1	0,1	0,01	1				
SEQ ID NO:145	ATCAAAAAGTTGGCGAACCTTTTCA	0									
SEQ ID NO:146	CAAAGAGCCGTGGAGAAACTATCA	0	3+	3+	2+	+	-				
VBmut1	CAAAGAGCCGTGGAGAAAGTA[CA]	1	3+	3+	2+	+	-				
VBmut2	CAAAGAGCCGTGGAGAAATA[CA]	1	3+	3+	2+	+	-				
VBmut3	CAAAGAGCCGTGGAGA[G]AAGTATCA	1	3+	3+	2+	+	-				
VBmut4	CAAAGAGCCGTGG[G]GAAGTATCA	1	3+	3+	2+	+	-				
VBmut5	CAAAGAGCC[G]GGAGAAAGTATCA	1	3+	3+	2+	+	-				
VBmut6	CAAAGAG[A]CCTGGAGAAAGTATCA	1	3+	3+	2+	+	-				
VBmut7	C[A]AGGCGTGGAGAAAGTATCA	1	3+	3+	2+	+	-				
VBmut8	C[T]AAAGAGCCGTGGAGAAAGTATCA	1	3+	3+	2+	+	-				
VBmut9	CAAAGAGCCGTGGAGA[G]AAGT[CA]	2	3+	3+	2+	+	-				
VBmut10	CAAAGAGCC[G]GGAGA[G]AAGTATCA	2	3+	3+	2+	+	-				
VBmut11	CAAAG[G]AGCC[G]GGAGAAAGTATCA	2	3+	3+	2+	+	-				
VBmut12	CAAAG[G]AGCC[G]GG[G]AAAGTAC[CA]	3	3+	3+	2+	+	-				
VBmut13	CAAAG[G]AGCC[G]GGAGA[G]AAGT[CA]	4	3+	3+	2+	+	-				

¹ All PCR tests were performed with SEQ ID NO:145 without modification combined with SEQ ID NO:146 or 13 modified versions of SEQ ID NO:146. Boxed nucleotides indicate changes in SEQ ID NO:146. All SEQ ID NOS. are from US patent 6,001,564.

² The tests with *S. epidermidis* were performed by using an annealing temperature of 55°C with 1 ng of genomic DNA or at 50°C with 1 ng of purified genomic DNA.

³ The tests with *S. aureus* were performed only at 50°C with 1 ng of genomic DNA.

⁴ The intensity of the positive amplification signal was quantified as follows: 3+ = strong signal, 2+ = intermediate signal and + = weak signal.

Table 24. Effect of the primer length on the efficiency of the PCR amplification¹: Example with the AT-rich SEQ ID NO: 145² and SEQ ID NO: 146³ from *S. epidermidis*.

Primer	Sequence	Length (nt)	45°C		55°C		Staphylococcus aureus	Staphylococcus haemolyticus	Staphylococcus capitis	Staphylococcus warneri
			1	0,1	0,01	1				
VBsep301	ATATCATCAAAAGTTGGCGAACCTTTTCA	30	NT	NT	NT	4+	3+	2+	NT	-
VBsep302	AATTGCAAAAGGCCGTGGAAAAAGTATCA	30	ATCAAAAAGTTGGCGAACCTTTTCA	25	4+ ⁵	3+	2+	3+	-	-
SEQ ID NO:145			CAAAGAGC GTGGAGAAAAGTATCA	25						
SEQ ID NO:146			AAAGTTGGCGAACCTTTTCA	20	NT	NT	4+	3+	2+	-
VBsep201			GAGCGTGGAGAAAAGTATCA	20						
VBsep202			GTTGGCGAACCTTTTCA	17	4+	3+	2+	2+	NT	-
VBsep171			CCTGGAGAAAAGTATCA	17						
VBsep172			TGGCAACCTTTTCA	15	3+	2+	2+	+	-	-
VBsep151										
VBsep152			TGGAGAAAAGTATCA	15						

¹ All PCR tests were performed using an annealing temperature of 45 or 55°C and 30 cycles of amplification.

² All SEQ ID NOs. in this Table are from US patent 6,001,546.

³ The tests with *S. epidermidis* were made with 1, 0,1 and 0,01 ng of purified genomic DNA.

⁴ The tests with all other bacterial species were made only with 1 ng of purified genomic DNA.

⁵ The Intensity of the positive amplification signal was quantified as follows: 4+ = very strong signal, 3+ = strong signal, 2+ = intermediate signal and + = weak signal. NT = not tested.

Table 25. Effect of the primer length on the efficiency of the PCR amplification¹: Example with the GC-rich SEQ ID NO: 83² and SEQ ID NO: 84² from *P. aeruginosa*.

Primer	Sequence	Length (nt)	0,01		
			1	0,1	0,01
SEQ ID NO 83	CGAGGGGTGGTTCATC	19	-	-	-
SEQ ID NO 84	CAAGTCGTCGTCGGAGGA	19	2+ ⁵	+	-
Pse854-16a	CGAGGGGTGGTTC	16	-	-	-
Pse8674-16a	GTCGTCGTCGGAGGA	16	2+	+	-
Pse854-13b	GCGGTGGTGTTC	13	-	-	-
Pse8674-13a	GTCGTCGGAGGA	13	2+	+	-

*Pseudomonas aeruginosa*³
ATCC 35554

Haemophilus parahaemolyticus
Nelsseria menningitiidis
Stenotrophomonas maltophilia
Shewanella putida
Burkholderia cepacia
Pseudomonas fluorescens

¹ All PCR tests were performed using an annealing temperature of 55°C and 30 cycles of amplification.

² All SEQ ID NOs. in this Table are from US patent 6,001,546.

³ The tests with *P. aeruginosa* were made with 1, 0,1 and 0,01 ng of purified genomic DNA.

* The tests with all other bacterial species were made only with 1 ng of purified genomic DNA.

⁵ The intensity of the positive amplification signal was quantified as follows: 2+ = strong signal and + = moderately strong signal.

Annex I: Specific and ubiquitous primers for nucleic acid amplification (tuf sequences).

	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10		Bacterial species: <i>Acinetobacter baumannii</i>		
	1692	5'-GGT GAG AAC TGT GGT ATC TTA CTT	1	478-501
	1693 ^a	5'-CAT TTC AAC GCC TTC TTT CAA CTG	1	691-714
15		Bacterial species: <i>Chlamydia pneumoniae</i>		
	630	5'-CGG AGC TAT CCT AGT CGT TTC A	20	2-23
	629 ^a	5'-AAG TTC CAT CTC AAC AAG GTC AAT A	20	146-170
20	2085	5'-CAA ACT AAA GAA CAT ATC TTG CTA	20	45-68
	2086 ^a	5'-ATA TAA TTT GCA TCA CCT TCA AG	20	237-259
	2087	5'-TCA GCT CGT GGG ATT AGG AGA G	20	431-452
	2088 ^a	5'-AGG CTT CAC GCT GTT AGG CTG A	20	584-605
25		Bacterial species: <i>Chlamydia trachomatis</i>		
	554	5'-GTT CCT TAC ATC GTT GTT TTT CTC	22	82-105
	555 ^a	5'-TCT CGA ACT TTC TCT ATG TAT GCA	22	249-272
30		Parasitical species: <i>Cryptosporidium parvum</i>		
	798	5'-TGG TTG TCC CAG CCG ATC GTT T	865	158-179
	804 ^a	5'-CCT GGG ACG GCC TCT GGC AT	865	664-683
35	799	5'-ACC TGT GAA TAC AAG CAA TCT	865	280-300
	805 ^a	5'-CTC TTG TCC ATC TTA GCA GT	865	895-914
	800	5'-GAT GAA ATC TTC AAC GAA GTT GAT	865	307-330
40	806 ^a	5'-AGC ATC ACC AGA CTT GAT AAG	865	946-966
	801	5'-ACA ACA CCG AGA AGA TCC CA	865	353-372
	803 ^a	5'-ACT TCA GTG GTA ACA CCA GC	865	616-635
45	802	5'-TTG CCA TTT CTG GTT TCG TT	865	377-396
	807 ^a	5'-AAA GTG GCT TCA AAG GTT GC	865	981-1000
		Bacterial species: <i>Enterococcus faecium</i>		
50	1696	5'-ATG TTC CTG TAG TTG CTG GA	64	189-208
	1697 ^a	5'-TTT CTT CAG CAA TAC CAA CAA C	64	422-443
		Bacterial species: <i>Klebsiella pneumoniae</i>		
55	1329	5'-TGT AGA GCG CGG TAT CAT CAA AGT A	103	352-377
	1330 ^a	5'-AGA TTC GAA CTT GGT GTG CGG G	103	559-571

^a These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex I: Specific and ubiquitous primers for nucleic acid amplification (tuf sequences) (continued).

	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10		Bacterial species: <i>Mycoplasma pneumoniae</i>		
	2093	5'-TGT TGG CAA TCG AAG ACA CC	2097 ^a	635-654
	2094 ^b	5'-TTC AAT TTC TTG ACC TAC TTT CAA	2097 ^a	709-732
15		Bacterial species: <i>Neisseria gonorrhoeae</i>		
	551	5'-GAA GAA AAA ATC TTC GAA CTG GCT A	126	256-280
	552 ^b	5'-TAC ACG GCC GGT GAC TAC G	126	378-396
20	2173	5'-AAG AAA AAA TCT TCG AAC TGG CTA	126	257-280
	2174 ^b	5'-TCT ACA CGG CCG GTG	126	384-398
	2175	5'-CCG CCA TAC CCC GTT T	126	654-669
	2176 ^b	5'-CGG CAT TAC CAT TTC CAC ACC TTT	126	736-759
25		Bacterial species: <i>Pseudomonas aeruginosa</i>		
	1694	5'-AAG GCA AGG ATG ACA ACG GC	153	231-250
	1695 ^b	5'-ACG ATT TCC ACT TCT TCC TGG	153	418-438
30		Bacterial species: <i>Streptococcus agalactiae</i>		
	549	5'-GAA CGT GAT ACT GAC AAA CCT TTA	207-210 ^c	308-331 ^d
	550 ^b	5'-GAA GAA CAC CAA CGT TG	207-210 ^c	520-539 ^d
35		Bacterial species: <i>Streptococcus pyogenes</i>		
	999	5'-TTG ACC TTG TTG ATG ACG AAG AG	1002	143-165
	1000 ^b	5'-TTA GTG TGT GGG TTG ATT GAA CT	1002	622-644
40	1001	5'-AAG AGT TGC TTG AAT TAG TTG AG	1002	161-183
	1000 ^b	5'-TTA GTG TGT GGG TTG ATT GAA CT	1002	622-644
45		Parasitical species: <i>Trypanosoma brucei</i>		
	820	5'-GAA GGA GGT GTC TGC TTA CAC	864	513-533
	821 ^b	5'-GGC GCA AAC GTC ACC ACA TCA	864	789-809
50	820	5'-GAA GGA GGT GTC TGC TTA CAC	864	513-533
	822 ^b	5'-CGG CGG ATG TCC TTA ACA GAA	864	909-929

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^c These sequences were aligned to derive the corresponding primer.

^d The nucleotide positions refer to the *S. agalactiae* tuf sequence fragment (SEQ ID NO. 209).

Annex I: Specific and ubiquitous primers for nucleic acid amplification (tuf s qu nc s) (continued).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10		<u>Parasitical species:</u> <i>Trypanosoma cruzi</i>		
	794	5'-GAC GAC AAG TCG GTG AAC TT	840-842 ^a	281-300 ^c
	795 ^b	5'-ACT TGC ACG CGA TGT GGC AG	840-842 ^a	874-893 ^c
15		<u>Bacterial genus:</u> <i>Clostridium sp.</i>		
	796	5'-GGT CCA ATG CCW CAA ACW AGA	32,719- 724,736 ^a	32-52 ^d
20	797 ^b	5'-CAT TAA GAA TGG YTT ATC TGT SKC TCT	32,719- 724,736 ^a	320-346 ^d
	808	5'-GCI TTA IWR GCA TTA GAA RAY CCA	32,719- 724,736 ^a	224-247 ^d
25	809 ^b	5'-TCT TCC TGT WGC AAC TGT TCC TCT	32,719- 724,736 ^a	337-360 ^d
	810	5'-AGA GMW ACA GAT AAR SCA TTC TTA	32,719- 724,736 ^a	320-343 ^d
	811 ^b	5'-TRA ART AGA ATT GTG GTC TRT ATC C	32,719- 724,736 ^a	686-710 ^d
30		<u>Bacterial genus:</u> <i>Corynebacterium sp.</i>		
	545	5'-TAC ATC CTB GTY GCI CTI AAC AAG TG	34-44,662 ^a	89-114 ^e
	546 ^b	5'-CCR CGI CCG GTR ATG GTG AAG AT	34-44,662 ^a	350-372 ^e
35		<u>Bacterial genus:</u> <i>Enterococcus sp.</i>		
	656	5'-AAT TAA TGG CTG CAG TTG AYG A	58-72 ^a	273-294 ^f
40	657 ^b	5'-TTG TCC ACG TTC GAT RTC TTC A	58-72 ^a	556-577 ^f
	656	5'-AAT TAA TGG CTG CAG TTG AYG A	58-72 ^a	273-294 ^f
	271 ^b	5'-TTG TCC ACG TTG GAT RTC TTC A	58-72 ^a	556-577 ^f
45	1137	5'-AAT TAA TGG CTG CWG TTG AYG AA	58-72 ^a	273-295 ^f
	1136 ^b	5'-ACT TGT CCA CGT TSG ATR TCT	58-72 ^a	559-579 ^f

^a These sequences were aligned to derive the corresponding primer.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^c The nucleotide positions refer to the *T. cruzi* tuf sequence fragment (SEQ ID NO. 842).

^d The nucleotide positions refer to the *C. perfringens* tuf sequence fragment (SEQ ID NO. 32).

^e The nucleotide positions refer to the *C. diphtheriae* tuf sequence fragment (SEQ ID NO. 662).

^f The nucleotide positions refer to the *E. durans* tuf sequence fragment (SEQ ID NO. 61).

Annex I: Specific and ubiquitous primers for nucleic acid amplification (tuf sequences) (continued).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10	<u>Bacterial genus:</u>	Legionella sp.		
	2081	5'-GRA TYR TYA AAG TTG GTG AGG AAG	111-112 ^a	411-434 ^b
	2082 ^c	5'-CMA CTT CAT CYC GCT TCG TAC C	111-112 ^a	548-569 ^b
15	<u>Bacterial genus:</u>	Staphylococcus sp.		
	553	5'-GGC CGT GTT GAA CGT GGT CAA ATC A	176-203 ^a	313-337 ^d
	575 ^c	5'-TIA CCA TTT CAG TAC CTT CTG GTA A	176-203 ^a	653-677 ^d
20	553	5'-GGC CGT GTT GAA CGT GGT CAA ATC A	176-203 ^a	313-337 ^d
	707 ^c	5'-TWA CCA TTT CAG TAC CTT CTG GTA A	176-203 ^a	653-677 ^d
	<u>Bacterial genus:</u>	Streptococcus sp.		
25	547	5'-GTA CAG TTG CTT CAG GAC GTA TC	206-231 ^a	372-394 ^e
	548 ^c	5'-ACG TTC GAT TTC ATC ACG TTG	206-231 ^a	548-568 ^e
	<u>Fungal genus:</u>	Candida sp.		
30	576	5'-AAC TTC RTC AAG AAG GTY GGT TAC AA	407-426, 428-432 ^a	332-357 ^f
	632 ^c	5'-CCC TTT GGT GGR TCS TKC TTG GA	407-426, 428-432 ^a	791-813 ^f
35	631	5'-CAG ACC AAC YGA IAA RCC ATT RAG AT	407-426, 428-432 ^a	523-548 ^f
	632 ^c	5'-CCC TTT GGT GGR TCS TKC TTG GA	407-426, 428-432 ^a	791-813 ^f
40	633	5'-CAG ACC AAC YGA IAA RCC ITT RAG AT	407-426, 428-432 ^a	523-548 ^f
	632 ^c	5'-CCC TTT GGT GGR TCS TKC TTG GA	407-426, 428-432 ^a	791-813 ^f

45 ^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the *L. pneumophila* tuf sequence fragment (SEQ ID NO. 112).

50 ^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^d The nucleotide positions refer to the *S. aureus* tuf sequence fragment (SEQ ID NO. 179).

^e The nucleotide positions refer to the *S. agalactiae* tuf sequence fragment (SEQ ID NO. 209).

55 ^f The nucleotide positions refer to the *C. albicans* tuf(EF-1) sequence fragment (SEQ ID NO. 408).

Annex I: Specific and ubiquitous primers for nucleic acid amplification (tuf sequences) (continued).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10 Fungal genus: <i>Cryptococcus</i> sp.				
	1971	5'-CYG ACT GYG CCA TCC TYA TCA	434, 623, 1281,	150-170 ^b
			1985, 1986 ^a	
15	1973 ^c	5'-RAC ACC RGI YTT GGW ITC CTT	434, 623, 1281,	464-484 ^b
			1985, 1986 ^a	
	1972	5'-MGI CAG CTC ATY ITT GCW KSC	434, 623, 1281,	260-280 ^b
			1985, 1986 ^a	
20	1973 ^c	5'-RAC ACC RGI YTT GGW ITC CTT	434, 623, 1281,	464-484 ^b
			1985, 1986 ^a	
Parasitical genus: <i>Entamoeba</i> sp.				
25	703	5'-TAT GGA AAT TCG AAA CAT CT	512	38-57
	704 ^c	5'-AGT GCT CCA ATT AAT GTT GG	512	442-461
	703	5'-TAT GGA AAT TCG AAA CAT CT	512	38-57
	705 ^c	5'-GTA CAG TTC CAA TAC CTG AA	512	534-553
30	703	5'-TAT GGA AAT TCG AAA CAT CT	512	38-57
	706 ^c	5'-TGA AAT CTT CAC ATC CAA CA	512	768-787
	793	5'-TTA TTG TTG CTG CTG GTA CT	512	149-168
35	704 ^c	5'-AGT GCT CCA ATT AAT GTT GG	512	442-461
Parasitical genus: <i>Giardia</i> sp.				
	816	5'-GCT ACG ACG AGA TCA AGG GC	513	305-324
40	819 ^c	5'-TCG AGC TTC TGG AGG AAG AG	513	895-914
	817	5'-TGG AAG AAG GCC GAG GAG TT	513	355-374
	818 ^c	5'-AGC CGG GCT GGA TCT TCT TC	513	825-844
Parasitical genus: <i>Leishmania</i> sp.				
45	701	5'-GTG TTC ACG ATC ATC GAT GCG	514-526 ^a	94-114 ^d
	702 ^c	5'-CTC TCG ATA TCC GCG AAG CG	514-526 ^a	913-932d

50 ^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the *C. neoformans* tuf (EF-1) sequence fragment (SEQ ID NO. 623).

^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

55 ^d The nucleotide positions refer to the *L. tropica* tuf (EF-1) sequence fragment (SEQ ID NO. 526).

Annex I: Specific and ubiquitous primers for nucleic acid amplification (tuf sequences) (continued).

	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10	<u>Parasitical genus:</u>	Trypanosoma sp.		
	823	5'-GAG CGG TAT GAY GAG ATT GT	529,840-	493-512 ^b
	824 ^c	5'-GGC TTC TGC GGC ACC ATG CG	842,864 ^a	
15			529,840-	1171-1190 ^b
			842,864 ^a	
	<u>Bacterial family:</u>	Enterobacteriaceae		
20	933	5'-CAT CAT CGT ITT CMT GAA CAA RTG	78,103,146,	390-413 ^d
	934 ^c	5'-TCA CGY TTR RTA CCA CGC AGI AGA	168,238,698 ^a	
			78,103,146,	831-854 ^d
			168,238,698 ^a	
25	<u>Bacterial family:</u>	Mycobacteriaceae		
	539	5'-CCI TAC ATC CTB GTY GCI CTI AAC AAG	122	85-111
	540 ^c	5'-GGD GCI TCY TCR TCG WAI TCC TG	122	181-203
30	<u>Bacterial group:</u>	Escherichia coli and Shigella		
	1661	5'-TGG GAA GCG AAA ATC CTG	1668 ^e	283-300
	1665 ^c	5'-CAG TAC AGG TAG ACT TCT G	1668 ^e	484-502
35	<u>Bacterial group:</u>	Pseudomonads group		
	541	5'-GTK GAA ATG TTC CGC AAG CTG CT	153-155 ^a	476-498 ^f
	542 ^c	5'-CGG AAR TAG AAC TGS GGA CGG TAG	153-155 ^a	679-702 ^f
40	541	5'-GTK GAA ATG TTC CGC AAG CTG CT	153-155 ^a	476-498 ^f
	544 ^c	5'-AYG TTG TCG CCM GGC ATT MCC AT	153-155 ^a	749-771 ^f

^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the *T. brucei tuf* (EF-1) sequence fragment (SEQ ID NO. 864).

^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^d The nucleotide positions refer to the *E. coli tuf* sequence fragment (SEQ ID NO. 698).

^e Sequence from databases.

^f The nucleotide positions refer to the *P. aeruginosa tuf* sequence fragment (SEQ ID NO. 153).

Annex I: Specific and ubiquitous primers for nucleic acid amplification (tuf sequences) (continued).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10	<u>Parasitical group:</u>		Trypanosomatidae family	
	923	5'-GAC GCI GCC ATC CTG ATG ATC	511, 514-526, 529, 840-842, 864 ^a	166-188 ^b
15	924 ^c	5'-ACC TCA GTC GTC ACG TTG GCG	511, 514-526, 529, 840-842, 864 ^a	648-668 ^b
20	925	5'-AAG CAG ATG GTT GTG TGC TG	511, 514-526, 529, 840-842, 864 ^a	274-293 ^b
	926 ^c	5'-CAG CTG CTC GTG GTG CAT CTC GAT	511, 514-526, 529, 840-842,	676-699 ^b
25	927	5'-ACG CGG AGA AGG TGC GCT T	511, 514-526, 529, 840-842, 864 ^a	389-407 ^b
30	928 ^c	5'-GGT CGT TCT TCG AGT CAC CGC A	511, 514-526, 529, 840-842, 864 ^a	778-799 ^b
Universal primers (bacteria)				
35	636	5'-ACT GGY GTT GAI ATG TTC CGY AA	7, 54, 78, 100, 103, 159, 209, 224, 227 ^b	470-492 ^d
	637 ^c	5'-ACG TCA GTI GTA CGG AAR TAG AA	7, 54, 78, 100, 103, 159, 209, 224, 227 ^b	692-714 ^d
40	638	5'-CCA ATG CCA CAA ACI CGT GAR CAC AT	7, 54, 78, 100, 103, 159, 209, 224, 227 ^b	35-60 ^e
45	639 ^c	5'-TTT ACG GAA CAT TTC WAC ACC WGT IAC A	7, 54, 78, 100, 103, 159, 209, 224, 227 ^b	469-496 ^e

- 50 ^a These sequences were aligned to derive the corresponding primer.
 ^b The nucleotide positions refer to the *L. tropica* tuf (EF-1) sequence fragment (SEQ ID NO. 526).
 ^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.
 ^d The nucleotide positions refer to the *E. coli* tuf sequence fragment (SEQ ID NO. 78).
 ^e The nucleotide positions refer to the *B. cereus* tuf sequence fragment (SEQ ID NO. 7).

Annex I: Specific and ubiquitous primers for nucleic acid amplification (tuf sequences) (continued).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10 Universal primers (bacteria) (continued)				
15	643	5'-ACT GGI GTI GAR ATG TTC CGY AA	1,3,4,7,12, 13,16,49,54, 72,78,85,88, 91,94,98,103, 108,112,115, 116,120,121, 126,128,134, 136,146,154, 159,179,186, 205,209,212, 224,238 ^a	470-492 ^b
20	644 ^c	5'-ACG TCI GTI GTI CKG AAR TAG AA	same as SEQ ID NO. 643	692-714 ^b
25	643	5'-ACT GGI GTI GAR ATG TTC CGY AA	1,3,4,7,12, 13,16,49,54, 72,78,85,88, 91,94,98,103, 108,112,115, 116,120,121, 126,128,134, 136,146,154, 159,179,186, 205,209,212, 224,238 ^a	470-492 ^b
30	645 ^c	5'-ACG TCI GTI GTI CKG AAR TAR AA	same as SEQ ID NO. 643	692-714 ^b
35	646	5'-ATC GAC AAG CCI TTC YTI ATG SC	2,13,82 122,145 ^a	317-339 ^d
40	647 ^c	5'-ACG TCC GTS GTR CGG AAG TAG AAC TG	2,13,82 122,145 ^a	686-711 ^d
45	646	5'-ATC GAC AAG CCI TTC YTI ATG SC	2,13,82 122,145 ^a	317-339 ^d
50	648 ^c	5'-ACG TCS GTS GTR CGG AAG TAG AAC TG	2,13,82 122,145 ^a	686-711 ^d

^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the *E. coli* tuf sequence fragment (SEQ ID NO. 78).

^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^d The nucleotide positions refer to the *A. meyeri* tuf sequence fragment (SEQ ID NO. 2).

Annex I: Specific and ubiquitous primers for nucleic acid amplification (tuf sequences) (continued).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10 Universal primers (bacteria) (continued)				
	649	5'-GTC CTA TGC CTC ARA CWC GIG AGC AC	8,86,141,143 ^a	33-58 ^b
	650 ^c	5'-TTA CGG AAC ATY TCA ACA CCI GT	8,86,141,143 ^a	473-495 ^b
15	636	5'-ACT GGY GTT GAI ATG TTC CGY AA	8,86,141,143 ^a	473-495 ^b
	651 ^c	5'-TGA CGA CCA CCI TCY TCY TTY TTC A	8,86,141,143 ^a	639-663 ^b
Universal primers (fungi)				
20	1974	5'-ACA AGG GIT GGR MSA AGG AGA C	404,405,433,	443-464 ^d
			445,898,1268,	
	1975 ^c	5'-TGR CCR GGG TGG TTR AGG ACG	1276,1986 ^a	
25			404,405,433,	846-866 ^d
			445,898,1268,	
	1976	5'-GAT GGA YTC YGT YAA ITG GGA	1276,1986 ^a	
30			407-412,	286-306 ^e
			414-426,428-	
	1978 ^c	5'-CAT CIT GYA ATG GYA ATC TYA AT	431,439,443,447,	
35	1977	5'-GAT GGA YTC YGT YAA RTG GGA	448,622,624,665,	
	1979 ^c	5'-CAT CYT GYA ATG GYA ASC TYA AT	1685,1987-1990 ^a	
40	1981	5'-TGG ACA CCI SCA AGI GGK CYG	same as SEQ ID NO. 1976	553-575 ^e
45			same as SEQ ID NO. 1976	286-306 ^e
			same as SEQ ID NO. 1976	553-575 ^e
50	1980 ^c	5'-TCR ATG GCI TCI AIR AGR GTY T	401-405,	281-301 ^d
			433,435,436,	
			438,444,445,449,	
			453,455,457,779,	
			781-783,785,786,	
			788-790,897-903,	
			1267-1272,1274-1280,	
			1282-1287,1991-1998 ^a	
			same as SEQ ID NO. 1981	488-509 ^d

^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the *B. distasonis* tuf sequence fragment (SEQ ID NO. 8).

^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^d The nucleotide positions refer to the *A. fumigatus* tuf (EF-1) sequence fragment (SEQ ID NO. 404).

^e The nucleotide positions refer to the *C. albicans* tuf (EF-1) sequence fragment (SEQ ID NO. 407).

Annex I: Specific and ubiquitous primers for nucleic acid amplification (tuf sequences) (continued).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10 Universal primers (fungi) (continued)				
	1982	5'-TGG ACA CYI SCA AGI GGK CYG	same as SEQ ID NO. 1981	281-301 ^a
15	1980 ^b	5'-TCR ATG GCI TCI AIR AGR GTY T	same as SEQ ID NO. 1981	488-509 ^a
	1983	5'-CYG AYT GCG CYA TIC TCA TCA	same as SEQ ID NO. 1981	143-163 ^a
20	1980 ^b	5'-TCR ATG GCI TCI AIR AGR GTY T	same as SEQ ID NO. 1981	488-509 ^a
	1984	5'-CYG AYT GYG CYA TYC TSA TCA	same as SEQ ID NO. 1981	143-163 ^a
25	1980 ^b	5'-TCR ATG GCI TCI AIR AGR GTY T	same as SEQ ID NO. 1981	488-509 ^a
Sequencing primers				
30	556	5'-CGG CGC NAT CYT SGT TGT TGC	668 ^c	306-326
	557 ^b	5'-CCM AGG CAT RAC CAT CTC GGT G	668 ^c	1047-1068
	694	5'-CGG CGC IAT CYT SGT TGT TGC	668 ^c	306-326
	557 ^b	5'-CCM AGG CAT RAC CAT CTC GGT G	668 ^c	1047-1068
35	664	5'-AAY ATG ATI ACI GGI GCI GCI CAR ATG GA	619 ^c	604-632
	652 ^b	5'-CCW AYA GTI YKI CCI CCY TCY CTI ATA	619 ^c	1482-1508
	664	5'-AAY ATG ATI ACI GGI GCI GCI CAR ATG GA	619 ^c	604-632
40	561 ^b	5'-ACI GTI CGG CCR CCC TCA CGG AT	619 ^c	1483-1505
	543	5'-ATC TTA GTA GTT TCT GCT GCT GA	607	8-30
	660 ^b	5'-GTA GAA TTG AGG ACG GTA GTT AG	607	678-700
	658	5'-GAT YTA GTC GAT GAT GAA GAA TT	621	116-138
45	659 ^b	5'-GCT TTT TGI GTT TCW GGT TTR AT	621	443-465
	658	5'-GAT YTA GTC GAT GAT GAA GAA TT	621	116-138
	661 ^b	5'-GTA GAA YTG TGG WCG ATA RTT RT	621	678-700
50	558	5'-TCI TTY AAR TAY GCI TGG GT	665 ^c	157-176
	559 ^b	5'-CCG ACR GCR AYI GTY TGI CKC AT	665 ^c	1279-1301
	813	5'-AAT CYG TYG AAA TGC AYC ACG A	665 ^c	687-708
55	559 ^b	5'-CCG ACR GCR AYI GTY TGI CKC AT	665 ^c	1279-1301

^a The nucleotide positions refer to the *A. fumigatus tuf* (EF-1) sequence fragment (SEQ ID NO. 404).

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^c Sequences from databases.

Annex I: Specific and ubiquitous primers for nucleic acid amplification (tuf sequences) (continu d).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10 Sequencing primers (continued)				
	558	5'-TCI TTY AAR TAY GCI TGG GT	665 ^a	157-176
	815 ^b	5'-TGG TGC ATY TCK ACR GAC TT	665 ^a	686-705
15	560	5'-GAY TTC ATY AAR AAY ATG ATY AC	665 ^a	289-311
	559 ^b	5'-CCG ACR GCR AYI GTY TGI CKC AT	665 ^a	1279-1301
	653	5'-GAY TTC ATI AAR AAY ATG AT	665 ^a	289-308
20	559 ^b	5'-CCG ACR GCR AYI GTY TGI CKC AT	665 ^a	1279-1301
	558	5'-TCI TTY AAR TAY GCI TGG GT	665 ^a	157-176
	655 ^b	5'-CCR ATA CCI CMR ATY TTG TA	665 ^a	754-773
	654	5'-TAC AAR ATY KGI GGT ATY GG	665 ^a	754-773
25	559 ^b	5'-CCG ACR GCR AYI GTY TGI CKC AT	665 ^a	1279-1301
	696	5'-ATI GGI CAY RTI GAY CAY GGI AAR AC	698 ^a	52-77
	697 ^b	5'-CCI ACI GTI CKI CCR CCY TCR CG	698 ^a	1132-1154
30	911	5'-GAC GGM KKC ATG CCG CAR AC	853	22-41
	914 ^b	5'-GAA RAG CTG CGG RCG RTA GTG	853	700-720
	912	5'-GAC GGC GKC ATG CCG CAR AC	846	20-39
35	914 ^b	5'-GAA RAG CTG CGG RCG RTA GTG	846	692-712
	913	5'-GAC GGY SYC ATG CCK CAG AC	843	251-270
	915 ^b	5'-AAA CGC CTG AGG RCG GTA GTT	843	905-925
	916	5'-GCC GAG CTG GCC GGC TTC AG	846	422-441
40	561 ^b	5'-ACI GTI CGG CCR CCC TCA CGG AT	619 ^a	1483-1505
	664	5'-AAY ATG ATI ACI GGI GCI GCI CAR ATG GA	619 ^a	604-632
	917 ^b	5'-TCG TGC TAC CCG TYG CCG CCA T	846	593-614

45

^a Sequences from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex I: Specific and ubiquitous primers for nucleic acid amplification (tuf sequences) (continu d).

5	SEQ ID NO.	Nucleotide sequenc	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10 Sequencing primers (continued)				
	1221	5'-GAY ACI CCI GGI CAY GTI GAY TT	1230 ^a	292-314
	1226 ^b	5'-GTI RMR TAI CCR AAC ATY TC	1230 ^a	2014-2033
15	1222	5'-ATY GAY ACI CCI GGI CAY GTI GAY TT	1230 ^a	289-314
	1223 ^b	5'-AYI TCI ARR TGI ARY TCR CCC ATI CC	1230 ^a	1408-1433
	1224	5'-CCI GYI HTI YTI GAR CCI ATI ATG	1230 ^a	1858-1881
20	1225 ^b	5'-TAI CCR AAC ATY TCI SMI ARI GGI AC	1230 ^a	2002-2027
	1227	5'-GTI CCI YTI KCI GAR ATG TTY GGI TA	1230 ^a	2002-2027
	1229 ^b	5'-TCC ATY TGI GCI GCI CCI GTI ATC AT	698 ^a	4-29
25	1228	5'-GTI CCI YTI KCI GAR ATG TTY GGI TAY GC	1230 ^a	2002-2030
	1229 ^b	5'-TCC ATY TGI GCI GCI CCI GTI ATC AT	698 ^a	4-29
	1999	5'-CAT GTC AAY ATT GGT ACT ATT GGT CAT GT 498-500, 502,505,506, 508,619,2004,2005 ^c		25-53 ^d
30	2000 ^b	5'-CCA CCY TCI CTC AMG TTG AAR CGT T	same as SEQ ID NO. 1999	1133-1157 ^d
	2001	5'-ACY ACI TTR ACI GCY GCY ATY AC	same as SEQ ID NO. 1999	67-89 ^d
35	2003 ^b	5'-CAT YTC RAI RTT GTC ACC TGG	same as SEQ ID NO. 1999	1072-1092 ^d
	2002	5'-CCI GAR GAR AGA GCI MGW GGT	same as SEQ ID NO. 1999	151-171 ^d
40	2003 ^b	5'-CAT YTC RAI RTT GTC ACC TGG	same as SEQ ID NO. 1999	1072-1092 ^d

^a Sequences from databases.

45 ^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^c These sequences were aligned to derive the corresponding primer.

^d The nucleotide positions refer to the *C. albicans* tuf sequence fragment (SEQ ID NO. 2004).

50

Annex II: Specific and ubiquitous primers for nucleic acid amplification (*atpD* sequences).

	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10				
	<u>Bacterial species:</u>	<i>Acinetobacter baumannii</i>		
	1690	5'-CAG GTC CTG TTG CGA CTG AAG AA	243	186-208
	1691 ^b	5'-CAC AGA TAA ACC TGA GTG TGC TTT C	243	394-418
15				
	<u>Bacterial species:</u>	<i>Bacteroides fragilis</i>		
	2134	5'-CGC GTG AAG CTT CTG TG	929	184-200
	2135 ^b	5'-TCT CGC CGT TAT TCA GTT TC	929	395-414
20				
	<u>Bacterial species:</u>	<i>Bordetella pertussis</i>		
	2180	5'-TTC GCC GGC GTG GGC	1672 ^c	544-558
	2181 ^b	5'-AGC GCC ACG CGC AGG	1672 ^c	666-680
25				
	<u>Bacterial species:</u>	<i>Enterococcus faecium</i>		
	1698	5'-GGA ATC AAC AGA TGG TTT ACA AA	292	131-153
	1699 ^b	5'-GCA TCT TCT GGG AAA GGT GT	292	258-277
30				
	1700	5'-AAG ATG CGG AAA GAA GCG AA	292	271-290
	1701 ^b	5'-ATT ATG GAT CAG TTC TTG GAT CA	292	439-461
	<u>Bacterial species:</u>	<i>Klebsiella pneumoniae</i>		
35	1331	5'-GCC CTT GAG GTA CAG AAT GGT AAT GAA GTT	317	88-118
	1332 ^b	5'-GAC CGC GGC GCA GAC CAT CA	317	183-203

^a These sequences were aligned to derive the corresponding primer.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^c Sequence from databases.

Annex II: Specific and ubiquitous primers for nucleic acid amplification (atpD sequences).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10	Bacterial species: <i>Streptococcus agalactiae</i>			
	627	5'-ATT GTC TAT AAA AAT GGC GAT AAG TC	379-383 ^a	42-67 ^b
	625 ^c	5'-CGT TGA AGA CAC GAC CCA AAG TAT CC	379-383 ^a	206-231 ^b
15	628	5'-AAA ATG GCG ATA AGT CAC AAA AAG TA	379-383 ^a	52-77 ^b
	625 ^c	5'-CGT TGA AGA CAC GAC CCA AAG TAT CC	379-383 ^a	206-231 ^b
	627	5'-ATT GTC TAT AAA AAT GGC GAT AAG TC	379-383 ^a	42-67 ^b
20	626 ^c	5'-TAC CAC CTT TTA AGT AAG GTG CTA AT	379-383 ^a	371-396 ^b
	628	5'-AAA ATG GCG ATA AGT CAC AAA AAG TA	379-383 ^a	52-77 ^b
	626 ^c	5'-TAC CAC CTT TTA AGT AAG GTG CTA AT	379-383 ^a	371-396 ^b
25	Bacterial group: <i>Campylobacter jejuni</i> and <i>C. coli</i>			
	2131	5'-AAG CMA TTG TTG TAA ATT TTG AAA G	1576, 1600, 1849, 1863, 2139 ^{d,a}	7-31 ^e
	2132 ^c	5'-TCA TAT CCA TAG CAA TAG TTC TA	1576, 1600, 1849, 1863, 2139 ^{d,a}	92-114 ^e
30	Bacterial genus: <i>Bordetella</i> sp.			
	825	5'-ATG AGC ARC GSA ACC ATC GTT CAG TG	1672 ^d	1-26
	826 ^c	5'-TCG ATC GTG CCG ACC ATG TAG AAC GC	1672 ^d	1342-1367
35	Fungal genus: <i>Candida</i> sp.			
	634	5'-AAC ACY GTC AGR RCI ATT GCY ATG GA	460-472, 474-478 ^a	101-126 ^f
40	635 ^c	5'-AAA CCR GTI ARR GCR ACT CTI GCT CT	460-472, 474-478 ^a	617-642 ^f

^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the *S. agalactiae* *atpD* sequence fragment (SEQ ID NO. 380).

^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^d Sequence from databases.

^e The nucleotide positions refer to the *C. jejuni* *atpD* sequence fragment (SEQ ID NO. 1576).

^f The nucleotide positions refer to the *C. albicans* *atpD* sequence fragment (SEQ ID NO. 460).

Annex II: Specific and ubiquitous primers for nucleic acid amplification (*atpD* specific) (continued).

5	Originating DNA fragment		
	SEQ ID NO.	Nucleotide sequence	SEQ ID NO.
10 Universal primers			
562	5'-CAR ATG RAY GAR CCI CCI GGI GYI MGI ATG	243,244,262, 264,280,284, 291,297,309, 311,315,317, 324,329,332, 334-336,339, 342,343,351, 356,357,364- 366,370,375, 379,393 ^a	528-557 ^b
563 ^c	5'-GGY TGR TAI CCI ACI GCI GAI GGC AT	243,244,262, 264,280,284, 291,297,309, 311,315,317, 324,329,332, 334-336,339, 342,343,351, 356,357,364- 366,370,375, 379,393 ^a	687-712 ^b
564	5'-TAY GGI CAR ATG AAY GAR CCI CCI GGI AA	243,244,262, 264,280,284, 291,297,309, 311,315,317, 324,329,332, 334-336,339, 342,343,351, 356,357,364- 366,370,375, 379,393 ^a	522-550 ^b
565 ^c	5'-GGY TGR TAI CCI ACI GCI GAI GGD AT	243,244,262, 264,280,284, 291,297,309, 311,315,317, 324,329,332, 334-336,339, 342,343,351, 356,357,364- 366,370,375, 379,393 ^a	687-712 ^b

- 55 ^a These sequences were aligned to derive the corresponding primer.
^b The nucleotide positions refer to the *K. pneumoniae* *atpD* sequence fragment (SEQ ID NO. 317).
^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex II: Specific and ubiquitous primers for nucleic acid amplification (*atpD* sequences) (continued).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10 Universal primers (continued)				
	640	5'-TCC ATG GTI TWY GGI CAR ATG AA	248, 284, 315, 317, 343, 357, 366, 370, 379, 393 ^a	513-535 ^b
15	641 ^c	5'-TGA TAA CCW ACI GCI GAI GGC ATA CG	248, 284, 315, 317, 343, 357, 366, 370, 379, 393 ^a	684-709 ^b
20	642	5'-GGC GTI GGI GAR CGI ACI CGT GA	248, 284, 315, 317, 343, 357, 366, 370, 379, 393 ^a	438-460 ^b
	641 ^c	5'-TGA TAA CCW ACI GCI GAI GGC ATA CG	248, 284, 315, 317, 343, 357, 366, 370, 379, 393 ^a	684-709 ^b
25	Sequencing primers			
	566	5'-TTY GGI GGI GCI GGI GTI GGI AAR AC	669 ^d	445-470
30	567 ^c	5'-TCR TCI GCI GGI ACR TAI AYI GCY TG	669 ^d	883-908
	566	5'-TTY GGI GGI GCI GGI GTI GGI AAR AC	669 ^d	445-470
	814	5'-GCI GGC ACG TAC ACI GCC TG	666 ^d	901-920
35	568	5'-RTI ATI GGI GCI GTI RTI GAY GT	669 ^d	25-47
	567 ^c	5'-TCR TCI GCI GGI ACR TAI AYI GCY TG	669 ^d	883-908
	570	5'-RTI RYI GGI CCI GTI RTI GAY GT	672 ^d	31-53
	567 ^c	5'-TCR TCI GCI GGI ACR TAI AYI GCY TG	669 ^d	883-908
40	572	5'-RTI RTI GGI SCI GTI RTI GA	669 ^d	25-44
	567 ^c	5'-TCR TCI GCI GGI ACR TAI AYI GCY TG	669 ^d	883-908
	569	5'-RTI RTI GGI SCI GTI RTI GAT AT	671 ^d	31-53
45	567 ^c	5'-TCR TCI GCI GGI ACR TAI AYI GCY TG	669 ^d	883-908
	571	5'-RTI RTI GGI CCI GTI RTI GAT GT	670 ^d	31-53
	567 ^c	5'-TCR TCI GCI GGI ACR TAI AYI GCY TG	669 ^d	883-908

- 50 ^a These sequences were aligned to derive the corresponding primer.
 ^b The nucleotide positions refer to the *K. pneumoniae* *atpD* sequence fragment (SEQ ID NO. 317).
 ^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.
 ^d Sequences from databases.

Annex II: Specific and ubiquitous primers for nucleic acid amplification (atpD sequences) (continued).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10 Sequencing primers (continued)				
	700	5'-TIR TIG AYG TCG ART TCC CTC ARG	669 ^a	38-61
	567 ^b	5'-TCR TCI GCI GGI ACR TAI AYI GCY TG	669 ^a	883-908
15	568	5'-RTI ATI GGI GCI GTI RTI GAY GT	669 ^a	25-47
	573 ^b	5'-CCI CCI ACC ATR TAR AAI GC	666 ^a	1465-1484
	574	5'-ATI GCI ATG GAY GGI ACI GAR GG	666 ^a	283-305
20	573 ^b	5'-CCI CCI ACC ATR TAR AAI GC	666 ^a	1465-1484
	574	5'-ATI GCI ATG GAY GGI ACI GAR GG	666 ^a	283-305
	708 ^b	5'-TCR TCC ATI CCI ARI ATI GCI ATI AT	666 ^a	1258-1283
	681	5'-GGI SSI TTG GGI ISI GGI AAR AC	685	694-716
25	682 ^b	5'-GTI ACI GGY TCY TCR AAR TTI CCI CC	686	1177-1202
	681	5'-GGI SSI TTG GGI ISI GGI AAR AC	685	694-716
	683 ^b	5'-GTI ACI GGI TCI SWI AWR TCI CCI CC	685	1180-1205
30	681	5'-GGI SSI TTG GGI ISI GGI AAR AC	685	694-716
	699	5'-GTI ACI GGY TCY TYR ARR TTI CCI CC	686	1177-1202
	681	5'-GGI SSI TTG GGI ISI GGI AAR AC	685	694-716
35	812 ^b	5'-GTI ACI GGI TCY TYR ARR TTI CCI CC	685	1180-1205
	1213	5'-AAR GGI GGI ACI GCI GCI ATH CCI GG	714 ^a	697-722
	1212 ^b	5'-CCI CCI RGI GGI GAI ACI GCW CC	714 ^a	1189-1211
	1203	5'-GGI GAR MGI GGI AAY GAR ATG	709 ^a	724-744
40	1207 ^b	5'-CCI TCI TCW CCI GGC ATY TC	709 ^a	985-1004
	1204	5'-GCI AAY AAC ITC IWM YAT GCC	709 ^a	822-842
	1206 ^b	5'-CKI SRI GTI GAR TCI GCC A	709 ^a	926-944
45	1205	5'-AAV ACI TCI AWY ATG CCI GT	709 ^a	826-845
	1207 ^b	5'-CCI TCI TCW CCI GGC ATY TC	709 ^a	985-1004
	2282	5'-AGR RGC IMA RAT GTA TGA	714 ^a	84-101
50	2284 ^b	5'-TCT GWG TRA CIG GYT CKG AGA	714 ^a	1217-1237
	2283	5'-ATI TAT GAY GGK ITT CAG AGG C	714 ^a	271-292
	2285 ^b	5'-CMC CIC CWG GTG GWG AWA C	714 ^a	1195-1213

55 ^a Sequences from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex III: Internal hybridization probes for specific detection of tuf sequences.

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10	<u>Bacterial species:</u> <i>Abiotrophia adiacens</i>			
	2170	5'-ACG TGA CGT TGA CAA ACC A	1715	313-331
15	<u>Bacterial species:</u> <i>Chlamydia pneumoniae</i>			
	2089	5'-ATG CTG AAC TTA TTG ACC TT	20	136-155
	2090	5'-CGT TAC TGG AGT CGA AAT G	20	467-485
20	<u>Bacterial species:</u> <i>Enterococcus faecalis</i>			
	580	5'-GCT AAA CCA GCT ACA ATC ACT CCA C	62-63, 607 ^a	584-608 ^b
	603	5'-GGT ATT AAA GAC GAA ACA TC	62-63, 607 ^a	440-459 ^b
	1174	5'-GAA CGT GGT GAA GTT CGC	62-63, 607 ^a	398-415 ^b
25	<u>Bacterial species:</u> <i>Enterococcus faecium</i>			
	602	5'-AAG TTG AAG TTG TTG GTA TT	64, 608 ^a	426-445 ^c
30	<u>Bacterial species:</u> <i>Enterococcus gallinarum</i>			
	604	5'-GGT GAT GAA GTA GAA ATC GT	66, 609 ^a	419-438 ^d
	<u>Bacterial species:</u> <i>Escherichia coli</i>			
35	579	5'-GAA GGC CGT GCT GGT GAG AA	78	503-522
	2168	5'-CAT CAA AGT TGG TGA AGA AGT TG	78	409-431
40	<u>Bacterial species:</u> <i>Neisseria gonorrhoeae</i>			
	2166	5'-GAC AAA CCA TTC CTG CTG	126	322-339 ^e
	<u>Fungal species:</u> <i>Candida albicans</i>			
45	577	5'-CAT GAT TGA ACC ATC CAC CA	407-411 ^a	406-425 ^f
	<u>Fungal species:</u> <i>Candida dubliniensis</i>			
50	578	5'-CAT GAT TGA AGC TTC CAC CA	412, 414-415 ^a	418-437 ^g

^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the *E. faecalis* tuf sequence fragment (SEQ ID NO. 607).

^c The nucleotide positions refer to the *E. faecium* tuf sequence fragment (SEQ ID NO. 608).

^d The nucleotide positions refer to the *E. gallinarum* tuf sequence fragment (SEQ ID NO. 609).

^e The nucleotide positions refer to the *N. gonorrhoeae* tuf sequence fragment (SEQ ID NO. 126).

^f The nucleotide positions refer to the *C. albicans* tuf(EF-1) sequence fragment (SEQ ID NO. 408).

^g The nucleotide positions refer to the *C. dubliniensis* tuf(EF-1) sequence fragment (SEQ ID NO. 414).

Annex III: Internal hybridization probes for specific detection of tuf sequences (continued).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10	<u>Bacterial species:</u> <i>Haemophilus influenzae</i>			
	581	5'-ACA TCG GTG CAT TAT TAC GTG G	610 ^a	551-572
15	<u>Bacterial species:</u> <i>Mycoplasma pneumoniae</i>			
	2095	5'-CGG TCG GGT TGA ACG TGG	2097 ^a	687-704
20	<u>Bacterial species:</u> <i>Staphylococcus aureus</i>			
	584	5'-ACA TGA CAC ATC TAA AAC AA	176-180 ^b	369-388 ^c
	585	5'-ACC ACA TAC TGA ATT CAA AG	176-180 ^b	525-544 ^c
	586	5'-CAG AAG TAT ACG TAT TAT CA	176-180 ^b	545-564 ^c
	587	5'-CGT ATT ATC AAA AGA CGA AG	176-180 ^b	555-574 ^c
	588	5'-TCT TCT CAA ACT ATC GTC CA	176-180 ^b	593-612 ^c
25	<u>Bacterial species:</u> <i>Staphylococcus epidermidis</i>			
	589	5'-GCA CGA AAC TTC TAA AAC AA	185, 611 ^b	445-464 ^d
	590	5'-TAT ACG TAT TAT CTA AAG AT	185, 611 ^b	627-646 ^d
30	591	5'-TCC TGG TTC TAT TAC ACC AC	185, 611 ^b	586-605 ^d
	592	5'-CAA AGC TGA AGT ATA CGT AT	185, 611 ^b	616-635 ^d
	593	5'-TTC ACT AAC TAT CGC CCA CA	185, 611 ^b	671-690 ^d
35	<u>Bacterial species:</u> <i>Staphylococcus haemolyticus</i>			
	594	5'-ATT GGT ATC CAT GAC ACT TC	186, 188-190 ^b	437-456 ^e
	595	5'-TTA AAG CAG ACG TAT ACG TT	186, 188-190 ^b	615-634 ^e
40	<u>Bacterial species:</u> <i>Staphylococcus hominis</i>			
	596	5'-GAA ATT ATT GGT ATC AAA GA	191, 193-196 ^b	431-450 ^f
	597	5'-ATT GGT ATC AAA GAA ACT TC	191, 193-196 ^b	437-456 ^f
	598	5'-AAT TAC ACC TCA CAC AAA AT	191, 193-196 ^b	595-614 ^f

45 ^a Sequences from databases.

^b These sequences were aligned to derive the corresponding probe.

^c The nucleotide positions refer to the *S. aureus* tuf sequence fragment (SEQ ID NO. 179).

50 ^d The nucleotide positions refer to the *S. epidermidis* tuf sequence fragment (SEQ ID NO. 611).

^e The nucleotide positions refer to the *S. haemolyticus* tuf sequence fragment (SEQ ID NO. 186).

^f The nucleotide positions refer to the *S. hominis* tuf sequence fragment (SEQ ID NO. 191).

Annex III: Internal hybridization probes for specific detection of tuf sequences (continued).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10	<u>Bacterial species:</u> <i>Staphylococcus saprophyticus</i>			
	599	5'-CGG TGA AGA AAT CGA AAT CA	198-200 ^a	406-425 ^b
	600	5'-ATG CAA GAA GAA TCA AGC AA	198-200 ^a	431-450 ^b
	601	5'-GTT TCA CGT GAT GAT GTA CA	198-200 ^a	536-555 ^b
15	695	5'-GTT TCA CGT GAT GAC GTA CA	198-200 ^a	563-582 ^b
<u>Bacterial species:</u> <i>Streptococcus agalactiae</i>				
20	582 ^c	5'-TTT CAA CTT CGT CGT TGA CAC GAA CAG T	207-210 ^a	404-431 ^d
	583 ^c	5'-CAA CTG CTT TTT GGA TAT CTT CTT TAA TAC CAA CG	207-210 ^a	433-467 ^d
	1199	5'-GTA TTA AAG AAG ATA TCC AAA AAG C	207-210 ^a	438-462 ^d
<u>Bacterial species:</u> <i>Streptococcus pneumoniae</i>				
25	1201	5'-TCA AAG AAG AAA CTA AAA AAG CTG T	971,977, 979,986 ^a	513-537 ^e
<u>Bacterial species:</u> <i>Streptococcus pyogenes</i>				
30	1200	5'-TCA AAG AAG AAA CTA AAA AAG CTG T	1002	473-497
<u>Bacterial group:</u> <i>Enterococcus casseliflavus-flavescens-gallinarum group</i>				
35	620	5'-ATT GGT GCA TTG CTA CGT	58,65,66 ^a	527-544 ^f
	1122	5'-TGG TGC ATT GCT ACG TGG	58,65,66 ^a	529-546 ^f
<u>Bacterial group:</u> <i>Enterococcus sp., Gemella sp., A. adiacens</i>				
40	2172	5'-GTG TTG AAA TGT TCC GTA AA	58-62,67-71, 87-88,607-609, 727,871 1715,1722 ^a	477-496 ^g

^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the *S. saprophyticus* tuf sequence fragment (SEQ ID NO. 198).

^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^d The nucleotide positions refer to the *S. agalactiae* tuf sequence fragment (SEQ ID NO. 209).

^e The nucleotide positions refer to the *S. pneumoniae* tuf sequence fragment (SEQ ID NO. 986).

^f The nucleotide positions refer to the *E. flavescens* tuf sequence fragment (SEQ ID NO. 65).

^g The nucleotide positions refer to the *E. faecium* tuf sequence fragment (SEQ ID NO. 608).

Annex III: Internal hybridization probes for specific detection of tuf sequences (continued).

	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10	<u>Bacterial genus:</u>	Gemella		
	2171	5'-TCG TTG GAT TAA CTG AAG AA	87, 88 ^a	430-449 ^b
15	<u>Bacterial genus:</u>	Staphylococcus sp.		
	605	5'-GAA ATG TTC CGT AAA TTA TT	176-203 ^a	403-422 ^c
	606	5'-ATT AGA CTA CGC TGA AGC TG	176-203 ^a	420-439 ^c
	1175	5'-GTT ACT GGT GTA GAA ATG TTC	176-203 ^a	391-411 ^c
	1176	5'-TAC TGG TGT AGA AAT GTT C	176-203 ^a	393-411 ^c
20	<u>Bacterial genus:</u>	Streptococcus sp.		
	1202	5'-GTG TTG AAA TGT TCC GTA AAC A	206-231, 971, 977, 979, 982-986 ^a	466-487 ^d
25	<u>Fungal species:</u>	Candida albicans		
	1156	5'-GTT GAA ATG CAT CAC GAA CAA TT	407-412, 624 ^a	680-702 ^e
30	<u>Fungal group:</u>	Candida albicans and C. tropicalis		
	1160	5'-CGT TTC TGT TAA AGA AAT TAG AAG	407-412, 429, 624 ^a	748-771 ^e
35	<u>Fungal species:</u>	Candida dubliniensis		
	1166	5'-ACG TTA AGA ATG TTT CTG TCA A	414-415 ^a	750-771 ^f
	1168	5'-GAA CAA TTG GTT GAA GGT GT	414-415 ^a	707-726 ^f
40	<u>Fungal species:</u>	Candida glabrata		
	1158	5'-AAG AGG TAA TGT CTG TGG T	417	781-799
	1159	5'-TGA AGG TTT GCC AGG TGA	417	718-735
45	<u>Fungal species:</u>	Candida krusei		
	1161	5'-TCC AGG TGA TAA CGT TGG	422	720-737

^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the *G. haemolyans* tuf sequence fragment (SEQ ID NO. 87).

^c The nucleotide positions refer to the *S. aureus* tuf sequence fragment (SEQ ID NO. 179).

^d The nucleotide positions refer to the *S. pneumoniae* tuf sequence fragment (SEQ ID NO. 986).

^e The nucleotide positions refer to the *C. albicans* tuf(EF-1) sequence fragment (SEQ ID NO. 408).

^f The nucleotide positions refer to the *C. dubliniensis* tuf(EF-1) sequence fragment (SEQ ID NO. 414).

Annex III: Internal hybridization probes for specific detection of tuf sequences (continued).

		Originating DNA fragment		
5	SEQ ID NO.	Nucleotide sequence	SEQ ID NO.	Nucleotide position
10	<u>Fungal group:</u>		<i>Candida lusitaniae</i> and <i>C. guillermondii</i>	
	1162	5'-CAA GTC CGT GGA AAT GCA	418, 424 ^a	682-699 ^b
15	<u>Fungal species:</u>		<i>Candida parapsilosis</i>	
	1157	5'-AAG AAC GTT TCA GTT AAG GAA AT	426	749-771
	<u>Fungal species:</u>		<i>Candida zeylanoides</i>	
20	1165	5'-GGT TTC AAC GTG AAG AAC	432	713-730
	<u>Fungal genus:</u>		<i>Candida</i> sp.	
25	1163	5'-GTT GGT TTC AAC GTT AAG AAC	407-412, 414-415, 417, 418, 422, 429 ^a	728-748 ^c
	1164	5'-GGT TTC AAC GTC AAG AAC	413, 416, 420, 421, 424, 425, 426, 428, 431 ^a	740-757 ^b
30	1167	5'-GTT GGT TTC AAC GT	406-426, 428-432,	728-741 ^c 624 ^a

^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the *C. lusitaniae* tuf(EF-1) sequence fragment (SEQ ID NO. 424).

^c The nucleotide positions refer to the *C. albicans* tuf(EF-1) sequence fragment (SEQ ID NO. 408).

PAGE INTENTIONALLY LEFT BLANK

Annex IV: Strategy for the selection of amplification/sequencing primers from atpD (Fr-type) sequences.

The sequence numbering refers to the *Escherichia coli atpD* gene fragment (SEQ ID NO. 669). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences displayed.

"R" "Y" "M" "K" "W" and "S" designate nucleotide positions which are degenerated. "R" stands for A or G; "Y" stands for C or T; "M" stands for A or C; "K" stands for G or T; "W" stands for A or T; "S" stands for C or G. "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

40 * This sequence is the reverse-complement of the selected primer.

Annex V: Strategy for the selection of universal amplification/sequencing primers from atpD (V-type) sequences.

		SEQ ID NO.:	
5		691	719 1177 1208
	<i>E. hirae</i>	CC AGTCCGTT GGTGGAGGA AGACAGT . . . TCTGGTGGAG ATATCtctGA ACCACtGACT CA	
	<i>H. salinarum</i>	CC GGGGCCGTC GGGTCCGGGA AGACGGT . . . CCCGGGGGG ACTTtccGA GCCGGtCACC CA	
	<i>T. thermophilus</i>	CC TGGGCCCCTC GGCAGGGCA AGACCGT . . . CGGGGGGGCG ACatgttGA GCGCGtGACG CA	
10	Human	CC TGGGGCCGTC GGATGtGGCA AGACTGT . . . CCCGGtGGAG ACTtCtGA tCCCCTGACG AC	
	<i>T. congolense</i>	CC TGGCGGTtTT GGATGGGGAA AGACGGT . . . CCTGGAGGTtG ACTTTtctGA cCCAGtGACG TC	
	<i>P. falciparum</i>	CC TGGTGCATT GGTTGtGGAA AACTTG . . . CCAGGGtG ATTtCtctGA cCCtGTAACT AC	
	<i>C. pneumoniae</i>	CC AGGACCTTT GGtGtCAGGA AACAGT . . . GCAGGAGAA ACTtGAAGA ACCAGtCAGT CA	
15	Selected sequences for universal primers	GGTTTtTtTtGtttGtttAARAC	681
20	Selected sequences for universal primers*	GGGGGIA AYTtYARGA RCCtGtAC GGtCCtG AYTtWtSIGA ICCtGtAC	682 683
25		272	

The sequence numbering refers to the *Enterococcus hirae* *atpD* gene fragment (SEQ ID NO. 685). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches for SEQ ID Nos. 681 and 682 are indicated by lower-case letters. Mismatches for SEQ ID NO. 683 are indicated by underlined nucleotides. Dots indicate gaps in the sequences displayed.

"R" "Y" "M" "K" "W" and "S" designate nucleotide positions which are degenerated. "R" stands for C or T; "M" stands for A or C; "K" stands for G or T; "W" stands for A or T; "S" stands for C or G. "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

* These sequences are the reverse-complement of the selected primers.

Annex VI: Strategy for the selection of universal amplification/sequencing primers from tuf (M) sequences (organelle origin).

				SEQ ID Accession
5	C. neoformans ^a S. cerevisiae O. volvulus Human ^d	601	635 1479	NO. : #: U81803 X00779 M64333 X03558
10	G. max B1b G. max B2b E. coli S. aureofaciens ^c	635	AGAA CATGATCACC GGTAACCTCCC AGgtGA <u>T</u> CG... CGCggTCCGA GAcatGGCAC AGACCGTTGC CGT AGAA CATGATTACT GTGACTTCG... CGCTggTCA <u>G</u> AGtGAGAC GAcatGGAC AAACGTTGC TGT AGAA TATGATCACA GGACATTC <u>T</u> CG... CGCTggTCA <u>G</u> AGtGAGAC GAtatGGAC AAACGTTGC GGT AAAAA CATGATTACA GGACATTC <u>T</u> CG... CGCTggTCA <u>G</u> AGtGAGAC GAtatGGAC AAACGTTGC TGT	665 - - -
15	E. tenella ^b T. gondii ^b S. cerevisiae ^b A. thaliana ^b	635	AGAA CATGATCACC GGCGCTGCC AGATGGACGG... TGCTATTAGA CAAGGGGGCA AAACGTTGC AAAAA CATGATCACC GGCGCCGCC AGATGGACGG... TGCTATTAGA CAAGGGGGCA AAACGTTGC AAAAA CATGATCACC GGTCGCTGTC AGATGGACGG... CGCAATTCGT GAAGGGGGCC GTACCGTTGG CGC AAAAA TATGATTACA GGACCGGCC AGATGGACGG... CGCCATTCGT GAAGGGGGTC GTACCGTTGG CGC	- Y15107 Y15108 AF007125 AI755521
20	Selected sequences for universal primers	635	AA TATGATTACT GGAGCTGGCC AAATGGATGG... TGCTATTAGA CAAGGGGGTC GTACCGTTGG AGC AA TATGATTACT GGAGCTGGCC AAATGGATGG... TGCTATTAGA CAAGGGGGTC GTACCGTTGG AGC AA TATGATTACT GGAGCTGGCC AAATGGATGG... CAATAATAGA GAGGGTGGAA GAACGTTGG TAC AAAAA TATGATTACT GGAGCTGGCC AAATGGATGG... TGCCctTAAGG GAAGGGGCTTAAGG GAACGAGGTA AGC	619 - - X89227
25	Selected sequences for universal primers	635	TATIAGR GARGGGGIM RIACTR ^d WGG ATCCGT GAGGGGGCC GITCIGTd	652 561
30	The sequence numbering refers to the <i>Saccharomyces cerevisiae tuf (M)</i> gene (SEQ ID NO. 619). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches for SEQ ID NOS. 652 and 664 are indicated by lower-case letters. Mismatches for SEQ ID NO. 561 are indicated by underlined nucleotides. Dots indicate gaps in the sequences displayed.	635	"R" "Y" "M" "K" "W" and "S" designate nucleotide positions which are degenerated. "R" stands for A or G; "Y" stands for C or T; "M" stands for A or C; "K" stands for G or T; "W" stands for A or T; "S" stands for C or G. "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.	664
35	^a This sequence refers to <i>tuf</i> (EF-1) gene. ^b This sequence refers to <i>tuf</i> (M) or organelle gene. ^c This sequence refers to <i>tuf</i> gene from bacteria. ^d These sequences are the reverse-complement of the selected primers.	635		

Annex VII: Strategy for the selection of eukaryotic sequencing primers from tuf (EF-1) sequences.

		SEQ ID	Accession NO.:
5		154	665 X00779
	S. cerevisiae	GG TTCTTCAAG TAGGCTGGG TTTT...AGACA TTTCATCAAG AACATGATTAA CTGG...	- D64080
	B. hominis	GG CTCCCTCAAG TAGGGGTGGG TGCT...CGTGA CTTCATCAAAG AACATGATCA CGGG...	- M29934
	C. albicans	GG TTCTTCAAA TAGGCTGGG TCTT...AGAGA TTTCATCAAG AACATGATCA CTGG...	- U81803
10	C. neoformans	TC TTCTTCAAG TAGGCTGGG TTCT...CGAGA TTTCATCAAG AACATGATCA CCGG...	- M92073
	E. histolytica	GG ATCATTCAAA TAGGCTGGG TCTT...AGAGA TTTCATTAAG AACATGATTAA CTGG...	- D14342
	G. lamblia	GG CTCCCTCAAG TAGGCTGGG TCCT...CGCGA CTTCATCAAG AACATGATCA CGGG...	- U14100
	H. capsulatum	AA ATCCCTCAAA TAGGCTGGG TCCT...CGTGA CTTCATCAAG AACATGATCA CTGG...	- X03558
	Human	GG CTCCCTCAAG TAGGCTGGG TCTT...AGAGA CTTTATCAA AACATGATTAA CAGG...	- U72244
	L. braziliensis	GC GTCCCTCAAG TAGGCTGGG TGCT...CGCGA CTTCATCAAG AACATGATCA CCGG...	- M64333
	O. volvulus	GG CTCATTTAAA TAGGCTGGG TATT...CGTGA TTTCATTAAG AACATGATCA CAGG...	- AJ224150
	P. berghei	GG TagTTTCAAA TAGGATGGG TTTT...AAAC <u>A</u> TTTTATAAA AACATGATTAA CTGG...	- AJ224153
	P. knowlesi	GG AagtTTTAAAG TAGGCATGGG TGTT...AAGGA TTTCATCAA AACATGATTAA CCGG...	- U42189
	S. pombe	GG TTCCCTCAAG TAGGCTGGG TTTT...CGTGA TTTCATCAAG AACATGATTAA CCGG...	- L76077
20	T. cruzi	TC TTCTTCAAG TAGGCTGGG TCCT...CGCGA CTTCATCAAG AACATGATCA CGGG...	- AE054510
	Y. lipolytica	GG TTCTTCAAG TAGGCTGGG TTCT...CGAGA TTTCATCAAG AACATGATCA CGGG...	-

Selected sequences for
amplification primers

TCITTYAAR TAYGCITGGG T
GA YTTCATYAAR AAYATGATYA C

SEQ ID
NO.:

558
560
653

30 The sequence numbering refers to the *Saccharomyces cerevisiae* tuf (EF-1) gene fragment (SEQ ID NO. 665). Nucleotides in capitals are identical to the selected sequences SEQ ID NOs. 558, 560 or 653, or match those sequences. Mismatches for SEQ ID no. 558 and 560 are indicated by lower-case letters. Mismatches for SEQ ID NO. 653 are indicated by underlined nucleotides. Dots indicate gaps in the sequences displayed.

35 "R" "Y" "M" "K" "W" and "S" designate nucleotide positions which are degenerated. "R" stands for A or G; "Y" stands for C or T; "M" stands for A or C; "K" stands for G or T; "W" stands for A or T; "S" stands for C or G. "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

Annex VII: Strategy for the selection of eukaryotic sequencing primers from tuf (EF-1) sequences (continued).

		SEQ ID Accession NO. : #:
5	751	1304
S. cerevisiae	... GTTACAA GATCGGTGGT ATGGTAC... GACATG AGACAAACTG TCGCTGTGG TGT	665 X00779
B. hominis	... GTGACAA GATTGGGGT ATGGTAC... GATATG AGACAGACTG TCGCTGTGG TAT	- D64080
C. albicans	... GTTACAA GATCGGTGGT ATGGTAC... GATATG AGACAAACCG TTGCTGTGG TGT	- M29934
10 C. neoformans	... GTCTACAA GATCGGTGGT ATCGGCAC... GACATG CGACAGACCG TTGCGGTGG TGT	- U81803
E. histolytica	... GTTACAA GATTGAGGT ATGGTAC... GATATG AACAAACCG TTGCTGTGG AGT	- M92073
G. lamblia	... GTCTACAA GATCTGGCC GTCGGGAC... ~~~~~~	- D14342
H. capsulatum	... GTGACAA AATCTctGGT ATGGTAC... GACATG AGACAAACCG TCGCTGTGG TGT	- U14100
Human	... GTCTACAA AATTGGTGGT ATGGTAC... GATATG AGACAGACAG TTGCGGTGG TGT	- X03558
15 L. braziliensis	... GTGACAA GATCGGGGT ATCGGCAC... GACATG CGCAGAACCG TTGCGGTGG CAT	- U72244
O. volvulus	... GTTACAA AATTGGAGGT ATGGTAC... GATATG AGACAAACAG TTGCTGTGG CGT	- M64333
P. berghei	... GTATACAA AATTGGTGGT ATGGTAC... GATATG AGACAAACAA TTGCTGTGG TAT	- AJ224150
P. knowlesi	... GTATACAA AATCGGTGGT ATGGTAC... GATATG AGACAAACCA TTGCTGTGG TAT	- AJ224153
S. pombe	... GTTACAA GATCGGTGGT ATGGTAC... GACATG CGTCAAACCG TCGCTGTGG TGT	- U42189
20 T. cruzi	... GTGACAA GATCGGGGT ATCGGCAC... GACATG CGCCAGACGG TCGCGGTGG CAT	- L76077
Y. lipolytica	... GTCTACAA GATCGGTGGT ATCGGCAC... GACATG CGACAGACCG TTGCTGTGG TGT	- AF054510

Selected sequence for
amplification primer

TACAA RATYKGIGGT ATYGG

654

25 Selected sequences for
amplification primers*

TACAA RATYKGIGGT ATYGG

655
559

30 The sequence numbering refers to the *Saccharomyces cerevisiae tuf (EF-1)* gene fragment (SEQ ID NO. 665). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. "—" indicate incomplete sequence data. Dots indicate gaps in the sequences displayed.

"R" "Y" "M" "K" "W" and "S" designate nucleotide positions which are degenerated. "R" stands for A or G; "Y" 35 stands for C or T; "M" stands for A or C; "K" stands for G or T; "W" stands for C or G. "If" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

* This sequences are the reverse-complement of the selected primers.

Annex VII: Strategy for the selection of Streptococcus agalactiae-specific amplification primers from tuf sequences.

		SEQ ID NO.:	Accession #:
5	<i>S. agalactiae</i>	334	517
	<i>S. agalactiae</i>	CCAGAA CGTGATACTG ACAAACCTT ACTT...GGAC AACGTGGTG TCTCTTCG TG	207
	<i>S. agalactiae</i>	CCAGAA CGTGATACTG ACAAACCTT ACTT...GGAC AACGTGGTG TCTCTTCG TG	208
	<i>S. agalactiae</i>	CCAGAA CGTGATACTG ACAAACCTT ACTT...GGAC AACGTGGTG TCTCTTCG TG	209
10	<i>S. anginosus</i>	CCAGAA CGTGATACTG ACAAACCTT ACTT...GGAC AACGTGGTG TCTCTTCG TG	210
	<i>S. anginosus</i>	CCAGAA CGTGATACTG ACAAACCTT GCTT...AGAT AACGTGGG TCTCTTCG TG	211
	<i>S. bovis</i>	CCAGAA CGTGATACTG ACAAACCTT GCTT...AGAT AACGTGGG TCTCTTCG TG	221
	<i>S. gordoni</i>	CCAGAA CGTGACAATG ACAAACCTT GCTT...GGAT AACGTGGG TCTCTTCG TG	212
	<i>S. mutans</i>	CCAGAA CGTGATACTG ACAAGCCGT CCTT...GGAT AACGTGGG TCTCTTCG TG	223
15	<i>S. pneumoniae</i>	CCAGAA CGTGACAATG ACAAACCTT GCTT...AGAT AACGTGGG TCTCTTCG TG	224
	<i>S. sanguinis</i>	CCAGAA CGCGATACTG ACAAGCCATT GCTT...GGAC AACGTGGG TCTCTTCG TG	145 ^a
	<i>S. sobrinus</i>	CCAGAA CGCGATACTG ATAAGCCATT GCTT...AGAT AACGTGGG TCTCTTCG TG	227
	<i>B. cepacia</i>	CCGGAG CGTGcgatTT ACGGCCTT CCTG...CGAC AACGTGGG TCTCTTCG CG	16
	<i>B. fragilis</i>	CCTccg CGGcgatTT ATAACCTT cttG...TGAC AACGTGGG TCTCTTCG TG	-
	<i>B. subtilis</i>	CCAGAA CGGCGACATC AAAAACATT CATG...TGAC AACGTGGG TCTCTTCG CG	299104
20	<i>C. diphtheriae</i>	CCAGAG CGTGAGACCG ACAAGCCATT CCTC...CGAC AACGTGGG TCTCTTCG TG	662
	<i>C. trachomatis</i>	CCAGAA agacaattG ACAAGCCTT CTTA...AGAG AACGTGGG TCTCTTCG AG	22
	<i>E. coli</i>	CCAGAG CGTGcgatTG ACAAGCCGT CCTG...TGAG AACGTGGG TCTCTTCG TG	78
	<i>G. vaginalis</i>	CCAGCT CACGATctTG ACAAGCCATT CTG...CGAT RACacTGGTC TCTCTTCG CG	135 ^a
25	<i>S. aureus</i>	CCAGAA CGTGATtcTG ACAAACATT CATG...TGAC AACGTGGG catatracc TG	-

Selected sequence for species-specific primer

GAA CGTGATACTG ACAAACCTT A

549

Selected sequence for species-specific primer^b

C AACGTGGTG TCTCTTC

550

The sequence numbering refers to the *Streptococcus agalactiae tuf* gene fragment (SEQ ID No. 209). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences displayed.

"R" "Y" "W" "K" "W" and "S" designate nucleotide positions which are degenerated. "R" stands for A or G; "Y" stands for C or T; "M" stands for A or C; "K" stands for G or T; "W" stands for A or T; "S" stands for C or G. "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

40 ^a The SEQ ID NO. refers to previous patent publication WO98/20157.
^b This sequence is the reverse-complement of the selected primer.

Annex IX: Strategy for the selection of *Streptococcus agalactiae*-specific hybridization probes from tuf sequences.

Selected sequences for species-specific hybridization probes.

ACTGT TCGTGTCAAC GACCGAAGTTG AAA

CGTTGG TATTAAAGAA GATATCCAAA AAGCAGTTC

The sequence numbering refers to the *Streptococcus agalactiae tuf* gene fragment (SEQ ID NO. 209). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences displayed.

The SEQ ID NO. refers to previous patent publication WO98/20157. These sequences are the reverse-complement of the selected probes.

2

Annex X: Strategy for the selection of *Streptococcus* amplification primers from atpD sequences.

The sequence numbering refers to the *Streptococcus agalactiae tuf* gene fragment (SEQ ID NO. 380). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences displayed. 40 ..d.. These sequences were obtained from Genbank and have accession #: a=AB009314, d=AF001955, e=U31170, and f=V00311.

40 These sequences were obtained from Genbank and have accession #: a=AB009314, b=EF001955, c=AF001170, and d=EF003111.

^{b,c} These sequences were obtained from genome sequencing projects.

These sequences are the reverse-complement of the selected Primers.

I: Strategy for the selection of *Candida albicans/dubliniensis*-specific amplification primers, *Candida albicans*-specific hybridization probe and *Candida dubliniensis*-specific hybridization probe from tuf sequences.

30 Selected sequence for species-specific amplification primers: 5'-AGGAGCTTCGTTACAAAG-3'

35

Selected sequences
for species-specific
amplification primer.^b

Selected sequences
for species-specific
hybridization probes

The sequence numbering refers to the *Candida albicans* tuf gene fragment (SEQ ID NO. 408). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches for SEQ ID NO 577 are indicated by lower-case letters. Mismatches for SEQ ID NO. 578 are indicated by underlined nucleotides. Dots indicate gaps in the sequences displayed. "R" stands for A or G; "Y" stands for C or T; "M" stands for "R" or "W"; "K" and "S" designate nucleotide positions which are degenerated. "W" stands for A or T; "S" stands for C or G. "T" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

• *C. albicans* primers have been described in a previous patent (publication WO98/20157, SEQ ID NOS. 11-12)

^a this sequence is the reverse-complement of the selected primer.

Annex XII: Strategy for the selection of *Staphylococcus*-specific amplification primers from tuf sequences.

		SEQ ID NO.:	Accession #:	
5	<i>S. aureus</i>	340	652	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	179	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	176	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	177	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	180	-	
10	<i>S. auricularis</i>	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	181	-
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	182	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	183	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	184	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	185	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	141*	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	186	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	188	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	189	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	191	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	193	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	194	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	195	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	196	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	197	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	198	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	199	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	200	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	201	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	187	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	192	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	202	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	-	299104	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	78	-	
	A CAGGCCGTG TGAACTGGT CAATCAAG...CACTTACCA GAAGCTACTG AAATGGTAAAT GC	138*	-	
20	<i>S. hominis</i>	35	selected sequence for genus-specific primer	
	Selected sequences for genus-specific primers	553	575	
25	<i>S. saprophyticus</i>		TTACCA GAAGCTACTG AAATGGTAA	
	<i>S. saprophyticus</i>		TTACCA GAAGCTACTG AAATGGTAA	
	<i>S. sciuri</i>			
	<i>S. sciuri</i>			
	<i>S. warneri</i>			
	<i>S. warneri</i>			
30	<i>B. subtilis</i>	40		
	<i>E. coli</i>			
	<i>L. monocytogenes</i>			

The sequence numbering refers to the *Staphylococcus aureus* tuf gene fragment (SEQ ID NO. 179). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. "-" indicate incomplete sequence data. Dots, indicate gaps in the sequences displayed.

45 "R" "Y" "M" "K" "W" and "S" designate nucleotide positions which are degenerated. "R" stands for A or G; "Y" stands for C or T; "M" stands for A or C; "K" stands for G or T; "W" stands for A or T; "S" stands for C or G. "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

* The SEQ ID NO. refers to previous Patent Publication WO98/20157. These sequences are the reverse-complement of the selected primers.

**Annex XIII: Strategy for th selection of the
Staphylococcus-sp cific hybridization prob
from tuf sequences.**

5

	400	425	SEQ ID NO.:	Accession #:
	G TTGAAATGTT CCGTAAATTa TTAGA		179	-
10	G TTGAAATGTT CCGTAAATTa TTAGA		176	-
	G TTGAAATGTT CCGTAAATTa TTAGA		177	-
	G TTGAAATGTT CCGTAAATTa TTAGA		178	-
	G TTGAAATGTT CCGTAAATTa TTAGA		180	-
	G TAGAAATGTT CCGTAAATTa TTAGA		181	-
15	G TAGAAATGTT CCGTAAATTa TTAGA		182	-
	G TAGAAATGTT CCGTAAATTa TTAGA		183	-
	G TAGAAATGTT CCGTAAATTa TTAGA		184	-
	G TAGAAATGTT CCGTAAATTa TTAGA		185	-
	G TAGAAATGTT CCGTAAATTa TTAGA		186	-
20	G TAGAAATGTT CCGTAAATTa TTAGA		189	-
	G TAGAAATGTT CCGTAAATTa TTAGA		190	-
	G TAGAAATGTT CCGTAAATTa TTAGA		188	-
	G TAGAAATGTT CCGTAAATTa TTAGA		196	-
	G TAGAAATGTT CCGTAAATTa TTAGA		194	-
25	G TAGAAATGTT CCGTAAATTa TTAGA		191	-
	G TAGAAATGTT CCGTAAATTa TTAGA		193	-
	G TAGAAATGTT CCGTAAATTa TTAGA		195	-
	G TAGAAATGTT CCGTAAATTa TTAGA		197	-
	G TAGAAATGTT CCGTAAATTa TTAGA		198	-
30	G TAGAAATGTT CCGTAAATTa TTAGA		200	-
	G TAGAAATGTT CCGTAAATTa TTAGA		199	-
	G TTGAAATGTT CCGTAAATTa TTAGA		201	-
	G TAGAAATGTT CCGTAAGTTa TTAGA		187	-
	G TAGAAATGTT CCGTAAGTTa TTAGA		192	-
35	G TAGAAATGTT CCGTAAGTTa TTAGA		202	-
	G TAGAAATGTT CCGTAAGTTa TTAGA		203	-
	G TTGAAATGTT CCGTAAGcTt cTTGA		-	299104
	G TTGAAATGTT CCGcAAAACtg cTGGA		78	-
	G TAGAAATGTT CCGTAAATTa cTAGA		138*	-
40	Selected sequence for genus-specific hybridization probe	GAAATGTT CCGTAAATTa TT	605	

45 The sequence numbering refers to the *Staphylococcus aureus* tuf gene fragment (SEQ ID NO. 179). Nucleotides in capitals are identical to the selected sequence or match that sequence. Mismatches are indicated by lower-case letters.

50 * The SEQ ID NO. refers to previous patent publication WO98/20157.

Annex XIV: Strategy for the selection of *Staphylococcus saprophyticus*-specific and of *Staphylococcus haemolyticus*-specific hybridization probes from tuf sequences.

5

		SEQ ID
10		339
	<i>S. aureus</i>	383 NO.:
	<i>S. aureus</i>	179
	<i>S. aureus</i>	176
	<i>S. aureus</i>	177
	<i>S. aureus</i>	178
15	<i>S. aureus aureus</i>	180
	<i>S. auricularis</i>	181
	<i>S. capitis capitis</i>	182
	<i>M. caseolyticus</i>	183
	<i>S. cohnii</i>	184
20	<i>S. epidermidis</i>	185
	<i>S. haemolyticus</i>	186
	<i>S. haemolyticus</i>	189
	<i>S. haemolyticus</i>	190
	<i>S. haemolyticus</i>	188
25	<i>S. hominis</i>	194
	<i>S. hominis hominis</i>	191
	<i>S. hominis</i>	193
	<i>S. hominis</i>	195
	<i>S. hominis</i>	196
30	<i>S. lugdunensis</i>	197
	<i>S. saprophyticus</i>	198
	<i>S. saprophyticus</i>	200
	<i>S. saprophyticus</i>	199
	<i>S. sciuri sciuri</i>	201
35	<i>S. warneri</i>	187
	<i>S. warneri</i>	192
	<i>S. warneri</i>	202
	<i>S. warneri</i>	203
	<i>B. subtilis</i>	"
40	<i>E. coli</i>	78
	<i>L. monocytogenes</i>	138 ^b
	Selected sequences for species-specific hybridization probes	
45	CGGTGAAGA AATCGAAATC A (<i>S. saprophyticus</i>) (<i>S. haemolyticus</i>) ATTGGTATCC ATGACACTTC	599 594

The sequence numbering refers to the *Staphylococcus aureus* tuf gene fragment (SEQ ID NO. 179). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters.

^a This sequence was obtained from Genbank accession #Z99104.

^b The SEQ ID NO. refers to previous patent publication WO98/20157.

Annex XV: Strategy for the selection of *Staphylococcus aureus*-specific and of *Staphylococcus epidermidis*-specific hybridization probes from tuf sequences.

5

		SEQ ID NO.:
10	<i>S. aureus</i>	521 592 617 NO.:
	<i>S. aureus</i>	TACACCACA TACTGAATTC AAAGCAG... TTCTTCTca AACTATCGtc CACAATT 179
	<i>S. aureus</i>	TACACCACA TACTGAATTC AAAGCAG... TTCTTCTc ----- ----- 178
	<i>S. aureus</i>	TACACCACA TACTGAATTC AAAGCAG... TTCTTCTca AACTATCGtc CACAATT 176
	<i>S. aureus</i>	TACACCACA TACTGAATTC AAAGCAG... TTCTTCTca AACTATCGtc CACAATT 177
15	<i>S. aureus aureus</i>	TACACCACA TACTGAATTC AAAGCAG... TTCTTCTca AACTATCGtc CACAATT 180
	<i>S. auricularis</i>	TACACCACA CACTaAATTC ActGCAG... TTCTTCTCT AACTACCGtc CACAATT 181
	<i>S. capitis capitis</i>	CACACCACA CACTaAATTC AAAGCGG... TTCTTCAGt AACTACCGGCC CACAATT 182
	<i>M. caseolyticus</i>	TACTCCACA TACTaAATTC AAAGCTG... TTCTTCACT AACTACCGGCC CtCAGTT 183
	<i>S. cohnii</i>	TACACCACA CACaaAcTTT AAAGCGG... TTCTTCAGt AACTACCGGCC CACAATT 184
20	<i>S. epidermidis</i>	TACACCACA CACaaAATTC AAAGCTG... TTCTTCACT AACTACCGGCC CACAATT 185
	<i>S. haemolyticus</i>	CACACCTCA CACaaAATTt AAAGCAG... TTCTTCACA AACTATCGtc CACAATT 186
	<i>S. haemolyticus</i>	CACACCTCA CACaaAATTt AAAGCAG... TTCTTCACA AACTATCGtc CACAATT 189
	<i>S. haemolyticus</i>	CACACCTCA CACaaAATTt AAAGCAG... TTCTTCACA AACTATCGtc CACAATT 190
	<i>S. hominis</i>	TACACCTCA CACaaAATTC AAAGCAG... TTCTTCACT AACTATCGtc CACAATT 188
25	<i>S. hominis</i>	CACACCTCA CACaaAATTC AAAGCAG... TTCTTCACT AACTATCGtc CACAATT 195
	<i>S. hominis hominis</i>	TACACCTCA CACaaAATTC AAAGCAG... TTCTTCACT AACTATCGtc CACAATT 196
	<i>S. hominis</i>	TACACCTCA CACaaAATTC AAAGCAG... TTCTTCCT AACTATCGtc CACAATT 191
	<i>S. hominis</i>	TACACCTCA CACaaAATTC AAAGCAG... TTCTTCCT AACTATCGtc CACAATT 193
	<i>S. lugdunensis</i>	TACACCTCA CACTaAATTt AAAGCTG... TTCTTCACA AACTACCGGCC CACAATT 197
30	<i>S. saprophyticus</i>	TACACCACA TACaaAATTC AAAGCGG... TTCTTCACT AACTACCGGCC CACAATT 198
	<i>S. saprophyticus</i>	TACACCACA TACaaAATTC AAAGCGG... TTCTTCACT AACTACCGGCC CACAATT 199
	<i>S. saprophyticus</i>	TACACCACA TACaaAATTC AAAGCGG... TTCTTCACT AACTACCGGCC CACAATT 200
	<i>S. sciuri sciuri</i>	CACACCTCA CACTaAATTC AAAGCTG... TTCTTCACA AACTACCGGCC CACAATT 201
	<i>S. warneri</i>	TACACCACA TACaaAATTC AAAGCGG... ----- ----- 192
35	<i>S. warneri</i>	TACACCACA TACaaAATTC AAAGCGG... TTCTTCAGt AACTACCGGCC CACAATT 187
	<i>S. warneri</i>	TACACCACA TACaaAATTC AAAGCGG... TTCTTCAGt AACTACCGGCC CACAATT 202
	<i>S. warneri</i>	TACACCACA TACaaAATTC AAAGCGG... TTCTTCAGt AACTACCGGCC CACAATT 203
	<i>B. subtilis</i>	CACtCCACA cAGcaAATTC AAAGCTG... TTCTTCCT AACTACCGtc CtCAGTT - ^a
	<i>E. coli</i>	CAAGCCgCA CACcaAgTTC gAACTG... TTCTTCAAA ggCTACCGtc CgCAGTT 78
40	<i>L. monocytogenes</i>	TACTCCACA CACTaAcTTC AAAGCTG... TTCTTCAAc AACTACCGGCC CACAATT 138 ^b
	Selected sequences for species-specific hybridization probes	
45	ACCACA TACTGAATTC AAAG (<i>S. aureus</i>) (<i>S. epidermidis</i>) TTCACT AACTATCGCC CACA	585 593

The sequence numbering refers to the *Staphylococcus aureus* tuf gene fragment (SEQ ID NO. 179). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. "-" indicate incomplete sequence data. Dots indicate gaps in the sequences displayed.

^a This sequence was obtained from Genbank accession #Z99104.

^b The SEQ ID NO. refers to previous patent publication WO98/20157.

**Ann x XVI: Strategy for the selection of the
Staphylococcus hominis-specific hybridization
probe from tuf species.**

5

		358	383	SEQ ID NO.:
	<i>S. aureus</i>	ATC ATcGGTtTac AtGAcACaTC	TAA	179
10	<i>S. aureus</i>	ATC ATcGGTtTac AtGAcACaTC	TAA	176
	<i>S. aureus</i>	ATC ATcGGTtTac AtGAcACaTC	TAA	177
	<i>S. aureus</i>	ATC ATcGGTtTac AtGAcACaTC	TAA	178
	<i>S. aureus aureus</i>	ATC ATcGGTtTac AtGAcACaTC	TAA	180
	<i>S. auricularis</i>	ATC ATcGGTATgA AAGAcggTTC	AAA	181
15	<i>S. capitis capitis</i>	ATC ATcGGTATCc AcGAAAActTC	TAA	182
	<i>M. caseolyticus</i>	ATC ATTGGTtTaA ctGAAgaacC	AAA	183
	<i>S. cohnii</i>	ATC ATcGGTATgc AAGAAgaATTC	CAA	184
	<i>S. epidermidis</i>	ATC ATcGGTATgc AcGAAAActTC	TAA	185
	<i>S. haemolyticus</i>	ATC ATTGGTATCc AtGAcACTTC	TAA	186
20	<i>S. haemolyticus</i>	ATC ATTGGTATCc AtGAcACTTC	TAA	189
	<i>S. haemolyticus</i>	ATC ATTGGTATCc AtGAcACTTC	TAA	190
	<i>S. haemolyticus</i>	ATT ATTGGTATCA AAGAAAActTC	TAA	188
	<i>S. hominis</i>	ATT ATTGGTATCA AAGAtACTTC	TAA	196
	<i>S. hominis</i>	ATT ATTGGTATCA AAGAAAActTC	TAA	194
25	<i>S. hominis hominis</i>	ATT ATTGGTATCA AAGAAAActTC	TAA	191
	<i>S. hominis</i>	ATT ATTGGTATCA AAGAAAActTC	TAA	193
	<i>S. hominis</i>	ATT ATTGGTATCA AAGAAAActTC	TAA	195
	<i>S. lugdunensis</i>	ATT ATTGGTATCc AcGAtACTaC	TAA	197
	<i>S. saprophyticus</i>	ATC ATcGGTATgc AAGAAgaATC	CAA	198
30	<i>S. saprophyticus</i>	ATC ATcGGTATgc AAGAAgaATC	CAA	200
	<i>S. saprophyticus</i>	ATC ATcGGTATgc AAGAAgaATC	CAA	199
	<i>S. sciuri sciuri</i>	ATC ATcGGTtTaA ctGAAgaatC	TAA	201
	<i>S. warneri</i>	ATC ATcGGTtTac AtGAcACTTC	TAA	187
	<i>S. warneri</i>	ATC ATcGGTtTac AtGAcACTTC	TAA	192
35	<i>S. warneri</i>	ATC ATcGGTtTac AtGAcACTTC	TAA	202
	<i>S. warneri</i>	ATC ATcGGTtTac AtGAcACTTC	TAA	203
	<i>B. subtilis</i>	ATC ATcGGTcTtc AAGAAgagag	AAA	- ^a
	<i>E. coli</i>	ATC gTTGGTATCA AAGAgACTca	GAA	78
	<i>L. monocytogenes</i>	GTT ATcGGTATCg AAGAAgasag	AAA	138 ^b
40	Selected sequence for species-specific hybridization probe	ATTGGTATCA AAGAAAActTC		597

45 The sequence numbering refers to the *Staphylococcus aureus* tuf gene fragment (SEQ ID NO. 179). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences displayed.

50 ^a This sequence was obtained from Genbank accession #Z99104.
^b The SEQ ID NO. refers to previous patent publication WO98/20157.

Annex XVII: Strategy for the selection of the Enterococcus-specific amplification primers from tuf sequences.

			SEQ ID NO.:	Accession #:
5	E. avium	270	298	556
	E. casseliflavus	TAGAATTAT GGCTGCAGTT GACGAATAAT.	TGAA GATATCCAAC GTGGACAACT ATT	131*
	E. cecorum	TCGAATTAT GGCTGCAGTT GACGAATAAC.	TGAA GACATCCAAC GTGGACAACT ATT	58
	E. dispar	TAGAATTAT GGCTGCAGTT GACGAATAAC.	TGAA GATATCCAAC GTGGACAACT ATT	59
10	E. durans	TAGAATTAT GGCTGCAGTT GACGAATAAT.	TGAA GATATCCAAC GTGGACAACT ATT	60
	E. flavescentis	TGGAATTAT GGCTGCAGTT GACGAATAAC.	TGAA GACATCCAAC GTGGACAACT ATT	61
	E. faecium	TGGAATTAT GGCTGCAGTT GACGAATAAC.	TGAA GACATCCAAC GTGGACAACT ATT	65
	E. faecalis	TAGAATTAT GGCTGCAGTT GACGAATAAT.	TGAA GATATCCAAC GTGGACAACT ATT	608
	E. gallinarum	TGGAATTAT GGCTGCAGTT GACGAATAAC.	TGAA GACATCCAAC GTGGACAACT ATT	607
	E. hirae	TGCAATTAT GGCTGCAGTT GACGAATAAT.	TGAA GACATCCAAC GTGGACAACT ATT	609
15	E. mundtii	TGGAATTAT GGCTGCAGTT GACGAATAAT.	TGAA GACATCCAAC GTGGACAACT ATT	67
	E. pseudoavium	TGGAATTAT GSCTGCAGTT GACGAATAAC.	TGAA GACATCCAAC GTGGACAACT ATT	68
	E. raffinosus	TAGAATTAT GGCTGCAGTT GATGAATAAC.	TGAA GACATCCAAC GTGGACAACT ATT	69
	E. saccharolyticus	TGGAATTAT GGCTGCAGTT GACGAATAAT.	TGAA GACATCCAAC GTGGACAACT ATT	70
	E. solitarius	TGCAATTAT GGATGCAGTT GATGAATAC.	TGAC GATATCCGAC GTGGACAACT ATT	71
20	E. coli	TGGAATTAT TGCTTCTCTG GATTCCTTAY.	TGAA GATATCCAAC GTGGACAACT ATT	72
	B. cepacia	TGAGCCTGGG GAGCCTGCTG GACAGTAC.	TGAA GACATCCAAC GTGGACAACT ATT	78
	B. fragilis	TGGAACCTGG GAGAGCTCTT GATTCCTGG.	GAAAC GDAATCCAAC GTGGACAACT ATT	16
	B. subtilis	TGCAAGCTAT GGTCTCTT GATGAATAC.	TGAA GAAATCCAAC GTGGACAACT ATT	-
	C. diphtheriae	TCGACCTCAT Gcaggcttc KTGATTC.	CGAA GACGTTGAGC GTGGACAACT TGT	662
25	C. trachomatis	GAGAGCTAT GCAAGCCCTC GATGATAAT.	GAAC GATGTGGRAA GEGGAAATGTT TGT	22
	G. vaginalis	ACGAACCTAT Gaaagcttt GCTGAGTAC.	TACG GACGTTGAGC GTCGTCAGT TGT	135*
	S. aureus	TAGAATTAT GGAGCTGTA GATTCAGT.	TGAA GACGTTGAGC GTGGACAACT ATT	179
	S. pneumoniae	TGGAATTAT Gaaacacttt GATGAGTAT.	TGAT GAAATCGAAC GTGGACAACT TAT	145*
30	A. adiacens	TGGAATTAT GGCTGCAGTT GACGAATAAC.	TGAA GACATCCGAC GTGGACAACT ATT	118*
	G. haemolyans	TGGAATTAT Gaaaaacactt GACGAATAC.	TGAA GATATCCGAC GTGGACAACT ATT	87
	G. morbillorum	TGGAATTAT GGaaaacactt GACGAATAC.	TGAA GATATCCGAC GTGGACAACT ATT	88

Selected sequence for
amplification primer:
35

Selected sequence for
amplification primer:
35

Selected sequence for
amplification primer:
35

1137

A GAYATCSAAC GTGGACAACT

The sequence numbering refers to the *Enterococcus durans tuf* gene fragment (SEQ ID NO. 61). Nucleotides in capitals are identical to the selected sequences or match those sequences. Dots indicate by lower-case letters. Dots indicate gaps in the sequences displayed.

*Y, *W, and *S* designate nucleotide positions which are degenerated. *Y* stands for C or T; *W* stands for A or T; *S* stands for C or G. *I* stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

* The SEQ ID NO. refers to previous patent publication WO98/20157.
b This sequence is the reverse-complement of the selected primer.

Annex XIX: Strategy for the selection of primers for the identification of platelets contaminants from tuf sequences.

		SEQ ID NO.:	Accession #:
5	B. cereus	467	GTA ACTGGGTAG AGATGTTCCG TAAACT . . C AGTCTACTT CGGTACACT GACGTAAC 717
	B. subtilis		GTT ACAGGGTTG AAATGTTCCG TAACTT . . C AGTCTACTT CGGTACACT GACGTAAC - 7 - 299104
	E. cloacae		TCT ATCGGCTTG AAATGTTCCG CAACT . . C AGTCTACTT CGGTACACT GACGTAAC 54
	E. coli		TCT ATCGGCTTG AAATGTTCCG CAACT . . C AGTCTACTT CGGTACACT GACGTAAC 78
10	K. oxytoca		TGT ATCGGCTTG AAATGTTCCG CAACT . . C AGTCTACTT CGGTACACT GACGTAAC 100
	K. pneumoniae		TGT ATCGGCTTG AAATGTTCCG CAACT . . C AGTCTACTT CGGTACACT GACGTAAC 103
	P. aeruginosa		TGC ACGGGTTG AAATGTTCCG CAACT . . C AGTCTACTT CGGTACACT GACGTAAC 153
	S. agalactiae		GTT ATCGGCTTG AAATGTTCCG TAAACA . . C AATCTACTT CGGTACACT GACGTAAC 209
	S. aureus		GTT ACAGGGTTG AAATGTTCCG TAAATT . . C AATCTACTT CGGTACACT GACGTAAC 140*
	S. choleraesuis		TGT ATCGGCTTG AAATGTTCCG CAACT . . C AGTCTACTT CGGTACACT GACGTAAC 159
	S. epidermidis		GTT ATCGGCTTG AAATGTTCCG TAAATT . . C AATCTACTT CGGTACACT GACGTAAC 611
	S. marcescens		TGT ATCGGCTTG AAATGTTCCG CAACT . . C AGTCTACTT CGGTACACT GACGTAAC 168
	S. mutans		GTT ATCGGCTTG AAATGTTCCG TAAACA . . C AATCTACTT CGGTACACT GACGTAAC 224
	S. pyogenes		GTT ATCGGCTTG AAATGTTCCG TAAACA . . C AATCTACTT CGGTACACT GACGTAAC -
	S. salivarius		GTT ATCGGCTTG AAATGTTCCG TAAACA . . C AGTCTACTT CGGTACACT GACGTAAC 146*
	S. sanguinis		GTT ATCGGCTTG AAATGTTCCG TAAACA . . C AGTCTACTT CGGTACACT GACGTAAC 227
	Y. enterocolitica		TGT ATCGGCTTG AAATGTTCCG CAACT . . C AGTCTACTT CGGTACACT GACGTAAC 235
287	Selected sequence for amplification primer	ACTGGGTAG AAATGTTCCG YAA	636
20	Selected sequence for amplification primer	TTCTAYTT CGGTACACT GACGTAAC	637

30 The sequence numbering refers to the *E. coli tuf* gene fragment (SEQ ID NO. 78). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences displayed.

*R" "Y" "M" "K" "W" and "S" designate nucleotide positions which are degenerated. "R" stands for A or G; "Y" stands for C or T; "M" stands for A or C; "K" stands for G or T; "W" stands for A or T; "S" stands for C or G. "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

* The SEQ ID NO. refers to previous patent publication WO98/20157.

† This sequence is the reverse-complement of the selected primer.

Annex XX: Strategy for the selection of the universal amplification primers from *atpD* sequences.

The sequence numbering refers to the *Escherichia coli atpD* gene fragment (SEQ ID NO. 669). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches for SEQ ID Nos. 562 and 565 are indicated by lower-case letters. Mismatches for SEQ ID Nos. 564 and 563 are indicated by underlined nucleotides. Dots indicate gaps in the sequences displayed.

"R" "Y" "M" "K" "W" and "S" letters designate nucleotide positions which are degenerated. "R" stands for A or G; "Y" stands for C or T; "M" stands for A or C; "K" stands for G or T; "W" stands for A, C or T; "S" stands for C or G. "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

* These sequences are the reverse-complement of the selected primers.

Annex XXI: Specific and ubiquitous primers for nucleic acid amplification (recA sequences).

	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
Universal primers (recA)				
	919	5'-GGI CCI GAR TCI TMI GGI AAR AC	918 ^a	437-459
	920 ^b	5'-TCI CCV ATI TCI CCI TCI AIY TC	918 ^a	701-723
Sequencing primers (recA)				
	1605	5'-ATY ATY GAA RTI TAY GCI CC	1704 ^a	220-239
	1606	5'-CCR AAC ATI AYI CCI ACT TTT TC	1704 ^a	628-650
Universal primers (rad51)				
	935	5'-GGI AAR WSI CAR YTI TGY CAY AC	939 ^a	568-590
	936 ^b	5'-TCI SIY TCI GGI ARR CAI GG	939 ^a	1126-1145
Universal primers (dmcl)				
	937	5'-ATI ACI GAR GYI TTY GGI GAR TT	940 ^a	1038-1060
	938 ^b	5'-CYI GTI GYI SWI GCR TGI GC	940 ^a	1554-1573

^a Sequences from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex XXII: Specific and ubiquitous primers for nucleic acid amplification (*speA* sequences).

5	Originating DNA fragment			
	SEQ ID NO.	Nucleotide sequence	SEQ ID NO.	Nucleotide position
10 Bacterial species: <i>Streptococcus pyogenes</i>				
	994	5'-TGG ACT AAC AAT CTC GCA AGA GG	993 ^a	60-82
	995 ^b	5'-ACA TTC TCG TGA GTA ACA GGG T	993 ^a	173-194
15	996	5'-ACA AAT CAT GAA GGG AAT CAT TTA G	993 ^a	400-424
	997 ^b	5'-CTA ATT CTT GAG CAG TTA CCA TT	993 ^a	504-526
20	998	5'-GGA GGG GTA ACA AAT CAT GAA GG	993 ^a	391-413
	997 ^b	5'-CTA ATT CTT GAG CAG TTA CCA TT	993 ^a	504-526

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

annex XXIII: First strategy for the selection of *Streptococcus* pyogenes-specific amplification primers from speA sequences.

SEQ ID NO.:	Accession #	5	10	15	20	25	
X61573	sp A	CCTT	GGGCTAACAA	CCTCACACAA	AGTAT...	GTCACCCCT...GT	AGTCAGAG
AF029051	sp A	-----	GGGCTAACAA	CCTCACACAA	AGTAT...	GTCACCCCT...GT	AGTCAGAG
X61571	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61570	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61568	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61569	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61572	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61560	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
U40453	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61554	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61557	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61559	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61558	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61556	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61555	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61560	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61561	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61566	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61567	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61562	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61563	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61564	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X61565	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
AF055698	sp A	---	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG
X03929*	sp A	TCTT	GGACTAACAA	TCTCGCAAGA	GGTAT...	GTCACCCCT...GT	AGTCAGAG

Selected sequence for species-specific primer

31 Selected sequence for species-specific primer^b

T. GOLDBLATT ET AL. 33

ACCCCT : CT TACTCACCG MWT

The sequence numbering refers to the *Streptococcus pyogenes speA* gene fragment (SEQ ID NO. 993). Nucleotides in capitals are identical to the selected sequences or match those sequences. Nucleotides indicated by lower-case letters, "—" indicate incomplete sequence.

- a. Dots indicate gaps in the sequences displayed.
- b. The extra G nucleotide introducing a gap in the sequence is probably a sequencing error.
- c. This sequence is the reverse-complement of the selected primer.

xxiv: Second strategy for the selection of *Streptococcus* pyogenes-specific amplification primers from speA sequences.

SEQ ID NO.	Accession #	5	10	15	20	25	
388	spae X61573	TA TGGAGGGGTA ACAAAATCATG AGGGAAATCA TTAGAAA... AAAAATGGT AACGTCTCAA GAATTAGACT	TA TGGAGGGGTA ACAAAATCATG AGGGAAATCA TTAGAAA... AAAAATGGT AACGTCTCAA GAATTAGACT	TA CGGAGGGGTA ACAAAATCATG AGGGAAATCA TTAGAAA... AAAAATGGT AACGTCTCAA GAATTAGACT	TA CGGAGGGGTA ACAAAATCATG AGGGAAATCA TTAGAAA... AAAAATGGT AACGTCTCAA GAATTAGACT	TA CGGAGGGGTA ACAAAATCATG AGGGAAATCA TTAGAAA... AAAAATGGT AACGTCTCAA GAATTAGACT	TA CGGAGGGGTA ACAAAATCATG AGGGAAATCA TTAGAAA... AAAAATGGT AACGTCTCAA GAATTAGACT
	spae AF029051						
	spae X61571						
	spae X61570						
	spae X61568						
	spae X61569						
	spae X61572						
	spae X61560						
	spae U40453						
	spae X61554						
	spae X61557						
	spae X61559						
	spae X61558						
	spae X61556						
	spae X61555						
	spae X61560						
	spae X61561						
	spae X61566						
	spae X61567						
	spae X61562						
	spae X61563						
	spae X61564						
	spae X61565						
	spae AF055698						
	spae X03929						
393		529	501	427	292	501	

Selected sequences for species-specific primers

GGACCCGCTA ACGATTCATG AGGG
ACGATTCATG AGGGATCA TTTCAG

The sequence numbering refers to the *Streptococcus pyogenes speA* gene fragment (SEQ ID NO. 993). Dots indicate gaps in the sequences species-specific primer^a

- * This sequence is the reverse-complement of the selected primer displayed.

Strategy for the selection of *Streptococcus* amplification primers from tuf sequences.

		NO.:	647	619	186	619
5	<i>S. anginosus</i>	A AGTTGACTTGTGACGATG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT CTCACACAA CTAAATT 211				
	<i>S. bovis</i>	A AGTTGACCTTGTGATGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT CTCACACAA CTAAATT 212				
	<i>S. dysgalactiae</i>	A ATTTGACCTTGTGATGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT CTCACACAA CTAAATT 217				
10	<i>S. pyogenes</i>	A AGTTGACCTTGTGATGACG AAGAATTGGCT TGAATTGGTT GAGATG . . CC AGTTCAATT AACCCACACA CTAAATT 1002				
	<i>S. agalactiae</i>	A AGTTGACCTTGTGATGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 144*				
	<i>S. oralis</i>	A AGTTGACTTGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 985				
	<i>S. pneumoniae</i>	A AGTTGACTTGTGACG AAGAATTGGCT TGAATTGGTT AACCCACACA CTAAATT 145*				
	<i>S. cristatus</i>	A GATCGACTTGTGATGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 215				
	<i>S. mitis</i>	A GATCGACTTGTGATGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 982				
	<i>S. gordonii</i>	A AGTTGACTTGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 200				
15	<i>S. sanguinis</i>	A AGTTGACTTGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 227				
	<i>S. parasanguinis</i>	A AGTTGACTTGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 225				
	<i>S. salivarius</i>	A AGTTGACTTGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC TGTTCAATT AACCCACACA CTAAATT 146*				
	<i>S. vestibularis</i>	A AGTTGACTTGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC TGTTCAATT AACCCACACA CTAAATT 231				
	<i>S. suis</i>	A AGTTGACTTGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 229				
20	<i>S. mutans</i>	A AGTTGACTTGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 224				
	<i>S. rattii</i>	A AGTTGACTTGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 226				
	<i>S. macacae</i>	A AGTTGACTTGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 222				
	<i>S. cricetus</i>	A AGTTGACTTGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 214				
	<i>E. faecalis</i>	A ATTTGATAATGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC AGTTCAATT AACCCACACA CTAAATT 607				
25	<i>S. aureus</i>	A AGTTGACATGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC TGTTCAATT AACCCACACA CTAAATT 176				
	<i>B. cereus</i>	A ATTCGACATGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . AG CGTTCTGTTA AAGGCTCAGG CTAAATT 7				
	<i>E. coli</i>	A ATTCGACATGTGACG AAGAATTGGCT TGAATTGGTT GAAATG . . CC GGCGACCATC AAGGCCACAA CCAAGTT 78				

Selected sequences for species-specific primers

Selected sequence for species-specific primer^b

TTGACCTT GTTGATGACG AAGAG

AGTTCAATC ACCCCACACA CTTAA 1000

The sequence numbering refers to the *Streptococcus pyogenes tuf* gene fragment (SEQ ID NO. 1002). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences displayed.

- i The SEQ ID NO. refers to previous patent publication WO98/20157.
- b This sequence is the reverse-complement of the selected primer.

Annex XXVI: Strategy for the selection *stx_i*-specific amplification primers and hybridization probe.

ATGTC AATGGGATAG ATCCAGGGA AGG

Selected sequence for

hybridization probe

40 Selected sequence for amplification primer

ACAT TGTCTGGAA CAGTAGCTTA 1080

The sequence numbering refers to the *Escherichia coli* *sxt* gene fragment (SEQ ID NO. 1076). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences displayed. This sequence is the reverse-complement of the selected primer.

Annex XXVII: strategy for the selection of *stx*-specific amplification primers and hybridization probe.

	Accession #	543	570	614	641	684	708	SEQ ID NO.:
5	stx1	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	M16625	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	stx1	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	M17358	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	stx1	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	Z36900	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
10	stx1	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	L04539	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	stx1	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	M19437	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	N24352	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	stx1	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
15	stx1	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	Z36899	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	stx1	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						-
	236901	AGCga TttTAcGTT TttTAcGTT ACA...CAAC ACTGGATGAT ctcAGTGGC GtttTA...A AGGTtGAGA						1076
	X61283	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	stx2	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
20	stx2	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	M11079	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	M21534	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	stx2	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	M36727	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	stx2	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
25	stx2	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	X81415	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	X81416	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	stx2	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	X81417	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	X81418	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
30	stx2	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	E03962	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	X07865	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	stx2	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	Y10775	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	Z57725	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						1077
35	stx2	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	X67514	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	IJ11078	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	X65949	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	AF043627	AGCAG TTCTGCgtT TttTAcGTT ACA...AGGC ACTGCTGA...AACATCTC CtttTA...G CGAAATCAGCA ATGtGCTCC GGAG						-
	Selected sequence for amplification primer	A G T T C T G C T T T T C T A C G T G C						1078
40	Selected sequence for hybridization probe	C A C T G C T G A . . . A A C T G C T C C C T G T						1085
	Selected sequence for amplification primer*	A A T C A G C A A A T G A T C A G C A A A T G A T C A G C A A A						1079
	The sequence numbering refers to the <i>Escherichia coli stx</i> gene fragment (SEQ ID NO. 1077). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences displayed.							
45	* This sequence is the reverse-complement of the selected primer.							

Annex XXVIII: Strategy for the selection of vanA-specific amplification primers from van sequences.

		Accession #	926	952	1230		SEQ ID NO.:
5	vanA	X56895	GTCATAAT AGCGCGGACG AATTGGACTA C...GT AGAGGTCTAG CCCGTGTGGA TATG				1255
	vanA	M97297	GTCATAAT AGCGCGGACG AATTGGACTA C...GT AGAGGTCTAG CCCGTGTGGA TATG				1139
	vanA	-	GTCATAAT AGCGCGGACG AATTGGACTA C...GT AGAGGTCTAG CCCGTGTGGA TATG				1141
	vanA	-	GTCATAAT AGCGCGGACG AATTGGACTA C...GT AGAGGTCTAG CCCGTGTGGA TATG				1051
	vanA	-	GTCATAAT AGCGCGGACG AATTGGACTA C...GT AGAGGTCTAG CCCGTGTGGA TATG				1052
10	vanA	-	GTCATAAT AGCGCGGACG AATTGGACTA C...GT AGAGGTCTAG CCCGTGTGGA TATG				1053
	vanA	-	GTCATAAT AGCGCGGACG AATTGGACTA C...GT AGAGGTCTAG CCCGTGTGGA TATG				1054
	vanA	-	GTCATAAT AGCGCGGACG AATTGGACTA C...GT AGAGGTCTAG CCCGTGTGGA TATG				1055
	vanA	-	GTCATAAT AGCGCGGACG AATTGGACTA C...GT AGAGGTCTAG CCCGTGTGGA TATG				1056
	vanA	-	GTCATAAT AGCGCGGACG AATTGGACTA C...GT AGAGGTCTAG CCCGTGTGGA TATG				1057
	vanA	-	GTCATAAT AGCGCGGACG AATTGGACTA C...GT AGAGGTCTAG CCCGTGTGGA TATG				1049
15	vanA	-	GTCATAAT AGCGCGGACG AATTGGACTA C...GT AGAGGTCTAG CCCGTGTGGA TATG				1050
	vanB	U94526	GTAaac ggtaacggaaG Aacttaaacgc T...GC AGAGGGCTTG CCCGGTGTGA TCtt				1117
	vanB	U94527	GTAaac AGtaacggaaG Aacttaaacgc T...GC AGAGGGCTTG CCCGGTGTGA TCtt				-
	vanB	U94528	GTAaac ggtaacggaaG Aacttaaacgc T...GC AGAGGGCTTG CCCGGTGTGA TCtt				-
	vanB	U94529	GTAaac ggtaacggaaG Aacttaaacgc T...GC AGAGGGCTTG CCCGGTGTGA TCtt				-
	vanB	U94530	GTAaac ggtaacggaaG Aacttaaacgc T...GC AGAGGGCTTG CCCGGTGTGA TCtt				-
20	vanB	203305	GTAaac ggtaacggaaG Aacttaaacgc T...GC AGAGGGCTTG CCCGGTGTGA TCtt				-
	vanB	U81452	GTAaac ggtaacggaaG Aacttaaacgc T...GC AGAGGGCTTG CCCGGTGTGA TCtt				-
	vanB	U35369	GTAaac AGtaacggaaG Aacttaaacgc T...GC AGAGGGCTTG CCCGGTGTGA TCtt				-
	vanB	U72704	GTAaac ggtaacggaaG Aacttaaacgc T...GC AGAGGGCTTG CCCGGTGTGA TCtt				-
	vanB	L06138	GTAaac AGtaacggaaG Aacttaaacgc T...GC AGAGGGCTTG CCCGGTGTGA TCtt				-
	vanB	L15304	GTAaac ggtaacggaaG Aacttaaacgc T...GC AGAGGGCTTG CCCGGTGTGA TCtt				-
	vanB	U00456	GTAaac AGtaacggaaG Aacttaaacgc T...GC AGAGGGCTTG CCCGGTGTGA TCtt				-
	vanD	AF130997	GTatgc Aaggcagaag Aacttcaggc A...GC AGAGGatttg CCCGGatTTGA CCTG				-
	vanE	AF136925	GTAGAA caaaaaatgt ATTtatataA A...GC AaggattAG CGaaatcgA CTtt				-

Selected sequence for amplification primer AAT AGCGCGGACG AATTGGAC

Selected sequence for amplification primer^a GAGGTCTAG CCCGTGTGGA T 1089

The sequence numbering refers to the *Enterococcus faecium* vanA gene fragment (SEQ ID NO. 1139). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences displayed.

^a This sequence is the reverse-complement of the above selected primer.

Annex XXIX: Strategy for the selection of vanB-specific amplification primers from van sequences.

	SEQ ID NO.:	Accession #	470	495	608	633
5	vana	X56895	A CGCATTGAA	tCGGCAaggAC	AATAT . . ACG	GaATCTTtCG
	vana	M97297	A CGCATTGAA	tCGGCAaggAC	AATAT . . ACG	tATtCATCAG
	vana	-	A CGCATTGAA	tCGGCAaggAC	AATAT . . ACG	GaATCTTtCG
	vana	-	A CGCATTGAA	tCGGCAaggAC	AATAT . . ACG	GaATCTTtCG
10	vana	-	A CGCATTGAA	tCGGCAaggAC	AATAT . . ACG	GaATCTTtCG
	vana	-	A CGCATTGAA	tCGGCAaggAC	AATAT . . ACG	tATtCATCAG
	vana	-	A CGCATTGAA	tCGGCAaggAC	AATAT . . ACG	GaATCTTtCG
	vana	-	A CGCATTGAA	tCGGCAaggAC	AATAT . . ACG	GaATCTTtCG
15	vana	-	A CGCATTGAA	tCGGCAaggAC	AATAT . . ACG	GaATCTTtCG
	vanB	U94526	C TGGATAGAA	GCggCAggAC	AATAT . . ACG	GTATCTTCCG
	vanB	U94527	C TGGATAGAA	GCggCAggAC	AATAT . . ACG	tATCCATCAG
	vanB	U94528	C TGGATAGAA	GCggCAggAC	AATAT . . ACG	GTATCTTCCG
	vanB	U94529	C TGGATAGAA	GCggCAggAC	AATAT . . ACG	tATCCATCAG
	vanB	U94530	C TGGATAGAA	GCggCAggAC	AATAT . . ACG	GTATCTTCCG
20	vanB	28305	C TGGATAGAA	GCggCAggAC	AATAT . . ACG	GTATCTTCCG
	vanB	U81452	C TGGATAGAA	GCggCAggAC	AATAT . . ACG	tATCCATCAG
	vanB	U35369	C TGGATAGAA	GCggCAggAC	AATAT . . ACG	GTATCTTCCG
	vanB	U72704	C TGGATAGAA	GCggCAggAC	AATAT . . ATG	GTATCTTCCG
	vanB	L06138	C TGGATAGAA	GCAGCAggAC	AATAT . . ACG	GTATCTTCCG
	vanB	L15304	C TGGATAGAA	GCggCAggAC	AATAT . . ACG	GTATCTTCCG
	vanB	U00456	C TGGATAGAA	GCAGCAggAC	AATAT . . ACG	GTATCTTCCG
	vanD	AF130997	C AGCAATGAA	GAAGCAaggAC	AATAT . . ACG	Gtttttttaa
	vanE	AF136925	A AGcaATAGAC	GAAGCTtCAA	AATAT . . ATG	GtttttttCgA CttatgaagAG

Selected sequence for amplification primer

卷之三

223

1030

The sequence numbering refers to the *Enterococcus faecium* vanB gene fragment (SEQ ID NO. 1117). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequence.

* This sequence is the reverse-complement of the above vanB sequence.

Annex XXX: Strategy for the selection of vanC-specific amplification primers from vanC sequences.

	Accession #	929	957	1064	1064	1092	SEQ ID NO.:
5	vanC1	-	GT CGACGGCTTT TTGATTTC ARGAGAA... ACGGTC TGGCTGAAAT CGATTTC GT				1058
	vanC1	-	GT CGACGGCTTT TTGATTTC ARGAGAA... ACGGTC TGGCTGAAAT CGATTTC GT				1059
	vanC1	M75132	GT CGACGGCTTT TTGATTTC ARGAGAA... ACGGTC TGGCTGAAAT CGATTTC GT				1138
	vanC2	-	GT AGACGGCTTT TTGATTTC ARGAGAA... AAAGTC TTGCTCGCAT CGACTTTT GT				1060
	vanC2	-	GT AGACGGCTTT TTGATTTC ARGAGAA... AAAGTC TTGCTCGCAT CGACTTTT GT				1061
10	vanC2	-	GT AGACGGCTTT TTGATTTC ARGAGAA... AAAGTC TTGCTCGCAT CGACTTTT GT				1062
	vanC2	-	GT AGACGGCTTT TTGATTTC ARGAGAA... AAAGTC TTGCTCGCAT CGACTTTT GT				1063
	vanC2	L29638	GT AGACGGCTTT TTGATTTC ARGAGAA... AAAGTC TTGCTCGCAT CGACTTTT GT				-
	vanC2	L29638	GT AGACGGCTTT TTGATTTC ARGAGAA... AAAGTC TTGCTCGCAT CGACTTTT GT				-
	vanC3	-	GT AGACGGCTTT TTGATTTC ARGAGAA... AAAGTC TTGCTCGCAT CGACTTTT GT				1064
	vanC3	-	GT AGACGGCTTT TTGATTTC ARGAGAA... AAAGTC TTGCTCGCAT CGACTTTT GT				1065
	vanC3	-	GT AGACGGCTTT TTGATTTC ARGAGAA... AAAGTC TTGCTCGCAT CGACTTTT GT				1066
	vanC3	L29639	GT AGACGGCTTT TTGATTTC ARGAGAA... AAAGTC TTGCTCGCAT CGACTTTT GT				-
	Selected sequence for resistance primer		GACGGYTT TTGATTTC AGAA				1101
20	Selected sequence for resistance primer ^a		GGTC TTGCTCGMAT CGATTTC				1102
25	The sequence numbering refers to the vanC1 gene fragment (SEQ ID NO. 1138). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequence displayed.						
298 15	"R" "Y" "M" "K" "W" and "S" designate nucleotide positions which are degenerated. "R" stands for A or G; "Y" stands for C or T; "M" stands for A or C; "K" stands for G or T; "W" stands for A or T; "S" stands for C or G. "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.						
30	^a This sequence is the reverse-complement of the selected sequence.						

Annex XXXI: Strategy for the selection of *Streptococcus pneumoniae*-specific amplification primers and hybridization probes from *pbp1a* sequences.

		Accession #	SEQ ID NO.:
5	<i>pbp1a</i>	M90528	453 A TGCATTCGG AGACATCAC TATCTAATG CTATTCAAG TAATACACC 505 A TGCATTCGG AGACATCAC TATCTAATG CTATTCAAG TAATACACC 706
	<i>pbp1a</i>	X67873	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
	<i>pbp1a</i>	AB006868	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
10	<i>pbp1a</i>	AF046234	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
	<i>pbp1a</i>	<i>pbp1a</i>	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
	<i>pbp1a</i>	AB006873	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
	<i>pbp1a</i>	AF139883	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
15	<i>pbp1a</i>	<i>pbp1a</i>	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
	<i>pbp1a</i>	AP159448	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
	<i>pbp1a</i>	X67867	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
20	<i>pbp1a</i>	<i>pbp1a</i>	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
	<i>pbp1a</i>	249094	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
	<i>pbp1a</i>	X67870	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
25	<i>pbp1a</i>	AJ002290	A TGCATTCGG AGCTATGGTCTAC TATCTAATG CCATTCAAG TAAGCAACCC G...
	<i>pbp1a</i>	X67871	A TCGACTAACG AGATTCAC TATCTAATG CCATTCAAG TAAGCAACCC G...
			Selected sequences for amplification primers
			GACTATCC AGGATGCGAT TATG
35			Arg ATGACGAGMA TGATGAAAC
			1130
			Selected sequence for hybridization probe
			CAGACG CCATTCAAG TAATACAC
			1129

The sequence numbering refers to the *Streptococcus pneumoniae pbp1a* gene fragment (SEQ ID NO. 1004). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences displayed.

R "Y" "M" "K" "W" and "S" designate nucleotide positions which are degenerated. "R" stands for A or G; "Y" stands for C or T; "M" stands for A or C; "K" stands for G or T; "W" stands for A or T; "H" stands for C or T; "S" stands for C or G. "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

Annex XXXI: Strategy for the selection of *Streptococcus pneumoniae*-specific amplification primers and hybridization probes from *ppbla* sequences (continued).

		Accession #	SEQ ID NO.:
5		M90528	756
	<i>ppbla</i>	X67873	...GCTGGTAA AACGGTACG TCTAATCTA... A ATACGGTTA TGTAGCTCCG GACGAAA
	<i>ppbla</i>	AB006868	... GCTGGTAA SACGGAAAC TCTAATCTA... A CCTCTCAATT TGTAGCACCT GATGAAAC
	<i>ppbla</i>	AF046234	... GCTGGTAA SACGGAAAC TCTAATCTA... A CCTCTCAATT TGTAGCACCT GACGGAAC
10			... GCAAGTAA SACGGTACT TCTAATCTA... A ACATGGTTA CGTAGCTCCA GATGAAA
	<i>ppbla</i>		... GCTGGTAA SACGGTACT TCTAATCTA... A ACATGGTTA CGTAGCTCCA GATGAAA
	<i>ppbla</i>	AB006873	... GCAAGTAA GACGGTACT TCTAATCTA... A ACATGGTTA CGTAGCTCCA GATGAAA
	<i>ppbla</i>	AF139883	... GCTGGTAA SACGGAAAC TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
15			... GCTGGTAA SACGGAAAC TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>		... GCTGGTAA SACGGAAAC TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>		... GCTGGTAA SACGGAAAC TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>		... GCTGGTAA SACGGAAAC TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>		... GCTGGTAA SACGGAAAC TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
20			... GCTGGTAA SACGGAAAC TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>	AF159448	... GCTGGTAA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>		... GCTGGTAA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>		... GCTGGTAA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>		... GCTGGTAA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>		... GCTGGTAA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
300		X67867	... GCTGGTAA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
25			... GCAAGTAA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>	249094	... GCAGGTTA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>		... GCAGGTTA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>		... GCAGGTTA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>	X67870	... GCAGGTTA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
30			... GCAGGTTA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>	AJ002290	... GCAGGTTA GACGGTACT TCTAATCTA... A ACATGGCTA TGTAGCTCCA GATGAAA
	<i>ppbla</i>	X67871	... GCTGGTAA SACGGTACG TCTAATCTA... A ACATGGTTA CGTAGCTCCA GATGAAA
35			
	Selected sequence for hybridization probe		1193
	Selected sequence for amplification primer*		1131

- The sequence numbering refers to the *Streptococcus pneumoniae* *ppbla* gene fragment (SEQ ID NO. 1004). Nucleotides in capitals are identical to the selected sequences or match those sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences displayed.
- * indicates incomplete sequence data.
- 'R' 'Y' 'W' and 'S' designate nucleotide positions which are degenerated. 'R' stands for A or G, 'Y' stands for C or T, 'W' stands for A or T; 'S' stands for C or G. 'I' stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.
- This sequence is the reverse-complement of the selected primer.

Annex XXXII: Specific and ubiquitous primers for nucleic acid amplification (toxin sequences).

5	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10	<u>Toxin gene:</u>	cdtA		
	2123	5'-TCT ACC ACT GAA GCA TTA C	2129 ^a	442-460
	2124 ^b	5'-TAG GTC CTG TAG GTT TAT TG	2129 ^a	580-599
15	<u>Toxin gene:</u>	cdtB		
	2126	5'-ATA TCA GAG ACT GAT GAG	2130 ^a	2665-2682
	2127 ^b	5'-TAG CAT ATT CAG AGA ATA TTG T	2130 ^a	2746-2767
20	<u>Toxin gene:</u>	stx₁		
	1081	5'-ATG TCA GAG GGA TAG ATC CA	1076 ^a	233-252
	1080 ^b	5'-TAT AGC TAC TGT CAC CAG ACA ATG T	1076 ^a	394-418
25	<u>Toxin gene:</u>	stx₂		
	1078	5'-AGT TCT GCG TTT TGT CAC TGT C	1077 ^a	546-567
	1079 ^b	5'-CGG AAG CAC ATT GCT GAT T	1077 ^a	687-705
30	<u>Toxin genes:</u>	stx₁ and stx₂		
	1082	5'-TTG ARC RAA ATA ATT TAT ATG TG	1076 ^a	278-300
	1083 ^b	5'-TGA TGA TGR CAA TTC AGT AT	1076 ^a	781-800

35

^a Sequences from databases.^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex XXXIII: Molecular beacon int rnal hybridization probes for specific d tection of toxin sequenc s.

		Originating DNA fragment	
	SEQ ID NO. Nucleotide sequence ^a	SEQ ID NO.	Nucleotide position
10	<u>Toxin gene:</u> cdtA		
	2125 ^b 5'-CAC GCG GAT TTT GAA TCT CTT CCT CTA GTA GCG CGT G	2129 ^c	462-488
15	<u>Toxin gene:</u> cdtB		
	2128 5'-CAA CGC TGG AGA ATC TAT ATT TGT AGA AAC TGC GTT G	2130 ^c	2714-2740
20	<u>Toxin gene:</u> stx₁		
	1084 5'-CCA CGC CGC TTT GCT GAT TTT TCA CAT GTT ACC GCG TGG	1076 ^c	337-363
25	2012 ^d 5'-CCG CGG ATT ATT AAA CCG CCC TTC CGC GG-MR-HEG-ATG TCA GAG GGA TAG ATC CA	1076 ^c	248-264
30	<u>Toxin gene:</u> stx₂		
	1085 5'-CCA CGC CAC TGT CTG AAA CTG CTC CTG TG CGT GG	1077 ^c	617-638

^a Underlined nucleotides indicate the molecular beacon's stem.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^c Sequences from databases.

^d Scorpion primer.

Annex XXXIV: Specific and ubiquitous primers for nucleic acid amplification (van sequences).

			Originating DNA fragment	
5	SEQ ID NO.	Nucleotide sequence	SEQ ID NO.	Nucleotide position
10		<u>Resistance gene:</u> <u>vanA</u>		
	1086	5'-CTA CTC CCG CCT TTT GGG TT	1049-1057 ^a	513-532 ^b
	1087 ^c	5'-CTC ACA GCC CGA AAC AGC CT	1049-1057 ^a	699-718 ^b
15	1086	5'-CTA CTC CCG CCT TTT GGG TT	1049-1057 ^a	513-532 ^b
	1088 ^c	5'-TGC CGT TTC CTG TAT CCG TC	1049-1057 ^a	885-904 ^b
	1086	5'-CTA CTC CCG CCT TTT GGG TT	1049-1057 ^a	513-532 ^b
20	1089 ^c	5'-ATC CAC ACG GGC TAG ACC TC	1049-1057 ^a	933-952 ^b
	1090	5'-AAT AGC GCG GAC GAA TTG GAC	1049-1057 ^a	629-649 ^b
	1091 ^c	5'-AAC GCG GCA CTG TTT CCC AA	1049-1057 ^a	734-753 ^b
	1090	5'-AAT AGC GCG GAC GAA TTG GAC	1049-1057 ^a	629-649 ^b
25	1089 ^c	5'-ATC CAC ACG GGC TAG ACC TC	1049-1057 ^a	933-952 ^b
	1092	5'-TCG GCA AGA CAA TAT GAC AGC	1049-1057 ^a	662-682 ^b
	1088 ^c	5'-TGC CGT TTC CTG TAT CCG TC	1049-1057 ^a	885-904 ^b
30		<u>Resistance gene:</u> <u>vanB</u>		
	1095	5'-CGA TAG AAG CAG CAG GAC AA	1117 ^d	473-492
	1096 ^c	5'-CTG ATG GAT GCG GAA GAT AC	1117 ^d	611-630
35		<u>Resistance genes:</u> <u>vanA, vanB</u>		
	1112	5'-GGC TGY GAT ATT CAA AGC TC	1049-1057, 1117 ^a	437-456 ^b
	1113 ^c	5'-ACC GAC CTC ACA GCC CGA AA	1049-1057, 1117 ^a	705-724 ^b
40	1112	5'-GGC TGY GAT ATT CAA AGC TC	1049-1057, 1117 ^a	437-456 ^b
	1114 ^c	5'-TCW GAG CCT TTT TCC GGC TCG	1049-1057, 1117 ^a	817-837 ^b
	1115	5'-TTT CGG GCT GTG AGG TCG GBT GHG CG	1049-1057, 1117 ^a	705-730 ^b
45	1114 ^c	5'-TCW GAG CCT TTT TCC GGC TCG	1049-1057, 1117 ^a	817-837 ^b
	1116	5'-TTT CGG GCT GTG AGG TCG GBT GHG CGG	1049-1057, 1117 ^a	705-731 ^b
	1114 ^c	5'-TCW GAG CCT TTT TCC GGC TCG	1049-1057, 1117 ^a	817-837 ^b
50	1112	5'-GGC TGY GAT ATT CAA AGC TC	1049-1057, 1117 ^a	437-456 ^b
	1118 ^c	5'-TTT TCW GAG CCT TTT TCC GGC TCG	1049-1057, 1117 ^a	817-840 ^b

^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the vanA sequence fragment (SEQ ID NO. 1051).

^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^d Sequences from databases.

Annex XXXIV: Specific and ubiquitous primers for nucleic acid amplification (van sequences) (continued).

	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10 Resistance genes: vanA, vanB (continued)				
1115	5'-TTT CGG GCT GTG AGG TCG GBT GHG CG	1049-1057,1117 ^a	705-730 ^b	
1118 ^c	5'-TTT TCW GAG CCT TTT TCC GGC TCG	1049-1057,1117 ^a	817-840 ^b	
1116	5'-TTT CGG GCT GTG AGG TCG GBT GHG CGG	1049-1057,1117 ^a	705-731 ^b	
1118 ^c	5'-TTT TCW GAG CCT TTT TCC GGC TCG	1049-1057,1117 ^a	817-840 ^b	
1119	5'-TTT CGG GCT GTG AGG TCG GBT GHG C	1049-1057,1117 ^a	705-729 ^b	
1118 ^c	5'-TTT TCW GAG CCT TTT TCC GGC TCG	1049-1057,1117 ^a	817-840 ^b	
1120	5'-TTT CGG GCT GTG AGG TCG GBT GHG	1049-1057,1117 ^a	705-728 ^b	
1118 ^c	5'-TTT TCW GAG CCT TTT TCC GGC TCG	1049-1057,1117 ^a	817-840 ^b	
1121	5'-TGT TTG WAT TGT CYG GYA TCC C	1049-1057,1117 ^a	408-429 ^b	
1111 ^c	5'-CTT TTT CCG GCT CGW YTT CCT GAT G	1049-1057,1117 ^a	806-830 ^b	
1112	5'-GGC TGY GAT ATT CAA AGC TC	1049-1057,1117 ^a	437-456 ^b	
1111 ^c	5'-CTT TTT CCG GCT CGW YTT CCT GAT G	1049-1057,1117 ^a	806-830 ^b	
1123	5'-TTT CGG GCT GTG AGG TCG GBT G	1049-1057,1117 ^a	705-726 ^b	
1111 ^c	5'-CTT TTT CCG GCT CGW YTT CCT GAT G	1049-1057,1117 ^a	806-830 ^b	
1112	5'-GGC TGY GAT ATT CAA AGC TC	1049-1057,1117 ^a	437-456 ^b	
1124 ^c	5'-GAT TTG RTC CAC YTC GCC RAC A	1049-1057,1117 ^a	757-778 ^b	
35 Resistance gene: vanC1				
1103	5'-ATC CCG CTA TGA AAA CGA TC	1058-1059 ^a	519-538 ^d	
1104 ^c	5'-GGA TCA ACA CAG TAG AAC CG	1058-1059 ^a	678-697 ^d	
40 Resistance genes: vanC1, vanC2, vanC3				
1097	5'-TCY TCA AAA GGG ATC ACW AAA GTM AC	1058-1066 ^a	607-632 ^d	
1098 ^c	5'-TCT TCA AAA TCG AAA AAG CCG TC	1058-1066 ^a	787-809 ^d	
1099	5'-TCA AAA GGG ATC ACW AAA GTM AC	1058-1066 ^a	610-632 ^d	
1100 ^c	5'-GTA AAK CCC GGC ATR GTR TTG ATT TC	1058-1066 ^a	976-1001 ^d	
1101	5'-GAC GGY TTT TTY GAT TTT GAA GA	1058-1066 ^a	787-809 ^d	
1102 ^c	5'-AAA AAR TCG ATK CGA GCM AGA CC	1058-1066 ^a	922-944 ^d	
55 Resistance genes: vanC2, vanC3				
1105	5'-CTC CTA CGA TTC TCT TGA YAA ATC A	1060-1066,1140 ^a	487-511 ^e	
1106 ^c	5'-CAA CCG ATC TCA ACA CCG GCA AT	1060-1066,1140 ^a	690-712 ^e	

^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the vanA sequence fragment (SEQ ID NO. 1051).

^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^d The nucleotide positions refer to the vanC1 sequence fragment (SEQ ID NO. 1058).

^e The nucleotide positions refer to the vanC2 sequence fragment (SEQ ID NO. 1140).

Annex XXXIV: Specific and ubiquitous primers for nucleic acid amplification (van sequences) (continued).

			Originating DNA fragment	
5	SEQ ID NO.	Nucleotide sequence	SEQ ID NO.	Nucleotide position
10 Resistance gene: vanD				
	1591	5'-ATG AGG TAA TAG AAC GGA TT	1594	797-837
	1592 ^b	5'-CAG TAT TTC AGT AAG CGT AAA	1594	979-999
15 Resistance gene: vanE				
	1595	5'-AAA TAA TGC TCC ATC AAT TTG CTG A	1599a	74-98
	1596 ^b	5'-ATA GTC GAA AAA GCC ATC CAC AAG	1599a	394-417
20	1597	5'-GAT GAA TTT GCG AAA ATA CAT GGA	1599a	163-186
	1598 ^b	5'-CAG CCA ATT TCT ACC CCT TTC AC	1599a	319-341
Sequencing primers (vanAB)				
25	1112	5'-GGC TGY GAT ATT CAA AGC TC	1139a	737-756
	1111 ^b	5'-CTT TTT CCG GCT CGW YTT CCT GAT G	1139a	1106-1130
Sequencing primers (vanA, vanX, vanY)				
30	1150	5'-TGA TAA TCA CAC CGC ATA CG	1141a	860-879
	1151 ^b	5'-TGC TGT CAT ATT GTC TTG CC	1141a	1549-1568
	1152	5'-ATA AAG ATG ATA GGC CGG TG	1141a	1422-1441
	1153 ^b	5'-CTC GTA TGT CCC TAC AAT GC	1141a	2114-2133
35	1154	5'-GTT TGA AGC ATA TAG CCT CG	1141a	2520-2539
	1155 ^b	5'-CAG TGC TTC ATT AAC GTA GTC	1141a	3089-3109

40

^a Sequences from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex XXXIV: Specific and ubiquitous primers for nucleic acid amplification (sequences) (continued).

		Originating DNA fragment	
5	SEQ ID NO. Nucleotide sequence SEQ ID	Nucleotide NO.	position
Sequencing primers (vanC1)			
10	1110 5'-ACG AGA AAG ACA ACA GGA AGA CC	1138 ^a	122-144
	1109 ^b 5'-ACA TCG TGA TCG CTA AAA GGA GC	1138 ^a	1315-1337
Sequencing primers (vanC2, vanC3)			
15	1108 5'-GTA AGA ATC GGA AAA GCG GAA GG	1140 ^a	1-23
	1107 ^b 5'-CTC ATT TGA CTT CCT CCT TTG CT	1140 ^a	1064-1086
20			

^a Sequences from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex XXXV: Internal hybridization probes for specific detection of vancomycin resistances.

5	Originating DNA fragment			
	SEQ ID NO.	Nucleotide sequence	SEQ ID NO.	Nucleotide position
10				
	<u>Resistance gene:</u>	vanA		
	1170	5'-ACG AAT TGG ACT ACG CAA TT	1049-1057 ^a	639-658 ^b
	2292	5'-GAA TCG GCA AGA CAA TAT G	2293 ^c	583-601
15				
	<u>Resistance gene:</u>	vanB		
	1171	5'-ACG AGG ATG ATT TGA TTG TC	1117 ^c	560-579
	2294	5'-AAA CGA GGA TGA TTT GAT TG	2296 ^a	660-679
20	2295	5'-TTG AGC AAG CGA TTT CGG	2296 ^a	614-631
	<u>Resistance gene:</u>	vanD		
25	2297	5'-TTC AGG AGG GGG ATC GC	1594 ^c	458-474

^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the vanA sequence fragment (SEQ ID NO. 1051).

^c Sequences from databases.

Annex XXXVI: Specific and ubiquitous primers for nucleic acid amplification (pbp sequences).

		Originating DNA fragment		
5	SEQ ID NO.	Nucleotide sequence	SEQ ID NO.	Nucleotide position
10	<u>Resistance gene:</u>	pbp1a		
	1129	5'-ATG ATG ACH GAM ATG ATG AAA AC	1004-1018 ^a	681-703 ^b
	1131 ^c	5'-CAT CTG GAG CTA CRT ARC CAG T	1004-1018 ^a	816-837 ^b
15	1130	5'-GAC TAT CCA AGC ATG CAT TAT G	1004-1018 ^a	456-477 ^b
	1131	5'-CAT CTG GAG CTA CRT ARC CAG T	1004-1018 ^a	816-837 ^b
	2015	5'-CCA AGA AGC TCA AAA ACA TCT G	2047 ^d	909-930
20	2016 ^c	5'-TAD CCT GTC CAW ACA GCC AT	2047 ^d	1777-1796
	Sequencing primers (pbp1a)			
	1125	5'-ACT CAC AAC TGG GAT GGA TG	1169 ^d	873-892
25	1126 ^c	5'-TTA TGG TTG TGC TGG TTG AGG	1169 ^d	2140-2160
	1125	5'-ACT CAC AAC TGG GAT GGA TG	1169 ^d	873-892
	1128 ^c	5'-GAC GAC YTT ATK GAT ATA CA	1169 ^d	1499-1518
	1127	5'-KCA AAY GCC ATT TCA AGT AA	1169 ^d	1384-1403
30	1126 ^c	5'-TTA TGG TTG TGC TGG TTG AGG	1169 ^d	2140-2160
	Sequencing primers (pbp2b)			
	1142	5'-GAT CCT CTA AAT GAT TCT CAG GTG G	1172 ^d	1-25
35	1143 ^c	5'-CAA TTA GCT TAG CAA TAG GTG TTG G	1172 ^d	1481-1505
	1142	5'-GAT CCT CTA AAT GAT TCT CAG GTG G	1172 ^d	1-25
	1145 ^c	5'-AAC ATA TTK GGT TGA TAG GT	1172 ^d	793-812
	1144	5'-TGT YTT CCA AGG TTC AGC TC	1172 ^d	657-676
40	1143 ^c	5'-CAA TTA GCT TAG CAA TAG GTG TTG G	1172 ^d	1481-1505
	Sequencing primers (pbp2x)			
45	1146	5'-GGG ATT ACC TAT GCC AAT ATG AT	1173 ^d	219-241
	1147 ^c	5'-AGC TGT GTT AGC VCG AAC ATC TTG	1173 ^d	1938-1961
	1146	5'-GGG ATT ACC TAT GCC AAT ATG AT	1173 ^d	219-241
50	1149 ^c	5'-TCC YAC WAT TTC TTT TTG WG	1173 ^d	1231-1250
	1148	5'-GAC TTT GTT TGG CGT GAT AT	1173 ^d	711-730
	1147 ^c	5'-AGC TGT GTT AGC VCG AAC ATC TTG	1173 ^d	1938-1961

^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the pbp1a sequence fragment (SEQ ID NO. 1004).

^c These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^d Sequences from databases.

Annex XXXVII: Internal hybridization probes for specific detection of *pbp* sequences.

	SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
			SEQ ID NO.	Nucleotide position
10		<u>Resistance gene:</u> <i>pbp1a</i>		
	1132	5'-AGT GAA AAR ATG GCT GCT GC	1004-1018 ^a	531-550 ^b
	1133	5'-CAT CAA GAA CAC TGG CTA YGT AG	1004-1018 ^a	806-828 ^b
15	1134	5'-CTA GAT AGA GCT AAA ACC TTC CT	1004-1018 ^a	417-439 ^b
	1135	5'-CAT TAT GCA AAC GCC ATT TCA AG	1004-1018 ^a	471-493 ^b
	1192	5'-GGT AAA ACA GGA ACC TCT AAC T	1004-1018 ^a	759-780 ^b
	1193	5'-GGT AAG ACA GGT ACT TCT AAC T	1004-1018 ^a	759-780 ^b
	1194	5'-CAT TTC AAG TAA TAC AAC AGA ATC	1004-1018 ^a	485-508 ^b
20	1195	5'-CAT TTC AAG TAA CAC AAC TGA ATC	1004-1018 ^a	485-508 ^b
	1196	5'-GCC ATT TCA AGT ATC ACA ACA GAA	1004-1018 ^a	483-506 ^b
	1197	5'-CAA ACG CCA TTT CAA GTA ATA CAA C	1004-1018 ^a	478-502 ^b
	1094	5'-GGT AAA ACA GGT ACT TCT AAC TA	1004-1018 ^a	759-781 ^b
	1214	5'-GGT AAA ACA GGT ACC TCT AAC TA	1004-1018 ^a	759-781 ^b
25	1216	5'-GGT AAG ACT GGT ACA TCA AAC TA	1004-1018 ^a	759-781 ^b
	1217	5'-CAA ATG CCA TTT CAA GTA ACA CAA C	1004-1018 ^a	478-502 ^b
	1218	5'-CAA ACG CCA TTT CAA GTA ACA CAA C	1004-1018 ^a	478-502 ^b
	1219	5'-CAA ATG CTA TTT CAA GTA ATA CAA C	1004-1018 ^a	478-502 ^b
	1220	5'-CAA ACG CCA TTT CAA GTA ATA CGA C	1004-1018 ^a	478-502 ^b
30	2017	5'-ACT TTG AAT AAG GTC GGT CTA G	2047 ^c	1306-1327
	2018	5'-ACA CTA AAC AAG GTT GGT TTA G	2063	354-375
	2019	5'-ACA CTA AAC AAG GTC GGT CTA G	2064	346-367
	2020	5'-GTA GCT CCA GAT GAA ATG TTT G	2140 ^c	1732-1753
	2021	5'-GTA GCT CCA GAC GAA ATG TTT G	2057	831-852
35	2022	5'-GTA GCT CCA GAT GAA ACG TTT G	2053 ^c	805-826
	2023	5'-GTA ACT CCA GAT GAA ATG TTT G	2056	819-840
	2024	5'-AGT GAA AAG ATG GCT GCT GC	2048 ^c	1438-1457
	2025	5'-AGT GAG AAA ATG GCT GCT GC	2047 ^c	1438-1457
	2026	5'-TCC AAG CAT GCA TTA TGC AAA CG	2047 ^c	1368-1390
40	2027	5'-TCG GTC TAG ATA GAG CTA AAA CG	2047 ^c	1319-1341
	2028	5'-TAT GCT CTT CAA CAA TCA CG	2047 ^c	1267-1286
	2029	5'-AGC CGT TGA GAC TTT GAA TAA G	2047 ^c	1296-1317
	2030	5'-CTT AAT GGT CTT GGT ATC G	2047 ^c	1345-1366
	2031	5'-CGT GAC TGG GGT TCT GCT ATG A	2049 ^c	1096-1117
45	2032	5'-CGT GAC TGG GGA TCA TCA ATG A	2047 ^c	1096-1117
	2033	5'-CGT GAC TGG GGT TCT GCC ATG A	2057	195-216
	2034	5'-ATC AAG AAC ACT GGC TAT GTA G	2050 ^c	787-808

50 ^a These sequences were aligned to derive the corresponding primer.

^b The nucleotide positions refer to the *pbp1a* sequence fragment (SEQ ID NO. 1004).

^c Sequence from databases.

Annex XXXVII: Internal hybridization probes for specific detection of *pbp* sequences (continued).

5	Originating DNA fragment			
	SEQ ID NO.	Nucleotide sequence	SEQ ID NO.	Nucleotide position
10				
	<u>Resistance gene:</u>	<i>pbp1a (continued)</i>		
15	2035	5'-ATC AAG AAC ACT GGC TAC GTA G	2051c	787-808
	2036	5'-ATC AAG AAC ACT GGT TAC GTA G	2047	1714-1735
	2037	5'-ATC AAA AAT ACT GGT TAT GTA G	2057	813-834
	2038	5'-ATC AAG AAT ACT GGC TAC GTA G	2052c	757-778
	2039	5'-ATC AAA AAC ACT GGC TAT GTA G	2053c	787-808

20

Annex XXXVIII: Strategy for the selection of *vanAB*-specific amplification primers and *vanB*-specific hybridization probes from van sequences.

SEQ ID NO.:	Accession #	Sequence	Accession #	Sequence
1139	X56695	GCGATTT GCGATCT	734	GCGATTT GCGATCT
1141	M97297	GTAGGCT GCGATTT [CA AAGCTCAGC . . .		GTAGGCT GCGATTT [CA AAGCTCAGC . . .
1051	vana	GTAGGCT GCGATTT [CA AAGCTCAGC . . .		GTAGGCT GCGATTT [CA AAGCTCAGC . . .
1052	vana	GTAGGCT GCGATTT [CA AAGCTCAGC . . .		GTAGGCT GCGATTT [CA AAGCTCAGC . . .
1053	vana	GTAGGCT GCGATTT [CA AAGCTCAGC . . .		GTAGGCT GCGATTT [CA AAGCTCAGC . . .
1054	vana	GTAGGCT GCGATTT [CA AAGCTCAGC . . .		GTAGGCT GCGATTT [CA AAGCTCAGC . . .
1055	vana	GTAGGCT GCGATTT [CA AAGCTCAGC . . .		GTAGGCT GCGATTT [CA AAGCTCAGC . . .
1056	vana	GTAGGCT GCGATTT [CA AAGCTCAGC . . .		GTAGGCT GCGATTT [CA AAGCTCAGC . . .
1057	vana	GTAGGCT GCGATTT [CA AAGCTCAGC . . .		GTAGGCT GCGATTT [CA AAGCTCAGC . . .
1049	vanB	U94526	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
1050	vanB	U94527	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
1117	vanB	U94528	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
-	vanB	U94529	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
-	vanB	U94530	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
-	vanB	283305	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
-	vanB	U81452	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
-	vanB	U35369	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
-	vanB	U72704	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
-	vanB	L06138	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
-	vanB	L15304	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
-	vanB	U00456	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
-	vanD	AP130997	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
-	vanE	AF136925	GTCGGCT GTGATTT [CA AAGCTCAGC . . .	GTCGGCT GTGATTT [CA AAGCTCAGC . . .
30				Selected sequence for amplification primer

The sequence numbering refers to the Ente to the selected sequences or match those s displayed.

卷之三

21

Clostridium *faecium* *vana* gene fragment (SEQ ID NO.: 1139). Nucleotides in capitals are identical sequences. Mismatches are indicated by lower-case letters. Dots indicate gaps in the sequences.

"R" "Y" "M" "K" "W" and "S" designate nucleotides for A or C; "K" stands for G or T; nucleotide positions which are degenerated. "R" stands for A or G; "Y" stands for C or T; "M" stands for A or T; "W" stands for A or G. "S" stands for C or G. "I" stands for inosine which is a nucleotide analog that can bind to any of the four nucleotides A, C, G or T.

Annex XXXVIII: Strategy for *vana*- and *rana*-specific amplification primers and probes from van sequences (continued).

amplification primer^a

amplification primer^a

The sequence numbering refers to the Enter

三三

to the selected sequences or match those sequences displayed.

5 in cap
icate ga

"R" and "W" designate nucleotide positions

T

TIME PERIODS IN THE REVERBATION-COMPRESSION

Annex XXXIX: Internal hybridization probe for specific detection of *mecA*.

5			Originating DNA fragment			
	SEQ ID NO.	Nucleotide sequence	SEQ ID NO.	Nucleotide position		
10	<u>Resistance gene:</u>	<i>mecA</i>	1177	5'-GCT CAA CAA GTT CCA GAT TA	1178a	1313-1332

15

^a Sequence from databases.

Annex XL: Specific and ubiquitous primers for nucleic acid amplification (hexA sequences).

5	Originating DNA fragment		
	SEQ ID NO.	Nucleotide sequence	SEQ ID NO.
10			Nucleotide position
Bacterial species: <i>Streptococcus pneumoniae</i>			
15	1179	5'-ATT TGG TGA CGG GTG ACT TT	1183 ^a 431-450
	1181 ^b	5'-AGC AGC TTA CTA GAT GCC GT	1183-1191 ^c 652-671 ^d
Sequencing primers			
20	1179	5'-ATT TGG TGA CGG GTG ACT TT	1183 ^a 431-450
	1182 ^b	5'-AAC TGC AAG AGA TCC TTT GG	1183 ^a 1045-1064

a Sequences from databases.

b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

c These sequences were aligned to derive the corresponding primer.

d The nucleotide positions refer to the hexA sequence fragment (SEQ ID NO. 1183).

Annex XLI: Internal hybridization probe for specific detection of hexA sequences.

5	Originating DNA fragment			
	SEQ ID NO.	Nucleotide sequence	SEQ ID NO.	Nucleotide position
10				
	<u>Bacterial species:</u> <i>Streptococcus pneumoniae</i>			
	1180 ^a	5'-TCC ACC GTT GCC AAT CGC A	1183-1191 ^b	629-647 ^c
15				

^a This sequences is from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^b These sequences were aligned to derive the corresponding primer.

20 ^c The nucleotide positions refer to the hexA sequence fragment (SEQ ID NO. 1183).

Annex XLII: Strategy for the amplification prime selection of *Streptococcus pneumoniae* species-specific primers and hybridization probe from hexA sequences.

5

		SEQ ID		
		428	TOC ATTGGTAC GGTGACTTT	453 626
			-----TGAC GGTGACTTT	TAT...ATTG COATTGCAA CCGTGGAGCA AACGCCATT AGTAGCTGC TCCA...
10	<i>S. pneumoniae</i>		-----TGAC GGTGACTTT	AATCCAAAG GATCTCTTC AGTTGGC
	<i>S. pneumoniae</i>	1183	-----TGAC GGTGACTTT	1183
	<i>S. pneumoniae</i>	1184	-----TGAC GGTGACTTT	TAT...ATTG COATTGCAA CCGTGGAGCA AACGCCATT AGTAGCTGC TCCA...
	<i>S. pneumoniae</i>	1185	-----TGAC GGTGACTTT	AATCCAAAG GATCTCTTC AGTTGGC
	<i>S. pneumoniae</i>	1186	-----TGAC GGTGACTTT	1186
	<i>S. oralis</i>	1187	-----GGTGACTTT	TAT...ATTG COATTGCAA CCGTGGAGCA AACGCCATT AGTAGCTGC TCCA...
	<i>S. mitis</i>	1188	-----GGTGAC GGTGACTTT	1188
	<i>S. mitis</i>	1189	-----TGAC GGTGACTTT	TAT...ATTG COATTGCAA CCGTGGAGCA AACGCCATT AGTAGCTGC TCCA...
	<i>S. mitis</i>	1190	-----TGAC GGTGACTTT	AATCCAAAG GATCTCTTC AGTTGGC
		1191		
20	Selected sequence for amplification primer		ATTGGTAC GGTGACTTT	1179
	Selected sequences for amplification primers:			
25	Selected sequence for hybridization probe:		ACGCCATT AGTAGCTGC T	1181
			CCAAAG GATCTCTTC AGTT	1182
30			TG COATTGCAA CCGTGGAGCA	1180

The sequence numbering refers to the *Streptococcus pneumoniae* hexA gene fragment (SEQ ID NO. 1183). Nucleotides in capitals are identical to the selected sequences or match those sequences. Nucleotides indicated by lower-case letters. Dots indicate gaps in the sequences displayed.

- This sequence is the reverse-complement of the selected primer.

Ann x XLIII: Specific and ubiquitous primers for nucleic acid amplification (pcp sequence).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Bacterial species:</u> <i>Streptococcus pyogenes</i>			
1211	5'-ATT CTT GTA ACA GGC TTT GAT CCC	1215 ^a	291-314
1210 ^b	5'-ACC AGC TTG CCC AAT ACA AAG G	1215 ^a	473-494

a Sequences from databases.

b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex XLIV: Specific and ubiquitous primers for nucleic acid amplification of *S. saprophyticus* sequences of unknown coding potential.

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Bacterial species:</u> <i>Staphylococcus saprophyticus</i>			
1208	5'-TCA AAA AGT TTT CTA AAA AAT TTA C	74,1093, 1198 ^b	169-193 ^c
1209 ^a	5'-ACG GGC GTC CAC AAA ATC AAT AGG A	74,1093, 1198 ^b	355-379 ^c

^a This sequence is from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^b These sequences were aligned to derive the corresponding primer.

^c The nucleotide positions refer to the *S. saprophyticus* unknown gene sequence fragment (SEQ ID NO. 1198).

Annex XLV: Molecular beacon internal hybridization probes for specific detection of antimicrobial agents resistance gene sequences.

		Originating DNA fragment	
SEQ ID NO.	Nucleotide sequence ^a	SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> <i>gyrA</i>			
2250	5'- <u>CCG TCG</u> GAT GGT GTC GTC GTC TAC CGC GGA GTC GCC GAC GG	1954 ^b	218-243
2251	5'- <u>CGG AGC</u> CGT TCT CGC TGC GTT ACA TGC TGG TGG CTC CG	1954 ^b	259-286
<u>Resistance gene:</u> <i>mecA</i>			
1231	5'- <u>GCG AGC</u> CCG AAG ATA AAA AAG AAC CTC TGC TGC TCG C	1178 ^b	1291-1315
<u>Resistance gene:</u> <i>parC</i>			
1938 ^b	5'- <u>CCG CGC</u> ACC ATT GCT TCG TAC ACT GAG GAG TCT CCG CGC GG	1321 ^c	232-260
1939	5'- <u>GCA CCC GGA</u> TGG TAG TAT CGA TAA TGA TCC GCC AGC CGC CGG GTC G	1321 ^c	317-346
1955 ^b	5'- <u>CCG GCA</u> ACC ATT GCT TCG TAC ACT GAG GAG TCT CGC CG	1321 ^c	235-260
<u>Resistance gene:</u> <i>vanA</i>			
1239	5'- <u>GCG AGC</u> GCA GAC CTT TCA GCA GAG GAG GCT CGC	1051	860-880
1240	5'- <u>GCG AGC</u> CGG CAA GAC AAT ATG ACA GCA AAA TCG CTC GC	1051	663-688
<u>Resistance gene:</u> <i>vanB</i>			
1241	5'- <u>GCG AGC</u> GGG GAA CGA GGA TGA TTT GAT TGG CTC GC	1117	555-577
<u>Resistance gene:</u> <i>vanD</i>			
1593	5'- <u>CCG AGC</u> GAT TTA CCG GAT ACT TGG CTG ICG CTC GG	1594	835-845

^a Underlined nucleotides indicate the molecular beacon's stem.

^b This sequence is from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^c Sequence from databases.

Annex XLVI: Molecular beacon internal hybridization probe for specific detection of *S. aureus* genes sequences of unknown coding potential.

		Originating DNA fragment	
SEQ ID NO.	Nucleotide sequence ^a	SEQ ID NO.	Nucleotide position
<u>Bacterial species:</u> <i>S. aureus</i>			
1232	5'- <u>GGA</u> GCC GCG CGA TTT TAT AAA TGA ATG TTG ATA ACC <u>GGC</u> TCC	1244	53-80

^a Underlined nucleotides indicate the molecular beacon's stem.

Annex XLVII: Molecular beacon int rnal hybridization probes for specific detection of tuf sequences.

SEQ ID NO.	Nucleotide sequence ^a	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
Bacterial species: <i>Chlamydia pneumoniae</i>			
2091	5'- <u>GCG</u> GAC TTG AGA TGG AAC TTA GTG AGC TTC TTG <u>GTC</u> GCG	20	157-183
2092	5'- <u>GCG</u> GAC GAA AGA ACT TCC TGA AGG TCG TGC AGG <u>TCC</u> AG	20	491-516
Bacterial species: <i>Chlamydia trachomatis</i>			
2213	5'- <u>CGT</u> <u>GCC</u> ATT GAC ATG ATT TCC GAA GAA GAC GCT GAA <u>GCC</u> ACG	1739 ^b	412-441
Bacterial species: <i>Enterococcus faecalis</i>			
1236	5'- <u>GCG</u> <u>AGC</u> CGT GGT GAA GTT CGC GTT GGT GGC TCG C	883	370-391
Bacterial species: <i>Enterococcus faecium</i>			
1235	5'- <u>GCG</u> <u>AGC</u> CGA AGT TGA AGT TGT TGG TAT TGC TGG <u>CTC</u> GC	64	412-437
Bacterial species: <i>Legionella pneumophila</i>			
2084 ^c	5'- <u>CAC</u> GCG TCA ACA CCC GTA CAA GTC GTC TTT TGC <u>GCG</u> TG	112	461-486
Bacterial species: <i>Mycoplasma pneumoniae</i>			
2096 ^c	5'- <u>GCG</u> <u>GAC</u> CGG TAC CAC GGC CAG TAA TCG TGT <u>GCG</u> G	2097 ^b	658-679
Bacterial species: <i>Neisseria gonorrhoeae</i>			
2177	5'- <u>GGC</u> <u>ACG</u> GAC AAA CCA TTC CTG CTG CCT ATC GAA ACG TGT TCC <u>CGT</u> GCC	126	323-357
2178	5'- <u>GGC</u> <u>ACG</u> ACA AAC CAT TCC TGC TGC CTA TCG AAC <u>GTC</u> CC	126	323-348
2179	5'- <u>GGC</u> <u>ACG</u> TCT ACT TCC GTA CCA CTG ACG TAA CCG <u>GCT</u> CCC	126	692-718

^a Underlined nucleotides indicate the molecular beacon's stem.

^b Sequence from databases.

^c This sequence is from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex XLVII: Molecular beacon internal hybridization probes for specific detection of tuf sequences (continued).

		Originating DNA fragment	
SEQ ID NO.	Nucleotide sequence ^a	SEQ ID NO.	Nucleotide position
Bacterial species: <i>Pseudomonas aeruginosa</i>			
2122	5'- <u>CCG AGC</u> GAA TGT AGG AGT CCA GGG TCT <u>CTG CTC GG</u>	153,880,2138 ^{b,c}	280-302 ^d
Bacterial species: <i>Staphylococcus aureus</i>			
2186	5'- <u>ACG CGC</u> TCA AAG CAG AAG TAT ACG TAT <u>TAT CAA AAG ACG CGC GT</u>	1728	615-646
Bacterial group: <i>Staphylococcus</i> sp. other than <i>S. aureus</i>			
1233	5'- <u>GCG AGC</u> GTT ACT GGT GTA GAA ATG TTC <u>CGG CTC GC</u>	878	372-394
Fungal species: <i>Candida albicans</i>			
2073	5'- <u>CCG AGC</u> AAC ATG ATT GAA CCA TCC ACC <u>AAC TGG CTC GG</u>	408	404-429
Fungal species: <i>Candida dubliniensis</i>			
2074	5'- <u>CCG AGC</u> AAC ATG ATT GAA GCT TCC ACC <u>AAC TGG CTC GG</u>	414	416-441
Fungal species: <i>Candida glabrata</i>			
2110 ^b	5'- <u>GCG GGC</u> CCT TAA CGA TTT CAG CGA ATC <u>TGG ATT CAG CCC GC</u>	417	307-335
2111	5'- <u>GCG GGC</u> ATG TTG AAG CCA CCA CCA ACG <u>CTT CCT GGC CCG C</u>	417	419-447
Fungal species: <i>Candida krusei</i>			
2112 ^b	5'- <u>GCG GGC</u> TTG ATG AAG TTT GGG TTT CCT <u>TGA CAA TTG CCC GC</u>	422	318-347
2113	5'- <u>GCG GGC</u> ACA AGG GTT GGA CTA AGG AAA <u>CCA AGG CAG CCC GC</u>	422	419-447
2114	5'- <u>GCG GGC</u> ATC GAT GCT ATT GAA CCA CCT <u>GTC AGA CCG CCC GC</u>	422	505-533

^a Underlined nucleotides indicate the molecular beacon's stem.

^b Sequence from databases.

^c These sequences were aligned to derive the corresponding primer.

^d The nucleotide positions refer to the *P. aeruginosa* tuf sequence fragment (SEQ ID NO. 153).

Annex XLVII: Molecular beacon int rnal hybridization probes for specific detection of tuf sequences (continued).

		Originating DNA fragment	
SEQ ID NO.	Nucleotide sequence ^a	SEQ ID NO.	Nucleotide position
Fungal species: <i>Candida lusitaniae</i>			
2115 ^b	5'- <u>GCG</u> <u>GCC</u> GGT AAG TCC ACC GGT AAG ACC TTG TTG <u>GCC</u> <u>GCG</u>	424	304-330
2116	5'- <u>GCG</u> <u>GCC</u> GTA AGT CAC CGG TAA GAC CTT GTT <u>GCC</u> <u>GCG</u> C	424	476-502
2117	5'- <u>GCG</u> <u>GCC</u> GAC GCC ATT GAG CCA CCT TCG AGA <u>GCC</u> <u>GCG</u>	424	512-535
Fungal species: <i>Candida parapsilosis</i>			
2118 ^b	5'- <u>GCG</u> <u>GCC</u> TCC TTG ACA ATT TCT TCG TAT CTG TTC TTG <u>GCC</u> <u>GCG</u>	426	301-330
Fungal species: <i>Candida tropicalis</i>			
2119	5'- <u>GCG</u> <u>GCC</u> TTA CAA CCC TAA GGC TGT TCC ATT CGT <u>TGC</u> <u>CCG</u> C	429	357-384
2120	5'- <u>GCG</u> <u>GCC</u> AGA AAC CAA GGC TGG TAA GGT TAC CGG <u>AGC</u> <u>CCG</u> C	429	459-487
Fungal species: <i>Cryptococcus neoformans</i>			
2106	5'- <u>GCG</u> <u>AGC</u> AGA GCA CGC CCT CCT <u>CCG</u> <u>GCG</u> . TCG C	623, 1985, 1986 ^c	226-244 ^d
2107	5'- <u>GCG</u> <u>AGC</u> TCC CCA TCT CTG GTT GGC <u>ACG</u> CTC <u>GC</u>	623, 1985, 1986 ^c	390-408 ^d
Bacterial genus: <i>Legionella sp.</i>			
2083	5'- <u>CCG</u> <u>CCG</u> ATG TTC CGT AAA TTA CTT GAI GAA GGT CGA <u>GCC</u> <u>GCG</u> GG	111-112 ^a	488-519 ^e

^a Underlined nucleotides indicate the molecular beacon's stem.

^b This sequence is from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

^c These sequences were aligned to derive the corresponding primer.

^d The nucleotide positions refer to the *C. neoformans* tuf (EF-1) sequence fragment (SEQ ID NO. 623).

^e The nucleotide positions refer to the *L. pneumophila* tuf (EF-1) sequence fragment (SEQ ID NO. 112).

Annex XLVII: Molecular beacon internal hybridization probes for specific detection of tuf sequences (continued).

		Originating DNA fragment	
SEQ ID NO.	Nucleotide sequence ^a	SEQ ID NO.	Nucleotide position
Fungal genus: <i>Candida sp.</i>			
2108	5'- <u>GCG</u> GGC AAC TTC RTC AAG AAG GTT GGT TAC AAC CCG <u>CCC</u> GC	414, 417, 422, 424, 426, 429, 624 ^b	52-80 ^c
2109	5'- <u>GCG</u> GGC CCA ATC TCT GGT TGG AAY GGT GAC AAG <u>CCC</u> GC	Same as SEQ ID NO. 2108	100-125 ^c
Bacterial group: <i>Pseudomonads</i>			
2121	5'- <u>CGA</u> <u>CCG</u> CIA GCC GCA CAC CAA GTT <u>CCG</u> <u>GTC</u> G	153-155, 205, 880, 2137 ^d , 2138 ^{d,b}	598-616 ^e

^a Underlined nucleotides indicate the molecular beacon's stem.

^b These sequences were aligned to derive the corresponding primer.

^c The nucleotide positions refer to the *C. albicans* tuf (EF-1) sequence fragment (SEQ ID NO. 624).

^d Sequence from databases.

^e The nucleotide positions refer to the *P. aeruginosa* tuf sequence fragment (SEQ ID NO. 153).

Annex XLVIII: Molecular beacon internal hybridization probes for specific detection of *ddl* and *mtl* gene sequences.

		Originating DNA fragment	
SEQ ID NO.	Nucleotide sequence ^a	SEQ ID NO.	Nucleotide position
<u>Bacterial species:</u> <i>E. faecium</i> (<i>ddl</i>)			
1237	5'- <u>GCG</u> AGC CGC GAA ATC GAA GTT GCT GTA TTA <u>GGG</u> <u>CTC</u> GC	1242 ^b	334-359
<u>Bacterial species:</u> <i>E. faecalis</i> (<i>mtl</i>)			
1238	5'- <u>GCG</u> AGC GGC GTT AAT TTT GGC ACC GAA GAA GAG <u>CTC</u> <u>GC</u>	1243 ^b	631-656

^a Underlined nucleotides indicate the molecular beacon's stem.

^b Sequence from databases.

**Annex XLIX: Internal hybridization probe for specific detection
of *S. aureus* sequences of unknown coding potential.**

		Originating DNA fragment	
SEQ ID NO.	Nucleotide sequence	SEQ ID NO.	Nucleotide position
<u>Bacterial species:</u> <i>Staphylococcus aureus</i>			
1234	5'-ACT AAA TAA ACG CTC ATT CG	1244	35-54

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes sequences).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> <i>aac(2')-Ia</i>			
1344	5'-AGC AGC AAC GAT GTT ACG CAG CAG	1348 ^a	163-186
1345 ^b	5'-CCC GCC GAG CAT TTC AAC TAT TG	1348 ^a	392-414
1346	5'-GAT GTT ACG CAG CAG GGC AGT C	1348 ^a	172-193
1347 ^b	5'-ACC AAG CAG GTT CGC AGT CAA GTA	1348 ^a	467-490
<u>Resistance gene:</u> <i>aac(3')-Ib</i>			
1349	5'-CAG CCG ACC AAT GAG TAT CTT GCC	1351 ^a	178-201
1350 ^b	5'-TAA TCA GGG CAG TTG CGA CTC CTA	1351 ^a	356-379
<u>Resistance gene:</u> <i>aac(3')-IIb</i>			
1352	5'-CCA CGC TGA CAG AGC CGC ACC G	1356 ^a	383-404
1353 ^b	5'-GGC CAG CTC CCA TCG GAC CCT G	1356 ^a	585-606
1354	5'-CAC GCT GAC AGA GCC GCA CCG	1356 ^a	384-404
1355 ^b	5'-ATG CCG TTG CTG TCG AAA TCC TCG	1356 ^a	606-629
<u>Resistance gene:</u> <i>aac(3')-IVa</i>			
1357	5'-GCC CAT CCA TTT GCC TTT GC	1361 ^a	295-314
1358 ^b	5'-GCG TAC CAA CTT GCC ATC CTG AAG	1361 ^a	517-540
1359	5'-TGC CCC TGC CAC CTC ACT C	1361 ^a	356-374
1360 ^b	5'-CGT ACC AAC TTG CCA TCC TGA AGA	1361 ^a	516-539
<u>Resistance gene:</u> <i>aac(3')-VIa</i>			
1362	5'-CGC CGC CAT CGC CCA AAG CTG G	1366 ^a	285-306
1363 ^b	5'-CGG CAT AAT GGA GCG CGG TGA CTG	1366 ^a	551-574
1364	5'-TTT CTC GCC CAC GCA GGA AAA ATC	1366 ^a	502-525
1365 ^b	5'-CAT CCT CGA CGA ATA TGC CGC G	1366 ^a	681-702
<u>Resistance gene:</u> <i>aac(6')-Ia</i>			
1367	5'-CAA ATA TAC TAA CAG AAG CGT TCA	1371 ^a	56-79
1368 ^b	5'-AGG ATC TTG CCA ATA CCT TTA T	1371 ^a	269-290
1379	5'-AAA CCT TTG TTT CGG TCT GCT AAT	1371 ^a	153-176
1380 ^b	5'-AAG CGA TTC CAA TAA TAC CTT GCT	1371 ^a	320-343

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes sequences) (continued).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> <i>aac(6')-Ic</i>			
1372	5'-GCT TTC GTT GCC TTT GCC GAG GTC	1376 ^a	157-180
1373 ^b	5'-CAC CCC TGT TGC TTC GCC CAC TC	1376 ^a	304-326
1374	5'-AGA TAT TGG CTT CGC CGC ACC ACA	1376 ^a	104-127
1375 ^b	5'-CCC TGT TGC TTC GCC CAC TCC TG	1376 ^a	301-323
<u>Resistance gene:</u> <i>ant(3')-Ia</i>			
1377	5'-GCC GTG GGT CGA TGT TTG ATG TTA	1381 ^a	100-123
1378 ^b	5'-GCT CGA TGA CGC CAA CTA CCT CTG	1381 ^a	221-244
1379	5'-AGC AGC AAC GAT GTT ACG CAG CAG	1381 ^a	127-150
1380 ^b	5'-CGC TCG ATG ACG CCA ACT ACC TCT	1381 ^a	222-245
<u>Resistance gene:</u> <i>ant(4')-Ia</i>			
1382	5'-TAG ATA TGA TAG GCG GTA AAA AGC	1386 ^a	149-172
1383 ^b	5'-CCC AAA TTC GAG TAA GAG GTA TT	1386 ^a	386-408
1384	5'-GAT ATG ATA GGC GGT AAA AAG C	1386 ^a	151-172
1385 ^b	5'-TCC CAA ATT CGA GTA AGA GGT A	1386 ^a	388-409
<u>Resistance gene:</u> <i>aph(3')-Ia</i>			
1387	5'-TTA TGC CTC TTC CGA CCA TCA AGC	1391 ^a	233-256
1338 ^b	5'-TAC GCT CGT CAT CAA AAT CAC TCG	1391 ^a	488-511
1389	5'-GAA TAA CGG TTT GGT TGA TGC GAG	1391 ^a	468-491
1390 ^b	5'-ATG GCA AGA TCC TGG TAT CGG TCT	1391 ^a	669-692
<u>Resistance gene:</u> <i>aph(3')-IIa</i>			
1392	5'-TGG GTG GAG AGG CTA TTC GGC TAT	1396 ^a	43-66
1393 ^b	5'-CAG TCC CTT CCC GCT TCA GTG AC	1396 ^a	250-272
1394	5'-GAC GTT GTC ACT GAA GCG GGA AGG	1396 ^a	244-267
1395 ^b	5'-CTT GGT CGA ATG GGC AGG TAG	1396 ^a	386-409

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes sequences) (continued).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> <i>aph(3')-IIIa</i>			
1397	5'-GTG GGA GAA AAT GAA AAC CTA T	1401 ^a	103-124
1398 ^b	5'-ATG GAG TGA AAG AGC CTG AT	1401 ^a	355-374
1399	5'-ACC TAT GAT GTG GAA CGG GAA AAG	1401 ^a	160-183
1400 ^b	5'-CGA TGG AGT GAA AGA GCC TGA TG	1401 ^a	354-376
<u>Resistance gene:</u> <i>aph(3')-VIa</i>			
1402	5'-TAT TCA ACA ATT TAT CGG AAA CAG	1406 ^a	18-41
1403 ^b	5'-TCA GAG AGC CAA CTC AAC ATT TT	1406 ^a	175-197
1404	5'-AAA CAG CGT TTT AGA GCC AAA TAA	1406 ^a	36-59
1405 ^b	5'-TTC TCA GAG AGC CAA CTC AAC ATT	1406 ^a	177-200
<u>Resistance gene:</u> <i>blaCARB</i>			
1407	5'-CCC TGT AAT AGA AAA GCA AGT AGG	1411 ^a	351-374
1408 ^b	5'-TTG TCG TAT CCC TCA AAT CAC C	1411 ^a	556-577
1409	5'-TGG GAT TAC AAT GGC AAT CAG CG	1411 ^a	205-227
1410 ^b	5'-GGG GAA TAG GTC ACA AGA TCT GCT T	1411 ^a	329-353
<u>Resistance gene:</u> <i>blaCMY-2</i>			
1412	5'-GAG AAA ACG CTC CAG CAG GGC	1416 ^a	793-813
1413 ^b	5'-CAT GAG GCT TTC ACT GCG GGG	1416 ^a	975-995
1414	5'-TAT CGT TAA TCG CAC CAT CAC	1416 ^a	90-110
1415 ^b	5'-ATG CAG TAA TGC GGC TTT ATC	1416 ^a	439-459
<u>Resistance genes:</u> <i>blaCTX-M-1, blaCTX-M-2</i>			
1417	5'-TGG TTA ACT AYA ATC CSA TTG CGG A	1423 ^a	314-338
1418 ^b	5'-ATG CTT TAC CCA GCG TCA GAT T	1423 ^a	583-604
<u>Resistance gene:</u> <i>blaCTX-M-1</i>			
1419	5'-CGA TGA ATA AGC TGA TTT CTC ACG	1423 ^a	410-433
1420 ^b	5'-TGC TTT ACC CAG CGT CAG ATT ACG	1423 ^a	580-603
1421	5'-AAT TAG AGC GGC AGT CGG GAG GAA	1423 ^a	116-139
1422 ^b	5'-GAA ATC AGC TTA TTC ATC GCC ACG	1423 ^a	405-428

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes sequences) (continued).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> <i>blaCTX-M-2</i>			
1424	5'-GTT AAC GGT GAT GGC GAC GCT AC	1428 ^a	30-52
1425 ^b	5'-GAA TTA TCG GCG GTG TTA ATC AGC	1428 ^a	153-176
1426	5'-CAC GCT CAA TAC CGC CAT TCC A	1428 ^a	510-531
1427 ^b	5'-TTA TCG CCC ACT ACC CAT GAT TTC	1428 ^a	687-710
<u>Resistance gene:</u> <i>blaIMP</i>			
1429	5'-TTT ACG GCT AAA GAT ACT GAA AAG T	1433 ^a	205-229
1430 ^b	5'-GTT TAA TAA AAC AAC CAC CGA ATA AT	1433 ^a	513-538
1431	5'-TAA TTG ACA CTC CAT TTA CGG CTA A	1433 ^a	191-215
1432 ^b	5'-ACC GAA TAA TAT TTT CCT TTC AGG CA	1433 ^a	497-522
<u>Resistance gene:</u> <i>blaOXA2</i>			
1434	5'-CAC AAT CAA GAC CAA GAT TTG CGA T	1438 ^a	319-343
1435 ^b	5'-GAA AGG GCA GCT CGT TAC GAT AGA G	1438 ^a	532-556
<u>Resistance gene:</u> <i>blaOXA10</i>			
1436	5'-CAG CAT CAA CAT TTA AGA TCC CCA	1439 ^a	194-217
1437 ^b	5'-CTC CAC TTG ATT AAC TGC GGA AAT TC	1439 ^a	479-504
<u>Resistance gene:</u> <i>blaPER-1</i>			
1440	5'-AGA CCG TTA TCG TAA ACA GGG CTA AG	1442 ^a	281-306
1441 ^b	5'-TTT TTT GCT CAA ACT TTT TCA GGA TC	1442 ^a	579-604
<u>Resistance gene:</u> <i>blaPER-2</i>			
1443	5'-CTT CTG CTC TGC TGA TGC TTG GC	1445 ^a	32-54
1444 ^b	5'-GGC GAC CAG GTA TTT TGT AAT ACT GC	1445 ^a	304-329
<u>Resistance genes:</u> <i>blaPER-1, blaPER-2</i>			
1446	5'-GGC CTG YGA TTT GTT ATT TGA ACT GGT	1442 ^a	414-440
1447 ^b	5'-CGC TST GGT CCT GTG GTG GTT TC	1442 ^a	652-674
1448	5'-GAT CAG GTG CAR TAT CAA AAC TGG AC	1442 ^a	532-557
1449 ^b	5'-AGC WGG TAA CAA YCC TTT TAA CCG CT	1442 ^a	671-696

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes sequences) (continued).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> <i>blaSHV</i>			
1883	5'-AGC CGC TTG AGC AAA TTA AAC TA	1900 ^a	71-93
1884 ^b	5'-GTA TCC CGC AGA TAA ATC ACC AC	1900 ^a	763-785
1885	5'-AGC GAA AAA CAC CTT GCC GAC	1900 ^a	313-333
1884 ^b	5'-GTA TCC CGC AGA TAA ATC ACC AC	1900 ^a	763-785
<u>Resistance gene:</u> <i>blaTEM</i>			
1906	5'-CCT TAT TCC CTT TTT TGC GG	1927 ^a	27-46
1907 ^b	5'-CAC CTA TCT CAG CGA TCT GTC T	1927 ^a	817-838
1908	5'-AAC AGC GGT AAG ATC CTT GAG AG	1927 ^a	148-170
1907 ^b	5'-CAC CTA TCT CAG CGA TCT GTC T	1927 ^a	817-838
<u>Resistance gene:</u> <i>catI</i>			
2145	5'-GCA AGA TGT GGC GTG TTA CGG T	2147 ^a	363-384
2146 ^b	5'-GGG GCG AAG AAG TTG TCC ATA TT	2147 ^a	484-506
<u>Resistance gene:</u> <i>catII</i>			
2148	5'-CAG ATT AAA TGC GGA TTC AGC C	2150 ^a	67-88
2149 ^b	5'-ATC AGG TAA ATC ATC AGC GGA TA	2150 ^a	151-173
<u>Resistance gene:</u> <i>catIII</i>			
2151	5'-ATA TTT CAG CAT TAC CTT GGG TT	2153 ^a	419-441
2152 ^b	5'-TAC ACA ACT CTT GTA GCC GAT TA	2153 ^a	603-625
<u>Resistance gene:</u> <i>catP</i>			
2154	5'-CGC CAT TCA GAG TTT AGG AC	2156 ^a	178-197
2155 ^b	5'-TTC CAT ACC GTT GCG TAT CAC TT	2156 ^a	339-361
<u>Resistance gene:</u> <i>cat</i>			
2157	5'-CCA CAG AAA TTG ATA TTA GTG TTT TAT	2159 ^a	89-115
2158 ^b	5'-TCG CTA TTG TAA CCA GTT CTA	2159 ^a	201-221
2160	5'-TTT TGA ACA CTA TTT TAA CCA GC	2162 ^a	48-70
2161 ^b	5'-GAT TTA ACT TAT CCC AAT AAC CT	2162 ^a	231-253

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes sequences) (continued).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
Resistance gene: <i>dfrA</i>			
1450	5'-ACC ACT GGG AAT ACA CTT GTA ATG GC	1452 ^a	106-131
1451 ^b	5'-ATC TAC CTG GTC AAT CAT TGC TTC GT	1452 ^a	296-321
Resistance gene: <i>dhfrIa</i>			
1457	5'-CAA AGG TGA ACA GCT CCT GTT T	1461 ^a	75-96
1458 ^b	5'-TCC GTT ATT TTC TTT AGG TTG GTT AAA	1461 ^a	249-275
1459	5'-AAG GTG AAC AGC TCC TGT TT	1461 ^a	77-96
1560 ^b	5'-GAT CAC TAC GTT CTC ATT GTC A	1461 ^a	207-228
Resistance genes: <i>dhfrIa, dhfrIV</i>			
1453	5'-ATC GAA GAA TGG AGT TAT CGG RAA TG	1461 ^a	27-52
1454 ^b	5'-CCT AAA AYT RCT GGG GAT TTC WGG A	1461 ^a	384-408
1455	5'-CAG GTG GTG GGG AGA TAT ACA AAA	1461 ^a	290-313
1456 ^b	5'-TAT GTT AGA SRC GAA GTC TTG GKT AA	1461 ^a	416-441
Resistance gene: <i>dhfrIb</i>			
1466	5'-AAG CAT TGA CCT ACA ATC AGT GT	1470 ^a	98-120
1467 ^b	5'-AAT ACA ACT ACA TTG TCA TCA TTT GAT	1470 ^a	204-230
1468	5'-CGT TAC CCG CTC AGG TTG GAC ATC AA	1470 ^a	183-208
1469 ^b	5'-CAT CCC CCT CTG GCT CGA TGT CG	1470 ^a	354-376
Resistance gene: <i>dhfrV</i>			
1471	5'-GAT AAT GAC AAC GTA ATA GTA TTC CC	1475 ^a	208-233
1472 ^b	5'-GCT CAA TAT CAA TCG TCG ATA TA	1475 ^a	342-364
1473	5'-TTA AAG CCT TGA CGT ACA ACC AGT GG	1475 ^a	95-120
1474 ^b	5'-TGG GCA ATG TTT CTC TGT AAA TCT CC	1475 ^a	300-325
Resistance genes: <i>dhfrIb, dhfrV</i>			
1462	5'-GCA CTC CCY AAT AGG AAA TAC GC	1470 ^a	157-179
1463 ^b	5'-AGT GTT GCT CAA AAA CAA CTT CG	1470 ^a	405-427
1464	5'-ACG TTY GAA TCT ATG GGM GCA CT	1470 ^a	139-161
1465 ^b	5'-GTC GAT AAG TGG AGC GTA GAG GC	1470 ^a	328-350

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes) (continued).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
Resistance gene: dhfrVI			
1476	5'-GGC GAG CAG CTC CTA TTC AAA G	1480 ^a	79-100
1477 ^b	5'-TAG GTA AGC TAA TGC CGA TTC AAC A	1480 ^a	237-261
1478	5'-GAG AAT GGA GTA ATT GGC TCT GGA TT	1480 ^a	31-56
1479 ^b	5'-GCG AAA TAC ACA ACA TCA GGG TCA T	1480 ^a	209-233
Resistance gene: dhfrVII			
1485	5'-AAA ATG GCG TAA TCG GTA ATG GC	1489 ^a	32-54
1486 ^b	5'-CAT TTG AGC TTG AAA TTC CTT TCC TC	1489 ^a	189-214
1487	5'-AAT CGA AAA TAT GCA GTA GTG TCG AG	1489 ^a	166-191
1488 ^b	5'-AGA CTA TTG TAG ATT TGA CCG CCA	1489 ^a	294-317
Resistance genes: dhfrVII, dhfrXVII			
1481	5'-RTT ACA GAT CAT KTA TAT GTC TCT	1489 ^a	268-291
1482 ^b	5'-TAA TTT ATA TTA GAC AWA AAA AAC TG	1489 ^a	421-446
1483	5'-CAR YGT CAG AAA ATG GCG TAA TC	1489 ^a	23-45
1484 ^b	5'-TKC AAA GCR WTT TCT ATT GAA GGA AA	1489 ^a	229-254
Resistance gene: dhfrVIII			
1490	5'-GAC CTA TGA GAG CTT GCC CGT CAA A	1494 ^a	144-168
1491 ^b	5'-TCG CCT TCG TAC AGT CGC TTA ACA AA	1494 ^a	376-401
1492	5'-CAT TTT AGC TGC CAC CGC CAA TGG TT	1494 ^a	18-43
1493 ^b	5'-GCG TCG CTG ACG TTG TTC ACG AAG A	1494 ^a	245-269
Resistance gene: dhfrIX			
1495	5'-TCT CTA AAC ATG ATT GTC GCT GTC	1499 ^a	7-30
1496 ^b	5'-CAG TGA GGC AAA AGT TTT TCT ACC	1499 ^a	133-156
1497	5'-CGG ACG ACT TCA TGT GGT AGT CAG T	1499 ^a	171-195
1498 ^b	5'-TTT GTT TTC AGT AAT GGT CGG GAC CT	1499 ^a	446-471

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes & sequences) (continued).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> <i>dhfrXII</i>			
1500	5'-ATC GGG TTA TTG GCA ATG GTC CTA	1504 ^a	50-73
1501 ^b	5'-GCG GTA GTT AGC TTG GCG TGA GAT T	1504 ^a	201-225
1502	5'-GCG GGC GGA GCT GAG ATA TAC A	1504 ^a	304-325
1503 ^b	5'-AAC GGA GTG GGT GTA CGG AAT TAC AG	1504 ^a	452-477
<u>Resistance gene:</u> <i>dhfrXIII</i>			
1505	5'-ATT TTT CGC AGG CTC ACC CAG AGC	1507 ^a	106-129
1506 ^b	5'-CGG ATG AGA CAA CCT CGA ATT CTG CTG	1507 ^a	413-439
<u>Resistance gene:</u> <i>dhfrXV</i>			
1508	5'-AGA ATG TAT TGG TAT TTC CAT CTA TCG	1512 ^a	215-241
1509 ^b	5'-CAA TGT CGA TTG TTG AAA TAT GTA AA	1512 ^a	336-361
1510	5'-TGG AGT GCC AAA GGG GAA CAA T	1512 ^a	67-88
1511 ^b	5'-CAG ACA CAA TCA CAT GAT CCG TTA TCG	1512 ^a	266-292
<u>Resistance gene:</u> <i>dhfrXVII</i>			
1513	5'-TTC AAG CTC AAA TGA AAA CGT CC	1517 ^a	201-223
1514 ^b	5'-GAA ATT CTC AGG CAT TAT AGG GAA T	1517 ^a	381-405
1515	5'-GTG GTC AGT AAA AGG TGA GCA AC	1517 ^a	66-88
1516 ^b	5'-TCT TTC AAA GCA TTT TCT ATT GAA GG	1517 ^a	232-257
<u>Resistance gene:</u> <i>emhR</i>			
2102	5'-CAC CTT CAC CCT GAC CGA CG	2105 ^a	822-841
2103 ^b	5'-CGA ACC AGC GGA AAT AGT TGG AC	2105 ^a	948-970
<u>Resistance genes:</u> <i>ereA, ereA2</i>			
1528	5'-AAC TTG AGC GAT TTT CGG ATA CCC TG	1530 ^a	80-105
1529 ^b	5'-TTG CCG ATG AAA TAA CCG CCG ACT	1530 ^a	317-340

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes sequences) (continu d).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
Resistance gene: ereB			
1531	5'-TCT TTT TGT TAC GAC ATA CGC TTT T	1535 ^a	152-176
1532 ^b	5'-AGT GCT TCT TTA TCC GCT GTT CTA	1535 ^a	456-479
1533	5'-CAG CGG ATA AAG AAG CAC TAC ACA TT	1535 ^a	461-486
1534 ^b	5'-CCT CCT GAA ATA AAG CCC GAC AT	1535 ^a	727-749
Resistance gene: gyra			
1340	5'-GAA CAA GGT ATG ACA CCG GAT AAA T	1299 ^a	163-188
1341 ^b	5'-GAT AAC TGA AAT CCT GAG CCA TAC G	1299 ^a	274-299
1936	5'-TAC CAC CCG CAC GGC	1954 ^a	205-219
1937 ^b	5'-CGG AGT CGC CGT CGA TG	1954 ^a	309-325
1942	5'-GAC TGG AAC AAA GCC TAT AAA AAA TCA	1954 ^a	148-174
1937 ^b	5'-CGG AGT CGC CGT CGA TG	1954 ^a	309-325
2040	5'-TGT GAC CCC AGA CAA ACC C	2054 ^a	33-51
2041 ^b	5'-GTT GAG CGG CAG CAC TAT CT	2054 ^a	207-226
Resistance gene: inhA			
2098	5'-CTG AGT CAC ACC GAC AAA CGT C	2101 ^a	910-931
2099 ^b	5'-CCA GGA CTG AAC GGG ATA CGA A	2101 ^a	1074-1095
Resistance genes: linA, linA'			
1536 ^a	5'-AGA TGT ATT AAC TGG AAA ACA ACA A	1540 ^a	99-123 ^a
1537 ^b	5'-CTT TGT AAT TAG TTT CTG AAA ACC A	1540 ^a	352-376
1538	5'-TTA GAA GAT ATA GGA TAC AAA ATA GAA G	1540 ^a	187-214
1539 ^b	5'-GAA TGA AAA AGA AGT TGA GCT T	1540 ^a	404-425
Resistance gene: linB			
1541	5'-TGA TAA TCT TAT ACG TGG GGA ATT T	1545 ^a	246-270
1542 ^b	5'-ATA ATT TTC TAA TTG CCC TGT TTC AT	1545 ^a	359-384
1543	5'-GGG CAA TTA GAA AAT TAT TTA TCA GA	1545 ^a	367-392
1544 ^b	5'-TTT TAC TCA TGT TTA GCC AAT TAT CA	1545 ^a	579-604

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes sequences) (continued).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> <i>mefA</i>			
1546	5'-CAA GAA GGA ATG GCT GTA CTA C	1548 ^a	625-646
1547 ^b	5'-TAA TTC CCA AAT AAC CCT AAT AAT AGA	1548 ^a	816-842
<u>Resistance gene:</u> <i>mefE</i>			
1549	5'-GCT TAT TAT TAG GAA GAT TAG GGG GC	1551 ^a	815-840
1550 ^b	5'-TAG CAA GTG ACA TGA TAC TTC CGA	1551 ^a	1052-1075
<u>Resistance genes:</u> <i>mefA, mefE</i>			
1552	5'-GGC AAG CAG TAT CAT TAA TCA CTA	1548 ^a	50-73
1553 ^b	5'-CAA TGC TAC GGA TAA ACA ATA CTA TC	1548 ^a	318-343
1554	5'-AGA AAA TTA AGC CTG AAT ATT TAG GAC	1548 ^a	1010-1035
1555 ^b	5'-TAG TAA AAA CCA ATG ATT TAC ACC G	1548 ^a	1119-1143
<u>Resistance genes:</u> <i>mphA, mphK</i>			
1556	5'-ACT GTA CGC ACT TGC AGC CCG ACA T	1560 ^a	33-57
1557 ^b	5'-GAA CGG CAG GCG ATT CTT GAG CAT	1560 ^a	214-237
1558	5'-GTG GTG GTG CAT GGC GAT CTC T	1560 ^a	583-604
1559 ^b	5'-GCC GCA GCG AGG TAC TCT TCG TTA	1560 ^a	855-878
<u>Resistance gene:</u> <i>mupA</i>			
2142	5'-GCC TTA ATT TCG GAT AGT GC	2144 ^a	1831-1850
2143 ^b	5'-GAG AAA GAG CCC AAT TAT CTA ATG T	2144 ^a	2002-2026
<u>Resistance gene:</u> <i>parC</i>			
1342	5'-GAT GTT ATT GGT CAA TAT CAT CCA	1321 ^a	205-229
1343 ^b	5'-AAG AAA CTG TCT CTT TAT TAA TAT CAC GT	1321 ^a	396-425
1934	5'-GAA CGC CAG CGC GAA ATT CAA AAA G	1781	67-91
1935 ^b	5'-AGC TCG GCA TAC TTC GAC AGG	1781	277-297
2044	5'-ACC GTA AGT CGG CCA AGT CA	2055 ^a	176-195
2045 ^b	5'-GTT CTT TCT CCG TAT CGT C	2055 ^a	436-454

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes sequences) (continu d).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> <i>ppflo-like</i>			
2163	5'-ACC TTC ATC CTA CCG ATG TGG GTT	2165 ^a	922-945
2164 ^b	5'-CAA CGA CAC CAG CAC TGC CAT TG	2165 ^a	1136-1158
<u>Resistance gene:</u> <i>rpoB</i>			
2065	5'-CCA GGA CGT GGA GGC GAT CAC A	2072 ^a	1218-1239
2066 ^b	5'-CAC CGA CAG CGA GCC GAT CAG A	2072 ^a	1485-1506
<u>Resistance gene:</u> <i>satG</i>			
1581	5'-AAT TGG GGA CTA CAC CTA TTA TGA TG	1585 ^a	93-118
1582 ^b	5'-GGC AAA TCA GTC AGT TCA GGA GT	1585 ^a	310-332
1583	5'-CGA TTG GCA ACA ATA CAC TCC TG	1585 ^a	294-316
1584 ^b	5'-TCA CCT ATT TTT ACG CCT GGT AGG AC	1585 ^a	388-413
<u>Resistance gene:</u> <i>sulII</i>			
1961	5'-GCT CAA GGC AGA TGG CAT TCC C	1965 ^a	222-243
1962 ^b	5'-GGA CAA GGC GGT TGC GTT TGA T	1965 ^a	496-517
1963	5'-CAT TCC CGT CTC GCT CGA CAG T	1965 ^a	237-258
1964 ^b	5'-ATC TGC CTG CCC GTC TTG C	1965 ^a	393-411
<u>Resistance gene:</u> <i>tetB</i>			
1966	5'-CAT GCC AGT CTT GCC AAC G	1970 ^a	66-84
1967 ^b	5'-CAG CAA TAA GTA ATC CAG CGA TG	1970 ^a	242-264
1968	5'-GGA GAG ATT TCA CCG CAT AG	1970 ^a	457-476
1969 ^b	5'-AGC CAA CCA TCA TGC TAT TCC A	1970 ^a	721-742
<u>Resistance gene:</u> <i>tetM</i>			
1586	5'-ATT CCC ACA ATC TTT TTT ATC AAT AA	1590 ^a	361-386
1587 ^b	5'-CAT TGT TCA GAT TCG GTA AAG TTC	1590 ^a	501-524
1588	5'-GTT TTT GAA GTT AAA TAG TGT TCT T	1590 ^a	957-981
1589 ^b	5'-CTT CCA TTT GTA CTT TCC CTA	1590 ^a	1172-1192

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes sequences) (continued).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> <i>vatB</i>			
1609	5'-GCC CTG ATC CAA ATA GCA TAT A	1613 ^a	11-32
1610 ^b	5'-CCT GGC ATA ACA GTA ACA TTC TG	1613 ^a	379-401
1611	5'-TGG GAA AAA GCA ACT CCA TCT C	1613 ^a	301-322
1612 ^b	5'-ACA ACT GAA TTC GCA GCA ACA AT	1613 ^a	424-446
<u>Resistance gene:</u> <i>vatC</i>			
1614	5'-CCA ATC CAG AAG AAA TAT ACC C	1618 ^a	26-47
1615 ^b	5'-ATT AGT TTA TCC CCA ATC AAT TCA	1618 ^a	177-200
1616	5'-ATA ATG AAT GGG GCT AAT CAT CGT AT	1618 ^a	241-266
1617 ^b	5'-GCC AAC AAC TGA ATA AGG ATC AAC	1618 ^a	463-486
<u>Resistance gene:</u> <i>vga</i>			
1619	5'-AAG GCA AAA TAA AAG GAG CAA AGC	1623 ^a	641-664
1620 ^b	5'-TGT ACC CGA GAC ATC TTC ACC AC	1623 ^a	821-843
1621	5'-AAT TGA AGG ACG GGT ATT GTG GAA AG	1623 ^a	843-868
1622 ^b	5'-CGA TTT TGA CAG ATG GCG ATA ATG AA	1623 ^a	975-1000
<u>Resistance gene:</u> <i>vgaB</i>			
1624	5'-TTC TTT AAT GCT CGT AGA TGA ACC TA	1628 ^a	354-379
1625 ^b	5'-TTT TCG TAT TCT TCT TGT TGC TTT C	1628 ^a	578-602
1626	5'-AGG AAT GAT TAA GCC CCC TTC AAA AA	1628 ^a	663-688
1627 ^b	5'-TTA CAT TGC GAC CAT GAA ATT GCT CT	1628 ^a	849-874
<u>Resistance genes:</u> <i>vgb, vgh</i>			
1629	5'-AAG GGG AAA GTT TGG ATT ACA CAA CA	1633 ^a	73-98
1630 ^b	5'-GAA CCA CAG GGC ATT ATC AGA ACC	1633 ^a	445-468
1631	5'-CGA CGA TGC TTT ATG GTT TGT	1633 ^a	576-596
1632 ^b	5'-GTT AAT TTG CCT ATC TTG TCA CAC TC	1633 ^a	850-875

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes sequences) (continu d).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> <i>vgbB</i>			
1634	5'-TTA ACT TGT CTA TTC CCG ATT CAG G	1882 ^a	23-47
1635 ^b	5'-GCT GTG GCA ATG GAT ATT CTG TA	1882 ^a	267-289
1636	5'-TTC CTA CCC CTG ATG CTA AAG TGA	1882 ^a	155-178
1637 ^b	5'-CAA ACT GCG TTA TCC GAA CCT AA	1882 ^a	442-464
<u>Sequencing primers</u>			
<u>Resistance gene:</u> <i>gyrA</i>			
1290	5'-GAY TAY GCI ATG ISI GTI ATH GT	1299 ^a	70-83
1292 ^b	5'-ARI SCY TCI ARI ATR TGI GC	1299 ^a	1132-1152
1291	5'-GCI YTI CCI GAY GTI MGI GAY GG	1299 ^a	100-123
1292 ^b	5'-ARI SCY TCI ARI ATR TGI GC	1299 ^a	1132-1152
1293	5'-ATG GCT GAA TTA CCT CAA TC	1299 ^a	1-21
1294 ^b	5'-ATG ATT GTT GTA TAT CTT CTT CAA C	1299 ^a	2626-2651
1295 ^b	5'-CAG AAA GTT TGA AGC GTT GT	1299 ^a	1255-1275
1296	5'-AAC GAT TCG TGA GTC AGA TA	1299 ^a	1188-1208
1297	5'-CGG TCA ACA TTG AGG AAG AGC T	1300 ^a	29-51
1298 ^b	5'-ACG AAA TCG ACC GTC TCT TTT TC	1300 ^a	415-437
<u>Resistance gene:</u> <i>gyrB</i>			
1301	5'-GTI MGT ATI MGT CCI GST ATG TA	1307 ^a	82-105
1302 ^b	5'-TAI ADI GGI GGI KKI GCI ATR TA	1307 ^a	1600-1623
1303	5'-GGI GAI GAI DYI MGI GAR GG	1307 ^a	955-975
1304 ^b	5'-CIA RYT TIK YIT TIG TYT G	1307 ^a	1024-1043
1305	5'-ATG GTG ACT GCA TTG TCA GAT G	1307 ^a	1-23
1306 ^b	5'-GTC TAC GGT TTT CTA CAA CGT C	1307 ^a	1858-1888

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex L: Specific and ubiquitous primers for nucleic acid amplification (antimicrobial agents resistance genes sequences) (continued).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment		
		SEQ ID NO.	Nucleotide position	
Sequencing primers (continued)				
<u>Resistance gene:</u> parC				
1308	5'-ATG TAY GTI ATI ATG GAY MGI GC	1320 ^a	67-90	
1309 ^b	5'-ATI ATY TTR TTI CCY TTI CCY TT	1320 ^a	1993-2016	
1310	5'-ATI ATI TSI ATI ACY TCR TC	1320 ^a	1112-1132	
1311 ^b	5'-GAR ATG AAR ATI MGI GGI GAR CA	1320 ^a	1288-1311	
1312	5'-AAR TAY ATI ATI CAR GAR MGI GC	1321 ^a	67-90	
1313 ^b	5'-AMI AYI CKR TGI GGI TTI TTY TT	1321 ^a	2212-2235	
1314	5'-TAI GAI TTY ACI GAI SMI CAR GC	1321 ^a	1228-1251	
1315 ^b	5'-ACI ATI GCI TCI GCY TGI KSY TC	1321 ^a	1240-1263	
1316	5'-GTG AGT GAA ATA ATT CAA GAT T	1321 ^a	1-23	
1317 ^b	5'-CAC CAA AAT CAT CTG TAT CTA C	1321 ^a	2356-2378	
1318	5'-ACC TAY TCS ATG TAC GTR ATC ATG GA	1320 ^a	58-84	
1319 ^b	5'-AGR TCG TCI ACC ATC GGY AGY TT	1320 ^a	832-855	
<u>Resistance gene:</u> parE				
1322	5'-RTI GAI AAY ISI GTI GAY GAR G	1328 ^a	133-155	
1325 ^b	5'-RTT CAT YTC ICC IAR ICC YTT	1328 ^a	1732-1752	
1323	5'-ACI AWR SAI GGI GGI ACI CAY G	1328 ^a	829-850	
1324 ^{a,b}	5'-CTT CCT TGT GCT SWR TCT CCY TC	1328 ^{a,b}	1280-1302 ^{a,b}	
1326	5'-TGA TTC AAT ACA GGT TTT AGA G	1328 ^a	27-49	
1327 ^b	5'-CTA GAT TTC CTC CTC ATC AAA T	1328 ^a	1971-1993	

^a Sequence from databases.

^b These sequences are from the complementary DNA strand of the sequence of the originating fragment given in the Sequence Listing.

Annex LI: Internal hybridization probes for specific detection of antimicrobial agents resistance genes sequences.

		Originating DNA fragment	
SEQ ID NO.	Nucleotide sequence	SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> aph3'VIa			
2252	5'-CCA CAT ACA GTG TCT CTC	1406 ^a	149-166
<u>Resistance gene:</u> blaSHV			
1886	5'-GAC GCC CGC GCC ACC ACT	1900 ^a	484-501
1887	5'-GAC GCC CGC GAC ACC ACT A	1899 ^a	514-532
1888	5'-GAC GCC CGC AAC ACC ACT A	1901 ^a	514-532
1889	5'-GTT CGC AAC TGC AGC TGC TG	1899 ^a	593-612
1890	5'-TTC GCA ACG GCA GCT GCT G	1899 ^a	594-612
1891	5'-CCG GAG CTG CCG AIC GGG	1902 ^a	692-709
1892	5'-CGG AGC TGC CAA RCG GGG	1903 ^a	693-710
1893	5'-GGA GCT GGC GAR CGG GGT	1899 ^a	694-711
1894	5'-GAC CGG AGC TAG CGA RCG	1904 ^a	690-707
1895	5'-CGG AGC TAG CAA RCG GGG T	1905 ^a	693-711
1896	5'-GAA ACG GAA CTG AAT GAG GCG	1899 ^a	484-504
1897	5'-CAT TAC CAT GGG CGA TAA CAG	1899 ^a	366-386
1898	5'-CCA TTA CCA TGA GCG ATA ACAG	1899 ^a	365-386
<u>Resistance gene:</u> blaTEM			
1909	5'-ATG ACT TGG TTA AGT ACT CAC C	1928 ^a	293-314
1910	5'-ATG ACT TGG TTG AGT ACT CAC C	1927 ^a	293-314
1911	5'-CCA TAA CCA TGG GTG ATA ACA C	1928 ^a	371-392
1912	5'-CCA TAA CCA TGA GTG ATA ACA C	1927 ^a	371-392
1913	5'-CGC CTT GAT CAT TGG GAA CC	1928 ^a	475-494
1914	5'-CGC CTT GAT CGT TGG GAA CC	1927 ^a	475-494
1915	5'-CGC CTT GAT AGT TGG GAA CC	1929 ^a	475-494
1916	5'-CGT GGG TCT TGC GGT ATC AT	1927 ^a	712-731
1917	5'-CGT GGG TCT GGC GGT ATC AT	1930 ^a	712-731
1918	5'-GTG GGT CTC ACG GTA TCA TTG	1927 ^a	713-733
1919	5'-CGT GGG TCT CTC GGT ATC ATT	1931 ^a	712-732
1920	5'-CGT GGI TCT CGC GGT ATC AT	1927 ^a	712-731
1921	5'-CGT GGG TCT AGC GGT ATC ATT	1932 ^a	713-733
1922	5'-GTT TTC CAA TGA TTA GCA CTT TTA	1927 ^a	188-211
1923	5'-GTT TTC CAA TGA TAA GCA CTT TTA	1927 ^a	188-211
1924	5'-GTT TTC CAA TGC TGA GCA CTT TT	1932 ^a	188-210
1925	5'-CGT TTT CCA ATG ATG AGC ACT TT	1927 ^a	187-209
1926	5'-GTT TTC CAA TGG TGA GCA CTT TT	1933 ^a	188-210
2006	5'-TGG AGC CGG TGA GCG TGG	1927 ^a	699-716

^a Sequence from databases.

Annex LI: Internal hybridization probes for specific detection of antimicrobial agents resistance genes sequences (continued).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> blATEM (continued)			
2007	5'-TGG AGC CAG TGA GCG TGG	2010 ^a	699-716
2008	5'-TCT GGA GCC GAT GAG CGT G	1929 ^a	697-715
2009	5'-CTG GAG CCA GTA AGC GTG G	2011 ^a	698-716
2141	5'-CAC CAG TCA CAG AAA AGC	1927 ^a	311-328
<u>Resistance gene:</u> dhfrIa			
2253	5'-CAT TAC CCA ACC GAA AGT A	1461 ^a	158-176
<u>Resistance gene:</u> embB			
2104	5'-CTG GGC ATG GCI CGA GTC	2105 ^a	910-927
<u>Resistance gene:</u> gyrA			
1333	5'-TCA TGG TGA CTT ATC TAT TTA TG	1299 ^a	240-263
1334	5'-CAT CTA TTT ATA AAG CAA TGG TA	1299 ^a	251-274
1335	5'-CTA TTT ATG GAG CAA TGG T	1299 ^a	254-273
1940	5'-GTA TCG TTG GTG ACG TAA T	1299 ^a	206-224
1943	5'-GCT GGT GGA CGG CCA G	1954 ^a	279-294
1945	5'-CGG CGA CTA CGC GGT AT	1954 ^a	216-232
1946	5'-CGG CGA CTT CGC GGT AT	1954 ^a	216-232
1947	5'-CGG TAT ACG GCA CCA TCG T	1954 ^a	227-245
1948	5'-GCG GTA TAC AAC ACC ATC G	1954 ^a	226-244
1949	5'-CGG TAT ACG CCA CCA TCG T	1954 ^a	227-245
2042	5'-CAC GGG GAT TTC TCT ATT TA	2054 ^a	103-122
2043	5'-CAC GGG GAT TAC TCT ATT TA	2054 ^a	103-122
<u>Resistance gene:</u> inhA			
2100	5'-GCG AGA CGA TAG GTT GTC	2101 ^a	1017-1034
<u>Resistance gene:</u> parC			
1336	5'-TGG AGA CTA CTC AGT GT	1321 ^a	232-249
1337	5'-TGG AGA CTT CTC AGT GT	1321 ^a	232-249
1338	5'-GTG TAC GGA GCA ATG	1321 ^a	245-260
1339	5'-CCA GCG GAA ATG CGT	1321 ^a	342-357
1941	5'-GCA ATG GTC CGT TTA AGT	1321 ^a	253-270
1944	5'-TTT CGC CGC CAT GCG TTA C	1781	247-265
1950	5'-GGC GAC ATC GCC TGC	1781	137-151
1951	5'-GGC GAC AGA GCC TGC TA	1781	137-153

^a Sequence from databases.

Annex LI: Internal hybridization probes for specific detection of antimicrobial agents resistance genes sequences (continued).

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Resistance gene:</u> <i>parC</i> (continued)			
1952	5'-CCT GCT ATG GAG CGA TGG T	1781	147-165
1953	5'-CGC CTG CTA TAA AGC GAT GGT	1781	145-165
2046	5'-ACG GGG ATT TTT CTA TCT AT	2055 ^a	227-246
<u>Resistance gene:</u> <i>xpoB</i>			
2067	5'-AGC TGA GCC AAT TCA TGG	2072 ^a	1304-1321
2068	5'-ATT CAT GGA CCA GAA CAA C	2072 ^a	1314-1332
2069	5'-CGC TGT CGG GGT TGA CCC	2072 ^a	1334-1351
2070	5'-GTT GAC CCA CAA GCG CCG	2072 ^a	1344-1361
2071	5'-CGA CTG TCG GCG CTG GGG	2072 ^a	1360-1377
<u>Resistance gene:</u> <i>tetM</i>			
2254	5'-ACC TGA ACA GAG AGA AAT G	1590 ^a	1062-1080

^a Sequence from databases.

Annex LII: Molecular beacon internal hybridization probes for specific detection of *atpD* sequences.

		Originating DNA fragment	
SEQ ID NO.	Nucleotide sequence ^a	SEQ ID NO.	Nucleotide position
<u>Bacterial species:</u> <i>Bacteroides fragilis</i>			
2136	5'- <u>CCA</u> ACG CGT CCT CAA TCA TTT CTA ACT TCT ATG GCC GGC GTT GG	929	353-382
<u>Bacterial species:</u> <i>Bordetella pertussis</i>			
2182	5'- <u>GCG</u> CGC CAA CGA CTT CTA CCA CGA AAT GGA AGA GTC <u>GCG</u> CGC	1672	576-605
<u>Bacterial group:</u> <i>Campylobacter jejuni</i> and <i>C. coli</i>			
2133	5'- <u>CCA</u> CGC ACA WAA ACT TGT TTT AGA AGT AGC AGC WCA <u>GCG</u> TGG	1576, 1600, 1849, 1863, 2139b,c	44-73 ^d
<u>Fungal species:</u> <i>Candida glabrata</i>			
2078	5'- <u>CCG</u> AGC CTT GGT CTT CGG CCA AAT GAA CGC <u>TCG</u> G	463	442-463
<u>Fungal species:</u> <i>Candida krusei</i>			
2075	5'- <u>CCG</u> AGC CAG GTT CTG AAG TCT CTG CAT TAT TAG GTG <u>CTC</u> GG	468	720-748
<u>Fungal species:</u> <i>Candida lusitaniae</i>			
2080	5'- <u>CCG</u> AGC CGA AGA GGG CCA AGA TGT CGC <u>TCG</u> G	470	520-538
<u>Fungal species:</u> <i>Candida parapsilosis</i>			
2079	5'- <u>CCG</u> AGC GTT CAG TTA CTT CAG TCC AAG CCG <u>GCT</u> CGG	472	837-860
<u>Fungal species:</u> <i>Candida tropicalis</i>			
2077	5'- <u>CCG</u> AGC AAC CGA TCC AGC TCC AGC TAC <u>GCT</u> CGG	475	877-897
<u>Bacterial species:</u> <i>Klebsiella pneumoniae</i>			
2281	5'- <u>CCC</u> CCA GCT GGG CGG CGG TAT CGA TGG GGG	317	40-59

^a Underlined nucleotides indicate the molecular beacon's stem.

^b Sequence from databases.

^c These sequences were aligned to derive the corresponding primer.

^d The nucleotide positions refer to the *C. jejuni* *atpD* sequence fragment (SEQ ID NO. 1576).

Annex LII: Molecular beacon internal hybridization probes for specific detection of *atpD* sequences (continued).

		Originating DNA fragment	
SEQ ID NO.	Nucleotide sequence ^a	SEQ ID NO.	Nucleotide position
<u>Fungal genus:</u> <i>Candida sp.</i>			
2076	5' - <u>CCG AGC</u> YGA YAA CAT TTT CAG ATT CAC CCA 460-478, RGC <u>GCT CGG</u>	663 ^b	697-723 ^c

^a Underlined nucleotides indicate the molecular beacon's stem.

^b These sequences were aligned to derive the corresponding primer.

^c The nucleotide positions refer to the *C. albicans* *atpD* sequence fragment (SEQ ID NO. 460).

Annex LIII: Internal hybridization probes for specific detection of *atpD* sequences.

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
<u>Bacterial species:</u> <i>Acinetobacter baumannii</i>			
2169	5'-CCC GTT TGC GAA AGG TGG	243	304-321
<u>Bacterial species:</u> <i>Klebsiella pneumoniae</i>			
2167	5'-CAG CAG CTG GGC GGC GGT	317	36-53

Annex LIV: Internal hybridization probes for specific detection of *ddl* and *mtl* sequences.

SEQ ID NO.	Nucleotide sequence	Originating DNA fragment	
		SEQ ID NO.	Nucleotide position
Bacterial species: <i>Enterococcus faecium</i> (<i>ddl</i>)			
2286	5'-AGT TGC TGT ATT AGG AAA TG	2288 ^a	784-803
2287	5'-TCG AAG TTG CTG TAT TAG GA	2288 ^a	780-799
Bacterial species: <i>Enterococcus faecalis</i> (<i>mtl</i>)			
2289	5'-CAC CGA AGA AGA TGA AAA AA	1243 ^a	264-283
2290	5'-TGG CAC CGA AGA AGA TGA	1243 ^a	261-278
2291	5'-ATT TTG GCA CCG AAG AAG A	1243 ^a	257-275

^a Sequence from databases.

What is claimed is:

1. A method for generating a repertory of nucleic acids of *tuf*, *fus*, *atpD* and/or *recA* genes from which are derived probes or primers, or both, useful for the detection of one, more than one related microorganisms, or substantially all microorganisms of a group selected from algae, archaea, bacteria, fungi and parasites, which comprises the step of:
 - amplifying the nucleic acids of a plurality of determined algal, archaeal, bacterial, fungal and parasitical species with any combination of the primer pairs defined in SEQ ID NOs.: 543, 556-574, 636-655, 664, 681-683, 694, 696-697, 699-700, 708, 812-815, 911-917, 919-922, 935-938, 1203-1207, 1212-1213, 1221-1229, 1605-1606, 1974-1984, 1999-2003, 2282-2285.
2. A method for generating a repertory of nucleic acid sequences, which comprises the steps of:
 - reproducing the method of claim 1, and
 - adding the step of:
 - sequencing said nucleic acids.
3. A method for generating sequences of probes, or primers, or both, useful for the detection of one, more than one related microorganisms, or substantially all microorganisms of a group selected from algae, archaea, bacteria, fungi and parasites, which comprises the steps of:
 - reproducing the method of claim 2, and
 - adding the steps of:
 - aligning a subset of nucleic acid sequences of said repertory,
 - locating nucleic acid stretches that are present in the nucleic acids of strains or representatives of said one, more than one related microorganisms, or substantially all microorganisms of said group, and not present in the nucleic acid sequences of other microorganisms, and

- deriving consensus nucleic acid sequences useful as probes or primers from said stretches.

4. A bank of nucleic acids comprising the repertory of nucleic acids obtained from the method of claim 1.

5. A bank of nucleic acid sequences comprising the repertory of nucleic acid sequences obtained from the method of claim 2.

6. A method for generating sequences of probes, or primers, or both, useful for the detection of one, more than one related microorganisms, or substantially all microorganisms of a group selected from algae, archaea, bacteria, fungi and parasites, which comprises the steps of:

- aligning a subset of nucleic acid sequences of the bank as defined in claim 5,
- locating nucleic acid sequence stretches that are present in the nucleic acid sequences of strains or representatives of said one, more than one related microorganisms, or substantially all microorganisms of said group, and not present in the nucleic acid sequences of other microorganisms, and
- deriving consensus nucleic acid sequences useful as probes or primers from said stretches.

7. A method for generating probes, or primers or both, useful for the detection of one, more than one related microorganisms, or substantially all microorganisms of a group selected from algae, archaea, bacteria, fungi and parasites, which comprises the steps of:

- reproducing the method of claim 3 or 6, and
- adding the step of:
 - synthesising said probes or primers upon the nucleic acid sequences thereof.

8. A nucleic acid used for universal detection of any one of alga, archaeon, bacterium, fungus and parasite which is obtained from the method of claim 7.

9. A nucleic acid used for universal detection as set forth in claim 8, which has a nucleic acid sequence of at least 12 nucleotides capable of hybridizing with said any one of alga, archaeon, bacterium, fungus and parasite and with any one of SEQ ID NOs.: 543, 556-574, 636-655, 658-661, 664, 681-683, 694, 696, 697, 699, 700, 708, 812-815, 911-917, 919-922, 935-938, 1203-1207, 1212-1213, 1221-1229, 1605-1606, 1974-1984, 1999-2003, 2282-2285.

10. A nucleic acid used for the specific and ubiquitous detection and for identification of any one of a algal, archaeal, bacterial, fungal and parasitital species, genus, family and group, which is obtained from the method of claim 7.

11. A nucleic acid as set forth in claim 10 having any one of the nucleotide sequences which are defined in SEQ ID NOs.:

539, 540	for the detection and/or identification of <i>Mycobacteriaceae</i> family
541, 542, 544, 2121	for the detection and/or identification of Pseudomonads group
545, 546	for the detection and/or identification of <i>Corynebacterium</i> sp.
547, 548, 1202	for the detection and/or identification of <i>Streptococcus</i> sp.
549, 550, 582, 583, 625, 626, 627, 628,	for the detection and/or identification of <i>Streptococcus agalactiae</i>
1199	
551, 552, 2166, 2173, 2174, 2175, 2176, 2177, 2178, 2179	for the detection and/or identification of <i>Neisseria gonorrhoeae</i>
553, 575, 605, 606, 707, 1175, 1176	for the detection and/or identification of <i>Staphylococcus</i> sp.
554, 555, 2213	for the detection and/or identification of <i>Chlamydia trachomatis</i>

- 576, 631, 632, 633, for the detection and/or identification of *Candida* sp.
634, 635, 1163,
1164, 1167, 2076,
2108, 2109
577, 1156, 1160 for the detection and/or identification of *Candida albicans*
2073
578, 1166, 1168, for the detection and/or identification of *Candida dubliniensis*
2074
579, 2168 for the detection and/or identification of *Escherichia coli*
580, 603, 1174, for the detection and/or identification of *Enterococcus*
1236, 1238, 2289,
2290, 2291
581 for the detection and/or identification of *Haemophilus influenzae*
584, 585, 586, 587, for the detection and/or identification of *Staphylococcus aureus*
588, 1232, 1234,
2186
589, 590, 591, 592, for the detection and/or identification of *Staphylococcus epidermidis*
593
594, 595 for the detection and/or identification of *Staphylococcus haemolyticus*
596, 597, 598 for the detection and/or identification of *Staphylococcus hominis*
599, 600, 601, 695, for the detection and/or identification of *Staphylococcus saprophyticus*
1208, 1209
602, 1235, 1237,
1696, 1697, 1698,
1699, 1700, 1701,
2286, 2287
604 for the detection and/or identification of *Enterococcus gallinarum*
620, 1122 for the detection and/or identification of *Enterococcus casseliflavus*, *E. flavescent* and *E. gallinarum*
629, 630, 2085, for the detection and/or identification of *Chlamydia pneumoniae*
2086, 2087, 2088,
2089, 2090, 2091,
2092

636, 637, 638, 639,
640, 641, 642 for the detection and/or identification of at least the following:

Abiotrophia adiacens, Abiotrophia defectiva, Acinetobacter baumannii, Acinetobacter lwoffii, Aerococcus viridans, Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Brucella abortus, Burkholderia cepacia, Citrobacter diversus, Citrobacter freundii, Enterobacter aerogenes, Enterobacter agglomerans, Enterobacter cloacae, Enterococcus avium, Enterococcus casseliflavus, Enterococcus dispar, Enterococcus durans, Enterococcus faecalis, Enterococcus faecium, Enterococcus flavescens, Enterococcus gallinarum, Enterococcus mundtii, Enterococcus raffinosus, Enterococcus solitarius, Escherichia coli, Gemella morbillorum, Haemophilus ducreyi, Haemophilus haemolyticus, Haemophilus influenzae, Haemophilus parahaemolyticus, Haemophilus parainfluenzae, Hafnia alvei, Kingella kingae, Klebsiella oxytoca, Klebsiella pneumoniae, Legionella pneumophila, Megamonas hypermegale, Moraxella atlantae, Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Pasteurella aerogenes, Pasteurella multocida, Peptostreptococcus magnus, Proteus mirabilis, Providencia alcalifaciens, Providencia rettgeri, Providencia rustigianii, Providencia stuartii, Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas stutzeri, Salmonella bongori, Salmonella choleraesuis, Salmonella enteritidis, Salmonella gallinarum, Salmonella typhimurium, Serratia liquefaciens, Serratia marcescens, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus capitis, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus lugdunensis, Staphylococcus saprophyticus, Staphylococcus simulans, Staphylococcus warneri, Stenotrophomonas maltophilia, Streptococcus acidominimus, Streptococcus agalactiae, Streptococcus anginosus, Streptococcus bovis, Streptococcus constellatus, Streptococcus cricetus, Streptococcus cristatus, Streptococcus dysgalactiae, Streptococcus equi, Streptococcus ferus, Streptococcus gordonii, Streptococcus intermedius, Streptococcus macacae, Streptococcus mitis, Streptococcus mutans, Streptococcus oralis, Streptococcus parasanguinis, Streptococcus parauberis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus ratti, Streptococcus salivarius, Streptococcus sanguinis, Streptococcus sobrinus, Streptococcus subberis, Streptococcus vestibularis, Vibrio cholerae, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis.

656, 657, 271,

for the detection and/or identification of *Enterococcus* sp.

1136, 1137

701, 702

for the detection and/or identification of *Leishmania* sp.

- 703, 704, 705, 706, for the detection and/or identification of *Entamoeba* sp.
793
794, 795 for the detection and/or identification of *Trypanosoma cruzi*
796, 797, 808, 809, for the detection and/or identification of *Clostridium* sp.
810, 811
798, 799, 800, 801, for the detection and/or identification of *Cryptosporidium*
802, 803, 804, 805, *parvum*
806, 807
816, 817, 818, 819 for the detection and/or identification of *Giardia* sp.
820, 821, 822 for the detection and/or identification of *Trypanosoma*
brucei
823, 824 for the detection and/or identification of *Trypanosoma* sp.
825, 826 for the detection and/or identification of *Bordetella* sp.
923, 924, 925, 926, for the detection and/or identification of *Trypanosomatidae*
927, 928 family
933, 934 for the detection and/or identification of *Enterobacteriaceae*
group
994, 995, 996, 997, for the detection and/or identification of *Streptococcus*
998, 999, 1000, *pyogenes*
1001, 1200, 1210,
1211
1157, 2079, 2118 for the detection and/or identification of *Candida*
parapsilosis
1158, 1159, 2078, for the detection and/or identification of *Candida glabrata*
2110, 2111
1160, 2077, 2119, for the detection and/or identification of *Candida tropicalis*
2120
1161, 2075, 2112, for the detection and/or identification of *Candida krusei*
2113, 2114
1162 for the detection and/or identification of *Candida*
guilliermondii
1162, 2080, 2115 for the detection and/or identification of *Candida lusitaniae*
2116, 2117
1165 for the detection and/or identification of *Candida*
zeylanoides
1201 for the detection and/or identification of *Streptococcus*
pneumoniae

1233	for the detection and/or identification of <i>Staphylococcus</i> sp. other than <i>S. aureus</i>
1329, 1330, 1331, 1332, 2167, 2281	for the detection and/or identification of <i>Klebsiella pneumoniae</i>
1661, 1665	for the detection and/or identification of <i>Escherichia coli</i> and <i>Shigella</i> sp.
1690, 1691, 1692, 1693, 2169	for the detection and/or identification of <i>Acinetobacter baumanii</i>
1694, 1695, 2122	for the detection and/or identification of <i>Pseudomonas aeruginosa</i>
1971, 1972, 1973	for the detection and/or identification of <i>Cryptococcus</i> sp.
2081, 2082, 2083	for the detection and/or identification of <i>Legionella</i> sp.
2084	for the detection and/or identification of <i>Legionella pneumophila</i>
2093, 2094, 2095, 2096	for the detection and/or identification of <i>Mycoplasma pneumoniae</i>
2106, 2107	for the detection and/or identification of <i>Cryptococcus neoformans</i>
2131, 2132, 2133	for the detection and/or identification of <i>Campylobacter jejuni</i> and <i>C. coli</i>
2134, 2135, 2136	for the detection and/or identification of <i>Bacteroides fragilis</i>
2170	for the detection and/or identification of <i>Abiotrophia adiacens</i>
2171	for the detection and/or identification of <i>Gemella</i> sp.
2172	for the detection and/or identification of <i>Enterococcus</i> sp., <i>Gemella</i> sp., <i>A. adiacens</i>
2180, 2181, 2182	for the detection and/or identification of <i>Bordetella pertussis</i> .

12. A method for detecting the presence in a test sample of a microorganism that is an alga, archaeum, bacterium, fungus or parasite, which comprises:

- a) putting in contact any test sample *tuf* or *atpD* or *recA* nucleic acids and nucleic acid primers and/or probes, said primers and/or probes having

been selected to be sufficiently complementary to hybridize to one or more *tuf* or *atpD* or *recA* nucleic acids that are specific to said group of microorganisms;

- b) allowing the primers and/or probes and any test sample *tuf* or *atpD* or *recA* nucleic acids to hybridize under specified conditions such as said primers and/or probes hybridize to the *tuf* or *atpD* or *recA* nucleic acids of said microorganism and does not detectably hybridize to *tuf* or *atpD* or *recA* sequences from other microorganisms; and,
- c) testing for hybridization of said primers and/or probes to any test sample *tuf* or *atpD* or *recA* nucleic acids.

13. The method of claim 12 wherein c) is based on a nucleic acid target amplification method.

14. The method of claim 12 wherein c) is based on a signal amplification method.

15. The method of any one of claims 12 to 14 wherein said primers and/or probes that are sufficiently complementary are perfectly complementary.

16. The method of any one of claims 12 to 14 wherein said primers and/or probes that are sufficiently complementary are not perfectly complementary.

17. A method for the specific detection and/or identification of a microorganism that is an algal, archaeal, bacterial, fungal or parasitical species, genus, family or group in any sample, using a panel of probes or amplification primers or both, each individual probe or primer being derived from a nucleic acid which has a nucleotide sequence of at least 12 nucleotides in length capable of hybridizing with the nucleic acids of said microorganism and with a nucleic acid having any one of the nucleotide sequences defined in SEQ ID NOS.:

- | | |
|---------------------|---|
| 539, 540 | for the detection and/or identification of <i>Mycobacteriaceae</i> family |
| 541, 542, 544, 2121 | for the detection and/or identification of Pseudomonads group |

- 545, 546 for the detection and/or identification of *Corynebacterium* sp.
- 547, 548, 1202 for the detection and/or identification of *Streptococcus* sp.
- 549, 550, 582, 583, 625, 626, 627, 628, 1199 for the detection and/or identification of *Streptococcus agalactiae*
- 551, 552, 2166, 2173, 2174, 2175, 2176, 2177, 2178, 2179 for the detection and/or identification of *Neisseria gonorrhoeae*
- 553, 575, 605, 606, 707, 1175, 1176 for the detection and/or identification of *Staphylococcus* sp.
- 554, 555, 2213 for the detection and/or identification of *Chlamydia trachomatis*
- 576, 631, 632, 633, 634, 635, 1163, 1164, 1167, 2076, 2108, 2109 for the detection and/or identification of *Candida* sp.
- 577, 1156, 1160, 2073 for the detection and/or identification of *Candida albicans*
- 578, 1166, 1168, 2074 for the detection and/or identification of *Candida dubliniensis*
- 579, 2168 for the detection and/or identification of *Escherichia coli*
- 580, 603, 1174, 1236, 1238, 2289, 2290, 2291 for the detection and/or identification of *Enterococcus faecalis*
- 581 for the detection and/or identification of *Haemophilus influenzae*
- 584, 585, 586, 587, 588, 1232, 1234, 2186 for the detection and/or identification of *Staphylococcus aureus*
- 589, 590, 591, 592, 593 for the detection and/or identification of *Staphylococcus epidermidis*
- 594, 595 for the detection and/or identification of *Staphylococcus haemolyticus*
- 596, 597, 598 for the detection and/or identification of *Staphylococcus hominis*

599, 600, 601, 695, for the detection and/or identification of *Staphylococcus saprophyticus*
 1208, 1209
 602, 1235, 1237, for the detection and/or identification of *Enterococcus faecium*
 1696, 1697, 1698,
 1699, 1700, 1701,
 2286, 2287
 604 for the detection and/or identification of *Enterococcus gallinarum*
 620, 1122 for the detection and/or identification of *Enterococcus casseliflavus*, *E. flavescentis* and *E. gallinarum*
 629, 630, 2085, for the detection and/or identification of *Chlamydia pneumoniae*
 2086, 2087, 2088,
 2089, 2090, 2091,
 2092
 636, 637, 638, 639, for the detection and/or identification of at least the following:
 640, 641, 642 *Abiotrophia adiacens*, *Abiotrophia defectiva*, *Acinetobacter baumannii*, *Acinetobacter lwoffii*, *Aerococcus viridans*, *Bacillus anthracis*, *Bacillus cereus*, *Bacillus subtilis*, *Brucella abortus*, *Burkholderia cepacia*, *Citrobacter diversus*, *Citrobacter freundii*, *Enterobacter aerogenes*, *Enterobacter agglomerans*, *Enterobacter cloacae*, *Enterococcus avium*, *Enterococcus casseliflavus*, *Enterococcus dispar*, *Enterococcus durans*, *Enterococcus faecalis*, *Enterococcus faecium*, *Enterococcus flavescentis*, *Enterococcus gallinarum*, *Enterococcus mundtii*, *Enterococcus raffinosus*, *Enterococcus solitarius*, *Escherichia coli*, *Gemella morbillorum*, *Haemophilus ducreyi*, *Haemophilus haemolyticus*, *Haemophilus influenzae*, *Haemophilus parahaemolyticus*, *Haemophilus parainfluenzae*, *Hafnia alvei*, *Kingella kingae*, *Klebsiella oxytoca*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Megamonas hypermegale*, *Moraxella atlantae*, *Moraxella catarrhalis*, *Morganella morganii*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella aerogenes*, *Pasteurella multocida*, *Peptostreptococcus magnus*, *Proteus mirabilis*, *Providencia alcalifaciens*, *Providencia rettgeri*, *Providencia rustigianii*, *Providencia stuartii*, *Pseudomonas aeruginosa*, *Pseudomonas fluorescens*, *Pseudomonas stutzeri*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enteritidis*, *Salmonella gallinarum*, *Salmonella typhimurium*, *Serratia liquefaciens*, *Serratia marcescens*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus capitis*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Staphylococcus hominis*, *Staphylococcus lugdunensis*, *Staphylococcus saprophyticus*, *Staphylococcus simulans*, *Staphylococcus warneri*, *Stenotrophomonas*

- maltophilia*, *Streptococcus acidominimus*, *Streptococcus agalactiae*, *Streptococcus anginosus*, *Streptococcus bovis*, *Streptococcus constellatus*, *Streptococcus cricetus*, *Streptococcus cristatus*, *Streptococcus dysgalactiae*, *Streptococcus equi*, *Streptococcus ferus*, *Streptococcus gordonii*, *Streptococcus intermedius*, *Streptococcus macacae*, *Streptococcus mitis*, *Streptococcus mutans*, *Streptococcus oralis*, *Streptococcus parasanguinis*, *Streptococcus parauberis*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Streptococcus ratti*, *Streptococcus salivarius*, *Streptococcus sanguinis*, *Streptococcus sobrinus*, *Streptococcus uberis*, *Streptococcus vestibularis*, *Vibrio cholerae*, *Yersinia enterocolitica*, *Yersinia pestis*, *Yersinia pseudotuberculosis*.
- 656, 657, 271, for the detection and/or identification of *Enterococcus* sp.
- 1136, 1137
- 701, 702 for the detection and/or identification of *Leishmania* sp.
- 703, 704, 705, 706, 793 for the detection and/or identification of *Entamoeba* sp.
- 794, 795 for the detection and/or identification of *Trypanosoma cruzi*
- 796, 797, 808, 809, for the detection and/or identification of *Clostridium* sp.
- 810, 811
- 798, 799, 800, 801, for the detection and/or identification of *Cryptosporidium*
- 802, 803, 804, 805, *parvum*
- 806, 807
- 816, 817, 818, 819 for the detection and/or identification of *Giardia* sp.
- 820, 821, 822 for the detection and/or identification of *Trypanosoma brucei*
- 823, 824 for the detection and/or identification of *Trypanosoma* sp.
- 825, 826 for the detection and/or identification of *Bordetella* sp.
- 923, 924, 925, 926, for the detection and/or identification of *Trypanosomatidae*
- 927, 928 family
- 933, 934 for the detection and/or identification of *Enterobacteriaceae* group
- 994, 995, 996, 997, for the detection and/or identification of *Streptococcus*
- 998, 999, 1000, *pyogenes*
- 1001, 1200, 1210,
- 1211
- 1157, 2079, 2118 for the detection and/or identification of *Candida parapsilosis*

1158, 1159, 2078, 2110, 2111	for the detection and/or identification of <i>Candida glabrata</i>
1160, 2077, 2119, 2120	for the detection and/or identification of <i>Candida tropicalis</i>
1161, 2075, 2112, 2113, 2114	for the detection and/or identification of <i>Candida krusei</i>
1162	for the detection and/or identification of <i>Candida guilliermondii</i>
1162, 2080, 2115 2116, 2117	for the detection and/or identification of <i>Candida lusitaniae</i>
1165	for the detection and/or identification of <i>Candida zeylanoides</i>
1201	for the detection and/or identification of <i>Streptococcus pneumoniae</i>
1233	for the detection and/or identification of <i>Staphylococcus</i> sp. other than <i>S. aureus</i>
1329, 1330, 1331, 1332, 2167, 2281	for the detection and/or identification of <i>Klebsiella pneumoniae</i>
1661, 1665	for the detection and/or identification of <i>Escherichia coli</i> and <i>Shigella</i> sp.
1690, 1691, 1692, 1693, 2169	for the detection and/or identification of <i>Acinetobacter baumanii</i>
1694, 1695, 2122	for the detection and/or identification of <i>Pseudomonas aeruginosa</i>
1971, 1972, 1973	for the detection and/or identification of <i>Cryptococcus</i> sp.
2081, 2082, 2083	for the detection and/or identification of <i>Legionella</i> sp.
2084	for the detection and/or identification of <i>Legionella pneumophila</i>
2093, 2094, 2095, 2096	for the detection and/or identification of <i>Mycoplasma pneumoniae</i>
2106, 2107	for the detection and/or identification of <i>Cryptococcus neoformans</i>
2131, 2132, 2133	for the detection and/or identification of <i>Campylobacter jejuni</i> and <i>C. coli</i>
2134, 2135, 2136	for the detection and/or identification of <i>Bacteroides fragilis</i>

- 2170 for the detection and/or identification of *Abiotrophia adiacens*
2171 for the detection and/or identification of *Gemella* sp.
2172 for the detection and/or identification of *Enterococcus* sp.,
Gemella sp., *A. adiacens*
2180, 2181, 2182 for the detection and/or identification of *Bordetella pertussis*,

said method comprising the step of contacting the nucleic acids of the sample with said primers or probes under suitable conditions of hybridization or of amplification and detecting the presence of hybridized probes or amplified products as an indication of the presence of said specificalgal, archaeal, bacterial, fungal or parasitical species, genus, family or group.

18. A method for the universal detection of any bacterium, fungus or parasite in a sample, using a panel of probes or amplification primers or both, each individual probe or primer being derived from a nucleic acid as defined in claims 8 or 9, the method comprising the step of contacting the nucleic acids of the sample with said primers or probes under suitable conditions ofhybridization or of amplification and detecting the presence of any alga, archaeon, bacterium, fungus or parasite.

19. A method as set forth in claim 17 or 18, which further comprises probes or primers, or both, for the detection of at least one antimicrobial agent resistance gene.

20. A method as set forth in claim 17, 18 or 19, which further comprises probes or primers, or both, for the detection of at least one toxin gene.

21. A method as set forth in claim 19 or 20, wherein the probes or primers for the detection of said antimicrobial agent resistance gene or toxin gene have at least 12 nucleotides in length capable ofhybridizing with an antimicrobial agent resistance gene and/or toxin gene selected from SEQ ID NOs.:

- 1078, 1079, 1085 for the detection and/or identification of the *E. coli* Shiga-like toxin 2 (*stx*₂) gene

1080, 1081, 1084, 2012	for the detection and/or identification of the <i>E. coli</i> Shiga-like toxin 1 (<i>stx</i> ₁) gene
1082, 1083	for the detection and/or identification of <i>E. coli</i> Shiga-like toxins 1 and 2 (<i>stx</i>) genes
1086, 1087, 1088, 1089, 1090, 1091, 1092, 1170, 1239, 1240, 2292	for the detection and/or identification of the <i>vanA</i> resistance gene
1095, 1096, 1171, 1241, 2294, 2295	for the detection and/or identification of the <i>vanB</i> resistance gene
1111, 1112, 1113, 1114, 1115, 1116, 1118, 1119, 1120, 1121, 1123, 1124	for the detection and/or identification of the <i>vanAB</i> resistance genes
1103, 1104, 1109, 1110	for the detection and/or identification of the <i>vanC1</i> resistance gene
1105, 1106, 1107, 1108	for the detection and/or identification of the <i>vanC2</i> and <i>vanC3</i> resistance genes
1097, 1098, 1099, 1100, 1101, 1102	for the detection and/or identification of the <i>vanC1</i> , <i>vanC2</i> and <i>vanC3</i> resistance genes
1150, 1153, 1154, 1155	for the detection and/or identification of the <i>vanAXY</i> resistance genes
1094, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1192, 1193, 1194, 1195, 1196, 1197, 1214, 1216, 1217, 1218, 1219, 1220, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039	for the detection and/or identification of the <i>S. pneumoniae</i> <i>pbp1a</i> gene

1142, 1143, 1144, 1145	for the detection and/or identification of the <i>S. pneumoniae pbp2b</i> gene
1146, 1147, 1148, 1149	for the detection and/or identification of the <i>S. pneumoniae pbp2x</i> gene
1177, 1231	for the detection and/or identification of the <i>mecA</i> resistance gene
1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1333, 1334, 1335, 1340, 1341, 1936, 1937, 1940, 1942, 1943, 1945, 1946, 1947, 1948, 1949, 2040, 2041, 2042, 2043, 2250, 2251 1301, 1302, 1303, 1304, 1305, 1306 1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1336, 1337, 1338, 1339, 1342, 1343, 1934, 1935, 1938, 1939, 1941, 1944, 1950, 1951, 1952, 1953, 1955, 2044, 2045, 2046	for the detection and/or identification of the <i>gyrB</i> resistance gene for the detection and/or identification of the <i>parC</i> resistance gene
1322, 1323, 1324, 1325, 1326, 1327 1344, 1345, 1346, 1347 1349, 1350	for the detection and/or identification of the <i>parE</i> resistance gene for the detection and/or identification of the <i>aac(2')-Ia</i> resistance gene for the detection and/or identification of the <i>aac(3')-Ib</i> resistance gene
1352, 1353, 1354, 1355 1357, 1358, 1359, 1360 1362, 1363, 1364, 1365	for the detection and/or identification of the <i>aac(3')-IIb</i> resistance gene for the detection and/or identification of the <i>aac(3')-IVa</i> resistance gene for the detection and/or identification of the <i>aac(3')-VIa</i> resistance gene

- 1367, 1368, 1369, for the detection and/or identification of the *aac(6')-Ia*
1370 resistance gene
1372, 1373, 1374, for the detection and/or identification of the *aac(6')-Ic*
1375 resistance gene
1377, 1378, 1379, for the detection and/or identification of the *ant(3')-Ia*
1380 resistance gene
1382, 1383, 1384, for the detection and/or identification of the *ant(4')-Ia*
1385 resistance gene
1387, 1388, 1389, for the detection and/or identification of the *aph(3')-Ia*
1390 resistance gene
1392, 1393, 1394, for the detection and/or identification of the *aph(3')-IIa*
1395 resistance gene
1397, 1398, 1399, for the detection and/or identification of the *aph(3')-IIIa*
1400 resistance gene
1402, 1403, 1404, for the detection and/or identification of the *aph(3')-VIa*
1405, 2252 resistance gene
1407, 1408, 1409 for the detection and/or identification of the *blaCARB*
1410 resistance gene
1412, 1413, 1414, for the detection and/or identification of the *blaCMY-2*
1415 resistance gene
1417, 1418 for the detection and/or identification of the *blaCTX-M-*
1 and *blaCTX-M-2* resistance genes
1419, 1420, 1421, for the detection and/or identification of the *blaCTX-M-1*
1422 resistance gene
1424, 1425, 1426, for the detection and/or identification of the *blaCTX-M-2*
1427 resistance gene
1429, 1430, 1431, for the detection and/or identification of the *blaIMP*
1432 resistance gene
1434, 1435 for the detection and/or identification of the *blaOXA2*
resistance gene
1436, 1437 for the detection and/or identification of the *blaOXA10*
resistance gene
1440, 1441 for the detection and/or identification of the *blaPER-1*
resistance gene

1443, 1444	for the detection and/or identification of the <i>blaPER-2</i> resistance gene
1446, 1447, 1448, 1449	for the detection and/or identification of the <i>blaPER-1</i> and <i>blaPER-2</i> resistance genes
1450, 1451	for the detection and/or identification of the <i>dfrA</i> resistance gene
1453, 1454, 1455, 1456	for the detection and/or identification of the <i>dhfrIa</i> and <i>dhfrXV</i> resistance genes
1457, 1458, 1459, 1460, 2253	for the detection and/or identification of the <i>dhfrIa</i> resistance gene
1462, 1463, 1464, 1465	for the detection and/or identification of the <i>dhfrIb</i> and <i>dhfrV</i> resistance genes
1466, 1467, 1468, 1469	for the detection and/or identification of the <i>dhfrIb</i> resistance gene
1471, 1472, 1473, 1474	for the detection and/or identification of the <i>dhfrV</i> resistance gene
1476, 1477, 1478, 1479	for the detection and/or identification of the <i>dhfrVI</i> resistance gene
1481, 1482, 1483, 1484	for the detection and/or identification of the <i>dhfrVII</i> and <i>dhfrXVII</i> resistance genes
1485, 1486, 1487, 1488	for the detection and/or identification of the <i>dhfrVII</i> resistance gene
1490, 1491, 1492, ¹⁴⁹³ 1493	for the detection and/or identification of the <i>dhfrVIII</i> resistance gene
1495, 1496, 1497, 1498	for the detection and/or identification of the <i>dhfrIX</i> resistance gene
1500, 1501, 1502, 1503	for the detection and/or identification of the <i>dhfrXII</i> resistance gene
1505, 1506	for the detection and/or identification of the <i>dhfrXIII</i> resistance gene
1508, 1509, 1510, 1511	for the detection and/or identification of the <i>dhfrXV</i> resistance gene
1513, 1514, 1515, 1516	for the detection and/or identification of the <i>dhfrXVII</i> resistance gene

- 1528, 1529 for the detection and/or identification of the *ereA* and *ereA2* resistance genes
- 1531, 1532, 1533, 1534 for the detection and/or identification of the *ereB* resistance gene
- 1536, 1537, 1538, 1539 for the detection and/or identification of the *linA* and *linA'* resistance genes
- 1541, 1542, 1543, 1544 for the detection and/or identification of the *linB* resistance gene
- 1546, 1547 for the detection and/or identification of the *mefA* resistance gene
- 1549, 1550 for the detection and/or identification of the *mefE* resistance gene
- 1552, 1553, 1554, 1555 for the detection and/or identification of the *mefA* and *mefE* resistance genes
- 1556, 1557, 1558, 1559 for the detection and/or identification of the *mphA* and *mphK* resistance genes
- 1581, 1582, 1583, 1584 for the detection and/or identification of the *satG* resistance gene
- 1586, 1587, 1588, 1589, 2254 for the detection and/or identification of the *tetM* resistance gene
- 1591, 1592, 1593, 2297 for the detection and/or identification of the *vanD* resistance gene
- 1595, 1596, 1597, 1598 for the detection and/or identification of the *vanE* resistance gene
- 1609, 1610, 1611, 1612 for the detection and/or identification of the *vatB* resistance gene
- 1614, 1615, 1616, 1617 for the detection and/or identification of the *vatC* resistance gene
- 1619, 1620, 1621, 1622 for the detection and/or identification of the *vga* resistance gene
- 1624, 1625, 1626, 1627 for the detection and/or identification of the *vgaB* resistance gene
- 1629, 1630, 1631, 1632 for the detection and/or identification of the *vgb* and *vgh* resistance genes

1634, 1635, 1636, 1637	for the detection and/or identification of the <i>vgbB</i> resistance gene
1883, 1884, 1885, 1886, 1887, 1888, 1889, 1890, 1891, 1892, 1893, 1894, 1895, 1896, 1897, 1898	for the detection and/or identification of the <i>blaSHV</i> resistance gene
1906, 1907, 1908, 1909, 1910, 1911, 1912, 1913, 1914, 1915, 1916, 1917, 1918, 1919, 1920, 1921, 1922, 1923, 1924, 1925, 1926, 2006, 2007, 2008, 2009, 2141	for the detection and/or identification of the <i>blaTEM</i> resistance gene
1961, 1962, 1963, 1964	for the detection and/or identification of the <i>sulII</i> resistance gene
1966, 1967, 1968, 1969	for the detection and/or identification of the <i>tetB</i> resistance gene
2065, 2066, 2067, 2068, 2069, 2070, 2071	for the detection and/or identification of the <i>rpoB</i> resistance gene
2098, 2099, 2100	for the detection and/or identification of the <i>inhA</i> resistance gene
2102, 2103, 2104	for the detection and/or identification of the <i>embB</i> resistance gene
2123, 2124, 2125	for the detection and/or identification of the <i>C. difficile cdtA</i> toxin gene
2126, 2127, 2128	for the detection and/or identification of the <i>C. difficile cdtB</i> toxin gene
2142, 2143	for the detection and/or identification of the <i>mupA</i> resistance gene
2145, 2146	for the detection and/or identification of the <i>catI</i> resistance gene
2148, 2149	for the detection and/or identification of the <i>catII</i> resistance gene

2151, 2152	for the detection and/or identification of the <i>catIII</i> resistance gene
2154, 2155	for the detection and/or identification of the <i>catP</i> resistance gene
2157, 2158, 2160, 2161	for the detection and/or identification of the <i>cat</i> resistance gene
2163, 2164	for the detection and/or identification of the <i>ppflo</i> -like resistance gene.

22. A composition of matter comprising a specific nucleic acid as set forth in claim 10 or 11, which is specific for a bacterial, fungal or parasitical species, genus, family, or group, or a nucleic acid as set forth in claim 8 or 9 which is universal for a bacterium, fungus or parasite, or both specific and universal nucleic acids, in conjunction with a nucleic acid sequence of at least 12 nucleotides capable of hybridizing with an antimicrobial agent resistance gene and/or toxin gene.

23. A composition as set forth in claim 22, wherein the nucleic acid capable of hybridizing with an antimicrobial agent resistance gene and/or toxin gene is any one of:

1078, 1079, 1085	for the detection and/or identification of the <i>E. coli</i> Shiga-like toxin 2 (<i>stx</i> ₂) gene
1080, 1081, 1084, 2012	for the detection and/or identification of the <i>E. coli</i> Shiga-like toxin 1 (<i>stx</i> ₁) gene
1082, 1083	for the detection and/or identification of <i>E. coli</i> Shiga-like toxins 1 and 2 (<i>stx</i>) genes
1086, 1087, 1088, 1089, 1090, 1091, 1092, 1170, 1239, 1240, 2292	for the detection and/or identification of the <i>vanA</i> resistance gene
1095, 1096, 1171, 1241, 2294, 2295	for the detection and/or identification of the <i>vanB</i> resistance gene
1111, 1112, 1113, 1114, 1115, 1116, 1118, 1119, 1120, 1121, 1123, 1124	for the detection and/or identification of the <i>vanAB</i> resistance genes

1103, 1104, 1109, 1110	for the detection and/or identification of the <i>vanC1</i> resistance gene
1105, 1106, 1107, 1108	for the detection and/or identification of the <i>vanC2</i> and <i>vanC3</i> resistance genes
1097, 1098, 1099, 1100, 1101, 1102	for the detection and/or identification of the <i>vanC1</i> , <i>vanC2</i> and <i>vanC3</i> resistance genes
1150, 1153, 1154, 1155	for the detection and/or identification of the <i>vanAXY</i> resistance genes
1094, 1125, 1126, 1127, 1128, 1129, 1130, 1131, 1132, 1133, 1134, 1135, 1192, 1193, 1194, 1195, 1196, 1197, 1214, 1216, 1217, 1218, 1219, 1220, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039	for the detection and/or identification of the <i>S. pneumoniae pbp1a</i> gene
1142, 1143, 1144, 1145	for the detection and/or identification of the <i>S. pneumoniae pbp2b</i> gene
1146, 1147, 1148, 1149	for the detection and/or identification of the <i>S. pneumoniae pbp2x</i> gene
1177, 1251	for the detection and/or identification of the <i>mecA</i> resistance gene
1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298, 1333, 1334, 1335, 1340, 1341, 1936, 1937, 1940, 1942, 1943, 1945, 1946, 1947, 1948, 1949, 2040, 2041, 2042, 2043, 2250, 2251	for the detection and/or identification of the <i>gyrA</i> resistance gene

1301, 1302, 1303, 1304, 1305, 1306	for the detection and/or identification of the <i>gyrB</i> resistance gene
1308, 1309, 1310, 1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1336, 1337, 1338, 1339, 1342, 1343, 1934, 1935, 1938, 1939, 1941, 1944, 1950, 1951, 1952, 1953, 1955, 2044, 2045, 2046	for the detection and/or identification of the <i>parC</i> resistance gene
1322, 1323, 1324, 1325, 1326, 1327	for the detection and/or identification of the <i>parE</i> resistance gene
1344, 1345, 1346, 1347	for the detection and/or identification of the <i>aac(2')-Ia</i> resistance gene
1349, 1350	for the detection and/or identification of the <i>aac(3')-Ib</i> resistance gene
1352, 1353, 1354, 1355	for the detection and/or identification of the <i>aac(3')-IIb</i> resistance gene
1357, 1358, 1359, 1360	for the detection and/or identification of the <i>aac(3')-IVa</i> resistance gene
1362, 1363, 1364, 1365	for the detection and/or identification of the <i>aac(3')-VIa</i> resistance gene
1367, 1368, 1369, 1370	for the detection and/or identification of the <i>aac(6')-Ia</i> resistance gene
1372, 1373, 1374, 1375	for the detection and/or identification of the <i>aac(6')-Ic</i> resistance gene
1377, 1378, 1379, 1380	for the detection and/or identification of the <i>ant(3')-Ia</i> resistance gene
1382, 1383, 1384, 1385	for the detection and/or identification of the <i>ant(4')-Ia</i> resistance gene
1387, 1388, 1389, 1390	for the detection and/or identification of the <i>aph(3')-Ia</i> resistance gene
1392, 1393, 1394, 1395	for the detection and/or identification of the <i>aph(3')-IIa</i> resistance gene
1397, 1398, 1399, 1400	for the detection and/or identification of the <i>aph(3')-IIIa</i> resistance gene

- 1402, 1403, 1404, for the detection and/or identification of the *aph(3')-VIIa*
1405, 2252 resistance gene
1407, 1408, 1409 for the detection and/or identification of the *blaCARB*
1410 resistance gene
1412, 1413, 1414, for the detection and/or identification of the *blaCMY-2*
1415 resistance gene
1417, 1418 for the detection and/or identification of the *blaCTX-M-*
1 and *blaCTX-M-2* resistance genes
1419, 1420, 1421, for the detection and/or identification of the *blaCTX-M-1*
1422 resistance gene
1424, 1425, 1426, for the detection and/or identification of the *blaCTX-M-2*
1427 resistance gene
1429, 1430, 1431, for the detection and/or identification of the *blaIMP*
1432 resistance gene
1434, 1435 for the detection and/or identification of the *blaOXA2*
resistance gene
1436, 1437 for the detection and/or identification of the *blaOXA10*
resistance gene
1440, 1441 for the detection and/or identification of the *blaPER-1*
resistance gene
1443, 1444 for the detection and/or identification of the *blaPER-2*
resistance gene
1446, 1447, 1448, for the detection and/or identification of the *blaPER-1* and
1449 *blaPER-2* resistance genes
1450, 1451 for the detection and/or identification of the *dfrA* resistance
gene
1453, 1454, 1455, for the detection and/or identification of the *dhfrIa* and
1456 *dhfrXV* resistance genes
1457, 1458, 1459, for the detection and/or identification of the *dhfrIa*
1460, 2253 resistance gene
1462, 1463, 1464, for the detection and/or identification of the *dhfrIb* and
1465 *dhfrV* resistance genes
1466, 1467, 1468, for the detection and/or identification of the *dhfrIb*
1469 resistance gene

- 1471, 1472, 1473, for the detection and/or identification of the *dhfrV* resistance
1474 gene
- 1476, 1477, 1478, for the detection and/or identification of the *dhfrVI*
1479 resistance gene
- 1481, 1482, 1483, for the detection and/or identification of the *dhfrVII* and
1484 *dhfrXVII* resistance genes
- 1485, 1486, 1487, for the detection and/or identification of the *dhfrVII*
1488 resistance gene
- 1490, 1491, 1492, for the detection and/or identification of the *dhfrVIII*
1493 resistance gene
- 1495, 1496, 1497, for the detection and/or identification of the *dhfrIX*
1498 resistance gene
- 1500, 1501, 1502, for the detection and/or identification of the *dhfrXII*
1503 resistance gene
- 1505, 1506 for the detection and/or identification of the *dhfrXIII*
resistance gene
- 1508, 1509, 1510, for the detection and/or identification of the *dhfrXV*
1511 resistance gene
- 1513, 1514, 1515, for the detection and/or identification of the *dhfrXVII*
1516 resistance gene
- 1528, 1529 for the detection and/or identification of the *ereA* and *ereA2*
resistance genes
- 1531, 1532, 1533, for the detection and/or identification of the *ereB* resistance
1534 gene
- 1536, 1537, 1538, for the detection and/or identification of the *linA* and *linA'*
1539 resistance genes
- 1541, 1542, 1543, for the detection and/or identification of the *linB* resistance
1544 gene
- 1546, 1547 for the detection and/or identification of the *mefA* resistance
gene
- 1549, 1550 for the detection and/or identification of the *mefE* resistance
gene
- 1552, 1553, 1554, for the detection and/or identification of the *mefA* and *mefE*
1555 resistance genes

- 1556, 1557, 1558, for the detection and/or identification of the *mphA* and
1559 *mphK* resistance genes
- 1581, 1582, 1583, for the detection and/or identification of the *satG* resistance
1584 gene
- 1586, 1587, 1588, for the detection and/or identification of the *tetM* resistance
1589, 2254 gene
- 1591, 1592, 1593, for the detection and/or identification of the *vanD* resistance
2297 gene
- 1595, 1596, 1597, for the detection and/or identification of the *vanE* resistance
1598 gene
- 1609, 1610, 1611, for the detection and/or identification of the *vatB* resistance
1612 gene
- 1614, 1615, 1616, for the detection and/or identification of the *vatC* resistance
1617 gene
- 1619, 1620, 1621, for the detection and/or identification of the *vga* resistance
1622 gene
- 1624, 1625, 1626, for the detection and/or identification of the *vgaB* resistance
1627 gene
- 1629, 1630, 1631, for the detection and/or identification of the *vgb* and *vgh*
1632 resistance genes
- 1634, 1635, 1636, for the detection and/or identification of the *vgbB* resistance
1637 gene
- 1883, 1884, 1885, for the detection and/or identification of the *blaSHV*
1886, 1887, 1888, resistance gene
- 1889, 1890, 1891,
1892, 1893, 1894,
1895, 1896, 1897,
1898
- 1906, 1907, 1908, for the detection and/or identification of the *blaTEM*
1909, 1910, 1911, resistance gene
- 1912, 1913, 1914,
1915, 1916, 1917,
1918, 1919, 1920,
1921, 1922, 1923,
1924, 1925, 1926,
2006, 2007, 2008,
2009, 2141
- 1961, 1962, 1963, for the detection and/or identification of the *sulII* resistance
1964 gene

1966, 1967, 1968, 1969	for the detection and/or identification of the <i>tetB</i> resistance gene
2065, 2066, 2067, 2068, 2069, 2070, 2071	for the detection and/or identification of the <i>rpoB</i> resistance gene
2098, 2099, 2100	for the detection and/or identification of the <i>inhA</i> resistance gene
2102, 2103, 2104	for the detection and/or identification of the <i>embB</i> resistance gene
2123, 2124, 2125	for the detection and/or identification of the <i>C. difficile cdtA</i> toxin gene
2126, 2127, 2128	for the detection and/or identification of the <i>C. difficile cdtB</i> toxin gene
2142, 2143	for the detection and/or identification of the <i>mupA</i> resistance gene
2145, 2146	for the detection and/or identification of the <i>catI</i> resistance gene
2148, 2149	for the detection and/or identification of the <i>catII</i> resistance gene
2151, 2152	for the detection and/or identification of the <i>catIII</i> resistance gene
2154, 2155	for the detection and/or identification of the <i>catP</i> resistance gene
2157, 2158, 2160, 2161	for the detection and/or identification of the <i>cat</i> resistance gene
2163, 2164	for the detection and/or identification of the <i>ppflo</i> -like resistance gene.

24. A nucleic acid having at least 12 nucleotides in length, capable of hybridizing with the nucleotide sequence of any one of the *tuf* sequences defined in SEQ ID NOS.: 1-73, 75-241, 399-457, 498-529, 612-618, 621-624, 675, 677, 717-736, 779-792, 840-855, 865, 868-888, 897-910, 932, 967-989, 992, 1266-1287, 1518-1526, 1561-1575, 1578-1580, 1662-1664, 1666-1667, 1669-1670, 1673-1683, 1685-1689, 1786-1843, 1874-1881, 1956-1960, 2183-2185, 2187-2188, 2193-2201, 2214-2249, 2255-2272.

25. A nucleic acid having at least 12 nucleotides in length, capable of hybridizing with the nucleotide sequence of any one of the *atpD* sequences defined in SEQ ID NOs.: 242-270, 272-398, 458-497, 530-538, 663, 667, 673, 674, 676, 678-680, 737-778, 827-832, 834-839, 856-862, 866-867, 889-896, 929-931, 941-966, 1245-1254, 1256-1265, 1527, 1576-1577, 1600-1604, 1638-1647, 1649-1660, 1671, 1684, 1844-1848, 1849-1865, 2189-2192.

26. A nucleic acid having at least 12 nucleotides in length, capable of hybridizing with the nucleotide sequence of any one of the *recA* sequences defined in SEQ ID NOs.: 990-991, 1003, 1288-1289, 1714, 1756-1763, 1866-1873 and 2202-2212.

27. A nucleic acid having at least 12 nucleotides in length, capable of selectively hybridizing with the nucleotide sequence of any one of the antimicrobial agent resistance gene sequences defined in SEQ ID NOs.: 1004-1075, 1255, 1607-1608, 1648, 1764-1785, 2013-2014, 2056-2064, 2273-2280.

28. The nucleic acid sequences of the nucleic acids of any one of claims 24 to 27.

29. The use of a nucleic acid having at least 12 nucleotides in length capable of hybridizing with the nucleic acids of any one of the antimicrobial agent resistance genes sequences defined in SEQ ID NOs.: 1004-1075, 1255, 1607-1608, 1648, 1764-1785, 2013-2014, 2056-2064, 2273-2280 for the detection and identification of microbial species.

30. The use of a nucleic acid having at least 12 nucleotides in length capable of hybridizing with the nucleic acids of any one of the toxin genes defined in SEQ ID NOs.: 1078-1085, 2012 and 2123 to 2128 for the detection and identification of microbial species.

31. A repertory of *hexA* nucleic acids used for the detection and/or identification of *Streptococcus pneumoniae*, which repertory is created by amplifying

the nucleic acids of any streptococcal species with any combination of primers SEQ ID NOs.: 1179, 1181 and 1182.

32. A repertory as defined in claim 31, which comprises the nucleic acids having a nucleotide sequence defined in SEQ ID NOs.: 1184 to 1191.

33. A repertory of nucleic acid sequences derived from the repertory of claim 31 or 32.

34. A nucleic acid used for the specific and ubiquitous detection and for identification of *Streptococcus pneumoniae*, which is derived from the repertory of claim 31.

35. A nucleic acid as set forth in claim 34 which has a nucleic acid sequence of at least 12 nucleotides capable of hybridizing with said any *Streptococcus pneumoniae* and with any one of SEQ ID NOs.: 1184 to 1187.

36. A nucleic acid as set forth in claim 34, which has a nucleic acid sequence of at least 12 nucleotides capable of hybridizing with the nucleic acids of *Streptococcus pneumoniae* and with any one of the nucleic acids having SEQ ID NOs.: 1179, 1180, 1181, 1182.

37. A peptide derived from the translation of the nucleic acids from the repertory obtained from the method of claim 1, 31 or 32, or of the nucleic acids defined in any one of claims 24 to 27, 35 and 36.

38. A peptide sequence derived from the peptide of claim 37.

39. A recombinant vector comprising a nucleic acid obtained from the method of claim 1, 31 or 32, or from the nucleic acids defined in any one of claims 24 to 27, 35 and 36.

40. A recombinant vector as defined in claim 39 which is an expression vector.

41. A recombinant host cell comprising the recombinant vector defined in claim 39 or 40.


42. The use of the nucleic acid sequences defined in claim 28 or 33, or obtained from the method of claim 2 and of the protein sequences deduced from said nucleic acid sequences, for the design of a therapeutic agent effective against said microorganisms.

43. The use as defined in claim 42, wherein said therapeutic agent is an antimicrobial agent, a vaccine or a genic therapeutic agent.


44. A method for identification of a microorganism in a test sample, comprising the steps of:

- a) obtaining a nucleic acid sequence for a *tuf*, *atpD*, and/or *recA* genes of said microorganisms, and
- b) comparing said nucleic acid sequence with the nucleic acid sequences of a bank as defined in claim 5, said repertory comprising a nucleic acid sequence obtained from the nucleic acids of said microorganism, whereby said microorganism is identified when said comparison results in a match between said sequences.


1127



2 / 27



3/27



4/27

<i>S. aureus</i>	120	130	140	150	160	170	180	190	200
<i>E. epidermidis</i>	REHILLSRNVGVPALWV	LINKMDMVDEELLELVEVERDLILSEYDFPGDDPVVIAGSALKALE
<i>E. durans</i> (A)	REHILLSRNVGVPALWV	LINKMDMVDEELLELVEVERDLILSEYDFPGDDPVVIAGSALKALE
<i>E. hirae</i> (A)	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILTEYEFPGDDPVVIAGSALKALE
<i>E. mundtii</i> (A)	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILTEYEFPGDDPVVIAGSALKALE
<i>E. faecium</i> (A)	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILTEYEFPGDDPVVIAGSALKALE
<i>E. cecorum</i>	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILTEYEFPGDDPVVIAGSALKALE
<i>E. columbae</i>	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILTEYEFPGDDPVVIAGSALKALE
<i>E. cassel. flavius</i> (A)	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILTEYEFPGDDPVVIAGSALKALE
<i>E. gallinarum</i> (A)	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILSEYDFPGDDPVVIAGSALKALE
<i>E. faecalis</i>	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILSEYDFPGDDPVVIAGSALKALE
<i>E. avium</i> (A)	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILSEYDFPGDDTPVIAGSALKALE
<i>E. raffinosis</i> (A)	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILSEYDFPGDDTPVIAGSALKALE
<i>E. dispers</i> (A)	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILSEYDFPGDDTPVIAGSALKALE
<i>E. maderoratus</i> (A)	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILSEYDFPGDDTPVIAGSALKALE
<i>E. pectoavium</i> (A)	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILSEYDFPGDDTPVIAGSALKALE
<i>E. sulfureus</i>	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILSEYDFPGDDTPVIAGSALKALE
<i>E. saccharolyticus</i>	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILSEYDFPGDDTPVIAGSALKALE
<i>E. solitarius</i>	REHILLSRNVGVPVIWF	LINKMDMVDEELLELVEVERDLILSEYDFPGDDTPVIAGSALKALE


7 = - 4 3

5/27

<i>S. aureus</i>	
<i>S. epidermidis</i>	
<i>E. durans</i>	(A)
<i>E. hirae</i>	(A)
<i>E. mundtii</i>	(A)
<i>E. faecium</i>	(A)
<i>E. cecorum</i>	
<i>E. columbae</i>	
<i>E. cassel.</i>	<i>flavus</i> (A)
<i>E. gallinarum</i>	(A)
<i>E. faecalis</i>	
<i>E. avium</i>	(A)
<i>E. raffinosus</i>	(A)
<i>E. dispar</i>	(A)
<i>E. malodoratus</i>	(A)
<i>E. pseudoavium</i>	(A)
<i>E. sulfureus</i>	
<i>E. saccharolyticus</i>	
<i>E. solitarius</i>	

6/27

<i>L. monocytogenes</i>	<i>E. cassel. flavius</i> (B)	<i>E. gallinarum</i> (B)	<i>E. durans</i> (B)	<i>E. faecium</i> (B)	<i>E. hirae</i> (B)	<i>E. mundtii</i> (B)	<i>E. avium</i> (B)	<i>E. pseudoavium</i> (B)	<i>E. malodoratus</i> (B)	<i>E. raffinosus</i> (B)	<i>E. dispar</i> (B)	<i>S. pneumoniae</i>	<i>S. suis</i>	<i>S. pyogenes</i>	<i>S. mutans</i>	<i>S. lactis</i>	<i>T. aquaticus</i>	<i>E. coli</i>
REHILLISROVGVPYIIV	REHILLISROVGKHLIV	REHILLISROVGKHLIV																
FMNKCDMVDDEELLELVE MEIRDLLTEYEFPGDDIPVI KGSAALKALE.....	FMNKCDMVDDEELLELVE MEIRDLLTEYDFPGDDIPV KGSAALKALE.....																	




7/27


J.	<i>monocytogenes</i>	(B)
E.	<i>cassej. flatus</i>	(B)
E.	<i>gallinarum</i>	(B)
E.	<i>durans</i>	(B)
E.	<i>faecium</i>	(B)
E.	<i>hirae</i>	(B)
E.	<i>mundtii</i>	(B)
E.	<i>avium</i>	(B)
E.	<i>pseudoavium</i>	(B)
E.	<i>malodoratus</i>	(B)
E.	<i>rafinosus</i>	(B)
E.	<i>dispar</i>	(B)
S.	<i>pneumoniae</i>	
S.	<i>suis</i>	
S.	<i>pyogenes</i>	
S.	<i>mutans</i>	
S.	<i>lactis</i>	
F.	<i>aquaticus</i>	
F.	<i>co11</i>	

$$\Rightarrow \overrightarrow{a_2} = \overrightarrow{b_2} - \overrightarrow{c_2} - \overrightarrow{d_2} - \overrightarrow{e_2} - \overrightarrow{f_2} - \overrightarrow{g_2} - \overrightarrow{h_2} + \overrightarrow{i_2} - \overrightarrow{j_2} - \overrightarrow{k_2}$$


8/27

~~FIG. 5a~~

9/27

~~75~~ - 56


10/27




11/27

301	<i>E. coli</i>	GAGATCGGT ^T G	AAGAAGAGCG G	TTGGG.	CGATTCAACCG	I~~H~~R~~
311	<i>E. agglomerans</i>	GACATCGGT ^T G	AAGAAGAGCG G	TTGGG.	CGATCCACCG	I~~H~~R~~
321	<i>P. agglomerans</i>	GAGCTGAAA ^G	AAGAAGATGG G	CAGGGCACTA GAGATCGCCT	CTATTCAACCG CTATTCATCG	I~~H~~R~~
331	<i>P. dispersa</i>	GACCTGAAA ^G	AAGAAGACGG G	CAGGGCTGTA GAGGTTTCCT	CTATTCAACCG CTATTCATCG	I~~H~~R~~
	<i>T. ptyseos</i>	GACCTGAAG ^A	ACGAAGATGG A	TAGCAAATGTT GAGGTGAACT	CTATTCAACCG CTATTCATCG	I~~H~~R~~



7





13/27




14/27


~~75 - 85~~






17/27







19/27




20/27




21/27

7-2-96


22/27




23/27




24/27



25/27



26/27



27 / 27

